

EANM'15

A stylized illustration of the Hamburg skyline, featuring several prominent church spires and buildings along a waterfront. The illustration is rendered in a sketchy, hand-drawn style with green and yellow tones.

Hamburg, Germany

Annual Congress of the
European Association of Nuclear Medicine

October 10–14, 2015
Hamburg, Germany

www.eanm.org

Final Programme



Visit us on
[.com/officialEANM](https://www.facebook.com/officialEANM)



WATCH CME SESSIONS WHEREVER YOU ARE

All CME sessions will be
available at elearning.eanm.org*



*24 hours after the CME session

Table of Contents

General	Welcome Message	2
	EANM Committees	4
	EANM'15 Reviewers	5
	EANM National Societies: Delegates & Deputies	6
	UEMS/EBNM Committees	7
	UEMS/EBNM National Delegates & Deputies	8
	General Information	9
	Programme at a Glance	13
	Business Meetings & other Activities during EANM'15	18
	CCH – Congress Center Hamburg	20
Scientific Programme	PRE-CONGRESS SYMPOSIA	21
	Do.MoRe – 6 th International Symposium on DOSimetry and MOlecular Radiotherapy	25
	M2M – 2 nd Molecule to Man Track	25
	INVITED SPEAKER SESSIONS	26
	Young EANM	28
	ORAL SESSIONS	
	Sunday, October 11, 2015	29
	Monday, October 12, 2015	48
	Tuesday, October 13, 2015	66
	Wednesday, October 14, 2015	84
	POSTER SESSIONS	
	Poster Walks	95
	Posters	109
	Technologist Posters	202
Industry	Sponsored Symposia	211
	List of Exhibitors	214
	Company Profiles	222
	Exhibition Floor Plan	272
	Corporate Members CM	274
	Imprint	275





Welcome to the EANM Congress 2015 in Hamburg

With great pleasure the European Association of Nuclear Medicine welcomes you to its 28th Annual Congress in Hamburg, Germany.

During the EANM Congress you will be able to discuss the state-of-the-art that clinical, translational and fundamental nuclear medicine has to offer in the usual multidisciplinary setting that is so typical for our profession. From all over the world physicians, scientists and technologists will travel to Hamburg for EANM'15 to attend plenary lectures, scientific sessions and the state of the art in nuclear medicine and molecular imaging presented in Continuing Medical Education (CME).

This year's plenary sessions will focus on Clinical Molecular Imaging on Sunday, October 11 (including the Marie Curie Lecture by Prof. Stefano Fanti from Bologna, Italy on the role of nuclear medicine in prostate cancer), and on Therapeutic Nuclear Medicine on Monday, October 12. As part of the M2M - Molecule to Man track, which this year is featured over three days of the Congress, the plenary session on Tuesday, October 13 will focus on Targets and Probes. We are very pleased that Prof. Paul Workman, President and CEO of The Institute of Cancer Research, London, UK will address target discovery and probe identification in oncology, to be followed by lectures of Dr. Matthias Friebe and Prof. Guus van Dongen on probe selection and development for molecular imaging and therapy from the perspective of industry and academia, respectively. Of course the traditional Highlights Lecture on Wednesday, October 14 is scheduled, this year presented by Prof. Andreas Buck and Prof. Clemens Decristoforo.

This year we again feature special tracks. Last year's very successful Biology track has been renamed to the M2M - Molecule to Man track. Thanks to the efforts of the EANM Translational Molecular Imaging, Drug Development and Radiopharmacy Committees, you will find a wealth of events on basic and translational research in molecular imaging and therapy on Monday, Tuesday and Wednesday, including Tuesday's plenary session. As a sequel to "ISTARD", the collaborative efforts of the EANM Dosimetry and Radionuclide Therapy Committees resulted in an annual track now named Dosimetry and Molecular Radiotherapy (Do.MoRe) which will run throughout the Congress.

The Scientific Programme Committee, representing all EANM Committees, received a total of 1.916 abstracts, of which 1.710 were accepted for oral sessions (500 presentations) or poster sessions (1.210 presentations). In the pre-congress and joint symposia, a large number of experts from disciplines outside nuclear medicine together with experts from the EANM Committees will provide new data and will share with you how nuclear medicine contributes to better science and enhanced patient care throughout the areas in which nuclear medicine is utilised.

In collaboration with the European School of Nuclear Medicine, the EANM Committees organised a full track of CME sessions, including the highly appreciated interactive sessions. Education in cross-sectional imaging has been expanded to meet the needs of nuclear medicine physicians for performing state-of-the-art hybrid imaging. The Young EANM organised activities focussed on the career perspective of young professionals in nuclear medicine. Serving the nuclear medicine technologists, the EANM Technologist Committee again designed a full parallel programme of oral and poster sessions as well as Continuing Technologist Education (CTE) sessions and courses.

Organisation of the EANM'15 Congress has been the work of many members of the EANM Committees, strongly supported by the staff of the EANM Executive Office. During the meeting the speakers and presenters will share their data with you. I thank all those who contributed their time and effort into presenting a five-day meeting for you to learn, discuss and enjoy.

On behalf of the EANM Board, the EANM Scientific Programme Committee, the Local Organising Committee and the staff of the EANM Executive Office in Vienna, I welcome you to the 28th EANM Congress in 2015 and I hope you will experience a scientific, educational and successful meeting that meets your expectations and offers you a pleasant stay in Hamburg.



Prof. Dr. Wim J.G. Oyen
EANM Congress Chair 2014-2016

EANM Committees

EANM Board

President 2015-2016

A. Chiti (Italy)

President Elect

K. Muylle (Belgium)

Committee Coordinator 2015-2016

B.J. Krause (Germany)

Congress Chair 2014-2016

W.J.G. Oyen (United Kingdom)

Education Chair 2014-2016

V. Lewington (United Kingdom)

Secretary 2014-2015

S. Frangos (Cyprus)

Treasurer 2015-2016

J. Kunikowska (Poland)

EANM Advisory Council

The EANM Advisory Council is composed of the members of the Board and of the Committee Chairs:

Committees

Bone & Joint Committee, F. Paycha (France)
Cardiovascular Committee, M. Hacker (Austria)
Dosimetry Committee, M.W. Konijnenberg (Netherlands)
Drug Development Committee, A. Gee (United Kingdom)
Inflammation & Infection Committee, A. Signore (Italy)
Neuroimaging Committee, M. Pagani (Italy)
Oncology Committee, F. Giammarile (France)
Paediatrics Committee, Z. Bar-Sever (Israel)
Physics Committee, B. Sattler (Germany)
Radionuclide Therapy Committee, L. Bodei (Italy)
Radiopharmacy Committee, M. Behe (Switzerland)
Technologist Committee, G. Testanera (Italy)
Thyroid Committee, M. Luster (Germany)
Translational Molecular Imaging Committee,
M. de Jong (Netherlands)
Young EANM Committee, I. Zerizer (United Kingdom)

EANM'15 Local Organising Committee

Local Ambassador

S. Klutmann (Hamburg, Germany)

Members

S. Schwarzenböck (Rostock, Germany)
G. von Gogh (Hamburg, Germany)
M. Yanar (Hamburg, Germany)

EANM'15 Scientific Programme Committee

Chair

W.J.G. Oyen (United Kingdom)

Members

L. Borgwardt (Denmark)
J.R. Buscombe (United Kingdom)
M. de Jong (Netherlands)
A.H. Dias (Denmark)
P.H. Elsinga (Netherlands)
A. Gee (United Kingdom)
F. Giammarile (France)
M.W. Konijnenberg (Netherlands)
I. Law (Denmark)
M. Luster (Germany)
F. Paycha (France)
G. Testanera (Italy)
H.J. Verberne (Netherlands)
W. Waddington (United Kingdom)

EANM'15 Technologist Programme Committee

Chair

G. Testanera (Italy)

Members

M. Federspiel (Denmark)
P. Fragoso Costa (Germany)
M. Hinterreiter (Austria)
C. Pestean (Romania)
S. Rep (Slovenia)
B. Vidovic (Germany)

EANM Congress Strategy Committee

Congress Chair 2014-2016

W.J.G. Oyen (United Kingdom)

Committee Coordinator 2015-2016

Ex officio: B.J. Krause (Germany)

Education Chair 2014-2016

Ex officio: V. Lewington (United Kingdom)

Members

J. Darcourt (France)
C. Hindorf (Sweden)
E. Lazzeri (Italy)
D. Le Guludec (France)
H.-J. Wester (Germany)

EANM'15 Reviewers

W. Acampa (Italy)	A. Cuocolo (Italy)	M. Kostkiewicz (Poland)	F. Rogowski (Poland)
R.M. Aigner (Austria)	D. Daou (France)	J. Kotzerke (Germany)	A. Roivainen (Finland)
L. Aloj (Italy)	C. De Labriolle-Vaylet (France)	F. Kraeber-Bodéré (France)	J. Roland (Belgium)
C. Altini (Italy)	D. De Palma (Italy)	S. Kraemer (Switzerland)	A. Rominger (Germany)
V. Ambrosini (Italy)	C. Decristoforo (Austria)	B.J. Krause (Germany)	C. Rossetti (Italy)
S. Ametamey (Switzerland)	S. Del Vecchio (Italy)	L. Krolicki (Poland)	F. Rouzet (France)
C. Anagnostopoulos (Greece)	R.C. Delgado-Bolton (Spain)	J. Kunikowska (Poland)	L.M. Salgado (Portugal)
J. Arbizu (Spain)	B.H. Erbas (Turkey)	T. Kuwert (Germany)	P.A. Salvador (Italy)
V. Artiko (Serbia)	T. Ertay (Turkey)	T. Lahoutte (Belgium)	M. Samal (Czech Republic)
S. Asenbaum (Austria)	L. Evangelista (Italy)	P. Lass (Poland)	A.I. Santos (Portugal)
S. Baldari (Italy)	H. Everaert (Belgium)	M. Lassmann (Germany)	B. Sattler (Germany)
J. Ballinger (United Kingdom)	S. Fanti (Italy)	I. Law (Denmark)	S. Savolainen (Finland)
J. Barbet (France)	M.K. Federspiel (Denmark)	E. Lazzeri (Italy)	M. Schäfers (Germany)
M. Bardiès (France)	A. Fikrle (Czech Republic)	D. Le Guludec (France)	R. Schibli (Switzerland)
P. Bartenstein (Germany)	G. Flux (United Kingdom)	O. Lindner (Germany)	T.H. Schindler (USA)
H. Barthel (Germany)	I. Földes (Hungary)	E. Lopci (Italy)	J. Sciuk (Germany)
J.J. Bax (Netherlands)	F. Forrer (Switzerland)	M. Maccauro (Italy)	G. Sgouros (USA)
A. Beer (Germany)	S. Förster (Germany)	G. Madeddu (Italy)	K. Sjögreen Gleisner (Sweden)
M. Behe (Switzerland)	P.A. Fragoso Costa (Germany)	A. Maes (Belgium)	R. Slart (Netherlands)
M. Beheshti (Austria)	M. Gabriel (Austria)	L. Maffioli (Italy)	H. Steinert (Switzerland)
G. Berding (Germany)	H-J. Gallowitsch (Austria)	T. Maina-Nock (Greece)	H. Stevens (Netherlands)
K. Bergström (Finland)	A. Galuska (Hungary)	A. Maldonado (Spain)	A. Sundin (Sweden)
M. Bernsen (Netherlands)	A. Garcia Vicente (Spain)	P. Mapelli (Italy)	J-N. Talbot (France)
B.E. Bilgin (Turkey)	A. Gee (United Kingdom)	C. Marcassa (Italy)	M. Teräs (France)
A. Bischof Delaloye (Switzerland)	F. Giammarile (France)	G. Marengo (Italy)	G. Testanera (Italy)
K.J.A.K. Blokland (Netherlands)	A. Gimelli (Italy)	G. Mariani (Italy)	G. Treglia (Italy)
R. Boellaard (Netherlands)	A. Glaudemans (Netherlands)	M. Meignan (France)	C. Türkmen (Turkey)
O.C. Boerman (Netherlands)	G. Gnanasegaran (United Kingdom)	P.M. Meyer (Germany)	P. Unak (Turkey)
J. Booij (Netherlands)	S. Graf (Austria)	J. Mihailovic (Serbia)	M. Unlu (Turkey)
K. Borbely (Hungary)	S. Gratz (Germany)	R. Mikolajczak (Poland)	I. Vaccaro (Italy)
M.F.R. Botelho (Portugal)	C. Halldin (Sweden)	T.L. Mindt (Switzerland)	R.A. Valdés Olmos (Netherlands)
M.F. Bozkurt (Turkey)	D. Handkiewicz-Junak (Poland)	H.R.I. Minn (Finland)	T. Van den Wyngaert (Belgium)
W. Brenner (Germany)	K. Herholz (United Kingdom)	L. Mu (Switzerland)	B. van Eck-Smit (Netherlands)
M. Brom (Netherlands)	K. Herrmann (Germany)	A. Muxi Pradas (Spain)	J. Varga (Hungary)
A.H. Brouwers (Netherlands)	S. Heskamp (Netherlands)	K.A. Nagren (Denmark)	H.J. Verberne (Netherlands)
R. Buchert (Germany)	S. Hesse (Germany)	F. Nobili (Italy)	A. Versari (Italy)
Z.E. Burak (Turkey)	C. Hindorf (Sweden)	B.A. Nock (Greece)	B. Vidovic (Germany)
W. Cai (USA)	R. Hustinx (Belgium)	E. Noriega (Spain)	R. Vieira (Portugal)
C. Caldarella (Italy)	O. Israel (Israel)	M.A. Ozguven (Turkey)	I. Virgolini (Austria)
M.G. Cantinho-Lopes (Portugal)	F. Jamar (Belgium)	M. Pagani (Italy)	M. Vljakovic (Serbia)
G. Capa Kaya (Turkey)	B. Jarzab (Poland)	M. Pappata (Italy)	D. Vriens (Netherlands)
M.R. Castellani (Italy)	L. Kabasakal (Turkey)	S. Pappata (Italy)	W. Waddington (United Kingdom)
R. Chakravartty (United Kingdom)	P.A. Kaufmann (Switzerland)	P. Payoux (France)	S. Walrand (Belgium)
A. Chiaravalloti (Italy)	S. Kirac (Turkey)	C. Pestean (Romania)	W. Weber (Germany)
F. Cicone (Italy)	M. Kirienko (Italy)	P. Pilkington (Spain)	A. Welch (United Kingdom)
E.F.I. Comans (Netherlands)	W.H. Knapp (Germany)	A. Plachcinska (Poland)	K. Zambo (Hungary)
G. Cook (United Kingdom)	P. Kolenc Peitl (Slovenia)	B. Degirmenci Polack (Turkey)	S.I. Ziegler (Germany)
G.M.L.M. Costa (Portugal)	M.W. Konijnenberg (Netherlands)	V. Prassopoulos (Greece)	
C. Crivellaro (Italy)	I. Kostadinova (Bulgaria)	A. Pupi (Italy)	
		S. Rep (Slovenia)	
		M. Rijpkema (Netherlands)	
		N. Ristevska (FYROM)	
		M. Rodari (Italy)	
		V. Roelants (Belgium)	

EANM National Societies: Delegates & Deputies

Sequence by Council of Europe, Member States – www.coe.int

-  **Armenian Society of Nuclear Medicine**
Delegate: V. Barsegian
Deputy: G. Kevorkian
-  **Austrian Society of Nuclear Medicine**
Delegate: A. Becherer
Deputy: W. Langsteger
-  **Azerbaijan Society of Nuclear Medicine**
Delegate: F. Novruzov
Deputy: A. Aliyev
-  **Belgian Society of Nuclear Medicine**
Delegate: F. Jamar
Deputy: P. De Bondt
-  **Bosnian Society of Nuclear Medicine**
Delegate: Z. Rajkovaca
Deputy: D. Rozic
-  **British Nuclear Medicine Society**
Delegate: J.B. Neilly
Deputy: S. Vinjamuri
-  **Bulgarian Society of Nuclear Medicine**
Delegate: P. Bochev
Deputy: V. Hadziyska
-  **Croatian Society of Nuclear Medicine**
Delegate: N. Girotto
Deputy: M. Franceschi
-  **Cyprus Society of Nuclear Medicine**
Delegate: R.K. Demetriadou
Deputy: D. Kaolis
-  **Czech Society of Nuclear Medicine**
Delegate: O. Lang
Deputy: M. Kaminek
-  **Danish Society of Clinical Physiology and Nuclear Medicine**
Delegate: L. Jensen
Deputy: P.S. Oturai
-  **Dutch Society of Nuclear Medicine**
Delegate: A. Rijnders
Deputy: W. Schreurs
-  **Estonian Nuclear Medicine Society**
Delegate: K. Ulst
Deputy: S. Nazarenko
-  **Finnish Society of Nuclear Medicine**
Delegate: M.P. Seppänen
Deputy: H. Mussalo
-  **FYR of Macedonia Society of Nuclear Medicine**
Delegate: A. Ugrinska
Deputy: E. Janevik-Ivanovska
-  **French Society of Nuclear Medicine**
Delegate: O.J. Mundler
Deputy: J.-P. Vuillez
-  **German Society of Nuclear Medicine**
Delegate: J. Kotzerke
Deputy: F. M. Mottaghy
-  **Greek Society of Nuclear Medicine & Biology**
Delegate: D. Aposolopoulos
Deputy: V.C. Prassopoulos
-  **George de Hevesy Hungarian Society of NM**
Delegate: L. Pavics
Deputy: J. Varga
-  **Icelandic Society of Nuclear Medicine**
Delegate: E. Bjorgvinsson
Deputy: J. Gudjonsdottir

-  **Irish Nuclear Medicine Association**
Delegate: M. O'Connell
Deputy: J. Feeney
-  **Israeli Society of Nuclear Medicine**
Delegate: Z. Bar-Sever
Deputy: Z. Keidar
-  **Italian Society of Nuclear Medicine**
Delegate: M. Picchio
Deputy: E. Milan
-  **Latvian Society of Nuclear Medicine**
Delegate: J. Kedrova
Deputy: M. Ratniece
-  **Lithuanian Society of Nuclear Medicine**
Delegate: I. Kulakiene
Deputy: N. Jurkiene
-  **Luxembourg Society of Nuclear Medicine**
Delegate: C. Als
Deputy: C.J. Picard
-  **Malta**
Delegate: A. Samuel
Deputy: M.A. Aquilina
-  **Norwegian Society of Nuclear Medicine**
Delegate: R. Sundset
Deputy: L. Fjerdingsby
-  **Polish Society of Nuclear Medicine**
Delegate: R. Czepczynski
Deputy: A. Sowa-Staszczak
-  **Portuguese Society of Nuclear Medicine**
Delegate: M.T. Rezio
Deputy: A.C. Oliveira
-  **Romanian Society of Nuclear Medicine**
Delegate: R. Mititelu
Deputy: V.C. Mazilu
-  **Russian Society of Nuclear Medicine**
Delegate: V. Soukhov
Deputy: P. Rummyantsev
-  **Serbian Nuclear Medicine Society**
Delegate: V. Artiko
Deputy: D. Sobic-Saranovic
-  **Slovak Society of Nuclear Medicine**
Delegate: P. Povinec
Deputy: L. Kaliska
-  **Slovenian Society of Nuclear Medicine**
Delegate: S. Gaberscek
Deputy: I. Zagar
-  **Spanish Society of Nuclear Medicine**
Delegate: A. Soriano Castrejon
Deputy: E. Prats-Rivera
-  **Swedish Society of Nuclear Medicine**
Delegate: P. Gjerstsson
Deputy: P. Grybäck
-  **Swiss Society of Nuclear Medicine**
Delegate: T. Krause
Deputy: M. Wissmeyer
-  **Turkish Society of Nuclear Medicine**
Delegate: B.H. Erbas
Deputy: L.Ö. Atay
-  **Ukrainian Society of Nuclear Medicine**
Delegate: to be announced
Deputy: to be announced

UEMS/EBNM Committees

Executive Committee

President

D.C. Costa (Portugal)

Secretary & Treasurer

M. Bajc (Sweden)

Member

L.S. Maffioli (Italy)

Fellowship Examination

Chair

T.V. Bogsrud (Norway)

Members

A. Boubaker (Switzerland)

D. Fuster (Spain)

I. Kulakiene (Lithuania)

Z. Ozcan (Turkey)

Ex officio

D. Huic (Croatia)

Education & Syllabus

Chair

A. Prigent (France)

Members

A.K.A. Ahonen (Finland)

T.V. Bogsrud (Norway)

F. Brunotte (France)

G.M.L.M. Costa (Portugal)

D. Huic (Croatia)

R. Hustinx (Belgium)

H.B. Sayman (Turkey)

Ex officio

L.S. Maffioli (Italy)

CME Accreditation

Chair

T. Varetto (Italy)

Members

R.P. Baum (Germany)

D. Costa (Portugal)

P.H. Jarritt (United Kingdom)

T. Krause (Switzerland)

L. Pavics (Hungary)

Ex officio

D.C. Costa (Portugal)

Accreditation of Nuclear Medicine Departments & Training Centres

Chair

S. Mirzaei (Austria)

Vice Chair

J. Prior (Switzerland)

Members

A. García-Burillo (Spain)

N. Mutlukoca (Norway)

P.A.L. Van Boxem (Belgium)

M.L. Hall (United Kingdom)

Ex officio

M. Bajc (Sweden)

Corresponding Members

F. Giesel (Germany)

A. Jiménez Heffernan (Spain)

I. Sipponen-Tuunonen (Finland)

N.G. Hartman (United Kingdom)

S.E. Bouyoucef (Algeria)

A. Ciarmiello (Italy)

O. Ekmekcioglu Young EANM Group (Turkey)

UEMS/EBNM National Delegates & Deputies nominated from full UEMS Member Countries

-  **AUSTRIA**
Delegate: I. Virgolini
Deputy: T. Leitha
-  **BELGIUM**
Delegate: K. Spaepen
Deputy: G. Moulin-Romsee
-  **BULGARIA**
Delegate: E. Piperkova
Deputy: A.D. Tzonevska
-  **CROATIA**
Delegate: D. Huic
Deputy: S. Tezak
-  **CYPRUS**
Delegate: S. Frangos
Deputy: R.K. Demetriadou
-  **CZECH REPUBLIC**
Delegate: O. Lang
Deputy: M. Kaminek
-  **DENMARK**
Delegate: P.S. Oturai
Deputy: L.T. Jensen
-  **ESTONIA**
Delegate: E. Kelk
Deputy: A. Poksi
-  **FINLAND**
Delegate: H. Mussalo
Deputy: A. Loimaala
-  **FRANCE**
Delegate: E. Gremillet
Deputy: J.-L. Pelletier
-  **GERMANY**
Delegate: L.S. Freudenberg
Deputy: C. Franzius
-  **GREECE**
Delegate: I. Iakovou
Deputy: S. Tsiouris
-  **HUNGARY**
Delegate: L. Pavics
Deputy: I. Szilvasi
-  **IRELAND**
Delegate: S. Skehan
Deputy: R. McDermott
-  **ITALY**
Delegate: M. Chianelli
Deputy: B. Palumbo
-  **LATVIA**
Delegate: I. Vevere
Deputy: A. Berzina
-  **LITHUANIA**
Delegate: D. Vajauskas
Deputy: N. Jurkienė

-  **LUXEMBOURG**
Delegate: P. Paulus
Deputy: M. Doat
-  **MALTA**
Delegate: A. Samuel
Deputy: M. A. Aquilina
-  **NETHERLANDS**
Delegate: J.M.H. de Klerk
Deputy: J.F. Verzijlbergen
-  **NORWAY**
Delegate: R. Midha
Deputy: M. Revheim
-  **POLAND**
Delegate: M. Dziuk
Deputy: B. Birkenfeld
-  **PORTUGAL**
Delegate: M. Baptista
Deputy: G. Lopes Magalhães Costa
-  **ROMANIA**
Delegate: A. Rimbu
Deputy: G. Andries
-  **SLOVAKIA**
Delegate: A. Vondrak
-  **SLOVENIA**
Delegate: S. Hojker
Deputy: D. Hrastnik
-  **SPAIN**
Delegate: A. Soriano
Deputy: F. Pons
-  **SWEDEN**
Delegate: E. Trägårdh
Deputy: P. Grybäck
-  **SWITZERLAND**
Delegate: A. Boubaker
Deputy: J. Müller-Brand
-  **UNITED KINGDOM**
Delegate: S. Dizdarevic

UEMS/EBNM National Delegates & Deputies nominated from UEMS Associate Member Countries

-  **TURKEY**
Delegate: Y. Yurekli
Deputy: Z. Ozcan

UEMS/EBNM National Delegates & Deputies nominated from UEMS Observer Countries

-  **ISRAEL**
Delegate: A. Steinmetz
Deputy: M. Quastel

General Information (A – Z)

Congress Venue

CCH – Congress Center Hamburg
Am Dammtor / Marseiller Strasse
20355 Hamburg, Germany

The Congress Center Hamburg has a total area of 17,887 m² including 27 event spaces of different sizes for exhibitions, conferences and concerts. The complex's unique location within the parc "Planten un Blomen" is perfect for a walk outside. Due to the proximity of the station "Dammtor", the congress venue is in easy reach for participants arriving by underground (U-Bahn), rapid transit (S-Bahn), bus, express bus and InterCity trains. The Radisson Blu Hotel is directly connected to the congress venue and is one of the highest buildings in the city.

Audio & Video Recordings

Audio and/or video recordings during the congress are strictly prohibited and may not be made without prior written permission of the EANM Executive Office.

Badges

Badges must be worn at all times throughout the entire congress and during social events. Colour codes are as follows:

Clear - Attendees

Blue - Exhibitors

Green - Day Badges

Red - Accompanying Persons

Banks & ATMs

Banks are usually open from 09:00 – 16:00 (Monday–Friday) – some until 19:00 – and closed during the weekends and public holidays. Banks at airports, ports and main railway stations are generally open longer. ATM machines are plentiful and easy to use.

Certificate of Attendance

To obtain your certificate of attendance please visit www.eanm.org, log in to the [vEANM Area](#) with your personal account information and refer to the section [vConfirmation > Congress related](#). The certificate will be available within 24 hours after you have scanned your congress badge.

Churches, Synagogues, Mosques

As Hamburg is a multi-national city there are different religions. One third of the population are Protestant, whereas the majority do not have any or have a different religion.

Nevertheless there are many Catholic churches as well as synagogues and mosques. Churches usually have services in English once a week. Please contact your hotel concierge for current times of services.

Climate

Hamburg has a warm temperate climate. Due to the maritime influence winters are mild and summers are cooler compared to the eastern part of the country. The average day temperature in October ranges between 6–13°C. Despite the relatively mild weather and a pleasant climate during the autumn months, October is the time of the year in which rainfall is at its highest levels, so an umbrella and wet weather gear are essential.

Closing Ceremony & Farewell Cocktail

Wednesday, October 14, 2015

Closing Ceremony: 13:15 – 13:20 (Hall 1)

Farewell Cocktail: 13:15 – 14:30 (Foyers)

(Access granted only for persons holding a valid congress badge)

CME Credits & Certificates

To acquire CME credits, attendees are required to scan their congress badge upon first arrival at the congress venue as well as upon entrance into each CME session. For CME sessions, an evaluation form must also be completed for each session attended.

To obtain your CME certificate(s) please visit www.eanm.org, log in to the [vEANM Area](#) with your personal account information and refer to the section [vConfirmation > Congress related](#). The certificate(s) will be available within 24 hours after you have scanned your congress badge.

CTE Credits & Certificates



This year's Technologist Programme has been accredited by the DIW-MTA/DVTA. These German associations collaborate to provide Continuing Education accreditation for Technologists. For further information please refer to the website <http://diw-mta.de/>.

To acquire CTE credits, attendees of the CTE sessions are required to scan their congress badge upon first arrival at the congress venue.

To obtain your CTE certificate please visit www.eanm.org, log in to the [vEANM Area](#) with your personal account information and refer to the section [vConfirmation > Congress related](#). The certificate will be available within 24 hours after you have scanned your congress badge.

Congress Language

The congress language is English. No simultaneous translation will be provided.

Congress Office & Registration Desk

Saturday, October 10, 2015: 07:30 – 19:00

Sunday, October 11, 2015: 07:30 – 18:00

Monday, October 12, 2015: 07:30 – 18:00

Tuesday, October 13, 2015: 07:30 – 18:00

Wednesday, October 14, 2015: 07:30 – 12:00

Credit Cards

All major credit cards, including Eurocard, Diners, Visa and Mastercard are accepted in restaurants, hotels, shopping centres and stores. Travel cheques can be cashed in most of banks and exchange offices.

Currency

The monetary unit is the Euro (€). A number of exchange offices are located in central Hamburg and at the airport. When exchanging your currency, you may need your passport or official ID card. If you do not have it with you, the bank may refuse to exchange your currency. Travellers' cheques are barely accepted as payment throughout Germany; however, it is still possible to change these at many banks in Hamburg.

Disclaimer

Please note that in the event that the congress is cancelled by the organisers in case of force majeure, the registration fee, hotel deposit and any other service ordered through the registration will be partially refunded or forfeited, subject to the commitments of the congress organisers at that time. You may wish to insure yourself directly against such a risk.

EANM Executive Office

Schmalzhofgasse 26

1060 Vienna, Austria

Phone: +43-(0)1-890 44 27 | Fax: +43-(0)1-890 44 27-9

Email: office@eanm.org | URL: www.eanm.org

EANM Members Assembly

Saturday, October 10, 2015

16:00 – 18:00 (Hall 6)

Please note! Only members in good standing (who have fully paid their membership dues) are entitled to participate. Of course you can also pay your membership dues onsite. Please contact the EANM booth in the Entrance Hall.

Electricity

The electrical current in Germany is 220 V/50 Hz. Round European-style two-pin plugs are used.

Industry Exhibition

Sunday, October 11 – Tuesday, October 13, 2015

09:00 – 17:00 (Hall H)

Insurance & Liability

Neither the organisers nor the Conference Bureau will assume any responsibility whatsoever for damage or injury to persons or property during the congress. It is recommended that participants arrange for their personal travel and health insurance.

Internet Café

Internet access will be provided at stations within the industry exhibition in Hall H. Please limit the viewing time to max. 5 minutes per person.

Lost & Found

A lost and found service will be provided in the EANM Congress Office for the duration of the congress.

Medical Facilities

Medical assistance and an ambulance service will be available throughout the congress.

Messages

Messages and announcements can be posted/will be available at the International Meetings & Announcements Desk.

Mobile Phones

The use of mobile phones is forbidden in lecture halls and poster areas.

Museums

In Hamburg you can find approx. 60 museums of which seven are state-run. The most important are the art gallery and the museum for art and industry. There are several museums for regional history, such as the museum of the history of Hamburg. The museum of ethnology or the modern planetarium show items related to technology and work and scientific collections. The world's largest model railway can be found in the Miniatur-Wunderland at the Speicherstadt and the oldest waxworks of Germany can be found in the Panoptikum. As Hamburg also has a trading port there are various museums with maritime themes. For prices and opening hours please refer to the hotel reception, tourist information or the EANM Hamburg Information Desk at the congress venue.

Opening Ceremony & Welcome Reception

Saturday, October 10, 2015

Opening Ceremony: 19:00 – 20:00 (Hall 1)

Welcome Reception: 20:00 – 22:30 (Foyers)

(Access granted only for persons holding a valid congress badge)

Poster Exhibition

The Poster Exhibition will be located in Hall 3 (ground floor) and will be open from Sunday, October 11 to Tuesday, October 13 (09:00 – 17:00) and on Wednesday, October 14 (09:00 – 12:00).

Public Bicycle Sharing System

There are several bike stations throughout the city where it is possible to borrow a bike using your cash card, credit card or a bike card. One can borrow up to two bikes and use the bike stations 7 days a week, 24 hours a day as the StadtRAD Hamburg is a self-service bike rental system. The first 30 minutes are free of charge, afterwards it will cost up to 0,08 EUR per minute. The daily rate is 12 EUR. Registration costs 5 EUR once, which will be credited for your next rentals. The rental period begins when taking the bike and ends when returning the bike to one of the bike stations.

For further information on the StadtRAD Hamburg please visit: www.hamburg-travel.com/info/out-and-about-in-hamburg/stadtrad-hamburg

Public Transportation Ticket (PTT)

All congress participants who book a hotel through the online registration page of EANM which is more than a ten-minute walk away from the congress venue will receive a complimentary public transportation ticket upon check-in at the hotel.

As the airport is within the city borders, the PTT is also valid for the return transfer to the airport by public transport.

For further information on the public transportation system please visit www.hvv.de/en

Restaurants & Nightlife

Mostly known for its parties is the Hamburg Reeperbahn, where a lot of clubs and discos are located on the main street and its side streets. Here you will find all different types of music, events, cultures and people. Of course there are numerous other venues throughout the city, from clubbing to jazz or blues.

As a port, Hamburg offers a large range of fish restaurants mostly situated close to the lake Alster or the river Elbe as well as traditional Hamburg dishes and international food. In the past few years the restaurants have been honoured with different prizes such as the Michelin star.

For more information about restaurants please visit: www.hamburg-travel.com/experience/eating-drinking

Shopping

The city offers a lot of shops with an exciting mixture, from luxury to fair trade and second hand stores as well as jumble sale and weekly food markets. The largest shopping centre is the Alstertal-Shopping centre with approx. 240 stores outside the city. The largest shopping centre in the city is the Europa Passage in the old town, with over 120 shops. The most famous

market is the fish market at the Hamburg harbour. Every Sunday morning at 5 am (in winter at 7 am) until 9:30 am the trading begins not only for fish but also for flowers, meat and fruits. For those who do not wish to get up so early Hamburg offers a wide variety of different markets, such as the one in Blankenese, the noble part of Hamburg, or in Altona.

Most shops are usually open from 10:00 - 20:00, whereas some shops such as supermarkets are open 24 hours a day from Monday to Saturday.

For more information about shopping please visit: www.hamburg-travel.com/experience/shopping

Social Media

The EANM is represented on several social media platforms to keep members, fans, followers and subscribers up to date on offers and activities of the EANM!

Follow us on  and share your experiences by using the Hashtag #EANM ! With the tag #EANMLive you can address questions to the lecturers of CME & Plenary Sessions, which you are attending at that very moment.

With EANM on  you can be sure never to miss anything and to always be right on time.

Subscribe to  to become one of over 1,100 viewers and enjoy exclusive interviews, videos about social events, making of, insider-information and much more.

Follow us on , where the EANM shares photos of the annual congress and further meetings & events with you.

Taxis

Taxi companies have fixed kilometre prices. The basis price for all transfers is 3,20 EUR and the first four kilometers cost 2,35 EUR each. The price for kilometre five to nine is 2,10 EUR and afterwards 1,45 EUR for each further kilometre. If you would like to be driven outside the city you can arrange for a fixed price. Additional charges will be calculated for the St. Pauli Elbtunnel and Van-taxis (6 EUR). All prices are subject to change. Credit cards are usually accepted. To calculate your journey, please visit <http://www.taxi-calculator.com/> for an overview of the taxi rate.

The major taxi companies are:

Taxi Hamburg (+49 40-66 66 66) and Hansa Taxi 211211 (+49 40-211 211)

You can either call or book online.

Youngster Lounge

Junior members of the EANM and other young professionals have the opportunity to meet, greet and chill-out in the Youngster Lounge. The Lounge is open to all congress participants with a junior or student registration.

Opening Hours:

Sunday, October 11, 2015: 08:00 – 18:00

Monday, October 12, 2015: 08:00 – 18:00

Tuesday, October 13, 2015: 08:00 – 18:00

EANM'16



Barcelona, Spain

Annual Congress of the
European Association of Nuclear Medicine

October 15–19, 2016
Barcelona, Spain

www.eanm.org



Visit us on
[.com/officialEANM](https://www.facebook.com/officialEANM)

Saturday, October 10, 2015

 Time Schedule

Time/ Room	Hall 1	Hall 16	Hall 7	Hall 6	Hall 8	Hall E	Hall D	Hall F	Hall 3 – Poster Exhibition
Capacity	3000	30	60	370	260	260	230	260	
08:00 – 19:00		EANM Advisory Council Meeting (11:00 – 13:00)	EANM Delegates Assembly (13:45 – 16:00)	EANM Members Assembly (16:00 – 18:00)	 Pre-Symposium 1: Current Trends in Diagnosis and Therapy of Prostate Cancer (09:00 – 16:00)	 Pre-Symposium 2: New Imaging Techniques and Impact on Clinical Care: Balance between Quality and Dose Reduction (09:00 – 12:30) ***** Pre-Symposium 3: Neuroinflammation (13:30 – 17:00)	 Pre-Symposium 4: Meeting with Industry (09:00 – 12:30) ***** Pre-Symposium 5: Translation of Radiopharmaceuticals from Molecule to Man (13:30 – 17:00)	 Pre-Symposium 6: Pharmacokinetic Modelling and Dosimetry (09:00 – 12:30) ***** Pre-Symposium 7: Translational Molecular Imaging to Support Drug Development (13:30 – 17:00)	Poster Setup (08:00 – 18:00)
19:00 – 20:00	OPENING CEREMONY (19:00 – 20:00) & WELCOME RECEPTION (20:00 – 22:30)								

Sunday, October 11, 2015

Time Schedule

Time/ Room	Hall 1	Hall 2	Hall 4	Hall G1	Hall G2	Hall 6	Hall F	Hall E	Hall 8	Hall D	Hall 3 – Poster Exhibition
Capacity	3000	1100	800	580	560	370	260	260	260	230	
08:00 – 09:30	CME 101 CME 1 Interactive Bone and Joint Bone Planar and Hybrid Scintigraphy: Patterns, Pearls, Pitfalls	102 Joint Symposium 1: EANM/EACVI: Cost-effectiveness in Cardiac Imaging: From Theory to Practice	103 Technologists 08:00 – 08:12 Opening Ceremony 08:15 – 09:45 CTE 1: Brain Imaging (Tech Guide Book Launch)		105 Do.MoRe: PRRT Treatment Planning			108 Pitfalls & Artefacts & Physiology – Interactive: Clinical Consequences of Neuroimaging			Poster Walks PW01, PW04, PW07, PW10 (08:30 – 09:30)
10:00 – 11:15	201 Plenary 1 incl. Marie Curie Lecture Clinical Molecular Imaging		203 In Hall 1: Plenary 1 incl. Marie Curie Lecture Clinical Molecular Imaging								
11:30 – 13:00	CME 301 CME 2 Oncology & Paediatrics & Bone and Joint Sarcomas	302 Joint Symposium 2: EANM/EATA-CRN: What the Doctor Tells and the Patient Understands – Update on Thyroid Cancer Communication	303 Technologists CTE 2 – Interactive: Multiprofessional Discussion on Extended Competencies for Nuclear Medicine technologists	304 Special Symposium: Evidence-based Medicine – Implications for Imaging	305 Do.MoRe: Novel Therapies	306 Physics & Instrumentation & Data Analysis: PET/MR	307 Neurosciences: Basic Neuroscience		309 Clinical Oncology: Gastroesophageal & Colorectal Cancer	310 Cardiovascular System: Cardiac Innovation Imaging	
13:00 – 14:30					Industry Sponsored Symposium	Industry Sponsored Symposium		Industry Sponsored Symposium	Young EANM Daily Forum: Team Leadership Skills		Poster Sessions P01 – P19 (16:00 – 16:30)
14:30 – 16:00	CME 401 CME 3 Paediatrics & Cardiovascular Paediatric Heart and Lung Disease	402 Joint Symposium 3: EANM/ESSO: Radioguided Surgery	403a Technologists 14:30 – 15:30 Mini Course 1 – Interactive: Signs in Nuclear Medicine Imaging ***** 403b 15:45 – 16:45 Mini Course 2 – Interactive: PET/CT Artefacts ***** 403c 17:00 – 18:00 Mini Course 3 – Interactive: SPECT/CT Artefacts	404 Clinical Oncology – Featured: Prostate (PSMA)	405 Do.MoRe – Featured: Endocrine & Neuroendocrine Tumours	406 Teaching Session: Anatomy Refresher and Cross-sectional Imaging: Thorax	407 Radiopharmaceuticals & Radiochemistry: Radiochemistry – Methods	408 Conventional & Specialised Nuclear Medicine: Infection & Inflammation	409 Physics & Instrumentation & Data Analysis: Data Analysis & Management I	410 Cardiovascular System: PET Perfusion Imaging	
16:30 – 18:00	CME 501 CME 4 Inflammation & Infection Imaging Infection in the Immunocompromised Patient	502 Joint Symposium 4: EANM/EORTC: Hypoxia Imaging: A Powerful Tool to Better Understand Tumour Biology and Guide Cancer Therapy			505 Do.MoRe: Treatment of Bone Metastases	506 Teaching Session: Anatomy Refresher and Cross-sectional Imaging: Abdomen & Pelvis	507 Clinical Oncology: Lung	508 Conventional & Specialised Nuclear Medicine: Thyroid & Parathyroid	509 Physics & Instrumentation & Data Analysis: Data Analysis & Management II	510 Cardiovascular System: SPECT & PET Perfusion Imaging	

Monday, October 12, 2015



Time/ Room	Hall 1	Hall 2	Hall 4	Hall G1	Hall G2	Hall 6	Hall F	Hall E	Hall 8	Hall D	Hall 3 – Poster Exhibition
Capacity	3000	1100	800	580	560	370	260	260	260	230	
08:00 – 09:30	601 CME 5 Interactive PET with Choline Tracers	602 Joint Symposium 5: EANM/MDS: Dopamine Transporter Imaging: Current Topics	603 Technologists Oral Presentations 1		605 Do.MoRe: PRRT Dose Response	606 M2M: SPECT Translational Studies		608 Pitfalls & Artefacts & Physiology – Interactive Imaging in Inflammation and Infection		610 UEMS/CANMD Session: Practical Quality Management in Nuclear Medicine	Poster Walks PW02, PW05, PW08, PW11 (08:30 – 09:30)
10:00 – 11:15	701 Plenary 2 Therapeutic Nuclear Medicine		703 In Hall 1: Plenary 2 Therapeutic Nuclear Medicine								
11:30 – 13:00	801 CME 6 Neuroimaging Brain Tumours – PET vs MRI: Therapy Planning and Response Assessment	802 Joint Symposium 6: EANM/ESTRO: Molecular PET Imaging in Adaptive Radiotherapy: Focus on Current Trends, Challenges and Solutions	803 Technologists Oral Presentations 2	804 Clinical Oncology – Featured: Image Guided Surgery	805 Do.MoRe – Featured: Prostate Cancer Therapy	806 M2M: Radiopharmaceuticals & Radiochemistry: Macromolecules I	807 Teaching Session: Anatomy Refresher and Hybrid Imaging of the Foot and Ankle		809 Clinical Oncology: Prostate I – Choline	810 Conventional & Specialised Nuclear Medicine: Bone & Joint	
13:00 – 14:30					Industry Sponsored Symposium	Industry Sponsored Symposium		Industry Sponsored Symposium	Young EANM Daily Forum: Career Speed Date		
14:30 – 16:00	901 CME 7 Physics & Paediatrics Radiation Protection	902 Joint Symposium 7: EANM/EACVI/FESC: New Clinical Guidelines on Infectious Endocarditis and CIED Infections	903 Technologists CTE 3 – Interactive: Comprehensive PET/MRI Practice	904 Committee Symposium – Neuroimaging Counteracting Dementia: Imaging Evidence for Cognitive and Brain Reserve	905 Do.MoRe: Radiobiology – Molecular Radiotherapy	906 M2M: Radiopharmaceuticals & Radiochemistry: Radiotracers – Brain	907 Teaching Session: The Spine: Anatomy, Pathology and Correlative Imaging	908 Clinical Oncology: Prostate II – Beyond Choline		910 Clinical Oncology: Rapid Fire Session	Poster Sessions P20 – P38 (16:00 – 16:30)
16:30 – 18:00	1001 CME 8 Cardiovascular EANM/EACVI Joint Session: Imaging in Heart Failure: Focus on Nuclear Medicine Techniques and Clinical Implications	1002 Joint Symposium 8: EANM/EAU: PET Imaging of Genito- urinary Malignancies beyond Prostate	1003 Technologists CTE 4: Infection Imaging in Nuclear Medicine	1004 Neurosciences – Featured: Dementia	1005 Do.MoRe: 90Y SIRT Treatment Planning	1006 M2M: Radiopharmaceuticals & Radiochemistry: Peptides	1007 DGN-Sponsored Symposium: PET/MRI	1008 Conventional & Specialised Nuclear Medicine: General & Miscellaneous	1009 Physics & Instrumentation & Data Analysis: Image Reconstruction, Quantification & PET/MR	1010 Clinical Oncology: Melanoma & Lymphoma	

Tuesday, October 13, 2015

Time Schedule

Time/ Room	Hall 1	Hall 2	Hall 4	Hall G1	Hall G2	Hall 6	Hall F	Hall E	Hall 8	Hall D	Hall 3 – Poster Exhibition
Capacity	3000	1100	800	580	560	370	260	260	260	230	
08:00 – 09:30	1101 CME 9 Radionuclide Therapy & Thyroid & Translational Molecular Imaging Theranostics: What We Can Have and What We Can Achieve	1102 Joint Symposium 9: EANM/ESSR/ESSKA: Evaluation of the Painful Knee Arthroplasty	Technologists In Hall 3 – Poster Exhibition: TP01, TP02, TP03, TP04		1105 Do.MoRe: Quantitative Molecular Imaging	1106 M2M: Molecular & Multimodality Imaging: Tumour Biology & Optical Imaging	1107 SNMMI Symposium: Hepatobiliary Scintigraphy in Abdominal Pain	1108 Pitfalls & Artefacts & Physiology (Cardiovascular) – Interactive: MPS, SPECT–CT, PET, Newer techniques such as CZT and IQ-SPECT			Technologist Poster Sessions TP01, TP02, TP03, TP04 (08:00 – 09:30) Poster Walks PW03, PW06, PW09, PW12 (08:30 – 09:30)
10:00 – 11:15	1201 Plenary 3 (M2M – Molecule to Man Track) Targets and Probes		1203 In Hall 1: Plenary 3 (M2M – Molecule to Man Track) Targets and Probes		1305 Do.MoRe – Featured: Therapy – Miscellaneous	1306 M2M – Featured: Molecular & Multimodality Imaging: PSMA	1307 Cardiovascular System: Myocarditis, Amyloidosis, Sarcoidosis & Vasculitis	1308 Conventional & Specialised Nuclear Medicine: Paediatric – General	1309 Physics & Instrumentation & Data Analysis: Quality Control, Performance, Standardisation	1310 Clinical Oncology: Miscellaneous	
11:30 – 13:00	1301 CME 10 Dosimetry & Translational Molecular Imaging Preclinical Quantitative Imaging and Dosimetry	1302 Joint Symposium 10: EANM/ELL: Lymphoma and PET/CT Update	1303 Technologists Oral Presentations 3								
13:00 – 14:30									Young EANM Daily Forum: Young Investigator Meeting		
14:30 – 16:00	1401 CME 11 Radiopharmacy New Protein Deposition Tracers	1402 Joint Symposium 11: EANM/ENETS: Management of Neuroendocrine Tumours	1403 Technologists CITE 5: Lean Principles and Improved Departmental Management	1404 Cardiovascular System – Featured: Imaging of Plaques, Angiogenesis & Ischaemic Memory	1405 M2M: Radiopharmaceuticals & Radiochemistry: Radiochemistry & Instrumentation	1406 M2M: Molecular & Multimodality Imaging: Therapy – Preclinical Studies, α & β Radiation	1407 Teaching Session: Interactive Quiz: Radiology and Cross-sectional Imaging	1408 Clinical Oncology: Paediatric Oncology	1409 Physics & Instrumentation & Data Analysis: Instrumentation	1410 Neurosciences: Psychiatry	Poster Sessions P39 – P63 (16:00 – 16:30)
16:30 – 18:00	1501 CME 12 Drug Development & Radiopharmacy Radiopharmaceutical Design	1502 Joint Symposium 12: (M2M – Molecule to Man Track) EANM/ESMI/COST: Lead Compounds in Theranostics			1505 Do.MoRe: Thyroid	1506 M2M: Molecular & Multimodality Imaging: PET – Translational & Clinical Studies	1507 Teaching Session: Interactive Quiz: Nuclear Medicine with Correlative Imaging	1508 Cardiovascular System: Miscellaneous	1509 Clinical Oncology: Neuroendocrine	1510 Neurosciences: Neuroimaging – Data Analysis	

Wednesday, October 14, 2015

Time Schedule

Time/ Room	Hall 1	Hall 2	Hall 4	Hall G1	Hall G2	Hall 6	Hall F	Hall E	Hall 8	Hall D	Hall 3 – Poster Exhibition
Capacity	3000	1100	800	580	560	370	260	260	260	230	
08:00											
–											
09:30	1601 CME 13 Translational Molecular Imaging & Radiopharmacy Image Guided Surgery in Urological Malignancies	1602 Joint Symposium 13: EANM/ESPGHAN: Paediatric Gastrointestinal Nuclear Medicine	1603 Technologists 09:30 – 10:45 CTE 6: Imaging Protocols in Radionuclide Therapy		1605 Do.MoRe: 90Y SIRT Dose Effects	1606 M2M: Radiopharmaceuticals & Radiochemistry: Macromolecules II		1608 Clinical Oncology: Breast & Gynaecology		1610 Clinical Oncology: Brain, Head & Neck	
10:00											
–											
11:30	1701 CME 14 Drug Development & Translational Molecular Imaging Multimodal Imaging Agents (Probes, Techniques & Applications)				1705 Do.MoRe: Miscellaneous	1706 M2M: Molecular & Multimodality Imaging: PET Tracers – Preclinical Studies		1708 Clinical Oncology: Therapy Response & External Beam RT	1709 Physics & Instrumentation & Data Analysis: Radiation Exposure & Protection	1710 Neurosciences: Movement Disorders	
11:45	1801 11:45 – 12:15: Awards Ceremony 12:15 – 13:15: Highlights Lecture 13:15 – 13:20: Closing Ceremony		1803 In Hall 1: 11:45 – 12:15: Awards Ceremony 12:15 – 13:15: Highlights Lecture 13:15 – 13:20: Closing Ceremony								
–											
13:20											

- Pre-Congress Meetings/Sessions
- Plenary Sessions
- Continuing Medical Education Sessions
- Scientific Symposia
- Technologist Sessions

- Featured Sessions
- Special Features
- Industry Sponsored Symposia
- Poster Sessions
- Parallel Sessions

Business Meetings & other Activities during EANM'15

Friday, October 09, 2015	Time	Room	Level
EANM Board Meeting	09:00 – 16:00	Hall C 4.3	1
ESNM Inflammation & Infection Revision Group Meeting	09:30 – 18:00	Hall B 4.1	1
EANM Strategy Meeting	18:00 – 19:30	Hall C 4.3	1

Saturday, October 10, 2015	Time	Room	Level
FEBNM Preparation Session	08:30 – 11:00	Hall 18/19	0
EANM Advisory Council Meeting	11:00 – 13:00	Hall 16	0
EANM Advisory Council & Delegates Lunch	13:00 – 13:45	Foyer Hall 2	2
FEBNM Written Examination (MCQ)	13:00 – 16:00	Hall 18/19	0
EANM Inflammation & Infection Committee Meeting	13:30 – 16:00	Hall B4.4	1
EANM Delegates Assembly	13:45 – 16:00	Hall 7	1
EANM Dosimetry Committee Meeting	14:00 – 15:30	Hall 16	0
EANM Members Assembly	16:00 – 18:00	Hall 6	0
EANM Neuroimaging Committee Meeting	18:00 – 19:00	Hall B4.1	1
EANM Drug Development Committee Interest Group Meeting	18:00 – 19:00	Hall B4.4	1

Sunday, October 11, 2015	Time	Room	Level
ESNM PET/CT Revision Group Meeting	08:00 – 10:00	Hall B4.1	1
EANM Radionuclide Therapy Committee Meeting	09:00 – 10:00	Hall 18/19	0
EANM Drug Development Committee Meeting	09:00 – 11:00	Hall B4.4	1
WARMTH Governing Board Meeting	09:00 – 12:00	Hall B4.3	1
Joint Editorial Board Meeting EJNMMI, EJNMMI Research & EJNMMI Physics	13:00 – 14:30	Hall 7	1
WFNMB Governing Council Meeting	14:00 – 16:00	Hall B4.3	1
EANM Radiopharmacy Committee Meeting	14:00 – 16:00	Hall B4.4	1
ESNM Meeting	15:00 – 17:00	Hall 16	0
EANM:SNMMI Leadership Meeting	16:00 – 17:00	Hall C4.3	1
EANM:SNMMI Guidelines Steering Committee Meeting	17:00 – 18:00	Hall C4.3	1

Business Meetings & other Activities during EANM'15

Sunday, October 11, 2015 continued	Time	Room	Level
EANM Radiopharmacy Committee Interest Group Meeting	16:00 – 17:30	Hall B4.4	1
EANM Delegates Assembly – Affiliated Societies	16:00 – 17:00	Hall 18/19	0
EANM Radionuclide Therapy Committee Interest Group Meeting	16:30 – 17:30	Hall B4.3	1
Dosimetry Task Force Meeting	18:00 – 19:00	Hall 16	0

Monday, October 12, 2015	Time	Room	Level
EANM Exhibitors Meeting	10:00 – 11:15	Hall 18/19	0
Seventh Plenary Meeting of the European Observatory on the Supply of Medical Radioisotopes	10:00 – 16:00	Hall 16	0
EANM Oncology Committee Meeting	10:15 – 11:15	Hall B4.4	1
Young EANM Committee Interest Group Meeting	11:00 – 12:00	Youngster Lounge	0
EANM Oncology Committee Interest Group Meeting	11:15 – 12:45	Hall 7	1
EANM:SSGTM-SSMN Meeting	11:30 – 13:00	Hall C4.3	1
EANM Physics Committee Meeting	11:30 – 13:00	Hall B4.1	1
Editorial Board Meeting Review Journal Clinical and Translational Imaging	13:00 – 14:00	Hall 18/19	0
Radiopharmacy Educational Board Meeting	13:30 – 14:30	Hall B4.1	1
WFNMB Extraordinary Delegates Assembly	16:00 – 17:00	Hall 7	1
EANM Congress Strategy Committee Meeting	17:00 – 18:00	Hall C4.3	1
EANM Past/Present RT Committee Meeting	17:00 – 18:30	Hall B4.1	1

Tuesday, October 13, 2015	Time	Room	Level
EANM Physics Committee Interest Group Meeting	08:30 – 10:00	Hall 16	0
Extraordinary EANM Committees' Meeting	13:00 – 14:30	Hall D	2
UEMS/EBNM Executive Committee & Committee Chairs Meeting	14:00 – 16:00	Hall B4.1	1
UEMS/EBNM Delegates Assembly	16:00 – 18:00	Hall 18/19	0
Scientific Advisory Board Meeting	16:00 – 18:00	Hall B4.3	1
EANM'16 Barcelona Scientific Programme Committee Meeting	16:30 – 18:00	Hall 16	0




EANM'15




Second Floor



First Floor



Ground Floor



Pre-Congress Symposia | Saturday, October 10, 2015

09:00 – 16:00



Hall 8

▶ Current Trends in Diagnosis and Therapy of Prostate Cancer

Programme:

Chairs

S. Klutmann (Hamburg)

H.-J. Wester (Munich)

- | | |
|---------------|---|
| 09:00 – 09:20 | P.J. Olbert (Marburg): The Urologists' Unmet Clinical Needs – Can Nuclear Medicine Offer Solutions? |
| 09:20 – 09:35 | S. Boschi (Bologna): Metabolic Tracers to Image Prostate Cancer |
| 09:35 – 09:50 | S. Perner (Bonn): PSMA Expression in Prostate Cancer |
| 09:50 – 10:05 | K. Kopka (Heidelberg): Radiochemical Concepts of PSMA Targeting |
| 10:05 – 10:20 | H.-J. Wester (Munich): Prostate Cancer: Innovative Imaging Biomarkers under Development |
| 10:20 – 10:30 | Discussion |
| 10:30 – 11:00 | Coffee Break in Foyer Hall G, Second Floor |

Chairs

P. Castellucci (Bologna)

S. Perner (Bonn)

- | | |
|---------------|--|
| 11:00 – 11:20 | P. Castellucci (Bologna): Choline PET/CT Imaging |
| 11:20 – 11:40 | W. Langsteger (Linz): Bone Imaging |
| 11:40 – 12:00 | M. Eiber (Munich): PSMA PET/CT and PET/MRI Imaging |
| 12:00 – 12:10 | Discussion |
| 12:10 – 13:10 | Lunch Break in Foyer Hall G, Second Floor |

Chairs

P.J. Olbert (Marburg)

J.E. Gschwend (Munich)

- | | |
|---------------|---|
| 13:10 – 13:30 | J.E. Gschwend (Munich): Concepts in Prostate Cancer Therapy |
| 13:30 – 13:50 | M. Graefen (Hamburg): Principles for Local Therapy of Prostate Cancer |
| 13:50 – 14:10 | P. Mapelli (Milan): PET-guided Radiation Therapy |
| 14:10 – 14:30 | R.A. Valdes Olmos (Amsterdam): Sentinel Node Imaging |
| 14:30 – 15:00 | Coffee Break in Foyer Hall G, Second Floor |

Chairs

J. O'Sullivan (Belfast)

U. Haberkorn (Heidelberg)

- | | |
|---------------|---|
| 15:00 – 15:20 | J. O'Sullivan (Belfast): Ra-223 Therapy |
| 15:20 – 15:40 | U. Haberkorn (Heidelberg): PSMA Therapy |
| 15:40 – 16:00 | Discussion |

09:00 – 12:30

CME

Hall E

▶ **New Imaging Techniques and Impact on Clinical Care:
Balance between Quality and Dose Reduction**

Chairs

M.W. Konijnenberg (Rotterdam)

F.M. Bengel (Hannover)

Programme

- 09:00 – 09:05 Introduction by Chairs
- 09:05 – 09:30 K. Bacher (Gent): The Concept of Radiation Exposure: Risks and Benefits
- 09:30 – 09:55 W. Acampa (Naples): Conventional SPECT: Stress Only
- 09:55 – 10:20 A. Gimelli (Pisa): CZT
- 10:20 – 10:30 Discussion
- 10:30 – 11:00 Coffee Break in Foyer Hall G, Second Floor
- 11:00 – 11:25 D. Agostini (Caen): SPECT/CT
- 11:25 – 11:50 F. Bamberg (Tuebingen): CT Angiography
- 11:50 – 12:15 F. Hyafil (Paris): PET
- 12:15 – 12:30 Discussion and Summary by Chairs

Lunch in Foyer Hall G, Second Floor

13:30 – 17:00

CME

Hall E

▶ **Neuroinflammation**

Chairs

I. Law (Copenhagen)

A.A. Lammertsma (Amsterdam)

Programme

- 12:00 – 13:00 Lunch in Foyer Hall G, Second Floor
- 13:30 – 14:00 A.D. Windhorst (Amsterdam): PET/SPECT Imaging of Neuroinflammation: The State of Art and Targets for Radiopharmaceuticals
- 14:00 – 14:30 F. Roncaroli (London): Neuroinflammation on a Histopathological Level: TSPO – Glioma, Neuro-degeneration and Multiple Sclerosis
- 14:30 – 15:00 A.A. Lammertsma (Amsterdam): Quantifying TSPO Binding with PET: Making it Simple – What to do and what not to do
- 15:00 – 15:30 Coffee Break in Foyer Hall G, Second Floor
- 15:30 – 16:15 A. Gerhard (Manchester): Imaging TSPO Binding in Neurological Disorders
- 16:15 – 16:45 A. Nordberg (Stockholm): Other Potential Markers for Neuroinflammation Imaging: Astrocytosis in MCI and AD
- 16:45 – 17:00 Discussion

09:00 – 12:30

Hall D

▶ **Meeting with Industry**

Chairs

G. Flux (London)

M.W. Konijnenberg (Rotterdam)

Programme

09:00 – 09:10 G. Flux (London): Welcome & Introduction

09:10 – 09:35 M.W. Konijnenberg (Rotterdam): The Development and Introduction of New Radiotherapeutics: Perspective of the Health Centre

09:35 – 10:00 W. Mullet (BTG): Treatment with Y-90 Glass Microspheres: The BTG Experience

10:00 – 10:25 S. Buono (AAA): The Development and Introduction of New Radiotherapeutics: The AAA Experience

10:25 – 10:50 Coffee Break in Foyer Hall G, Second Floor

10:50 – 11:15 N. Stevens (IEL Research): Development and Clinical Introduction of New Radiotherapeutics

11:15 – 11:30 O. Petrenciuc (Bayer): Experience we made throughout the Clinical Development of Radium-223 Dichloride (Xofigo)

11:30 – 11:45 J. Gay (Bayer): Prerequisites and Challenges as to Handling of Radium-223 Dichloride (First-in-Class Alpha Emitter)

11:45 – 12:10 M. Tapner (Sirtex): Treatment with Y-90 Resin Microspheres: The Sirtex Experience

12:10 – 12:30 Discussion

Lunch in Foyer Hall G, Second Floor

13:30 – 17:00



Hall D

▶ **Translation of Radiopharmaceuticals from Molecule to Man**

Chairs

G. Bormans (Leuven)

J. Barbet (Nantes)

P.H. Elsinga (Groningen)

Programme

12:00 – 13:00 Lunch in Foyer Hall G, Second Floor

13:30 – 13:50 A. Gee (London): Translation from Molecule to Man: An Overview

13:50 – 14:40 J. Knuuti (Turku): Translation of Radiopharmaceuticals for Cardiology: From Molecule to Man

14:40 – 15:00 Discussion and Panel Debate I

15:00 – 15:30 Coffee Break in Foyer Hall G, Second Floor

15:30 – 15:50 E. Hostetler (West Point): Translation of Radiopharmaceuticals for Drug Discovery and Development

15:50 – 16:40 D. Wild (Basel): Somatostatin Antagonists from Bench to Bedside

16:40 – 17:00 Discussion and Panel Debate II

09:00 – 12:30

CME

Hall F

▶ **Pharmacokinetic Modelling and Dosimetry**

Chairs

B. Sattler (Leipzig)

R. Boellaard (Amsterdam)

M.W. Konijnenberg (Rotterdam)

Programme

- 09:00 – 09:45 G. Glatting (Mannheim): From Time Activity Measurements to Time Integrated Activity Coefficients
- 09:45 – 10:30 A.A. Lammertsma (Amsterdam): Physiologically-based PK Modelling for PET incl. Tumour, Brain, Cardiac Applications
- 10:30 – 11:00 Coffee Break in Foyer Hall G, Second Floor
- 11:00 – 11:30 P. Kletting (Ulm): Physiologically-based PK Modelling for Radiopharmaceutical Dosimetry in Molecular Radiotherapy incl. MoAbs and Peptides
- 11:30 – 11:55 K. Sjögren Gleisner (Lund): PK Modelling for Assessment of Tissue Accumulation in Molecular Immunotherapy
- 11:55 – 12:20 B. Sattler (Leipzig): Radiopharmaceutical Dosimetry – F18 Brain PET as an Example Application; Imaging Protocol and Data Analysis
- 12:20 – 12:30 Discussion: Controversies in PKM and Dosimetry – When is PKM required? When is Dosimetry required?

Lunch in Foyer Hall G, Second Floor

13:30 – 17:00

CME

Hall F

▶ **Translational Molecular Imaging to Support Drug Development**

Chairs

R. Boellaard (Amsterdam)

A. Gee (London)

Programme

- 12:00 – 13:00 Lunch in Foyer Hall G, Second Floor
- 13:30 – 13:50 A. Ussi (EATRIS): Overview of Aims and Organisation of EATRIS Infrastructure
- 13:50 – 14:20 G.A.M.S. van Dongen (Amsterdam): The Need for Translation and Quantitative Imaging
- 14:20 – 14:50 B.M. Zeglis (New York): Overview of 89Zr PET Applications
- 14:50 – 15:00 Discussion
- 15:00 – 15:30 Coffee Break in Foyer Hall G, Second Floor
- 15:30 – 15:50 C. Halldin (Stockholm): Overview of Small Molecule Tracers to Support Drug Development
- 15:50 – 16:10 M. Lub-de Hooge (Groningen): Quality Aspects (GMP Facilities)
- 16:10 – 16:30 R. Boellaard (Amsterdam): Introduction of the EARL/EATRIS 89Zr-PET/CT Accreditation Programme
- 16:30 – 16:50 G. Glatting (Mannheim): PK/PD Modelling / PET Dosimetry Aspects / Justification of Programme
- 16:50 – 17:00 Discussion

Do.MoRe – 6th International Symposium on DOsimetry and MOlecular Radiotherapy

during the 28th Annual Congress of the European Association of Nuclear Medicine in Hamburg, Germany, October 10– 14, 2015

The format of the dosimetry and therapy meeting has evolved from a series of interesting and important Radiopharmaceutical and dosimetry symposia held approximately every 5 years since 1970. This series was continued at the EANM congresses 2004 (Helsinki), 2006 (Athens), Milano (2012) and the SNM congress 2009 (Toronto). The last meeting was held in conjunction with the EANM congress in Gothenburg, Sweden in 2014 ("5th International Symposium on Targeted Radiotherapy and Radiopharmaceutical Dosimetry" – ISTARD). From this year onwards these symposia will be organised annually and, in order to emphasize this, the name has changed to Do.MoRe.

As a separate track within the EANM congress, this symposium will aim to bring together all disciplines concerned with Radiopharmaceutical Dosimetry, Physics, Radiobiology and Molecular Radiotherapy stimulating interdisciplinary scientific discussion.

As a prelude to Do.MoRe, a pre-symposium will be organised on dosimetry developments within the camera systems, radiopharmaceutical, and software industry, focusing on the quantification, clinical use of dosimetry and image reconstruction.

The EANM Dosimetry, Therapy and Physics Committees coordinated the scientific programme for the meeting jointly.

Welcome to EANM 2015 in Hamburg!

Mark Konijnenberg
Glenn Flux

*Dosimetry Committee,
EANM*

Lisa Bodei

*Therapy Committee,
EANM*

Bernhard Sattler

*Physics Committee,
EANM*

Markus Luster

*Thyroid Committee,
EANM*

M2M – 2nd Molecule to Man Track on Basic and Translational Research in Molecular Imaging and Therapy

during the 28th Annual Congress of the European Association of Nuclear Medicine in Hamburg, Germany, October 10 – 14, 2015

As a separate track within the EANM congress, we aim to bring together all disciplines concerned with basic and translational research in molecular imaging and therapy, stimulating the interdisciplinary scientific discussion and educating the clinic for future developments in the field.

The format of the track consists of a series of plenary lectures, CME sessions, symposia and scientific sessions with a special focus on Basic and Translational Research. The track will run on Monday, October 12 to Wednesday, October 14 during the EANM congress.

The EANM Translational Molecular Imaging, Drug Development and Radiopharmacy Committees coordinated the scientific programme for the meeting jointly.

Welcome to EANM 2015 in Hamburg!

Marion de Jong
*Translational Molecular Imaging
Committee, EANM*

Philip Elsinga
*Radiopharmacy
Committee, EANM*

Antony Gee
*Drug Development
Committee, EANM*

Invited Speaker Sessions

Plenary Sessions

- Plenary 1: Clinical Molecular Imaging (**incl. Marie Curie Lecture**)
- Plenary 2: Therapeutic Nuclear Medicine
- Plenary 3: Targets and Probes
- Plenary 4: Highlights Lecture

Continuing Medical Education Sessions

- CME 1: Bone & Joint (Interactive): Bone Planar & Hybrid Scintigraphy: Patterns, Pearls, and Pitfalls
- CME 2: Oncology & Paediatrics & Bone and Joint: Sarcomas
- CME 3: Paediatrics & Cardiovascular: Paediatric Heart and Lung Diseases
- CME 4: Inflammation and Infection: Imaging Infection in the Immunocompromised Patient
- CME 5: Interactive: PET with Choline Tracers
- CME 6: Neuroimaging: Brain Tumours – PET vs MRI: Therapy Planning and Response Assessment
- CME 7: Physics & Paediatrics: Radiation Protection
- CME 8: Cardiovascular & EACVI: Imaging in Heart Failure: Focus on Nuclear Medicine Techniques and Clinical Implications
- CME 9: Radionuclide Therapy & Thyroid & Translational Molecular Imaging: Theranostics: What We Have and What We Can Achieve
- CME 10: Dosimetry & Translational Molecular Imaging: Preclinical Quantitative Imaging and Dosimetry
- CME 11: Radiopharmacy: New Protein Deposition Tracers
- CME 12: Drug Development & Radiopharmacy: Radiopharmaceutical Design
- CME 13: Translational Molecular Imaging & Radiopharmacy: Image Guided Surgery in Urological Malignancies
- CME 14: Drug Development & Translational Molecular Imaging: Multimodal Imaging Agents

Continuing Technologist Education Sessions

- CTE 1: Brain Imaging (Tech Guide Book Launch)
- CTE 2: Interactive: Multi-Professional Discussion on Extended Competencies for Nuclear Medicine Technologists
- CTE 3: Interactive: Comprehensive PET/MRI Practice
- CTE 4: Joint Session with Inflammation & Infection Committee: Infection Imaging in Nuclear Medicine
- CTE 5: Lean Principles and Improved Departmental Management
- CTE 6: Imaging Protocols in Radionuclide Therapy
- Mini Course 1: Interactive: Signs in Nuclear Medicine Imaging
- Mini Course 2: Interactive: PET/CT Artefacts
- Mini Course 3: Interactive: SPECT/CT Artefacts

Joint Symposia

- Symposium 1: EANM/EACVI: Cost-effectiveness in Cardiac Imaging: From Theory to Practice
- Symposium 2: EANM/ETA-CRN: What the Doctor Tells and the Patient Understands – Update on Thyroid Cancer Communication
- Symposium 3: EANM/ESSO: Radioguided Surgery
- Symposium 4: EANM/EORTC: Hypoxia Imaging: A Powerful Tool to Better Understand Tumour Biology and Guide Cancer Therapy
- Symposium 5: EANM/MDS: Dopamine Transporter Imaging: Current Topics
- Symposium 6: EANM/ESTRO: Molecular PET Imaging in Adaptive Radiotherapy: Focus on Current Trends, Challenges and Solutions
- Symposium 7: EANM/EACVI/ESC: New Clinical Guidelines on Infectious Endocarditis and CIED Infections
- Symposium 8: EANM/EAU: PET Imaging of Genito-urinary Malignancies beyond Prostate
- Symposium 9: EANM/ESSR/ESSKA: Evaluation of the Painful Knee Arthroplasty
- Symposium 10: EANM/ELI: Lymphoma and PET/CT Update
- Symposium 11: EANM/ENETS: Management of Neuroendocrine Tumours
- Symposium 12: EANM/ESMI/COST: Lead Compounds in Theranostics
- Symposium 13: EANM/ESPGHAN: Paediatric Gastrointestinal Nuclear Medicine

Other Symposia

- Special Symposium: Evidence-based Medicine - Implications for Imaging Communication
- DGN-Sponsored Symposium: PET/MRI
- SNMMI Symposium: Hepatobiliary Scintigraphy in Abdominal Pain
- Committee Symposium: Neuroimaging – Counteracting Dementia: Imaging Evidence for Cognitive and Brain Reserve

Teaching Sessions

- Session 1: Anatomy Refresher and Cross-sectional Imaging: Thorax
- Session 2: Anatomy Refresher and Cross-sectional Imaging: Abdomen & Pelvis
- Session 3: Anatomy Refresher and Hybrid Imaging of the Foot and Ankle
- Session 4: The Spine: Anatomy, Pathology and Correlative Imaging
- Session 5: Interactive Quiz: Radiology and Cross-sectional Imaging
- Session 6: Interactive Quiz: Nuclear Medicine with Correlative Imaging

Pitfalls & Artefacts & Physiology Sessions (Interactive)

- Session 1: Clinical Consequences of Neuroimaging
- Session 2: Imaging in Inflammation and Infection
- Session 3: Cardiovascular: MPS, SPECT-CT, PET, Newer Techniques such as CZT and IQ SPECT

Young EANM

Young EANM Daily Forum

Join the EANM'15 Young EANM Daily Forum! Meet with your peers and learn about the EANM Young Investigator Opportunities, Research and how to get actively involved in the EANM.

The Young EANM Daily Forum lays the foundation for a continuously growing "Young EANM community", bringing together the Members of the Young EANM Committee, the Young EANM National Advisors and all Junior EANM Members attending EANM'15 Hamburg.

All young investigators are encouraged to participate and to bring their colleagues. The Forum is open to everybody who is interested in the Young EANM initiatives – including senior experts who would like to observe the discussions and meet the young talent in Nuclear Medicine.

Sunday, October 11, 2015 | 13:00 – 14:30 | Hall 8 | Level 1

Monday, October 12, 2015 | 13:00 – 14:30 | Hall 8 | Level 1

Tuesday, October 13, 2015 | 13:00 – 14:30 | Hall 8 | Level 1

Youngster Lounge

Following last year's positive reactions, we will continue to offer young participants the opportunity to meet, greet and chill-out in a dedicated area during the congress. This year the Youngster Lounge will be located in the Entrance Hall area.

The Lounge will be open to all congress participants with a junior or student registration and will be equipped with sofas, bar tables, music, soft drinks and eLearning stations.

The Youngster Lounge shall serve as a platform for networking by bringing together young professionals, but also with senior experts.

Sunday, October 11 – Tuesday, October 13, 2015

08:00 – 18:00 | Foyer Hall 18/19 | Ground Floor (Entrance Hall)

ORAL SESSIONS

101 Hall 1

08:00 – 09:30

CME 1 – Bone & Joint (Interactive): Bone Planar & Hybrid Scintigraphy: Patterns, Pearls, and Pitfalls

OP001
Patterns

G. Gnanasegaran, UK

OP002
Pearls

F. Paycha, FRANCE

OP003
Pitfalls

K. Strobel, SWITZERLAND

102 Hall 2

08:00 – 09:30

Joint Symposium 1: EANM/EACVI: Cost-effectiveness in Cardiac Imaging: From Theory to Practice

OP004
What is Cost-effectiveness: Theory and Implications/Implementation

S. S. Tan, NETHERLANDS

OP005
Cost-effectiveness of the Different Myocardial (Perfusion) Imaging Techniques

S. E. Petersen, UK

103 Hall 4

08:15 – 09:45

CTE 1: Brain Imaging (Tech Guide Book Launch)

OP006
Imaging in Oncological Brain Diseases (PET/CT)

G. Testanera, ITALY

OP007
Tracers for Brain Imaging

A. Socan, SLOVENIA

OP008
Principles of Functional Brain Imaging with Radiotracers

A. Signore, ITALY

105 Hall G2

08:00 – 09:30

Do.MoRe: PRRT Treatment Planning

OP009
Investigation on the number of PET measurements needed for accurate prediction of therapeutic biodistribution in PRRT

D. Hardiansyah^{1,2}, W. Guo¹, P. Kletting³, B. Müller⁴, F. Mottaghy⁴, G. Glatting¹; ¹Medical Radiation Physics/Radiation Protection, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, GERMANY, ²Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, GERMANY, ³Klinik für Nuklearmedizin, Universität Ulm, Ulm, GERMANY, ⁴Klinik für Nuklearmedizin, University Hospital, RWTH Aachen University, Aachen, GERMANY.

OP010
The prediction accuracy of therapeutic biodistribution in PET-based treatment planning of PRRT with different Bayesian parameter estimation methods

W. Guo¹, D. Hardiansyah^{1,2}, A. A. Attarwala^{1,2}, C. Maaß¹, G. Glatting¹; ¹Medical Radiation Physics/Radiation Protection, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, GERMANY, ²Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, GERMANY.

OP011

Fractional contribution of extrapolations after 96 h in absorbed dose calculation to kidneys in 450 patients with neuroendocrine tumours receiving ¹⁷⁷Lu-DOTATATE therapy

M. Sandstrom, U. Garske-Román, D. Granberg, A. Sundin, M. Lubberink; Nuclear medicine & PET, Uppsala University, SWEDEN.

OP012

Preliminary results of a Dosimetry-Based peptide receptor radionuclide therapy in patients with advanced neuroendocrine tumors

A. Filice¹, F. Fioroni², E. Grassi², V. Ferri², M. Casali¹, M. Roncali¹, M. Sollini³, A. Frasoldati⁴, A. Versari¹; ¹Department of Nuclear Medicine IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, ITALY; ²Medical Physics Unit, IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, ITALY; ³IRCCS MultiMedica, Sesto San Giovanni, Reggio Emilia, ITALY; ⁴Endocrinology Unit IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, ITALY.

OP013

Pre-treatment intensity of DOTATOC uptake for prediction of response to selective intravascular radionuclide therapy

T. D. Poeppel¹, H. V. Ngo¹, I. Binse¹, H. Lahner¹, N. Unger¹, A. Bellendorf¹, S. Ezziddin², A. Bockisch¹, A. Sabet¹; ¹Universitaetsklinikum Essen, Essen, GERMANY; ²Universitaetsklinikum des Saarlandes, Homburg, GERMANY.

OP014

An image based method for bone marrow dosimetry in ¹⁷⁷Lu-DOTATATE therapy

J. Svensson¹, J. Söderström², T. Magnander², E. Wikberg², B. Wängberg³, P. Bernhardt²; ¹Department of Oncology, The Sahlgrenska Academy, Sahlgrenska University Hospital, Göteborg, SWEDEN; ²Department of Radiation Physics, The Sahlgrenska Academy, Sahlgrenska University Hospital, Göteborg, SWEDEN; ³Department of Surgery, The Sahlgrenska Academy, Sahlgrenska University Hospital, Göteborg, SWEDEN.

OP015

Prediction accuracy of therapeutic biodistribution in peptide receptor radionuclide therapy: Role of patient-based treatment planning

D. Hardiansyah^{1,2}, C. Maaß¹, A. Attarwala^{1,2}, P. Kletting³, B. Müller⁴, F. Mottaghy⁴, G. Glatting¹; ¹Medical Radiation Physics/Radiation Protection, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, GERMANY; ²Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, GERMANY; ³Klinik für Nuklearmedizin, Universität Ulm, Ulm, GERMANY; ⁴Klinik für Nuklearmedizin, University Hospital, RWTH Aachen University, Aachen, GERMANY.

OP016

The variability of predicted area under the curves for different degrees of noise in PET measurements for treatment planning in peptide-receptor radionuclide therapy

D. Hardiansyah^{1,2}, W. Guo¹, P. Kletting³, B. Müller⁴, F. Mottaghy⁴, G. Glatting¹; ¹Medical Radiation Physics/Radiation Protection, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, GERMANY; ²Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, GERMANY; ³Klinik für Nuklearmedizin, Universität Ulm, Ulm, GERMANY; ⁴Klinik für Nuklearmedizin, University Hospital, RWTH Aachen University, Aachen, GERMANY.

108

Hall E

08:00 – 09:30

Pitfalls & Artefacts & Physiology – Interactive: Clinical Consequences of Neuroimaging

OP017

Value and Pitfalls of Neuroimaging in a Memory Clinic

B. N. M. van Berckel, NETHERLANDS

OP018

Value and Pitfalls of Neuroimaging in a Primary Care Setting

A. Fellgiebel, GERMANY

OP019

Value and Pitfalls of Neuroimaging in Preclinical Stages of Dementia

F. Jessen, GERMANY

201/203 Hall 1

10:00 – 11:15

**Plenary 1: Clinical Molecular Imaging
(incl. Marie Curie Lecture)**

OP020

Marie Curie Lecture: Prostate Cancer

S. Fanti, ITALY

OP021

**Imaging of Atherosclerosis: Translation from
Research to Practice**

J. H. F. Rudd, UK

OP022

**Neuroimaging - Mandatory Biomarker in Dementia
Assessment?**

P. Scheltens, NETHERLANDS

301 Hall 1

11:30 – 13:00

**CME 2 – Oncology & Paediatrics & Bone and
Joint: Sarcomas**

OP023

**Molecular Imaging in Bone Sarcomas: Implementing
the Role of PET/CT**

E. Lopci, ITALY

OP024

**Enchondroma, Osteochondroma, Chondrosarcoma:
A Multimodality Imaging Challenge**

F. Paycha, FRANCE

OP025

Soft Tissue Sarcomas, Role of PET/MR

F. Giammarile, FRANCE

302 Hall 2

11:30 – 13:00

**Joint Symposium 2: EANM/ETA-CRN:
What the Doctor Tells and the Patient
Understands – Update on Thyroid Cancer
Communication**

OP026

**The New American Thyroid Association Guidelines on
the Diagnosis and Management of Thyroid Nodules
and Differentiated Thyroid Cancer: a Summary of the
European Perspective and Commentaries**

M. Hoffmann, AUSTRIA

OP027

Patient Information in Thyroid Cancer

J. Taylor, UK

OP028

Patient Information in General Oncology

W. T. van der Graaf, NETHERLANDS

303 Hall 4

11:30 – 13:00

**CTE 2 – Interactive: Multi-Professional
Discussion on Extended Competencies for
Nuclear Medicine Technologists**

OP029

How It All Began: 1999 Competencies

J. A. Jorge, SWITZERLAND

OP030

**How It All Developed: Advance Practice and
Interaction with External Societies**

G. Testanera, ITALY

OP031

**Adapting to the Future: EANM-TC Document on
Competencies**

P. Fragoso Costa, GERMANY

304

Hall G1

11:30 – 13:00

Special Symposium: Evidence-based Medicine – Implications for Imaging Communication

OP032

Evidence-based Imaging - The Editor's View

D. Delbeke, USA

OP033

Evidence for Advanced Imaging in Radiotherapy Practice - The Clinician's View

U. Nestle, GERMANY

OP034

Beyond RECIST: Progressing Advanced MRI Applications into Clinical Practice

D. M. Koh, UK

305

Hall G2

11:30 – 12:45

Do.MoRe: Novel Therapies

OP035

First-in-man experience of CXCR4-directed endoradiotherapy with ¹⁷⁷Lu- and ⁹⁰Y-labelled pentixather in heavily pretreated multiple myeloma with extensive intra- and extramedullary disease

K. Herrmann¹, M. Schottelius², C. Lapa¹, A. Poschenrieder², H. Hänscheid¹, U. Keller², A. Schirbel¹, S. Kropf³, A. K. Buck¹, S. Knop¹, H. Einsele¹, H. Wester²; ¹Universitätsklinikum Würzburg, Würzburg, GERMANY, ²Technische Universität München, München, GERMANY, ³Scintomics GmbH, Fürstfeldbruck, GERMANY.

OP036

Radionuclide treatment with ⁶⁴Cu-Cl2 in patients with progressive malignant gliomas.

E. Capasso, Jr.¹, M. C. Valentini², S. Mirzaei³, P. Knoll³, C. Meleddu¹; ¹U.O.C. Nuclear Medicine, Cagliari, ITALY, ²S.C. Neuroradiology, C.T.O., Turin, ITALY, ³Department of Nuclear Medicine with PET-Center, Wilhelminenspital, Vienna, AUSTRIA.

OP037

Clinical Feasibility and Effectiveness of Intraperitoneal Radionuclide Therapy with Lu-177 3BP-227 in Metastatic Adenocarcinoma of Pancreas

A. Singh¹, H. Kulkarni¹, C. Schuchardt¹, S. Wiessalla¹, M. Sayeg¹, I. Klette¹, F. Osterkamp², U. Reineke², C. Smerling², R. P. Baum¹; ¹Zentralklinik Bad Berka, THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging (PET/CT), Bad Berka, GERMANY, ²3B Pharmaceuticals GmbH, Berlin, GERMANY.

OP038

Nanovectorized radiotherapy by convection-enhanced delivery (CED), a promising strategy that demonstrates high efficacy in a murine model of human endometrial adenocarcinoma.

A. Genin^{1,2,3}, C. Lefebvre-Lacoeuille^{1,3,2}, J. Rousseau^{4,5}, N. Chouin^{4,5}, P. Fosse⁶, D. Dabli⁶, F. Bouchet⁶, N. Lepareur⁷, P. Descamps^{1,3}, F. Hindré^{1,8,2}, O. F. Couturier^{1,6,2}, F. Lacoeuille^{1,2,6}; ¹LUNAM Université, Angers, FRANCE, ²Inserm UMR5_1066 MINT, Angers, FRANCE, ³Department of Obstetrics and Gynaecology, CHU Angers, Angers, FRANCE, ⁴LUNAM Université, Nantes, FRANCE, ⁵AMaROC, ONIRIS, Nantes, FRANCE, ⁶Nuclear Medicine Department, CHU Angers, Angers, FRANCE, ⁷Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, FRANCE, ⁸PRIMEX Plateforme de Radiobiologie et d'Imagerie Expérimentale, Angers, FRANCE.

OP039

Tumour-Absorbed Dose for Patients in a Phase I study undergoing antibody-radionuclide-conjugate (ARC) therapy with ¹⁷⁷Lu-DOTA-HH1

C. Stokke¹, A. Løndalen², J. Blakkisrud¹, J. Dahle³, T. Bach-Gansmo², J. Høltedahl¹, A. Martinsen¹, B. Bolstad³, H. Holte⁴, A. Kolstad⁴; ¹The Intervention Centre, Oslo University Hospital, Oslo, NORWAY, ²Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY, ³Nordic Nanovector ASA, Oslo, NORWAY, ⁴Department of Oncology, Radiumhospitalet, Oslo University Hospital, Oslo, NORWAY.

OP040

Preliminary Dosimetry Results from a Phase II Study Evaluating the Efficacy and Safety of Ultratrace® Iobenguane I 131 in Patients with Relapsed/Refractory Malignant Pheochromocytoma/Paraganglioma

D. A. Pryma¹, C. Jimenez², B. Chin³, J. R. Olsen⁴, M. H. Pampaloni⁵, L. B. Solnes⁶, J. Stubbs⁷, T. Armor⁸, J. D. Jensen⁸, V. Wong⁸; ¹Hospital of the University of Pennsylvania, Philadelphia, PA, UNITED STATES, ²University of Texas M.D. Anderson Cancer Center, Houston, TX, UNITED STATES, ³Duke University Medical Center, Durham, NC, UNITED STATES, ⁴Washington University School of Medicine, St. Louis, MO, UNITED STATES, ⁵University of California, San Francisco, San Francisco, CA, UNITED STATES, ⁶Johns Hopkins University, Baltimore, MD, UNITED STATES, ⁷Radiation Dosimetry Systems, Inc., Milton, GA, UNITED STATES, ⁸Progenics Pharmaceuticals, Inc, Tarrytown, NY, UNITED STATES.

OP041

Lu-177-Trastuzumab as a potential radiopharmaceutical for targeted radionuclide therapy of HER2/neu expressing metastatic breast cancer patients: feasibility study

J. Shukla, P. Bhusari, R. Vatsa, M. Parmar, G. Singh, B. R. Mittal; Post Graduate Institute of Medical Education & Research, Chandigarh, INDIA.

306

Hall 6

11:30 – 12:45

Physics & Instrumentation & Data Analysis: PET/MR

OP042

Multiparametric characterization of early tumour response using PET/MR in patients with lung cancer using a voxelwise analysis.

A. M. E. Engberg, A. E. Hansen, S. W. Langer, H. H. Johannesen, N. H. Langer, M. Nørgaard, J. Löfgren, S. H. Keller, L. Højgaard, A. Kjær, B. M. Fischer; Rigshospitalet, Copenhagen, DENMARK.

OP043

Yttrium-90 PET/MRI is superior to Bremsstrahlungs-SPECT/CT in treatment verification after selective internal radiotherapy - initial results

A. P. Bellendorf¹, B. Gomez¹, J. Schelhorn², A. Sabet¹, S. P. Müller¹, H. V. Ngo¹, A. Bockisch¹, T. D. Poeppel¹; ¹University Hospital Essen, Department of Nuclear Medicine, Essen, GERMANY, ²University Hospital Essen, Germany, Institute for Diagnostic and Interventional Radiology and Neuroradiology, Essen, GERMANY.

OP044

Lean body mass estimation from standard, Dixon-based attenuation correction in combined PET/MRI

I. Rausch¹, P. Rust², M. D. DiFranco¹, M. Lassen¹, A. Stadlbauer³, M. E. Mayerhöfer³, M. Hartenbach⁴, T. Beyer¹; ¹Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA, ²Department of Nutritional Sciences, University of Vienna, Vienna, AUSTRIA, ³Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA, ⁴Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA.

OP045

Semi-quantitative assessment of 18F FDG uptake in the normal skeleton using simultaneous PET/MRI: initial comparison to PET/CT in 50 patients

G. Xu, R. Minamimoto, A. Quon, E. Mittra, A. Iagaru; Stanford University School of Medicine, STANFORD, CA, UNITED STATES.

OP046

Evaluation of the influence of truncation artifacts using in-vivo based quantification accuracy methods in combined PET/MRI

J. Maus¹, G. Schramm^{2,1}, F. Hofheinz¹, L. Oehme³, A. Lougovski¹, J. Petr¹, I. Platzek⁴, B. Beuthien-Baumann³, J. Steinbach¹, J. Kotzerke³, J. van den Hoff^{1,3}; ¹PET Center, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, GERMANY, ²Medical Imaging Research Center, KU Leuven, Leuven, BELGIUM, ³Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, GERMANY, ⁴Department of Radiology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, GERMANY.

OP047

Improvements in PET Image quality from TOF PET/MRI

R. Minamimoto, M. Jamali, A. Barkhodari, D. Holley, G. Zaharchuk, C. Levin, A. Iagaru; Stanford University, STANFORD, CA, UNITED STATES.

307

Hall F

11:30 – 13:00

Neurosciences: Basic Neuroscience

OP048

In vivo evaluation of [¹¹C]preladenant for imaging of adenosine A_{2A} receptors in the conscious monkey

X. Zhou¹, E. de Vries¹, K. Ishiwata², R. Dierckx¹, S. Nishiyama³, H. Tsukada³, P. Elsinga¹; ¹University Medical Center Groningen, Groningen, NETHERLANDS, ²Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, Tokyo, JAPAN, ³Central Research Laboratory, Hamamatsu Photonics K.K., Hamamatsu, JAPAN.

OP049

Sigma-1 and dopamine D2 receptor occupancy of the dopamine stabilizer pridopidine in the brain of living rats

K. Sahlholm¹, J. W. A. Sijbesma², B. Maas², C. Kwizera², N. K. Ramakrishnan², R. A. J. O. Dierckx², P. H. Elsinga², A. Van Waarde²; ¹Department of Neuroscience, Karolinska Institute, Stockholm, SWEDEN, ²University of Groningen, University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, Groningen, NETHERLANDS.

OP050

PET/MR hybrid scanner imaging of cerebral blood flow using 15O-water positron emission tomography and arterial spin labeling magnetic resonance imaging in newborn piglets

J. B. Andersen¹, W. Henning¹, U. Lindberg², C. N. Ladefoged¹, L. Højgaard¹, G. Greisen³, I. Law¹; ¹Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, University of Copenhagen, Denmark, København Ø, DENMARK, ²Functional Imaging Unit, Rigshospitalet, Glostrup Hospital, University of Copenhagen, Denmark, København Ø, DENMARK, ³Department of Neonatology, Rigshospitalet, University of Copenhagen, Denmark, København Ø, DENMARK.

OP051

PET Imaging of Tau Pathology in two Transgenic Mouse Models using [¹⁸F]-THK-5117

M. Brendel¹, A. Jaworska², F. Probst¹, F. Overhoff¹, J. Carlsen¹, S. Lindner¹, J. Herms², P. Bartenstein¹, N. Okamura³, A. Rominger¹; ¹University of Munich, Munich, GERMANY, ²DZNE, Munich, GERMANY, ³Tohoku University, Sendai, JAPAN.

OP052

Altered brain serotonergic neurotransmission and glucose metabolism in an original mouse model of synucleinopathy

E. Levigoureux¹, C. Bouillot², T. Baron³, L. Zimmer¹, S. Lancelot¹; ¹Université Claude Bernard Lyon 1, Lyon, FRANCE, ²CERMEP-Imaging Platform, Lyon, FRANCE, ³ANSES, Lyon, FRANCE.

OP053

Longitudinal Imaging of Acute Neuroinflammation with [¹¹C]PBR28 in an Ischemic Stroke Rat Model

M. Tóth¹, P. Little^{1,2}, F. Arnberg^{1,2,3}, J. Häggkvist¹, J. Mulder⁴, A. Varrone¹, C. Halldin^{1,5}, B. Gulyás^{1,5}, S. Holmin^{1,2}; ¹Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, SWEDEN, ²Karolinska University Hospital, Department of Neuroradiology, Stockholm, SWEDEN, ³Karolinska University Hospital, Department of Radiology, Stockholm, SWEDEN, ⁴Karolinska Institutet, Department of Neuroscience, Stockholm, SWEDEN, ⁵Imperial College-NTU, Lee Kong Chian School of Medicine, Singapore, SINGAPORE.

OP054

Evaluation of the effect of radiotherapy on neuronal integrity in rats using [¹¹C]flumazenil PET

A. Parente, D. Vallez Garcia, P. van Luijk, J. A. Langendijk, R. A. J. O. Dierckx, J. Doorduyn, E. F. J. de Vries; RUG, Groningen, NETHERLANDS.

OP055

Inverse translation of PET auditory system activation studies to rats using F-18-FDG PET

M. Mamach^{1,2}, G. Berding^{1,2}, J. P. Bankstahl¹, F. Wilke¹, L. Geworski¹, F. M. Bengel¹, S. Kurt^{1,2}; ¹Medical School, Hannover, GERMANY, ²Cluster of Excellence "Hearing4All", Oldenburg, GERMANY.

309

Hall 8

11:30 – 13:00

Clinical Oncology: Gastroesophageal & Colorectal Cancer

OP056

18F-FDG PET/CT as Predictive of Response after Chemoradiation in Esophageal Cancer Patients

E. Elimova, X. Wang, E. C. Etchebehere, Y. Shimodaira, H. Shiozaki, R. Wadhwa, V. Planjery, N. Charalampakis, M. A. Blum, W. Hofstetter, J. Lee, B. R. Weston, M. S. Bhutani, H. A. Macapinlac, J. A. Ajani; The University of Texas MD Anderson Cancer Center, Houston, TX, UNITED STATES.

OP057

Diagnostic performance of 18F-fluorothymidine PET/CT for primary gastric cancer and its lymph node metastasis: Comparison with 18F-fluorodeoxyglucose PET/CT

M. Nakajo¹, Y. Kajiya², A. Tan², M. Jinguji¹, Y. Nakabeppu¹, M. Nakajo², S. Shimaoka³, T. Nihara³, S. Tanaka⁴, T. Yoshiura¹; ¹Department of Radiology, Kagoshima University, Graduate School of Medical and Dental Sciences, Kagoshima, JAPAN, ²Department of Radiology, Nanpuh Hospital, Kagoshima, JAPAN, ³Department of Gastroenterology, Nanpuh Hospital, Kagoshima, JAPAN, ⁴Department of Pathology, Nanpuh Hospital, Kagoshima, JAPAN.

OP058

Role of 18F-FDG PET/CT in predicting pathologic response to neoadjuvant chemo-radiotherapy and survival in patients of non-metastatic esophageal and gastro-esophageal junction carcinoma

A. Pruthi¹, S. Taywade², P. S. Choudhury²; ¹Sir Ganga Ram Hospital and Research Centre, New Delhi, INDIA, ²Rajiv Gandhi Cancer Institute & Research Centre, New Delhi, INDIA.

OP059

Recurrence Detection in Pancreatic Cancer: The Value of Quantitative FDG-PET/CT

J. T. Friis¹, O. S. Bjerring², M. G. Hildebrandt¹, S. Hess¹, O. Gerke¹, P. F. Højlund-Carlsen¹; ¹Dept. of Nuclear Medicine, Odense University Hospital, Odense C, DENMARK, ²Dept. of Surgery, Odense University Hospital, Odense C, DENMARK.

OP060

Contribution of 18F-FDG PET/CT in patients suspected for colorectal cancer recurrence, with normal or increased CEA.

H. Balink¹, E. van der Zee¹, J. P. E. N. Pierie¹, R. J. Bennink², H. J. Verberne¹; ¹Medical Center Leeuwarden, Leeuwarden, NETHERLANDS, ²Academic Medical Center, University of Amsterdam, Amsterdam, NETHERLANDS.

OP061

Evaluating Quantitative Measures in Incidental Colorectal PET Findings

T. Nguyen, S. Hess, H. Petersen, P. F. Højlund-Carlsen; Dept. of Nuclear Medicine, Odense University Hospital, Odense, DENMARK.

OP062

18F-FDG PET/CT versus CT evaluation of treatment response in patients with metastatic colorectal cancer receiving chemotherapy with a monoclonal antibody (bevacizumab or cetuximab)

Z. Nemeth¹, Z. Lengyel², K. Boér¹, E. Hitre³, K. Borbély³; ¹Szent Margit Hospital, Budapest, HUNGARY, ²Pozitron-Diagnosztika Kft, Budapest, HUNGARY, ³National Institute of Oncology, Budapest, HUNGARY.

OP063

Comparison of 18F-FDG PET-CT to conventional CT imaging in providing optimal pre-treatment staging in patients with incidentally diagnosed gall bladder cancer.

N. JAIN, J. Bal, C. Nagpal, B. Rajashekharrao, A. Velumani; Nuclear Healthcare Limited, Delhi, INDIA.

310

Hall D

11:30 – 13:00

Cardiovascular System: Cardiac Innervation Imaging

OP064

Variation in haplotypes of the norepinephrine transporter is not associated with sympathetic activity as measured by cardiac 123I-mIBG scintigraphy

D. O. Verschure^{1,2}, F. Baas¹, B. L. F. van Eck - Smit¹, G. A. Somsen³, H. J. Verberne¹; ¹Academic Medical Center, Amsterdam, NETHERLANDS, ²Medisch Centrum Alkmaar, Alkmaar, NETHERLANDS, ³Cardiology Centers of the Netherlands, Amsterdam, Amsterdam, NETHERLANDS.

OP065

Effect of standardization of I-123 MIBG heart-to-mediastinum ratio on the prognostic threshold: application to multicenter database of chronic heart failure

K. Nakajima¹, K. Okuda², S. Matsuo¹, T. Nakata³, S. Kinuya¹; ¹Kanazawa University Hospital, Kanazawa, JAPAN, ²Kanazawa Medical University, Uchinada, JAPAN, ³Hakodate Gryoukaku Hospital, Hakodate, JAPAN.

OP066

Proposal for a standardized method to evaluate 123I-MIBG SPECT in HF patients: importance in decision making of ICD implantation.

V. Frantellizzi, A. Farcomeni, P. Scarpato, G. A. Follacchio, S. Sollaku, N. Salvi, P. Scarpato, M. Liberatore, F. Monteleone, F. Fedele, G. De Vincentis; Sapienza University of Rome, Rome, ITALY.

OP067

Role of Myocardial Perfusion, Sympathetic Denervation, and Scar Size in Predicting Inducibility of Ventricular Arrhythmia in Ischemic Cardiomyopathy

M. T. Rijnierse, C. P. Allaart, S. De Haan, H. J. Harms, M. C. Huisman, A. M. Beek, A. A. Lammertsma, A. C. Van Rossum, P. Knaapen; VU University Medical Center, Amsterdam, NETHERLANDS.

OP068

Prognostic value of myocardial I-123 metaiodobenzylguanidine imaging in patients with atrial fibrillation

Y. Saushkina¹, Y. Lishmanov^{1,2}, I. Kisteneva¹, S. Popov¹; ¹RI Cardiology, Tomsk, RUSSIAN FEDERATION, ²National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

OP069

Cardiac sympathetic activity in 22q11 deletion syndrome

D. O. Verschure^{1,2}, E. Boot^{1,3}, T. A. van Amelsvoort⁴, J. Booij¹, B. L. F. van Eck - Smit¹, G. A. Somsen⁵, H. J. Verberne¹; ¹Academic Medical Center, Amsterdam, NETHERLANDS, ²Medisch Centrum Alkmaar, Alkmaar, NETHERLANDS, ³The Dalglish Family Hearts and Minds Clinic for Adults with 22q11.2 Deletion Syndrome, Toronto, ON, CANADA, ⁴University of Maastricht, Maastricht, NETHERLANDS, ⁵Cardiology Centers of the Netherlands, Amsterdam, NETHERLANDS.

OP070

Assessment of right ventricular sympathetic dysfunction in patients with Arrhythmogenic Right Ventricular Cardiomyopathy using 123I-Metaiodobenzylguanidin

A. Todica¹, J. Siebermair², J. Schiller¹, M. Zacherl¹, W. Fendler¹, P. Bartenstein¹, R. Wakil², M. Hacker³, S. Lehner¹; ¹Department of Nuclear Medicine - University of Munich, Munich, GERMANY, ²Medical Department I - University of Munich, Munich, GERMANY, ³Division of Nuclear Medicine - Medical University Vienna, Vienna, AUSTRIA.

OP071

Sleep-disordered breathing is associated with impaired cardiac sympathetic innervation and predict prognosis in patients with heart failure

T. Pellegrino¹, S. Paolillo², V. Piscopo², A. Boemio², R. Carotenuto², B. Russo², S. Pellegrino², G. De Matteis², P. Perrone Filardi², A. Cuocolo²; ¹Institute of Biostructures and Bioimages, Naples, ITALY, ²University of Naples - Federico II, Naples, ITALY.

YE1

Hall 8

13:00 – 14:30

Young EANM Daily Forum 1: Leadership Skills

OP071b

Welcome to Hamburg

R. Freudenberg, GERMANY

OP071c

Building a Successful Nuclear Medicine Department

S. Fanti, ITALY

OP071d

Become the Leaders of Tomorrow

I. Carrio, SPAIN

OP071e

Dealing with Stress at Work

J. Buscombe, UNITED KINGDOM

OP071f

Closing Remarks

401

CME

Hall 1

14:30 – 16:00

CME 3 – Paediatrics & Cardiovascular: Paediatric Heart and Lung Diseases

OP072

Paediatric Cardiology and Nuclear Medicine

O. Milanesi, ITALY

OP073

Paediatric Lung Scintigraphy

L. Drubach, USA

OP074

Myocardial Molecular Imaging in Paediatrics

P. Zucchetta, ITALY

402

Hall 2

14:30 – 16:00

Joint Symposium 3: EANM/ESSO: Radioguided Surgery

OP075

Sentinel Lymph Node in Breast Cancer: Why Surgeons need Isotopes

R. Audisio, UK

OP076

Sentinel Lymph Node in Breast Cancer: Imaging or not Imaging: That is the Question?

F. Giammarile, FRANCE

OP077

Sentinel Lymph Node in Melanoma: What a Clinician Expects

O. Zoras, GREECE

OP078

Sentinel Lymph Node in Melanoma: The EANM Guideline

C. Bluemel, GERMANY

403a

Hall 4

14:30 – 15:30

**Mini Course 1 – Interactive:
Signs in Nuclear Medicine Imaging**

OP079

Signs in Nuclear Medicine Imaging

G. Gnanasegaran, UK

403b

Hall 4

15:45 – 16:45

**Mini Course 2 – Interactive:
PET/CT Artefacts**

OP080

PET/CT Artefacts

L. Lezaic, SLOVENIA

403c

Hall 4

17:00 – 18:00

**Mini Course 3 – Interactive:
SPECT/CT Artefacts**

OP082

SPECT/CT Artefacts

A. C. Geão, PORTUGAL

404

Hall G1

14:30 – 16:00

**Clinical Oncology – Featured:
Prostate (PSMA)**

OP083

Upgrading and downgrading of prostate biopsy results in a phase 2 study of MIP-1404 SPECT/CT in men undergoing radical prostatectomy

K. Goffin¹, S. Joniau¹, P. Tenke², G. Dabas³, K. Slawin⁴, W. Ellis⁵, B. Alekseev⁶, I. Buzogány⁷, S. Mishugin⁸, E. Klein⁹, J. Stolz¹⁰, V. Student¹¹, P. Koranda¹², V. Matveev¹³, T. Armor¹⁴; ¹University Hospitals Leuven, Leuven, BELGIUM, ²Jahn Ferenc South Pest Hospital, Budapest, HUNGARY, ³Semmelweis University, Budapest, HUNGARY, ⁴Vanguard Urologic Institute, Houston, TX, UNITED STATES, ⁵University of Washington, Seattle, WA, UNITED STATES, ⁶Moscow Research Oncological Institute, Moscow, RUSSIAN FEDERATION, ⁷Peterfy Sandor Street Hospital, Budapest, HUNGARY, ⁸City Clinical Hospital # 57, Moscow, RUSSIAN FEDERATION, ⁹Cleveland Clinic, Cleveland, OH, UNITED STATES, ¹⁰University Hospital Motol, Prague, CZECH REPUBLIC, ¹¹University Hospital Olomouc, Olomouc, CZECH REPUBLIC, ¹²University Hospital Olomouc, Olomouc, CZECH REPUBLIC, ¹³Russian Oncology Research Center, Moscow, RUSSIAN FEDERATION, ¹⁴Progenics Pharmaceuticals, Inc., Tarrytown, NY, UNITED STATES.

OP084

Differences in biodistribution of Lu-177-DKFZ-PSMA-617 and Ga-68-DKFZ-PSMA-11 in the same patient group

O. E. SAHIN¹, J. NEMATYAZAR¹, B. RAZAVI¹, N. YEYIN¹, A. AYGUN¹, M. OCAK², E. DEMIRCI³, L. KABASAKAL¹; ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Nuclear Medicine, Istanbul, TURKEY, ²Istanbul University, Pharmacy Faculty, Department of Pharmaceutical Technology, Istanbul, TURKEY, ³Sisli Etfal Training and Research Hospital, Department of Nuclear Medicine, Istanbul, TURKEY.

OP085

(68)Ga-labelled PSMA in prostate cancer: its diagnostic value in patients with biochemical recurrence of prostate cancer

S. Vöö, A. van Kroonenburgh, F. M. Mottaghy; Maastricht University Medical Center, Maastricht, NETHERLANDS.

OP086

Pelvic Dynamic Imaging with Pixel-Based Analysis of Ga-68 PSMA PET/CT

E. Hsiao, G. P. Schembri, D. L. Bailey, E. A. Bailey, P. J. Roach; Royal North Shore Hospital, St Leonards, AUSTRALIA.

OP087

Cervical lymph node metastases is not an uncommon finding in Ga-68-DKFZ-PSMA-11 PET/CT imaging in patients with prostate cancer

J. Nematyazar¹, O. E. SAHIN¹, B. RAZAVI¹, E. DEMIRCI², A. AYGUN¹, M. OCAK³, C. OBEK⁴, A. R. KURAL⁵, L. KABASAKAL¹;
¹Department of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, TURKEY, ²Department of Nuclear Medicine, Sisli Etfal Training and Research Hospital, Istanbul, TURKEY, ³Department of Pharmaceutical Technology, Pharmacy Faculty, Istanbul University, Istanbul, TURKEY, ⁴Department of Urology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, TURKEY, ⁵Department of Urology, Acibadem University Medical Faculty, Istanbul, TURKEY.

OP088

Prospective Comparison of the detection rate of 18F-Fluoromethylcholine and 68Ga-PSMA-HBED PET/CT in men with prostate cancer with rising PSA post curative intent therapy, being considered for targeted therapy

J. Morigi^{1,2}, P. Stricker^{3,4}, P. van Leeuwen^{3,4}, R. Tang^{2,5}, B. Ho², Q. Nguyen^{3,4}, A. Hickey², D. Stark², A. Young², S. Fantl¹, L. Tarlinton², L. Emmett^{2,5};
¹Nuclear Medicine OU, Policlinico S.Orsola-Malpighi / University of Bologna, Bologna, ITALY, ²Department of Diagnostic Imaging, St Vincent's Public Hospital, Sydney, NSW, AUSTRALIA, ³St Vincent's Prostate Cancer Centre, St Vincent's Clinic, Sydney, NSW, AUSTRALIA, ⁴Australian Prostate Cancer Research Centre – New South Wales, The Garvan Institute of Medical Research/ The Kinghorn Cancer Centre, Sydney, NSW, AUSTRALIA, ⁵University of New South Wales (UNSW), Sydney, NSW, AUSTRALIA.

405

Hall G2

14:30 – 16:00

Do.MoRe – Featured: Endocrine & Neuroendocrine Tumours

OP089

Ac-225-DOTATOC - dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors

C. Kratochwil¹, F. Bruchertsefert², F. L. Giesel¹, C. Apostolidis², U. Haberkorn¹, A. Morgenstern²;
¹University Hospital Heidelberg, Heidelberg, GERMANY, ²European Commission - Joint Research Centre, Institute for Transuranium Elements, Karlsruhe, GERMANY.

OP090

Optimal sampling schedule: accurate estimation of time-integrated activity coefficients in peptide receptor radionuclide therapy (PRRT)

C. Maaß¹, J. Sachs¹, D. Hardiansyah¹, P. Kletting², F. M. Mottaghy³, G. Glatting¹;
¹Medical Radiation Physics/ Radiation Protection, Medical Faculty Mannheim, Heidelberg University, Mannheim, GERMANY, ²Department of Nuclear Medicine, Ulm, GERMANY, ³Department of Nuclear Medicine, Aachen, GERMANY.

OP091

The intensity of 18FDG uptake is not a surrogate marker of morphological tumor progression in patients with metastatic differentiated thyroid cancer.

M. TERROIR, I. Borget, F. Bidault, D. Deandreis, A. Al Ghuzlan, D. Hartl, M. Ricard, A. Berdelou, L. Derle, J. Lumbroso, E. Baudin, M. Schlumberger, S. Leboulleux; Gustave Roussy, Villejuif, FRANCE.

OP092

Assessment of lesion response in differentiated thyroid cancer patients undergoing radioiodine treatment using 124I PET/CT

R. Wiers¹, B. Brans¹, B. Havekes¹, S. G. E. A. Halders¹, F. M. Mottaghy^{1,2}, W. Jentzen³;
¹Maastricht University Medical Center, Maastricht, NETHERLANDS, ²University Hospital RWTH Aachen University, Aachen, GERMANY, ³Klinik für Nuklearmedizin, Universität Duisburg-Essen, Essen, GERMANY.

OP093

Bone marrow dosimetry assessed with quantitative SPECT/CT is predictive of subacute thrombocytopenia following ¹⁷⁷Lu-octreotate PRRT

M. E. Marcotte, M. Del Prete, E. O. Gaudin, F. A. Buteau, P. Després, J. M. Beauregard; Université Laval, Quebec City, QC, CANADA.

OP094

Comparison of quantitative ¹⁷⁷Lu measurements in European hospitals

A. Fenwick¹, J. Merrett^{2,1,3}, L. Johansson¹;
¹National Physical Laboratory, Teddington, UNITED KINGDOM, ²University of Surrey, Guildford, UNITED KINGDOM, ³Royal Surrey County Hospital, Guildford, UNITED KINGDOM.

406

Hall 6

14:30 – 16:00

Teaching Session: Anatomy Refresher and Cross-sectional Imaging: Thorax

OP095

Anatomy Refresher and Cross-sectional Imaging: Thorax

C. Fowler, UNITED KINGDOM

407

Hall F

14:30 – 16:00

Radiopharmaceuticals & Radiochemistry: Radiochemistry – Methods

OP096

Enabling Research on Epilepsy through a New and Efficient Synthesis of [18F]UCB-H, a PET Tracer for the Imaging of SV2A

C. Warnier^{1,2}, C. Lemaire^{1,2}, J. Aerts^{1,2}, J. Mercier³, A. Plenevaux^{1,2}, A. Luxen^{1,2}; ¹University of Liege, Liege, BELGIUM, ²Cyclotron Research Centre, Liege, BELGIUM, ³UCB Pharma, Braine-L'Alleud, BELGIUM.

OP097

Radiolabeling of proteins using radiofluorinated nitrile oxides

P. Krapf^{1,2}, B. D. Zlatopolskiy^{1,2}, R. Kandler², B. Neumaier^{3,2,1}; ¹University Clinic of Cologne, Cologne, GERMANY, ²Max-Planck-Institute for metabolism research, Cologne, GERMANY, ³Forschungszentrum Jülich GmbH, Jülich, GERMANY.

OP098

Synthesis of PET tracers via SN2 radiofluorination under “minimalist” conditions

M. A. Omrane, B. D. Zlatopolskiy, E. A. Urusova, R. Richarz, P. Krapf, B. Neumaier; Institute of Radiochemistry and Experimental Molecular Imaging, Cologne, GERMANY.

OP099

Carbonylation via Conversion of [11C]CO₂ into [11C]CO Mediated by [11C]Silane Derivatives

C. Taddei, S. Bongarzone, A. Haji Dheere, A. D. Gee; The Rayne Institute, London, UNITED KINGDOM.

OP100

Synthesis and in vivo evaluation of a novel peptide-based N3S1 chelator for 99mTc-labeled radiotracer with enhanced renal clearance

D. Lee, K. Choi; Korea Atomic Energy Research Institute, Jeongeup, KOREA, REPUBLIC OF.

OP101

Influence of a novel, versatile bifunctional chelator on radiolabelling, pharmacological and targeting properties of a minigastrin analogue for molecular imaging and therapy applications

J. Pfister¹, D. Summer¹, C. Rangger¹, M. Petrik², E. von Guggenberg¹, P. Minazzi³, G. B. Giovenzana⁴, C. Decristoforo¹; ¹Medical University Innsbruck, Innsbruck, AUSTRIA, ²Institute of molecular and translational medicine, Faculty of medicine and dentistry, Palacky University, Olomouc, CZECH REPUBLIC, ³CAGE Chemicals srl, Novara, ITALY, ⁴DSF, Università del Piemonte Orientale “A. Avogadro”, Novara, ITALY.

OP102

Evaluation of configurationally restricted copper-64 labelled bis tetraazamacrocyclic as potential PET agents for CXCR4 expression in oncology imaging

G. S. Clemente, B. P. Burke, S. Nigam, C. Cawthorne, S. J. Archibald; University of Hull, Hull, UNITED KINGDOM.

OP103

Efficient production of PET tracers on a preparative scale via copper-mediated radiofluorination under “minimalist” conditions

J. Zischler^{1,2,3}, B. D. Zlatopolskiy^{1,3}, P. Krapf^{1,3}, F. Zarrad^{1,2,3}, E. A. Urusova^{1,3}, E. Kordys^{1,3}, H. Endepols^{1,3}, B. Neumaier^{1,2,3}; ¹University Clinic Cologne, Cologne, GERMANY, ²Forschungszentrum Jülich GmbH, Jülich, GERMANY, ³Max-Planck Institute for Metabolism Research, Cologne, GERMANY.

408

Hall E

14:30 – 16:00

Conventional & Specialised Nuclear Medicine: Infection & Inflammation

OP104

[18F]DPA-714 as a biomarker for an early detection with PET imaging of synovium inflammation in osteoarthritis model

S. Pesnel¹, F. Gimié¹, V. Meneyrol¹, G. Pottier², S. Bénard¹, R. Boisgard², F. Dollé², E. Jestin^{1,3,4}; ¹GIP CYROI - RIPA, Sainte Clotilde, RÉUNION, ²CEA, I2BM, SHFJ, IMIV UMR 1023 Inserm/CEA/Université Paris Sud /CNRS, Orsay, FRANCE, ³INSERM, UMR1 188 DeTROi, Sainte Clotilde, RÉUNION, ⁴Université de la Réunion, Sainte Clotilde, RÉUNION.

OP105

Liposomal corticosteroid treatment of experimental arthritis can be monitored non-invasively with radiolabeled anti-FAP antibodies

T. van der Geest¹, D. Gerrits¹, J. M. Metselaar^{2,3}, G. Storm^{2,4}, T. K. Nayak⁵, A. Freimoser-Grundschober⁶, C. Klein⁶, B. Walgreen⁷, M. M. Helsen⁷, M. I. Koenders⁷, P. Laverman¹, O. C. Boerman¹; ¹Department of Radiology and Nuclear Medicine, Radboud university medical center, Nijmegen, NETHERLANDS, ²Department of Targeted Therapeutics, MIRA Institute, University of Twente, Enschede, NETHERLANDS, ³Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH-Aachen University, Aachen, GERMANY, ⁴Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, NETHERLANDS, ⁵Roche Pharmaceutical Research and Early development, Innovation Center Basel, Basel, SWITZERLAND, ⁶Roche Pharmaceutical Research and Early development, Innovation Center Zurich, Schlieren, SWITZERLAND, ⁷Department of Experimental Rheumatology, Radboud university medical center, Nijmegen, NETHERLANDS.

OP106

Tc-99m-CXCL8 SPECT to image disease activity in inflammatory bowel disease

E. Aarntzen, D. De Jong, R. Hermesen, J. Drenth, O. Boerman, W. Oyen; Radboudumc, Nijmegen, NETHERLANDS.

OP107

Role of 18F-FDG PET/CT in the evaluation of response to antibiotic therapy in patients affected by infectious spondylodiscitis

F. Simone, A. Niccoli Asabella, D. Rubini, A. Notaristefano, F. Iuele, G. Rubini; Nuclear Medicine Unit, D.I.M., University of Bari "Aldo Moro", Bari, Italy, Bari, ITALY.

OP108

The role of 18FDG-PET/CT for interim evaluation of therapy response in spondylodiscitis

P. Ghedini¹, C. Nanni¹, I. Petri¹, L. Zanon¹, I. Grassi¹, S. Cambioli¹, D. Fiorenzo², S. Fanti¹; ¹Nuclear Medicine, University Hospital S. Orsola-Malpighi, Bologna, ITALY, ²Department of Diagnostic Imaging, University Hospital S. Orsola-Malpighi, Bologna, ITALY.

OP109

A Direct Comparison of 18F-FDG and 68Ga-DOTANOC PET/CT for Detection of Cardiac Sarcoidosis: Diagnostic Accuracy and Inter-observer Variability

L. C. Gormsen, A. Haraldsen, S. Kramer, W. Kim, P. Borghammer; Aarhus University Hospital, AARHUS C, DENMARK.

OP110

Comparison between ¹⁸F-FDG PET/CT and ^{99m}Tc-HMPAO-labelled leukocyte SPECT/CT in 50 patients with suspected osteomyelitis

P. Ferro¹, G. Cusato¹, S. Fiorino¹, M. Spallino¹, C. E. Popescu², R. Sara², L. Conversano², M. Milella², C. Rossetti²; ¹Università Milano-Bicocca, Milano, ITALY, ²Ospedale Niguarda, Milano, ITALY.

OP111

The added value of 18F-FDG PET for the staging of patients with invasive fungal infections

A. O. Ankrah^{1,2}, A. W. J. M. Glaudemans¹, E. F. J. de Vries¹, R. H. J. A. Slart^{1,3}, R. A. J. O. Dierrckx¹, M. M. Sathekge², H. C. Klein⁴; ¹Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, NETHERLANDS, ²Department of Nuclear Medicine, University of Pretoria, Pretoria, SOUTH AFRICA, ³Biomedical Photonic Imaging Group, University of Twente, Enschede, NETHERLANDS, ⁴Department of Psychiatry, University Medical Center Groningen, Groningen, NETHERLANDS.

409

Hall 8

14:30 – 16:00

Physics & Instrumentation & Data Analysis: Data Analysis & Management I

OP112

Pixel-based Source Depth Measurement for Cerenkov Luminescence Imaging

L. Altabella¹, C. R. Gigliotti¹, F. Bosch², A. E. Spinelli¹; ¹San Raffaele Scientific Institute, Milano, ITALY, ²University of Verona, Verona, ITALY.

OP113

Correcting for Patient Motion on a Solid State Multiple Pinhole Dedicated Cardiac Camera

S. Redgate¹, D. C. Barber², J. W. Fenner², A. Al-Mohammad³, J. C. Taylor¹, M. B. Hanney¹, W. B. Tindale¹; ¹Nuclear Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UNITED KINGDOM, ²Medical Physics Group (Cardiovascular Science), University of Sheffield, Sheffield, UNITED KINGDOM, ³Cardiothoracic Directorate, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UNITED KINGDOM.

OP114

Partial volume correction of Image Derived Input Functions using a novel Single Target Correction Technique

*J. C. Dickson¹, K. Erlandsson², H. Sari², S. Wan¹, A. Groves²;
¹University College London Hospital NHS Foundation Trust, London, UNITED KINGDOM, ²University College London, London, UNITED KINGDOM.*

OP115

Voxel-level dosimetry with a grid-based Boltzmann solver for patient-specific nuclear medicine dosimetry

J. Mikell^{1,2}, F. Mourtada³, T. Wareing⁴, S. C. Kappadath^{1,2}; ¹UT MD Anderson Cancer Center, Houston, TX, UNITED STATES, ²UT Graduate School of Biomedical Sciences, Houston, TX, UNITED STATES, ³Christiana Care Health System, Newark, DE, UNITED STATES, ⁴Varian Medical Systems, Palo Alto, CA, UNITED STATES.

OP116

FDG-PET/CT of Bronchial Carcinoma Under Neoadjuvant Chemotherapy: Background Based Adaptive Volume Metrics Outperform TLG and MTV in Predicting Therapy Response

I. A. Burger¹, R. Casanova¹, S. Steiger¹, P. Stolzmann¹, M. W. Huellner¹, P. Veit-Haibach¹, A. Soltermann¹, C. R. Schmidtlein²; ¹University of Zurich, Zurich, SWITZERLAND, ²Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES.

OP117

Automated organ segmentation in pre-clinical 4D PET/CT images

C. Maaß¹, J. Avelar Rivas¹, A. A. Attarwala¹, B. Abualhaj¹, S. Niedermoser², C. Wängler³, G. Glatting¹; ¹Medical Radiation Physics/Radiation Protection, Medical Faculty Mannheim, Heidelberg University, Mannheim, GERMANY, ²Molecular Imaging and Radiochemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, GERMANY, ³Biomedical Chemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, GERMANY.

OP118

Does Reducing Reconstruction Voxel Volume / Increasing Matrix Size Improve Lesion Detectability? A phantom and clinical feasibility demonstration using next generation digital PET/CT

J. Zhang¹, K. Binzel¹, C. Wright¹, V. Nagar¹, P. Bardos¹, P. Maniawski², M. V. Knopp¹; ¹The Ohio State University, Columbus, OH, UNITED STATES, ²Philips Healthcare, Cleveland, OH, UNITED STATES.

OP119

A New Statistical Model For Quantifying Tumor Heterogeneity in Emission Tomography

J. Varga¹, A. Forgács^{2,1}; ¹University of Debrecen, Debrecen, HUNGARY, ²ScanoMed Ltd., Debrecen, HUNGARY.

410

Hall D

14:30 – 16:00

Cardiovascular System: PET Perfusion Imaging

OP120

Relationship Between Coronary Artery Calcium Score and Coronary Flow Reserve in Patients Evaluated for Coronary Artery Disease: a Hybrid Rb-82 PET/CT Imaging Study

E. Zampella¹, P. Arumugam², R. Assante¹, D. Tout², V. Gaudieri¹, C. Nappi¹, T. Mannarino¹, M. Panico³, S. Daniele³, W. Acampa³, M. Petretta⁴, C. Tonge², A. Cuocolo¹; ¹Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, ITALY, ²Nuclear Medicine Centre, Central Manchester University Teaching Hospitals, Manchester, UNITED KINGDOM, ³Institute of Biostructure and Bioimaging, National Council of Research, Naples, ITALY, ⁴Department of Translational Medical Sciences, University of Naples 'Federico II', Naples, ITALY.

OP121

Low-dose relative and quantitative myocardial blood flow imaging using 82Rb-PET

C. M. Hoff, E. Dul, L. P. Tolbod, H. J. Harms, K. Bouchelouche, J. Frøkiær, J. Sørensen; Aarhus University Hospital, Department of Nuclear Medicine & PET-Centre, Aarhus, DENMARK.

OP122

Attenuated Coronary Flow Reserve Early after Implantation of a Bioresorbable Vascular Scaffold: one-month results of the VANISH-trial

W. Stuijzfand, R. Driessen, P. Raijmakers, A. Lammertsma, A. van Rossum, Y. Appelman, J. Lemkes, M. van Leeuwen, N. van Royen, P. Knaapen; VU University Medical Center, Amsterdam, NETHERLANDS.

OP123

Measurement of left ventricular volumes and function using oxygen-15 labelled water gated positron emission tomography: comparison with cardiovascular magnetic resonance imaging

R. S. Driessen, J. Van Timmeren, W. J. Stuijzand, M. T. Rijniere, I. Danad, P. G. Raijmakers, A. M. Beek, A. C. Van Rossum, A. A. Lammertsma, H. J. Harms, M. C. Huisman, P. Knaapen; VU University Medical Center, Amsterdam, NETHERLANDS.

OP124

Gated PET-measured cardiac synchrony correlates with QRS duration.

L. Juárez-Orozco¹, R. H. J. A. Slart¹, R. A. Tio¹, H. Boersma¹, R. A. Dierckx¹, A. Gonzalez-Monroy¹, F. Iñarra-Talbo², E. Alexanderson²; ¹University Medical Center Groningen, Groningen, NETHERLANDS, ²Instituto Nacional de Cardiología "Ignacio Chávez", Mexico City, MEXICO.

OP125

Stress-induced Systolic Dysfunction and Subendocardial Ischemia in Left Ventricular Hypertrophy Patients With Preserved Maximal Blood Flow in Ammonia PET

R. Sciagra, H. Castagnoli, F. Cipollini, R. Calabretta, S. Passantino, I. Olivetto; University of Florence, FLORENCE, ITALY.

OP126

AQUA-5: Four Software Tools for 15O-Water PET Myocardial Perfusion Quantification Exhibit Good Intraobserver Reproducibility

S. V. Nesterov^{1,2}, K. Yoshinaga³, Y. Tomiyama³, C. Han¹, R. Sciagra⁴, V. Berti⁴, P. Knappen⁵, I. Danad⁵, J. M. Knuuti¹; ¹Turku PET Centre, Turku, FINLAND, ²Institute of Evolutionary Biochemistry and Physiology, RAS, St. Petersburg, RUSSIAN FEDERATION, ³Hokkaido University Graduate School of Medicine, Sapporo, JAPAN, ⁴Nuclear Medicine Unit of the University of Florence, Florence, ITALY, ⁵Departments of Nuclear Medicine and PET Research, of VU University Medical Center, Amsterdam, NETHERLANDS.

OP127

Spill-over effect of radioactivity from right ventricular cavity on septum in cardiac PET ¹⁵O-water study

C. Han; Turku University Central Hospital and University of Turku, TURKU, FINLAND.

501

CME

Hall 1

16:30 – 18:00

CME 4 – Inflammation and Infection: Imaging Infection in the Immunocompromised Patient

OP128

Imaging Infection in the HIV Positive

M. M. Sathegke, SOUTH AFRICA

OP129

Imaging Infection in the Immunosuppressed Patient

C. Bleeker-Rovers, NETHERLANDS

OP130

Imaging Infection in the Post-Transplant Patient

J. Buscombe, UK

502

Hall 2

16:30 – 18:00

Joint Symposium 4: EANM/EORTC: Hypoxia Imaging: A Powerful Tool to Better Understand Tumour Biology and Guide Cancer Therapy

OP131

Hypoxia as Target for Cancer Therapy

K. Williams, UK

OP132

Imaging Hypoxia: Facts and Pitfalls

M. R. Horsman, DENMARK

OP133

Experience using Hypoxia Imaging in Clinical Trials

P. Lambin, NETHERLANDS

505

Hall G2

16:30 – 18:00

Do.MoRe: Treatment of Bone Metastases

OP134

Optimization of imaging following ²²³Ra administration in targeted alpha-emitting radionuclide therapy of bone metastases.

N. Benabdallah¹, M. Bernardin², C. de Labriolle Vaylet³, D. Franck¹, A. Desbrée¹; ¹IRSN, Fontenay aux Roses, FRANCE, ²Hôpital Européen George Pompidou, Paris, FRANCE, ³Hôpital Trousseau, Paris, FRANCE.

OP135

Progress of blood capacity under Radium-223 treatment

C. Körber, N. Körber-Hafner; Nuclear Medicine Fulda, Fulda, GERMANY.

OP136

Feasibility and efficacy of ²²³Ra-dichloride in treatment of bone metastases in patients with castration-refractory prostate cancer (mCRPC)

s. mazzarri¹, G. Boni¹, E. Borsò², L. Galli³, A. Farnesi⁴, F. Betti¹, L. Antonacci¹, A. Traino⁵, S. Ricci⁶, D. Volterrani¹; ¹Regional Center Of Nuclear Medicine, University Hospital Of Pisa, Pisa, ITALY, ²Division of Nuclear Medicine, Sant'Andrea Hospital of La Spezia, La Spezia, ITALY, ³Oncology Division, University Hospital of Pisa, Pisa, ITALY, ⁴Oncology Division, University Hospital of Pisa, Pisa, ITALY, ⁵Health Physics Unit, Section of Medical Physics, University Hospital, Pisa, Italy, Pisa, ITALY.

OP137

Metastatic control probability in patients with prostate cancer metastatic to bone treated ¹⁸⁶Re-HEDP

A. M. Denis-Bacelar¹, A. Divoli², S. Chittenden², Y. Du², G. D. Flux²; ¹Institute of Cancer Research, London, UNITED KINGDOM, ²Royal Marsden Hospital, London, UNITED KINGDOM.

OP138

A DOTA conjugated Zoledronic acid derivative: A novel bone targeting theranostic compound

M. Meckel¹, R. Bergmann², W. Mohnike³, M. Miederer⁴, F. Roesch¹; ¹University of Mainz, Mainz, GERMANY, ²Helmholtz Zentrum, Dresden-Rossendorf, GERMANY, ³Diagnostisch Therapeutisches Zentrum, Berlin, GERMANY, ⁴University Hospital, Mainz, GERMANY.

OP139

Dosimetry Results of Lu-177-DKFZ-PSMA-617 Treatment in Castration Resistant Prostate Cancer Patients

N. Yeyin¹, A. Mohammad¹, L. Kabasakal¹, E. Demirci², A. Aygun¹, M. Oca³, T. Toklu⁴, H. Tanyildizi¹, N. Selcuk⁴; ¹Department of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, TURKEY, ²Department of Nuclear Medicine, Sisli Etfal Training and Research Hospital, Istanbul, TURKEY, ³Department of Pharmaceutical Technology, Pharmacy Faculty, Istanbul University, Istanbul, TURKEY, ⁴Department of Nuclear Medicine, Yeditepe University Medical School, Istanbul, TURKEY.

OP140

Peptide Radioligand Therapy (PRLT) Using Lu-177 Labeled DOTAGA-PSMA Inhibitor Yields Objective Responses in Metastatic Castrate-resistant Prostate Cancer

H. R. Kulkarni¹, A. Singh¹, C. Schuchardt¹, I. Klette¹, H. J. Wester², R. P. Baum¹; ¹THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Bad Berka, GERMANY, ²Pharmaceutical Radiochemistry, Technical University Munich, Munich, GERMANY.

OP141

Quantifying the Effect of Peptide Amount on the Biologically Effective Dose for Therapy using Lu-177 Labeled PSMA Ligands

P. Kletting¹, C. Schuchardt², H. Kulkarni², M. Sayeg², S. Wiesalla², G. Winter¹, A. Singh², R. Baum², A. Beer¹; ¹Ulm University, Department of Nuclear Medicine, Ulm, GERMANY, ²Zentralklinik Bad Berka, THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging (PET/CT), ENETS Center of Excellence, Bad Berka, GERMANY.

506

Hall 6

16:30 – 18:00

Teaching Session: Anatomy Refresher and Cross-sectional Imaging: Abdomen & Pelvis

OP142

Anatomy Refresher and Cross-sectional Imaging: Abdomen & Pelvis

C. Fowler, UNITED KINGDOM

507

Hall F

16:30 – 18:00

Clinical Oncology: Lung

OP143

18F-fluorodeoxyglucose PET/CT and Dynamic Contrast-Enhanced MRI as prognostic indicators in Malignant Pleural Mesothelioma (the SWAMP trial)

D. O. Hall¹, I. D. Lyburn¹, J. Searle¹, C. E. Hooper², N. A. Maskell³; ¹Cobalt Health, Cheltenham, UNITED KINGDOM, ²Worcester Royal Hospital, Worcester, UNITED KINGDOM, ³University of Bristol, Bristol, UNITED KINGDOM.

OP144

Respiratory-gated FMISO-PET/CT detects tumor hypoxia with higher sensitivity in non-small cell lung cancer

S. Watanabe¹, S. Okamoto¹, T. Shiga¹, T. Inoue², K. Hirata¹, K. Magota¹, K. Nishijima³, Y. Kuge³, H. Shirato², N. Tamaki¹; ¹Department of Nuclear Medicine, Hokkaido University Graduate School of Medicine, Sapporo, JAPAN, ²Department of Radiation Medicine, Hokkaido University Graduate School of Medicine, Sapporo, JAPAN, ³Central Institute of Isotope Science, Hokkaido University, Sapporo, JAPAN.

OP145

Predictive value of intratumoral metabolic heterogeneity features for early treatment failure of tyrosine kinase inhibitor in patients with EGFR mutated NSCLC

S. Ha, S. Park, S. Lee, J. Paeng, B. Keam, T. Kim, D. Kim, D. Heo; Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.

OP146

Correlation of metabolic information on PET/CT and tissue expression of HIF-1 α and CD68⁺ macrophages in surgically treated NSCLC

E. Lopci^{1,2}, F. Grizzi¹, L. Toschi¹, D. Rahal¹, L. Olivari³, F. Marchesi¹, D. Qehajaj¹, N. Cortese¹, G. Finocchiaro¹, S. Mattioli², M. Roncalli¹, S. Fanti⁴, A. Santoro¹, A. Chiti¹; ¹Humanitas Clinical and Research Hospital, Rozzano (Milano), ITALY, ²Alma Mater Studiorum University, Bologna, ITALY, ³University of Milan, Milano, ITALY, ⁴University Hospital S. Orsola-Malpighi, Bologna, ITALY.

OP147

Correlation between circulating tumor biomarkers and positron-emission tomography in advanced non-small cell lung cancer

G. Ferrarazzo¹, F. Bongioanni¹, C. Genova², M. Massollo³, G. Karalis⁴, E. Rijavec², F. Biello², G. Barletta², S. Coco², A. Alama², A. Truini², I. Vanni², G. Sambuceti¹, F. Grossi², S. Morbelli¹; ¹Nuclear Medicine Unit, IRCCS San Martino - IST, University of Genoa, Genoa, ITALY, ²Lung Cancer Unit, IRCCS San Martino - IST, Genoa, ITALY, ³Nuclear Medicine Unit, Galliera Hospital, Genoa, ITALY, ⁴PET/CT Alliance Medical, Istituto Salus, Genoa, ITALY.

OP148

Density cut off value for metastatic mediastinal and hilar lymph nodes in lung cancer patients

P. Flechsig, P. Frank, D. Rath, C. Kratochwil, H. Kauczor, U. Haberkorn, F. Giesel; University Hospital Heidelberg, Heidelberg, GERMANY.

OP149

Comparison of predicted FEV1 and observed FEV1 post lung surgery Using lung Perfusion scintigraphy

V. Rangarajan, N. Purandare, A. Agrawal, S. Shah, S. Nag, P. Ranganathan, C. S. Pramesh; Tata Memorial centre, Mumbai, INDIA.

OP150

The Relationship between Staging and SUVmax in Non-Small Cell Lung Cancer

H. Kaya¹, T. Balci², H. Komek³, M. Cengiz⁴; ¹Dicleuniversity Medical Faculty, Diyarbakir, TURKEY, ²Firat University Medical Faculty, ELAZIG, TURKEY, ³Diyarbakir State Hospital, DIYARBAKIR, TURKEY, ⁴Dicle University Medical Faculty, DIYARBAKIR, TURKEY.

508

Hall E

16:30 – 18:00

Conventional & Specialised Nuclear Medicine: Thyroid & Parathyroid

OP151

Size doesn't matter: predictive value of new quantitative analysis for differential diagnosis of primary hyperparathyroidism lesions vs. thyroid nodular disease in parathyroid scintigraphy

A. V. Koljevic Markovic^{1,2}, M. Jankovic, G. Pucić¹, R. Džodić¹; ¹National Cancer Research Center Serbia, Belgrade, SERBIA, ²Faculty of Electrical Engineering, University of Belgrade, Belgrade, SERBIA.

OP152

A prospective comparative study of parathyroid dual-phase scintigraphy, dual-isotope subtraction scintigraphy, 4D CT, and ultrasonography in primary hyperparathyroidism

M. Krakauer¹, B. Wieslander¹, P. S. Myschetzky¹, A. Lundström¹, T. Backer¹, C. H. Sørensen², W. Trolle², B. Nygaard³, F. N. Bennedbaek³; ¹Gentofte Hospital, Helleup, DENMARK, ²Rigshospitalet, Copenhagen, DENMARK, ³Herlev Hospital, Herlev, DENMARK.

OP153

Comparison of 99mTc-sestamibi/123I subtraction SPECT/CT and combined 99mTc-sestamibi/123I sub-traction SPECT/CT with planar pinhole image in hyperparathyroidism

V. Tunninen¹, P. Varjo¹, M. Seppänen²; ¹Satakunta Central Hospital, PORI, FINLAND, ²Turku University Hospital, Turku, FINLAND.

OP154

Value of 18F-Choline PET-CT in the assessment of primary hyperparathyroidism comparing with 99mTc-Sestamibi SPECT-CT

M. Beheshti¹, L. Imamovic¹, G. Spaun², M. Steinmair¹, K. Emmanuel², V. Alibegovic³, C. Pirich⁴, W. Langsteger¹; ¹PET-CT Center Linz, St. Vincent's Hospital, Linz, AUSTRIA, ²Department of Surgery, St. Vincent's Hospital, Linz, AUSTRIA, ³Department of Clinical Pathology, St. Vincent's Hospital, Linz, AUSTRIA, ⁴Nuclear Medicine & Endocrinology, Paracelsus Medical University, Salzburg, AUSTRIA.

OP155

Tc-99m MIBI-scintigraphy for malignancy risk assessment of hypofunctioning thyroid nodules

K. Rösel, C. Schneider, C. Kobe, M. Dietlein, A. Drzezga, M. C. Schmidt; University Hospital of Cologne, Department of Nuclear Medicine, GERMANY.

OP156

Role of real time ultrasound elastography in diagnosing hyper functional thyroid nodules and predicting treatment response

V. Stebner¹, M. Ruhlmann¹, R. Görges¹, J. Farahati¹, D. Simon², A. Bockisch¹, S. Rosenbaum-Krumme¹, J. Nagarajah³; ¹Department of Nuclear Medicine, Medical Faculty, University Duisburg-Essen, Essen, GERMANY, ²Department of General and Visceral Surgery, Bethesda Hospital, Duisburg, GERMANY, ³Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES.

OP157

Cancer Risk After Medical Exposure to 131I in Benign Thyroid Diseases

I. CILLERO ETXEBESTE, A. MENDIOLA, P. SANTESTEBAN, M. MITXELENA, I. ARIAS-CAMISON, G. RIOS, F. RODRIGUEZ; FUNDACIÓN ONKOLOGIKOA, SAN SEBASTIAN, SPAIN.

OP158

Contribution of SPECT/CT in extrathyroid radioiodine uptake in patients with differentiated thyroid cancer.

J. Villanueva Curto, A. Sainz-Esteban, A. Cobo Rodríguez, C. Gamazo Laherrán, M. Ruiz Gómez, M. González Selma, M. Alonso Rodríguez, R. Olmos García; HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID, Valladolid, SPAIN.

509

Hall 8

16:30 – 18:00

Physics & Instrumentation & Data Analysis: Data Analysis & Management II

OP159

18F-FDG PET/CT: Is SUV reliable to evaluate the adrenal glands normal metabolic behavior?

I. Rodrigues, A. Martins, J. Pereira, R. Domingos, S. Carmona, L. Oliveira; Joaquim Chaves Saúde – Nuclear Medicine Department, Lisbon, PORTUGAL.

OP160

Partial Volume Correction of Amyvid and FDG PET data using the discrete iterative Yang technique

J. C. Dickson¹, K. Erlandsson², M. Lehmann², M. Modat², N. Burgos², A. Groves², J. Schott²; ¹University College London Hospital NHS Foundation Trust, London, UNITED KINGDOM, ²University College London, London, UNITED KINGDOM.

OP161

Prognostic and predictive values of initial 18FDG PET features using random forest classifier: Application to patients after chemo-radiotherapy for oesophageal cancer

P. Desbordes^{1,2}, R. Modzelewski^{3,1}, S. Vauclin², P. Vera^{3,1}, I. Gardin^{3,1}; ¹QuantIF LITIS - EA4108, University of Rouen, Rouen, FRANCE, ²Dosisoft, Cachan, FRANCE, ³Henri Becquerel Center, Rouen, FRANCE.

OP162

Biomathematical modeling approach to predict clinical SUVR in amyloid PET imaging towards efficient radioligand discovery and development

Y. Arakawa¹, M. Shidahara¹, Y. Naito², S. Furumoto², C. Seki³, N. Okamura¹, M. Tashiro², M. Tashiro², Y. Kudo¹, K. Yanai¹, K. Gonda¹, H. Watabe²; ¹Tohoku University School of Medicine, Sendai, JAPAN, ²CYRIC, Tohoku University, Sendai, JAPAN, ³National Institute of Radiological Sciences, Chiba, JAPAN.

OP163

Correlation of SUV and tumor to blood standard uptake ratio (SUR) with the metabolic uptake rate derived from quantitative dual time point measurements.

F. Hofheinz¹, J. van den Hoff¹, A. Lougovski¹, K. Ego², H. Amthauer², I. Apostolova²; ¹Helmholtz-Zentrum Dresden-Rossendorf, Dresden, GERMANY, ²Clinic of Radiology and Nuclear Medicine, University Hospital, Magdeburg, GERMANY.

OP164

Impact of Use of Fanbeam Collimator in Interpretation of 99mTc-TRODAT Scans and Comparison of Image Quality with Low Energy High Resolution Collimator by Inter-observer Agreement Using Kappa Statistics

H. Rathore¹, T. Bharadwaj¹, H. Shah¹, P. Aland¹, B. Jois KS¹, S. Ghosh¹, L. Reddy¹, P. Chandrak², M. Prabhu³, P. Kumar¹, P. Chaudhuri¹, C. Sekhar¹, S. Shraddha¹, V. Lele¹; ¹Jaslok Hospital and Research centre, Mumbai, INDIA, ²Tata Memorial Hospital, Mumbai, INDIA, ³Narayana Hrudayalaya, Bangalore, INDIA.

OP165

Standardized uptake values of 99mTc-MDP SPECT bone scans - a novel method for absolute SPECT/CT quantification

W. He, W. Zhai, W. Yu; Huadong Hospital, Shanghai, CHINA.

OP166

Development of Motion Correction Methods for Cardiac PET Imaging

T. Noponen^{1,2}, R. Klén^{1,3}, T. Kokki^{1,2}, J. Teuho¹, K. Thielemans⁴, J. Koikkalainen⁵, E. Hoppela¹, H. Sipilä¹, J. Lötjönen⁵, M. Teräs¹, J. Knuuti¹; ¹Turku PET Centre, Turku University Hospital and University of Turku, FINLAND, ²Department of Nuclear Medicine, Turku University Hospital, FINLAND, ³Department of Mathematics and Statistics, University of Turku, FINLAND, ⁴University College London, London, UNITED KINGDOM, ⁵Knowledge Intensive Services, VTT Technical Research Centre of Finland, FINLAND.

510

Hall D

16:30 – 18:00

Cardiovascular System: SPECT & PET Perfusion Imaging

OP167

Long-term Prognostic Value of Stress Myocardial Perfusion Imaging and Coronary Computed Tomography Angiography: a Meta-analysis

V. Cantoni¹, R. Green¹, W. Acampa², M. Petretta³, G. De Matteis¹, B. Russo¹, T. Mannarino¹, M. Salvatore⁴, A. Cuocolo¹; ¹Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, ITALY, ²Institute of Biostructure and Bioimaging, National Council of Research, Naples, ITALY, ³Department of Translational Medical Sciences, University of Naples 'Federico II', Naples, ITALY, ⁴IRCCS SDN, Naples, ITALY.

OP168

Clinical utilization of submillisievert stress only myocardial perfusion imaging and concurrent coronary artery calcium score: A single institutional experience of a novel cardiac SPECT camera using cadmium zinc telluride (CZT) semiconductor technology

J. Liu, E. Hasche, J. Kilian, H. Dixon, B. Elison, C. Bui, H. Tie, R. Dunn, C. Smillie, Q. Chiam, K. Lee; Bankstown-Lidcombe Hospital, Bankstown, AUSTRALIA.

OP169

Detection of myocardial ischemia using artificial neural network: different characteristics from conventional defect scoring methods

K. Nakajima¹, S. Matsuo¹, K. Okuda², K. Yokoyama³, H. Bunko⁴, S. Kinuya¹, L. Edenbrandt⁵; ¹Kanazawa University Hospital, Kanazawa, JAPAN, ²Kanazawa Medical University, Uchinada, JAPAN, ³Matto Ishikawa Central Hospital, Hakusan, JAPAN, ⁴Kanazawa Cardiovascular Hospital, Kanazawa, JAPAN, ⁵University of Gothenburg, Gothenburg, SWEDEN.

OP170

Nuclear Cardiac Imaging Versus Fractional Flow Reserve in Diagonal Side Branch Ostial Stenosis After Left Anterior Descending Crossover Stenting

S. Fukuzawa, S. Okino, J. Maekawa, S. Ichikawa, N. Kuroiwa, K. Yamanaka, T. Igarashi, M. Inagaki; Funabashi Municipal Medical Center, FUNABASHI, JAPAN.

OP171

In vivo validation of gated myocardial SPECT imaging for quantification of small hearts: comparison with cardiac MRI

C. Kondo, E. Watanabe, M. Momose, K. Fukushima, K. Abe, N. Hagiwara, S. Sakai; Tokyo Women's Medical University, Tokyo, JAPAN.

OP172

Diabetes Mellitus independently determines PET-derived systolic function

L. Juárez-Orozco¹, R. J. J. Kno², R. A. Tio³, S. Lazarenko², R. H. J. A. Slart³, F. M. van der Zant²; ¹Rijksuniversiteit Groningen, Groningen, NETHERLANDS, ²Medical Center Alkmaar, Alkmaar, NETHERLANDS, ³University Medical Center Groningen, Groningen, NETHERLANDS.

OP173

Are myocardial perfusion reserve and LVEF modified by diabetes mellitus? A cardiac PET study.

L. Juárez-Orozco¹, R. H. J. A. Slart¹, R. A. Tio¹, H. H. Boersma¹, A. Ayala-German², L. Walls-Laguarda², R. A. Dierckx¹, E. Alexanderson³; ¹University Medical Center Groningen, Groningen, NETHERLANDS, ²Universidad Nacional Autónoma de México, Mexico City, MEXICO, ³Instituto Nacional de Cardiología "Ignacio Chávez", Mexico City, MEXICO.

OP174

Coronary Artery Calcium and Coronary Flow Reserve by Hybrid Rb-82 PET/CT Imaging in Non-diabetic and Diabetic Patients With Normal Myocardial Perfusion

R. Assante¹, P. Arumugam², E. Zampella¹, V. Gaudieri¹, C. Nappi¹, T. Mannarino¹, D. Tout², M. Larobina³, B. Russo¹, W. Acampa³, M. Petretta⁴, C. Tonge², A. Cuocolo¹; ¹Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, ITALY, ²Nuclear Medicine Centre, Central Manchester University Teaching Hospitals, Manchester, UNITED KINGDOM, ³Institute of Biostructure and Bioimaging, National Council of Research, Naples, ITALY, ⁴Department of Translational Medical Sciences, University of Naples 'Federico II', Naples, ITALY.

601

CME

Hall 1

08:00 – 09:30

**CME 5 – Interactive:
PET with Choline Tracers**

OP175

Basic Premises to Imaging with 11C or 18F Choline

L. Mansi, ITALY

OP176

11C or 18F Choline in Diagnosing, Staging, Re-Staging and Detecting Occult Recurrences of Prostate Cancer

P. Castellucci, ITALY

OP177

18F-Fluorocholine in Castration-Resistant Prostate Cancer and in other Malignancies

S. Balogova, SLOWAKIA

OP178

18F-Fluorocholine in the Management of Non-Malignant Pathologies

J.-N. Talbot, FRANCE

602

Hall 2

08:00 – 09:30

Joint Symposium 5: EANM/MDS: Dopamine Transporter Imaging: Current Topics

OP179

Quantification Approaches to DAT Imaging

L. Tossici, UK

OP180

DAT Normal Values: Results from the ENC-DAT Study

A. Varrone, SWEDEN

OP181

Is DAT in Essential Tremor Really Normal?

A. Antonini, ITALY

OP182

DAT Imaging and Cognition in Early PD

D. Aarsland, NORWAY

603

Hall 4

08:00 – 09:30

Technologist Oral Presentations 1

OP183

¹⁸F-FDG PET-CT and Radiotherapy Planning in Lung Cancer - Technical aspects and benefits from metabolic radiotherapy planning

J. Pinto¹, L. Vieira¹, D. Faria², J. Vale³, G. Fonseca³; ¹Lisbon School of Health Technology, Lisbon, PORTUGAL, ²Hospital Lusíadas Porto, Oporto, PORTUGAL, ³Júlio Teixeira S.A – Radioterapia, Oporto, PORTUGAL.

OP184

Influence of attenuation correction methods in the renal scintigraphy with 99mTc-DMSA

A. I. Santos¹, A. Amaro², E. Carolino², H. Silva², L. Vieira³, T. F. Vaz²; ¹Hospital Garcia de Orta, Almada, PORTUGAL, ²Escola Superior de Tecnologia da Saúde de Lisboa, Lisbon, PORTUGAL, ³Escola Superior de Tecnologia da Saúde de Lisboa & Instituto de Biofísica e Engenharia Biomédica, Faculdade de Ciências, Universidade de Lisboa, Lisbon, PORTUGAL.

OP185

The role of the Nuclear Medicine Technologists in Cyclotron related Research & Development

P. Costa¹, L. Cunha², L. F. Metello²; ¹Nuclear Medicine Department, ESTSP:IPP & CADCTR, Vila Nova de Gaia, PORTUGAL, ²Nuclear Medicine Department, ESTSP:IPP & CADCTR & IsoPor SA, Vila Nova de Gaia, PORTUGAL.

OP186

Occurrence and Characterisation of Perfusion Defects on ¹³NH₃ Myocardial PET/CT Due to Side Branch Occlusion After Ramus Descendens Anterior Stenting

H. Kan, R. J. J. Knol, S. V. Lazarenko, M. Wondergem, N. J. Hoogvorst, F. M. van der Zant; MCA, Alkmaar, NETHERLANDS.

OP187

Usefulness of simultaneous intermediate-level exercise for dobutamine stress myocardial perfusion imaging.

T. Kasai¹, M. Aiga¹, Y. Iwasaki², K. Oshima¹, Y. Fujita¹, Y. Sasaki¹, N. Tanaka¹, A. Yamashina²; ¹Tokyo Medical University Hachioji Medical Center, Tokyo, JAPAN, ²Tokyo Medical University, Tokyo, JAPAN.

OP188

Low-dose hybrid CCTA/SPECT image acquisition based on BMI : a case report

V. Weichselbaumer, J. Trinckauf, E. Müller, D. Benz; University hospital Zurich, Zurich, SWITZERLAND.

OP189

Impact of dynamic acquisition in dual-phase ¹⁸fluorocholine PET-CT on radiation exposure of staff and patients

J. BARBIAUX, C. CHNINA, C. HASBROUCQ, S. PETIT, M. THELU, A. BAILLIEZ, T. BLAIRE; GIE HumaniTEP - Hôpital Saint Philibert, LOMME, FRANCE.

OP190

Radiation Dose to the Eye Lens: Does Positioning Really Matter?

C. Baun¹, K. Falch¹, K. D. Nielsen², S. Shanmuganathan¹, O. Gerke¹, P. Hoelund-Carlsen¹; ¹Odense University Hospital, Odense, DENMARK, ²University College Lillebaelt, Odense, DENMARK.

605

Hall G2

08:00 – 09:30

Do.MoRe: PRRT Dose Response

OP191

PRRT toxicity: DOTATOC versus DOTATATE

M. Sollini¹, E. Grassi², F. Fioroni², A. Filice², V. Ferri², A. Frasoldati², A. Versari²; ¹IRCCS MultiMedica, Sesto San Giovanni, ITALY, ²Santa Maria Nuova Hospital IRCCS, Reggio Emilia, Reggio Emilia, ITALY.

OP192

[¹⁷⁷Lu-DOTA]-D-Phe₁-Tyr₃-Octreotide (¹⁷⁷Lu-DOTATOC) for Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Retrospective Phase II Study of Efficacy and Safety

H. R. Kulkarni¹, R. P. Baum¹, A. W. Kluge², M. Sayeg¹, U. Schorr-Neufing², K. Niepsch¹, N. Biterlich², C. van Echteld³; ¹Zentralklinik Bad Berka, THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging (PET/CT), Bad Berka, GERMANY, ²ABX-CRO GmbH, Dresden, GERMANY, ³ABX-CRO, Dresden, GERMANY.

OP193

Long term survival analysis after i.a. 90Y-DOTATATE PRRT, in patients with non-resectable, advance progressive liver dominant neuroendocrine neoplasms.

M. L. Nowicki¹, S. J. Konsek², L. Jaskiewicz², M. Mo³, A. Sankowski¹, J. R. Buscombe⁴, L. Bodei⁵, R. Mikolajczak⁶, J. B. Cwikla²; ¹Department of Radiology and Diagnostic Imaging, Hospital Ministry of Internal Affairs & Administration, Warsaw, POLAND, ²Department of Radiology, Faculty of Medical Sciences, University of Warmia and Mazury, Olsztyn, POLAND, ³Radiology and Diagnostic Imaging, Medical Center for Postgraduate Education, Warsaw, POLAND, ⁴Department of Nuclear Medicine, Addenbrooke's Hospital, Cambridge, UNITED KINGDOM, ⁵Division of Nuclear Medicine, European Institute of Oncology, Milan, ITALY, ⁶Centre POLATOM, National Centre for Nuclear Research Radioisotope, Otwock, POLAND.

OP194

Early assessment of renal impairment in patients undergoing Peptide Receptor Radionuclide Therapy evaluated by MAG3 renal scintigraphy

R. A. Werner^{1,2}, S. Beykan¹, C. Lapa¹, C. Bluemel¹, U. Eberlein¹, T. Higuchi^{1,2}, H. Wakabayashi¹, K. Herrmann^{1,3}, A. K. Buck¹, M. Lassmann¹, H. Hänscheid¹; ¹Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY, ²Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, GERMANY, ³Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, UNITED STATES.

OP195

Super-selective Hepatic Arterial Infusions of n.c.a. Lu-177-Dotatoc in Inoperable Neuroendocrine Liver Metastases of Gastro-Entero-Pancreatic (GEP) Tumors; Preliminary Results

G. S. Limouris¹, N. Trompoukis¹, V. Poulantzas¹, I. Karfis², A. Chatzioannou¹, M. Lyra¹, V. Michalaki³, N. Triantaphyllou⁴, G. Nikou⁵, M. Paphiti⁶, V. R. McCready⁶, L. Mouloupoulou¹; ¹Nucl Med Div-1st Radiology Dept, "Areteiaion" Hospital, Athens University Medical Faculty, Athens, GREECE, ²Nuclear Medicine Dept, Institute "Bordet", Brussels, BELGIUM, ³Department of Surgical Oncology, "Areteiaion" Hospital, Athens University Medical Faculty, Athens, GREECE, ⁴Neurology Dept, "Aeginiteion" Hosp, Athens Univ Medical Faculty, Athens, GREECE, ⁵Gastrointestinal Div, I Dept of Propedeutic Internal Medicine "Laikon" Hospital, Athens, GREECE, ⁶Nuclear Medicine Dept, Royal Sussex County Hosp, Brighton, UNITED KINGDOM.

OP196

Relationship between baseline GFR, [Lu-177]-DOTATATE Clearance and Radiation Dose to Kidneys During Radionuclide Therapy for Somatostatin-Expressing Tumours

D. L. Bailey¹, T. M. Hennessy², K. P. Willows², D. L. Chan¹, G. P. Schembri¹, A. Aslani¹, N. Pavlakis¹; ¹Royal North Shore Hospital, Sydney, AUSTRALIA, ²University of Sydney, Sydney, AUSTRALIA.

OP197

Recurrent glioblastoma multiforme - local alpha emitters targeted therapy with ²¹³Bi-DOTA-substance P

L. Królicki¹, A. Morgenstern², J. Kunikowska¹, H. Koziara³, B. Królicki³, M. Jakuciński⁴, D. Pawlak⁵, C. Apostolidis², F. Bruchertseifer²; ¹Nuclear Medicine Department, Medical University of Warsaw, Warsaw, POLAND, ²European Commission, Joint Research Centre, Institute for Transuranium Elements, Karlsruhe, GERMANY, ³Department of Neurosurgery, Institute of Psychiatry and Neurology, Warsaw, POLAND, ⁴Department of Nuclear Medicine, Brodnowski Hospital, Warsaw, POLAND, ⁵Radioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, POLAND.

606

Hall 6

08:00 – 09:30

M2M: SPECT Translational Studies

OP198

Non-invasive determination of the Beta Bell Mass with ¹¹¹In-exendin-3 in a Rat Model of spontaneous Type 1 Diabetes

L. Joosten¹, M. Brom¹, D. Bos¹, C. Frielink¹, P. Hanneke², O. Boerman¹, M. Gotthardt¹; ¹Radboud university medical center, Nijmegen, NETHERLANDS, ²GROW mumm, Maastricht, NETHERLANDS.

OP199

Preclinical imaging of the co-stimulatory ligands CD80/CD86 with ¹¹¹In-DOTA-Belatacept in oncology and atherosclerosis

A. Müller Herde¹, R. Meletta¹, P. Dennler², E. Fischer², R. Schibli¹, S. D. Krämer¹; ¹ETH Zurich, Zurich, SWITZERLAND, ²Paul Scherrer Institute, PSI-Villigen, SWITZERLAND.

OP200

Initial experiences with the Mediso nanoSCAN preclinical SPECT/MR

M. Segbers¹, J. C. Haeck¹, I. L. Bakker¹, J. de Swart¹, M. Kovács², M. R. Bernsen¹, M. de Jong¹; ¹Erasmus Medical Center, Rotterdam, NETHERLANDS, ²Mediso Medical Imaging Systems, Budapest, HUNGARY.

OP201

Noninvasive visualization of microRNA by Tc-99m radiolabeled anti-microRNA oligonucleotide in tumor xenografts

L. KANG; PEKING UNIVERSITY FIRST HOSPITAL, BEIJING, CHINA.

OP202

Quantitative and longitudinal SPECT imaging of intramuscular transplanted islets of Langerhans using [¹²³I]IBZM

S. M. A. Willekens, I. van der Kroon, D. Bos, L. Joosten, C. Frielink, O. C. Boerman, M. Brom, M. Gotthardt; Radboud university medical center, Nijmegen, NETHERLANDS.

OP203

Radioimmunoimaging of targeting CD133 antigen for colorectal cancer stem cells, a preliminary study

R. An, X. Jin, J. Lang, D. Weng, X. Lan; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

OP204

SPECT/CT Imaging of Programmed-Death Ligand 1 Expression of Tumors and Antigen-Presenting Cells

S. Heskamp¹, W. Hobo¹, J. D. M. Molkenboer-Kuening¹, D. Olive², W. J. G. Oyen¹, H. Dolstra¹, O. C. Boerman¹; ¹Radboud University Medical Center, Nijmegen, NETHERLANDS, ²CRMC, Immunity and Cancer, Inserm, Marseille, FRANCE.

OP205

Radiolabelled superagonist rhTSH analogues TR1401 and TR1402 for in vivo imaging of poorly differentiated thyroid cancer

F. Galli^{1,2}, I. Manni³, G. Piaggio³, L. Balogh⁴, B. D. Weintraub⁵, M. W. Skudlinski⁵, R. A. J. O. Dierckx², A. Signore^{1,2}; ¹Nuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, "Sapienza" University of Rome, Rome, ITALY, ²Department of Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen, University of Groningen, Groningen, NETHERLANDS, ³Molecular Oncogenesis Laboratory, Experimental Oncology Department, Regina Elena National Cancer Institute, Rome, Italy, Rome, ITALY, ⁴National "Frederic Joliot Curie" Research Institute for Radiobiology and Radiohygiene, Budapest, HUNGARY, ⁵Trophogen Inc., Rockville, MD, UNITED STATES.

608 Hall E

08:00 – 09:30

**Pitfalls & Artefacts & Physiology –
Interactive: Imaging in Inflammation and
Infection**

OP206

**Pitfalls and Artefacts in Imaging Inflammation and
Infection: Radiopharmaceuticals**

N. Hartman, UK

OP207

**Pitfalls and Artefacts in Imaging Inflammation and
Infection: Labelled Leucocytes**

E. Lazzeri, ITALY

OP208

**Pitfalls and Artefacts in Imaging Inflammation and
Infection: PET**

A. Glaudemans, NETHERLANDS

610 Hall D

08:00 – 09:30

**UEMS/CANMD Session: Practical Quality
Management in Nuclear Medicine**

OP209

Welcome by the Committee Chair

S. Mirzaei, AUSTRIA

OP209b

**Request to Different Levels of a Radiopharmacy
Laboratory**

K. Solanki, UNITED KINGDOM

OP209c

Good Clinical Practice for Pulmonary SPECT

M. Bajc, SWEDEN

OP209d

**Good Medical Practice of Hybrid Imaging in
Neurology**

A. Ciarmiello, ITALY

OP209e

Quality Check in Hot Lab. State of the Art in Italy

M. Riondato, ITALY

OP209f

Importance of a QM in a NM Department

E. Bombardieri, ITALY

OP209g

PET/CT Audit in the UK

W-L. Wong, UNITED KINGDOM

701/703 Hall 1

10:00 – 11:15

Plenary 2: Therapeutic Nuclear Medicine

OP210

Paediatric Radionuclide Therapy

M. Gaze, UK

OP211

**Radiosynoviorthesis - State of the Art after 60 Years
of Experience**

W. U. Kampen, GERMANY

OP212

Radioembolisation of Liver Metastases and HCC

E. Garin, FRANCE

801 Hall 1

11:30 – 13:00

**CME 6 – Neuroimaging: Brain Tumours –
PET vs MRI: Therapy Planning and Response
Assessment**

OP213

**Molecular Aspects of Brain Tumours and Specific PET
Radiotracers**

K. Herholz, UK

OP214

Neurosurgery Planning

R. Díez-Valle, SPAIN

OP215

Radiotherapy Planning

A. Grosu, GERMANY

OP216

**Treatment Response Assessment and Treatment
Monitoring**

N. Galldiks, GERMANY

802

Hall 2

11:30 – 13:00

**Joint Symposium 6: EANM/ESTRO:
Molecular PET Imaging in Adaptive
Radiotherapy: Focus on Current Trends,
Challenges and Solutions**

OP217

Lung Cancer: The Radiation Oncologist's Point of View

B. Dubray, FRANCE

OP218

Lung Cancer: The Nuclear Medicine Physician's Point of View

P. Vera, FRANCE

OP219

Head and Neck Cancer: The Radiation Oncologist's Point of View

V. Grégoire, BELGIUM

OP220

Head and Neck Cancer: The Nuclear Medicine Physician's Point of View

W.J.G. Oyen, NETHERLANDS

803

Hall 4

11:30 – 13:00

Technologist Oral Presentations 2

OP221

Investigation of kidney function with a dynamic FDG-PET/MR

B. K. Geist, A. Staudenherz; Medical University of Vienna, Vienna, AUSTRIA.

OP222

Wholebody Blood Pool in Bone Scintigraphy: Usefulness in the differential diagnosis of inflammatory arthritis - Preliminary Results

M. Casanova Martins, B. Patel, C. Humphreys, P. Ali; ABMU HB, Swansea, UNITED KINGDOM.

OP223

Comparison of Ga-68-DOTATATE PET/CT and In-111-octreotide SPECT/CT for the detection of neuroendocrine tumors

M. Kieft, E. A. Aalbersberg, M. P. M. Stokkel; NKI-AVL, Amsterdam, NETHERLANDS.

OP224

Phase analysis using ECG-gated myocardial FDG PET in the rat in comparison with speckle tracking echocardiography

A. Mizutani¹, I. Matsunari², M. Kobayashi³, K. Nishi⁴, W. Fujita⁵, S. G. Nekolla⁶, K. Kawai⁷, K. Fukuchi¹; ¹Osaka University, Osaka, JAPAN, ²Saitama Medical University Hospital, Saitama, JAPAN, ³Kanazawa University, Kanazawa, JAPAN, ⁴Nagasaki University, Nagasaki, JAPAN, ⁵Kanazawa Medical University, Ishikawa, JAPAN, ⁶Technical University Munich, Munich, JAPAN, ⁷Osaka University Kanazawa University, Kanazawa, JAPAN.

OP225

Eye Spy: An Investigation into Tc-99m Pertechetate Lacrimal Scitigraphy for Protocol Optimization

E. Souza, V. Janse van Rensburg, P. Sandhu, L. Perry, H. Tam, Z. Win; Imperial College Healthcare NHS Trust, London, UNITED KINGDOM.

OP226

Radionuclide therapy of metastatic melanoma with benzamide derivate I-131-BA100 after patient stratification with F-18-DOPA

F. O. Spohn, K. Kunze, F. Giesel, W. Mier, U. Haberkorn, C. Kratochwil; Heidelberg University Hospital, Heidelberg, GERMANY.

OP227

Impact of syringe residual activity in SUV measurement

P. Felício¹, J. Hunter², N. G. Dowell², T. Vaz¹, F. Lucena¹; ¹Lisbon School of Health Technology, Lisbon, PORTUGAL, ²Clinical Imaging Sciences Centre, Brighton and Sussex Medical School, University of Sussex, Brighton, UNITED KINGDOM.

OP228

Protocol Optimisation of [⁶⁸Ga]-PSMA PET/CT Imaging on a High Sensitivity Time-of-Flight Pet Scanner

E. A. Bailey, E. Hsiao, G. Schembri; Royal North Shore Hospital, Sydney, AUSTRALIA.

804

Hall G1

11:30 – 13:00

Clinical Oncology – Featured: Image Guided Surgery

OP229

SPECT/CT for Anatomical Mapping of Lymphatic Drainage in Vulvar Cancer: Possible Implications for the Extent of Inguinal Lymph Node Dissection

A. Collarino^{1,2}, M. L. Donswijk², W. J. van Driel³, M. P. Stokkel², R. A. Valdés Olmos^{2,4}; ¹Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Roma, ITALY, ²Department of Nuclear Medicine, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS, ³Department of Gynaecological Oncology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS, ⁴Interventional Molecular Imaging Laboratory and Nuclear Medicine Section, Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS.

OP230

3D freehand-SPECT navigation for intraoperative radioactive seed localisation using single or multiple 125I seeds in breast-conserving cancer surgery

B. Pouw, L. J. de Wit-van der Veen, F. van Duijnhoven, E. J. T. Rutgers, R. A. Valdés Olmos, M. P. M. Stokkel, M. T. F. D. Vrancken Peeters; Netherlands Cancer Institute, Amsterdam, NETHERLANDS.

OP231

Intraoperative evaluation of a true hybrid modality for combined radio- and fluorescence guided sentinel node biopsy

N. S. van den Berg^{1,2}, H. Simon³, G. H. KleinJan^{1,2}, J. Chambron³, B. M. Tjink², S. Horenblas², F. W. B. van Leeuwen^{1,2}; ¹LUMC, Leiden, NETHERLANDS, ²AVL-NKI, Amsterdam, NETHERLANDS, ³Eurorad, Strassbourg, FRANCE.

OP232

Role of Robotic assisted PET-CT guided biopsy in 18F-FDG/Ga68 DOTANOC avid suspicious lesions

S. Gambhir, A. Prashanth, S. Barai, H. Lal, A. Nath, G. Sankar, N. Kumar, M. Ravina; Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, INDIA.

OP233

FDG PET/CT Guided Biopsy

C. Nanni¹, A. Cappelli¹, T. Balbi¹, F. Mangiacotti¹, A. Gasbarrini², T. Graziani¹, I. Sandler¹, R. Golfieri¹, S. Fanti¹; ¹Aou S.orsola-Malpighi, Bologna, ITALY, ²Ior, Bologna, ITALY.

OP234

MRI based identification of lymph nodes and nerves, the next step in sentinel node procedures for head and neck cancer?

T. Buckle¹, B. M. Verbist¹, G. H. KleinJan¹, M. de Ruiter¹, M. A. van Buchem¹, A. J. Balm², F. W. B. van Leeuwen¹; ¹LUMC, Leiden, NETHERLANDS, ²NKI-AvL, Amsterdam, NETHERLANDS.

805

Hall G2

11:30 – 12:45

Do.MoRe – Featured: Prostate Cancer Therapy

OP235

The potential of F-18 Fluoride PET as a surrogate for Radium-223 chloride lesion dosimetry in hormone refractory prostate cancer patients

I. Murray, S. J. Chittenden, C. C. Parker, G. Flux; Royal Marsden NHS Foundation Trust, Sutton, UNITED KINGDOM.

OP236

Feasibility of 223Ra quantitative imaging for lesion dosimetry

G. A. Follacchio¹, V. Frantellizzi¹, R. Pellegrini¹, R. Pani¹, M. Pacilio², B. Cassano², M. Liberatore¹, F. Monteleone¹, T. Garkavaya¹, G. Ventroni², L. Mango², G. De Vincentis¹; ¹Policlinico Umberto I – Sapienza University, Rome, ITALY, ²A.O. San Camillo-Forlanini, Rome, ITALY.

OP237

A Monte Carlo study of small-scale dosimetry in capillary vessels during internal radionuclide therapies with 223Ra, 111In, 131I and 177Lu

S. Leotta¹, E. Amato¹, A. Italiano², L. Auditore¹, R. Gentile¹, S. Baldari¹; ¹University of Messina, MESSINA, ITALY, ²Istituto Nazionale di Fisica Nucleare, MESSINA, ITALY.

OP238

Factors Affecting RADIUM-223 Therapy

E. Etchebehere, J. Araujo, D. Milton, N. Swanston, H. Macapinlac, E. Rohren; The University of Texas MD Anderson Cancer Center, Houston, TX, UNITED STATES.

OP239

Therapy of Metastasized Prostate Cancer Using a Lu-177 Labeled PSMA Inhibitor (I&T): First Dosimetric Results in Patients

C. Schuchardt¹, S. Wiessalla¹, A. Özkan², H. R. Kulkarni¹, M. Shahinfar¹, M. Sayeg¹, M. Weineisen³, H. J. Wester³, R. P. Baum¹; ¹THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, BAD BERKA, GERMANY, ²Yildiz Technical University, Department of Physics, Istanbul, TURKEY, ³Technical University Munich, Pharmaceutical Radiochemistry, Faculties of Chemistry and Medicine, Munich, GERMANY.

OP240

Radiation Sensitivity of Prostate Cancer Cells for Beta- or Auger-Electron, Alpha-Particle, or Photon Irradiation.

J. Elgqvist, K. Claesson, E. Larsson, S. Oredsson, O. Vilhelmsson-Timmermand, T. Tran, S. Strand; Institute for Clinical Sciences, LUND, SWEDEN.

806

Hall 6

11:30 – 12:45

M2M: Radiopharmaceuticals & Radiochemistry: Macromolecules I

OP242

Influence of Histidine-Containing Tags on Biodistribution of Radiolabelled ADAPT-Based Imaging Probes

S. Lindbo¹, J. Garousi², M. Åstrand¹, H. Honarvar², A. Orlova², S. Hober¹, V. Tolmachev²; ¹Royal Institute of Technology-KTH, Stockholm, SWEDEN, ²Uppsala University, UPPSALA, SWEDEN.

OP243

Preclinical development of a novel combination therapy against ovarian carcinoma: Combination of anti-L1CAM Lutetium-177 radioimmunotherapy and clinically relevant protein kinase inhibitors

D. Lindenblatt¹, G. Pellegrini², S. Cohrs¹, P. R. Spycher¹, D. Vukovic¹, E. Fischer¹, R. Schibli^{1,3}, J. Grünberg¹; ¹Paul Scherrer Institut, Villigen PSI, SWITZERLAND, ²University of Zurich, Institut für Veterinärpathologie, SWITZERLAND, ³Department of Chemistry and Applied Biosciences, ETH Zurich, SWITZERLAND.

OP244

Feasibility of Affibody molecule-based PNA-mediated pretargeting.

H. Honarvar¹, K. Westerlund², M. Altai³, M. Sandström⁴, A. Orlova⁵, V. Tolmachev³, A. Eriksson Karlström²; ¹Institute for Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN, ²School of Biotechnology, Division of Protein Technology, KTH Royal Institute of Technology, Stockholm, SWEDEN, ³Rudbeck Laboratoriet, Uppsala, SWEDEN, ⁴Uppsala University Hospital, Uppsala, SWEDEN, ⁵Preclinical PET Platform, Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN.

OP245

An Anti-HER2 Nanobody Labeled with 18F Using a Residualizing Label for Assessing HER2 Status

G. Vaidyanathan¹, D. McDougald¹, J. Choi¹, E. Koumariannou¹, M. Pruszyński², T. Osada¹, H. Lyster¹, T. Lahoutte³, M. R. Zalutsky¹; ¹Duke University Medical Center, Durham, NC, UNITED STATES, ²Institute of Nuclear Chemistry and Technology, Warsaw, POLAND, ³Free University of Brussels, Brussels, BELGIUM.

OP246

DOTAGA vs DOTA: an extra negative charge reduces hepatic uptake of Affibody molecules labelled with 111In and 68Ga

J. Strand¹, H. Honarvar¹, K. Westerlund², B. Mitran³, A. Orlova³, A. Eriksson Karlström⁴, V. Tolmachev¹; ¹Department of Immunology, Genetics and Pathology, Uppsala, SWEDEN, ²Division of protein technology, Stockholm, SWEDEN, ³Preclinical PET Platform, Uppsala, SWEDEN, ⁴Division of protein technology, Uppsala, SWEDEN.

OP247

Generalized syntheses of tumor targeted yolk/shell structured multifunctional nanosystems

F. Chen, H. Hong, S. Shi, H. F. Valdovinos, T. E. Barnhart, W. Cai; University of Wisconsin-Madison, MADISON, WI, UNITED STATES.

807

Hall F

11:30 – 13:00

Teaching Session: Anatomy Refresher and Hybrid Imaging of the Foot and Ankle

OP248

Anatomy Refresher and Hybrid Imaging of the Foot and Ankle

C. Fowler, UNITED KINGDOM

809

Hall 8

11:30 – 13:00

Clinical Oncology: Prostate I – Choline

OP249

Role of [11C]choline PET/CT in tailored Cyberknife stereotactic Therapy in patients with prostate recurrent isolated lymph node.

P. Gandolfo¹, F. Ria², A. Bergantin², A. S. Martinotti², I. Redaelli², M. Invernizzi², A. Vai², I. Bossi Zanetti², L. C. Bianchi², G. Beltramo²; ¹Nuclear Medicine Unit - Centro Diagnostico Italiano, Milan, ITALY, ²Cyberknife Unit - Centro Diagnostico Italiano, Milan, ITALY.

OP250

Comparison of [18F] choline PET/CT with integrated [18F] choline PET/MRI in patients with suspected recurrent prostate cancer.

A. Wetter¹, B. M. Schaarschmidt², M. Schenck³, H. Rübber³, S. Lütje⁴, T. Pöppel⁴, M. Forsting¹, T. Lauenstein¹; ¹University Hospital Essen, Dept. of Radiology and Neuroradiology, Essen, GERMANY, ²University Hospital Düsseldorf, Dept. of Radiology, Düsseldorf, GERMANY, ³University Hospital Essen, Department of Urology, Essen, GERMANY, ⁴University Hospital Essen, Department of Nuclear Medicine, Essen, GERMANY.

OP251

Prognostic value of FCH PET/CT in response to radical radiotherapy in patients with localized prostate cancer

M. Sepulcri, A. Negri, E. Agostini, S. Galuppo, A. Cervino, G. Saladini, A. Scaggion, M. Paiusco, L. Evangelista; Istituto Oncologico Veneto I.R.C.C.S., PADOVA, ITALY.

OP252

Predictive role of 11C-Choline PET/CT on the lymph nodal relapse in prostate cancer patients treated by salvage radiotherapy

E. Incerti¹, A. Fodor², P. Mapelli¹, C. Fiorino³, P. Alongi⁴, M. Kirienko⁴, G. Giovacchini⁵, E. Busnardo¹, G. Berardi², R. Calandrino³, L. Gianolli¹, N. Di Muzio², M. Picchio¹; ¹Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY, ²Radiotherapy Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY, ³Medical Physics Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY, ⁴University of Milano-Bicocca, Milan, ITALY, ⁵Department of Radiology and Nuclear Medicine, Stadtspital Waid, Zurich, SWITZERLAND.

OP253

Dynamic 11C-Choline PET/CT in biochemical relapse of prostate cancer: feasibility, clinical role and potential impact in guiding radiotherapy

P. Alongi¹, M. Spallino², E. Incerti¹, L. Gianolli¹, M. Picchio¹; ¹IRCCS San Raffaele Scientific Institute, Milano, ITALY, ²University of Milano-Bicocca, Milano, ITALY.

OP254

11C-choline PET/CT in castrate-resistant prostate cancer patients treated with Docetaxel

F. Ceci¹, P. Castellucci¹, T. Graziani¹, R. Renzi¹, J. J. Morigi¹, G. M. Lima¹, F. Lodi¹, R. Schiavina², A. Ardizzoni³, S. Fanti¹; ¹Nuclear Medicine - S.Orsola-Malpighi Hospital - University of Bologna, Bologna, ITALY, ²Department of Urology - S.Orsola-Malpighi Hospital - University of Bologna, Bologna, ITALY, ³Department of Oncology - S.Orsola-Malpighi Hospital - University of Bologna, Bologna, ITALY.

OP255

Usefulness of 18F-fluorocholine positron emission tomography - computed tomography in occult biochemical recurrence of prostate cancer. A prospective multicentre study

Q. Gillebert¹, V. Huchet¹, C. Rousseau², A. Cochet³, P. Olivier⁴, F. Courbon⁵, V. Nataf¹, J. Talbot¹; ¹Department of Nuclear Medicine, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris, FRANCE, ²Nuclear Medicine Department, Institut de Cancérologie de l'Ouest René Gauducheau, Nantes, FRANCE, ³Department of Nuclear Medicine, Centre Georges-François Leclerc, Dijon, FRANCE, ⁴Department of Nuclear Medicine, Hôpital de Brabois, Nancy, FRANCE, ⁵Department of Nuclear Medicine, IUCT-Oncopole/Institut Claudius Regaud, Toulouse, FRANCE.

OP256

Helical tomotherapy and bone metastases in prostate cancer patients: role of Choline-PET/CT

P. Mapelli¹, V. Gangemi², E. Incerti¹, G. Giovacchini³, C. Deantonio⁴, A. Fodor⁴, S. Baldari², L. Gianolli¹, N. Di Muzio⁴, M. Picchio¹; ¹Nuclear Medicine Unit, IRCCS San Raffaele Scientific Institute, Milano, ITALY, ²Nuclear Medicine Unit, Department of Biomedical Sciences and of Morphologic and Functional Images, University of Messina, Messina, ITALY, ³Department of Nuclear Medicine and Radio-Oncology, Stadtspital Triemli, Zurich, SWITZERLAND, ⁴Radiation Oncology Department, IRCCS San Raffaele Scientific Institute, Milano, ITALY.

810

Hall D

11:30 – 13:00

Conventional & Specialised Nuclear Medicine: Bone Joint

OP257

The Clinical Impact of Tc-99m HDP SPECT-CT in the diagnosis and management of complex foot and ankle pathology

C. Tang¹, K. Alsey², H. Zaw², M. Nathan¹; ¹Royal Free Hospital, London, UNITED KINGDOM, ²Hillingdon Hospital, London, UNITED KINGDOM.

OP258

Altered bone metabolism of the spine in ankylosing spondylitis demonstrated by ¹⁸F-fluoride PET/CT - A novel evaluation tool in patients with relatively low modified Stoke Ankylosing Spondylitis Spine Scores

J. Kim, Y. Choi, S. Lee, Y. Joo, T. Kim; Hanyang University Medical Center, Seoul, KOREA, REPUBLIC OF.

OP259

99mTc-labelled D-Glucosamine Uptake Reflects Disease Activity in Patients with Ankylosing Spondylitis and Rheumatoid Arthritis

S. Angelides, A. Markewycz, N. Manolios, M. Ali, K. Pavic, R. de Costa, B. Camden; Westmead Hospital, Westmead, AUSTRALIA.

OP260

Bone SPECT-CT in the diagnosis and management of facial asymmetry due to mandibular condylar hyperplasia

L. Mohamed Salem, Sr., M. Ibañez Ibañez, V. Godoy Bravo, L. Álvarez Nieto, R. Reyes Marles, D. Segarra Fenoll, M. Castellón Sanchez, P. Nicolas Ruiz, L. Frutos Esteban, J. Navarro Fernandez, M. Murcia Durendez, A. Montellano Fenoy, M. Claver Valderas, M. Roldan Rubio, A. Abella Tarazona; Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN.

OP261

Optimising Quantitative SPECT in Condylar Hyperplasia

D. O. Hall, A. Demmery, J. Kabala; UH Bristol NHS FT, Bristol, UNITED KINGDOM.

OP262

Clinical value of SPECT/CT in the 'unhappy' total knee arthroplasty (TKA)- a prospective study in a consecutive series of 100 painful knees after TKA

M. T. Hirschmann^{1,2}, H. Rasch³; ¹Kantonsspital Baselland (Bruderholz, Liestal, Laufen), Department of Orthopaedic Surgery and Traumatology, Bruderholz, SWITZERLAND, ²University, Basel, SWITZERLAND, ³Kantonsspital Baselland (Bruderholz, Liestal, Laufen), Institute of Radiology and Nuclear Medicine, Bruderholz, SWITZERLAND.

OP263

Multimodality work-up of patients with suspected infected hip prosthesis: radiography, ESR/CRP testing, joint aspiration, and 18F-FDG PET/CT

W. Broos, R. Kwee, J. Geurts, S. Vöö, B. Brans, R. Weijers; Maastricht UMC, Maastricht, NETHERLANDS.

OP264

The evolution of radiologically occult bone metastases detected on FDG-PET/CT

P. Martineau, M. Pelletier-Galarneau, X. Pham, A. Sheikh; The Ottawa Hospital, Ottawa, ON, CANADA.

YE2

Hall 8

13:00 – 14:30

Young EANM Daily Forum 2: Career Speed Date

OP264b

Meet the Experts

*C. Decristoforo, AUSTRIA
M. Hofman, AUSTRALIA
D. Delbeke, USA
F. Jamar, BELGIUM*

901

CME

Hall 1

14:30 – 16:00

CME 7 – Physics & Paediatrics: Radiation Protection

OP265

The New European BSS and its Implications in Nuclear Medicine

G. O'Reilly, IRELAND

OP266

Individual Justification in Paediatrics – from Concepts to Practice

A. I. Santos, PORTUGAL

OP267

Dose Optimisation in Paediatric Nuclear Medicine

F. Fahey, USA

OP268

Radiation Protection Issues in Therapy with Lu-177, Y-90 and Ra-223

S. Holm, DENMARK

902

Hall 2

14:30 – 16:00

Joint Symposium 7: EANM/EACVI/ESC: New Clinical Guidelines on Infectious Endocarditis and CIED Infections

OP269

Infective Endocarditis; the Clinical Problem and Needs

J. M. Miro, SPAIN

OP270

Imaging Infective Endocarditis: How Molecular Imaging got into our Clinical Guidelines

P.A. Erba, ITALY

OP271

New Guidelines on the Management of Infective Endocarditis

G. Habib, FRANCE

903

Hall 4

14:30 – 16:00

CTE 3 – Interactive: Comprehensive PET/MRI Practice

OP272

MR Basics and Clinical Applications

J. Graessner, GERMANY

OP273

MR/PET: Technical Challenges and Clinical Applications

V. Diehl, GERMANY

OP274

Clinical PET/MR – Where Are We after Five Years?

A. Beer, GERMANY

904

Hall G1

14:30 – 16:00

Committee Symposium – Neuroimaging: Counteracting Dementia: Imaging Evidence for Cognitive and Brain Reserve

OP274b

Relevance of Brain Reserve for Clinical Nuclear Neurology

S. Morbelli, ITALY

OP274c

Brain Structural and Functional Correlates of Reserve Across Different Dementias

R. Pernecky, UK

OP274d

Multimodal Neuroimaging Correlates of Reserve from Cognitively Normal Older Adults to Alzheimer's Disease

E.M. Arenaza-Urquijo

905

Hall G2

14:30 – 16:00

Do.MoRe: Radiobiology – Molecular Radiotherapy

OP275

Novel treatment strategy for glioblastomas using Auger-electron therapy and concomitant chemotherapy - in vitro studies

A. Therkelsen¹, B. B. Olsen¹, B. Halle², P. Høiland-Carlsen¹, H. Thisgaard¹; ¹Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK, ²Department of Neurosurgery, Odense University Hospital, Odense, DENMARK.

OP276

The effects of dose-rate on radiation induced platelet toxicity in internal radiotherapy.

J. Rousseau¹, S. Becavin¹, F. Nguyen¹, N. Sas¹, M. Magnen¹, M. Bourgeois^{2,3,4}, M. Meckel⁵, F. Roesch⁵, N. Chouin^{6,4}; ¹LUNAM Université, Oniris, "AMaROC", Nantes, FRANCE, ²CRCNA, INSERM, Université de Nantes, UMR_S 892, Nantes, FRANCE, ³ARRONAX cyclotron, Saint Herblain, FRANCE, ⁴CHU Nantes, Nuclear medicine department, Nantes, FRANCE, ⁵Institute of Nuclear Chemistry, Johannes-Gutenberg-University Mainz, Mainz, GERMANY, ⁶LUNAM Université, Oniris,, Nantes, FRANCE.

OP277

Different DNA Damage Repair Rates in Blood Lymphocytes after Peptide Receptor Radionuclide Therapy and Radioiodine Therapy of Thyroid Cancer

U. Eberlein¹, C. Nowak², C. Lapa¹, C. Bluemel¹, M. Peper², R. A. Werner¹, A. K. Buck¹, H. Scherthan², M. Lassmann¹; ¹Department of Nuclear Medicine, University of Würzburg, Würzburg, GERMANY, ²Bundeswehr Institute of Radiobiology affil. to the Univ. of Ulm, Munich, GERMANY.

OP278

Impact of Bi-Exponential Repair Kinetics of Sub-lethal Damage on the Relative Effectiveness in Molecular Radiotherapy

A. Malaroda¹, A. J. Green², A. B. Rosenfeld¹; ¹University of Wollongong, Wollongong, AUSTRALIA, ²National Physical Laboratory, Teddington, UNITED KINGDOM.

OP279

Terbium-161 a Promising Radionuclide for the Irradiation of Tumor Cells and Micrometastases: Monte Carlo Dose Assessment using CELDOSE

E. Hindie¹, M. A. Quinto², P. Zanotti-Fregonara¹, C. Morgat¹, C. Champion²; ¹CHU Bordeaux - University of Bordeaux - UMR 5287, Bordeaux, FRANCE, ²Université de Bordeaux, CNRS/IN2P3, Centre d'Etudes Nucléaires de Bordeaux Gradignan (CENBG), Gradignan, FRANCE.

OP280

Alpha radioimmunotherapy using ²¹³Bi-anti MISRII mAb in ovarian cancer

R. LADJOHOUNLOU, Jr.^{1,2,3}, A. PICHARD^{1,2,3}, V. BOUDOUSQ^{1,2,3}, N. CHOUIN⁴, F. BRUCHERTSEIFER⁵, A. MORGENSTERN⁵, I. Navarro-Teulon^{1,2,3}, J. Pouget^{1,2,3}; ¹Inserm U1194, MONTPELLIER, FRANCE, ²IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, FRANCE, ³Université de Montpellier, Montpellier, F-34090, Montpellier, FRANCE, ⁴AMAROC, ONIRIS, NANTES, FRANCE, ⁵European Commission, Joint Research Centre, Institute for Transuranium Elements, Karlsruhe, GERMANY.

OP281

Monte Carlo evaluation of Auger-electron emitting radionuclides in 3-D cellular models

N. Falzone^{1,2}, S. Able¹, S. Terry¹, J. M. Fernández-Varea³, K. A. Vallis¹; ¹University of Oxford, Oxford, UNITED KINGDOM, ²Tshwane University of Technology, Department of Biomedical Science, Pretoria, SOUTH AFRICA, ³Universitat de Barcelona, Facultat de Física (ECM and ICC), Barcelona, SPAIN.

OP282

Potential radioprotectors and radiosensitizers in neuroendocrine tumor cells

S. Exner¹, S. Poenick¹, V. Prasad², C. Grötzinger¹; ¹Charité - Universitätsmedizin Berlin, Gastroenterology, Berlin, GERMANY, ²Charité - Universitätsmedizin Berlin, Nuclear Medicine, Berlin, GERMANY.

906

Hall 6

14:30 – 16:00

M2M: Radiopharmaceuticals & Radiochemistry: Radiotracers – Brain

OP283

Pharmacokinetic analysis of [¹¹C]PBR28 in the rat model of herpes encephalitis: comparison with (R)-[¹¹C]PK11195 for pre-clinical imaging

P. Kopschina Feltes¹, A. Parente¹, D. Vázquez García¹, J. W. A. Sijbesma¹, C. M. Moriguchi Jeckel², R. A. J. O. Dierckx¹, E. F. J. de Vries¹, J. Doorduyn¹; ¹University of Groningen, Groningen, NETHERLANDS, ²Pontificia Universidade Católica do Rio Grande do Sul, Porto Alegre, BRAZIL.

OP284

Radiosynthesis and fundamental evaluation of (R)-[¹¹C]emopamil as a novel tracer for imaging enhanced P-glycoprotein function in the brain

J. Toyohara¹, M. Okamoto^{1,2}, H. Aramaki², Y. Zaitzu², I. Shimizu², S. Hosokawa², K. Ishiwata¹; ¹Tokyo Metropolitan Institute of Gerontology, Tokyo, JAPAN, ²Waseda University, Tokyo, JAPAN.

OP285

Discovery of a Fluorinated 4-Oxo-Quinoline Derivative as a Potential PET Radiotracer for Targeting CB2 Receptor

L. Mu¹, R. Slavik², A. Herde Müller², S. D. Krämer², M. Weber³, R. Schibli², S. Ametamey²; ¹UniversitätsSpital Zürich, ZÜRICH, SWITZERLAND, ²ETH Zurich, ZÜRICH, SWITZERLAND, ³Kantonsspital St. Gallen, ZÜRICH, SWITZERLAND.

OP286

PET imaging of P-glycoprotein function at the rodent BBB: Diurnal fluctuations and impact of sleep deprivation

H. Savolainen¹, P. Meerlo¹, A. van Waarde¹, P. Elsinga¹, A. D. Windhorst², N. Colabufo^{3,4}, G. Luurtsema¹; ¹University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS, ²VU University Medical Center, Amsterdam, NETHERLANDS, ³Università degli Studi di Bari, Bari, ITALY, ⁴Biofordrug, Bari, ITALY.

OP287

Comparative Evaluation of Two PET Radioligands for PDE10A, [¹¹C]T-773 and [¹⁸F]FM-T-773-d2 in Nonhuman Primates

A. Takano¹, V. Stepanov¹, R. Nakao¹, N. Amini¹, H. Kimura², C. Halldin¹; ¹Karolinska Institutet, STOCKHOLM, SWEDEN, ²Takeda Pharmaceutical Company, Limited., FUJISAWA, JAPAN.

OP288

Quantification of Available NMDA (GluN) Receptor NTD Drug Binding Sites with the GluN2B-targeting PET Tracer [¹¹C]NB1

S. D. Krämer¹, T. Betzel¹, L. Mu², B. Tewes³, B. Frehland³, D. Schepmann³, R. Schibli¹, B. Wünsch³, S. M. Ametamey¹; ¹ETH, Zurich, SWITZERLAND, ²University Hospital Zurich, Zurich, SWITZERLAND, ³Westfälische Wilhelms-Universität, Münster, GERMANY.

OP289

Autoradiography and microPET rodent evaluation of the [¹⁸F]MCL-524 - an 18F-labelled dopamine D2/D3 receptor agonist

V. Stepanov¹, J. Häggkvist¹, M. Svedberg¹, R. Krasikova², S. J. Finnema¹, A. W. Sromek³, J. L. Neumeyer³, C. Halldin¹; ¹Karolinska Institutet, Stockholm, SWEDEN, ²N.P. Bechtereva Institute of Human Brain, St.-Petersburg, RUSSIAN FEDERATION, ³McLean Hospital/Harvard Medical School, Belmont, MA, UNITED STATES.

OP290

Comparative evaluation of (R)-[11C]verapamil and [11C]-N-desmethyl-loperamide to assess P-glycoprotein function at the mouse blood-brain barrier

T. Wanek¹, S. Mairinger¹, J. Stanek^{1,2}, M. Sauberer¹, T. Filip¹, A. Traxl¹, C. Kuntner¹, J. Pahnke³, M. Müller², O. Langer^{1,2}; ¹AIT Austrian Institute of Technology, Seibersdorf, AUSTRIA, ²Medical University of Vienna, Vienna, AUSTRIA, ³University of Oslo (UiO) and Oslo University Hospital (OUS), Oslo, NORWAY.

907

Hall F

14:30 – 16:00

Teaching Session: The Spine: Anatomy, Pathology and Correlative Imaging

OP291

The Spine: Anatomy, Pathology and Correlative Imaging

I. Pressney, UNITED KINGDOM

908

Hall E

14:30 – 16:00

Clinical Oncology: Prostate II – Beyond Choline

OP292

Noninvasive Quantification of Tumor Blood Flow in Prostate Cancer using 82Rb PET/CT

L. P. Tolbod¹, M. M. Nielsen¹, H. J. Harms¹, B. G. Pedersen², P. Borghammer¹, M. Borre³, K. Bouchelouche¹, J. Frøkiær¹, J. Sørensen¹; ¹Dept. Nuclear Medicine & PET-Centre, Aarhus University Hospital, Aarhus N, DENMARK, ²Department of Radiology, MR-Centre, Aarhus University Hospital, Aarhus N, DENMARK, ³Dept. Urology, Aarhus University Hospital, Aarhus N, DENMARK.

OP293

Phase I Safety and Biodistribution Study of 124I-PEG-AVP0458 Diabody in Patients with TAG-72 Positive Ovarian and Prostate Cancer

A. M. Scott^{1,2}, T. Akhurst³, F. Lee², M. Ciprotti¹, I. Davis¹, A. Weickhardt¹, H. Gan¹, P. Kocovski², N. Guo², D. Murphy³, R. Hicks³, S. Lee¹, G. O'Keefe¹, S. Gong¹, P. Hudson⁴; ¹Austin Health, Melbourne, AUSTRALIA, ²Olivia Newton-John Cancer Research Institute, Melbourne, AUSTRALIA, ³Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, ⁴Avipec Pty Ltd, Melbourne, AUSTRALIA.

OP294

Parasympathetic Imaging of Prostate Cancer using 11C-Donepezil PET.

M. Stokholm¹, S. Høyer², S. Jakobsen¹, D. Bender¹, M. Borre³, J. Frøkiær¹, P. Borghammer¹; ¹Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, DENMARK, ²Department of Pathology, Aarhus University Hospital, Aarhus, DENMARK, ³Department of Urology, Aarhus University Hospital, Aarhus, DENMARK.

OP295

Effect of androgen deprivation therapy on the results of PET/CT with [18F]fluciclovine in patients with prostate cancer

T. Bach-Gansmo¹, H. Sletten², M. C. Småstuen², A. M. Løndalen¹, T. V. Bogsrud¹; ¹Oslo University Hospital, Oslo, NORWAY, ²Oslo and Akershus University College, Oslo, NORWAY.

OP296

68Ga-DOTATATE compared with 11C-Choline PET/CT in patients with hormone-resistant prostate cancer at biochemical relapse.

O. Alonso^{1,2}, G. Dos Santos^{1,2}, E. Savio¹, M. Garcia-Fontes¹, H. Engler¹; ¹Uruguayan Centre of Molecular Imaging (CUDIM), Montevideo, URUGUAY, ²Clinical Hospital, University of Uruguay, Montevideo, URUGUAY.

OP297

Two-phase 68Ga-PSMA-HBED-PET/CT in patients with high-risk prostate carcinoma or PSA-relapse

C. Bouter, B. Meller, C. O. Ritter, J. Lotz, J. Meller, S. Hijazi, C. O. Sahlmann; UMG Göttingen, Göttingen, GERMANY.

OP298

A Direct Comparison Study of Ga-68-NODAGA-MJ9 (MJ9, Bombesin) to F-18-FCH (FCH) in Recurrent Prostate Cancer

P. Mitsakis¹, T. Zilli², M. Kosinski³, J. Delage¹, H. Maecke⁴, R. Mansi⁴, J. Bourhis⁵, F. Buchegger¹, R. Miralbell^{2,6}, J. O. Prior¹; ¹Department of Nuclear Medicine, Lausanne University Hospital, Lausanne, SWITZERLAND, ²Department of Radiation Oncology, University Hospital of Geneva, Geneva, SWITZERLAND, ³Institute of Radiation Physics, Lausanne, SWITZERLAND, ⁴Department of Nuclear Medicine, University Hospital of Freiburg, Freiburg, GERMANY, ⁵Department of Radiation Oncology, Lausanne University Hospital, Lausanne, SWITZERLAND, ⁶Institut Oncològic Teknon, Barcelona, SPAIN.

OP299

A Novel Gallium-68-Labelled GRP Receptor Antagonist, [68Ga]Sarabesin 3, for Prostate Cancer Imaging: First Results in Therapy Naïve Primary Patients

I. L. Bakker¹, A. C. Fröberg¹, M. Busstra¹, G. J. L. H. van Leenders¹, E. de Blois¹, I. Schoots¹, J. Veenland¹, T. Maina², W. M. van Weerden¹, B. Nock², M. de Jong¹; ¹Erasmus MC, Rotterdam, NETHERLANDS, ²National Center for Scientific Research "Demokritos", Athens, GREECE.

910

Hall D

14:30 – 16:00

Clinical Oncology: Rapid Fire Session

OP300

Use of 18FDG-PET/CT to predict outcome in patient with locally advanced pancreatic cancer

L. Locantore¹, P. Mapelli¹, E. Incerti¹, P. Alongi², V. Gangemi³, P. Passoni⁴, N. Slim⁴, N. Di Muzio⁴, L. Gianolli¹, M. Picchio¹; ¹Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY, ²University of Milano-Bicocca, Milan, ITALY, ³Nuclear Medicine Unit, Department of Biomedical Sciences and of Morphologic and Functional Images, University of Messina, Messina, ITALY, ⁴Radiotherapy Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY.

OP301

Predictive value of 18F-FDG PET/CT in patients after primary radio-chemotherapy of head and neck cancers.

I. SANDLER¹, P. Castellucci¹, R. Frakulli², U. Caliceti³, G. M. Lima¹, J. J. Morigi¹, A. Bellusci³, S. Cammelli², S. Fanti¹; ¹Università di Bologna, Nuclear Medicine Unit, S.Orsola-Malpighi Hospital, Bologna, ITALY, ²Università di Bologna, Radiotherapy Unit, S. Orsola-Malpighi Hospital, Bologna, ITALY, ³Università di Bologna, Head and Neck Unit, S. Orsola-Malpighi Hospital, Bologna, ITALY.

OP302

Predictive value of 18F-FDG PET/CT in restaging patients affected by ovarian cancer: a multicenter study.

F. Caobelli¹, P. Alongi², L. Evangelista³, M. Rensi⁴, A. Castello⁵, I. Lagha⁶, C. E. Popescu⁶, C. Dolci⁶, S. Seghezzi⁷, Young AIMN Working Group; ¹Hannover Medical School, Hannover, GERMANY, ²University of Milano Bicocca, Milan, ITALY, ³Istituto Oncologico Veneto, Padua, ITALY, ⁴Hospital of Udine, Udine, ITALY, ⁵University of Florence, Florence, ITALY, ⁶Niguarda Hospital, Milan, ITALY, ⁷Hospital of Treviglio, Treviglio (BG), ITALY.

OP303

Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in NSCLC

V. De Rosa¹, F. Iommelli¹, M. Monti², C. Mainolfi², R. Fonti¹, S. Del Vecchio²; ¹Institute of Biostructures and Bioimages, National Research Council, Naples, ITALY, ²Department of Advanced Biomedical Sciences, University of Naples "Federico II", Naples, ITALY.

OP304

Integrated 18F-FDG PET/MR imaging in the assessment of soft tissue sarcoma: initial experience with surgical and histopathological correlation

S. Vöö, D. Loeffen, R. Weijers, F. Mottaghy; Maastricht University Medical Center, Maastricht, NETHERLANDS.

OP305

Evaluation of tumor hypoxia prior to and during radiotherapy in intermediate-risk prostate cancer using ¹⁸F-Misonidazole PET/CT

M. Dore^{1,2}, S. Supiot^{1,2}, C. Cheze-Le-Rest³, L. Ferrer^{1,2}, G. Delpon^{1,2}, M. Hatt⁴, S. Guerif³, D. Visvikis⁴, C. Rousseau^{1,2}; ¹Institut de Cancerologie de l'ouest Nantes, Saint Herblain, FRANCE, ²INSERM UMR 892 CRCNA, Nantes, FRANCE, ³University Hospital, Poitiers, FRANCE, ⁴INSERM UMR 1101 LaTIM, Brest, FRANCE.

OP306

Multimodal imaging agents for sentinel node mapping as a means to (re)connect nuclear medicine to advances made in robot assisted surgery.

G. H. KleinJan^{1,2}, N. S. Van den Berg^{1,2}, E. Wit², E. Vegt², F. W. B. Van Leeuwen¹, H. G. Van der Poel²; ¹Leiden University Medical Centre, Leiden, NETHERLANDS, ²NKI-AVL, Amsterdam, NETHERLANDS.

OP307

68Ga-OPS202/177Lu-OPS201, a high performance theranostic pair of radiolabelled somatostatin antagonists for PET imaging and radionuclide therapy: translational aspects

G. P. Nicolas¹, R. Mansi¹, F. Kaul¹, S. Vomstein¹, J. Kaufmann², H. Bouterfa², D. Wild¹, M. Fani¹; ¹University Hospital Basel, BASEL, SWITZERLAND, ²OctreoPharm Sciences GmbH, BERLIN, GERMANY.

OP308

First results with Lu-177-PSMA617 in targeted radionuclide therapy of patients with metastatic hormone-refractory prostate cancer

C. Kratochwil¹, F. L. Giesel¹, A. Afshar-Oromieh¹, M. Benešová², W. Mier¹, M. Eder², K. Kopka², U. Haberkorn¹; ¹University Hospital Heidelberg, Heidelberg, GERMANY, ²Division of Radiopharmaceutical Chemistry, German Cancer Research Center (DKFZ), Heidelberg, GERMANY.

OP309

Baseline 18F-FDG PET/CT Predicts Progression-Free Survival After Radium-223

E. Etchebehere, J. Araujo, G. Ray, D. Milton, N. Swanston, H. Macapinlac, E. Rohren; The University of Texas MD Anderson Cancer Center, Houston, TX, UNITED STATES.

OP310

⁶⁴Cu-ATSM PET/CT in solid tumours: a prognostic evaluation for disease outcome

E. Lopci^{1,2}, I. Grassi³, S. Cambioli³, A. Gamboni⁴, F. Salvi⁵, G. Cicoria³, F. Lodi³, C. Dazzi⁶, S. Mattioli⁷, S. Fanti³; ¹Humanitas Clinical and Research Hospital, Milano, ITALY, ²Alma Mater Studiorum University, Bologna, ITALY, ³University Hospital S. Orsola-Malpighi, Bologna, ITALY, ⁴Ospedale degli Infermi, Faenza, ITALY, ⁵Ospedale Bellaria, Bologna, ITALY, ⁶Istituto Oncologico Romagnolo, Ravenna, ITALY, ⁷Alma Mater Studiorum, Bologna, ITALY.

1001



Hall 1

16:30 – 18:00

CME 8 – Cardiovascular & EACVI: Imaging in Heart Failure: Focus on Nuclear Medicine Techniques and Clinical Implications

OP311

Clinical Perspective: Therapeutic Options

A. J. H. A. Scholte, NETHERLANDS

OP312

Selecting Patients for Revascularisation

O. Gaemperli, SWITZERLAND

OP313

Selecting Patients: CRT

C. Uebleis, GERMANY

OP314

Selecting Patients for ICD

H. J. Verberne, NETHERLANDS

1002

Hall 2

16:30 – 18:00

Joint Symposium 8: EANM/EAU: PET Imaging of Genito-urinary Malignancies beyond Prostate

OP315

Clinicians Needs for Kidney and Bladder Cancer Imaging

J. Walz, FRANCE

OP316

PET Imaging of Kidney and Bladder

C- Divgi, USA

OP317

Clinical Needs for Testis Cancer and other Malignancies

J. Walz, FRANCE

OP318

PET Imaging of Testis Cancer and other Malignancies

K. Herrmann, GERMANY

1003

Hall 4

16:30 – 18:00

CTE 4 – Joint Session with Inflammation & Infection Committee: Infection Imaging in Nuclear Medicine

OP319

Overview on Infection Imaging by SPECT and PET

O. Gheysens, BELGIUM

OP320

Overview on Inflammation/Infection and Standardised Cell Labelling Procedure

E. Lazzeri, ITALY

OP321

Image Acquisition and Interpretation Parameters for Planar, SPECT and PET

A. Signore, ITALY

1004

Hall G1

16:30 – 18:00

Neurosciences – Featured: Dementia

OP322

GLP-1 analogue liraglutide prevents decline of brain glucose metabolism in Alzheimer's Disease: Randomized, placebo-controlled double-blinded clinical trial

M. Gejl¹, L. Egejord², A. Møller¹, S. B. Hansen¹, K. Vang¹, A. Rodell¹, H. Brændgaard¹, H. Gottrup¹, A. Schacht¹, N. Møller¹, B. Brock¹, J. Rungby², A. Gjedde³; ¹Aarhus University Hospital, Aarhus, DENMARK, ²Aarhus University, Aarhus, DENMARK, ³University of Copenhagen, Copenhagen, DENMARK.

OP323

A randomized, controlled, multicenter, international study of the impact of florbetapir (18F) PET amyloid imaging on patient management and outcome

M. Pontecorvo¹, M. Grundman², B. Dubois³, F. Nobili⁴, C. Sadowsky⁵, A. McGeehan¹, M. Lowrey¹, A. Dudek¹, M. Flitter¹, G. Dell'Agnello⁶, A. Chevette⁷, W. Deberdt⁷, A. Arora¹, M. D. Devous Sr¹, M. Mintun¹; ¹Avid Radiopharmaceuticals, Philadelphia, PA, UNITED STATES, ²Global R&D Partners, LLC and University of California, San Diego, San Diego, CA, UNITED STATES, ³Salpêtrière Hospital, Paris, FRANCE, ⁴University of Genoa (DINOEMI), Genoa, ITALY, ⁵Nova SE University, Fort Lauderdale, FL, UNITED STATES, ⁶Eli Lilly Italia, Sesto Fiorentino, ITALY, ⁷Eli Lilly France, Paris, FRANCE.

OP324

18F-Florbetaben PET Imaging of Morphologically Distinct Amyloid β Deposits

O. Sabri¹, A. M. Catafau², H. Barthel¹, J. Seibyl³, B. Ghetti⁴, J. Leverenz⁵, J. W. Ironside⁶, S. Bullich², W. Schulz-Schaeffer⁷, A. Hoffmann⁸; ¹Leipzig University, Leipzig, GERMANY, ²Piramal Imaging, Berlin, GERMANY, ³IND, New Haven, CT, UNITED STATES, ⁴Indiana University School of Medicine, Indianapolis, IN, UNITED STATES, ⁵Cleveland Lou Ruvo Center for Brain Health, Cleveland, OH, UNITED STATES, ⁶University of Edinburgh, Edinburgh, UNITED KINGDOM, ⁷Georg August University Göttingen, Göttingen, GERMANY, ⁸Bayer Pharma, Berlin, GERMANY.

OP325

18F-Florbetaben beta-amyloid PET scan quantification: Do cerebellar plaques influence SUVR?

A. M. Catafau¹, S. Bullich¹, J. Seibyl², H. Barthel³, B. Ghetti⁴, J. B. Leverenz⁵, J. W. Ironside⁶, W. J. Schulz-Schaeffer⁷, A. Hoffmann⁸, O. Sabri³; ¹Piramal Imaging GmbH, Berlin, GERMANY, ²Molecular Neuroimaging, New Haven, CT, UNITED STATES, ³Leipzig University, Leipzig, GERMANY, ⁴Indiana University School of Medicine, Indianapolis, IN, UNITED STATES, ⁵Puget Sound Health Care System and University of Washington, Seattle, WA, UNITED STATES, ⁶University of Edinburgh, Edinburgh, UNITED KINGDOM, ⁷Georg-August University Göttingen, Göttingen, GERMANY, ⁸Bayer Pharma AG, Berlin, GERMANY.

OP326

Clinical [¹⁸F]Florbetaben-PET Imaging - Benefit of Early Acquisition

S. Daerr¹, M. Brendel¹, C. Zach¹, A. Danek¹, H. Barthel², O. Sabri², P. Bartenstein¹, A. Rominger¹; ¹University of Munich, Munich, GERMANY, ²University of Leipzig, Leipzig, GERMANY.

OP327

Resveratrol in Alzheimer's disease: a PIB positron emission tomography/computed tomography study

A. Damian¹, A. de la Fuente², G. Castellano³, E. Savio², P. Buccino², B. Aguiar⁴, A. Quagliata¹, F. Cano³, M. Gonzalez², S. Dansilio⁴, A. Kmaid⁵, I. Savio⁵, H. Engler²; ¹Uruguayan Centre of Molecular Imaging (CUDIM); Nuclear Medicine Centre, University of the Republic, Montevideo, URUGUAY, ²Uruguayan Centre of Molecular Imaging (CUDIM), Montevideo, URUGUAY, ³Department of Social and Preventive Medicine, University of the Republic, Montevideo, URUGUAY, ⁴Department of Neuropsychology, University of the Republic, Montevideo, URUGUAY, ⁵Department of Geriatrics, University of the Republic, Montevideo, URUGUAY.

1005

Hall G2

16:30 – 18:00

Do.MoRe: 90Y SIRT Treatment Planning

OP328

Partition model absorbed dose biases and variability due to tumor-to-normal-liver ratios following 90Y microsphere therapy

J. Mikell^{1,2}, A. Mahvash¹, W. Siman^{1,2}, F. Mourtada³, S. C. Kappadath^{1,2}; ¹UT MD Anderson Cancer Center, Houston, TX, UNITED STATES, ²UT Graduate School of Biomedical Sciences, Houston, TX, UNITED STATES, ³Christiana Care Health System, Newark, DE, UNITED STATES.

OP329

99mTc-MAA SPECT/CT lung shunt estimations are more accurate than those obtained from planar scintigraphy

J. Prince, A. F. van den Hoven, G. C. Krijger, N. de Wit, B. J. van Nierop, M. N. G. J. Braat, M. A. A. J. van den Bosch, H. M. Verkooijen, M. G. E. H. Lam; UMC Utrecht, Utrecht, NETHERLANDS.

OP330

Provisional dosimetry based on 99mTc-MAA SPECT for radioembolization of liver lesions with 90Y-loaded microspheres: impact of attenuation correction, scatter correction and calibration

M. Pacilio¹, C. Chiesa², M. E. Ferrari³, F. Botta³, L. Lorenzon¹, M. Mira², M. Ljungberg⁴, M. Cremonesi³; ¹Azienda Ospedaliera San Camillo Forlanini, Roma, ITALY, ²Istituto Nazionale dei Tumori, Milano, ITALY, ³European Institute of Oncology, Milano, ITALY, ⁴Lund University, Lund, SWEDEN.

OP331

Effect of Data-Driven Respiratory Gating on Radioactivity Quantification in Liver Lesions for Pre-Radioembolization Tc-99m-MAA SPECT/CT

J. C. Sanders^{1,2}, A. H. Vija³, T. Kuwert¹, P. Ritt¹; ¹Clinic of Nuclear Medicine, University Hospital Erlangen, Erlangen, GERMANY, ²Pattern Recognition Lab, University of Erlangen-Nuremberg, Erlangen, GERMANY, ³Siemens Molecular Imaging, Hoffman Estates, IL, UNITED STATES.

OP332

Feasibility and safety of selective internal radiation therapy (SIRT) procedure in one day

A. Dieudonné¹, A. Siebert², M. Abdel-Rehim², S. Legendre¹, S. Sebahoun¹, M. Ben-Reguiga¹, V. Vilgrain², R. Lebtahi¹; ¹Department of Nuclear Medicine, Beaujon Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Clichy, FRANCE, ²Department of Radiology, Beaujon Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Clichy, FRANCE.

OP333

Regularized reconstruction results in a major improvement of Y-90 PET/CT image quality after SIRT with Y-90 microspheres

K. Tatsch¹, J. Touati², M. Leicht¹, C. Puskas¹, L. Maron¹, H. Arques Aguilo²; ¹Municipal Hospital Karlsruhe Inc, Dept. of Nuclear Medicine, Karlsruhe, GERMANY, ²GE Healthcare, Buc, FRANCE.

OP334

A branching artery tree model in concordance with microscopy observations of microsphere distribution in liver following radioembolisation

J. Högberg¹, M. Rizell^{1,2}, R. Hultborn^{1,2}, J. Svensson^{1,2}, O. Henrikson^{1,2}, J. Mölne^{1,2}, P. Gjerdtsson², P. Bernhardt^{1,2}; ¹The Sahlgrenska Academy at The University of Gothenburg, Gothenburg, SWEDEN, ²Sahlgrenska University Hospital, Gothenburg, SWEDEN.

OP335

Reconstruction, volumetry and dosimetry optimisation for 99mTc-SPECT and 90Y-PET images: towards reliable DVH for SIRT treatments

M. Bernardini¹, H. Thevenet¹, C. Berthold², A. Fischer³, A. Petitguillaume⁴, A. Desbrée⁵, C. Smadja¹, P. Weinmann¹, N. Ghazdar¹; ¹European Hospital Georges Pompidou, PARIS, FRANCE, ²Gustave Roussy Institut, Villejuif, FRANCE, ³Philips GmbH Innovative Technologies, Aachen, GERMANY, ⁴Cancéropole Grand Sud Ouest, Toulouse, FRANCE, ⁵LEDI, IRSN, Fontanay aux Roses, FRANCE.

1006

Hall 6

16:30 – 18:00

M2M: Radiopharmaceuticals & Radiochemistry: Peptides

OP336

Assessing the impact of clinically certified NEP and/or ACE inhibitors on the in vivo profile of [111In-DOTA]MG11: A comparative study in mice

A. Kaloudi¹, E. Lymperis¹, E. P. Krenning², M. de Jong^{2,3}, B. A. Nock¹, T. Maina¹; ¹Molecular Radiopharmacy, INRASTES, NCSR Demokritos, ATHENS, GREECE, ²Institute of Nuclear Medicine, Erasmus MC, ROTTERDAM, NETHERLANDS, ³Institute of Radiology, Erasmus MC, Rotterdam, NETHERLANDS.

OP337

A phage display derived stabilised bicyclic peptide targeting MMP-14 shows high imaging contrast in small animal PET imaging

M. Eder¹, S. Pavan², U. Bauder-Wüst¹, K. van Rietschoten², L. Baldassarre², U. Schierbaum³, O. Seibert³, K. Leotta³, S. Campbell², H. Harrison², C. Stace², E. Walker², U. Haberkorn³, K. Kopka¹, D. P. Teufel²; ¹Radiopharmaceutical Chemistry, German Cancer Research Center, HEIDELBERG, GERMANY, ²Bicycle Therapeutics Limited, Cambridge, UNITED KINGDOM, ³CCU Nuclear Medicine, German Cancer Research Center, HEIDELBERG, GERMANY.

OP338

Sometimes, Less is More: Specific Activity of Radiopharmaceuticals and its Impact on Biodistribution and Imaging Contrast

J. Notni¹, D. Reich¹, J. Pollmann¹, F. Hofmann¹, M. Weineisen¹, T. Kapp², F. Rechenmacher¹, H. Kessler², H. Wester¹; ¹Pharmaceutical Radiochemistry, Garching, GERMANY, ²Center for Integrated Protein Research, Garching, GERMANY.

OP339

Assessment of the specificity of 99mTc-duramycin in a mouse model of colorectal cancer

F. Elvas^{1,2}, C. Vangestel^{1,2}, K. Y. Pak³, S. Stroobants^{1,2}, S. Staelens¹, L. Wyffels^{1,2}; ¹University of Antwerp - Molecular Imaging Center Antwerp, Wilrijk, BELGIUM, ²University Hospital Antwerp - Department of Nuclear Medicine, Edegem, BELGIUM, ³Molecular Targeting Technologies, Inc., West Chester, PA, UNITED STATES.

OP340

Development of radiocobalt-labeled GRPR antagonist NOTA-PEG2-RM26.

B. Mitran¹, Z. Varasteh¹, U. Rosenström², V. Tolmachev³, G. Lindeberg², M. Larhed⁴, A. Orlova¹; ¹Preclinical PET Platform, Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN, ²Organic Pharmaceutical Chemistry, Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN, ³Biomedical Radiation Sciences, Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN, ⁴Science for Life Laboratory, Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN.

OP341

⁶⁸Ga-RM2 for imaging of prostate cancer - Successful implementation of Synthesizer- and Kit-based production methods

M. Zerna, A. Müller, M. Berndt; Piramal Imaging, Berlin, GERMANY.

OP342

Kit formulation, preclinical evaluation and experimental radionuclide therapy using CCK2 receptor targeting cyclic minigastrin

E. von Guggenberg¹, C. Rangger¹, L. Balogh², Z. Pöstényi², D. Pawlak³, R. Mikołajczak³; ¹Department of Nuclear Medicine, Innsbruck Medical University, Innsbruck, AUSTRIA, ²"Frédéric Joliot-Curie" National Research Institute for Radiobiology and Radiohygiene (NRIR), Budapest, HUNGARY, ³Radioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, POLAND.

OP343

Development & application of an [18F] anti-amyloid peptide radiotracer

O. Morris¹, J. Gregory¹, A. Blykers², D. Allsop³, M. Taylor³, S. Allan¹, A. McMahon¹, H. Boutin¹, C. Prenant¹; ¹The University of Manchester, Manchester, UNITED KINGDOM, ²Vrije Universiteit Brussel, Brussels, BELGIUM, ³The University of Lancaster, Lancaster, UNITED KINGDOM.

1007

Hall F

16:30 – 18:00

DGN-Sponsored Symposium: PET/MRI

OP344

Welcome

S. Klutmann, GERMANY

OP345

PET/MRI - Methodology, Standardisation and Challenges

B. Sattler GERMANY

OP346

PET/MRI in Oncology

A. J. Beer, GERMANY

OP347

PET/MRI - Applications in Cardiology

M. Schwaiger, GERMANY

OP348

Brain Imaging with PET/MRI

O. Sabri, GERMANY

1008

Hall E

16:30 – 18:00

Conventional & Specialised Nuclear Medicine: General & Miscellaneous

OP351

Ga-68 macroaggregated albumin (MAA) Perfusion PET/CT for lobar pulmonary function quantification: comparison with anatomic method, volumetric CT and planar scintigraphy.

P. Le Roux, T. Leong, S. A. Barnett, R. J. Hicks, P. Eu, J. Callahan, R. Manser, M. S. Hofman; Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA.

OP352

The Importance Of Scintigraphic Pattern in the Suspected Diagnosis Of Sjögren's Syndrome.

B. Garcia-Garcia, M. J. Ribelles, E. F. Guillén, L. Sancho, M. Rodriguez, M. J. García-Velloso, P. DeCastro, E. Orilla, J. Á. Richter; Clinica Universidad de Navarra, Pamplona, SPAIN.

OP353

Surgical planning issues of radio-guided sentinel node biopsy (SNB) in patients (pts) with second primary ipsilateral breast cancer (SPIBC)

C. Peterle, C. Cittanti, P. Carcoforo, M. Portinari, V. de Cristoforo, I. Santi, S. Panareo, L. Feggi; S. Anna University Hospital, Cona (FE), ITALY.

OP354

Factors influencing brown fat activation in FDG PET/CT: a retrospective analysis of 21,000+ cases

J. Steinberg, E. Vegt; Netherlands Cancer Institute, Amsterdam, NETHERLANDS.

OP355

Role of HIF-1 in Hypoxia Stimulated Glucose Metabolism in Human Endothelial Cells

J. Paik¹, J. Park², K. Jung³, K. Lee⁴; ¹samsung medical center, seoul, KOREA, REPUBLIC OF, ²samsung medical center, sungkyunkwan university, seoul, KOREA, REPUBLIC OF, ³samsung medical center, Sungkyunhwan University, seoul, KOREA, REPUBLIC OF, ⁴samsung medical center, Samsung medical center, Sungkyunhwan University, seoul, KOREA, REPUBLIC OF.

OP356

Initial Experience with PET/MRI in the Evaluation of Diabetic Foot

D. Franceschi, K. Yaddanapudi, R. Matthews, V. Brunetti, B. Martin; SUNY at Stony Brook, StonyBrook, NY, UNITED STATES.

OP359

Absolute quantification in a commercial SPECT/CT: Tc-99m Activity recovery in NEMA/IEC and anthropomorphic phantoms.

S. Gnesin¹, P. Leite Ferreira², J. Malterre², J. Prior², F. Verdun¹; ¹Institute of Radiation Physics, Lausanne University Hospital, Lausanne, SWITZERLAND, ²Department of Nuclear Medicine, Lausanne University Hospital, Lausanne, SWITZERLAND.

OP360

Comparison of Image Reconstruction Techniques for Single Photon Emission Computed Tomography (SPECT)

M. Dimcheva, S. Sergieva, A. Jovanovska; Sofia Cancer Center, Sofia, BULGARIA.

OP361

Quantitative Yttrium-90 PET/CT acquisition and reconstruction optimization: An anthropomorphic phantom validation.

S. Gnesin¹, L. Paterne¹, A. Boubaker², S. Adib², M. Pappon², M. Kosinski¹, J. Prior², S. Baechler¹, F. Verdun¹; ¹Institute of Radiation Physics, Lausanne University Hospital, Lausanne, SWITZERLAND, ²Department of Nuclear Medicine, Lausanne University Hospital, Lausanne, SWITZERLAND.

OP362

FDG uptake quantification: a new approach using tumour delineation on maximum intensity projections

A. de Jong¹, B. A. Blomberg¹, R. A. Nievelstein¹, V. Frings¹, G. Kramer², A. J. de Langen², O. S. Hoekstra², R. Boellaard²; ¹UMC Utrecht, Utrecht, NETHERLANDS, ²VU Medical Center, Amsterdam, NETHERLANDS.

OP363

The influence of ignoring higher bone attenuation on pelvic and spinal lesions in [18F]NaF PET/MRI examinations.

G. Schramm^{1,2}, L. Oehme³, J. Maus², F. Hofheinz², J. Petr², A. Lougovski², B. Beuthien-Baumann³, J. van den Hoff²; ¹KU Leuven, Leuven, BELGIUM, ²Helmholtz-Zentrum Dresden-Rossendorf, Dresden, GERMANY, ³Universitätsklinikum Carl Gustav Carus, Dresden, GERMANY.

OP364

Evaluation of Siemens SMART Neuro AC Calculated Attenuation Correction for FET PET

P. Ritt, T. Kuwert, C. von Gall; Clinic of Nuclear Medicine, University Hospital, Erlangen, GERMANY.

1009

Hall 8

16:30 – 18:00

Physics & Instrumentation & Data Analysis: Image Reconstruction, Quantification & PET/MR

OP357

Scatter correction requirements for quantitative I-131 SPECT: Triple Energy Window and full Monte Carlo correction compared in phantom acquisitions

C. A. J. van Gils^{1,2}, R. van Rooij¹, C. Beijst¹, H. W. A. M. de Jong¹; ¹University Medical Center Utrecht, Utrecht, NETHERLANDS, ²St. Antonius Ziekenhuis, Nieuwegein, NETHERLANDS.

OP358

Absolute quantification in SPECT - a phantom study

J. Kupferschlaeger, J. Lott, L. Kuenzel, H. Dittmann, C. la Fougère; University Hospital Tuebingen/Department of Radiology/ Division of Nuclear Medicine, Tuebingen, GERMANY.

1010

Hall D

08:00 – 09:30

Clinical Oncology: Melanoma & Lymphoma

OP365

Interim [18F]-FDG-PET in MALT lymphoma patients treated with immunotherapy: which Deauville score is the best predictor of end-of-treatment outcome?

T. Traub-Weidinger, M. Raderer, B. Kiesewetter, M. Weber, G. Karanikas, M. Mitterhauser, M. Hacker, M. E. Mayerhoefer; Medical University of Vienna, Vienna, AUSTRIA.

OP366

The Deauville Criteria and Metabolic Parameters as Prognostic Factors in Interim PET in Hodgkin Lymphoma: a Single Centre Experience

M. Cuzzocrea¹, L. Guerra², F. Elisei², C. Crivellaro^{1,2,3}, E. De Ponti⁴, S. Bolis⁵, L. Baratto¹, S. Pacella¹, M. Arosio², C. Landoni¹; ¹Department of Nuclear Medicine, University of Milan-Bicocca, Milan, ITALY, ²Department of Nuclear Medicine, San Gerardo Hospital, Monza, ITALY, ³Tecnomed Foundation, University of Milan-Bicocca, Milan, ITALY, ⁴Department of Medical Physics, San Gerardo Hospital, Monza, ITALY, ⁵Department of Haematology, San Gerardo Hospital, Monza, ITALY.

OP367

PET/FDG and Interleukin-10 as prognostic indicators in Diffuse Large Type B-Cell Lymphoma

L. Tagliabue¹, L. Ottobrin², C. B. Colombo², S. Seghezzi³, I. Libani², A. Moro¹, M. Violati¹, L. De Fazio⁴, A. Bertolini⁵, P. Foa², G. Lucignani²; ¹AO San Paolo, Milano, ITALY, ²University of Milan, Milano, ITALY, ³AO Treviglio-Caravaggio, Treviglio, ITALY, ⁴AO Lodi, Lodi, ITALY, ⁵AO Valtellina e Chiavenna, Sondrio, ITALY.

OP368

Assessing Bone Marrow Involvement in DLBCL: Comparison of FDG PET and Bone Marrow Biopsy

V. Ptacnik, K. Benesova, E. Cmunt, J. Kubinyi, M. Trneny; Charles University Prague, Prague, CZECH REPUBLIC.

OP369

Prolonged overall survival in metastatic melanoma with low tumor burden at anti-PD1 initiation: CT-scan, 18-FDG-PET and blood samples

L. Dercle, S. Ammari, M. Texier, E. Lanoy, S. Champiat, D. Deandrei, M. Terroir, A. Marabelle, M. Schlumberger; Gustave Roussy, Villejuif, FRANCE.

OP370

Cost-effectiveness analysis of sentinel node biopsy in patients with primary cutaneous melanoma

P. Serra-Arbeloa^{1,2}, Á. O. Rabines-Juárez¹, S. Álvarez-Ruiz³, F. Guillén-Grima²; ¹Complejo Hospitalario de Navarra, Pamplona, SPAIN, ²Universidad Pública de Navarra, Pamplona, SPAIN, ³Hospital Universitario Miguel Servet, Zaragoza, SPAIN.

OP371

The role of preoperative lymph node ultrasound in patients with primary cutaneous melanoma: a meta-analysis

P. Serra-Arbeloa^{1,2}, Á. O. Rabines-Juárez¹, S. Álvarez-Ruiz³, F. Guillén-Grima²; ¹Complejo Hospitalario de Navarra, Pamplona, SPAIN, ²Universidad Pública de Navarra, Pamplona, SPAIN, ³Hospital Universitario Miguel Servet, Zaragoza, SPAIN.

OP372

Lymphoscintigraphy and Sentinel Lymph Node Biopsy in Cutaneous Melanoma: Analysis of 201 Patients From a Single Institution

L. Jaukovic, M. Rajović, M. Radulovic, L. Kandolf-Sekulovic; Military Medical Academy, Belgrade, SERBIA.

1101

CME

Hall 1

08:00 – 09:30

CME 9 – Radionuclide Therapy & Thyroid & Translational Molecular Imaging: Theranostics: What We Have and What We Can Achieve

OP373

Established and Innovative Applications for Diagnosis

W. Weber, USA

OP374

Theranostics in Clinical Experience: From Nets to Prostate Cancer

S. Ezzeddin, GERMANY

OP375

Theranostic Targeting Vectors and Nanoparticles

F. Kiessling, GERMANY

1102

Hall 2

08:00 – 09:30

**Joint Symposium 9: EANM/ESSR/ESSKA:
Evaluation of the Painful Knee Arthroplasty**

OP376

**Normal Knee Joint Biomechanics and Surgical
Techniques of Knee Arthroplasty**

R. Nizard, FRANCE

OP377

**What the Surgeon Wants to Know from Imaging in
Painful Knee Arthroplasty**

M. T. Hirschmann, SWITZERLAND

OP378

Radiologic Imaging

A. Hirschmann, SWITZERLAND

OP379

**Hybrid Imaging in the Painful Knee Arthroplasty:
Role and Limits**

H. K. Mohan, UK

1105

Hall G2

08:00 – 09:30

Do.MoRe: Quantitative Molecular Imaging

OP380

**Y-90 imaging for dosimetry in radioembolization:
comparison between scatter corrected
bremsstrahlung SPECT/CT and time-of-flight PET/CT**

*Y. K. Dewaraja¹, P. M. Novelli¹, J. A. Fessler¹, M. U. Feng¹,
R. Nelson¹, J. Rothley¹, M. Ljungberg², P. L. Roberson¹,
S. J. Wilderman¹; ¹University of Michigan, Ann Arbor, MI,
UNITED STATES, ²Lund University, Lund, SWEDEN.*

OP381

**Study of the impact of PSF and Noise on Dose
Volume Histograms (DVH) for the dosimetry of Y-90**

*H. Levillain, M. Sanchez-Garcia, A. Dieudonné; Department
of Nuclear Medicine, Beaujon Hospital, Assistance Publique-
Hôpitaux de Paris (APHP) & INSERM U1149, Clichy, FRANCE.*

OP382

**An inter-operator study of the accuracy of
Y-90/In-111 DOTATATE dosimetry using an
anthropomorphic phantom**

*T. Sanderson, J. Gear, A. Divoli, A. Craig, M. Gray, I. Murray,
G. Flux; The Royal Marsden NHSFT, Sutton, UNITED
KINGDOM.*

OP383

**Modelling of a Patient-Specific ¹⁷⁷Lu-Dotatate
Therapy Renal Dosimetry Process for Investigation of
Uncertainties**

*J. Gustafsson¹, G. Brolin¹, M. Cox², M. Ljungberg¹,
L. Johansson², K. Sjögreen Gleisner¹; ¹Department of Medical
Radiation Physics, Clinical Sciences Lund, Lund University,
Lund, SWEDEN, ²National Physical Laboratory, Teddington,
UNITED KINGDOM.*

OP384

**Dosimetry of Lu-177 DKFZ-PSMA-617 for the
treatment of metastatic prostate cancer using
quantitative SPECT/CT**

*A. Delker, W. Fendler, A. Brunegraf, A. Gosewisch,
F. Gildehaus, P. Bartenstein, G. Böning; University of Munich,
München, GERMANY.*

OP385

**Accuracy of Triple Energy Window vs. Analytical
Photon Distribution Scatter Corrections in Lu-177
Studies**

*C. F. Uribe^{1,2}, L. Frauenstein^{3,1}, P. L. Esquinas^{1,2}, J. Tanguay¹,
M. Gonzalez⁴, A. Celler¹; ¹Medical Imaging Research Group,
University of British Columbia, Vancouver, BC, CANADA,
²Department of Physics and Astronomy, University of
British Columbia, Vancouver, BC, CANADA, ³Department
of Computer Science, Otto von Guericke University of
Magdeburg, Magdeburg, GERMANY, ⁴Vancouver Coastal
Health, Vancouver, BC, CANADA.*

OP386

**Towards a quality assurance for dosimetry in
peptide receptor radionuclide therapy (PRRT) with
¹⁷⁷Lu-DOTATATE**

*G. Marin, B. Vanderlinden, Z. Wimana, T. Guiot, I. Karfis,
P. Flamen; Institut Jules Bordet, Bruxelles, BELGIUM.*

OP387

**International Multicentre Evaluation of Absolute
Quantification in Planar and SPECT Imaging**

*B. E. Zimmerman¹, I. Buvat², E. C. Frey³, A. J. Green⁴, D. Grošev⁵,
M. Lassmann⁶, M. Ljungberg⁷, G. Poli⁸; ¹National Institute
of Standards and Technology, Gaithersburg, MD, UNITED
STATES, ²Service Hospitalier Frédéric Joliot, Paris, FRANCE,
³Johns Hopkins Medical Institutions, Baltimore, MD, UNITED
STATES, ⁴National Physical Laboratory, Teddington, UNITED
KINGDOM, ⁵University Hospital Centre Zagreb, Zagreb,
CROATIA, ⁶Universitätsklinik Würzburg, Würzburg, GERMANY,
⁷Lund University, Lund, SWEDEN, ⁸International Atomic
Energy Agency, Vienna, AUSTRIA.*

1106

Hall 6

11:30 – 13:00

M2M: Molecular & Multimodality Imaging: Tumour Biology & Optical Imaging

OP388

Insights into the DNA damage response can improve peptide receptor radionuclide therapy outcomes

J. Nonnekens, C. Beerens, M. van Kranenburg, D. C. van Gent, M. de Jong; Erasmus MC, Rotterdam, NETHERLANDS.

OP389

Blocking DNA repair mechanism - the way to improve alpha targeted therapy of glioblastoma multiforme ?

E. Rosiak¹, H. Koziara², R. Matyskiel¹, B. Królicki², L. Królicki¹; ¹Department of Nuclear Medicine, Medical University of Warsaw, Warsaw, POLAND, ²Department of Neurosurgery, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, POLAND.

OP390

Radiation-Induced Media-Transferred Bystander Effect in Breast Cancer Cells

K. L. Madsen, P. F. Høilund-Carlsen, B. B. Olsen; Odense University Hospital, Odense, DENMARK.

OP391

Ex vivo tumor tissue culture to mechanistically examine DNA-damage after peptide receptor radionuclide therapy

J. Nonnekens, C. Beerens, D. C. van Gent, M. de Jong; Erasmus MC, Rotterdam, NETHERLANDS.

OP392

Clinical Relevance of Targeting SSTR2, GRPR and CXCR4 with Radioligands for Imaging and Therapy in Breast Cancer

S. Dalm, A. Sieuwerts, M. Look, M. Melis, C. van Deurzen, J. Foekens, M. de Jong, J. Martens; Erasmus MC, Rotterdam, NETHERLANDS.

OP393

Increase of PSMA Expression by Androgen Deprivation

B. Meller, C. O. Sahlmann, S. Hijazi, C. Bouter, L. Trojan, J. Meller, P. Thelen; Georg-August-University Göttingen, Göttingen, GERMANY.

OP394

Detrimental Effects of Radiation on the Fluorescence of Fluorophores: Implications for Dual-Modality Imaging

R. Hernandez¹, S. Heskamp², M. Rijpkema², D. M. Goldenberg³, W. McBride³, A. Morgenstern⁴, F. Bruchertseifer⁴, W. Cai¹, O. Boerman²; ¹University of Wisconsin-Madison, Madison, WI, UNITED STATES, ²Radboud University Medical Center, Nijmegen, NETHERLANDS, ³Immunomedics Inc., Morris Plains, NJ, UNITED STATES, ⁴Institute of Transuranium Elements, Karlsruhe, GERMANY.

OP395

Characterisation and quantification of fluorescently labeled Exendin for beta cell targeting and comparison with radiolabeled Exendin

S. Ekim, D. Bos, M. Brom, M. Gotthardt; Radboud University Medical Centre, Nijmegen, NETHERLANDS.

1107

Hall F

08:00 – 09:30

SNMMI Symposium: Hepatobiliary Scintigraphy in Abdominal Pain

OP396

Hepatobiliary Scintigraphy - Diagnosis of Abdominal Pain

H. A. Ziessman, USA

OP397

Development of Appropriate Use Criteria for Hepatobiliary Scintigraphy of Abdominal Pain

H. Jadvar, USA

1108

Hall F

08:00 – 09:30

Pitfalls & Artefacts & Physiology (Cardiovascular) – Interactive: MPS, SPECT-CT, PET, Newer Techniques such as CZT and IQ SPECT

OP398

SPECT

J. Bucerius, NETHERLANDS

OP399

SPECT-CT

R. Buechel, SWITZERLAND

OP400
PET

W. Burchert, GERMANY

OP401

Newer Technologies

D. Agostini, FRANCE

1201/1203

Hall 1

10:00 – 11:15

Plenary 3: Targets and Probes

OP402

Target Discovery and Probe Identification in Oncology

P. Workman, UK

OP403

Probe Selection and Development for Molecular Imaging and Therapy, the Perspective of Industry

M. Friebe, GERMANY

OP404

Probe Selection and Development for Molecular Imaging and Therapy, the Perspective of Academia

G. A. M. S. van Dongen, NETHERLANDS

1301



Hall 1

11:30 – 13:00

CME 10 – Dosimetry & Translational Molecular Imaging: Preclinical Quantitative Imaging and Dosimetry

OP405

Preclinical Quantitative Imaging for Dose Assessments

E. Visser, NETHERLANDS

OP406

Dosimetric Models in Preclinical Studies

M. Bardiés, FRANCE

OP407

PK Model Based Dose Calculations and Dose-effect Relations in Preclinical Studies

N. Chouin, FRANCE

1302

Hall 2

11:30 – 13:00

Joint Symposium 10: EANM/ELI: Lymphoma and PET/CT Update

OP408

FDG for Assessment of Lymphoma Subtypes other than HL, DLBCL and FL

S. Barrington, UK

OP409

Response Assessment for New Targeted Agents, What is known?

M. Meignan, FRANCE

OP410

How is PET-CT Impacting on Radiotherapy Planning in Lymphoma

L. Specht, DENMARK

1303

Hall 4

11:30 – 12:45

Technologist Oral Presentations 3

OP411

Adaptation of ^{13}N -NH $_3$ and ^{18}F -FDG Imaging Protocols for sarcoidosis for new scanner technology

C. Abreu¹, J. O'Doherty¹, S. Barrington¹, S. Pereira¹, L. Alves¹, J. John¹, P. Schleyer²; ¹PET Imaging Centre, King's College London, King's Health Partners, St Thomas' Hospital, London, UNITED KINGDOM, ²PET Imaging Centre, King's College London, London, UNITED KINGDOM.

OP412

Benign Iodine-131 Treatment - Passing tasks from physician to technologist

H. C. Larsen, L. F. Grønneberg, P. C. Holdgaard, MD; Department of Nuclearmedicine, Vejle Hospital - Part of Lillebaelt Hospital, Vejle, DENMARK.

OP414

Methods for preparing and acquiring PET/CT exams with ^{18}F -Fluorodeoxyglucose and ^{18}F -Fluoromethylcholine

R. Sanco, M. Zappalà, V. Arnoldo, L. Memo, E. Zaramella, A. Carraro, L. Evangelista; Istituto Oncologico Veneto I.R.C.C.S., PADOVA, ITALY.

OP415

SPECT Myocardial Perfusion Imaging Quantification in Obese Subjects: Influence of Attenuation Correction with Computed Tomography Attenuation Maps

O. Stakhiv¹, M. Clarke², M. Aplin², N. Singh², K. Day², S. Dizdarevic², M. Jessop², E. Sousa¹; ¹Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisbon, PORTUGAL, ²Nuclear Medicine, Department of Imaging, Brighton and Sussex University Hospital NHS Trust, Brighton, UNITED KINGDOM.

OP416

[18F]-FDG SUV of reference regions in PET/MRI following standard MR-based attenuation correction

I. Haidinger¹, I. Rausch¹, M. Mayerhöfer², M. Hartenbach³, T. Beyer¹; ¹Centre for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA, ²Division of Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA, ³Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA.

OP417

Do Metal Objects in the Topogram Influence the Patient Dose?

K. Falch¹, C. Baun¹, S. Shanmuganathan¹, M. Nikolajsen², O. Gerke¹, P. Hoelund-Carlsen¹; ¹Odense University Hospital, Odense, DENMARK, ²University College Lillebaelt, Odense, DENMARK.

OP418

The Effect of Type of Collimation, Duration of Image Acquisition and Scatter Correction in Heart-to-Mediastinum Ratio of I-123-MIBG Scintigraphy

S. Chaves, T. Vieira, A. Sá Pinto, V. Alves, A. Fernandes, J. G. Pereira; Centro Hospitalar de São João, Porto, PORTUGAL.

1305

Hall G2

11:30 – 12:45

Do.MoRe – Featured: Therapy – Miscellaneous

OP419

An automatic delineation method for bone marrow absorbed dose estimations of 89Zr PET/CT studies

N. E. MAKRIS, R. Boellaard, C. W. Menke-van der Houven van Oordt, A. A. Lammertsma, M. C. Huisman; VU University Medical Center, Amsterdam, NETHERLANDS.

OP420

Phase II Study of Lutetium-177-labeled Anti Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.

C. H. J. Muselaers¹, M. J. Boers-Sonderer², T. J. van Oostenbrugge¹, O. C. Boerman³, I. M. E. Desar², A. B. Stillebroer⁴, S. F. Mulder², C. M. L. van Herpen², J. F. Langenhuijsen⁴, E. Oosterwijk⁴, P. F. A. Mulders⁴, W. J. G. Oyen³; ¹Radboudumc, Dept. of Urology, Dept. of Radiology and Nuclear Medicine, Nijmegen, NETHERLANDS, ²Radboudumc, Dept. of Medical Oncology, Nijmegen, NETHERLANDS, ³Radboudumc, Dept. of Radiology and Nuclear Medicine, Nijmegen, NETHERLANDS, ⁴Radboudumc, Dept. of Urology, Nijmegen, NETHERLANDS.

OP421

Preliminary experience in treating high-risk neuroblastoma using tandem high dose dosimetry-guided 131I-MIBG treatment combined with chemotherapy

G. Boni¹, s. mazzari¹, M. Menconi², A. C. Traino³, E. Borsò⁴, S. Bernasconi², G. Casazza², C. Favre⁵, D. Volterrani¹; ¹Regional Center Of Nuclear Medicine, University Hospital Of Pisa, Pisa, ITALY, ²Division of Pediatric Onco-hematology, University Hospital, Pisa, Italy, Pisa, ITALY, ³Health Physics Unit, Section of Medical Physics, University Hospital, Pisa, Italy, Pisa, ITALY, ⁴Nuclear Medicine Division, Sant'Andrea Hospital of La Spezia, La Spezia, ITALY, ⁵Division of Pediatric Onco-hematology, Meyer Pediatric Hospital, Florence, Florence, ITALY.

OP422

Compared therapeutic efficacy of 177Lu-HH1 and 177Lu-rituximab in non-Hodgkin B-cell lymphoma

A. Pichard, Jr.^{1,2,3}, S. Marcattili^{4,5}, A. Courteau^{4,5}, R. Ladjounlou^{1,2,3}, G. Cartron⁶, I. Navarro-Teulon^{1,2,3}, A. Repetto-Llamazares⁷, H. Heyerdahl⁷, M. Bardies^{4,5}, J. Dahle⁷, J. Pouget^{1,2,3}; ¹Inserm U1194, Montpellier, FRANCE, ²IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, FRANCE, ³Université de Montpellier, Montpellier, FRANCE, ⁴UMR 1037 INSERM, Toulouse, FRANCE, ⁵Centre de Recherche en Cancérologie de Toulouse, Toulouse, FRANCE, ⁶Département d'Hématologie, Unités Mixtes de Recherche-Centre National de la Recherche Scientifique 5235, Centre Hospitalier Universitaire de Montpellier, Montpellier, FRANCE, ⁷Nordic Nanovector ASA, Kjelsåsveien 168 B, Oslo, NORWAY.

OP423

Efficacy of radioembolization with holmium-166 microspheres; primary outcome of the phase II HEPAR trial

J. Prince, B. A. Zonnenberg, J. F. W. Nijssen, M. L. J. Smits, A. F. van den Hoven, F. J. Wessels, R. C. G. Bruijnen, M. N. G. J. Braat, G. C. Krijger, M. G. E. H. Lam, M. A. A. J. van den Bosch; UMC Utrecht, Utrecht, NETHERLANDS.

OP424

Prolonged overall survival after 99mTc-MAA SPECT personalized treatment planning in radioembolization of hepatocarcinoma with 90Y glass microspheres: preliminary results of a 2 cohort study.

M. Maccauro¹, C. Chiesa¹, A. Facciorusso², M. Mira³, C. Spreafico⁴, R. Romito¹, C. Morosi⁴, C. Sposito², S. Bhoori², M. Migliorisi⁵, B. Padovano¹, E. Seregni¹, A. Marchiano⁴, F. Crippa¹, V. Mazzaferro²; ¹Nuclear Medicine, Foundation IRCCS Istituto Nazionale Tumori, Milan, ITALY, ²Surgery 1, Foundation IRCCS Istituto Nazionale Tumori, Milan, ITALY, ³Post graduate Health Physics School, University of Milan, Italy, Milan, ITALY, ⁴Radiology 2, Foundation IRCCS Istituto Nazionale Tumori, Milan, ITALY, ⁵Clinical engineering, Foundation IRCCS Istituto Nazionale Tumori, Milan, ITALY.

1306

Hall 6

11:30 – 13:00

M2M – Featured: Molecular & Multimodality Imaging: PSMA

OP425

One-step radiosynthesis of 68Ga-DKFZ-PSMA at room temperature

Z. Wimana, C. Artigas, P. Flamen, G. Ghanem; Institut Jules Bordet, Université Libre de Bruxelles, Brussel, BELGIUM.

OP426

Radiosyntheses and Preclinical Evaluation of Radiofluorinated PSMA-Ligands

J. Cardinale, M. Schäfer, M. Benesova, U. Bauder-Wüst, D. Komljenovic, M. Eder, M. E. Ladd, K. Kopka; German Cancer Research Center, Heidelberg, GERMANY.

OP427

NODA-GA-PSMA : A versatile probe for SPECT/PET imaging of PSMA-positive tumors.

E. Gourni^{1,2,3}, V. Goncalves⁴, F. Denat⁴, P. T. Meyer², H. R. Maecke²; ¹German Cancer Consortium (DKTK), Heidelberg, GERMANY, ²Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, GERMANY, ³German Cancer Research Center (DKFZ), Heidelberg, GERMANY, ⁴Institut de Chimie Moléculaire de l'Université de Bourgogne, Dijon, FRANCE.

OP428

68Ga-PSMA11-PET/CT - a new technique with high potential for the radiotherapeutic management of prostate cancer patients

F. Giesel¹, H. Fiedler¹, M. Stefanova¹, C. Kratochwil¹, A. Afshar-Oromieh¹, K. Kopka², J. Debus³, U. Haberkorn¹, F. Sterzing³; ¹Radiologische Klinik / Abt. für Nuklearmedizin, Heidelberg, GERMANY, ²Deutsches Krebsforschungszentrum (DKFZ) / Abteilung für Radiopharmazeutische Chemie, Heidelberg, GERMANY, ³Radiologische Klinik / Abt. für Strahlentherapie, Heidelberg, GERMANY.

OP429

The novel theranostic PSMA-ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry and first evaluation of tumor lesions

A. Afshar-Oromieh¹, H. Hetzheim², C. Kratochwil¹, M. Benesova³, M. Eder⁴, O. Neels⁴, W. Kübler⁵, F. L. Giesel¹, W. Mier⁶, K. Kopka⁴, U. Haberkorn¹; ¹University Hospital of Heidelberg, Heidelberg, GERMANY, ²Div. of Medical Physics in Radiology, German Cancer Research Center, Heidelberg, Germany, Heidelberg, GERMANY, ³Div. of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, GERMANY, ⁴Div. of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Heidelberg, GERMANY, ⁵Div. of Radiation Protection and Dosimetry, German Cancer Research Center, Heidelberg, Heidelberg, GERMANY, ⁶Division of Radiochemistry, University Hospital of Heidelberg, Heidelberg, GERMANY.

OP430

Value of Ga-68 PSMA PET/CT for Patient Selection and Follow-up of Metastasized Prostate Cancer Patients Undergoing Peptide Radioligand Therapy (PRLT) with Lu-177 DOTAGA-PSMA Inhibitor

H. R. Kulkarni¹, H. J. Wester², A. Singh¹, R. P. Baum¹; ¹THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Bad Berka, GERMANY, ²Pharmaceutical Radiochemistry, Technical University Munich, Munich, GERMANY.

1307

Hall F

11:30 – 12:45

Cardiovascular System: Myocarditis, Amyloidosis, Sarcoidosis & Vasculitis

OP431

FDG PET Imaging of a Rat Model of Autoimmune Myocarditis: Comparison with Histological Analysis

R. A. Werner^{1,2}, Y. Maya^{1,3}, V. Jahns⁴, H. Wakabayashi¹, M. Nakajo¹, K. Fukushima⁵, M. Javadi⁶, T. Yanagisawa⁷, R. Jahns⁸, T. Higuchi^{1,2}; ¹Department of Nuclear Medicine, Universitätsklinikum Würzburg, Würzburg, GERMANY, ²Comprehensive Heart Failure Center, Würzburg, GERMANY, ³Research Centre, Nihon Medi-Physics Co., Ltd., Chiba, JAPAN, ⁴Department of Pharmacology, Universitätsklinikum Würzburg, Würzburg, GERMANY, ⁵Hyogo College of Medicine, Hyogo, JAPAN, ⁶Division of Nuclear Medicine, Johns Hopkins University, MD, UNITED STATES, ⁷Department of Cardio-angiography, Kitazato University School of Medicine, Tokyo, JAPAN, ⁸Department of Internal Medicine I, University of Würzburg, Würzburg, GERMANY.

OP432

Assessment of radiolabeled methionine for imaging myocardial inflammation in a rat model of autoimmune myocarditis: Comparison with 18F-FDG and histological findings

Y. Maya^{1,2}, R. A. Werner^{1,3}, V. Jahns⁴, H. Wakabayashi¹, M. Nakajo¹, K. Fukushima⁵, T. Yanagisawa⁶, R. Jahns⁷, T. Higuchi^{1,3}; ¹Department of Nuclear Medicine, Universitätsklinikum Würzburg, Würzburg, GERMANY, ²Research Centre, Nihon Medi-Physics Co., Ltd., Chiba, JAPAN, ³Comprehensive Heart Failure Center, Würzburg, GERMANY, ⁴Department of Pharmacology, Universitätsklinikum Würzburg, Würzburg, GERMANY, ⁵Hyogo College of Medicine, Hyogo, JAPAN, ⁶Department of Cardio-angiography, Kitazato University School of Medicine, Kanagawa, JAPAN, ⁷Department of Internal Medicine I, University of Würzburg, Würzburg, GERMANY.

OP433

Imaging of myocardial inflammation with somatostatin receptor based PET/CT - a comparison to cardiac MRI

C. Lapa¹, T. Reiter¹, X. Li², R. Werner¹, S. Samnick¹, R. Jahns¹, A. K. Buck¹, G. Ertl¹, W. R. Bauer¹; ¹Universitätsklinikum Würzburg, Würzburg, GERMANY, ²AKH Wien, Wien, AUSTRIA.

OP434

Disphosphonates Cardiac Uptake in Familial Amyloid Neuropathy: Comparison between DPD and HMDP

H. Regaieg¹, R. De Paola Chequer¹, R. Ben Azzouna¹, V. Algarrondo², B. Mahida¹, M. Slama², D. Le Guludec¹, F. Rouzet¹; ¹Department of nuclear medicine, Bichat-Claude Bernard university hospital, Paris, FRANCE, ²Department of cardiology, Antoine Bécclère university hospital, Clamart, FRANCE.

OP435

Cardiac involvement in systemic sclerosis patients can be detected by dual single-photon emission computed tomography of thallium-201 and iodine-123-beta-methyl-p-iodophenyl-pentadecanoic acid scintigraphy

S. Matsuo, K. Nakajima, S. Kinuya, K. Takahara; Kanazawa University Hospital, Kanazawa, JAPAN.

OP436

Value of FDG-PET/CT and cardiac MR for the diagnosis and therapy monitoring in cardiac sarcoidosis.

B. SGARD, S. DJELBANI, J. TORDJMAN, G. POP, H. NUNES, D. VALEYRE, V. EDER, M. SOUSSAN; University paris XIII, Bobigny, FRANCE.

OP437

Relationship between active inflammation and myocardial injury in patients with cardiac sarcoidosis as detected by non-invasive multi-modality imaging

S. Kataoka, M. Momose, K. Fukushima, N. Serizawa, A. Suzuki, C. Kondo, K. Abe, S. Sakai, N. Hagiwara; Tokyo women's medical university, Tokyo, JAPAN.

OP438

Impact of 18F-FDG PET/CT in the management of patients with large vessel vasculitis associated to polymyalgia rheumatica.

C. Lavado-Pérez, I. Martínez-Rodríguez, I. Banzo, R. Quirce, J. Jiménez-Bonilla, M. De Arcocha-Torres, Z. Bravo-Ferrer, M. Jiménez-Alonso, J. L. López-Defilló, F. Gómez de la Fuente, D. Meza-Escobar, J. M. Carril; Nuclear Medicine. Molecular Imaging Group (IDIVAL). Marqués de Valdecilla University Hospital. University of Cantabria., Santander, SPAIN.

1308

Hall E

11:30 – 13:00

Conventional & Specialised Nuclear Medicine: Paediatric – General

OP439

Initial experience of DMSA SPECT-CT in the assessment of paediatric renal calculi

OP440

^{99m}Tc-DMSA in Biopsy Confirmed Paediatric Acute Tubulointerstitial Nephritis

P. Zucchetto¹, E. Miorin², L. Murer², F. Buil¹, D. Cecchin¹, E. Vidal²; ¹Nuclear Medicine Dept. - University Hospital - Padova, Padova, ITALY, ²Paediatric nephrology, dialysis and transplant - University Hospital - Padova, Padova, ITALY.

OP441

Evaluation of Schwartz eGFR-Cr in comparison with GFR measured by Tc-^{99m}-DTPA clearance in healthy and in children with urinary tract infection with and without vesicoureteral reflux

M. Vlaković¹, S. Ilić², M. Rajić¹, M. Stević¹, M. Božinović¹, V. Živković³, M. Matović⁴; ¹Center of Nuclear Medicine, Clinical Center Niš, Niš, SERBIA, ²Center of Nuclear Medicine, Clinical Center Niš, Niš, SERBIA, ³Clinic for Physical Medicine, Rehabilitation and Prosthetic, Clinical center Niš, Niš, SERBIA, ⁴Center of Nuclear Medicine, Clinical Center Kragujevac, Kragujevac, SERBIA.

OP442

Is the Clinical Diagnosis of Chronic Immune Thrombocytopenic Purpura in Pediatric Population Always Correct?

M. Todorovic-Tirnanic, D. Sobic-Saranovic, V. Artiko; Faculty of Medicine, University of Belgrade and Center of Nuclear Medicine, Clinical Center of Serbia, Belgrade, SERBIA.

OP443

Impact of colonic transit scintigraphy on clinical decision making in severely constipated children

E. Medaer, I. Hoffman, W. Thimister; KU Leuven, Leuven, BELGIUM.

OP444

Accuracy of ^{99m}TcO₄- Meckel's Scan and Other Diagnostic Indicators in Symptomatic Paediatric Meckel's Diverticulum

OP445

Clinical Value of Cerebral Perfusion SPECT Imaging in Children with Acute Sydenham's Chorea

S. M. d. A. Giorgio¹, M. G. Caprio¹, A. Romano², E. Vergara¹, G. Russo², M. Alessio², A. Cuocolo¹; ¹Department of Advanced Biomedical Sciences, Naples, ITALY, ²Department of Translational Medical Sciences, Naples, ITALY.

1309

Hall 8

11:30 – 13:00

Physics & Instrumentation & Data Analysis: Quality Control, Performance, Standardisation

OP446

Investigation of Image Quality with Sodium Pertechnetate ^{99m}Tc Produced by Cyclotron

S. V. Selivanova^{1,2}, É. Lavallée¹, O. Sarrihni¹, B. Guérin^{1,2}, É. Turcotte^{1,2}, R. Lecomte^{1,2}; ¹Sherbrooke Molecular Imaging Center, CRCHUS, Sherbrooke, QC, CANADA, ²Université de Sherbrooke, Sherbrooke, QC, CANADA.

OP447

One Size Fits All? Assessment of the Use of a Simple Calibration Protocol for Quantitative SPECT/CT Imaging of ¹⁷⁷Lu in European Hospitals

J. Merrett^{1,2,3}, A. Fenwick², J. Scuffham^{1,3}, L. Johansson², A. Nisbet^{1,3}; ¹University of Surrey, Guildford, UNITED KINGDOM, ²National Physical Laboratory, Teddington, UNITED KINGDOM, ³Royal Surrey County Hospital, Guildford, UNITED KINGDOM.

OP448

Standardised Time-Dose Regimen for Ga-DOTANOC PET Imaging

J. K. J. Archer, M. J. Carroll, S. Vinjamuri, E. Panagiotidis; Royal Liverpool University Hospital, Liverpool, UNITED KINGDOM.

OP449

Evaluation of the Performance of a Biograph mCT-Flow PET/CT System according to NEMA NU2-2012 standards

I. Rausch¹, J. Cal-Gonzalez¹, T. Beyer¹, G. Minear²; ¹Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA, ²Dept of Nuclear Medicine, Landeskrankenhaus St. Pölten, St. Pölten, AUSTRIA.

OP450

The effect of image reconstruction parameters in Mediso NanoScan PC PET/CT images obtained by two different positron emitting tracers under NEMA standards NU 4-2008

A. Gaitanis¹, E. Vlastou¹, P. Bouziotis², G. Kastis³, C. D. Anagnostopoulos¹; ¹Biomedical Research Foundation of the Academy of Athens (BRFAA), Athens, GREECE, ²Institute of Nuclear and Radiological Sciences, Technology, Energy and Safety (I.N.Ra.S.T.E.S.) N.C.S.R., Athens, GREECE, ³Research Center of Mathematics, Academy of Athens, Athens, GREECE.

OP451

Considerations for Interpreting SPECT SUVs: Image Noise, Post-filter and SUV Metric

N. A. Bebbington¹, L. C. Jenkins²; ¹Queen Elizabeth Hospital Birmingham, Birmingham, UNITED KINGDOM, ²HERMES Medical Solutions, London, UNITED KINGDOM.

OP452

Accurate model of a Capintec activity meter with the Monte Carlo code Fluka

F. Zagni¹, A. Evandri¹, G. Cicoria¹, A. Infantino², S. Vichi², S. Costa³, M. Marengo¹; ¹Medical Physics Department, University Hospital "S.Orsola – Malpighi", Bologna, ITALY, ²Montecuccolino Nuclear Engineering Laboratory, Department of Industrial Engineering, University of Bologna, Bologna, ITALY, ³PET Radiopharmacy Unit, University Hospital "S.Orsola – Malpighi", Bologna, ITALY.

OP453

Phase I Trial comparing a Digital Detector PET/CT System with current photomultiplier PET Technology in Diagnostic Oncology

M. V. Knopp¹, K. Binzel¹, C. L. Wright¹, V. Nagar¹, P. Bardos¹, P. Maniawski², J. Zhang¹; ¹The Ohio State University, Columbus, OH, UNITED STATES, ²Philips Healthcare, Cleveland, OH, UNITED STATES.

OP455

Initial FDG PET/CT predicts survival in adults ewing sarcoma family of tumors.

J. B. Bastien¹, B. Jamet¹, T. Carlier^{1,2}, L. Campion³, E. Bompas³, M. Colombié⁴, D. Rusu⁴, D. Goulon⁴, V. Fleury⁴, F. Kraeber-Bodéré^{1,2}, C. Rousseau^{2,4}, ¹Nuclear Medicine Unit, University Hospital, Nantes, France, ²INSERM U892, CRCNA, Nantes, France, ³Oncology Unit, ICO Cancer Center, Saint Herblain, France, ⁴Nuclear Medicine Unit, ICO Cancer Center, Saint Herblain, France

OP456

Soft tissue sarcomas: Comparison between visual assessment and metabolic parameters in FDG PET/CT

D. Lopez, A. Domenech, C. Achury, R. Jaller, J. Duch, M. Estorch, A. Flotats, I. Carrió; Nuclear Medicine department. Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN.

OP457

Tumour heterogeneity for differentiation between tumour and normal liver tissue in FDG-PET imaging

L. Jaritz¹, H. Ahmadzadehfard¹, M. Essler¹, N. Zsoter², L. Papp², F. Gaertner¹, R. A. Bundschuh¹, L. Thomas¹; ¹Department of Nuclear Medicine, Universitätsklinikum Bonn, Bonn, GERMANY, ²Mediso Medical Imaging Systems, Budapest, HUNGARY.

OP458

Factors of FDG uptake in the liver and blood pool on PET scans

K. Zhou, Sr.; West China Hospital of Sichuan University, Chengdu, CHINA.

OP459

18F-FDG PET/CT role in staging of gastric carcinomas: comparison with conventional Contrast Enhancement Computed Tomography.

C. Altini, A. Niccoli Asabella, A. Di Palo, M. Fanelli, D. Rubini, C. Ferrari, A. Notaristefano, G. Rubini; Nuclear Medicine Unit, D.I.M., University of Bari "Aldo Moro", Bari, Italy, Bari, ITALY.

1310

Hall D

11:30 – 13:00

Clinical Oncology: Miscellaneous

OP454

The role of 18F-FDG PET/CT for the detection of recurrent Osteosarcoma

F. Ceci¹, A. Angelini², P. Castellucci¹, T. Graziani¹, M. Polverini², P. Ghedini¹, S. Israel¹, R. Bonfiglioli¹, P. Ruggieri², S. Fanti¹; ¹Nuclear Medicine - S.Orsola-Malpighi Hospital - University of Bologna, Bologna, ITALY, ²Department of Orthopedics, Istituto Ortopedico Rizzoli, University of Bologna, Bologna, ITALY.

OP460

Utility of 18F-FDG PET/CT in Patients with Advanced Squamous Carcinoma of Uterine Cervix Receiving Concurrent Chemoradiotherapy: A Parallel Study of a Prospective Randomized Trial

F. Liu¹, C. Lai¹, L. Yang¹, C. Wang¹, G. Lin¹, C. Chang², S. Huang³, Y. Huang⁴, N. Peng⁵, J. Hong¹, A. Chao¹, H. Chou¹, Y. Chang¹, T. Yen¹; ¹Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, TAIWAN, ²Chang Gung University, Taoyuan, TAIWAN, ³Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TAIWAN, ⁴Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Chiayi, TAIWAN, ⁵Kaohsiung Veterans General Hospital, Kaohsiung, TAIWAN.

OP461

Face-To-Face 18F-FDG-PET/CT and CA125 (Serums Levels and Kinetic Values) in Patients with Suspected Recurrence of Ovarian Cancer.

A. Palomar Muñoz, J. M. Cordero García, G. A. Jiménez Londoño, M. P. Talavera Rubio, M. E. Bellón Guardia, B. González García, V. M. Poblete García, Á. Soriano Castrejón; Hospital General Universitario de Ciudad Real, Ciudad Real, SPAIN.

YE3

Hall 8

13:00 – 14:30

Young EANM Daily Forum 3: Young Investigator Meeting

OP461b

Welcome and Introduction

N. Ristevska, FYROM
A. Gee, UNITED KINGDOM
M. de Jong, NETHERLANDS

OP461c

YIM 2015 Winner Presentation

I. Bakker, NETHERLANDS

OP461d

Past YIM Experience and Outcome

G. Treglia, SWITZERLAND

L. Lezaic, SLOVENIA

OP461f

Become a Young EANM Committee Member - Oncology Committee

R. Delgado-Bolton, SPAIN

OP461g

Become a Young EANM Committee Member - Bone and Joint Committee

T. van den Wyngaert, BELGIUM

OP461e

Closing Remarks

1401

CME

Hall 1

14:30 – 16:00

CME 11 – Radiopharmacy: New Protein Deposition Tracers

OP462

Clinical View of Deposition Tracers

R. Ossenkoppele, USA

OP463

New Tracers in the Pipeline

A. Stephens, GERMANY

OP464

Deposit Tracers in the Preclinical Research

D. Guilloteau, FRANCE

1402

Hall 2

14:30 – 16:00

Joint Symposium 11: EANM/ENETS: Management of Neuroendocrine Tumours

OP465

Therapeutic Management of Neuroendocrine Tumours

M. E. Caplin, UK

OP466

The Role of PRRT in the Therapeutic Algorithm of Neuroendocrine Tumours

L. Bodei, ITALY

OP467

Future Therapeutic Scenarios: Combination or Competition?

A. Rinke, GERMANY

1403

Hall 4

14:30 – 16:00

CTE 5: Lean Principles and Improved Departmental Management

OP468

Making Your Department LEAN

D. Gilmore, USA

OP469

How to Implement the LEAN Concept

J. Löfgren, DENMARK

OP470

The Impact of LEAN in a PET Department

E. Sanchez Saxtoft, DENMARK

1404

Hall G1

14:30 – 16:00

Cardiovascular System – Featured: Imaging of Plaques, Angiogenesis & Ischaemic Memory

OP471

Simultaneous PET/MR imaging with FDG for the evaluation of symptomatic patients with non-stenotic carotid atherosclerotic plaques

F. Hyafil¹, A. Schindler², D. Sepp³, T. Obenhuber², S. Höhn², S. Nekolla¹, M. Dichgans³, M. Schwaiger¹, T. Saam², H. Poppert³; ¹Department of Nuclear Medicine, Klinikum rechts der Isar, Munich, GERMANY, ²Ludwig-Maximilians-University Hospital Munich, Institute for Clinical Radiology, Munich, GERMANY, ³Department of Neurology, Klinikum rechts der Isar, Munich, GERMANY.

OP472

Atherosclerotic Plaque 18F-NaF Uptake Predicts its Subsequent Morphologic Evolution and Calcification Density

F. Fiz¹, M. Bauckneht¹, G. Ferrarazzo¹, A. Piccardo², E. Pestarino², I. Calamia¹, M. Cabria², G. Villavecchia², C. Marini³, S. Morbelli¹, G. Sambucetti¹; ¹Nuclear Medicine Unit, Department of Health Sciences, University of Genoa, Genoa, ITALY, ²Nuclear Medicine Unit, Ente Ospedaliero Galliera, Genoa, ITALY, ³CNR-IBFM, Milano, ITALY.

OP473

18F-FDG-PET-CT assessed subclinical arterial inflammation is positively associated with non-invasive markers of arterial stiffness in recently diagnosed type 2 diabetes patients

S. A. de Boer¹, M. C. Hovinga - de Boer², J. D. Lefrandt¹, H. J. Lambers Heerspink³, A. W. J. M. Glaudemans⁴, D. J. Mulder¹, R. H. J. A. Slart^{4,5}; ¹Department of Vascular Medicine, University Medical Center Groningen, University of Groningen, Groningen, NETHERLANDS, ²Department of Radiology & Nuclear Medicine, Meander Medical Center, Amersfoort, NETHERLANDS, ³Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, NETHERLANDS, ⁴Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, NETHERLANDS, ⁵University of Twente, Department of Biomedical Photoacoustic Imaging (BMPI), Enschede, NETHERLANDS.

OP474

Evaluation of the radiotracer [68Ga]pentixafor targeting the CXCR4 receptor with PET-MRI in a rabbit model of atherosclerotic plaques

F. Hyafil¹, I. Laitinen¹, M. Schottelius², M. Mohring¹, A. Poschenrieder², J. Brandl³, C. Baumgartner³, J. Pelisek⁴, S. Nekolla¹, H. Wester⁵, M. Schwaiger¹; ¹Department of Nuclear Medicine, Klinikum rechts der Isar, Munich, GERMANY, ²Pharmaceutical Radiochemistry, Technische Universität München, Garching, GERMANY, ³Centre of Preclinical Research, Klinikum rechts der Isar, Munich, GERMANY, ⁴Department of Vascular Surgery, Klinikum rechts der Isar, Munich, GERMANY, ⁵Pharmaceutical Radiochemistry, Technische Universität München, Munich, GERMANY.

OP475

Targeting Aminopeptidase N (CD13) for molecular imaging of cardiac wound healing using ⁶⁸Ga-NOTA-c(NGR) in experimental myocardial infarction

S. Samnick¹, M. Schneider¹, J. Tillmanns², D. Fraccarollo², J. Bauersachs², A. Buck¹; ¹University of Würzburg, Würzburg, GERMANY, ²Hannover Medical School, Hannover, GERMANY.

OP476

Retrospective detection of remote and brief experimental myocardial ischemia using ^{99m}Tc-Fucoidan SPECT

N. Mikail¹, N. Anizan², L. Louedec², F. Al Shoukr¹, J. Miche², D. Letourneur², C. Chauvierre², D. LE GULUDEC¹, F. Rouzet¹; ¹Nuclear Medicine Department, Bichat-Claude Bernard Hospital, APHP, Paris, FRANCE, ²INSERM, U1148, Cardiovascular Bioengineering, Paris, FRANCE.

1405

Hall G2

14:30 – 16:00

M2M: Radiopharmaceuticals & Radiochemistry: Radiochemistry & Instrumentation

OP477

Preparation of Carrier Free Yttrium-90 for Medical Applications Using a Novel Home-Made Y-Imprinted Sorbent

M. Abedi¹, S. Shirvani Arani², A. Bahrami Samani³, M. Nabid¹;

¹Department of Chemistry, Faculty of Science, Shahid Beheshti University, Tehran, IRAN, ISLAMIC REPUBLIC OF,

²Assistant Professor Radiopharmaceutical Research and Development Lab (RRDL), Tehran, IRAN, ISLAMIC REPUBLIC OF,

³Radiopharmaceutical Research and Development Lab (RRDL), Tehran, IRAN, ISLAMIC REPUBLIC OF.

OP478

Cyclotron production of ⁴³Sc - new radionuclide for PET technique

A. Bilewicz¹, R. Walczak², K. Szkliniarz³, M. Sitarz⁴, S. Krajewski², K. Abbas⁵, J. Choinski⁴, I. Cydzik⁵, A. Jakubowski⁴, J. Jastrzębski⁴, A. Stolarz⁴, A. Trzcińska⁴, W. Zipper³;

¹Institute of Nuclear Chemistry and Technology, Warsaw, POLAND,

²Institute of Nuclear Chemistry and Technology, Warsaw, POLAND,

³Department of Nuclear Physics, University of Silesia, Katowice, Poland, Katowice, POLAND,

⁴Heavy Ion Laboratory, University of Warsaw, Warsaw, POLAND,

⁵European Commission, Joint Research Centre, Institute for Health and Consumer Protection, Ispra, ITALY.

OP479

Production of High Specific Activity ¹⁸⁶Re for Cancer Therapy Using WO₃ Targets in a Proton Beam

M. E. Fassbender¹, E. R. Birnbaum¹, J. W. Engle¹, M. D. Gott², K. D. John¹, J. R. Maassen¹, F. M. Nortier¹, J. W. Lenz³,

C. S. Cutler⁴, A. R. Ketrang⁴, S. S. Jurisson⁴, E. R. Balkin⁵, D. S. W. Wilbur⁵;

¹Los Alamos National Laboratory, Los Alamos, NM, UNITED STATES,

²University of Missouri, Columbia, MO, UNITED STATES,

³John Lenz and Associates, East Lansing, MI, UNITED STATES,

⁴University of Missouri, Columbia, MO, UNITED STATES,

⁵University of Washington, Seattle, WA, UNITED STATES.

OP480

Direct production of ^{99m}Tc-Technetium using low energy cyclotrons and radionuclidic purity: our results so far using natMo-Molybdenum

L. Metello^{1,2}, P. Costa¹, L. Cunha^{1,2}, R. Jonhson³, L. Matei³, W. Gelbart⁴, J. Obermair⁵, C. Artner⁵, P. Lass⁶, G. Currie⁷, L. Craciun⁸, D. Niculae⁸, S. Carmo⁹, F. Alves⁹, M. Botello¹⁰;

¹Nuclear Medicine Department, ESTSP/IPP, Porto, PORTUGAL,

²Nuclear Medicine Department, IsoPor SA, Porto, PORTUGAL,

³BSCI - Best Cyclotron Systems Inc, Vancouver, DC, CANADA,

⁴ASD - Advanced Systems Design Inc, Vancouver, DC, CANADA,

⁵IASON GmbH, Graz, AUSTRIA,

⁶Medical Faculty, University of Gdansk, Gdansk, POLAND,

⁷School of Dentistry and Health Sciences, Charles Sturt University, Wagga Wagga, AUSTRALIA,

⁸Horia Hulubei National Institute of Physics & Nuclear Engineering, Bucharest, ROMANIA,

⁹ICNAS - Institute for Nuclear Sciences Applied to Health, University of Coimbra, Coimbra, PORTUGAL,

¹⁰IBILI, Medical Faculty, University of Coimbra, Coimbra, PORTUGAL.

OP481

Extremely rapid, kit-based biomolecule labelling and molecular imaging with gallium-68: tris(hydroxypyridinone) chelators

M. T. Ma¹, J. D. Young¹, C. Imberti¹, C. Cullinane², M. S. Cooper¹, L. Meszaros¹, S. Y. A. Terry¹, B. Paterson¹,

G. E. D. Mullen¹, J. R. Ballinger¹, P. Roselt², R. J. Hicks², P. J. Blower¹;

¹King's College London, London, UNITED KINGDOM,

²Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA.

OP482

Microfluidics and Microwave Assisted Synthesis of ^{99m}Tc(CO)₃-MIP-1505, a ligand for carbonic anhydrase IX (CAIX). Comparison to Conventional Heating

J. Kelly, A. Amor-Coarasa, J. W. Babich; Weill Cornell Medical College, New York, NY, UNITED STATES.

OP483

Microfluidics Assisted Labeling of ⁶⁸Ga-DOTATOC: Advantages and Limitations.

A. Amor-Coarasa, J. M. Kelly, J. W. Babich; Weill Cornell Medical College, New York City, NY, UNITED STATES.

OP484

A Fast Optical Method for Radiochemical Purity Evaluation

A. E. Spinelli¹, C. R. Gigliotti¹, F. Boschi²; ¹San Raffaele Scientific Institute, Milano, ITALY,

²University of Verona, Verona, ITALY.

1406

Hall 6

14:30 – 16:00

M2M: Molecular & Multimodality Imaging: Therapy – Preclinical Studies, α & β Radiation

OP485

Alpha- versus beta-emitting particles for pretargeted radioimmunotherapy of CEA-expressing human colon cancer xenografts

S. Heskamp¹, R. Hernandez², J. D. M. Molkenboer-Kuene¹, M. Essler³, F. Bruchertseifer⁴, A. Morgenstern⁴, W. J. G. Oyen¹, C. Seidl⁵, W. McBride⁶, D. M. Goldenberg⁶, O. C. Boerman¹; ¹Radboud University Medical Center, Nijmegen, NETHERLANDS, ²University of Wisconsin, Madison, WI, UNITED STATES, ³University of Bonn, Bonn, GERMANY, ⁴Joint Research Centre – Institute for Transuranium Elements, Karlsruhe, GERMANY, ⁵Klinikum rechts der Isar der Technischen Universität München, München, GERMANY, ⁶Immunomedics, Morris Plains, NY, UNITED STATES.

OP486

Targeted Radionuclide Therapy using high-LET particle emitter-labeled vectors against alpha-v-beta6-expressing cancers

S. PAILLAS¹, A. DESAI², I. QUETIER², J. MARSHALL², J. POUGET³, J. SOSABOWSKI¹; ¹Centre for Molecular Oncology, Barts Cancer Institute, London, UNITED KINGDOM, ²Centre for Tumor Biology, Barts Cancer Institute, London, UNITED KINGDOM, ³Inserm U1194, Montpellier, FRANCE.

OP487

Involvement of direct and indirect (bystander) cytotoxic effects in alpha-RIT of small volume peritoneal carcinomatosis using ²¹²Pb-labeled mAbs

J. Pouget¹, R. Ladjounlou¹, A. Pichard¹, V. Boudousq¹, S. Paillass¹, M. Le Blay¹, C. Lozza¹, M. Bardies², S. Marcatili², N. Chouin³, J. Torgue⁴, I. Navarro-Teulon¹; ¹IRCM/INSERM U1194, MONTPELLIER, FRANCE, ²UMR 1037 INSERM/UPS, TOULOUSE, FRANCE, ³AMAROC, ONIRIS, Nantes, FRANCE, ⁴AREVA Med, BETHESDA, WI, UNITED STATES.

OP488

Targeted Alpha Radionuclide Therapy of Prostate Cancer Using a Small Molecule Inhibitor of Prostate-specific Membrane Antigen (PSMA)

K. L. S. Chatalic^{1,2,3}, S. Heskamp⁴, J. Nonnekens^{1,5}, J. D. M. Molkenboer-Kuene⁴, D. van Gent⁵, F. Bruchertseifer⁶, A. Morgenstern⁶, M. Weineisen⁷, H. Wester^{7,8}, W. M. van Weerden³, O. C. Boerman⁴, M. de Jong^{1,2}; ¹Department of Nuclear Medicine, Erasmus MC, Rotterdam, NETHERLANDS, ²Department of Radiology, Erasmus MC, Rotterdam, NETHERLANDS, ³Department of Urology, Erasmus MC, Rotterdam, NETHERLANDS, ⁴Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, Nijmegen, NETHERLANDS, ⁵Department of Genetics, Erasmus MC,

Rotterdam, NETHERLANDS, ⁶Joint Research Centre – Institute for Transuranium Elements, Karlsruhe, GERMANY, ⁷Pharmaceutical Radiochemistry, Technische Universität München, Munich, GERMANY, ⁸Scintomics GmbH, Fürstfeldbruck, GERMANY.

OP489

The next step in increasing the efficacy of PRRT: Preclinical studies in vivo and in vitro with ²¹³Bi-[DOTA⁰,Tyr³]-octreotate

H. S. Chan¹, M. W. Konijnenberg¹, E. de Blois¹, S. Koelewijn¹, T. Anderson², M. Nysus², W. A. P. Breeman¹, R. W. Atcher³, A. Morgenstern⁴, F. Bruchertseifer⁴, J. P. Norenberg², M. de Jong¹; ¹Nuclear Medicine and Radiology, Erasmus MC, ROTTERDAM, NETHERLANDS, ²College of pharmacy, University of New Mexico, Albuquerque, NM, UNITED STATES, ³Los Alamos National Laboratory, Los Alamos, NM, UNITED STATES, ⁴European Commission, JRC, Institute for Transuranium Elements, Karlsruhe, GERMANY.

OP490

Preclinical Comparison of Therapeutic response to Treatment with ¹⁷⁷-Lutetium labelled Somatostatin Receptor Agonists and Antagonists

S. Dalm¹, G. Doeswijk¹, S. Koelewijn¹, H. Maecke², M. de Jong¹; ¹Erasmus MC, Rotterdam, NETHERLANDS, ²University of Basel, Basel, SWITZERLAND.

OP491

[¹⁷⁷Lu]-OPS201 targeting somatostatin receptors: In vivo biodistribution and dosimetry in a pig model

S. Beykan¹, J. S. Dam², U. Eberlein¹, J. Kaufmann³, B. Kjærgaard⁴, L. Jødal², H. Bouterfa³, M. Lassmann¹, S. B. Jensen⁵; ¹Department of Nuclear Medicine, University of Würzburg, Würzburg, GERMANY, ²Department of Nuclear Medicine, Aalborg University Hospital, Aalborg, DENMARK, ³Octreopharm Science GmbH, Berlin, GERMANY, ⁴Biomedical Research Laboratory, Aalborg University Hospital, Aalborg, DENMARK, ⁵Department of Nuclear Medicine, Aalborg University Hospital, Department of Chemistry and Biochemistry, Aalborg University, Aalborg, DENMARK.

OP492

Development and human absorbed dose estimation of ⁴⁷Scandium-anti-CD20 for radioimmunotherapy

L. Moghaddam-Bnaem¹, A. Jalilian²; ¹Amirkabir Technical university, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Nuclear Science and Technology Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF.

1407 Hall F

14:30 – 16:00

Teaching Session: Interactive Quiz: Radiology and Cross-sectional Imaging

OP493

Interactive Quiz: Radiology and Cross-sectional Imaging

T. Lynch, UNITED KINGDOM

1408 Hall E

14:30 – 16:00

Clinical Oncology: Paediatric Oncology

OP494

Clinical Impact of simultaneous ¹⁸FET PET/MRI for Pediatric CNS-tumors

L. Marner¹, K. Nysom¹, A. Sehested¹, L. Borgwardt¹, R. Mathiasen¹, P. S. Wehner², M. Jørgensen¹, P. Munk af Rosenschöld¹, C. Thomsen¹, L. Bøgeskov¹, H. Broholm¹, D. Scheie¹, M. Juhler¹, L. Højgaard¹, I. Law¹; ¹Copenhagen University Hospital, Rigshospitalet, Copenhagen O, DENMARK, ²Odense University Hospital, Odense, DENMARK.

OP495

Evaluation of Early Response to Neoadjuvant Chemotherapy with FDG PET/CT and MRI in Pediatric Patients with Bone Sarcoma

M. Caglar, B. Aydin, B. Ergen, E. Karabulut, C. Akyuz; Hacettepe University, Ankara, TURKEY.

OP496

Clinical impact of FDG PET-CT in pediatric soft tissue sarcomas

M. Tuncel¹, N. Kurucu², P. Ö. Kıratlı¹, B. Erbaş¹, C. Akyüz²; ¹Hacettepe University, Department of Nuclear Medicine, ANKARA, TURKEY, ²Hacettepe University, Department of Pediatric Oncology, ANKARA, TURKEY.

OP497

Utility of PET/CT in children with Langerhans cell histiocytosis.

R. Czepczyński, E. Jodłowska, O. Zajac-Spychała, M. Ruchała, J. Wachowiak; Poznan University of Medical Sciences, Poznań, POLAND.

OP498

Value of FDG PET-CT in the therapy evaluation of Hodgkin's lymphoma

M. Tuncel¹, T. M. Kutluk², P. Ö. Kıratlı¹, B. G. Aydin², B. Erbaş¹, C. Akyüz²; ¹Hacettepe University, Department of Nuclear Medicine, ANKARA, TURKEY, ²Hacettepe University, Department of Pediatric Oncology, ANKARA, TURKEY.

OP499

Pediatric Hodgkin Lymphoma: visual and semiquantitative analysis of interim ¹⁸FDG-PET/CT in predicting treatment response and outcome.

C. Ferrari¹, A. Niccoli Asabella¹, M. Fanelli¹, N. Merenda¹, T. Perrillo², P. Muggeo², F. De Leonardi², N. Santoro², G. Rubini¹; ¹Nuclear Medicine Unit, D.I.M., University of Bari "Aldo Moro", Bari, Italy, Bari, ITALY, ²Department of Pediatric Hematology and Oncology, University of Bari "Aldo Moro", Bari, Italy, Bari, ITALY.

OP500

Prognostic Value Of Different F-18 FDG PET/CT Quantitative Analytical Methodologies In Pediatric Hodgkin's Lymphoma

A. A. Kandeel¹, O. M. Serry¹, M. A. Alhussieny¹, W. O. Soliman²; ¹Kasr Alaini center of Oncology and Nuclear Medicine NEMROCK, Cairo, EGYPT, ²57357 Children cancer Hospital, Cairo, EGYPT.

1409 Hall 8

14:30 – 16:00

Physics & Instrumentation & Data Analysis: Instrumentation

OP501

G -SPECT-I: a full ring high sensitivity and ultra-fast clinical molecular imaging system with < 3mm resolution

F. J. Beekman¹, F. van der Have², M. C. Goorden¹, P. E. B. Vaissier¹, J. van Roosmalen¹, H. During³, B. Vastenhouw¹; ¹TU Delft, Delft, NETHERLANDS, ²MILabs, Utrecht, NETHERLANDS, ³MILabs, Utrecht, NETHERLANDS.

OP502

Double-Sided Readout with Digital Photon Counters Enables Millimeter Spatial Resolution and 150 ps Time Resolution in 32 mm x 32 mm x 22 mm Monolithic LYSO:Ce Crystals

B. J. Peet, G. Borghi, V. Tabacchini, D. R. Schaart; Delft University of Technology, Delft, NETHERLANDS.

OP503

First measurements and Monte Carlo simulations of a BGO-PMTs blocks array intended for continuous energy spectrum tomography in bremsstrahlung imaging

M. Hesse¹, S. Walrand¹, R. Wojcik², R. Lhommel¹, F. Jamar¹;
¹Université Catholique de Louvain, Brussels, BELGIUM, ²Ray Visions, Inc, Yorktown, VA, UNITED STATES.

OP504

Gamma-cube and X-cube: A New Scanner Generation for Benchtop Small Animal SPECT/CT

R. Van Holen, K. Deprez, B. Vandeghinste, S. Vandenberghe;
Ghent University, Gent, BELGIUM.

OP505

Left ventricular function assessment using 123I/99mTc dual isotope acquisition with two semiconductor cadmium zinc telluride (CZT) cameras: a dynamic cardiac phantom study

T. Blaire^{1,2}, A. Bailliez^{1,2}, D. Legallois³, D. Agostini³, A. Manrique^{1,3}; ¹EA 4650, Normandy University, Caen, FRANCE, ²Nuclear Medicine Department, IRIS, Polyclinique du Bois, Lille, FRANCE, ³Nuclear Medicine Department, CHU Cote de Nacre, Caen, FRANCE.

OP506

Is there mutual interference between preclinical APD-PET and 3T MR in a sequential configuration ?

J. M. VRIGNEAUD¹, P. M. WALKER², B. BARBIER³, A. CAMACHO⁴, A. OUDOT¹, B. COLLIN¹, F. BRUNOTTE^{1,5}; ¹Centre Georges-François Leclerc, DIJON, FRANCE, ²LE2i CNRS UMR 5158, Faculty of Medicine, DIJON, FRANCE, ³Trifoil Imaging, DIJON, FRANCE, ⁴MR Solutions, GUILDFORD, UNITED KINGDOM, ⁵LE2i CNRS UMR 5158, Faculty of Medicine, Dijon, FRANCE.

OP507

Design of an Optimized Multi-pinhole Collimator for Brain SPECT

L. Chen, G. S. Mok; University of Macau, Taipa, MACAO.

OP508

Design of shields for counting Cr-51 EDTA plasma samples from patients having a Tc-99m imaging study on the same day

N. Bird, D. Gillett; Addenbrooke's Hospital, Cambridge, UNITED KINGDOM.

1410

Hall D

16:30 – 18:00

Neurosciences: Psychiatry

OP509

Blunted striatal dopamine release in cannabis dependence

E. van de Giessen^{1,2}, J. Weinstein¹, C. Cassidy¹, M. Haney¹, M. Slifstein¹, A. Abi-Dargham¹; ¹Columbia University College of Physicians and Surgeons/New York State Psychiatric Institute, New York, NY, UNITED STATES, ²Academic Medical Center, Amsterdam, NETHERLANDS.

OP510

Effect of chronic social defeat on neuroinflammation in rats: a PET imaging study with [11C]PK11195

P. Kopschina Feltes¹, E. F. J. de Vries¹, C. M. Moriguchi Jeckel², E. Kurtys¹, P. Michel¹, R. A. J. O. Dierckx¹, J. Doorduyn¹; ¹University of Groningen, Groningen, NETHERLANDS, ²Pontificia Universidade Católica do Rio Grande do Sul, Porto Alegre, BRAZIL.

OP511

Dopamine transporter availability in alcohol-dependent patients before and after deep repetitive transcranial magnetic stimulation: a ¹²³I-FP-CIT Study

D. Di Giuda¹, F. Cocciolillo¹, I. Bruno¹, I. Marini¹, M. Zollino¹, A. Ferrulli², M. Antonelli², G. Vassallo², A. Mirijello², G. Addolorato², A. Giordano¹; ¹Nuclear Medicine Institute, Università Cattolica del Sacro Cuore, Roma, ITALY, ²Internal Medicine Institute, Università Cattolica del Sacro Cuore, Roma, ITALY.

OP512

Regional cerebral blood flow changes in acute and transient psychotic disorders

R. Petrovic¹, A. T. Golubic¹, M. Rojnic², T. Samardzic¹; ¹Department of Nuclear Medicine and Radiation Protection, University Hospital Center Zagreb, Zagreb, CROATIA, ²Clinical Department of Psychiatry, University Hospital Center Zagreb, Zagreb, CROATIA.

OP513

Pedophilia and Child Sexual Abuse: Evidence for Altered Serotonergic Function in Pedophilic Offenders

G. Berding¹, G. Tenbergen², F. Wilke³, F. Paesler¹, L. Geworski³, F. M. Bengel¹, T. H. C. Kruger²; ¹Department of Nuclear Medicine, Hannover Medical School, Hannover, GERMANY, ²Clinic of Psychiatry, Socialpsychiatry and Psychotherapy, Hannover Medical School, Hannover, GERMANY, ³Department of Medical Physics and Radiation Protection, Hannover Medical School, Hannover, GERMANY.

OP514

Altered Regional Cerebral Blood Flow in Chronic Whiplash Associated Disorder

D. Váñez García¹, A. Otte², A. T. M. Willemsen¹, R. A. J. O. Dierckx¹, J. Doorduyn¹, G. Hostege³; ¹University Medical Center Groningen, Groningen, NETHERLANDS, ²Offenburg University of Applied Sciences, Offenburg, GERMANY, ³University of Queensland, Brisbane, AUSTRALIA.

OP515

Genetic influences in FDG uptake in precuneus and posterior cingulate cortex: a PET study in non-demented twins

S. Watanabe¹, H. Kato¹, E. Shimosegawa², J. Hatazawa¹, Osaka Twin Research Group; ¹Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Suita, Osaka, JAPAN, ²Department of Molecular Imaging in Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, JAPAN.

OP516

Decreased frontotemporal cerebral blood flow in congestive heart failure.

C. Pascovich¹, R. García², A. Damian¹, M. Langhain¹, E. Angarita², R. Ferrando¹; ¹Nuclear Medicine Centre, Clinical Hospital, University of the Republic, Montevideo, URUGUAY, ²Fundación Cardiovascular de Colombia, Bucaramanga, COLOMBIA.

1501



Hall 1

16:30 – 18:00

CME 12 – Drug Development & Radiopharmacy: Radiopharmaceutical Design

OP517

Perspectives of Developing New Radiopharmaceuticals: Research vs Clinical Application

H. Kung, USA

OP518

Strategy for the Discovery of New PET Radioligands at Pfizer R&D

L. Zhang, USA

OP519

Development of Peptide-Based Radiopharmaceuticals: From Bench-To-Bedside and Beyond

M. Fani, SWITZERLAND

1502

Hall 2

16:30 – 18:00

Joint Symposium 12: EANM/ESMI/COST: Lead Compounds in Theranostics

OP520

Radiopeptide-based Theranostics

M. de Jong, NETHERLANDS

OP521

Camelid Theranostics in Cancer

M. D'Huyvetter, BELGIUM

OP522

Gadolinium-based Multimodal Particles for Theranostic Applications in Oncology

O. Tillement, FRANCE

1505

Hall G2

16:30 – 18:00

Do.MoRe: Thyroid

OP523

The so-called thyroid stunning effect: quantitative radiobiological analysis and prediction of the remnant control probability.

S. Walrand, M. Hesse, F. Jamar; Université Catholique de Louvain, Brussels, BELGIUM.

OP524

Measuring the radiation dose to the thyroid with a simple collar detector system in patients with radionuclide therapy; A feasibility study

P. Brinks, D. B. M. Dickerscheid, E. Kranenborg, J. Lavalaye, J. B. A. Habraken; St. Antonius hospital, Nieuwegein, NETHERLANDS.

OP525

Relationship between circulating anti-thyroglobulin antibody (TgAb) and tumor metabolism in patients with Differentiated Thyroid Cancer (DTC): diagnostic and prognostic implications

E. Pomposelli¹, F. Pupo², I. Calamia¹, G. Ferrarazzo¹, G. Pesce², F. Fiz¹, G. Bottoni¹, M. Giusti³, G. Sambuceti¹, M. Bagnasco², S. Morbelli¹; ¹Nuclear Medicine Unit, IRCCS San Martino - IST, University of Genoa, Genoa, ITALY, ²Autoimmunity Unit, IRCCS San Martino - IST, University of Genoa, Genoa, ITALY, ³Endocrinology Unit, IRCCS San Martino - IST, University of Genoa, Genoa, ITALY.

OP526

The Survival and Outcome of Recurrent Differentiated Thyroid Carcinoma: Results of a Long-Term Follow-up Study

J. Mihailovic, E. Matovina, N. Klicov; Oncology Institute of Vojvodina, Sremska Kamenica, SERBIA.

OP527

The effect of post-ablation ¹³¹I SPECT/CT on the staging and initial risk-stratification of children with differentiated thyroid cancer

B. Liu, R. Tian; Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, CHINA.

OP528

Red marrow and blood dosimetry in ¹³¹I treatment of metastatic differentiated thyroid carcinoma: comparison in patients with repeated treatments

E. Richetta, M. Pasquino, C. Cutaia, A. Giostra, R. Pellerito, M. Stasi; AO Ordine Mauriziano di Torino, Turin, ITALY.

OP529

Pre-therapy Bone Marrow And Lesion Absorbed Dose Estimation Using Different Dosimetry Models In Metastatic Differentiated Thyroid Cancer

M. M. Abuqbeith, H. Tanyildizi, I. Cavdar, M. Demir, N. Yeyin, B. Vatankulu, L. Kabasakal; Istanbul University, Istanbul, TURKEY.

OP530

¹¹¹In-CP04 - A Novel CCK2/Gastrin Receptor-Localizing Radiolabelled Peptide Probe for management of Patients with Progressive/Metastatic Medullary Thyroid Carcinoma (MTC): Rationale, Study Design and the Initial Promising Results of a Multicentre First Phase Study.

A. Hubalewska-Dydejczyk¹, C. Decristoforo², P. Erba³, R. Mikolajczak⁴, H. Maecke⁵, K. Zaletel⁶, P. Kolenc-Peitl⁶, T. Maina⁷, P. Garnuszek⁴, I. Virgollini², G. Geobel², M. Konijnenberg⁸, M. Hendriks-deJong⁸, L. Froberg⁸, W. Lenda-Tracz¹, C. Rangger², A. Kunzmann⁵, A. Sowa-Staszczak¹, M. Trofimiuk-Muldner¹, M. Tomaszuk¹; ¹Jagiellonian University Medical College, Krakow, POLAND, ²Innsbruck Medical University, Innsbruck, AUSTRIA, ³Azienda Ospedaliero-Universitaria Pisana, Pisa, ITALY, ⁴Radioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, POLAND, ⁵University Hospital Freiburg, Freiburg, GERMANY, ⁶University Medical Centre Ljubljana, Ljubljana, SLOVENIA, ⁷INRASTES, NCSR "Demokritos", Athens, GREECE, ⁸Erasmus University Medical Center, Rotterdam, NETHERLANDS.

1506

Hall 6

16:30 – 18:00

M2M: Molecular & Multimodality Imaging: PET – Translational & Clinical Studies

OP531

Measurement of sorafenib concentrations using PET imaging in patients with advanced solid malignancies

L. H. Mammatas, M. Yaqub, N. H. Hendrikse, O. S. Hoekstra, R. J. Honeywell, M. Meijerink, L. A. Schwarte, G. J. Peters, A. A. Lammertsma, H. M. W. Verheul, C. W. Menke-van der Houven van Oordt; VU University Medical Center, Amsterdam, NETHERLANDS.

OP532

Early and late evaluation of solid tumours with ⁶⁴Cu-ATSM PET/CT: a computer-aided fractal analysis

E. Lopci^{1,2}, F. Grizzi¹, I. Grasso³, C. Russo¹, G. Cicoria³, S. Cambioli³, F. Lodi³, A. Chiti⁴, S. Mattioli⁵, S. Fanti⁵; ¹Humanitas Clinical and Research Hospital, Milano, ITALY, ²Alma Mater Studiorum University, Bologna, ITALY, ³Ospedale S. Orsola-Malpighi, Bologna, ITALY, ⁴Humanitas University, Milano, ITALY, ⁵Alma Mater Studiorum Bologna University, Bologna, ITALY.

OP533

Molecular imaging of neuroendocrine tumors with Scandium-44: a novel tool for THERANOSTICS

A. Singh¹, R. P. Baum¹, I. Klette¹, N. P. van der Meulen², C. Mueller³, A. Tuerler², R. Schibli³; ¹THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, ENETS Center of Excellence, Zentralklinik Bad Berka, Bad Berka, GERMANY, ²Laboratory for Radio- and Environmental Chemistry, Paul Scherrer Institute (PSI), Villigen, SWITZERLAND, ³Center for Radiopharmaceutical Sciences, Paul Scherrer Institute (PSI), Villigen, SWITZERLAND.

OP534

Determination of chemokine receptor CXCR4 by ⁶⁸Ga-Pentixafor PET in patients with adrenocortical carcinoma

C. Bluemel¹, S. Hahner¹, B. Heinze¹, A. Schirbel¹, M. Schottelius², C. Lapa¹, S. Kropf³, K. Lücknerath¹, B. Allolio¹, M. Fassnacht¹, H. Wester², A. K. Buck¹, K. Herrmann¹; ¹Universitätsklinikum Würzburg, Würzburg, GERMANY, ²Technische Universität München, München, GERMANY, ³Scintomics GmbH, Fürstentfeldbruck, GERMANY.

OP535

Diagnostic value of (68)Ga - PSMA PET/CT in biochemical recurrence of prostate carcinoma with low PSA levels

E. Demirci^{1,2}, J. Nematyazar¹, R. Akyel¹, B. Razavi¹, A. Aygun¹, M. Ocak³, M. Halac¹, A. Araman³, L. Kabasakal¹; ¹Department of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, TURKEY, ²Department of Nuclear Medicine, Sisli Etfal Training and Research Hospital, Istanbul, TURKEY, ³Department of Pharmaceutical Technology, Pharmacy Faculty, Istanbul University, Istanbul, TURKEY.

OP536

Preliminary comparison of PET/CT and PET/MRI hybrid systems using a Ga-68 labeled PSMA ligand for initial staging of prostate cancer

S. Lütje¹, B. Gomez¹, J. Cohnen¹, B. M. Schaarschmidt², R. Reichel¹, S. Rosenbaum-Krumme¹, A. Bockisch¹, T. D. Poeppel¹, A. Wetter³; ¹Clinic for Nuclear Medicine, University Hospital Essen, Essen, GERMANY, ²Department of Diagnostic and Interventional Radiology, Medical Faculty, University Düsseldorf, Düsseldorf, GERMANY, ³Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, GERMANY.

OP537

Evaluation of the role of F-18 FDG PET/CT in childhood rhabdomyosarcoma - preliminary results

R. K. Gupta, Jr., M. Tripathi, S. Bakshi, N. Damle, K. Kumar, R. Bhayana, C. Bal; All India Institute of Medical Sciences, New Delhi, INDIA.

OP538

Impact of 18F-FDG PET/CT in the diagnosis and therapeutic response of histiocytosis

L. M. Vija¹, G. Bera², J. Haroche², F. Cohen¹, P. Chaumet-Riffaud¹, A. Prigent¹, P. Maksud²; ¹Paris Sud University, Le Kremlin-Bicetre, FRANCE, ²Groupe Hospitalier La Pitié-Salpêtrière, Paris, FRANCE.

1507

Hall F

16:30 – 18:00

Teaching Session: Interactive Quiz: Nuclear Medicine with Correlative Imaging

OP539

Interactive Quiz: Nuclear Medicine with Correlative Imaging

T. Lynch, UNITED KINGDOM

1508

Hall E

08:00 – 09:30

Cardiovascular System: Miscellaneous

OP540

Increased myocardial 18F-FDG uptake after doxorubicin-based chemotherapy in Hodgkin disease: an early predictor of cardiotoxicity?

M. Bauckneht¹, G. Ferrarazzo¹, F. Fiz¹, P. Ghione², F. Bongioanni¹, A. Nieri¹, M. Pennone¹, S. Morbelli¹, P. Spallarossa², C. Marini³, G. Sambuceti¹; ¹Nuclear Medicine, IRCCS AOU San Martino IST, Genova, ITALY, ²Department of Internal Medicine, Chair of Cardiology, University of Genoa, Genova, ITALY, ³Institute of Bioimaging and Molecular Physiology, CNR, Milan, Genoa Section, Genova, ITALY, Genova, ITALY.

OP541

Reverse mismatch in a patient cohort undergoing 18F-FDG/82Rb dual isotope PET for assessment of myocardial viability: Is it a significant clinical problem?

A. K. Hansen, M. Gejl, K. Bouchelouche, L. P. Tolbod, L. C. Gormsen; Aarhus University Hospital, Aarhus, DENMARK.

OP542

Assessment of cardiac sympathetic nerve system in the rat heart using 11C-HED

Y. Maya^{1,2}, R. Werner^{1,3}, H. Wakabayashi¹, M. Nakajo¹, K. Fukushima⁴, C. Lapa¹, K. Herrmann¹, T. Higuchi^{1,3}; ¹Department of Nuclear Medicine, Universitätsklinikum Würzburg, Würzburg, GERMANY, ²Research Centre, Nihon Medi-Physics Co., Ltd., Chiba, JAPAN, ³Comprehensive Heart Failure Center, Würzburg, GERMANY, ⁴Hyogo College of Medicine, Hyogo, JAPAN.

OP543

Value of attenuation correction in stress-only myocardial perfusion imaging using CZT-SPECT

J. D. van Dijk^{1,2}, M. Mouden¹, J. Ottervanger¹, J. A. van Dalen¹, S. Knollemans¹, C. H. Slump², P. L. Jager¹; ¹Isala hospital, Zwolle, NETHERLANDS, ²MIRA: Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, NETHERLANDS.

OP544

Characterization of a dedicated myocardial cardio-centric SPECT-TC System: a preliminary phantom study

E. Richetta, M. Pasquino, C. Cutaia, G. Brusasco, G. Santopolo, I. Trabucco, A. Guida, R. Pellerito, M. Stasi; AO Ordine Mauriziano di Torino, Turin, ITALY.

OP545

Gated Myocardial Imaging: The impact of FBP and OSEM Image Reconstruction and Filtering on values of Left Ventricle function calculated with a commercial proqram – QGS*

D. S. Rosário; Karolinska Institutet, Stockholm, SWEDEN.

OP546

Feasibility of an eighth-time gated myocardial perfusion SPECT functional imaging using IQ-SPECT system.

F. Caobelli¹, J. T. Thackeray¹, A. Soffientini², F. M. Bengel¹, C. Pizzocaro², U. P. Guerra²; ¹Hannover Medical School, Hannover, GERMANY, ²Fondazione Poliambulanza, Brescia, ITALY.

OP547

Impact of Data-Driven Respiratory-Motion Correction on the Extent/Severity of Myocardial Perfusion Defects of MPI SPECT Acquired with Discovery NM 530c: REGAT Software

D. Daou^{1,2}, R. Sabbah³, H. Bouladhour³, C. Coaguila⁴; ¹Cochin Hospital, APHP, Paris, FRANCE, ²EA 7334 REMES, Université Paris-Diderot, Sorbonne Paris-Cité, Paris, FRANCE, ³CHU Jean Minjoz, Besançon, FRANCE, ⁴Centre Hospitalier de Bigorre, Tarbes, FRANCE.

1509

Hall 8

08:00 – 09:30

Clinical Oncology: Neuroendocrine

OP548

The Influence of ⁶⁸Ga-DOTATATE PET/CT Imaging in the Management Decision of Patients with Neuroendocrine Tumors

E. Skoura¹, O. M. AlMukhalid¹, E. Panagiotidis¹, M. Al Harbi¹, I. Kayani¹, S. Michopoulou¹, R. Syed¹, P. J. Ell¹, M. E. Caplin², J. Bomanji¹; ¹UCLH, London, UNITED KINGDOM, ²Royal Free Hospital, London, UNITED KINGDOM.

OP549

Do we need full-dose contrast-enhanced CT for extra-hepatic staging using Gallium-68-DOTATATE-PET/CT in patients with neuroendocrine tumors (NET)?

A. Heinzl¹, D. Albanus¹, F. Verburg¹, F. Behrendt¹, F. Mottaghy^{1,2}, Z. Erdem³, O. Erdem³, J. Apitzsch⁴; ¹UK Aachen, Aachen, GERMANY, ²Maastricht University Medical Center, Maastricht, NETHERLANDS, ³Bülent Ecevit University, Karaelmas, TURKEY, ⁴UK Gießen and Marburg, Marburg, GERMANY.

OP550

The clinical role of Ga-68 DOTATE PET-CT in patients with neuroendocrine tumors

M. Tuncel¹, S. Kılıçkap², E. Akdemir¹; ¹Hacettepe University, Department of Nuclear Medicine, ANKARA, TURKEY, ²Hacettepe University, Department of Medical Oncology, ANKARA, TURKEY.

OP551

Validation of parametric net influx rate images of ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE

E. Ilan, M. Sandström, I. Velikyan, A. Sundin, M. Lubberink; Section of Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN.

OP552

⁶⁸Ga-DOTA-NOC PET/CT SUVmax in patients with pancreatic NET: is it prognostic?

V. Ambrosini¹, G. Polverari¹, D. Campana², G. Cacciarì², C. Peterle¹, S. Diodato¹, C. Nanni¹, G. Montini¹, P. Tomassetti², S. Fanti¹; ¹Nuclear Medicine, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, ITALY, ²Internal Medicine, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, ITALY.

OP553

Head-to-head comparison of ⁶⁸Ga-DOTA-NOC and ¹⁸F-FDG PET/CT in neuroendocrine tumours: correlation between maximum standard uptake values and Ki67 proliferation index

R. Ferreira¹, R. Silva¹, A. Moreira¹, P. Lapa¹, P. Lapa¹, G. Costa¹, G. Costa¹, J. Lima²; ¹Serviço de Medicina Nuclear do Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, ²Instituto de Ciências Nucleares Aplicadas à Saúde, Coimbra, PORTUGAL.

OP554

⁶⁸Ga-DOTANOC PET/CT imaging in localizing the primary site in patients presenting with metastatic neuroendocrine tumors and its impact on clinical decision making: Experience from a tertiary care centre in India

A. Pruthi, P. Pankaj, R. Verma, A. Jain, E. S. Belho, H. Mahajan; Sir Ganga Ram Hospital and Research Centre, New Delhi, INDIA.

OP555

¹⁸F-DOPA PET/CT in patients with neuroendocrine tumors

A. T. Golubic, D. Huic, A. Mutvar, M. Zuvic; Department of Nuclear Medicine and Radiation Protection, University Hospital Center Zagreb, Zagreb, CROATIA.

1510

Hall D

08:00 – 09:30

Neurosciences: Neuroimaging – Data Analysis

OP556

Maps of serotonin transporter distribution in the human brainstem obtained using high-resolution PET correlates with post-mortem autoradiography data (ARG).

P. Fazio¹, M. Schain¹, K. Varnäs¹, C. Halldin¹, L. Farde^{1,2}, A. Varrone¹; ¹Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm, SWEDEN, ²AstraZeneca Translational Science Centre at Karolinska Institutet, Stockholm, SWEDEN.

OP557

Simplified quantification of the dopamine transporter using [¹⁸F]FE-PE2I in PD patients and control subjects

I. Sonni^{1,2}, P. Fazio¹, M. Schain¹, C. Halldin¹, P. Svenningsson¹, L. Farde¹, A. Varrone¹; ¹Department of Clinical Neuroscience - Karolinska Institutet, Stockholm, SWEDEN, ²Sapienza - University of Rome, Rome, ITALY.

OP558

Translational Imaging Improves Diagnostic Power of FP-CIT SPECT in Parkinsonian Syndrome

C. Paschetta, F. Buttari, A. Skanjeti, D. Gned, V. Podio; San Luigi Gonzaga Hospital, Orbassano (TO), ITALY.

OP559

Age- and sex-related differences in ¹⁸F-FDG brain metabolism in healthy subjects using a PET-driven partial volume effect correction method

S. Bonte^{1,2}, P. Vandemaele², S. Verleden³, K. Audenaert³, K. Deblaere², I. Goethals², R. Van Hoken¹; ¹Ghent University: MEDISIP (Department of Electronics and Information Systems), Ghent, BELGIUM, ²Ghent University Hospital: Department of Radiology and Nuclear Medicine, Ghent, BELGIUM, ³Ghent University Hospital: Department of Psychiatry, Ghent, BELGIUM.

OP560

Age-related changes in FDG brain uptake are more accurately assessed when applying an adaptive template to the SPM method of voxel-based quantitative analysis

A. Van Der Gucht¹, A. Verger¹, E. Guedj², G. Malandain³, G. Hossu⁴, Y. Yagdigul¹, V. Roch¹, S. Poussier¹, L. Maillard⁵, G. Karcher¹, P. Marie¹; ¹CHU Nancy, Nuclear Medecine & Nancyclotep Experimental Imaging Platform, Nancy, FRANCE, ²AP-HM, Hospital "La Timone", Department of Nuclear Medicine, Marseille, FRANCE, ³INRIA Sophia Antipolis-Méditerranée, Sophia Antipolis, Valbonne, FRANCE, ⁴INSERM, CIC-IT 1433, Nancy, FRANCE, ⁵CHU-Nancy, Department of Neurology, Nancy, FRANCE.

OP561

Head-to-head comparisons of semi-quantification tools for brain FDG-PET in diagnosis of prodromal Alzheimer's disease.

S. Morbelli¹, M. Pagani², F. De Carli³, J. Öberg⁴, A. Buschiazzo¹, G. Frisoni⁵, A. Drzezga⁶, B. N. van Berckel⁷, E. Guedj⁸, A. Picco⁹, D. Arnaldi⁹, M. Ferrara⁹, A. Chincari¹⁰, F. Nobili⁹, A. Brugnolo⁹; ¹Nuclear Medicine Unit, IRCCS San Martino - IST, University of Genoa, Genoa, ITALY, ²Institute of Cognitive Sciences and Technologies, Consiglio Nazionale delle Ricerche (CNR), Rome, ITALY, ³Institute of Bioimaging and Molecular Physiology, Consiglio Nazionale delle Ricerche (CNR), Genoa, Italy, Genoa, ITALY, ⁴Department of Hospital Physics, Karolinska Hospital, Stockholm, SWEDEN, ⁵University Hospitals and University of Geneva, Geneva, SWITZERLAND, ⁶Department of Nuclear Medicine, University of Cologne, Cologne, GERMANY, ⁷Department of Nuclear Medicine & PET Research, VU University Medical Center, Amsterdam, NETHERLANDS, ⁸APHM, CHU Timone, Service de Médecine Nucléaire, CERIMED, INT CNRS UMR7289, Aix-Marseille University, Marseille, FRANCE, ⁹Clinical Neurology, Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Mother-Child health (DINOEMI), University of Genoa, IRCCS AOU, San Martino-IST, Genoa, ITALY, ¹⁰National Institute for Nuclear Physics (INFN), Genoa, ITALY.

OP562

Agreement of brain amyloid PET interpretation between automated diagnosis using support vector machine and visual assessment by expert readers

I. Matsunari¹, J. Komatsu², M. Samuraki³, M. Noguchi-Shinohara², T. Hamaguchi², K. Ono², I. Kuji³, M. Yamada², S. Kinuya²; ¹Saitama Medical University Hospital, Iruma-gun, JAPAN, ²Kanazawa University, Kanazawa, JAPAN, ³Saitama Medical University International Medical Center, Hidaka, JAPAN.

OP563

Comparison of Reference Regions to Semiquantitatively Analyse 18F-Florbetaben PET Images

H. Barthel¹, S. Bullich², O. Sabri¹, J. Seibyl³, V. Villemagne⁴, C. Rowe⁴, N. Koglin², A. Stephens², A. M. Catafau²; ¹Leipzig University, Leipzig, GERMANY, ²Piramal Imaging, Berlin, GERMANY, ³IND, New Haven, CT, UNITED STATES, ⁴University of Melbourne, Melbourne, AUSTRALIA.

1601

CME

Hall 1

08:00 – 09:30

CME 13 – Translational Molecular Imaging & Radiopharmacy: Image Guided Surgery in Urological Malignancies

OP564

Combined Radio- and Fluorescence Guidance during Robot-Assisted Laparoscopic Sentinel Node Procedures (ERUS Lecture)

H. Van der Poel, NETHERLANDS

OP565

Combined Radio- and Fluorescence Guidance during Robot-Assisted Laparoscopic Sentinel Node Procedures (ERUS Lecture)

N. Van den Berg, NETHERLANDS

OP566

Tracers for Image-Guided Surgery of Prostate Cancer

H.-J. Wester, GERMANY

OP567

Cerenkov Imaging

J. Grimm, USA

1602

Hall 2

08:00 – 09:30

Joint Symposium 13: EANM/ESPGHAN: Paediatric Gastrointestinal Nuclear Medicine

OP568

Clinical Aspects of Neonatal Cholestasis

B. Fischler, SWEDEN

OP569

Hepatobiliary Scintigraphy in Paediatrics

R. Howman-Giles, AUSTRALIA

OP570

Scintigraphic Evaluation of Gastroesophageal Reflux and Gastric Emptying in Children

Z. Bar-Sever, ISRAEL

1603

Hall 4

09:30 – 10:45

CTE 6: Imaging Protocols in Radionuclide Therapy

OP571

Imaging Aspects in Peptide Receptor Radionuclide Therapy

L. Bodei, ITALY

OP572

Selective Internal Therapy - Imaging and Therapy

J. de la Roche, GERMANY

OP573

Scintigraphic Evaluation of Gastroesophageal Reflux and Gastric Emptying in Children

P.A. Erba, ITALY

1605

Hall G2

08:00 – 09:30

Do.MoRe: 90Y SIRT Dose Effects

OP574

Selective internal radiatiotherapy (SIRT) in hepatic metastases from uveal melanoma. Treatment response in comparison to transarterial chemoembolization (TACE) with Fotemustin

H. Duan¹, G. Berzacy², F. Waneck³, M. Funovics³, C. Hoeller⁴, M. Hoffmann¹; ¹Medical University of Vienna, Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Vienna, AUSTRIA, ²Medical University of Vienna, Department of Biomedical Imaging and Image-guided Therapy, Division of General Radiology, Vienna, AUSTRIA, ³Medical University of Vienna, Department of Biomedical Imaging and Image-guided Therapy, Division of Cardiovascular Radiology, Vienna, AUSTRIA, ⁴Medical University of Vienna, Department of Dermatology, Vienna, AUSTRIA.

OP575

Comparison of different dosimetric methods for tumor and normal tissue predicted absorbed dose calculation in liver radioembolization: preliminary results

M. FINESSI¹, E. GALLIO², E. RICHETTA³, M. STASI³, R. PELLERITO⁴, R. ROPOLLO², G. BISI¹; ¹S.C. Medicina Nucleare U, A.O.U. Città della Salute e della Scienza, Torino, ITALY, ²S.C. Fisica Sanitaria, A.O.U. Città della Salute e della Scienza, Torino, ITALY, ³S.C. Fisica Sanitaria, A.O. Ordine Mauriziano, Torino, ITALY, ⁴S.C. Medicina Nucleare, A.O. Ordine Mauriziano, Torino, ITALY.

OP576

Reduced lymphocyte proliferation and IFN- γ production after Selective Internal Radiotherapy

A. Domouchtsidou¹, M. Lindemann¹, J. Best², J. Ertle², S. P. Mueller³, S. Bedrel², P. A. Horn¹, A. Bockisch³, V. Barsegian⁴; ¹Institute for Transfusion Medicine, University Hospital Essen, GERMANY, ²Department of Gastroenterology and Hepatology, University Hospital Essen, GERMANY, ³Department of Nuclear Medicine, University Hospital Essen, GERMANY, ⁴Institute of Nuclear Medicine, Helios Kliniken Schwerin, GERMANY.

OP577

Retrospective analysis of dose-response for HCC lesions treated with 90Y resin microspheres

C. Pettinato¹, C. Mosconi², A. Cappelli², S. Civollani¹, P. Pini³, F. Monari⁴, C. Galaverni², B. Angelelli⁵, F. Trevisani³, R. Golfieri²; ¹Medical Physics Unit - AOU di Bologna, Bologna, ITALY, ²Radiology Unit - AOU di Bologna, Bologna, ITALY, ³Internal Medicine Unit - AOU di Bologna, Bologna, ITALY, ⁴Radiotherapy Unit - AOU di Bologna, Bologna, ITALY, ⁵Oncology Unit - AOU di Bologna, Bologna, ITALY.

OP578

PET-CT in the post-treatment evaluation of a HCC patient treated with Yttrium-90 radioembolization

R. Stoico, L. Dellavedova, M. Carletto, L. Maffioli; A.O. Ospedale Civile di Legnano, Legnano, ITALY.

OP579

Comparison of Survival, Safety and Efficacy After Chemo and Radioembolization of BCLC Stage B-C Hepatocellular Cancer Patients.

C. Soydal, M. F. Arslan, N. O. Kucuk, R. Idilman, S. Bilgic; Ankara University Medical Faculty, Ankara, TURKEY.

OP580

Safety of 90Y-glass microspheres therapy in hepatic malignancies, our experience.

P. Borrelli, P. Bello Arqués, P. Olivan Sasot, C. Igua Sáenz, V. Vera Pinto, J. Vercher-Conejero, J. Loaiza Góngora, C. Ruiz Llorca; Hospital Universitario y Politecnico La Fe, Valencia, SPAIN.

OP581

Yttrium-90 Radioembolisation for Colorectal Cancer Liver Metastases: Circulating Angiogenic Factors and Treatment Response

C. E. N. M. Rosenbaum; University Medical Center Utrecht, Utrecht, NETHERLANDS.

1606

Hall 6

10:00 – 11:30

M2M: Radiopharmaceuticals & Radiochemistry: Macromolecules II

OP582

The use of radiocobalt as a label improves PET imaging of EGFR using DOTA-conjugated affibody molecules.

J. Garousi¹, K. Anderson², J. H. Dam³, B. B. Olsen³, A. Orlova⁴, J. Buijs¹, S. Ståhl², H. Thisgaard³, V. Tolmachev¹; ¹Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN, ²Department of Protein Technology, KTH - Royal Institute of Technology, Stockholm, SWEDEN, ³Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK, ⁴Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN.

OP583

223Ra-NaA-silane-PEG-SP(5-11) radiobioconjugate as a new potential radiopharmaceutical for targeted α therapy of glioblastoma multiforme

A. Majkowska-Pilip¹, P. Koźmiński¹, A. Piotrowska¹, F. Bruchertseifer², A. Morgenstern², M. Bonelli³, M. Laurenza³, A. Bilewicz¹; ¹Institute of Nuclear Chemistry and Technology, Warsaw, POLAND, ²European Commission, Joint Research Centre, Institute for Transuranium Elements, Karlsruhe, GERMANY, ³Dept. Physiology and Pharmacology, Sapienza University of Rome, Rome, ITALY.

OP584

Gold Nanoparticle-Substance P(5-11) Conjugate as a Carrier for 211At in Alpha Particle Therapy

A. Bilewicz¹, & Janiszewska¹, P. Kozminski¹, M. Lyczko¹, M. Pruszyński^{1,2}, J. Jastrzębski², J. Chojński², A. Stolarz², A. Trzcińska², K. Szkliniarz³, W. Zipper³; ¹Institute of Nuclear Chemistry and Technology, Warsaw, POLAND, ²Heavy Ion laboratory, University of Warsaw, Warsaw, POLAND, ³Institute of Physics, Department of Nuclear Physics, University of Silesia, Katowice, POLAND.

OP585

Synergistically Enhanced Tumor Uptake via Dual-Targeting of CD105 and EGFR Using a "Click" Heterodimer

R. Hernandez, H. Luo, H. Hong, S. A. Graves, R. J. Nickles, W. Cai; University of Wisconsin-Madison, MADISON, WI, UNITED STATES.

OP586

Affibody-based bioorthogonal chemistry-mediated radionuclide pretargeting: proof-of-principle.

M. Altai¹, M. Tsourma¹, B. Mitran², H. Honarvar¹, A. Perols³, M. Robillard⁴, R. Rossin⁴, W. ten Hoeve⁵, M. Sandström⁶, A. Orlova², A. Eriksson Karlström³, V. Tolmachev¹; ¹Department of Immunology, Genetics and Pathology, Uppsala, SWEDEN, ²Preclinical PET Platform, Uppsala, SWEDEN, ³Division of Protein Technology, KTH, Stockholm, SWEDEN, ⁴Tagworks Pharmaceuticals, Eindhoven, NETHERLANDS, ⁵Syncom B.V., Gröningen, NETHERLANDS, ⁶Akademiska sjukhuset, Uppsala, SWEDEN.

OP587

Technetium-99m radiolabeled aptamer as a potential agent capable of identifying tumor in vivo

L. Kang; Peking University First Hospital, Beijing, CHINA.

OP588

89Zr-Affibody for specific detection of EGFR expression in HNSCC

T. Burley, C. D. Martins, C. Da Pieve, R. L. Paul, D. M. Ciobota, G. Smith, K. Harrington, G. Kramer-Marek; The Institute of Cancer Research, Sutton, UNITED KINGDOM.

OP589

Strategies for the development of high specific activity affibody based probes for the detection of HER3 positive tumours

C. Da Pieve¹, L. Allott¹, C. D. Martins¹, L. Carroll², R. L. Paul¹, E. O. Aboagye², G. Kramer-Marek¹, G. Smith¹; ¹Institute of Cancer Research, London, UNITED KINGDOM, ²Imperial College London, London, UNITED KINGDOM.

1608

Hall E

10:00 – 11:30

Clinical Oncology: Breast & Gynaecology

OP590

Identification of biomarkers including ¹⁸F-FDG-PET/CT for early prediction of response to neoadjuvant chemotherapy in Triple Negative Breast Cancer

O. Humbert^{1,2}, J. Riedinger¹, C. Charon-Barra¹, A. Berriolo-Riedinger¹, I. Desmoulins¹, V. Lorgis¹, S. Kanoun^{1,2}, C. Coutant¹, P. Fumoleau¹, F. Brunotte^{1,3,2}, A. Cochet^{1,2}; ¹Centre Georges-François Leclerc, DIJON, FRANCE, ²Université de Bourgogne, UMR CNRS 6306, Dijon, FRANCE, ³Centre Hospitalo-Universitaire, Dijon, FRANCE.

OP591

Fusion of prone FDG PET/CT and MRI improves staging of patients with breast cancer

M. J. Ribelles, M. Rodriguez, L. Sancho, F. Guillen, L. J. Pina, M. Idoate, F. Martinez Regueira, M. Santiesteban, J. A. Richter, M. J. Garcia-Velloso; CLINICA UNIVERSIDAD DE NAVARRA, PAMPLONA, SPAIN.

OP592

Comparison of dedicated hanging breast PET and standard whole body PET/CT for primary tumour visualization in breast cancer patients

S. Teixeira¹, J. Ferrer Rebolledo², B. B. Koolen¹, J. Wesseling¹, R. Sánchez Jurado¹, M. P. M. Stokkel¹, M. del Puig Cózar Santiago², V. van de Noort¹, E. J. T. Rutgers¹, R. A. Valdés Olmos¹; ¹Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS, ²ERESA, General university hospital of Valencia, Valencia, SPAIN.

OP593

Predictive value of dynamic and dual-phase 18 FDG PET/CT parameters in the assessment of neoadjuvant chemotherapy response in locally advanced breast cancer: A comparative study with dynamic contrast enhanced MRI.

O. Kupik, M. Tuncel, P. Kiratli, M. Akpınar, K. Altundağ, F. Demirkazık, B. Erbas; Hacettepe University, Ankara, TURKEY.

OP594

Treatment response evaluation by 18F-FLT positron emission tomography/ computed tomography after neoadjuvant chemotherapy in patients with locally advanced breast cancer

B. R. Mittal, J. Shukla, G. Singh, A. Bal, D. Kumar, M. Kumar, R. Vatsa, P. Bhusari, N. Rana, N. Khandelwal; Postgraduate Institute of Medical Education & Research, CHANDIGARH, INDIA.

OP595

Prognostic value of maximum standardized uptake value measured on F-18 FDG PET/CT in patients with recurrent epithelial ovarian cancer.

X. Palard; University Hospital of Brest, Brest, FRANCE.

OP596

Impact of the FDG PET/CT in the primary staging of locally advanced Cervical Squamous Cell Carcinoma (CSCC).

A. Alessi¹, A. Lorenzoni¹, D. Lorusso², A. Cerrotta³, V. Chiappa², B. Pappalardi³, B. Padovano¹, G. Serafini¹, F. Raspagliesi², F. Crippa¹; ¹Nuclear medicine PET Unit Fondazione IRCSS Istituto Nazionale Tumori, Milano, ITALY, ²Gynecologic Oncology Unit - Fondazione IRCSS Istituto Nazionale Tumori, Milano, ITALY, ³Radiotherapy Unit - Fondazione IRCSS Istituto Nazionale Tumori, Milano, ITALY.

OP597

Determinants of sentinel node localization failure in gynaecological cancers: a retrospective cohort study.

E. Odouard¹, A. Tescaru¹, F. Giammarile¹, C. Bournaud¹, S. Lancelot^{1,2}; ¹Hôpitaux de Lyon, Lyon, FRANCE, ²Lyon Neuroscience Research Center, Université Claude Bernard Lyon 1, INSERM, CNRS, Lyon, FRANCE.

1610

Hall D

10:00 – 11:30

Clinical Oncology: Brain, Head & Neck

OP598

Diagnostic and prognostic value of 18F-DOPA PET and 1H-MR Spectroscopy in pediatric supratentorial infiltrative gliomas: a comparative study.

M. Massollo¹, A. Piccardo¹, G. Morana², M. Puntoni³, C. Milanaccio⁴, M. Garrè⁴, A. Rossi², M. Cabria¹, A. Raso⁵, I. Bossert¹, M. Cabria¹; ¹Nuclear Medicine Unit E.O. Galliera Hospital, Genoa, ITALY, ²Neuroradiology Unit, Istituto G. Gaslini, Genova, Italy, Genoa, ITALY, ³Clinical Trial Unit, Scientific Directorate, Ospedali Galliera, Genova, Genoa, ITALY, ⁴Neuro-oncology Unit, Istituto G. Gaslini, Genova, Italy, Genoa, ITALY, ⁵Neurosurgery Unit, Istituto G. Gaslini, Genova, Italy, Genoa, ITALY.

OP599

[18F]-fluciclovine (FACBC) PET/CT as a Supplement to MRI in Patients with Suspected Recurrent Gliomas

A. Londalen, T. Bach-Gansmo, C. Saxhaug, P. Brandal, T. V. Bogsrud; Oslo University Hospital, Oslo, NORWAY.

OP600

PET/MR versus PET/CT in the Initial Staging of Head and Neck Cancer

T. Sekine^{1,2}, F. Barbosa¹, F. Kuhn¹, I. Burger¹, G. von Schulthess¹, P. Veit-Haibach¹, M. Huellner¹; ¹University Hospital Zurich, Zurich, SWITZERLAND, ²Nippon Medical School, Tokyo, JAPAN.

OP601

11C-methionine PET-CT for contouring and response evaluation of Head and Neck Adenocystic Carcinoma treated with CIRT (Carbon Ion Radiation Therapy)

L. Olivari¹, M. Bonora², M. Rodari³, M. Fiore², V. Vitolo², E. Lopci³, F. Valvo², P. Fossati², R. Orecchia¹, A. Chiti⁴; ¹University of Milan, Milano, ITALY, ²Division of Radiation Oncology and Radiobiology, National Center for Oncological Adrontherapy (CNAO) Foundation, Pavia, ITALY, ³Department of Nuclear Medicine, Humanitas Research Hospital, Milano, ITALY, ⁴Humanitas University, Milano, ITALY.

OP602

Value of FDG volumetric imaging parameters before radiotherapy treatment in inoperable Head and Neck cancer (HNC)

L. Olivari¹, E. Lopci², A. Poletti³, R. Cavina⁴, C. Arturo⁵;

¹University of Milan, Milano, ITALY, ²Department of Nuclear Medicine, Humanitas Research Hospital, Milano, ITALY, ³Department of Otorhinolaryngology, Humanitas Research Hospital, Milano, ITALY, ⁴Department of Oncology, Humanitas Research Hospital, Milano, ITALY, ⁵Humanitas University, Rozzano, Milano, ITALY.

OP603

Predictive role of FDG-PET/CT in patients with locally advanced oropharyngeal cancer undergoing tomotherapy with dose escalation

E. Incerti¹, I. Dell'Oca², M. Kirienko³, C. Fiorino⁴, P. Alongi³, S. Broggi⁴, P. Mapelli¹, N. Di Muzio², L. Gianolli¹, M. Picchio¹;

¹Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY, ²Radiotherapy Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY, ³University of Milano-Bicocca, Milan, ITALY, ⁴Medical Physics Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY.

OP604

Diagnostic accuracy of F18-FDG-PET/CT for the detection of perineural spread in head and neck cancer

L. Dercle, S. Ammari, L. Rozenblum, D. Deandreis, M. Terroir, M. Schlumberger, F. Bidault; GUSTAVE ROUSSY, Villejuif, FRANCE.

OP605

Head and neck cancer: can 18F-FDG PET/CT staging scan improve the predictive value of post-treatment 18F-FDG PET/CT assesment

I. Sandler¹, G. M. Lima¹, P. Castellucci¹, U. Caliceti², S. Cammelli³, V. Allegri¹, A. Morganti³, S. Fanti¹; ¹Università di Bologna, Nuclear Medicine Unit, S.Orsola-Malpighi Hospital, Bologna, ITALY, ²Università di Bologna, Head and Neck Unit, S. Orsola-Malpighi Hospital, Bologna, ITALY, ³Università di Bologna, Radiotherapy Unit, S. Orsola-Malpighi Hospital, Bologna, ITALY.

1701

CME

Hall 1

10:00 – 11:30

CME 14 – Drug Development & Translational Molecular Imaging: Multimodal Imaging Agents

OP606

Exploiting Multimodal Imaging Probes for Sentinel Lymph Node Imaging in Breast Cancer/Melanoma

R.T.M. de Rosales, UK

OP607

Quantitation and Qualities: Data and Images from Multimodal Read-Outs for Preclinical Discoveries

D. Mathe, HUNGARY

OP608

Multimodality Clinical PET/MR Imaging

M. Eiber, GERMANY

1705

Hall G2

10:00 – 11:30

Do.MoRe: Miscellaneous

OP609

3D patient absorbed dose estimation of monoclonal antibody targeting synovial sarcoma

D. Sarrut, J. Badel, A. Halty, D. Kryza, A. Giraudet; CREATIS / LUMEN, Lyon, FRANCE.

OP610

Implementation and validation of a collapsed cone superposition algorithm for radiopharmaceutical dosimetry of radionuclides with photon component

M. Sanchez-Garcia¹, I. Gardin², R. Lebtahi¹, A. Dieudonné¹; ¹Department of Nuclear Medicine, Beaujon Hospital, Assistance Publique-Hôpitaux de Paris (APHP) & INSERM U1149, Clichy, FRANCE, ²Department of Nuclear Medicine, Henri Becquerel Cancer Center and Rouen University Hospital, & QuantIF – LITIS [EA 4108], Rouen, FRANCE.

OP611

Targeted photodynamic therapy of insulinomas and congenital hyperinsulinism by Exendin-700DX

S. Ekim¹, D. Bos¹, F. Andreae², M. Brom¹, M. Gotthardt¹; ¹Radboud University Medical Centre, Nijmegen, NETHERLANDS, ²PICHEM, Graz, AUSTRIA.

OP612

Integration of micro- and macro-dosimetry for calculation of radiation doses to the islets of Langerhans due to radionuclide imaging with exendin

I. van der Kroon¹, W. Woliner-van der Weg¹, M. Brom¹, L. Joosten¹, C. Frielink¹, M. W. Konijnenberg², E. P. Visser¹, M. Gotthardt¹; ¹Radboud University Medical Center, Nijmegen, NETHERLANDS, ²Erasmus Medical Center, Rotterdam, NETHERLANDS.

OP613

The intrinsic absorbed dose resolution concept in voxel dosimetry - Application to 90Y microsphere radioembolization

C. Chiesa, M. Mira, M. Maccauro, E. Seregini, F. Crippa; Nuclear Medicine, Foundation IRCCS Istituto Nazionale Tumori, Milan, ITALY.

OP615

Improved treatment planning in radioimmunotherapy with 90Y-anti-CD66 antibody using population based modelling

C. Maaß¹, P. Kletting², D. Hardiansyah¹, B. Mahren³, D. Bunjes², A. Beer², G. Glatting¹; ¹Medical Radiation Physics/ Radiation Protection, Medical Faculty Mannheim, Heidelberg University, Mannheim, GERMANY, ²Department of Nuclear Medicine, Ulm, GERMANY, ³Department of Nuclear Medicine, Würzburg, GERMANY.

OP616

Metrology for molecular radiotherapy: what did the MetroMRT project achieve?

V. Smyth¹, C. Bobin², L. Johansson¹, L. Joulaeizadeh³, M. D'Arienzo⁴, M. Capogni⁴, H. Rabus⁵, M. Cox¹, J. Šolc⁶; ¹National Physical Laboratory, Teddington, Middlesex, UNITED KINGDOM, ²Laboratoire National Henri Becquerel/ Commissariat à l'Energie Atomique (LNE-LNHB), Gif-sur-Yvette Cedex, FRANCE, ³VSL, Dutch Metrology Institute, Delft, NETHERLANDS, ⁴National Institute of Ionizing Radiation Metrology, ENEA-INMRI, Rome, ITALY, ⁵Physikalisch-Technische Bundesanstalt (PTB), Braunschweig, GERMANY, ⁶Czech Metrology Institute (CMI), Prague, CZECH REPUBLIC.

1706

Hall 6

16:00 – 16:30

M2M: Molecular & Multimodality Imaging: PET Tracers – Preclinical Studies

OP617

Synthesis and evaluation of Androgen Receptor radioligand [18F]enzalutamide: comparison with [18F]FDHT

I. F. Antunes¹, R. Dost², A. van Waarde¹, R. Dierckx¹, D. Samplonius³, W. Helfrich³, D. Burg⁴, E. de Vries¹, I. de Jong²; ¹NMMI, University Medical Center of Groningen, Groningen, NETHERLANDS, ²Department of Urology, University Medical Center of Groningen, Groningen, NETHERLANDS, ³Surgical Research Laboratory, University Medical Center of Groningen, Groningen, NETHERLANDS, ⁴Astellas Pharma Europe, Leiden, NETHERLANDS.

OP618

Comparison of [11C]Choline and [18F]Galacto-RGD as pharmacodynamic biomarker for therapy response assessment of avastin therapy in a PC-3 Prostate Cancer Xenograft Model

S. Schwarzenböck^{1,2}, M. Souvatzoglou¹, M. Heuschkel², R. Nawroth³, U. Treiber³, T. Schuster⁴, R. Senekowitsch-Schmidtke¹, M. Schwaiger¹, S. I. Ziegler¹, G. Henriksen⁵, H. Wester⁵, A. J. Beer¹, B. J. Krause^{1,2}; ¹Technical University München, Department of Nuclear Medicine, München, GERMANY, ²Rostock University Medical Centre, Department of Nuclear Medicine, Rostock, GERMANY, ³Technical University München, Department of Urology, München, GERMANY, ⁴Technical University München, Institution of Statistics, München, GERMANY, ⁵Technical University München, Pharmaceutical Radiochemistry, Garching, GERMANY.

OP619

Broadcasting the HER3 receptor status in vivo

C. D. Martins, C. Da Pieve, D. M. Ciobota, R. L. Paul, T. Spinks, G. Smith, G. Kramer-Marek; The Institute of Cancer Research, London, UNITED KINGDOM.

OP620

PET Imaging of c-Met in Cancer with ⁶⁴Cu-Labeled Hepatocyte Growth Factor

H. Luo, H. Hong, S. Shi, S. A. Graves, R. J. Nickles, W. Cai; University of Wisconsin-Madison, MADISON, WI, UNITED STATES.

OP621

The PET tracer [18F]-tetrafluoroborate allows reporter gene-afforded metastasis tracking.

S. Diocou¹, G. Fruhwirth¹, K. Chuamsaamarkkee¹, M. Jauregui-Osoro¹, L. Livieratos¹, P. Blower¹, T. Ng^{1,2}, G. Mullen¹; ¹King's College London, London, UNITED KINGDOM, ²University College London, London, UNITED KINGDOM.

OP622

Molecular imaging of EGFR and EGFRvIII for prediction and response monitoring of HSP90 inhibition in an in vivo squamous cell carcinoma model

D. Spiegelberg¹, A. C. Mortensen¹, R. K. Selvaraju², O. Eriksson², B. Stenerlöv¹, A. Scott³, M. Nestor^{1,4}; ¹Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN, ²Preclinical PET Platform, Uppsala, SWEDEN, ³Ludwig Institute for Cancer Research, Olivia Newton-John Cancer Research Institute, and La Trobe University, Melbourne, AUSTRALIA, ⁴Department of Surgical Sciences, Academic hospital, Uppsala, SWEDEN.

OP623

Efficacy of the sequentially combined vinorelbine and gefitinib in Non-Small Cell Lung Cancer cell lines, an "in-vivo" study.

G. Bottoni¹, M. Dal Bello², A. Alama², S. Morbelli¹, C. Marini³, F. Grossi², G. Sambucetti¹; ¹Nuclear Medicine Unit, IRCCS-IST San Martino, University of Genoa, Genova, ITALY, ²Lung Cancer Unit IRCCS-IST San Martino, Genova, ITALY, ³Institute of Bioimaging and Molecular Physiology, CNR, Milan, Genoa Section, Genova, ITALY.

OP624

Oncologic Applications of High Resolution In Situ Correlations between Histopathology and FDG Tracer Uptake Obtained by Quantitative Autoradiography of Biopsy Specimens (QABS)

A. S. Kirov¹, L. M. Fanchon^{1,2}, S. Dogan¹, C. Czmielewski¹, E. Yorke¹, H. Schöder¹, J. O. Deasy¹, J. L. Humm¹, S. B. Solomon¹; ¹Memorial Sloan-Kettering Cancer Center, New York, NY, UNITED STATES, ²INSERM, UMR1101, LaTIM, Brest, FRANCE.

1708

Hall E

16:00 – 16:30

Clinical Oncology: Therapy Response & External Beam RT

OP625

Textural analysis of baseline 18F-FDG PET for predicting treatment response and prognosis in patients with locally advanced esophageal cancer

X. Sun, L. Sun, L. Xing; Shandong Cancer Hospital and Institute, Jinan, CHINA.

OP626

The predictive value of ¹⁸F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: "low-dose" fractionated radiotherapy with concurrent chemotherapy

M. Mattoli¹, M. Massacesi², V. Scolozzi¹, A. Castelluccia², G. Mantini², A. Giordano¹, M. Calcagni¹; ¹Institute of Nuclear Medicine, Rome, ITALY, ²Department of Radiation Oncology, Rome, ITALY.

OP627

Comparison of EORTC criteria and PERCIST for FDG PET/CT response evaluation of patients with metastatic breast cancer treated with a first line of systemic therapy.

E. Depardon¹, S. Kanoun^{1,2}, O. Humbert^{1,2}, J. Riedinger¹, M. Lasserre¹, M. Toubreau¹, A. Berriolo-Riedinger¹, I. Dygai-Cochet¹, P. Fumoleau³, F. Brunotte^{1,2}, A. Cochet^{1,2}; ¹Department of Nuclear Medicine, Centre Georges-Francois Leclerc, Dijon, FRANCE, ²Le2i CNRS UMR 6306, Dijon, FRANCE, ³Department of Medical Oncology, Centre Georges-Francois Leclerc, Dijon, FRANCE.

OP628

Monitoring Tumour Response to Neoadjuvant Chemotherapy using MRI and ¹⁸F-FDG PET/CT in Breast Cancer Subtypes

A. M. T. Schmitz¹, K. E. Pengel², C. E. Loo², W. Vogel², J. Wesseling², S. C. Teixeira², E. J. T. Rutgers², R. A. Valdés Olmos², G. S. Sonke², S. Rodenhuis², M. T. F. D. Vrancken-Peeters², K. G. A. Gilhuijs¹; ¹University Medical Centre Utrecht, Utrecht, NETHERLANDS, ²Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS.

OP629

Planning of radiotherapy with PET: Volumes only?

M. Beresova, J. Mucientes Rasilla, B. Rodriguez Alfonso, I. Zapata Paz, A. De la Torre Tomas, J. Romero Fernández, M. De Teresa Herrera, I. Plaza De Las Heras, M. Mitjavila Casanovas; HUPH Majadahonda, Madrid, SPAIN.

OP630

Feasibility and clinical utility of 4D PET/CT for SBRT planning of liver tumors

E. Deshayes¹, L. Santoro¹, M. Eberle¹, S. Guillemard¹, F. Marre¹, N. Aillères², P. Fenoglietto², D. Azria², P. Kotzki¹, O. Riou²; ¹Nuclear Medicine Department - Institut Cancer Montpellier, Montpellier Cedex 5, FRANCE, ²Radiotherapy Department - Institut Cancer Montpellier, Montpellier Cedex 5, FRANCE.

OP631

Other than restaging phase: Serial FCH PET/CT scans can predict the response to chemotherapy in castrate-resistant prostate cancer?

L. Evangelista¹, U. Basso¹, A. Guttilla², F. Zattoni², A. Cervino¹, M. Maruzzo¹, V. Zagonel¹, F. Zattoni², G. Saladini¹; ¹Istituto Oncologico Veneto I.R.C.C.S., PADOVA, ITALY, ²University of Padua, PADOVA, ITALY.

OP632

Role of ¹¹C-CHOLINE PET/CT in the Radiotherapy Treatment Planning of Prostate Cancer Patients

E. Lopci, G. R. D'Agostino, C. Franzese, E. Villa, M. Rodari, M. Scorsetti, A. Chiti; Humanitas Clinical and Research Hospital, Rozzano (Milano), ITALY.

1709

Hall 8

16:00 – 16:30

Physics & Instrumentation & Data Analysis: Radiation Exposure & Protection

OP633

Initial experience in the management of radiation protection in clinical use of Ra-223

G. CICORIA¹, F. ZAGNI¹, A. INFANTINO², A. CORAZZA¹, D. PANCALDI¹, M. MARENGO¹; ¹Medical Physics Department, University Hospital "S.Orsola - Malpighi", Bologna, ITALY, ²Department of Industrial Engineering, Montecuccolino Laboratory, University of Bologna, Bologna, ITALY.

OP634

Risk of Contamination and Incorporation during Preparation and Administering Radium-223-Dichlorid [XOFIGO]

L. Thomas¹, C. Scholl², S. Kürpig³, R. Bundschuh³, M. Essler³, H. Ahmadzadehfar³; ¹Universitätsklinikum Bonn, Klinik für Nuklearmedizin, Bonn, GERMANY, ²Landesinstitut für Arbeitsgestaltung des Landes Nordrhein-Westfalen, FG 1.3 Strahlenschutz, Düsseldorf, GERMANY, ³Universitätsklinikum Bonn, Klinik für Nuklearmedizin, Bonn, GERMANY.

OP635

18F-FDG whole body PET/CT: evaluation of effective dose in pediatric patients

F. Zito¹, G. Galetta², L. Rossi², L. Florimonte¹, E. Orunesu¹, M. Castellani¹, C. Canzi¹, F. Voltini¹, R. Benti¹; ¹FONDAZIONE IRCCS CA' GRANDA Ospedale Maggiore Policlinico, Milan, ITALY, ²Scuola di Specializzazione in Fisica Medica Università di Milano, Milan, ITALY.

OP636

Efficacy of Clinical Audit on administered activities to paediatric patients undergoing dynamic renal scintigraphy

V. de Sousa¹, F. Lourenço¹, P. Pepê², G. Cardoso¹, A. I. Santos^{1,3}, J. G. Santos¹; ¹Hospital Garcia de Orta, Almada, PORTUGAL, ²Escola Superior de Tecnologia e Gestão – Instituto Politécnico de Portalegre, Portalegre, PORTUGAL, ³Nova Medical School - Universidade Nova de Lisboa, Lisboa, PORTUGAL.

OP637

Cumulative Radiation Dose Received by Diagnostic Imaging During Staging and Treatment of Primarily Operable Ewing Sarcoma in Patients Diagnosed in Norway 2005-2012.

B. Johnsen¹, K. Fasmer¹, K. Boye², K. Rosendahl^{3,4}, M. Biermann^{1,4}, C. Trovik^{5,4}, S. M. Aukland^{3,4}; ¹Centre of Nuclear Medicine and PET, Department of Radiology, Haukeland University Hospital, Bergen, NORWAY, ²Department of Oncology, The Norwegian Radium, OSLO, NORWAY, ³Pediatric Section, Department of Radiology, Haukeland University Hospital, Bergen, NORWAY, ⁴Department of Clinical Medicine, University of Bergen, Bergen, NORWAY, ⁵Ortopedic Section, Department of Surgery, Haukeland University Hospital, Bergen, NORWAY.

OP638

Practical assessment of local diagnostic reference levels for PET/CT scans with ⁶⁸Ga-DOTA peptides

G. Lucconi^{1,2}, M. Rinaldo², F. Zagni², G. Cicoria², S. Fanti³, M. Marengo²; ¹Alma Mater Studiorum - Bologna University, Bologna, ITALY, ²Medical Physics Department, S.Orsola-Malpighi University Hospital, Bologna, ITALY, ³Nuclear Medicine Department, S.Orsola-Malpighi University Hospital, Bologna, ITALY.

OP639

External radiation exposure of nuclear medicine personnel using an automatic ¹⁸F dispenser

R. Matheoud¹, D. Lizio, G. Sacchetti, M. Brambilla; AOU Maggiore della Carità, novara, ITALY.

OP640

Skin dose saving of the staff in 90Y/177Lu PRRT therapy with the Automatic Dose-Dispenser (ADD)

F. Fioroni¹, E. Grassi¹, G. Cavatorta², S. Rubagotti¹, G. Feliciani¹, M. A. Sarti¹, A. Filice¹, A. Versari¹, M. Iori¹; ¹IRCCS-ASMN, Reggio Emilia, ITALY, ²University of Bologna, Bologna, ITALY.

1710

Hall D

16:00 – 16:30

Neurosciences: Movement Disorders

OP641

Evaluation of nigrostriatal oxidative stress intensity in patients with Parkinson's disease using [Cu-62] ATSM PET and FP-CIT SPECT

H. Okazawa¹, M. Ikawa¹, T. Tsujikawa¹, T. Mori¹, A. Makino¹, Y. Kiyono¹, M. Yoneda²; ¹University of Fukui, FUKUI, JAPAN, ²Fukui Prefectural University, FUKUI, JAPAN.

OP642

FDG-PET/CT in presymptomatic and symptomatic Huntington's disease: Possible predictor of disease progression?

D. Lopez¹, V. Camacho¹, A. Fernandez¹, J. Perez Perez², S. Martinez-Horta², F. Sampedro³, C. Achury¹, R. Jaller¹, A. Montes¹, I. Carrió¹; ¹Nuclear Medicine department. Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN, ²Neurology department. Movement Disorder Unit. Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN, ³Universitat Autònoma de Barcelona, Barcelona, SPAIN.

OP643

Frequency of ¹²³I FP-CIT image characteristics differ between movement disorder and Lewy Body dementia referrals

A. Nicol¹, R. Jampana², C. Santosh², M. T. Hansen²; ¹South Glasgow University Hospital, Glasgow, UNITED KINGDOM, ²Institute of Neurological Sciences, South Glasgow University Hospital, Glasgow, UNITED KINGDOM.

OP644

[¹¹C]Donepezil PET demonstrates parasympathetic denervation in the gut of most patients with de novo Parkinson's disease (PD).

T. Fedorova¹, L. Seidelin¹, S. Jakobsen¹, E. H. Danielsen², D. J. Brooks¹, P. Borghammer¹; ¹Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus C, DENMARK, ²Department of Neurology, Aarhus University Hospital, Aarhus C, DENMARK.

OP645

Brain metabolic changes in patients with Essential Tremor and progressive gait ataxia under thalamic deep brain stimulation

J. Brumberg¹, G. Marotta², M. Reich³, F. Steigerwald³, N. Pozzi³, C. Lapa¹, S. Samnick¹, K. Herrmann¹, J. Volkmann³, A. Buck¹, I. Isaías³; ¹Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY, ²Department of Nuclear Medicine, Fondazione IRCCS Ca Granda - Ospedale Maggiore Policlinico, Milano, ITALY, ³Department of Neurology, University Hospital Würzburg, Würzburg, GERMANY.

OP646

¹⁸F-FDOPA PET reveals a rostro-ventral striatal dopaminergic depletion in Parkinson's disease patients with impulse control disorder.

A. Mari Hualde, E. Prieto, L. Sancho, M. Ribelles, C. Juri, M. Rodríguez-Oroz, J. Obeso, J. Arbizu; Clinica Universidad de Navarra, Pamplona, SPAIN.

OP647

Correlation between ¹²³I-FP-CIT SPECT and cognitive outcome in Parkinson's disease: 5 years of follow-up

G. Puccini¹, R. Ceravolo², F. Guidoccio¹, D. Frosini², S. Chiacchio¹, M. Gennaro¹, U. Bonuccelli², D. Volterrani¹; ¹Regional Center of Nuclear Medicine, University of Pisa, PISA, ITALY, ²Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa, PISA, ITALY.

OP648

Initial Evaluation of [¹⁸F]GE-180 PET Imaging in Relapsing-Remitting Multiple Sclerosis Patients

S. Sridharan¹, C. Buckley², W. Trigg², W. Trigg², K. Heurling², P. Sherwin², D. Brooks², J. Crouch³, J. Crouch³, M. Lawler³, R. Hinz¹, R. Paulseth³, S. Amodeo³, K. Gulenchyn³; ¹University of Manchester, Manchester, UNITED KINGDOM, ²GE Healthcare, Amersham, UNITED KINGDOM, ³St. Joseph's Hospital, Hamilton Health Sciences, Hamilton, ON, CANADA.

1801/1803

Hall 1

12:15 – 13:15

Plenary 4: Highlights Lecture

OP649

Highlights Lecture

A.K. Buck, GERMANY
C. Decristoforo, AUSTRIA

POSTER WALKS

PW01 Sunday, October 11, 2015

08:30 – 09:30

Poster Walk 1 – Radiopharmaceuticals & Radiochemistry: Radiopharmaceuticals I

PW001

18F-5-FPN, a Novel PET Imaging Probe Targeting Malignant Melanoma

X. Lan, H. Feng, X. Xia, Y. Song, C. Qin, Q. Liu, Y. Zhang; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

PW002

PET imaging of a feeding center using [11C]BU99008 with ultra-high specific activity

K. Kawamura¹, Y. Shimoda¹, J. Yui¹, Y. Zhang¹, T. Yamasaki¹, H. Wakizaka¹, M. Fujinaga¹, K. Kumata¹, L. Xie¹, A. Hatori¹, M. Ogawa^{1,2}, Y. Kurihara^{1,2}, N. Nengaki^{1,2}, M. Zhang¹; ¹National Institute of Radiological Sciences, Chiba, JAPAN, ²SHI Accelerator Service, Tokyo, JAPAN.

PW003

Radiosynthesis of a [18F]-quinuclidine 1,2,3-triazole derivative as PET radioligand for neuroimaging of the $\alpha 7$ -nicotinic acetylcholine receptor

J. Sarasamkan^{1,2}, S. Fischer¹, M. Scheunemann¹, P. Brust¹, O. Vajracupta²; ¹Helmholz-Zentrum Dresden-Rossendorf, Leipzig, GERMANY, ²Mahidol University, Bangkok, THAILAND.

PW004

[11C]Me@HAPTHI - A Novel PET-ligand for the Norepinephrine Transporter: Target Affinity and Radiosynthesis

C. Rami-Mark¹, N. Berroteran-Infante¹, A. Hoepping², M. Hacker¹, M. Mitterhauser¹, W. Wadsak¹; ¹Medical University of Vienna, Vienna, AUSTRIA, ²ABX - Advanced Biochemical Compounds, Radeberg, GERMANY.

PW005

Bringing radiotracing to titanium-based antineoplastics: automated synthesis, PET and ex-vivo evaluation of [45Ti](salan)Ti-derivatives

F. Zhuravlev; G. W. Severin, C.H. Nielsen, J. Fonslet, A. Ingemann, A. Kjaer, Hevesy Laboratory, Roskilde, DENMARK.

PW006

[11C]Me@HAPTHI - A Novel PET-ligand for the Norepinephrine Transporter: Preclinical Evaluation

C. Rami-Mark¹, W. Wadsak¹, C. Philippe¹, C. Vranka¹, A. Hoepping², M. Hacker¹, M. Mitterhauser¹; ¹Medical University of Vienna, Vienna, AUSTRIA, ²ABX - Advanced Biochemical Compounds, Radeberg, GERMANY.

PW007

Preparation of 6-[18F]Anle138b: a novel PET-tracer potentially suitable for imaging of neurodegenerative and prion diseases

F. Zarrad^{1,2}, B. D. Zlatopolskiy², B. Neumaier^{1,2}; ¹Institute of Neuroscience and Medicine, Nuclear chemistry (INM-5), Forschungszentrum Jülich, Jülich, Jülich, GERMANY, ²Institute of Radiochemistry and Experimental Molecular Imaging, University Clinic Cologne, Cologne, GERMANY.

PW008

Radio-synthesis and biological evaluation in animal models of [11C] 1-(4-Fluorophenyl)-3-(2-methoxyethyl)-2-methyl-5-(4-methyl-sulfonyl)phenyl-1H-pyrrole (VA 426), a highly selective Cyclooxygenase-2 inhibitor

A. Carpinelli¹, G. Di Grigoli¹, A. Di Capua², A. Cappelli², M. Biava³, A. Coliva⁴, M. C. Gilardi¹, L. Gianolli⁵, M. Anzini², R. Moresco⁶; ¹CNR-IBFM, Milan, ITALY, ²Università di Siena, Siena, ITALY, ³Università La Sapienza, Rome, ITALY, ⁴Università Vita-Saluta S. Raffaele, Milan, ITALY, ⁵Ospedale S. Raffaele, Milan, ITALY, ⁶Università Bicocca, Milan, ITALY.

PW009

18F Labeling of a new naphthalene derivative as potential Alzheimer Disease PET imaging agent. Synthesis and preclinical studies.

L. Fernandez-Maza¹, S. Rivera-Marrero², M. Balcerzyk¹, I. Fernandez-Gomez¹, A. Parrado-Gallego¹, M. Sablon-Carrazana², R. Perez-Perera², O. Diaz-Garcia², A. Perera-Pintado³, A. Prats-Capote³, C. Rodriguez-Tanty²; ¹University of Seville, CSIC, Junta de Andalucía, Seville, SPAIN, ²Centro de Neurociencias (CNEURO), La Habana, CUBA, ³Centro de Isótopos (CENTIS), La Habana, CUBA.

PW010

Efficient synthesis of [18F]FEDAC, and evaluation of non-clinical safety and stability tests for clinical application.

K. Kawamura¹, M. Ogawa^{1,2}, M. Takei¹, K. Kumata¹, K. Furutsuka^{1,2}, T. Yamasaki¹, J. Yui¹, L. Xie¹, A. Hatori¹, Y. Zhang¹, N. Nengaki^{1,2}, K. Hirano³, M. R. Zhang¹; ¹National Institute of Radiological Sciences, Chiba, JAPAN, ²SHI Accelerator Service, Tokyo, JAPAN, ³NMP Business Support Company, Chiba, JAPAN.

PW02

Monday, October 12, 2015

08:30 – 09:30

Poster Walk 2 – Cardiovascular System: Miscellaneous

PW011

Efficacy of Gated-SPECT in Risk Stratification of Major Adverse Cardiac Events in Patients Over 60 Years with Known or Suspected Coronary Artery Disease Undergoing Noncardiac Surgery

M. Vakhromeeva, F. Chanakhchyan, E. Denisenko-Kankiya, N. Bolomatov; Pirogov National Medical Surgical Center, MOSCOW, RUSSIAN FEDERATION.

PW012

Hybrid PET/MR viability imaging compared with metabolism/perfusion pattern in acute myocardial infarction

I. Cho, E. Kong, K. Chun, S. Kwon; Yeungnam University Hospital, Daegu, KOREA, REPUBLIC OF.

PW013

Metabolic scintigraphy with radiolabeled fatty acid in prognosis of cardiac resynchronization therapy in patients with dilated cardiomyopathy

Y. B. Lishmanov^{1,2}, M. O. Gulya^{2,1}, K. W. Zavadovsky^{2,1}, S. I. Sazonova^{2,1}, D. I. Lebedev², V. S. Skuridin¹, V. D. Fillimonov¹; ¹National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION, ²Federal State Budgetary Scientific Institution "Research Institute for Cardiology", Tomsk, RUSSIAN FEDERATION.

PW014

Association between radiation dosimetry of the heart and the myocardial fatty acid metabolic impairment due to chemoradiation-therapy : Prospective study using I-123 BMIPP SPECT/CT

K. Takanami¹, R. Umezawa², N. Kadoya², A. Arai¹, K. Jingu², K. Takase¹; ¹Department of Diagnostic Radiology, Tohoku University Hospital, Sendai, JAPAN, ²Department of Radiation Oncology, Tohoku University Hospital, Sendai, JAPAN.

PW015

The first clinical experience with combined PET-CT myocardium in patients with multivessel coronary disease.

I. Shurupova, I. Aslanidis, A. Chernova, V. Makarenko, V. Bereznitskiy, E. Derevyanko, I. Ekaeva; Bakoulev Scientific Center for Cardiovascular Surgery, Moscow, MOSCOW, RUSSIAN FEDERATION.

PW016

Assessment of Right Ventricular Myocardial Perfusion and Fatty Acid Metabolism Using Planar Imaging in Patients with Chronic Thromboembolic Pulmonary Hypertension

H. Miyauchi¹, T. Iimori², K. Sawada², Y. Kuwabara¹, S. Sakao¹, K. Tatsumi¹, Y. Kobayashi¹; ¹Chiba University Graduate School of Medicine, Chiba, JAPAN, ²Chiba University Hospital, Chiba, JAPAN.

PW017

Diagnostic performance of attenuation corrected SPECT myocardial perfusion imaging for coronary artery disease: a systemic review and meta-analysis

J. Huang^{1,2}, M. Cheng¹, C. Lu^{1,2}, Y. Wu^{1,3,4}, R. Yen¹, K. Tzen¹, K. Chien^{3,2}; ¹Department of Nuclear Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TAIWAN, ²Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, TAIWAN, ³Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TAIWAN, ⁴Department of Nuclear Medicine and Cardiology Division of Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei, TAIWAN.

PW018

Systematic Underestimation of High Values of Coronary Flow Reserve Provided with Multi-Detector Computed Tomography: a Comparison with SPECT Technology.

M. Bauckneht¹, G. Ferrarazzo¹, F. Fiz¹, S. Seitun², C. Zawaideh³, F. Ticconi¹, I. Calamia¹, S. Morbelli¹, C. Brunelli³, C. Ferro², G. Bezante³, G. Sambucetti¹, C. Marini⁴; ¹Nuclear Medicine, IRCCS AUO San Martino IST, Genova, ITALY, ²Department of Radiology and Interventional Radiology, IRCCS-University Hospital San Martino-IST, Genova, ITALY, Genova, ITALY, ³Department of Internal Medicine, Chair of Cardiology, University of Genoa, Genova, ITALY, Genova, ITALY, ⁴Institute of Bioimaging and Molecular Physiology, CNR, Milan, Genoa Section, Genova, ITALY, Genova, ITALY.

PW019

Cardiac Sympathetic Innervation Assessed with 123I-MIBG Retains Prognostic Utility in Diabetic Patients with Severe Left Ventricular Dysfunction Evaluated for Primary Prevention Implantable Cardioverter-Defibrillator

M. Cozar Santiago¹, P. Garcia Gonzalez², R. Sanchez Jurado¹, R. Sanz Llorens¹, J. Aguilar Barrios¹, F. Ridocci Soriano², J. Ferrer Rebolledo¹; ¹Eresa-Nuclear Medicine Department. General University Hospital, Valencia, SPAIN, ²Eresa-Cardiology Department. General University Hospital, Valencia, SPAIN.

PW020

18F-FDG PET-CT in the Diagnosis of Infective Endocarditis over Native and Prosthetic Valves

A. Jiménez-Ballvé¹, M. J. Pérez-Castejón¹, M. Matínez de Bourio¹, C. Sánchez-Enrique², I. Vilacosta², C. Riola Parada¹, A. Ortega Candil¹, C. Olmos², J. L. Carreras-Delgado^{1,3}; ¹Nuclear Medicine Department, Hospital Clinico San Carlos, Madrid, SPAIN, ²Cardiology Department, Hospital Clinico San Carlos, Madrid, SPAIN, ³Universidad Complutense, Madrid, SPAIN.

PW03

Tuesday, October 13, 2015

08:30 – 09:30

Poster Walk 3 – Neurosciences: Neuroimaging

PW021

[18F]DPA-714: peripheral metabolism in healthy volunteers and patients.

M. Peyronneau¹, C. Letaillandier¹, S. Lavissee², B. Kuhnast¹, C. Baron¹, B. Jegou¹, P. Gervais¹, F. Dollé¹, B. Bodini³, B. Stankoff³, M. Sarazin³, P. Rémy², M. Bottlaender⁴; ¹CEA-DSV-I2BM-SHFJ-IMIV, Orsay, FRANCE, ²CEA-DSV-I2BM-Mircen, Orsay, FRANCE, ³APHP, Paris, FRANCE, ⁴CEA-DSV-I2BM-Neurospin-IMIV, Orsay, FRANCE.

PW022

A Novel SPECT-based Approach Reveals Early Effects of Systemic Inflammation on Brain Injury and Peripheral Organs After Cerebral Ischemia

D. Mathe¹, K. Szigeti², D. Veres², B. Martinecz³, N. Lenart³, N. Kovacs¹, A. Marta², M. Semjen¹, A. Denes^{3,4}; ¹CROmed Ltd, Budapest, HUNGARY, ²Dept. Biophysics and Radiation Biology Semmelweis University, Budapest, HUNGARY, ³Laboratory of Molecular Neuroendocrinology, Institute of Experimental Medicine, Budapest, HUNGARY, ⁴Faculty of Life Sciences, University of Manchester, Manchester, UNITED KINGDOM.

PW023

Effect of Normobaric Hyperoxia (NBO) on Hypoxic Volume and Infarct Volume Following Middle Cerebral Artery Occlusion (MCAo): An 18F-Fluoromisonidazole (FMISO) PET, MR and TTC Study

T. D. Fryer, S. Ejaz, D. J. Williamson, U. Jensen-Kondering, S. J. Sawiak, F. I. Aigbirhio, Y. T. Hong, J. Baron; University of Cambridge, Cambridge, UNITED KINGDOM.

PW024

Regional cerebral blood flow changes after accelerated repetitive transcranial magnetic stimulation of the canine frontal cortex.

R. Dockx¹, C. Baeken², R. Duprat², F. De Vos³, B. De Spiegeleer³, A. Dobbeleir¹, J. H. Saunders¹, I. Polis¹, K. Audenaert², K. Peremans¹; ¹Faculty of Veterinary Medicine, University Ghent, MERELBEKE, BELGIUM, ²Faculty of Medicine, University Ghent, Ghent, BELGIUM, ³Faculty of Pharmaceutical Sciences, University Ghent, Ghent, BELGIUM.

PW025

Metabolism of the Spinal Cord in Patients With Amyotrophic Lateral Sclerosis: A FDG-PET/CT Study.

E. Pomposelli¹, G. Sambuceti¹, M. Piana², C. Campi², M. Pennone¹, A. Buschiazio¹, A. Cistaro³, F. Bongioanni¹, A. Chiò⁴, F. Nobili⁵, C. Caponnetto⁶, C. Marini⁷; ¹Nuclear Medicine Unit, Department of Health Sciences, University of Genoa and IRCCS AOU San Martino-IST, Genoa, ITALY, ²Department of Mathematics, University of Genoa, Genoa, ITALY, ³Positron Emission Tomography Centre IRMET S.p.A., Euromedic inc, Turin, ITALY, ⁴Department of Neuroscience „Rita Levi Montalcini“, University of Turin, Turin, ITALY, ⁵Clinical Neurology, IRCCS AOU San Martino-IST, Genoa, ITALY, ⁶Department of Neuroscience, IRCCS AOU San Martino-IST, Genoa, ITALY, ⁷CNR Institute of Bioimages and Molecular Physiology, Section of Genoa, Genoa, ITALY.

PW026

Imaging of Brain TSPO Expression in a Mouse Model of Amyotrophic Lateral Sclerosis with [18F]DPA-714 and Micro-PET/CT.

S. Gargiulo^{1,2}, S. Anzillotti³, A. Coda¹, M. Gramanzini^{1,2}, A. Greco^{4,2}, M. Panico¹, F. Dollé⁵, G. Pignataro⁶, M. Quarantelli¹, L. Annunziato^{6,3}, A. Brunetti^{4,2}, M. Salvatore³, S. Pappatà¹; ¹Institute of Biostructure and Bioimaging, CNR, Naples, ITALY, ²Ceinge, Biotechnologie Avanzate s.c.a.r.l., Naples, ITALY, ³SDN IRCCS, Naples, ITALY, ⁴Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY, ⁵CEA, Institute for Biomedical Imaging, Orsay, FRANCE, ⁶Department of Neuroscience, Reproductive and Dentistry Sciences, Naples, ITALY.

PW027

Positive correlation between neuromelanin accumulation in the substantia nigra and striatal dopaminergic innervation in patients with Parkinson's disease

G. Marotta¹, I. U. Isaias², A. Costa¹, P. Trujillo¹, P. Summers¹, G. Pezzoli³, R. Benti¹; ¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, ITALY, ²Department of Neurology, University Hospital, Wurzburg, GERMANY, ³Parkinson Institute, Istituti Clinici di Perfezionamento, Milano, ITALY.

PW028

Quantification of Amyloid- β Deposition Using ¹⁸F-FC119S PET in Human Brains: A Phase 0-1 Study.

B. Byun¹, B. Kim¹, I. Lim¹, C. Choi¹, S. Park², J. Ha², K. Lee³, K. Kim³, S. Lim¹; ¹Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, KOREA, REPUBLIC OF, ²Department of Neurology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, KOREA, REPUBLIC OF, ³Molecular Imaging Research Center, Korea Institute of Radiological and Medical Sciences, Seoul, KOREA, REPUBLIC OF.

PW029

Comparison of Visual and Quantitative ¹⁸F-Florbetaben PET Scan Assessment

J. Seibyl¹, S. Bullich², D. Jennings¹, M. Sabbagh³, A. Stephens², H. Barthelemy⁴, O. Sabri⁴, A. Catafau²; ¹Molecular Neuroimaging, New Haven, CT, UNITED STATES, ²Piramal Imaging, Berlin, GERMANY, ³Univ of Arizona, Phoenix, AZ, UNITED STATES, ⁴Univ Leipzig, Leipzig, GERMANY.

PW030

Striatal dopamine transporter modulation after rotigotine: results from a pilot SPECT study in a group of early Parkinson's disease patients.

E. Filidei¹, C. Rossi², D. Genovesi¹, P. Marzullo¹, A. Giorgetti¹, G. U. Corsini², U. Bonuccelli², R. Ceravolo²; ¹Fondazione Toscana G. Monasterio, Pisa, ITALY, ²Azienda Ospedaliero-Universitaria Pisana, Pisa, ITALY.

PW04

Sunday, October 11, 2015

08:30 – 09:30

Poster Walk 4 – Clinical Oncology: Colorectal, Neuroendocrine & Lung

PW031

The role of ⁶⁸Ga-DOTATATE PET/CT imaging in the decision of Peptide Receptor Radionuclide Therapy (PRRT) administration

E. Skoura¹, S. Michopoulou¹, O. M. AlMukhalid¹, E. Panagiotidis¹, M. Al Harbi¹, I. Kayani¹, R. Syed¹, P. J. Ell¹, M. E. Caplin², J. Bomanji¹; ¹UCLH, London, UNITED KINGDOM, ²Royal Free Hospital, London, UNITED KINGDOM.

PW032

Radioguided laparoscopic surgery of occult colonic lesions

G. Manca¹, G. Boni¹, R. Spisni², S. Chiacchio¹, S. Mazzarri¹, E. Tardelli¹, M. Biricotti², D. Volterrani¹; ¹Regional Center of Nuclear Medicine, Pisa, ITALY, ²Department of Surgery, University of Pisa, Pisa, ITALY.

PW033

Is K-ras mutation affecting ¹⁸F-FDG uptake in colorectal cancer?

A. Ozen¹, M. Tokocin¹, E. Nama², E. Gokmen¹, T. Vartanoglu¹, F. Celebi¹; ¹Bagcilar Training and Research Hospital, Istanbul, TURKEY, ²Istanbul Bilim University, Istanbul, TURKEY.

PW034

Evaluating the risk of postoperative liver failure using preoperative ^{99m}Tc-GSA SPECT/CT fused imaging

M. Yoshida¹, S. Shiraishi², N. Tsuda², F. Sakamoto², S. Tomiguchi³, T. Beppu⁴, H. Baba⁴, Y. Yamashita²; ¹Amakusa Medical Center, Amakusa, JAPAN, ²Department of Diagnostic Radiology, Graduate School of Life Sciences, Kumamoto University, Kumamoto, JAPAN, ³Department of Diagnostic Medical Imaging, School of Health Faculty of Life Sciences, Kumamoto University, Kumamoto, JAPAN, ⁴Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, JAPAN.

PW035

Can Potassium Perchlorate and Sodium Iodine influence Iodine-131 uptake in Cholangiocarcinoma?

A. F. Brito¹, T. Puga¹, R. Teixo^{2,3}, A. Fernandes^{2,4,5}, A. F. Brito^{2,4,3}, A. M. Abrantes^{2,4,3}, **L. F. Metello**^{1,6}, J. G. Tralhão^{2,4,7}, M. F. Botelho^{2,4,3}; ¹Nuclear Medicine Department, High Institute for Allied Health Technologies, Polytechnic Institute of Porto, Vila Nova de Gaia, PORTUGAL, ²Biophysics Unit, Faculty of Medicine, University of Coimbra, Coimbra, PORTUGAL, ³CNC.IBILI, Faculty of Medicine, University of Coimbra, Coimbra, PORTUGAL, ⁴Center of Investigation on Environmental, Genetics and Oncobiology (CIMAGO), Faculty of Medicine, Coimbra, PORTUGAL, ⁵Gastroenterology Department, CHUC, Coimbra, PORTUGAL, ⁶Nuclear Medicine Department, IsoPor SA, Ermesinde, PORTUGAL, ⁷Surgical Department, Surgery A, CHUC, Coimbra, PORTUGAL.

PW036

Clinical Value of Metabolic Parameter for Evaluation of LN Metastasis in Clinical N0 Gastric Cancer

S. Choi, S. Lim, C. Na, J. Kim, Y. Han, H. Jeong, M. Sohn; Chonbuk National University Medical School and Hospital, Jeonju, Jeonbuk, KOREA, REPUBLIC OF.

PW037

Comparative Analysis of Metabolic Response to Clinical Outcome in Metastatic Pancreatic Adenocarcinoma following Modified Dose Folfirinox.

A. Boustani¹, V. Patel¹, X. Cong², I. Doddamani¹; ¹Yale University School of Medicine, New Haven, CT, UNITED STATES, ²Yale University School of Public Health, New Haven, CT, UNITED STATES.

PW038

Role of FDG-PET/CT in predicting response to neoadjuvant therapy in esophageal cancer. Correlation with pathological response and survival. Preliminary study.

J. J. Robles-Barba¹, C. Gámez-Cenzano¹, J. L. Vercher-Conejero¹, A. Sabaté-Llobera¹, M. Cortés-Romera¹, L. Rodríguez-Bel¹, L. M. Gràcia-Sánchez¹, F. Martínez-Torrens², R. Mast-Vilaseca², M. J. Paules-Villar³, M. Miró-Martín⁴, A. M. Boladeras-Inglada⁵, M. Calvo-Campos⁶, M. Galán-Guzmán⁶; ¹PET-CT Unit, Institut de Diagnòstic per la Imatge (IDI), Bellvitge Hospital, L'Hospitalet de Llobregat, SPAIN, ²Radiología, Bellvitge Hospital, L'Hospitalet de Llobregat, SPAIN, ³Anatomía Patológica, Bellvitge Hospital, L'Hospitalet de Llobregat, SPAIN, ⁴Cirugía General, Bellvitge Hospital, L'Hospitalet de Llobregat, SPAIN, ⁵Oncología Radioterápica, Institut Català d'Oncologia, L'Hospitalet de Llobregat, SPAIN, ⁶Oncología Médica, Institut Català d'Oncologia, L'Hospitalet de Llobregat, SPAIN.

PW039

Maximum standardized uptake value on FDG PET is associated with overall survival in limited-stage small cell lung cancer

S. Lee¹, S. Kwon¹, S. Hyun², Y. Oh¹, J. Choi¹, K. Park¹; ¹Ajou University School of Medicine, Suwon, KOREA, REPUBLIC OF, ²Sungkyunkwan University School of Medicine, Seoul, KOREA, REPUBLIC OF.

PW040

The correlation between 18F-FDG uptake and Glut-1, Stat-1 and Stat-3 in non-small cell lung cancer patients.

H. Kaida¹, K. Azuma², A. Kawahara², S. Hattori², S. Takamori², E. Sadashima², K. Fujimoto², M. Kage², S. Kurata², Y. Hirose², K. Ishii¹, T. Murakami¹, M. Ishibashi³; ¹Kinki University Faculty of Medicine, Osakasayama City, JAPAN, ²Kurume University School of Medicine, Kurume City, JAPAN, ³Fukuoka Tokushukai Hospital, Kasuga City, JAPAN.

PW05

Monday, October 12, 2015

08:30 – 09:30

**Poster Walk 5 – Physics & Instrumentation
Data Analysis: Data Analysis & Management**

PW041

Development of a new quantification method using the I-123 MIBG myocardial single photon emission tomography

Y. Kamiya^{1,2}, S. Okumiya¹, A. Takaki³, K. Yamashita³, S. Ito¹; ¹Kumamoto University, Kumamoto, JAPAN, ²Chibana Clinic, Okinawa, JAPAN, ³Fujifilm RI Pharma Co., Ltd., Tokyo, JAPAN.

PW042

Application of Novel Phase Parameters for Characterisation of Ventricular Mechanical Dyssynchrony with Radionuclide Ventriculography

K. Jones, N. E. R. Goodfield, J. Robinson, W. Martin, C. A. Paterson; NHS Greater Glasgow and Clyde, Glasgow, UNITED KINGDOM.

PW043

Improved scatter correction applying factor analysis

P. Knoll¹, M. Ljungberg², S. Mirzaei¹, M. Samal³; ¹Wilhelminenspital, Vienna, AUSTRIA, ²Department of Medical Radiation Physics, Clinical Sciences, Lund University, Lund, SWEDEN, ³Department of Nuclear Medicine, First Faculty of Medicine, Charles University, Prague, CZECH REPUBLIC.

PW044

Quantification of striatal uptake in DaTscan dopamine transporter imaging: Effect of systematically reduced count density on diagnostic accuracy

C. Paterson, J. Robinson, S. Smith, W. Martin; Glasgow Royal Infirmary, Glasgow, UNITED KINGDOM.

PW045

Statistical variance in standardised striatal uptake ratio in [123I]FP-CIT SPECT imaging

A. Niñerola-Baizán^{1,2}, J. Gallego², A. Cot^{1,2}, F. Lomeña^{3,4}, D. Ros^{1,2}, J. Pavia^{1,3}; ¹Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, SPAIN, ²Unitat de Biofísica i Bioenginyeria, Facultat de Medicina, Universitat de Barcelona, Barcelona, SPAIN, ³Servicio de Medicina Nuclear, Hospital Clínic, Barcelona, SPAIN, ⁴Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, SPAIN.

PW046

Is a system calibration required when using a I123-FP-CIT Normal Database?

J. C. Dickson¹, L. Tossici-Bolt², K. Tatsch³; ¹University College London Hospital NHS Foundation Trust, London, UNITED KINGDOM, ²University Hospital Southampton NHS Foundation Trust, Southampton, UNITED KINGDOM, ³EANM EARL ENCDAT Imaging Consortium, Vienna, AUSTRIA.

PW047

The effect of different reconstructions algorithms on the diagnostic performance of a 123-FP-CIT SPECT database

J. C. Dickson¹, L. Tossici-Bolt², K. Tatsch³; ¹University College London Hospital NHS Foundation Trust, London, UNITED KINGDOM, ²University Hospital Southampton NHS Foundation Trust, Southampton, UNITED KINGDOM, ³EANM EARL ENCDAT Imaging Consortium, Vienna, AUSTRIA.

PW048

Investigation of the Factors Affecting Quantification of Heterogeneity derived from PET Images of the Torso NEMA Phantom

M. Tamal, C. Robinson, D. Clarke, J. Anton-Rodriguez, D. Morris, A. Jackson, M. Asselin; The University of Manchester, UK, Manchester, UNITED KINGDOM.

PW049

Quantification Challenges in Dual-Time PET Scans

T. Nguyen, S. B. Christlieb, P. F. Hoeilund-Carlsen; Dept. of Nuclear Medicine, Odense University Hospital, Odense, DENMARK.

PW050

The clinical application of absolute quantification SUV SPECT 99mTc-MIBI myocardial perfusion imaging to translate myocardial viability

W. He, W. Yu, W. Zhai, J. Xi; Huadong Hospital, Shanghai, CHINA.

PW06

Tuesday, October 13, 2015

08:30 – 09:30

Poster Walk 6 – Radiopharmaceuticals & Radiochemistry: Radiopharmaceuticals II

PW051

One Pot Al18F Radiofluorination of GLU-UREA-LYS(AHX)-HBED-CC PSMA Ligand.

S. Boschi¹, F. Lodi¹, G. Cicoria², M. Marengo², S. Fanti¹; ¹Nuclear Medicine, Bologna University Hospital, Bologna, ITALY, ²Medical Physics, Bologna University Hospital, Bologna, ITALY.

PW052

We can do it without! Synthesis of F-18-labeled aromatic compounds without azeotropic drying, base and other additives

R. Richarz^{1,2}, P. Krapf^{1,2}, F. Zarrad^{1,3}, B. D. Zlatopolskiy^{1,2}, E. A. Urusova¹, B. Neumaier^{1,3,2}; ¹Institute for Radiochemistry and Experimental Molecular Imaging, Cologne, GERMANY, ²Max Planck Institute for Metabolic Research, Cologne, GERMANY, ³Forschungszentrum Jülich INM-5 Short-lived radionuclides for life sciences, Jülich, GERMANY.

PW053

Microscale Radiolabelling of Antibodies with Zirconium-89 for Positron Emission Tomography

J. C. Knight¹, S. J. Paisey², C. Marshall², B. Cornelissen¹; ¹University of Oxford, Oxford, UNITED KINGDOM, ²Cardiff University, Cardiff, UNITED KINGDOM.

PW054

Direct production of 99mTc with a cyclotron

M. Aboudzadeh Rovais; Nuclear Science and Technology Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF.

PW055

Determination of nickel in ⁶⁴Cu-ATSM preparations: development and validation of a colorimetric method as impurity limit test

S. Costa, C. De Nicolo, G. Cicoria, C. Malizia, S. Fanti, F. Lodi; S.Orsola-Malpighi University Hospital, Bologna, ITALY.

PW056

Synthesis of ⁶⁸Ga Radiopharmaceuticals for Cell Radiolabelling Using Anion Exchange Column

A. Socan¹, P. Kolenc Peitl¹, M. Kroselj¹, C. Rangger², C. Decristoforo²; ¹University Medical Centre Ljubljana, Ljubljana, SLOVENIA, ²University Clinic for Nuclear Medicine, University for Medicine, Innsbruck, AUSTRIA.

PW057

A real-time in vitro assay as a potential predictor of in vivo tumour imaging properties

D. Spiegelberg¹, J. Stenberg¹, A. Haylock², M. Nestor^{1,2}; ¹Department of Immunology, Genetics & Pathology, Uppsala, SWEDEN, ²Unit of Otolaryngology and Head & Neck Surgery, Department of Surgical Sciences, Uppsala, SWEDEN.

PW058

⁴⁴Sc- and ¹⁷⁷Lu-labeling of DKFZ-617 for dosimetry and therapy of prostate cancer

E. Eppard¹, A. de la Fuente², S. Kuerpig¹, F. Roesch², M. Essler¹; ¹University Hospital Bonn, Bonn, GERMANY, ²Johannes Gutenberg-University, Mainz, GERMANY.

PW059

Development of [¹⁸F]Fluoro-sugar based prosthetic groups for the PET imaging of radiolabel peptides

C. Collet^{1,2}, F. Maskali¹, S. Poussier^{1,2}, A. Mohamadi^{3,2}, V. Regnault^{3,2}, P. Lacolley^{3,2}, Y. Chapleur^{1,2,4}, P. Marie^{1,2,3}, G. Karcher^{1,2}, S. Lamandé-Langle^{4,2}; ¹Nancyclotep, Vandoeuvre les Nancy, FRANCE, ²Université de Lorraine, Vandoeuvre les Nancy, FRANCE, ³Inserm UMR 1116, Vandoeuvre les Nancy, FRANCE, ⁴UMR 7565, Vandoeuvre les Nancy, FRANCE.

PW060

Cyclotron production of ⁵¹Cr for clinical application

M. Aboudzadeh Rovais; Nuclear Science and Technology Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF.

PW07

Sunday, October 11, 2015

08:30 – 09:30

Poster Walk 7 – M2M: Molecular & Multimodality Imaging: Preclinical Imaging and Evaluation

PW061

Brown adipose tissue: Preclinical imaging beyond FDG?

M. Bauwens¹, G. Hendrikx¹, V. Schrauwen-Hinderling¹, J. Slenter¹, S. van Hoof¹, A. Vogg², I. Pooters¹, B. Brans¹, F. M. Mottaghly^{1,2}; ¹MUMC, Maastricht, NETHERLANDS, ²UKAachen, Aachen, GERMANY.

PW062

Pilot study of a novel peptide targeting GPC3 for HCC

D. Zhu¹, Y. Qin¹, L. Zhang², S. Zou¹, J. Wang², L. Zhu², X. Zhu¹; ¹Department of Nuclear Medicine & PET, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA, ²State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, CHINA.

PW063

A new lactam bridge ^{99m}Tc-α -melanocyte-stimulating hormone analog for diagnosis of metastatic melanoma

D. Beiki¹, D. Shamshirian², M. Erfani³, B. Fallahi¹; ¹Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Department of Radiopharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF.

PW064

Multispectral fluorescence imaging during robot-assisted laparoscopic sentinel node biopsy - a first step towards a real-time intraoperative patient-specific anatomical roadmap

N. S. van den Berg^{1,2}, G. H. KleinJan^{1,2}, T. Buckle¹, E. M. Wit², H. G. van der Poel², F. W. B. van Leeuwen^{1,2}; ¹LUMC, Leiden, NETHERLANDS, ²AVL-NKI, Amsterdam, NETHERLANDS.

PW065

Effect of different injection routes in tumor accumulation and biodistribution of radiolabeled Pluronic P94 unimers

C. Santini¹, A. Arranja², A. Denkova³, F. Schosseler², K. Morawska⁴, P. Dubruel⁴, E. Mendes⁵, M. de Jong¹, M. Bernsen¹; ¹Erasmus MC, Rotterdam, NETHERLANDS, ²CNRS, Institute Charles Sadron, Strasbourg, FRANCE, ³TU Delft, Radiation Science and Technology, Delft, NETHERLANDS, ⁴UGhent, Polymer Chemistry and Biomaterials Group (PBM), Gent, BELGIUM, ⁵TU Delft, Department of Chemical Engineering, Delft, NETHERLANDS.

PW066

A multiprobe approach to monitoring therapy response in rheumatoid arthritis

S. Y. A. Terry¹, M. I. Koenders², T. K. Nayak³, A. Freimoser-Grundschober⁴, C. Klein⁴, W. J. Oyen², O. C. Boerman², P. Laverman²; ¹King's College London, London, UNITED KINGDOM, ²Radboud UMC, Nijmegen, NETHERLANDS, ³Roche Pharmaceutical Research and Early Development, Basel, SWITZERLAND, ⁴Roche Pharmaceutical Research and Early Development, Zurich, SWITZERLAND.

PW067

The imaging study of a new ^{99m}Tc-labeled PSMA inhibitor

X. Xu; J. Zhang, S. He, J. Luo, Y. Zhang *Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; Center for Biomedical Imaging, Fudan University, Shanghai, China; Shanghai Engineering Research Center for Molecular Imaging Probes, Shanghai, CHINA

PW068

Preclinical evaluation of selected ⁶⁸Ga labelled peptides for glioblastoma imaging

M. Petrik¹, J. Stepankova¹, Z. Crlíkova¹, R. Trojanec¹, J. Drymlova², M. Hajduch¹, Z. Nový¹; ¹Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, CZECH REPUBLIC, ²Department of Nuclear Medicine, University Hospital Olomouc, Olomouc, CZECH REPUBLIC.

PW069

Preclinical evaluation of two DOTA-coupled minigastrin analogues (Met and corresponding Nle congener)

M. Kroselj¹, L. Claessens Joosten², R. Mansi³, J. Reubi⁴, H. Maecke³, P. Laverman², O. Boerman², P. Kolenc Peitl¹; ¹Department of Nuclear Medicine, UMC Ljubljana, Ljubljana, SLOVENIA, ²Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, NETHERLANDS, ³Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, GERMANY, ⁴Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Berne, SWITZERLAND.

PW070

Auger Electron Radioimmunotherapy with ¹¹¹In-Bn-DTPA-Nimotuzumab Inhibits the Growth of EGFR-Positive Human Breast Cancer Tumours in Mice at Doses that are Non-Toxic to Normal Tissues

C. Chan¹, H. Fong¹, K. Lam¹, R. Reilly^{1,2,3}; ¹Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, CANADA, ²Department of Medical Imaging, University of Toronto, Toronto, ON, CANADA, ³Toronto General Research Institute and Joint Department of Medical Imaging, University Health Network, Toronto, ON, CANADA.

PW08

Monday, October 12, 2015

08:30 – 09:30

Poster Walk 8 – Conventional & Specialised Nuclear Medicine: General & Miscellaneous

PW071

Bone scan and MRI in Chronic Recurrent Multifocal Osteomyelitis

L. Biassoni; Great Ormond Street Hospital for Children NHS Foundation Trust, London, UNITED KINGDOM.

PW072

Scintigraphic functional evaluation of intrathecal drug infusion devices

G. Garraffa¹, V. Scaglione², F. Felice¹, R. Ricapito¹; ¹Nuclear Medicine Unit, A.R.N.A.S. "Ospedale Civico, Di Cristina e Benfratelli", Palermo, ITALY, ²Neurosurgery Unit, A.R.N.A.S. "Ospedale Civico, Di Cristina e Benfratelli", Palermo, ITALY.

PW073

^{99m}Tc-HDP bone SPECT with voxel-based evaluation for temporomandibular asymmetry detection in diagnosis of the idiopathic condylar hyperplasia

D. Chroustova, J. Sebek, J. Trnka, J. Kubinyi; General University Hospital and 1st Faculty of Medicine Charles University, PRAGUE 2, CZECH REPUBLIC.

PW074

Assessment of ACL Graft Viability by Dynamic FDG PET: A Phase I Study

K. Binzel¹, R. Magnussen¹, C. Kaeding¹, W. Wei¹, M. U. Knopp², D. C. Flanagan¹, M. V. Knopp¹; ¹The Ohio State University Wexner Medical Center, Columbus, OH, UNITED STATES, ²Pepperdine University, Malibu, CA, UNITED STATES.

PW075

High Therapeutic Impact in New Indications of ¹⁸F-FDG PET/CT in High/Intermediate Recurrence Risk Differentiated Thyroid Carcinoma Patients

E. M. Triviño-Ibáñez¹, M. A. Muros¹, E. Torres-Vela², J. M. Llamas-Elvira¹; ¹Virgen de las Nieves University Hospital, Granada, SPAIN, ²San Cecilio University Hospital, Granada, SPAIN.

PW076

17 years follow-up from 1998 to 2015 of 123 medium-size (2-4 x normal) EU-and Hyperthyroid (EU, HT) goitres after treatment by ¹³¹I (RIT)

C. ALS, N. LENERS; Hôpitaux Robert Schuman - Zithaklinik, Luxembourg, LUXEMBOURG.

PW077

The Clinical Outcome and Mortality Rates in patients with Differentiated Thyroid Carcinoma with bone metastasis: Results of a 15- year clinical follow-up.

G. Ucmak, B. Demirel, **B. E. Akkas**, A. K. Fidan, N. Ercakmak; Ankara Oncology Research and Training Hospital Department of Nuclear Medicine, Ankara, TURKEY.

PW078

Evaluation of a fast and a standard protocol for bone scintigraphy SPECT/CT in patients suspected for having bone metastasis

K. Knudsen, A. Bekker, S. Jentoft Kramer, P. Iversen, A. Arveschoug; Aarhus University Hospital, Noerrebrogade, AARHUS, DENMARK.

PW079

Nephrotic Syndrome with pulmonary embolism: the role of lung scintigraphy

I. G. E. El Bez, A. Ezzine, B. Ltaief, I. Slim, D. Ben Sellem, L. Zaabar, I. Meddeb, I. Yeddes, B. Dhaoudi, A. Mhiri, M. Ben Slimene; Institut Salah Azaiez, Tunis, TUNISIA.

PW080

Lung V/Q scintigraphy and perfusion SPECT in the diagnosis of chronic thromboembolic pulmonary hypertension

J. A. Marroquín Gálvez, D. Sanchez Fuentes, A. Saviatto, A. C. Hernandez Martinez, J. P. Pilkington Woll, M. J. Tabuenca Mateo, S. Ruiz Solis, J. M. Estenoz Alfaro; Hospital Universitario 12 De Octubre, Madrid, SPAIN.

PW09

Tuesday, October 13, 2015

08:30 – 09:30

Poster Walk 9 – Clinical Oncology: Miscellaneous

PW081

Sentinel node detection with ferromagnetic particles in breast cancer. Preliminar results

U. Granados, S. Vidal-sicart, X. Caparrós, M. Alonso, P. Fernandez, P. Perlaza, A. Tápias, F. Lomeña; Hospital Clínic, Barcelona, SPAIN.

PW082

Gastrin-releasing peptide receptor expression is associated with estrogen receptor status in breast cancer: Findings of a PET/CT pilot study

C. Stoykow^{1,2,3}, T. Erbes⁴, S. Bulla¹, H. Mäcke¹, V. Drendel⁵, P. Bronsert^{5,6}, M. Werner^{5,6}, E. Stickeler⁴, P. T. Meyer¹; ¹University Medical Centre Freiburg, Department of Nuclear Medicine, Freiburg, GERMANY, ²German Cancer Consortium (DKTK), Freiburg, GERMANY, ³German Cancer Research Center (DKFZ), Heidelberg, GERMANY, ⁴University Medical Centre Freiburg, Department of Gynecology and Obstetrics, Freiburg, GERMANY, ⁵University Medical Centre Freiburg, Department of Clinical Pathology, Freiburg, GERMANY, ⁶German Cancer Consortium (DKTK), Heidelberg, GERMANY.

PW083

Measurement of early treatment response in patients with recurrent or metastatic breast cancer with 18F-FLT and 18F-FDG PET/CT: a pilot study

T. Su, S. Chan, K. Lui, J. Huang; Chang-Gung Memorial Hospital Keelung Branch, Keelung, TAIWAN.

PW084

Sentinel-node in cervical cancer patients: preoperative assessment with SPET/CT and comparison with intra-operative gamma-probe and methylene blue-dye

M. Cuzzocrea¹, F. Elisei², C. Crivellaro¹, C. Dolci¹, A. Buda³, M. Signorelli³, L. Guerra², D. Giuliani⁴, M. Arosio², R. Milani⁵, C. Landoni⁵; ¹University of Milan-Bicocca, Nuclear Medicine, Milan, ITALY, ²Nuclear Medicine Department, San Gerardo Hospital, Monza, ITALY, ³Gynaecology Department, San Gerardo Hospital, Monza, ITALY, ⁴University of Milan-Bicocca, Gynaecology, Milan, ITALY, ⁵University of Milan-Bicocca, Milan, ITALY.

PW085

Comparison of imaging modalities (CT, FDG-PET/CT) in head and neck cancer patients

Z. Besenyi¹, S. Urbán², K. Hideghethy³, T. Séra¹, Z. Lengyel⁴, L. Pávics¹; ¹University of Szeged Department of Nuclear Medicine, Szeged, HUNGARY, ²University of Szeged, Institute of Informatics, Szeged, HUNGARY, ³University of Szeged Department of Oncology, Szeged, HUNGARY, ⁴Positron Diagnostics Ltd, Budapest, HUNGARY.

PW086

Clinical Value of FAZA-PET/CT in Head and Neck Cancer Patients

T. Saga¹, M. Inubushi², M. Koizumi³, K. Yoshikawa¹, M. Zhang¹, T. Obata¹, R. Harada⁴, T. Uno⁴; ¹National Institute of Radiological Sciences, Chiba, JAPAN, ²Kawasaki Medical School, Kurashiki, JAPAN, ³Cancer Institute Hospital, Tokyo, JAPAN, ⁴Chiba University Graduate School of Medicine, Chiba, JAPAN.

PW087

Diagnostic accuracy of 18F-FDG PET/CT in primary staging of cutaneous malignant melanoma according to Breslow thickness: a preliminary study

S. Diodato¹, S. De Vivo¹, C. Baraldi², G. Veronesi², E. Dika², S. Fanti^{2,1}, A. Patrizi², S. Vaccari²; ¹Nuclear Medicine, Policlinico S.Orsola-Malpighi, University of Bologna, Bologna, ITALY, ²Dermatology Unit, Policlinico S.Orsola-Malpighi, University of Bologna, Bologna, ITALY.

PW088

Comparison of ¹²³I-IMP SPECT, ¹⁸F-FDG PET, and ¹⁸F-FDOPA PET in Detection of Uveal Malignant Melanoma

K. Kato¹, S. Tsuchiya¹, Y. Koshiba¹, T. Odagawa¹, S. Abe², T. Kubota³, H. Terasaki¹, S. Naganawa¹; ¹Nagoya University Graduate School of Medicine, Nagoya, JAPAN, ²Nagoya University Hospital, Nagoya, JAPAN, ³Nagoya Medical Center, National Hospital Organization, Nagoya, JAPAN.

PW089

Potential impact of 18F-Fluorothymidine PET/CT in lymphoma patients with suspect residual disease or relapse.

L. Zanoni¹, A. Broccoli², C. Nanni¹, C. Pellegrini², F. Lodi¹, C. Fonti¹, P. Ghedini¹, S. Cambioli¹, P. Zinzani², S. Fanti¹; ¹Nuclear Medicine, University Hospital S'Orsola-Malpighi, Bologna, ITALY, ²Hematology "L. e A. Seràgnoli", University Hospital S'Orsola-Malpighi, Bologna, ITALY.

PW090

Comparison of 18F-FDG PET/CT and PET/MRI for the assessment of multiple myeloma

C. Sachpekidis¹, J. Hillengass², H. Goldschmidt², J. Mosebach³, H. Schlemmer³, U. Haberkorn⁴, A. Dimitrakopoulou-Strauss¹; ¹Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, GERMANY, ²Medical Clinic V, University of Heidelberg, Heidelberg, GERMANY, ³Department of Radiology, German Cancer Research Center, Heidelberg, GERMANY, ⁴Division of Nuclear Medicine, University Clinic Heidelberg, Heidelberg, GERMANY.

PW10

Sunday, October 11, 2015

08:30 – 09:30

Poster Walk 10 – Do.MoRe: Thyroid

PW091

The thyroid stunning effect: according to Poisson statistics, a small fraction of an ablative dose already kills a large fraction of cells.

S. Walrand, M. Hesse, F. Jamar; Université Catholique de Louvain, Brussels, BELGIUM.

PW092

Thyroid remnant ablation in differentiated thyroid cancer: searching for the most effective radioiodine activity and stimulation strategy in a real life scenario

A. Campenni¹, L. Giovanella², S. Pignata¹, M. Murè¹, M. Siracusa¹, F. Cosentino¹, L. Sturiale¹, P. Coppolino¹, M. Ruggeri³, S. Baldari¹; ¹Nuclear Medicine Unit of Messina, Messina, ITALY, ²Nuclear Medicine and PET/CT centre, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, Bellinzona, SWITZERLAND, ³Department of Clinical and Experimental Medicine and Pharmacology, Section of Endocrinology, University of Messina, Messina, Italy, Messina, ITALY.

PW093

Selenium as a radiation protector of salivary glands in radioiodine remnant ablation therapy

M. Marx, S. Fastenmeier, M. Zuhayra, U. Lützen; Universitätsklinikum Schleswig-Holstein, KIEL, GERMANY.

PW094

Association between iodine intake and treatment outcomes of radioiodine remnant ablation in patients with intermediate risk papillary thyroid cancer

Y. Sun, W. Ouyang; Department of Nuclear Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, CHINA.

PW095

Prognostic significance of early thyroglobulin release after radioiodine therapy under rhTSH for thyroid cancer

M. Eberle¹, E. Gall², S. Guillemard¹, C. Espitalier¹, I. Raingeard², C. Cartier², M. Jarlier¹, H. De Forges¹, P. Kotzki¹, E. Deshayes¹; ¹Icm Val D'aurelle, Montpellier, France, ²Chu, Montpellier, FRANCE.

PW096

Low-dose radioiodine therapy versus reoperation in patients after non-radical thyroidectomy with differentiated thyroid cancer.

E. Vasilenko, M. Karalkina, I. Lagozhina, D. Fomin; Russian Scientific Center of Roentgenoradiology, Moscow, RUSSIAN FEDERATION.

PW098

Thyroid remnant ablation of differentiated thyroid carcinoma: a comparison of ablation success with high and low doses of radioiodine (I-131)

S. A. A. Elrasad¹, Y. Abdelhafeez², M. A. Hussein¹, R. A. A. Amin¹, S. Elrefaei¹; ¹Cairo university, Cairo, EGYPT, ²Assuit University, Assuit, EGYPT.

PW099

Theoretical model for release of patients with benign thyroid disease based on parameters obtained from EANM Standard Operational Procedures for Pre-Therapeutic Dosimetry II.

M. Salas¹, E. Mora²; ¹Nuclear Medicine Department, Hospital México, San Jose, COSTA RICA, ²Nuclear Medicine Department, Hospital San Juan de Dios, San Jose, COSTA RICA.

PW100

Standardisation of Dosimetry for a Multicentre trial of Selumetinib Enhanced Radioiodine Therapy for Thyroid Cancer

R. Gregory^{1,2}, A. Fenwick³, J. Merrett^{4,3}, J. Scuffham⁴, J. Gear^{1,2}, D. Rushforth^{1,2}, I. Murray^{1,2}, G. Flux^{1,2}; ¹Royal Marsden NHS Foundation Trust, Sutton, UNITED KINGDOM, ²Institute of Cancer Research, Sutton, UNITED KINGDOM, ³National Physical Laboratory, Teddington, UNITED KINGDOM, ⁴Royal Surrey County Hospital, Guildford, UNITED KINGDOM.

PW11

Monday, October 12, 2015

08:30 – 09:30

Poster Walk 11 – Do.MoRe: Imaging, Dosimetry & Radiobiology

PW101

NTCP calculations for Selective Internal RadioTherapy (SIRT) - demonstration of the methodology

E. M. Abbott¹, A. J. Craig², J. M. Franklin³, A. Denis-Bacelar², N. Syed³, G. Flux², R. Sharma¹, K. A. Vallis¹, N. Falzone^{1,4}; ¹MRC/CRUK Gray Institute for Radiation Oncology and Biology, Department of Oncology, University of Oxford, Oxford, UNITED KINGDOM, ²Physics Department, Royal Marsden NHSFT, Sutton, UNITED KINGDOM, ³Nuclear Medicine, Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, UNITED KINGDOM, ⁴Tshwane University of Technology, Department of Biomedical Science, Pretoria, SOUTH AFRICA.

PW102

Radiobiological Studies of Cancer Cell Using Novel External Alpha-Particle Irradiation Set-up.

J. Nilsson¹, J. Nilsson², M. Posaric Bauden³, S. Strand³, J. H. Elgqvist³; ¹Institute for Clinical Sciences, Gothenburg, SWEDEN, ²Institute for Clinical Sciences, Malmö, SWEDEN, ³Institute for Clinical Sciences, Lund, SWEDEN.

PW103

Assessing radiobiological effects of low doses of ionizing radiation on zebrafish muscle by two-dimensional gel electrophoresis

J. Lemos¹, A. Campos², M. Carneiro², T. Ribeiro², F. Ponte³, P. Costa³, L. Cunha⁴, A. Carvalho⁵, L. Metello⁴; ¹ICBAS.UP & ESTSP.IPP, Porto, PORTUGAL, ²CIIMAR/CIMAR.UP, Porto, PORTUGAL, ³Júlio Teixeira SA., Porto, PORTUGAL, ⁴ESTSP.IPP & IsoPor SA., Porto, PORTUGAL, ⁵FCUP.UP & CIIMAR/CIMAR.UP, Porto, PORTUGAL.

PW104

Gamma Camera Calibration for SPECT Based Quantitative Imaging with LU-177:

M. D'Arienzo^{1,2}, M. Cazzato³, S. Ungania³, L. Cozzella¹, G. Iaccarino³, M. D'Andrea³, L. Strigari³, A. Fenwick⁴, L. Johansson⁴, M. Cox⁴, P. De Felice¹; ¹National Institute of Ionizing Radiation Metrology, Via Anguillarese 301, 00123 Rome, ITALY, ²Department of Human Anatomy, Histology, Forensic Medicine and Orthopedics, Sapienza University of Rome, Via Borelli 50, 00161 Rome, ITALY, ³Laboratory of Medical Physics and Expert Systems, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00044 Rome, ITALY, ⁴National Physical Laboratory NPL, Hampton Road, Teddington, Middlesex, TW11 0LW, UK, UNITED KINGDOM.

PW105

The Impact of Registration Method on 3D Dose Distributions

E. Page^{1,2}, J. Tipping¹, D. Hamilton¹, A. Robinson², D. Cullen², C. Oldfield²; ¹The Christie NHS Foundation Trust, Manchester, UNITED KINGDOM, ²The University of Manchester, Manchester, UNITED KINGDOM.

PW106

Optimal sampling times for quantitative imaging

M. Kotzasarlidou¹, M. Cox², V. Smyth², V. Hatzipavlidou¹; ¹"Theagenio" Cancer Hospital, Thessaloniki, GREECE, ²National Physical Laboratory (NPL), Middlesex, London, UNITED KINGDOM.

PW107

Comparison of Sequential SPECT and CT for Targeted Radionuclide Therapy Dosimetry

T. Li, K. Leong, E. Ao, G. S. Mok; University of Macau, Taipa, MACAO.

PW108

Radiation protection impact of radioiodine therapy for hyperthyroidism after a patient specific dosimetric study

C. Canzi, V. Longari, M. Castellani, F. Buffoni, F. Zito, F. Voltini, R. Benti; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Milano, ITALY.

PW109

Estimates of exposure dose to the nuclear medicine staff from inpatient ¹³¹I therapy of differentiated thyroid carcinoma

B. Liu, R. Tian; Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, CHINA.

PW110

Correlation of Clinical Outcomes with Bremsstrahlung and Y-90 PET/CT Imaging Findings Following Y-90 Radiation Synovectomy

T. Barber^{1,2}, A. Powell³, M. Cherk^{1,2}, K. Yap¹, V. Kalf^{1,2}; ¹Department of Nuclear Medicine & PET Centre, The Alfred Hospital, Melbourne, AUSTRALIA, ²Department of Medicine, Monash University, Alfred Hospital Campus, Melbourne, AUSTRALIA, ³Department of Rheumatology, The Alfred Hospital, Melbourne, AUSTRALIA.

PW12

Tuesday, October 13, 2015

08:30 – 09:30

Poster Walk 12 – Do.MoRe: Miscellaneous Therapy

PW111

Acquisition parameters optimization for imaging with Ra-223

A. Corazza^{1,2}, G. Cicoria², F. Zagni², G. Lucconi^{1,2}, D. Pancaldi², M. Marengo²; ¹Postgraduate School in Medical Physics, University of Bologna, Bologna, ITALY, ²Medical Physics Department, University Hospital "S.Orsola - Malpighi", Bologna, ITALY.

PW112

Comparison and evaluation of the effectiveness of α - [²²³Ra Dichloride] and β - particle emission treatments [combined Re-186 HEDP / ⁸⁹Sr Chloride and/or Sm-153 EDTMP/ ⁸⁹Sr Chloride] on Tc-99m-MDP scintigraphic series in pts with painful osseous metastases due to castration-resistant prostate adeno-carcinoma

G. S. Limouris¹, M. Paphiti², S. Synefia¹, M. Lyra¹, L. Mouloupoulou¹, V. R. McCready²; ¹Nuclear Medicine Div - I Radiology Dept-, 'Aretaieion' Hosp, Athens Univ Medical Faculty, Athens, GREECE, ²Nuclear Medicine Dept, Royal Sussex County Hosp, Brighton, UNITED KINGDOM.

PW113

Clinical benefit of routine application of Rhenium-188-HEDP in patients with painful bone metastases from prostate or breast cancer

R. Lange¹, F. Overbeek¹, A. M. van den Berk¹, J. M. H. de Klerk¹, P. C. M. Pasker-de Jong¹, R. ter Heine^{1,2}, M. M. L. van der Westerlaken¹, C. J. Rodenburg¹, N. H. Hendrikse³, H. J. Bloemendaal¹; ¹Meander Medical Center, Amersfoort, NETHERLANDS, ²Radboud University Medical Center, Nijmegen, NETHERLANDS, ³VU University Medical Center, Amsterdam, NETHERLANDS.

PW114

Does cooling of the salivary glands reduce uptake of radiolabeled PSMA-ligands?

F. C. Gaertner, H. Ahmadzadehfard, R. A. Bundschuh, S. Kürpig, E. Eppard, M. Essler; University Hospital Bonn, Bonn, GERMANY.

PW115

The impact of imaging and dosimetry methodology on ¹⁸F NaF PET-based molecular radiotherapy treatment planning

A. M. Denis-Bacelar¹, G. D. Flux²; ¹Institute of Cancer Research, London, UNITED KINGDOM, ²Royal Marsden Hospital, London, UNITED KINGDOM.

PW116

Radiation Toxicity Concerning Salivary and Lachrymal Glands Caused by Peptide Radioligand Therapy Using a Lu-177 PSMA Inhibitor (I & T) in Patients with Metastasized Prostate Cancer: First in Human Studies

A. Özkan¹, C. Schuchardt², H. Kulkarni², M. Shahinfar², M. Sayeg², R. Baum²; ¹Yildiz Technical University, Physics Department, Istanbul, TURKEY, ²Zentralklinik Bad Berka, Theranostics Center for Molecular Radiotherapy and Molecular Imaging (PET/CT), Bad Berka, GERMANY.

PW118

Response Evaluation Criteria in Solid Tumours (RECIST) in a group of patients submitted to Y-90 resin microspheres radioembolization

L. G. da Costa, J. A. M. Santos, B. Gonçalves, L. Violante, F. G. S. Lopes, O. Soares, J. P. Teixeira, I. S. Lucena, A. F. Costa, L. H. T. Duarte; Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE, Porto, PORTUGAL.

PW119

Optimising methodologies for comparison of ^{99m}Tc-MAA and ⁹⁰Y-microsphere distributions

A. J. Craig¹, I. Murray¹, A. M. Denis-Bacelar², N. Khan³, A. Maenhout³, B. Rojas-Fisher⁴, L. Hossen⁴, G. Flux¹; ¹Royal Marsden NHSFT & The Institute of Cancer Research, Sutton, UNITED KINGDOM, ²The Institute of Cancer Research, Sutton, UNITED KINGDOM, ³Chelsea & Westminster NHSFT, London, UNITED KINGDOM, ⁴Royal Brompton NHSFT, London, UNITED KINGDOM.

PW120

Comparison of absorbed dose calculations for non-uniform activity distributions obtained via 90Y-PET/CT after liver radioembolization

M. D'Arienzo^{1,2}, M. Tapner³, E. Spezi⁴, N. Patterson⁵, P. Chiamida⁶, L. Filippi⁷, M. Ahrens⁸, T. Paulus⁹, O. Bagni⁷; ¹National Institute of Ionizing Radiation Metrology, Via Anguillarese 301, 00123 Roma, ITALY, ²Department of Human Anatomy, Histology, Forensic Medicine and Orthopedics, Sapienza University of Rome, Via Borelli 50, 00161 Rome, ITALY, ³Research & Development at Sirtex, North Sydney 2060, NSW, Australia, AUSTRALIA, ⁴Cardiff University, Cardiff CF10 3XQ, UNITED KINGDOM, ⁵Department of Medical Physics, Velindre Cancer Centre, Velindre Road, Whitchurch, Cardiff, CF14 2TL, UNITED KINGDOM, ⁶GE Healthcare Medical Systems, Milano, ITALY, ⁷Nuclear Medicine Department, Santa Maria Goretti Hospital, Latina, ITALY, ⁸Philips GmbH Innovative Technologies, Research Laboratories, Pauwelsstr. 17, 52074 Aachen, GERMANY, ⁹Philips Technologie GmbH Innovative Technologies, Research Laboratories, Pauwelsstr. 17, 52074 Aachen, GERMANY.

NuclearMedicine Nuklearmedizin

MOLECULAR IMAGING AND THERAPY



Submit your next paper to Nuklearmedizin
<http://mc.manuscriptcentral.com/nukmed>

- Organ der Deutschen Gesellschaft für Nuklearmedizin (DGN)
- Organ der Österreichischen Gesellschaft für Nuklearmedizin und Molekulare Bildgebung (ÖGN)
- Organ der Schweizerischen Gesellschaft für Nuklearmedizin (SGNM, SSNM)

2016. 55. Jahrgang. 6 Hefte
ISSN 0029-5566
www.nuklearmedizin-online.de
Verfügbar:
Abstracts/Volltext/Online-Archiv

Jährliche Bezugspreise

inkl. Online-Zugang*

Standard | Inkl. 9 Jahre Online-Archiv

Institute:	€ 594,-
Privatpersonen:	€ 270,-
Studierende:	€ 102,-
Einzelheft:	€ 58,-

Premium | Inkl. Online-Archiv ab 1961

Institute:	€ 652,-
Privatpersonen:	€ 294,-
Studierende:	€ 117,-
Einzelheft:	€ 58,-

* inkl. Versandkosten / incl. mailing costs

Als Standes- und Fachorgan von hohem wissenschaftlichen Anspruch befasst sich die CME-zertifizierte **Nuklearmedizin/NuclearMedicine** mit bildgebender Diagnostik, therapeutischen nuklearmedizinischen Verfahren, Radiopharmaka und mit Themen zum Strahlenschutz: Originalien, Übersichtsarbeiten, Referate und Kongressberichte stellen aktuelle Themen des Faches dar.

Berichte aus den Fachgesellschaften und den DGN-Arbeitskreisen, Nachrichten aus Forschung und Industrie sowie Beschreibungen innovativer technischer Geräte, Einrichtungen und Systeme runden das Konzept ab.

Die Abstracts der Jahrestagungen dreier europäischer Fachgesellschaften sind Bestandteil der Kongressausgaben.



www.nuklearmedizin-online.de

 **Schattauer**

POSTERS

P01 Sunday, October 11, 2015

16:00 – 16:30

Physics & Instrumentation & Data Analysis: Quality Control, Performance & Standardisation

P001

Quantitative Texture Analysis on a PET-CT... With Texture Standardization in Mind!

J. Cortes-Rodicio, G. Sanchez-Merino, R. Lope-Lope, J. Ruiz-Pomar, T. Martin-Gonzalez, M. Garcia-Fidalgo; Osakidetza, Vitoria-Gasteiz, SPAIN.

P002

Performance assessment of the Albira tri-modal pre-clinical PET system

A. Attarwala¹, Y. W. Karanja¹, C. Romanó¹, M. Roscher², C. Maaß¹, B. Wängler², G. Glatting¹; ¹Medical Radiation Physics/Radiation Protection, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, GERMANY, ²Molecular Imaging and Radiochemistry, Institute for Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, GERMANY.

P004

Comparison of time-of-flight PET-CT results for micro hollow spheres from 31 microliter to 8 milliliter for Fluorine-18, Gallium-68 and Yttrium-90

S. Kerschbaumer¹, L. Hofbauer², H. Kvaternik¹, C. Gstettner¹, R. M. Aigner¹; ¹Medical University, Division of Nuclear Medicine, Graz, AUSTRIA, ²University of Applied Science, Division of Radiography, Graz, AUSTRIA.

P005

Conflicting measures of uniformity on a Siemens Symbia gamma camera

M. J. Memmott, I. S. Armstrong, K. J. Saint, A. Bradley, R. S. Lawson, H. A. Williams, C. M. Tonge; Central Manchester University Hospitals NHS Foundation Trust, Manchester, UNITED KINGDOM.

P006

A Novel Method for Krypton-81m Intrinsic Uniformity Measurement

H. A. Williams, M. J. Memmott, R. S. Lawson; Nuclear Medicine, Manchester, UNITED KINGDOM.

P007

Metrology for ⁸⁹Zr in the clinic

A. J. Fenwick^{1,2}, L. Johansson¹, E. Spezi^{3,2}, W. Evans^{4,2}, C. Marshall^{4,2}; ¹National Physical Laboratory, Teddington, UNITED KINGDOM, ²Cardiff University School of Medicine, Cardiff, UNITED KINGDOM, ³Velindre NHS Trust, Cardiff, UNITED KINGDOM, ⁴Wales Research & Diagnostic Positron Emission Tomography (PET) Imaging Centre, Cardiff, UNITED KINGDOM.

P008

Usefulness of Mean Standardized Uptake Value for Liver as a Reference Organ on F-18 FDG PET/CT: Comparison with Standardized Uptake Values Corrected by Various Imaging and Clinical Parameters.

J. Choi¹, S. Lee¹, J. Lee²; ¹Soonchunhyang University Hospital Cheonan, Cheonan, KOREA, REPUBLIC OF, ²Catholic Kwandong University International St. Mary's Hospital, Incheon Metropolitan City, KOREA, REPUBLIC OF.

P009

Evaluation of Qualitative Expressions in Bone Scan Reports

P. Martineau, E. Saldenberg, W. Zeng; The Ottawa Hospital, Ottawa, ON, CANADA.

P010

Semi-quantitative Evaluation of Image Quality in Low Dose 18 F FDG PET/CT

S. C. Kapur, Arvind K Sinha, VP Sajjith, Donald Teh and Vijay Sharma; National University Hospital, Singapore, SINGAPORE.

P02

Sunday, October 11, 2015

16:00 – 16:30

Physics & Instrumentation & Data Analysis: Radiation Exposure & Protection

P011

Shielding gamma-rays from nuclear medicine rooms: Monte Carlo simulations of ceiling scatter in the diagnostic and therapeutic use of ^{99m}Tc, ¹³¹I and ¹⁸F

R. S. Schnerr¹, A. de Jong², C. R. L. P. Jeukens¹, G. Landry³, R. Wiertz¹; ¹Maastricht UMC+, Maastricht, NETHERLANDS, ²Amphia, Breda, NETHERLANDS, ³LMU, München, GERMANY.

P012

Measurement of radioactivity in breast milk following maternal administration of ¹¹¹Indium-Pentetreotide

R. Bidder, C. Humphreys, S. Evans, A. Smakovs, P. Ali; ABMU Health Board, Swansea, UNITED KINGDOM.

P013

Patient Increase Doses From Hybrid Spect-Ct: Evaluation In Common Clinical Practice

T. Ben Ghachem, A. Mhiri, M. Ghezaiel, I. Slim, M. F. Ben Slimène; Nuclear Medicine department; Salah Azaiez Institute, Tunis, TUNISIA.

P014

A Different Methodology Concept For Measurements And Release Criteria In Thyroid Therapy Procedures

V. R. Mc Cready¹, M. PAPHITI¹, G. S. LIMOURIS²; ¹Nuclear Medicine Dept, Royal Sussex County Hosp, Brighton, UNITED KINGDOM, ²"Aretaieion" Hospital, Athens University Medical Faculty, Athens,, GREECE.

P015

Hand Phantoms for Optimization of Radiation Protection of Nuclear Medicine Personnel

M. Fulop¹, J. Hudzietzová², J. Sabol³, P. Ragan⁴, P. Povinec⁵; ¹Slovak Medical University, Bratislava, SLOVAKIA, ²Faculty of Biomedical Engineering of CTU, Kladno, CZECH REPUBLIC, ³Faculty of Safety management of PACR, Prague, CZECH REPUBLIC, ⁴Slovak Centre of Scientific and Technical Information, Bratislava, SLOVAKIA, ⁵Nuclear Medicine Clinic BIONT, Bratislava, SLOVAKIA.

P016

Estimation of likely Radium-223 releases into the environment from filtration based sewage systems.

D. G. Morgan, A. Hallam; Oxford University Hospitals NHS Trust, OXFORD, UNITED KINGDOM.

P017

Preclinical small animal PET/MRI for radiopharmaceutical dosimetry

M. Kranz¹, B. Sattler², M. Patt², W. Deuther-Conrad¹, S. Fischer¹, R. Smits³, A. Hoepfing³, O. Sabri², P. Brust¹; ¹Helmholz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Leipzig, GERMANY, ²Dept. Nuclear Medicine, University Hospital Leipzig, Leipzig, GERMANY, ³ABX advanced biochemical compounds, Radeberg, GERMANY.

P018

Beta+ emitters: workers absorbed doses

G. Tosi¹, F. Provenzano¹, G. Testanera¹, A. Chiti²; ¹Istituto Clinico Humanitas, Rozzano, ITALY, ²Humanitas University, Milano, ITALY.

P019

Radiation protection in a veterinary nuclear medicine facility.

C. Pettinato¹, D. De Zani², M. Longo², G. Ravasio², M. Di Giancamillo², D. Zani²; ¹Medical Physics Unit, Bologna, ITALY, ²DIVET, University of Milano, Milano, ITALY.

P020

Recommended Administered Activity for Ga-68 labelled peptides in Pediatric Nuclear Medicine

J. S. Machado, Jr., S. Beykan, M. Lassmann; Department of Nuclear Medicine, University of Würzburg, Würzburg, GERMANY.

P021

Whole-body Biodistribution, Dosimetry and Metabolite Correction of ¹¹C-palmitate: A PET Tracer for Imaging of Fatty Acid Metabolism

N. L. Christensen, S. Jakobsen, O. L. Munk, S. Nielsen, L. C. Gormsen; Aarhus University Hospital, Aarhus C, DENMARK.

P022

Dosage in Pediatric Nuclear Medicine Diagnostics in Daily Practice

J. S. Machado, S. Beykan, M. Lassmann; Department of Nuclear Medicine, University of Würzburg, Würzburg, GERMANY.

P023

Automated Dispensing and Injection of ¹⁸F-FDG Decreases Personnel Radiation Burden

L. Beels, F. Lavent, D. Nicolaj, O. Gheysens, C. Van de Wiele, A. Maes; AZ Groeninge, Kortrijk, BELGIUM.

P024

Proposal of correction factors for the assessment of the maximum exposure to hands of workers handling radiopharmaceuticals labelled with F-18: Based on studies in CR and SR

J. Hudzietzova¹, M. Fülöp², J. Sabol³, J. Doležal⁴, J. Kubinyi⁵, P. Povinec⁶, I. Makaiová⁷, A. Vondrák⁸; ¹Faculty of Biomedical Engineering, CTU Prague, Kladno, CZECH REPUBLIC, ²Slovak Medical University, Bratislava, SLOVAKIA, ³Faculty of Safety Management of PACR, Prague, CZECH REPUBLIC, ⁴Department of Nuclear Medicine, University Hospital, Hradec Králové, CZECH REPUBLIC, ⁵Institute of Nuclear Medicine of GUH, Prague, CZECH REPUBLIC, ⁶Nuclear Medicine Clinic, BIONT, Bratislava, SLOVAKIA, ⁷Oncology Clinic of St. Elizabeth, Bratislava, SLOVAKIA, ⁸Isotope Centre, Nitra, SLOVAKIA.

P025

Assessing the effect of the amount of injected ^{99m}Tc-MIBI on the calculated cardiac volume in the myocardial Gated-SPECT, A clinical survey

S. Entezarmahdi¹, A. Kamali-asl¹, M. Haghighatafshar², F. Gheisari², M. Hemmatpour², F. Khajerahimi², ¹Radiation Medicine Engineering Department, Shahid Beheshti University, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Nuclear Medicine Department, Shiraz University of Medical Science, Shiraz, IRAN, ISLAMIC REPUBLIC OF.

P026

Transportation of radioactive material for Nuclear Medicine: risk assessment in the area of Bologna

S. Vichi¹, G. Cicoria², D. Pancaldi², A. Infantino¹, C. Po³, D. Mostacci¹, M. Marengo²; ¹Montecuccolino Nuclear Engineering Laboratory, Department of Industrial Engineering, University of Bologna, Bologna, ITALY, ²Medical Physics Department, "S. Orsola-Malpighi" Hospital, Bologna, ITALY, ³Servizio Sanità Pubblica, Regione Emilia Romagna, ITALY.

P027

Promotion of measures to counter radiation health concerns using the comic (manga)

k. ohno¹, T. Higashi², C. Okuyama³, Y. Nakamoto⁴, K. Endo¹; ¹Kyoto Collage of Medical Science, Nantan, JAPAN, ²Shiga Medical Center Research Institute, Moriyama, JAPAN, ³Image Communiation Corporation, kyoto, JAPAN, ⁴Graduate School of Medicine Kyoto University, kyoto, JAPAN.

P028

Radiation Protection Recommendations for Releasing Patients Treated with ¹³¹I for Thyroid Cancer

E. Mora Ramirez; Caja Costarricense del Seguro Social / Universidad de Costa Rica, San Jose, COSTA RICA.

P03

Monday, October 12, 2015

16:00 – 16:30

Physics & Instrumentation & Data Analysis: Image Reconstruction

P29

Standard OSEM vs. Regularized PET Image Reconstruction: Qualitative and Semi-Quantitative Comparison

A. Iagaru, J. Lantos, E. Mittra, C. Levin; Stanford University School of Medicine, STANFORD, CA, UNITED STATES.

P30

How Does Increasing the Matrix Size / Reducing Voxel Volume Impact Quantification in FDG PET? A Detailed Analysis for Optimizing the Clinical Utility of Next Generation Digital PET/CT

K. Binzel¹, J. Zhang¹, B. Zhang², Z. Hu², P. Bardos¹, M. V. Knopp¹; ¹The Ohio State University Wexner Medical Center, Columbus, OH, UNITED STATES, ²Philips Healthcare, Cleveland, OH, UNITED STATES.

P31

Optimisation of ventilation/perfusion (V/Q) SPECT reconstruction utilising advanced reconstruction methods: a phantom study

M. J. Memmott; Central Manchester University Hospitals NHS Foundation Trust, Manchester, UNITED KINGDOM.

P32

Q. Freeze Software for Respiratory Motion Correction in PET/CT: A Preliminary Investigation with a Respiratory Motion Phantom

G. Havariyou, D. Ruiz, E. Kalogianni, B. Corcoran, A. Eccles, N. Mulholland, G. Vivian; King's College Hospital, LONDON, UNITED KINGDOM.

P33

Reproducibility of quantification in F-18 FDG PET clinical application varying protocols parameters and lesions dimension

A. Zorz¹, E. De Ponti¹, L. Guerra², S. Morzenti¹, M. Cuzzocrea³, C. Crivellaro³, A. Crespi¹, M. Arosio², C. Landoni³; ¹Medical Physics, A.O. San Gerardo, Monza, ITALY, ²Nuclear Medicine, A.O. San Gerardo, Monza, ITALY, ³Nuclear Medicine, University of Milano Bicocca, Milano, ITALY.

P34

Impact of a new Bayesian penalised likelihood reconstruction algorithm on ⁶⁸Ga-DOTA-TOC PET/CT imaging

M. Scarlattei¹, G. Baldari¹, S. Migliari¹, C. Ghetti², C. Cidda¹, G. Serrelli², L. Ruffini¹; ¹Nuclear Medicine Dept, University Hospital of Parma, Parma, ITALY, ²Medical Physics, University Hospital of Parma, Parma, ITALY.

P35

Quantification with the new regularized reconstruction algorithm QClear in 4D and QFreeze acquisition

A. Zorz¹, S. Morzenti¹, L. Guerra², M. Cuzzocrea³, E. De Ponti¹, A. Crespi¹, M. Arosio², C. Landoni³; ¹Medical Physics, A.O. San Gerardo, Monza, ITALY, ²Nuclear Medicine, A.O. San Gerardo, Monza, ITALY, ³Nuclear Medicine, University of Milano Bicocca, Milano, ITALY.

P36

Quantitative SPECT/CT imaging using a commercial software

L. D'Ambrosio^{1,2}, L. Aloj¹, P. Chiaramida³, V. Cerciello², P. Gaballo¹, A. Prisco¹, S. Lastoria¹; ¹SC Medicina Nucleare, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, Napoli, ITALY, ²UOSD Fisica Sanitaria, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, Napoli, Italy, Napoli, ITALY, ³GE Healthcare, Rome, ITALY.

P37

Optimization of acquisition time of 68Ga-PSMA-ligand PET/MRI in patients with local and metastatic prostate cancer

S. Lütje¹, S. Blex², B. M. Schaarschmidt³, A. Bockisch¹, T. D. Poeppel¹, A. Wetter²; ¹Clinic for Nuclear Medicine, University Hospital Essen, Essen, GERMANY, ²Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, GERMANY, ³Department of Diagnostic and Interventional Radiology, Medical Faculty, University Düsseldorf, Düsseldorf, GERMANY.

P38

Development of advanced data acquisition methods for quantitative single photon emission computed tomography

K. Matsumoto^{1,2,3}, Y. Takahashi^{4,2}, A. Takaki⁵, K. Murase², Y. Wada³, Y. Watanabe³, K. Endo¹; ¹Kyoto College of Medical Science, Kyoto, JAPAN, ²Osaka University Graduate School of Medicine, Suita, JAPAN, ³Center for Life Science Technologies, RIKEN, Kobe, JAPAN, ⁴Gunma Prefectural College of Health Sciences, Maebashi, JAPAN, ⁵Fujifilm RI Pharma Co., Ltd., Tokyo, JAPAN.

P39

Effects of mis-registration of CT attenuation-corrected on myocardial perfusion images acquired using multi-focus fan beam collimator SPECT/CT and conventional SPECT

H. Onishi¹, K. Nakamoto², S. Kenda³, Y. Kangai¹, N. Yada¹, T. Saho¹, T. Sakai³, D. Hasegawa³, M. Fukunaga³, H. Amijima⁴; ¹Program in Biological System Sciences, Graduate School of Comprehensive Scientific Research, Prefectural University of Hiroshima, SHOBARA, HIROSHIMA, JAPAN, ²Department of Radiology, Hiroshima prefectural Hospital, HIROSHIMA, HIROSHIMA, JAPAN, ³Program in Health and Welfare Sciences, Graduate School of Comprehensive Scientific Research, Prefectural University of Hiroshima, MIHARA, HIROSHIMA, JAPAN, ⁴Graduate school of nursing, Hyogo University of Health Sciences, KOBE, HYOGO, JAPAN.

P40

Optimisation and clinical impact of PSF modelling reconstruction in PET-CT

B. J. Corcoran, C. Scott, D. RUIZ, E. Kalogianni, A. Eccles; King's College Hospital, London, UNITED KINGDOM.

P41

Influence of SPECT reconstruction algorithm on diagnostic accuracy of parathyroid scintigraphy: comparison of iterative reconstruction with filtered backprojection

G. Kara Gedik, O. Sari; Selcuk University Faculty of Medicine, Department of Nuclear Medicine, Konya, TURKEY.

P42

Optimization of image processing for better anatomical analysis of the striatum for SPECT scans of [99mTc] TRODAT-1

A. C. Trevisan¹, L. A. Santos², F. A. Pitella², E. N. Itikawa¹, M. Kato², V. Tumas², M. M. C. M. Brito², L. Wichert-Ana²; ¹Universidade de São Paulo, São Carlos, BRAZIL, ²Universidade de São Paulo, Ribeirão Preto, BRAZIL.

P04

Sunday, October 11, 2015

16:00 – 16:30

Physics & Instrumentation & Data Analysis: Instrumentation

P043

Continuous-spectrum Emission Tomography (CET) for quantifying the absorbed dose of in-vivo bremsstrahlung

S. Vandenberghe¹, H. W. A. De jong², M. Bardies³, D. Borys⁴, M. de Jong⁵, S. Walrand⁶; ¹MEDISIP, Department of Electronics and Information Systems, Ghent University, iMinds Medical IT-IBiTech, Gent, BELGIUM, ²University Medical Center Utrecht, Utrecht, NETHERLANDS, ³Institut national de la santé et de la recherche médicale, Toulouse, FRANCE, ⁴Silesian University of Technology, Comprehensive Cancer Centre, Gliwice, POLAND, ⁵Department of nuclear medicine, Erasmus Medical center, Rotterdam, NETHERLANDS, ⁶Department of nuclear medicine, UCL, Brussels, BELGIUM.

P044

Myocardial innervation and perfusion mismatch using cardiac dual isotope (123I-MIBG/99mTc-tetrofosmin) acquisition on two different CZT cameras: a phantom study

T. Blaire^{1,2}, A. Bailliez^{1,2}, D. Legallois³, D. Agostini³, A. Manrique^{1,3}; ¹EA 4650, Normandy University, Caen, FRANCE, ²Nuclear Medicine Department, IRIS, Polyclinique du Bois, Lille, FRANCE, ³Nuclear Medicine Department, CHU Cote de Nacre, Caen, FRANCE.

P045

Ultrafast Bone SPECT Imaging of the Hands Using a Solid State CZT SPECT Camera

A. Frenkel, M. Kurash, O. Israel, J. A. Kennedy; Rambam Medical Center, HAIFA, ISRAEL.

P046

18F-Choline intravenously infusion with an automatic combined dispenser and injector system.

A. Moretti¹, P. Caroli², R. Galassi¹, V. D'errico³, C. Donati⁴, L. Fantini², V. Mautone², G. Gualtieri², G. Battara², G. Paganelli², F. Matteucci²; ¹Nuclear Medicine Unit Ausl Romagna, Forlì, ITALY, ²Nuclear Medicine Irt, Meldola, ITALY, ³Medical Physics Unit Tirst, Meldola, Italy, ⁴Pharmacy Unit Irt, Meldola, ITALY.

P047

Development of Radionebulizer Equipment for Diagnostic in Nuclear Medicine

A. F. Viana¹, P. Nabinger¹, R. Madke¹, P. Madke¹, P. R. Ferreira², R. Anele, Filho³; ¹Grupo RPH, Porto Alegre, BRAZIL, ²Bhiosupply, Porto Alegre, BRAZIL, ³CETA/SENAI, Porto Alegre, BRAZIL.

P048

Monte Carlo Simulations of Beta Particle Measurement Using Cerenkov Luminescence Imaging or Beta Detection

L. Altabella, C. R. Gigliotti, A. E. Spinelli; San Raffaele Scientific Institute, Milano, ITALY.

P049

Attenuation Correction in Planar Scintigraphy Using Transmission Measurement with Flood Source

M. Samal, V. Sirova, D. Skibova, J. Trnka, V. Ptacnik, J. Kubinyi; Charles University Prague, Prague, CZECH REPUBLIC.

P050

The Influence of Cardiac ROIs Contour Definition at Heart-to-Mediastinum Ratio in 123I-MIBG Scintigraphy

A. Sá Pinto, T. Vieira, S. Chaves, V. Alves, T. Faria, A. Oliveira, A. Fernandes, M. Pérez, J. Pereira; Centro Hospitalar de São João, Porto, PORTUGAL.

P051

Performance Evaluation of a Gamma-Probe for High Energy source (131-Iodine) for Oncologic Purposes

E. N. I. Itikawa^{1,2}, L. A. S. Santos^{1,3}, D. K. S. Sonvenso^{1,3}, M. K. Kato^{1,3}, F. A. P. Pitella^{1,3}, C. E. P. B. Baltazar^{1,4}, A. C. T. Trevisan^{1,2}, E. R. M. Moraes^{1,5}, L. W. A. Wichert-Ana^{1,2,3}; ¹Ribeirão Preto School of Medicine, Ribeirão Preto, BRAZIL, ²Post-Graduation Program Interunits Bioengineering EESC/FMRP/IQSC-USP, São Carlos, BRAZIL, ³Postgraduation Program in Internal Medicine, Ribeirão Preto, BRAZIL, ⁴Faculty of Philosophy, Sciences and Literature of Ribeirão Preto, Ribeirão Preto, BRAZIL, ⁵Faculty of Philosophy, Sciences and Literature of Ribeirão Preto, Ribeirão Preto, Ribeirão Preto, BRAZIL.

P052

Evaluation of Physical Detection Parameters of a Gamma Probe for Sentinel Lymph Node Localization in Melanoma and Breast Cancer.

E. N. I. Itikawa^{1,2}, L. A. S. Santos^{1,3}, D. K. S. Sonvenso^{1,3}, M. K. Kato^{1,3}, F. A. P. Pitella^{1,3}, C. E. P. B. Baltazar^{1,4}, A. C. T. Trevisan^{1,2}, E. R. M. Moraes^{1,5}, L. W. A. Wichert-Ana^{1,2,3}; ¹Ribeirão Preto School of Medicine, Ribeirão Preto, BRAZIL, ²Post-Graduation Program Interunits Bioengineering EESC/FMRP/IQSC-USP, São Carlos, BRAZIL, ³Postgraduation Program in Internal Medicine, Ribeirão Preto, BRAZIL, ⁴Faculty of Philosophy, Sciences and Literature of Ribeirão Preto, Ribeirão Preto, BRAZIL, ⁵Faculty of Philosophy, Sciences and Literature of Ribeirão Preto, Ribeirão Preto, Ribeirão Preto, BRAZIL.

P053

The General Idea and the Functionality Behind Real-time Handheld Emission Spot Allocator (rthESA) for Simultaneous Fusion Imaging with Ultrasound

C. Kühnel, T. Winkens, M. Freesmeyer; Jena University Hospital, Jena, GERMANY.

P054

Hybrid Integration of Real-Time Ultrasound and Freehand-SPECT: First Experiences and additional informations about Radiation Exposure of the Investigator

C. Kühnel, T. Winkens, T. Opfermann, M. Freesmeyer; Jena University Hospital, Jena, GERMANY.

P055

An integrated framework of recovering triple coincidence for enhancing PET sensitivity

H. Lin, Z. Wei, C. Chiang, K. Chuang; National Tsing Hua university, Hsin Chu, TAIWAN.

P56

Monte Carlo Modelling and Experimental Verification of a GE Optima SPECT System: Towards Characterisation of Collimator Response

A. Grimwood¹, T. Kostou², P. Papadimitroulas³, G. Loudos², L. Livieratos³, J. Scuffham¹; ¹Royal Surrey County Hospital, Guildford, UNITED KINGDOM, ²Technological Educational Institute of Athens, Athens, GREECE, ³King's College London, London, UNITED KINGDOM.

P57

Preclinical validation of automated DXA- and CT-based body composition measurements

J. Devriese¹, L. Beels², A. Maes², C. Van de Wiele², O. Gheysens², H. Pottel¹; ¹KU Leuven campus Kulak, Kortrijk, BELGIUM, ²Department of Nuclear Medicine, AZ Groeninge, Kortrijk, BELGIUM.

P58

Evaluation of image quality on PET/CT with Flow motion technology – Does it keep quantitative performance and uniformity ?

K. Murakami, T. Nakahara, Y. Ogata, Y. Iwabuchi, M. Katagiri, Y. Matsusaka; Keio University, Tokyo, JAPAN.

P05

Sunday, October 11, 2015

16:00 – 16:30

Physics & Instrumentation & Data Analysis: Data Analysis

P059

18F-Fluorodeoxyglucose (18F-FDG) PET pulmonary imaging: comparative methodology in COPD patients

A. M. Fletcher¹, G. Choudhury¹, T. Clark¹, M. Connell¹, S. Fergusson¹, R. Rabinovich¹, N. Weir¹, B. Whitcher², I. Kilty², B. Vennart², E. J. R. van Beek¹, W. MacNee¹; ¹University of Edinburgh, Edinburgh, UNITED KINGDOM, ²Pfizer Worldwide Research and Development, Cambridge, MA, UNITED STATES.

P060

Correlation of texture parameters with conventionally used semi quantitative parameter: standard uptake values, metabolic tumor volume and total lesion glycolysis in 18F-FDG PET/CT examination for breast cancer

N. Rana¹, K. Agrawal¹, D. Dhawan², A. Bhati², B. Mittal¹; ¹Post-Grad. Inst. of Med. Education & Research, PGIMER, CHANDIGARH, INDIA, ²Panjab University, CHANDIGARH, INDIA.

P061

Comparison of 3D texture features and metabolic parameters obtained from 18-F FDG-PET/CT images for evaluating tumor stage and subtype in non-small cell lung cancer

S. Karacavus¹, B. Yilmaz², O. Kayaalti³, A. Tasdemir⁴, E. Kaya⁵, S. Icer⁶, O. Ayyildiz², K. Eset⁶, E. Vardarelis⁵, M. H. Asyali⁷; ¹Bozok University, School of Medicine, Department of Nuclear Medicine, Yozgat, TURKEY, ²Abdullah Gul University, Department of Electrical and Electronics Engineering, Kayseri, TURKEY, ³Erciyes University, Develi Hüseyin Şahin Vocational College, Department of Computer Technologies, Kayseri, TURKEY, ⁴Kayseri Educational and Research Hospital, Department of Pathology, Kayseri, TURKEY, ⁵Acibadem University, School of Medicine, Department of Nuclear Medicine, İstanbul, TURKEY, ⁶Erciyes University, Department of Biomedical Engineering, Kayseri, TURKEY, ⁷Department of Biomedical Engineering, Yıldız Technical University, İstanbul, TURKEY.

P062

The role of SUV SPECT perfusion defect quantification of the lung as a predictor of severe cardiovascular events in a cohort of patients with congestive heart failure

W. He, W. Yu, J. Xi, W. Zhai; Huadong Hospital, Shanghai, CHINA.

P063

Diagnostic accuracy of quantitative bone scintigraphy with artificial neural network in patients with breast cancer

A. Inaki, K. Nakajima, S. Watanabe, S. Kinuya; Kanazawa University Hospital, Kanazawa, JAPAN.

P064

Cerenkov Radiators for Preclinical Optical Imaging

C. R. Gigliotti, L. Altabella, A. E. Spinelli; San Raffaele Scientific Institute, Milano, ITALY.

P065

Striatum specific F-18 FP-CIT analysis in Parkinson disease

J. S. Oh¹, I. Lee^{1,2}, H. Moon¹, J. Kim², M. Oh¹, J. Kim¹; ¹Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF, ²Department of Nuclear Engineering & Radiologic Science, College of Health Science, Korea University, Seoul, KOREA, REPUBLIC OF.

P066

Quantitative Evaluation of Scattered Photons in a Myocardial Pinhole SPECT Imaging

K. Ogawa, N. Aitani, Y. Hemuki; Hosei University, Tokyo, JAPAN.

P067

Image noise estimation using sub-reconstructions of clinical Whole Body PET/CT data

A. K. Krizsan¹, A. Forgacs², G. K. Nagy¹, M. Szolik¹, M. Dahlbom³, L. Balkay¹; ¹University of Debrecen, Medical Center, Department of Nuclear Medicine, Debrecen, HUNGARY, ²ScanoMed Nuclear Medicine Centers, Debrecen, HUNGARY, ³University of California at Los Angeles, David Geffen School of Medicine, Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, Los Angeles, CA, UNITED STATES.

P068

Looking for physiological factors affecting texture analysis on clinical PET... with texture standardization in mind!

J. Cortes-Rodicio, G. Sanchez-Merino, R. Lope-Lope, J. Ruiz-Pomar, T. Martin-Gonzalez, M. Garcia-Fidalgo; Osakidetza, Vitoria-Gasteiz, SPAIN.

P069

Repeat (R)-[11C]PK11195 brain PET scans in glioma

M. Bauer^{1,2}, Z. Su¹, F. Roncaroli³, A. Gerhard¹, F. Turkheimer⁴, K. Herholz¹, R. Hinz¹; ¹University of Manchester, Manchester, UNITED KINGDOM, ²Medical University of Vienna, Vienna, AUSTRIA, ³Imperial College London, London, UNITED KINGDOM, ⁴King's College London, London, UNITED KINGDOM.

P070

Segmentation gross tumor volume on positron emission tomography by a method combined with numerical approximation and local gradient _ an animal study

Y. CHEN; Quanzhou First Hospital of Fujian Medical University, quanzhou, CHINA.

P071

Computer-aided Diagnosis System to Assess Metastatic Disease Presence and Evolution

I. V. Popa¹, I. Grierosu^{1,2}, A. Statescu¹, M. Gutu^{1,2}, R. Gherasim¹, S. Bilha¹, R. Olaru¹, C. Cijevschi-Prelipcean^{1,2}, C. Mihai^{1,2}, L. Ionescu^{1,2}, C. Vulpoi^{1,2}, C. Luca^{1,2}, C. Stefanescu^{1,2}; ¹"St. Spiridon" Hospital, Iasi, ROMANIA, ²Medicine Faculty, "Grigore T. Popa" University of Medicine and Pharmacy, Iasi, ROMANIA.

P072

Practical measures of dynamic 18 FDG time-activity curves.

M. Tuncel, O. Kupik, P. Kiratli, B. Erbas; Hacettepe University, Ankara, TURKEY.

P073

Early X-Ray CT Radiomic Identification of Lung Tissue Harm Origins in Mice

D. Mathe¹, F. Budan¹, C. Korom², D. Veres³, K. Szigeti³; ¹CROMed Ltd, Budapest, HUNGARY, ²Dept. Radiology Semmelweis University Budapest, Budapest, HUNGARY, ³Dept. Biophysics and Radiation Biology Semmelweis University, Budapest, HUNGARY.

P074

development of metabolic tumor volume measurement based on suvpeak

K. Koyama^{1,2}, T. Mitsumoto¹, K. Inoue², K. Tsuda³, K. Kotaka¹, K. Yoshikawa¹, K. Hatano¹, M. Fukushi²; ¹Tokyo Bay Advance Imaging & Radiation Oncology Clinic-MAKUHARI, Chiba, JAPAN, ²Tokyo Metropolitan University, Tokyo, JAPAN, ³Tsukuba International University, Ibaraki, JAPAN.

P075

Analysis of Inter-Detector Scattering in PET with Various Energy Window Settings

K. S. Chuang, Z. J. Wei, H. H. Lin; National Tsing-Hua University, Hsin-Chu, TAIWAN.

P076

Optimisation of automatic image segmentation for tumour volume determination in 18F-FDG PET/CT for patients with liver lesions

D. Ruiz, E. Kalogianni, B. Corcoran, A. Eccles, N. Mulholland, G. Vivian; King's College Hospital NHS Foundation Trust, London, UNITED KINGDOM.

P077

Aspects on quantification and detectability in 111In SPECT/CT and 68Ga PET/CT images of neuroendocrine tumours

A. Stenvall¹, E. Mattsson¹, E. Larsson¹, T. Ohlsson¹, C. Hindorf¹, L. Jonsson²; ¹Radiation Physics, Skane University Hospital, Lund, SWEDEN, ²Medical Radiation Physics, Lund University, Lund, SWEDEN.

P06

Sunday, October 11, 2015

16:00 – 16:30

Physics & Instrumentation & Data Analysis: Miscellaneous

P078

Optimisation of Y-90 post-SIRT PET imaging on GE Discovery systems

L. M. Rowley, D. R. McGowan, K. M. Bradley, A. Hallam; Oxford University Hospitals NHS Trust, Oxford, UNITED KINGDOM.

P079

Analysis of Radiation-Induced Liver Disease (RILD) and Evaluation of Relationship Between Therapeutic Activity and Liver Clearance(C) Rate with Tc-99m-Mebrofenin(M) in Y-90 Microspheres Treatment(MT)

H. Tanyildizi, M. Abuqbeith, L. Kabasakal, M. Demir;
Istanbul University, Istanbul, TURKEY.

P080

Monte Carlo simulations to evaluate dose for possible treatment of brain cancers by boron neutron capture therapy

Z. Jovanovic¹, D. Krstic¹, D. Nikezic¹, M. Matovic², R. Krstic³;
¹University of Kragujevac, Faculty of Science, Kragujevac, SERBIA, ²Clin Ctr Kragujevac, Kragujevac, SERBIA, ³KVARK Company, Kragujevac, SERBIA.

P081

What is the sensitivity of 90Y SPECT to microscale dose distribution?

C. Oldfield¹, D. Cullen¹, D. Hamilton², E. Page², A. P. Robinson¹, J. Tipping²; ¹University of Manchester, Manchester, UNITED KINGDOM, ²The Christie NHS foundation trust, Manchester, UNITED KINGDOM.

P07

Sunday, October 11, 2015

16:00 – 16:30

Molecular & Multimodality Imaging: PET – Clinical & Preclinical Evaluation

P082

A comparison of the utility of F18 Choline and Ga68 PSMA PET/CT in identifying distant disease in high risk prostate cancer patients being considered for radical prostatectomy.

S. A. Ali¹, L. Emmett¹, J. Wang¹, P. Van Leeuwen², D. Stark¹, J. Morigi¹, P. Stricker²; ¹St Vincents Public Hospital, Sydney, AUSTRALIA, ²Garvan Institute for medical research, Sydney, AUSTRALIA.

P083

Targeting VPAC1 for Imaging Prostate Cancer

M. L. Thakur, E. J. Trabulsi, S. Tripathi, S. Kim, P. McCue, R. Birbe, A. Gandhe, P. Kumar, C. Intenzo, L. Gomella; Thomas Jefferson University, Philadelphia, PA, UNITED STATES.

P084

The incremental value of FDG PET/CT over MDP bone scan in staging of Ewing's group of tumors.

r. K. kavindran, Sr., s. shah; TMH, mumbai, INDIA.

P085

[18F]PR04.MZ for Dopamine Transporter Quantification in Low Density Regions - Complete Evaluation and Dosimetry in Healthy Volunteers

V. Kramer¹, R. Pruzzo², E. Hernandez², P. Chana³, C. Jurí⁴, P. Riss⁵, F. Rösch⁶, H. Amaral¹; ¹PositronPharma SA, Santiago de Chile, CHILE, ²Nuclear Medicine and PET/CT Center FALP, Santiago de Chile, CHILE, ³Universidad de Santiago de Chile, Santiago de Chile, CHILE, ⁴Universidad Catolica, Santiago de Chile, CHILE, ⁵University of Oslo, Oslo, NORWAY, ⁶Johannes Gutenberg-Universität Mainz, Mainz, GERMANY.

P086

The potential impact of congestive heart failure (CHF) on FDG PET/CT studies

M. Ahmed¹, R. Muzaffar¹, M. M. Osman^{1,2}; ¹Saint Louis University, Saint Louis, MO, UNITED STATES, ²Saint Louis VA, Saint Louis, MO, UNITED STATES.

P087

The Effect of Pulmonary Hypertension on Standardized Uptake Values of the Liver and Pulmonary artery in FDG PET/CT Imaging.

M. Mikhayel¹, N. Parkar¹, R. Muzaffar¹, P. Kelly¹, M. M. Osman^{1,2}; ¹Saint Louis University, Saint Louis, MO, UNITED STATES, ²Saint Louis VA, Saint Louis, MO, UNITED STATES.

P088

Dynamic whole body distribution of FBPA in humans studied with 3D PET/CT

K. Isohashi¹, H. Kato¹, G. Horitsugi¹, S. Naka¹, I. Mochida¹, E. Shimosegawa², J. Hatazawa¹; ¹Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Suita, JAPAN, ²PET Molecular Imaging Center, Osaka University Graduate School of Medicine, Suita, JAPAN.

P089

Uptake of ⁶⁸Ga-DOTATATE and ⁶⁸Ga-DOTATOC in Primary Neuroendocrine Tumors, Metastases, and Normal Liver Tissue - is there a Significant Difference?

M. Todorovic-Tirnanic¹, M. Gajic², R. Baum³; ¹Faculty of Medicine, University of Belgrade and Center of Nuclear Medicine, Clinical Center of Serbia, Belgrade, SERBIA, ²Institute of Statistics, Faculty of Medicine, University of Belgrade, Belgrade, SERBIA, ³Theranostics Center for Molecular Radiotherapy and Imaging, Zentralklinik, Bad Berka, GERMANY.

P090

18FDG-PET/CT Imaging in Suspected Acute Renal Allograft Rejection

P. Lovinfosse, L. Weekers, C. Bonvoisin, C. Bovy, S. Grosch, J. Krzesinski, R. Hustinx, F. Jouret; CHU of Liege, Liege, BELGIUM.

P091

Effects of Long Acting Somatostatin Analogue Therapy on 68Ga-DOTA-Octreotate PET/CT uptake in Neuroendocrine Tumour Patients

M. H. Cherk, R. J. Hicks, M. S. Hofman; Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA.

P092

Ga-68 labelled PSMA ligand based PET/CT scan for the detection of recurrence in prostate cancer patient and comparison with F-18 choline-based PET/CT scan in a tertiary care center

B. R. Mittal, J. Shukla, R. V. Parghane, R. K. Phulsunga, R. Vatsa, P. Bhusari, N. Rana, A. Sood, A. Bhattacharya, S. K. Singh; Postgraduate Institute of Medical Education & Research, PGIMER, CHANDIGARH, INDIA.

P093

Breslow thickness and 18F-FDG PET-CT result in initial staging cutaneous melanoma: can a cut-off point be established?

A. Ortega Candil, C. Rodriguez Rey, E. Cala Zuluaga, M. Cabrera Martin, M. Perez Castejon, A. Jimenez Ballve, A. Serrano Palacio, L. Leon Ramirez, C. Riola Parada, M. Garcia Garcia-Esquinas, L. Lapeña Gutierrez, J. Carreras Delgado; Clinico San Carlos Hospital, Madrid, SPAIN.

P094

Positron Emission Tomography (PET) Imaging of Chemokine Receptor CXCR4 in Patients with Solid Cancers: First Results

T. Vag¹, C. Gerngross¹, U. Keller², H. Wester³, M. Schwaiger¹; ¹Clinic of Nuclear Medicine, Klinikum Rechts der Isar, Munich, GERMANY, ²III Medical Department, Klinikum Rechts der Isar, Munich, GERMANY, ³Institute of Pharmaceutical Radiochemistry, Munich, GERMANY.

P095

Colorectal pulmonary metastasis candidate to surgical resection: Preoperative prognostic value of ¹⁸F-FDG PET/CT SUVmax

E. Puta¹, O. Rena², F. Orsini¹, L. Leva¹, E. Papalia², C. Casadio², G. Sacchetti¹; ¹Nuclear Medicine Department, AOU "Maggiore della Carità", Novara, ITALY, ²Thoracic Surgery Department, AOU "Maggiore della Carità", Novara, ITALY.

P096

Correlation between Proliferation Index and Metabolic Activity at the biopsy site in newly diagnosed NHL

V. Agarwal, B. Suneetha, S. Pande; Medanta The Medicity Hospital, Gurgaon, INDIA.

P097

Complementary diagnostic role of Somatostatin Receptor Scintigraphy (SRS) and 18-F-FDG-PET-CT in neuroendocrine tumors management

M. Catalano, G. Annunziata, D. Scala, V. Ippolito; AORN, Naples, ITALY.

P098

A Comparison between PET/CT and CT in Head&Neck Radiotherapy Treatment Planning

O. Ferrando¹, F. Foppiano¹, T. Scolaro², A. Ciarmiello³; ¹Medical Physics Department, St Andrea Hospital - ASL5 Spezzino, La Spezia, ITALY, ²Radiotherapy Department, St Andrea Hospital - ASL5 Spezzino, La Spezia, ITALY, ³Nuclear Medicine Department, St Andrea Hospital - ASL5 Spezzino, La Spezia, ITALY.

P099

3D Volumetric lymph node assessment based on CT versus PSMA11-PET/CT in recurrent prostate cancer

F. Giesel¹, F. Sterzing², H. Fiedler¹, M. Rius³, M. Stefanova¹, A. Afshar-Oromieh¹, K. Kopka⁴, J. Debus², U. Haberkorn¹, C. Kratochwil¹; ¹Radiologische Klinik / Abt. für Nuklearmedizin, Heidelberg, GERMANY, ²Radiologische Klinik / Abt. für Strahlentherapie, Heidelberg, GERMANY, ³Joint Research Centre – Institute for Transuranium Elements, Karlsruhe, GERMANY, ⁴Deutsches Krebsforschungszentrum (DKFZ) / Abteilung für Radiopharmazeutische Chemie, Heidelberg, GERMANY.

P100

FDG uptake quantification: comparison of different delineation strategies and software platforms

A. de Jong¹, B. A. Blomberg¹, R. A. Nievelstein¹, V. Frings¹, G. Kramer², A. J. de Langen², O. S. Hoekstra², R. Boellaard²; ¹UMC Utrecht, Utrecht, NETHERLANDS, ²VU Medical Center, Amsterdam, NETHERLANDS.

P101

Sequential dynamic PET and dynamic MR imaging in N-staging of lung cancer patients

P. Flechsig, D. Rath, C. Heußel, C. Kratochwil, H. Kauczor, U. Haberkorn, F. Giesel; University Hospital Heidelberg, Heidelberg, GERMANY.

P102

Development of PET in Europe

A. Stevens; Medical Options, London, UNITED KINGDOM.

P103

Feasibility of Accelerating Yttrium-90 PET by Optimizing PET Volume Overlap

J. Zhang¹, C. Wright¹, K. Binzel¹, E. J. Wuthrick¹, P. Maniawski², M. V. Knopp¹; ¹The Ohio State University, Columbus, OH, UNITED STATES, ²Philips Healthcare, Cleveland, OH, UNITED STATES.

P104

Role of 18F-FDG PET/CT and a new score system to measure the pre-test clinical risk in patients suspected of paraneoplastic neurological syndrome

F. J. Pena Pardo¹, A. Palomar Muñoz¹, A. M. García Vicente¹, C. H. Vega Caicedo¹, M. Amo Salas², J. F. López-Fidalgo², J. A. Garrido Robles³, J. Á. de Ayala Fernández⁴, P. del Saz Saucedo⁵, M. Muñoz Pasadas⁶, Á. M. Soriano Castrejón¹;
¹Nuclear Medicine Sv. Hospital General Universitario, Ciudad Real, SPAIN, ²Mathematics Dep. Universidad de Castilla La Mancha, Ciudad Real, SPAIN, ³Neurology Sv. Complejo Hospitalario de Toledo, Toledo, SPAIN, ⁴Internal Medicine Sv. Complejo Hospitalario de Albacete, Albacete, SPAIN, ⁵Neurology Sv. Hospital la Mancha Centro, Alcázar de San Juan (Ciudad Real), SPAIN, ⁶Neurology Sv. Hospital de Puertollano, Puertollano (Ciudad Real), SPAIN.

P105

Repeatability of Quantitative [¹⁸F] Fluoromethylcholine PET/CT Measurements in Prostate Cancer

D. E. Oprea-Lager, G. M. Kramer, P. M. van de Ven, A. J. M. van den Eertwegh, R. J. A. van Moorselaar, O. S. Hoekstra, A. A. Lammertsma, R. Boellaard; VU University Medical Center, Amsterdam, NETHERLANDS.

P106

Effect of motion in the quantification of lesion heterogeneity with Positron Emission Tomography.

M. Carles¹, U. Nestle¹, A. Schaefer²; ¹Department of Radiation Oncology, University Medical Center, 79106 Freiburg, Germany, Freiburg, GERMANY, ²Department of Nuclear Medicine, Saarland University Medical Center, D-66421 Homburg, Germany, Freiburg, GERMANY.

P107

Comparison between Gallium-68 citrate PET-CT and Gallium-67 citrate scintigraphy for infection imaging

T. Segard¹, L. Morandeau¹, M. Dunne², O. Robinson², R. Murray¹, E. Geelhoed³, R. J. Francis³; ¹Sir Charles Gairdner Hospital, Nedlands, AUSTRALIA, ²Royal Perth Hospital, Perth, AUSTRALIA, ³University of Western Australia, Crawley, AUSTRALIA.

P108

Do Larger Matrix Sizes in Positron Emission Tomography always result in Increased Image Noise?

C. McKeown, G. Gillen, M. Dempsey, C. Findlay; NHS GG&C, GLASGOW, UNITED KINGDOM.

P109

Influence of Slice Overlap on Positron Emission Tomography Image Quality

C. McKeown, G. Gillen, M. Dempsey, C. Findlay; NHS GG&C, GLASGOW, UNITED KINGDOM.

P110

Normalized uptake fraction: a new approach for image quantification

P. Alves^{1,2}, A. F. Silva³, M. F. Botelho¹; ¹Faculty of Medicine, University of Coimbra, Coimbra, PORTUGAL, ²IPOCFG, Coimbra, PORTUGAL, ³IEETA, University of Aveiro, Aveiro, PORTUGAL.

P111

Influence of morphine exposure and withdrawal on the brain kinetics of [¹⁸F]DPA-714 and classical biomarkers of inflammation

S. Auvity¹, S. Goutal¹, B. Theze¹, B. Kuhnast¹, B. Hosten², W. Saba¹, R. Boisgard¹, S. Cisternino³, N. Tournier¹; ¹Cea, Orsay, France, ²Inserm U1144, Paris, FRANCE, ³INSERM U1144, Paris, FRANCE.

P112

Non-completed PET/CT scans - assessing its impact on service quality and patient experience

A. Nunes, G. Beynon, C. Strickland, W. Wong; Paul Strickland Scanner Centre, Mount Vernon Hospital - East and North Herts NHS Trust, London, UNITED KINGDOM.

P113

A Hybrid random walk algorithm with spatial fuzzy C-mean clustering for segmentation of liver tumors in FDG PET imaging

M. Soufi¹, A. Kamali Asl¹, P. Geramifar², M. Khazae Moghadam¹; ¹Radiation Medicine Department, Shahid Beheshti University, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

P114

Utility of Delayed 18 FDG PET/CT Imaging for Lesions Detection Enhancement.

F. Y. Risheq, M. F. Alrisheq, S. J. Al-Sadoon, A. A. Qwarik; Nuclear Medicine, Pet/Ct, Bmd, Dr. Farid Risheq Center, Amman, JORDAN.

P115

Assessment of reconstruction parameters impact on quantification of low dose Yttrium-90 activity based on PET-CT Imaging in radioembolization

M. Khazae Moghadam¹, A. Kamali Asl¹, P. Geramifar², M. soufi¹; ¹Shahid Beheshti University, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

P116

Clinical utility of 18F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in prostate cancer patients and comparing with 18 F-FDG PET/CT and conventional imaging modality

R. K. Phulsunga, Jr., R. Parghane, sr, J. Shukla, Consultant, B. Mittal, Prof; PGIMER, Chandigarh, INDIA.

P117

Qualitative evaluation of respiratory artifacts on PET/CT images

M. Shamsaie Zafarghandi, F. Gholami, B. Teimourian; Amirkabir University of Technology, tehran, IRAN, ISLAMIC REPUBLIC OF.

P118

Serial monitoring of denervated muscle with 18F-FDG PET

K. Pak, M. Shin, I. Kim; Pusan National University Hospital, Busan, KOREA, REPUBLIC OF.

P119

Usefulness of F-18 Flouromethylcholine (FCH) Positron Emission Tomography/Computed Tomography (PET/CT) in Evaluation of Bone Metastases in Suspected Recurrent Carcinoma Prostate and Comparative Role of Computed Tomography (CT) in Lesion Detection.

S. Z. Ali, C. J. Tan, L. W. C. Winnie; Singapore General Hospital, Singapore, SINGAPORE.

P120

PET/CT Use With Abdominal Compression Arch For Stereotactic Radiosurgery Planning With Arrested Lung And Extracorporeal Circulation

D. M. Ruiz Hernández, J. Nogueiras Alonso, F. Zelaya Reinquet, C. Castillo Berrio, M. Castrillón, A. Serena Puig, L. Campos Villarino, R. Guitian Iglesias; ESG36555100, Pontevedra, SPAIN.

P121

Motion management in clinical practice on Discovery IQ – GE PET/CT scanner

S. Morzenti¹, A. Zorz¹, F. Elisei², E. De Ponti¹, L. Guerra², A. Crespi¹, M. Arosio², C. Landoni³; ¹Medical Physics, A.O. San Gerardo, Monza, ITALY, ²Nuclear Medicine, A.O. San Gerardo, Monza, ITALY, ³Nuclear Medicine, University of Milano Bicocca, Milano, ITALY.

P122

Optimization of Dual Time Point Delayed Regional 18F FDG PET CT Protocol With Site Specific Interventions

M. Sarma, P. Subramanyam, P. Sundaram; Dept. Of Nuclear Medicine And Pet Ct, Amrita Institute Of Medical Sciences And Resaerch Centre, Amrita Vishwa Vidyapeetham, Cochin, INDIA.

P123

Performance of PET/CT for detecting the primary tumors of cervical metastases from unknown primary carcinoma: a systematic review and meta-analysis

G. Shen, Z. Jia, H. Deng; West China Hospital of Sichuan University, Chengdu, CHINA.

P124

Is 18F-FDG PET/CT Suitable for Selecting Lung Cancer Patients for Brain MR Under the Suspicion of Brain Metastasis?

K. Hjorthaug, Sr.¹, J. Hojbjerg¹, M. Knap¹, A. Tietze¹, A. Haraldsen¹, S. Kramer¹, H. Zacho², P. Borghammer¹; ¹Aarhus University Hospital, Aarhus, DENMARK, ²Aalborg University Hospital, Aarhus, DENMARK.

P125

Diagnostic Accuracy of 18F-FDG PET-CT for Detection of Primary Tumors in Patients with Cervical Metastases of Unknown Origin

A. Serrano Palacio¹, M. Cabrera Martín², C. Riola Parada¹, O. Salsidua Arroyo¹, M. Pedrera Canal¹, M. Martínez de Bourio¹, E. Cala Zuluaga¹, M. García García-Esquinas¹, J. Carreras Delgado²; ¹Nuclear Medicine Department. Hospital Clínico San Carlos, Madrid, SPAIN, ²Nuclear Medicine Department. Hospital Clínico San Carlos. Universidad Complutense, Madrid, SPAIN.

P126

Multiparametric Comparative Analysis of Positron Emission Tomography, Difussion Weighted Imaging and Difussion Tensor Imaging at 3T MRI: An Attempt to Provide More Accurate Data in Lung Cancer Patients Diagnosis

S. Lucic¹, I. Djan¹, M. Bjelan¹, S. Pena-Karan², A. Peter¹, O. Sveljo¹, D. Kozic¹, M. A. Lucic¹; ¹Oncology Institute of Vojvodina, Sremska Kamenica, Novi Sad, SERBIA, ²Institute of Pulmonary Diseases of Vojvodina, Sremska Kamenica, Novi Sad, SERBIA.

P127

The distribution of F-18-labeled Histone deacetylase inhibitor (HDACi) by PET/CT imaging

C. Y. Hu; Institute of Nuclear Energy Research, Taoyuan, TAIWAN.

P128

Value of Metabolic and Volumetric Indices of 18F-FDG PET-CT for the Prediction of Neoadjuvant Chemotherapy Outcomes in Locally Advanced Breast Cancer

O. Salsidua-Arroyo¹, M. García García-Esquinas², A. Jiménez-Ballvé¹, M. N. Cabrera-Martín^{1,3}, A. Ortega Candil¹, C. Rodríguez Rey¹, M. J. Pérez-Castejón^{1,3}, A. Serrano-Palacio¹, J. L. Carreras-Delgado^{1,3}; ¹Nuclear Medicine Department, Hospital Clínico San Carlos, Madrid, SPAIN, ²Nuclear Medicine Department/Radiology Department, Hospital Clínico San Carlos, Madrid, SPAIN, ³Nuclear Medicine Department, Hospital Clínico San Carlos, Universidad Complutense, Madrid, SPAIN.

P129

Assessment of bone healing in allogenic sternal graft with 18F-Fluoride PET/CT

S. Diodato¹, I. Sandler¹, S. De Vivo¹, H. Sviridenka¹, A. Dell'Amore², V. Pettinato¹, P. Guidalotti¹, F. Stella², S. Fanti¹; ¹Nuclear Medicine, Policlinico S.Orsola-Malpighi, University of Bologna, Bologna, ITALY, ²Thoracic Surgery Unit, Policlinico S.Orsola-Malpighi, University of Bologna, Bologna, ITALY.

P130

The effect of urinary activity on radiation dose in patients undergoing PET/BT

S. S. Gul¹, O. Dilek Ciftci², Z. Hasbek³, B. Ozturk¹, T. Sahiner²; ¹Gaziosmanpasa University Medicine Faculty, Tokat, TURKEY, ²The Ministry Of Health, Public Hospitals Association, Istanbul, TURKEY, ³Cumhuriyet University Medicine Faculty, Sivas, TURKEY.

P131

Partial Volume Effect Impact On PET Preclinical Dosimetry: An Analytical Simulation Study

A. Seret¹, M. Bahri¹, C. Comtat^{2,3,4}, F. Bretin¹, A. Plenevaux¹; ¹University of Liege, Liege, BELGIUM, ²CEA, DSV, I2BM, SHFJ, Orsay, FRANCE, ³UMR 1023 Inserm/CEA/Université Paris Sud, Orsay, FRANCE, ⁴ERL 9218 CNRS, Orsay, FRANCE.

P132

Normal SUV values measured from Ga-68 labeled somatostatin analogue DOTATE PET/CT in patients with neuroendocrine tumors

U. Elboga¹, H. Komek², M. Basibuyuk¹, S. Altindag², Y. Celen¹; ¹Gaziantep University, Gaziantep, TURKEY, ²Diyarbakır Training and Research Hospital, Nuclear Medicine Department, Diyarbakır, TURKEY.

P133

Detection of gastrointestinal cancer using 4'-[methyl-11C] thiothymidine PET/CT for proliferation imaging: comparison with 18F- FDG PET/CT

Y. Fukuda¹, Y. Yamamoto¹, H. Yamamoto², R. Ishikawa³, S. Akamoto⁴, J. Toyohara⁵, Y. Nishiyama¹; ¹Department of Radiology, Kagawa University, Kita-gun Kagawa, JAPAN, ²Department of Medical Physics, Kagawa University, Kita-gun Kagawa, JAPAN, ³Department of Diagnosis Pathology, Kagawa University, Kita-gun Kagawa, JAPAN, ⁴Department of Gastroenterological Surgery, Kagawa University, Kita-gun Kagawa, JAPAN, ⁵Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, Tokyo, JAPAN.

P134

Lung invasive fungal infection (IFI) in acute myeloid leukemia (AML) patients: has 18-FDG-PET/CT an additional role with respect to CT scan?

L. Baratto¹, F. Elisei², C. Crivellaro^{1,2,3}, E. De Ponti⁴, L. Verga⁵, F. Farina⁶, C. Dolci³, C. Zarcone¹, L. Guerra², C. Landoni¹; ¹Department of Nuclear Medicine, University of Milan-Bicocca, Milan, ITALY, ²Department of Nuclear Medicine, San Gerardo Hospital, Monza, ITALY, ³Tecnomed Foundation, University of Milan-Bicocca, Milan, ITALY, ⁴Department of Medical Physics, San Gerardo Hospital, Monza, ITALY, ⁵Department of Haematology, San Gerardo Hospital, Monza, ITALY, ⁶Department of Haematology, University of Milan-Bicocca, Milan, ITALY.

P135

Prognostic value of post-treatment 18F-FDG PET/CT imaging in patients undergoing radio-chemotherapy for inoperable lung cancer.

H. Sviridenka, S. Diodato, S. Sanfilippo, S. Cambioli, E. Tabacchi, C. Nanni, P. Castellucci, S. Fanti; Nuclear Medicine, Policlinico S.Orsola-Malpighi; University of Bologna, BOLOGNA, ITALY.

P136

Comparison of C-11 Choline and C-11 Acetate PET/CT imaging for tumor detection and localization in patients with prostate cancer

R. Haloi, L. G. Jordan, III, B. J. Kemp, N. Tosakulwong, S. D. Weigand, M. Nathan, R. C. Murphy, E. D. Kwon, V. J. Lowe; Mayo Clinic, Rochester, MN, UNITED STATES.

P137

Biodistribution of Ga-68 labelled PSMA ligand in normal tissues with PET/CT imaging

H. Komek¹, U. Elboga², C. Can¹, M. Basibuyuk², Y. Celen²; ¹Diyarbakır Training and Research Hospital, Nuclear Medicine Department, Diyarbakır, TURKEY, ²Gaziantep University, Department of Nuclear Medicine, Gaziantep, TURKEY.

P138

Metabolic Tumor Volume and Total Lesion Glycolysis in 18F-FDG PET-CT Studies. Are they Useful to Predict Recurrence in Locally Advanced Breast Cancer Patients?

O. Salsidua-Arroyo¹, A. Jiménez-Ballvé¹, M. García García-Esquinas², C. Rodríguez Rey¹, A. Ortega Candil¹, M. Pedrera-Canal¹, J. A. García Saenz³, C. Riola-Parada¹, J. L. Carreras-Delgado⁴; ¹Nuclear Medicine Department. Hospital Clinico San Carlos, Madrid, SPAIN, ²Nuclear Medicine Department/ Radiology Department. Hospital Clinico San Carlos, Madrid, SPAIN, ³Oncology Department. Hospital Clinico San Carlos, Madrid, SPAIN, ⁴Nuclear Medicine Department. Hospital Clinico San Carlos. Universidad Complutense Madrid, Madrid, SPAIN.

P139

Comparison between FDG-PET and DWIBS in Diagnosing Neuroblastoma of Child

H. Ishiguchi, S. Ito, Y. Sakurai, H. Kawai, K. Kato, S. Naganawa, A. Hama, H. Muramatsu, Y. Takahashi, S. Kojima; Nagoya University Graduate School of Medicine, Nagoya, JAPAN.

P140

18FDG PET/CT in initial staging of lung cancer : experience of a tertiary medical center in Casablanca Morocco

S. Taleb, G. Cherkaoui Salhi, M. Ait Idir, S. Choukry, A. Guensi; Nuclear Medicine Department, Casablanca, MOROCCO.

P141

Associations between brain global hypometabolism and various clinical parameters in healthy subjects

H. Nam¹, S. Jun²; ¹Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, KOREA, REPUBLIC OF, ²Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, KOREA, REPUBLIC OF.

P142

Assessment of heart injury induced by radiation therapy for esophageal cancer using FDG-PET/CT

K. Hanaoka, M. Hosono, M. Inada, K. Sakaguchi, K. Shimomura, M. Tamura, K. Matsumoto, H. Monzen, Y. Nishimura; Kinki University, Osaka Sakai-city, JAPAN.

P143

Molecular imaging of HER2 positive tumor cell by HER2 specific 18F-labeled aptamer

h. kim, Y. Cho, J. Chae, J. Park, W. Kang; yuhs, Seoul, KOREA, REPUBLIC OF.

P144

F-18 FDG PET metabolic parameters in nasopharyngeal carcinoma patients with and without distal metastases

W. Huang¹, K. Lee², S. Li³, Y. Kuo⁴, L. Wong¹, K. Ma⁴, C. Cheng⁴, B. Hsieh², M. Chen³; ¹Departments of Nuclear Medicine, Changhua Christian Hospital, Changhua, TAIWAN, ²Departments of Medical Imaging and Radiological Sciences, Central Taiwan University of Science and Technology, Taichung, TAIWAN, ³Departments of Otorhinolaryngology, Changhua Christian Hospital, Changhua, TAIWAN, ⁴Departments of Biology and Anatomy and Nuclear Medicine, National Defense Medical Center, Taipei, TAIWAN.

P145

Study of game-theoretical image segmentation algorithm for PET imaging

D. Borys, D. Pierscinska, M. Danch-Wierzchowska; Silesian University of Technology, Gliwice, POLAND.

P146

Investigation of how the activity quantification using different blood pool volume of interests and reconstruction methods influence the absolute myocardial blood flow determined with 13N-NH3 cardiac PET

S. Akil¹, F. Hedeer¹, J. Jögi¹, H. Engblom¹, C. Hindorf²; ¹Dept of Clinical Physiology, Lund University, Lund University Hospital, Lund, SWEDEN, ²Radiation Physics, Skåne University Hospital, Lund, SWEDEN.

P08

Sunday, October 11, 2015

16:00 – 16:30

Molecular & Multimodality Imaging: Preclinical Studies

P147

PET probe detecting acquired drug resistance against EGFR targeted molecular therapy

A. Makino^{1,2}, A. Miyazaki², A. Tomoike², H. Kimura², M. Hirata³, Y. Ohmomo³, M. Ono², H. Okazawa¹, Y. Kiyono¹, H. Saji²; ¹University of Fukui, Eiheiji-cho, Yoshida-gun, Fukui, JAPAN, ²Kyoto University, Kyoto, JAPAN, ³Osaka University of Pharmaceutical Sciences, Takatsuki, Osaka, JAPAN.

P148

PET with 89Zr-anti-MT1-MMP in an orthotopic mouse model of pancreatic ductal adenocarcinoma

M. A. Morcillo¹, A. Garcia-Lucas¹, F. Mulero², P. P. Lopez-Casas², M. Oteo¹, E. Romero¹, A. Martínez¹, A. G. Arroyo³, M. Hidalgo², J. Martínez-Torrecuadrada²; ¹CIEMAT, Madrid, SPAIN, ²CNIO, Madrid, SPAIN, ³CNIC, Madrid, SPAIN.

P149

Evaluation on pancreatic tumor model of 68Ga-labeled somatostatin derivatives using SnCl₂-based 68Ge/68Ga generator

S. Pesnel¹, D. Prince², C. Naidoo², S. Bénard¹, V. Méneyrol¹, F. Gimié¹, E. Jestin^{1,3,4}; ¹GIP CYROI, Saint Denis, RÉUNION, ²iThemba LABS, Somerset West, SOUTH AFRICA, ³Inserm, UMR 1188 Diabète athérombose Thérapies Réunion Océan Indien (DéTROl), plateforme CYROI, Saint Denis, RÉUNION, ⁴Université de La Réunion, UMR 1188, Saint Denis, RÉUNION.

P150

In vivo SPECT of neuro-endocrine tumour on chicken CAM

J. de Swart, S. J. Koelewijn, M. R. Bernsen, A. M. Bahnerth, R. S. de Bruijn, M. de Jong; Erasmus MC, Rotterdam, NETHERLANDS.

P151

X-Ray CT Imaging of Stomach Passage of Contrast-Enhanced Floating Tablets in a New Rat Model

D. Mathe¹, F. Budan^{1,2}, S. Pal³, I. Kiss², P. Dios², K. Szigeti⁴; ¹CROmed Ltd, Budapest, HUNGARY, ²Dept. Public Health Medicine, University of Pecs, Pecs, HUNGARY, ³Institute of Pharmaceutical Technology and Biopharmacy, University of Pecs, Pecs, HUNGARY, ⁴Dept. Biophysics and Radiation Biology Semmelweis University, Budapest, HUNGARY.

P152

Is enteral radioiodine administration the best route for radiotherapy in thyroid diseases? A preclinical study.

K. Chatti^{1,2}, T. Pourcher^{3,1,2}, J. Guglielmi^{1,2}, J. Darcourt^{4,1,2}; ¹UNS, Nice, FRANCE, ²TIRO, Nice, FRANCE, ³CEA, Nice, FRANCE, ⁴CAL, Nice, FRANCE.

P153

Investigation of 18FDG uptake in common carp (Cyprinus carpio) using PET/CT imaging

G. Trencsényi¹, S. Zaheri-A², R. Csipkés², A. Forgács¹, I. Komlosi², I. Garai¹; ¹University of Debrecen/Scanomed Ltd., Debrecen, HUNGARY, ²University of Debrecen, Department of Animal Husbandry, Debrecen, HUNGARY.

P154

The role of ADAMTS-12 gene on the pathogenesis of radioiodine-induced salivary gland damage

M. Sadic¹, M. Korkmaz¹, S. S. Gültekin², K. Demircan³; ¹Ministry of Health Ankara Training and Research Hospital, ANKARA, TURKEY, ²Kastamonu School of Medicine, Hacettepe University and Ministry of Health Diskapi Training and Research Hospital, ANKARA, TURKEY, ³Turgut Ozal University, School of Medicine, Department of Molecular Biology, ANKARA, TURKEY.

P155

Impact of quantification accuracy on dosimetric calculations in small animal preclinical imaging: a study in sodium/iodide symporter (NIS) radiotracers

K. Chuamsaamarkkee^{1,2}, P. J. Blower¹, L. Livieratos^{1,3}; ¹King's College London, Division of Imaging Sciences and Biomedical Engineering, London, UNITED KINGDOM, ²Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, THAILAND, ³Nuclear Medicine Dept, Guy's & St Thomas' Hospitals NHS Foundation Trust, London, UNITED KINGDOM.

P156

Preclinical Dosimetric Comparison of 186Re- and 188Re-perrhenate versus 131I-Nal for Treatment of Non-thyroidal NIS-expressing Tumour

K. Chuamsaamarkkee^{1,2}, S. Diocou¹, P. J. Blower¹, L. Livieratos^{1,3}; ¹King's College London, Division of Imaging Sciences and Biomedical Engineering, London, UNITED KINGDOM, ²Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine Ramathibodi Hospital, Bangkok, THAILAND, ³Nuclear Medicine Dept, Guy's & St Thomas' Hospitals NHS Foundation Trust, London, UNITED KINGDOM.

P157

Quantitative Imaging of ⁸⁹Zr on a pre-clinical PET/CT system

A. Fenwick^{1,2}, C. Marshall^{3,1}, E. Spezi^{4,1}, W. Evans^{3,1}, L. Johansson²; ¹Cardiff University School of Medicine, Cardiff, UNITED KINGDOM, ²National Physical Laboratory, Teddington, UNITED KINGDOM, ³Wales Research & Diagnostic Positron Emission Tomography (PET) Imaging Centre, Cardiff, UNITED KINGDOM, ⁴Velindre NHS Trust, Cardiff, UNITED KINGDOM.

P158

Biodistribution study of EGFR targeting monoclonal antibody [177Lu]-Nimotuzumab

M. Kropacek, M. Tomeš, K. Kontrová, J. Zimová, M. Mirzajevová, F. Melichar; RadioMedic Ltd., REZ, CZECH REPUBLIC.

P159

Synthesis and evaluation of Gallium-68 labeled Fe₃O₄ - Citric acid nanoparticles for dual modality.

B. Cho¹, M. Moon¹, J. Lee², J. Park², M. Hur², K. Yu¹; ¹Dongguk university-seoul, Seoul, KOREA, REPUBLIC OF, ²Korea Atomic Energy Research Institute, Jeongseup, KOREA, REPUBLIC OF.

P160

High Frequency Ultrasound for the development of an Orthotopic mouse model of Human Follicular Thyroid Carcinoma.

S. Albanese^{1,2}, L. Auletta³, A. Zannetti⁴, G. Di Maro³, P. Mirabelli³, C. D'Alterio⁵, G. Salvatore^{2,3,6}, A. Soricelli^{3,6}, M. Salvatore³, A. Greco^{7,2}; ¹Università Parthenope, Naples, ITALY, ²Ceinge, Biotecnologie Avanzate, Scarl, Naples, ITALY, ³IRCCS-SDN, Naples, ITALY, ⁴Istituto di Biostrutture e Bioimmagini – CNR, Naples, ITALY, ⁵Dipartimento di Immunologia Oncologica- Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione Giovanni Pascale"-IRCCS, Naples, ITALY, ⁶Dipartimento di Scienze Motorie e del Benessere, Università Parthenope, Naples, ITALY, ⁷Dipartimento di Scienze Biomediche Avanzate, Università degli studi di Napoli Federico II, Naples, ITALY.

P161

PET and SPECT imaging of breast cancer xenografts using optimized CMKLR1-targeted DOTA-conjugated peptide tracers

S. Poenick¹, N. Beindorff², E. Koziolk², J. Castillo Gómez², I. Apostolova², R. Michel², S. Hallmann¹, A. Wagener¹, V. Prasad², S. Bandholtz¹, P. Schulz¹, B. Wiedenmann¹, W. Brenner¹, C. Gröttinger¹; ¹Charité - Universitätsmedizin Berlin, Gastroenterology, Berlin, GERMANY, ²Charité - Universitätsmedizin Berlin, Nuclear Medicine, Berlin, GERMANY.

P162

Comparison of murine and chimeric version of the anti-CD37 antibody HH1 used for antibody-radionuclide-conjugate (ARC) therapy of Non-Hodgkin Lymphoma

J. Dahle¹, A. Repetto-Llamazares¹, K. B. Melhus¹, A. O'Shea¹, R. Generalov¹, J. Andersen², H. Heyerdahl¹; ¹Nordic Nanovector ASA, OSLO, NORWAY, ²Oslo University Hospital, OSLO, NORWAY.

P163

In vivo evaluation of inhibitory role of microRNA on glucose transporter by micro-PET in hepatocellular carcinoma xenografts

L. Kang; Peking University First Hospital, BEIJING, CHINA.

P164

18F-FES and 18F-FDG micro-PET/CT imaging for the evaluation of nanovectorized radiotherapy with 188Re in a murine model of endometrial cancer.

C. Lefebvre-Lacoeuille^{1,2,3}, A. Genin^{1,3}, F. Bouchet^{1,4}, N. Chouin^{5,6}, A. Croué¹, L. Preisser^{1,7}, F. Hindré^{2,8,1}, P. Descamps^{1,3}, O. F. Couturier^{1,2,4}, F. Lacoeuille^{1,2,4}; ¹LUNAM Université, Angers, FRANCE, ²Inserm UMR5_1066 MINT, Angers, FRANCE, ³Department of Obstetrics and Gynaecology, CHU Angers, Angers, FRANCE, ⁴Nuclear Medicine Department, CHU Angers, Angers, FRANCE, ⁵LUNAM Université, Nantes, FRANCE, ⁶AMaROC, ONIRIS, Nantes, FRANCE, ⁷Inserm U892, Angers, FRANCE, ⁸PRIMEX Plateforme de Radiobiologie et d'Imagerie Expérimentale, Angers, FRANCE.

P165

PET imaging of CD-30 positive lymphomas using radiolabelled antibodies.

S. Rylova^{1,2,3}, C. Klingeborg¹, L. Del Pozzo^{1,2,3}, R. Tonnesmann¹, A. Illert¹, P. T. Meyer^{1,2,3}, H. Maecke¹, J. P. Holland^{1,2,3}; ¹Freiburg University Hospital, Freiburg, GERMANY, ²DKTK, Heidelberg, GERMANY, ³DKFZ, Heidelberg, GERMANY.

P166

Imaging of CDH17-positive gastric cancer xenografts with 64Cu-labeled anti-CDH17 IgG PET.

K. Fujiwara¹, K. Koyama¹, K. Suga², M. Takahashi¹, O. Kusano-Arai³, K. Mitsui³, H. Akiba⁴, H. Iwanari³, K. Tsumoto⁴, T. Hamakubo³, T. Momose¹; ¹Department of Radiology, Graduate School of Medicine, The University of Tokyo, Tokyo, JAPAN, ²SANKYO LABO SERVICE Co., Ltd., Tokyo, JAPAN, ³Department of Quantitative Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, JAPAN, ⁴Department of Bioengineering, School of Engineering, The University of Tokyo, Tokyo, JAPAN.

P167

Preclinical evaluation of a novel bombesin peptide analog for targeting bombesin receptor expressing tumors

S. Okarvi, I. Jammaz; King Faisal Specialist Hospital & Research Centre, Riyadh, SAUDI ARABIA.

P168

Monitoring of re-differentiation effect of radio-iodine refractory thyroid cancer using the new tracer F-18-TFB

J. Nagarajah, A. Boländer, C. Irwin, J. A. Fagin, W. A. Weber; MSKCC, New York, NY, UNITED STATES.

P169

18F-FLT versus 18F-FDG for the assessment of therapeutic response to a BRAF inhibitor in a melanoma xenograft model

L. S. Vercellino¹, A. Martineau¹, C. Lebbé^{2,3}, E. Barré¹, F. Cartigny¹, S. Mourah^{4,3}, P. Merlet^{1,3}; ¹Service de Médecine Nucléaire Hôpital Saint Louis Assistance Publique Hôpitaux de Paris, Paris, FRANCE, ²Service d'Onco-dermatologie Hôpital Saint Louis, Paris, FRANCE, ³Université Paris-Diderot, Paris, FRANCE, ⁴Laboratoire de Pharmacologie Génétique Hôpital Saint Louis, Paris, FRANCE.

P170

Evaluation of 99mTc-duramycin for imaging conatumumab-induced tumor apoptosis: a comparative study with 18F-FDG

F. Elvas^{1,2}, C. Vangestel^{1,2}, N. Challouk¹, K. Y. Pak³, S. Staelens¹, S. Stroobants^{1,2}, L. wyffels^{1,2}; ¹University of Antwerp, Wilrijk, BELGIUM, ²University Hospital Antwerp - Department of Nuclear Medicine, Edegem, BELGIUM, ³Molecular Targeting Technologies, Inc., West Chester, PA, UNITED STATES.

P171

Development of short and specific MC1R-targeted DOTA-conjugated peptide tracers for PET imaging of melanoma xenografts

J. Körner¹, J. Castillo Gómez², N. Beindorff², E. Koziolk², V. Prasad², B. Wiedenmann¹, W. Brenner², C. Gröttinger¹; ¹Charité - Universitätsmedizin Berlin, Gastroenterology, Berlin, GERMANY, ²Charité - Universitätsmedizin Berlin, Nuclear Medicine, Berlin, GERMANY.

P172

Evaluation of [18F]BR420 and [18F]BR351 as potential PET radiotracers for MMP-9 imaging in a colorectal cancer tumor model

N. Vazquez^{1,2}, S. Missault¹, C. Vangestel^{1,2}, D. Thomae^{1,2}, P. Van Der Veken¹, S. Staelens¹, S. Dedeurwaerdere¹, w. Leonie²; ¹University of Antwerp, Antwerp, BELGIUM, ²University Hospital Antwerp, Antwerp, BELGIUM.

P173

Estimation of tumour volumes by [11C]MeAIB and [18F]FDG PET in an orthotopic glioblastoma model

C. Aaberg-Jessen¹, B. Halle^{2,3,4}, H. Thisgaard^{1,4}, S. Hvidsten¹, J. H. Dam¹, A. S. Thykjaer⁴, P. F. Høilund-Carsen^{1,4}, M. K. Schulz², C. Andersen², B. W. Kristensen^{3,4}; ¹Odense University Hospital, Department of Nuclear Medicine, Odense, DENMARK, ²Odense University Hospital, Department of Neurosurgery, Odense, DENMARK, ³Odense University Hospital, Department of Pathology, Odense, DENMARK, ⁴University of Southern Denmark, Institute of Clinical Research, Odense, DENMARK.

P174

Identification of a set of imaging procedures for the accurate assessment of tumour progression and response to treatment in a Glioma animal model.

C. Martelli^{1,2}, S. Valtorta^{3,4}, L. S. Politi⁵, R. Isabella^{4,6}, D. Cecilia^{7,8}, B. Sara^{3,4}, S. Sudati⁴, G. Di Grigoli^{4,3}, G. Lucignani^{9,10,2}, R. M. Moresco^{3,6}, L. Ottobri^{7,2,3}; ¹University of Milan, Segrate, ITALY, ²Centre of Molecular and Cellular Imaging-IMAGO, University of Milan, Segrate, ITALY, ³IBFM-CNR, Segrate, ITALY, ⁴Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milano, ITALY, ⁵Neuroradiology Department & Neuroradiology Research Group, IRCCS San Raffaele Scientific Institute, Milano, ITALY, ⁶Department of Health Sciences, University of Milano-Bicocca, Milano, ITALY, ⁷Department of Medical-Surgical Physiopathology and Transplants, University of Milan, Segrate, ITALY, ⁸Supported by a fellowship from the Doctorate School of Molecular Medicine, University of Milan, Segrate, ITALY, ⁹Department of Health Sciences, University of Milan, Milano, ITALY, ¹⁰San Paolo Hospital, Department of Diagnostic Services, Unit of Nuclear Medicine, Milano, ITALY.

P175

Longitudinal evaluation with High Frequency Ultrasound imaging of response to CXCR4 new cyclic peptide antagonist with conventional chemotherapy in colorectal cancer mice model

A. Greco^{1,2}, C. D'Alterio³, L. Auletta⁴, S. Albanese^{5,2}, M. Napolitano³, L. Portella³, S. Santagata³, C. Ieranò³, A. Brunetti¹, S. Scala³, A. Zannetti⁶; ¹Dipartimento di Scienze Biomediche Avanzate, Università degli studi di Napoli Federico II, Napoli, ITALY, ²CEINGE scari, Naples, ITALY, ³National Cancer Institute, "Fondazione G. Pascale", Napoli, ITALY, ⁴IRCCS SDN, Napoli, ITALY, ⁵Università degli Studi di Napoli Parthenope, Napoli, ITALY, ⁶Institute of Biostructures and Bioimages of the National Council of Research, Napoli, ITALY.

P176

Establishment of a Chinese Lung Adenocarcinoma Cell Line CPA-Yang1 with Osteolytic, Brian Metastases Properties by Molecular Imaging

C. Chang, B. Lei, C. Liu, J. Cao, G. Tao, G. Tao, W. Xie, W. Xie, S. Yang, S. Yang; Shanghai Chest Hospital, Shanghai, CHINA.

P177

Development of a DOTA-conjugated peptide tracer targeted against gastric inhibitory polypeptide (GIP) receptor for PET imaging of neuroendocrine tumor xenografts

J. Körner¹, J. Castillo Gómez², N. Beindorff², E. Koziolk², V. Prasad², B. Wiedenmann¹, W. Brenner², C. Gröttinger¹; ¹Charité - Universitätsmedizin Berlin, Gastroenterology, Berlin, GERMANY, ²Charité - Universitätsmedizin Berlin, Nuclear Medicine, Berlin, GERMANY.

P178

Biological characterisation and [¹⁸F]FDG microPET/CT monitoring of relevant orthotopic preclinical models of malignant pleural mesothelioma

D. J. Colin¹, C. D'Amato-Brito², S. Germain¹, F. Triponez², Y. Seimille³, V. Serre-Beinier²; ¹Centre for Biomedical Imaging, University of Geneva, Geneva, SWITZERLAND, ²Thoracic Surgery Unit, University Hospitals and University of Geneva, Geneva, SWITZERLAND, ³Cyclotron Unit, University Hospitals of Geneva, Geneva, SWITZERLAND.

P179

The impact of single or dual NEP/ACE-inhibition on the performance of 99mTc-labeled neurotensins in mice bearing human WiDr xenografts

T. Maina¹, A. Kaloudi¹, E. Lymperis¹, A. Tatsi¹, E. P. Krenning², M. de Jong^{2,3}, B. A. Nock¹; ¹Molecular Radiopharmacy, INRASTES, NCSR Demokritos, ATHENS, GREECE, ²Institute of Nuclear Medicine, Erasmus MC, ROTTERDAM, NETHERLANDS, ³Institute of Radiology, Erasmus MC, Rotterdam, NETHERLANDS.

P180

μPET as non-invasive read-out for a novel human organotypic lung tumor model

D. Fecher¹, G. Dandekar¹, S. Nietzer¹, R. A. Bundschuh², H. Walles¹, A. K. Buck³, M. Steinke¹, K. Lücknerath³; ¹Uniklinik Würzburg, Department of Tissue Engineering and Regenerative Medicine, Würzburg, GERMANY, ²Uniklinik Bonn, Nuclear Medicine, Bonn, GERMANY, ³Uniklinik Würzburg, Nuclear Medicine, Würzburg, GERMANY.

P181

Realistic Multi-cellular Dosimetry for 177Lu labelled Antibodies: Model and Application

S. Marcatili¹, A. Pichard², A. Courteau¹, R. Ladjohounlou², I. Navarro-Teulon², A. Repetto-Llamazares³, H. Heyerdahl³, J. Dahle³, J. Pouget², M. Bardiès¹; ¹Centre de Recherche en Cancérologie de Toulouse, UMR 1037 INSERM, Toulouse, FRANCE, ²Institut de Recherche en Cancérologie de Montpellier, U 1194 INSERM, Montpellier, FRANCE, ³Nordic Nanovector ASA, Kjelsåsveien 168, Oslo, NORWAY.

P182

Development of 47Scandium-Bleomycin and estimation of absorbed dose as an antibiotic tumor seeking radiopharmaceutical

L. Moghaddam-Banaem; Amirkabir Technical University, Tehran, IRAN, ISLAMIC REPUBLIC OF.

P183

The effect of 1-day melatonin and pulse magnetic field administration on PET/CT scan and testicular scintigraphy in a rat model of testicular torsion-detorsion

S. S. Gul, M. Uysal, S. Gurgul, F. Erdemir; Gaziosmanpasa university medicine faculty, Tokat, TURKEY.

P184

Enhancing the effect of radiotherapy in cultured tumour cells using p53 therapy

*A. C. Mortensen¹, D. Spiegelberg¹, A. M. Scott², D. P. Lane³, M. Nestor^{1,4}; ¹Department of Immunology, Genetics and Pathology, Uppsala, SWEDEN, ²Ludwig Institute for Cancer Research, Olivia Newton-John Cancer Research Institute, and La Trobe University, Melbourne, Victoria, AUSTRALIA, ³p53Lab, Agency for Science Technology and Research (A*STAR), Singapore, SINGAPORE, ⁴Department of Surgical Sciences, Uppsala, SWEDEN.*

P185

131I labelled multifunctional dendrimers for targeted SPECT imaging and radiotherapy of cancer

Y. Cheng¹, J. Zhu², L. Zhao¹, Y. Tang³, X. Shi², J. Zhao¹; ¹Department of Nuclear Medicine, Shanghai General Hospital, Shanghai Jiaotong University, shanghai, CHINA, ²State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, Donghua University, shanghai, CHINA, ³Experiment Center, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, shanghai, CHINA.

P187

The effect of omeprazole usage on the viability of random pattern skin flaps in rats

H. Sen¹, M. Oruc¹, V. M. Isik¹, M. Sadic², H. Sayar³, M. Korkmaz², U. Kocer¹; ¹Department of Plastic and Reconstructive Surgery, Ministry of Health Ankara Training and Research Hospital, ANKARA, TURKEY, ²Ministry of Health Ankara Training and Research Hospital, ANKARA, TURKEY, ³Kahramanmaraş Sutcu Imam University, Department of Pathology, Kahramanmaraş, TURKEY.

P09 Sunday, October 11, 2015

16:00 – 16:30

Molecular & Multimodality Imaging: Optical Imaging

P188

Ex Vivo Perfusion of Tumorous Kidneys with a Dual-Modality Tumor-Targeting Imaging Probe

M. Hekman, P. Mulders, M. de Weijert, D. Bos, E. Oosterwijk, H. Langenhuis, O. Boerman, M. Rijpkema; Radboudumc, Nijmegen, NETHERLANDS.

P189

Intraoperative fluorescence guidance under ambient light conditions using a new modified fluorescence camera

N. S. van den Berg^{1,2}, G. H. KleinJan^{1,2}, M. Miwa³, T. Sato³, Y. Maeda³, B. Karakullukcu², S. Horenblas², F. W. B. van Leeuwen^{1,2}; ¹LUMC, Leiden, NETHERLANDS, ²AVL-NKI, Amsterdam, NETHERLANDS, ³Hamamatsu Photonics KK, Hamamatsu, JAPAN.

P190

Hybrid guidance towards the sentinel node; a comparison of fluorescence- and blue dye- based optical detection in 458 patients

G. KleinJan^{1,2}, N. S. Van den Berg^{1,2}, E. Van Werkhoven², J. A. Van der Hage², S. Horenblas², W. M. N. Klop², R. A. Valdes Olmos², F. W. B. Van Leeuwen¹; ¹Leiden University Medical Centre, Leiden, NETHERLANDS, ²NKI-AVL, Amsterdam, NETHERLANDS.

P191

Fluorescent lectins for peripheral nerve visualization during surgery

G. H. KleinJan, D. M. Van Willigen, M. N. Van Oosterom, F. W. B. Van Leeuwen, T. Buckle; Leiden University Medical Centre, Leiden, NETHERLANDS.

P192

Evaluation of the optical and physical properties of symmetric NIR dyes towards intraoperative fluorescent markers

S. van der Wal, J. Kuil, R. R. P. M. Valentijn, F. W. B. van Leeuwen; Leiden University Medical Center, Leiden, NETHERLANDS.

P193

(Near-infrared) fluorescence guidance during surgery: What is the detection limit?

G. H. KleinJan^{1,2}, A. Bunschoten¹, T. Engelen¹, N. S. van den Berg^{1,2}, R. A. Valdés Olmos^{1,2}, H. Wester³, F. W. B. van Leeuwen^{1,2}; ¹LUMC, Leiden, NETHERLANDS, ²AVL-NKI, Amsterdam, NETHERLANDS, ³TUM, Munich, GERMANY.

P194

Multimodal Optical System from Macro to Micro Bioluminescence Imaging

C. R. Gigliotti, L. Altabella, M. Crippa, A. E. Spinelli; San Raffaele Scientific Institute, Milano, ITALY.

P195

Optical Imaging of Radiation-Induced Light Emission of Luminophores

A. K. Kondakov¹, I. L. Gubskiy¹, E. Y. Prokop'eva¹, I. A. Znamenskiy^{1,2}; ¹Pirogov RNRMU, Moscow, RUSSIAN FEDERATION, ²CCH RAS, Moscow, RUSSIAN FEDERATION.

P10 Sunday, October 11, 2015

16:00 – 16:30

Molecular & Multimodality Imaging: PET/ MRI & SPECT/MRI

P196

The clinical efficacy of endometriosis diagnosis using I-123 MIBG SPECT and MRI image fusion

K. Utsunomiya¹, K. Yasuda², Y. Kono³, Y. Ueno³, S. K. Harkawa³, A. Stundzia⁴, N. Tanigawa³; ¹Department of Radiology, Takii hospital, Kansai Medical University, Moriguchi, JAPAN, ²Department of Gynecology, Takii hospital, Kansai Medical University, Moriguchi, JAPAN, ³Department of Radiology, Kansai Medical University, Hirakata, JAPAN, ⁴Tomographix, Toronto, ON, CANADA.

P197

Simultaneous respiratory gating in PET/MR: clinical quantification of neoplastic lesions and physiological structures

F. G. Barbosa¹, G. Delso², M. Huellner¹, P. Stolzmann¹, E. Ter Voert¹, P. Veit-Haibach¹; ¹Zurich University Hospital, Zuerich, SWITZERLAND, ²GE HEALTHCARE, Zuerich, SWITZERLAND.

P198

Evaluating carotid plaque inflammation in patients with active rheumatoid arthritis (RA) using 3T magnetic resonance imaging (MRI) and Fludeoxyglucose(18F) PET (18FDG-PET) : a pilot study

S. Skeoch^{1,2}, H. A. Williams³, P. Cristinacce⁴, P. Hockings^{5,6}, J. James³, Y. Alexander⁷, J. Waterton⁸, I. Bruce⁹; ¹Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, UNITED KINGDOM, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, University of Manchester, Manchester, UNITED KINGDOM, ³Nuclear Medicine, Manchester, UNITED KINGDOM, ⁴Biomedical Imaging Institute, University of Manchester, Manchester, UNITED KINGDOM, ⁵Drug Safety and Metabolism, AstraZeneca, Mوندal, SWEDEN, ⁶MedTech West, Chalmers University of Technology, Gothenburg, SWEDEN, ⁷Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, UNITED KINGDOM, ⁸Personalised Healthcare and Biomarkers, AstraZeneca, Manchester, UNITED KINGDOM, ⁹Kellgren Centre for Rheumatology, NIHR Manchester, Manchester, UNITED KINGDOM.

P199

Performance of an Ultralow-Dose High-Resolution Pediatric TOF-PET Scanner Based on Monolithic Scintillators

E. Mikhaylova¹, V. Tabacchini², G. Borghi², W. Vogel³, P. Mollet¹, E. D'Hoe¹, D. Schaart², S. Vandenberghe¹; ¹University of Ghent, Ghent, BELGIUM, ²Delft University of Technology, Delft, NETHERLANDS, ³Netherlands Cancer Institute, Amsterdam, NETHERLANDS.

P200

Incorporation of TOF information reduces artifacts in simultaneous TOF PET/MR scanning

E. ter Voert^{1,2}, H. Davison^{1,3}, F. de Galiza Barbosa^{1,2}, M. Huellner^{1,2}, S. Ahn⁴, F. Wiesinger⁵, C. Levin⁶, A. Iagaru⁶, G. Zaharchuk⁶, G. Delso⁷, P. Veit-Haibach^{1,2}; ¹University Hospital Zurich, Zurich, SWITZERLAND, ²University of Zurich, Zurich, SWITZERLAND, ³Royal United Hospitals Bath NHS Foundation Trust, Bath, UNITED KINGDOM, ⁴GE Global Research, Niskayuna, NY, UNITED STATES, ⁵GE Global Research, Munchen, GERMANY, ⁶Stanford University, Stanford, CA, UNITED STATES, ⁷GE Healthcare, Waukesha, WI, UNITED STATES.

P201

Brain PET/MR attenuation correction for pediatric patients

C. Ladefoged, J. B. Andersen, L. Marner, A. E. Hansen, I. Law, L. Højgaard, F. L. Andersen; Dept. of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen, DENMARK.

P202

Combined 18F NaF/18F FDG and TOF simultaneous PET/ MRI: One-Stop Shop Staging of Patients with Breast and Prostate Cancers

R. Minamimoto, A. Loening, P. Obara, V. Taviani, S. S. Gambhir, S. Vasanawala, A. Iagaru; Stanford University School of Medicine, STANFORD, CA, UNITED STATES.

P203

68Ga-DOTATATE PET/CT vs PET/ MRI in neuroendocrine tumours: A comparative study

A. Alshammari, E. Skoura, S. Michopoulou, F. Fraioli, R. Syed, J. Bomanji; Nuclear medicine department, UCL hospital, London, UNITED KINGDOM.

P204

Diagnostic accuracy of whole-body PET/MRI for tumor staging in patients with various cancers: a meta-analysis

G. Shen, A. Kuang; West China Hospital of Sichuan University, Chengdu, CHINA.

P205

Comparison of 18F-FDG-PET/MRI and 18F-FDG-PET/CT for initial staging in pulmonary carcinoma

S. Lütje¹, V. Ruhlmann¹, A. Bellendorf¹, T. D. Poeppel¹, K. Beiderwellen², P. Heusch³, B. M. Schaarschmidt³, H. H. Quick⁴, J. Nagarajah¹, B. Gomez¹; ¹Clinic for Nuclear Medicine, University Hospital Essen, Essen, GERMANY, ²Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, GERMANY, ³Department of Diagnostic and Interventional Radiology, Medical Faculty, University Düsseldorf, Düsseldorf, GERMANY, ⁴High Field and Hybrid MR Imaging, University Hospital Essen, Essen, GERMANY.

P206

Analysis of simultaneous FDG image and DWI acquired with hybrid PET/MRI in thyroid cancer

I. Cho, E. Kong, K. Chun, S. Kwon; Yeungnam University Hospital, Daegu, KOREA, REPUBLIC OF.

P11 Sunday, October 11, 2015

16:00 – 16:30

**Molecular & Multimodality Imaging:
SPECT Tracers and Evaluations**

P207

[123/131I](R)-1-[1-(4-Iodophenyl)ethyl]-1H-imidazole-5-carboxylic acid azetidinyamide (IMAZA) a novel radiotracer for diagnosis and treatment of adrenocortical tumours - first clinical experience

A. Schirbel¹, K. Herrmann¹, C. Bluemel¹, B. Heinze², H. Haenscheid¹, M. Fassnacht², A. K. Buck¹, B. Allolio², S. Hahner²; ¹University Hospital of Wuerzburg; Department of Nuclear Medicine, Wuerzburg, GERMANY, ²University Hospital of Wuerzburg; Endocrinology & Diabetes Unit, Department of Internal Medicine I, Wuerzburg, GERMANY.

P208

Study of Novel Molecular Probe 99mTc-3PRGD2 in Diagnosis of Rheumatoid Arthritis

C. Huang, Q. Zheng, W. Miao; the 1st Affiliated Hospital of Fujian Medical University, Fuzhou, CHINA.

P209

SPECT/Low Dose CT Perfusion Study in the Investigation of Suspected Pulmonary Embolism

T. Pipikos, F. Vlachou, A. Nikaki, K. Dalianis, V. Prassopoulos; Nuclear Medicine Department Hygeia SA, Athens, Marousi, GREECE.

P210

Evaluation Of Cerebral Circulatory Compensation With Tc99m-HMPAO SPECT And Bilateral Transcranial Doppler Monitoring Of Middle Cerebral Artery In Patients With Chronic Carotid Artery Occlusions

I. S. Kostina, A. V. Scherbinin, D. V. Ryzhkova; North-West Federal Research Center, Saint-Petersburg, RUSSIAN FEDERATION.

P211

Comparison of SPECT/CT, SPECT, and Planar Imaging in the Management of Primary Hyperparathyroidism: A Systematic Review and Meta-analysis

W. Wei, Q. Luo; Shanghai Sixth People's Hospital, Shanghai, CHINA.

P212

Nuclear Medicine Imagine of aseptic loosening of joint prostheses: new data

V. Soukhov¹, K. Zaplatnikov²; ¹Military Medical Academy, ST. PETERSBURG, RUSSIAN FEDERATION, ²MAZ Clinic for Nuclear Medicine, Nurnberg, GERMANY.

P213

Evaluation of SPECT/low dose CT Imaging in the assesment of equivocal spine lesions in planar bone scintigraphy

T. Pipikos¹, F. Vlachou¹, A. Nikaki¹, K. Dalianis², R. Efthymiadou³, V. Prassopoulos¹; ¹Nuclear Medicine Department Hygeia SA, Athens, Marousi, GREECE, ²Medical Physics Department, Hygeia S.A., Athens, Marousi, GREECE, ³CT- MRI Department Hygeia SA, Athens, Marousi, GREECE.

P214

Interpolated CT for Respiratory Gated SPECT Attenuation Correction

D. Zhang, C. Y. Ho, G. S. Mok; University of Macau, Taipa, MACAO.

P215

Accuracy of Quantification Methods for Renography with 99mTc-MAG3: A Study on Virtual and Clinical Image Data

I. Cerici¹, J. Bartosik², M. Ljungberg¹, G. Brolin³, M. Sydorff⁴; ¹Medical radiation physics, Lund, SWEDEN, ²Clinical Physiology and Nuclear Medicine, Helsingborg, SWEDEN, ³Medical Radiation physics, Lund, SWEDEN, ⁴Radiation physics, Lund, SWEDEN.

P216

The application of MIBI-Tc99m SPECT/CT scintigraphy in the diagnosis of thyroid - 5 years follow-up.

M. H. Listewnik, H. Piwowarska-Bilska, M. Chosia, K. Jasiakiewicz, A. Dobrowolska, B. Birkenfeld; Pomeranian Medical University in Szczecin, Szczecin, POLAND.

P217

Determination of functional reserve capacity with fusion SPECT-CT examination after hepatic resection

H. Papp, K. Dede, Z. Egyed, F. Salamon, A. Bursics, Z. Galler; Uzsoki Teaching Hospital, Budapest, HUNGARY.

P218

A Pilot Study of 99mTc-3PRGD2 in Diagnosis of Primary Hepatic Carcinoma

Z. Jieliang, M. Weibing; Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University, Fuzhou City, Fujian Province, CHINA.

P219

Utility of 99mTc HYNIC-TOC SPECT/CT in Neuroendocrine tumors

K. Kamaleshwaran, N. Sudhakar, S. Paulvannan, A. Shinto; Kovai medical center and hospital limited, Coimbatore, INDIA.

P220

Impact of hybrid imaging SPECT / CT in the first staging of children's neuroblastoma

I. Meddeb, I. Slim, I. Yeddes, H. Boudriga, A. Mhiri, M. Ben Slimène; Salah Azaiez Institute, Tunis, TUNISIA.

P221

SPECT/CT and planar bone scintigraphy in the evaluation of vascularised graft reconstruction of the mandible; our experience

S. Rodriguez Martinez de Llano, I. Candal Casado, P. Pais Silva; Centro Oncologico de Galicia, Coruña, SPAIN.

P222

Complex 99mTc-PDA-DTPA for myocardial imaging

E. A. Nesterov¹, S. I. Sazonova², V. S. Skuridin¹, S. M. Minin³, E. S. Stasyuk¹, N. V. Varlamova¹, E. A. Ilina¹, A. A. Nesterov⁴, V. I. Otmakhov⁵; ¹Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION, ²Research Institute of Cardiology, Tomsk, RUSSIAN FEDERATION, ³Novosibirsk Research Institute of Circulation Pathology, Novosibirsk, RUSSIAN FEDERATION, ⁴Sibnuclon Ltd, Tomsk, RUSSIAN FEDERATION, ⁵Tomsk State University, Tomsk, RUSSIAN FEDERATION.

P223

Quantification of left ventricular function using gated SPECT with two different automated software packages and cardiac MRI

K. Koyama¹, K. Kubota¹, M. Mochiki¹, T. Ogura¹, H. Hoshizaki¹, S. Oshima¹, T. Higuchi², Y. Tsushima²; ¹Gunma Prefectural cardiovascular center, Maebashi, JAPAN, ²Gunma faculty of medicine, Maebashi, JAPAN.

P224

Value of Hybrid Imaging with 111In-Pentethreotide in Endocrine Tumors

D. Ben Sellem, L. Zaabar, B. Dhaouadi, B. Letaief, M. F. Ben Slimene; Nuclear Medicine Department, Salah Azaiez Institute, Tunis, TUNISIA.

P225

SPECT/CT in metastatic skeletal lesions

O. V. Solodyannikova; Institute of Oncology AMS of Ukraine, KIEV, UKRAINE.

P226

The influence of age, sex and circadian rhythm on kidney function in mice measured by Tc-99m-MAG3 SPECT

K. P. Huang, I. G. Steffen, M. Lukas, C. Lange, C. Rosner, W. Brenner, N. Beindorff; Charite - Universitaetsmedizin Berlin, Berlin, GERMANY.

P227

Preclinical SPECT-CT imaging studies with cyclotron produced Tc-99m

G. Pupillo¹, A. Boschi², P. Martini³, L. Uccelli², M. Pasquali², A. Duatti², G. Di Domenico³, M. Loriggiola¹, M. Giganti², A. Taibi³, M. Gambaccini³, A. Salvini⁴, L. Strada⁴, M. Prata⁴, M. Marengo⁵, G. Lucconi⁵, S. Manenti⁶, F. Gropp⁶, G. Cicoria⁵, M. Bello⁷, N. Uzunov⁸, J. Esposito¹; ¹Legnaro National Laboratories of the Italian Institute of Nuclear Physics (INFN), Legnaro (Padova), ITALY, ²Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, ITALY, ³Department of Physics and Earth Science, University of Ferrara, Ferrara, ITALY, ⁴Applied Nuclear Energy Laboratory and Department of Chemistry, University of Pavia, Pavia, ITALY, ⁵Nuclear Medicine S. Orsola Hospital, Bologna, ITALY, ⁶Accelerator and Applied Superconductivity Laboratory and Physics Department, University of Milano, Milano, ITALY, ⁷Department of Physics and Astronomy, University of Padova, Padova, ITALY, ⁸Faculty of Natural Sciences, Shumen University, Shumen, BULGARIA.

P228

Development of cancer-targeted Nuclear/NIRF/PTT multi-modality theranostic probe

C Peng¹, Y. Shih¹, T. Luo¹, M. Shieh²; ¹Institute of Nuclear Energy Research, Taoyuan, TAIWAN, ²Institute of Biomedical Engineering, National Taiwan University, Taipei, TAIWAN.

P229

Synthesis and Evaluation of a Novel Tc-99m Labeled HGK-containing Hexa-Peptide for Non-Invasive Tumor Imaging

D. Kim¹, W. Kim², M. Kim¹, C. Kim¹; ¹Wonkwang University School Of Medicine, IKSAN, JEOLLABUK-DO, KOREA, REPUBLIC OF, ²Seoul National University Hospital, Jongno-Gu, Seoul, KOREA, REPUBLIC OF.

P230

SPECT/CT Imaging of Radionuclide-carrying Liposomes Predict Therapeutic Effects of Liposomal Anti-cancer Agents in Mouse Xenograft Models

I. O. Umeda¹, K. Ito², S. Hamamichi¹, M. Asano², M. Iwata², J. Matsui², Y. Hori², Y. Funahashi², H. Fujii¹; ¹National Cancer Center, Kashiwa, JAPAN, ²Eisai Co., Ltd., Tsukuba, JAPAN.

P231

Imaging somatostatin receptor expression on macrophages in osteoarthritis models

S. T. van Tiel, J. de Swart, L. Utomo, M. de Jong, M. R. Bernsen; ErasmusMC, Rotterdam, NETHERLANDS.

P12 Sunday, October 11, 2015

16:00 – 16:30

Molecular & Multimodality Imaging: Tumour Biology

P232

The Metabolic Role of Carbenoxolone in Cancer: a Possible Interference in Glucose Metabolism and FDG Uptake Through the Inhibition of the Endoplasmic Reticulum Hexose-6-Phosphate Deydrogenase.

A. Orenzo¹, A. Buschiazzo¹, G. Sambuceti¹, S. Ravera², S. Bruno³, F. Fais³, C. Ghersi¹, G. Bianchi⁴, R. Martella⁴, L. Raffaghello⁴, C. Marini⁵; ¹Nuclear Medicine Unit, Department of Health Sciences, University of Genoa and IRCCS AOU San Martino-IST, Genoa, ITALY, ²Department of Pharmacy, University of Genoa, Genoa, ITALY, ³Department of Experimental Medicine, University of Genoa and IRCCS AOU San Martino-IST, Genoa, ITALY, ⁴Laboratory of Oncology, G. Gaslini Institute, Genoa, ITALY, ⁵CNR Institute of Bioimages and Molecular Physiology, Section of Genoa, Genoa, ITALY.

P233

Inhibiting hexose-6-phosphate dehydrogenase gene expression significantly reduces 18F-fluorodeoxyglucose uptake and cancer cells proliferation in two experimental models of colon and breast carcinoma.

C. Marini¹, G. Sambuceti², S. Bruno³, A. Orenzo², A. Buschiazzo², S. Ravera⁴, A. Democrito², G. Bianchi⁵, L. Raffaghello⁵, G. Caviglia⁶, F. Fais³; ¹CNR Institute of Bioimages and Molecular Physiology, Section of Genoa, Genoa, ITALY, ²Nuclear Medicine Unit, Department of Health Sciences, University of Genoa and IRCCS AOU San Martino-IST, Genoa, ITALY, ³Department of Experimental Medicine, University of Genoa and IRCCS AOU San Martino-IST, Genoa, ITALY, ⁴Department of Pharmacy, University of Genoa, Genoa, ITALY, ⁵Laboratory of Oncology, G. Gaslini Institute, Genoa, ITALY, ⁶Department of Mathematics, University of Genoa, Genoa, ITALY.

P234

The Metabolic Role of Metformin in Cancer: the Divergent Effect Between FDG Kinetic and Glucose Consumption on Cancer Aggressiveness

A. Buschiazzo¹, A. Orenzo¹, S. Ravera², B. Salani³, U. Pfeffer⁴, F. Pastorino⁵, A. Brizzolara⁶, L. Raffaghello⁵, G. Bianchi⁵, F. Bongioanni¹, G. Sambuceti¹, C. Marini⁷; ¹Nuclear Medicine Unit, Department of Health Sciences, University of Genoa and IRCCS AOU San Martino-IST, Genoa, ITALY, ²Department of Pharmacy, University of Genoa, Genoa, ITALY, ³Department of Internal Medicine, University of Genoa, Genoa, ITALY, ⁴Department of Integrated Molecular Pathology, IRCCS AOU San Martino-IST, Genoa, ITALY, ⁵Laboratory of Oncology, G. Gaslini Institute, Genoa, ITALY, ⁶Department of Experimental Medicine, University of Genoa and IRCCS-AOU San Martino-IST, Genoa, ITALY, ⁷CNR Institute of Bioimages and Molecular Physiology, Section of Genoa, Genoa, ITALY.

P235

Cellular uptake and localization of a novel NSCLC penetrating peptide

H. Zhou, P. Dong, H. Cai, X. Wu, L. Li; West China Hospital, Chengdu, CHINA.

P236

Effect of Metformin on Cancer Glucose Metabolism: Correlation Between FDG Escape and Glucose-6-Phosphatase Activity in the Endoplasmic Reticulum.

A. Buschiazzo¹, G. Sambuceti¹, A. Orenzo¹, S. Ravera², F. Fais³, S. Bruno³, E. Monteverde¹, L. Garaboldi¹, G. Bottoni¹, L. Raffaghello⁴, G. Bianchi⁴, M. Piana⁵, S. Garbarino⁵, G. Caviglia⁵, C. Marini⁶; ¹Nuclear Medicine Unit, Department of Health Sciences, University of Genoa and IRCCS AOU San Martino-IST, Genoa, ITALY, ²Department of Pharmacy, University of Genoa, Genoa, ITALY, ³Department of Experimental Medicine, University of Genoa and IRCCS AOU San Martino-IST, Genoa, ITALY, ⁴Laboratory of Oncology, G. Gaslini Institute, Genoa, ITALY, ⁵Department of Mathematics, University of Genoa, Genoa, ITALY, ⁶CNR Institute of Bioimages and Molecular Physiology, Section of Genoa, Genoa, ITALY.

P237

Changes of glycolytic pathway and upregulation of oxidative phosphorylation in BCR-ABL-driven human leukemia cells treated with imatinib

M. Monti¹, V. De Rosa², F. Iommelli², R. Fonti², F. Pane¹, S. Del Vecchio³; ¹Hematology Division, University of Naples "Federico II", Naples, ITALY, ²Institute of Biostructures and Bioimages, National Research Council, Naples, ITALY, ³Department of Advanced Biomedical Sciences, University of Naples, Naples, ITALY.

P238

Glucose metabolism and lactate production in-vitro.

*T. Bach-Gansmo¹, T. V. Bogsrud¹, T. A. Saga², E. Munthe³;
¹Oslo University Hospital, Oslo, NORWAY, ²Norwegian Cyclotron Center, Oslo, NORWAY, ³Oslo Cancer Cluster, OUS, Oslo, NORWAY.*

P239

Papillary thyroid carcinoma tissues and clinical significance of GRIM-19

Z. Zhao, G. Shen, H. Cai; West China Hospital of Sichuan University, Chengdu, CHINA.

P240

Assessment of tumor IGF1- and insulin receptor expression and its linkage to anti-receptor treatment response

M. H. Vendelbo, M. Busk, D. A. Bender, A. B. Iversen, N. Jessen, J. Frøkiær, A. Morsing; Aarhus University Hospital, Aarhus, DENMARK.

P241

Inverse correlation between hexokinase activity and glucose-6-phosphatase activity in ovarian cancer

B. B. Olsen¹, M. H. Vilstrup¹, I. B. G. Johnsen², G. Neumann³, A. Alavi⁴, P. F. Høilund-Carlsen¹; ¹Odense University Hospital, Dept. of Nuclear Medicine, Odense C, DENMARK, ²Odense University Hospital, Dept. of Clinical Pathology, Odense C, DENMARK, ³Odense University Hospital, Dept. Gynaecology and Obstetrics, Odense C, DENMARK, ⁴University of Pennsylvania, Dept. of Radiology, Philadelphia, PA, UNITED STATES.

P13

Sunday, October 11, 2015

16:00 – 16:30

**Radiopharmaceuticals & Radiochemistry:
Radiopharmaceuticals – SPECT**

P242

Production and characterization of chitosan-198Au nanocomposite with high radionuclide purity: A Comparative study on activity of gold-198 and its nanoparticles

M. Aboudzadeh Rovais, M. Sadeghi, M. Sahafipour, F. Bolouri; Nuclear Science and Technology Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF.

P243

Validation of solid phase extraction (SPE) coupled with autoradiochromatography for 99mTc-MAG3 radiochemical purity determination and comparison with traditional TLC

M. Di Franco¹, S. Tamburri², A. Filieri¹, V. Podio²; ¹Ospedale San Luigi Gonzaga, Orbassano (TO), ITALY, ²Università degli Studi, Torino, ITALY.

P244

Production of 81Rb for the 81Rb/81mKr generator by Kr gas tar

M. Aboudzadeh Rovais; Nuclear Science and Technology Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF.

P245

Labelling procedure of autologous leukocytes with 99mTc-HMPAO using Leukokit: Description of our hospital experience

A. Kolindou¹, M. Papachristou², A. Velidaki¹, A. Evagellatou¹, G. Bramis¹, I. Datseris³, E. Kitsiou¹; ¹Nuclear Medicine Department, GHA "LAIKO", Athens, GREECE, ²Nuclear Medicine Department-PET/CT, GHA, Athens, GREECE, ³Nuclear Medicine Department-PET/CT, GHA "Evangelismos", Athens, GREECE.

P246

The experimental study of nano-colloidal radiopharmaceuticals based on modified molecules of DTPA labeled with technetium

S. Sazonova¹, V. S. Skuridin², E. Stasuk³, N. V. Varlamova³, Y. A. Nesterov³, A. S. Rogov³, V. L. Sadkin³, Y. Lishmanov¹, J. N. Ilushenkova¹; ¹Institute of Cardiology, Tomsk, RUSSIAN FEDERATION, ²Politechnical University, Tomsk, RUSSIAN FEDERATION, ³Polytechnic University, Tomsk, RUSSIAN FEDERATION.

P247

Preparation of 99mTc-TRODAT-1 with high specific activity for dopamine transporter imaging of brain

M. Erfani, M. Shafiei; Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), P.O.Box: 14395-836, Tehran, IRAN, ISLAMIC REPUBLIC OF.

P248

Validation of Multidose Protocol of ^{99m}Tc-HMPAO to Label Autologous Leukocytes

T. Scotognella¹, V. Lanni¹, I. Salvatori², M. Maussier¹, A. Giordano¹; ¹Policlinico A. Gemelli - Institute of Nuclear Medicine, Rome, ITALY, ²Catholic University of Sacred Heart, Rome, ITALY.

P249

One step synthesis of a radioiodinated tumor-targeted oligonucleotide and preliminary in vivo evaluation in tumor xenografts

L. Kang; Peking University First Hospital, Beijing, CHINA.

P250

Remotely controlled solvent extraction of high purity Tc-99m produced by conventional medical cyclotrons

P. Martini^{1,2}, A. Boschi³, L. Uccelli^{3,4}, M. Pasquali³, G. Cicoria⁵, M. Marengo⁵, M. Giganti³, G. Di Domenico¹, G. Pupillo², A. Taibi¹, A. Duatti⁶, J. Esposito²; ¹Department of Physics and Earth Sciences, University of Ferrara, FERRARA, ITALY, ²Legnaro Laboratories of the Italian National Institute for Nuclear Physics (INFN), Legnaro (Padova), ITALY, ³Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, FERRARA, ITALY, ⁴Nuclear Medicine S. Anna Hospital, Ferrara, ITALY, ⁵Nuclear Medicine S. Orsola Hospital, Bologna, ITALY, ⁶Department of Chemical and Pharmaceutical Sciences, University of Ferrara, FERRARA, ITALY.

P251

^{99m}Tc-Labeled Estradiol: Preparation and Preclinical Evaluation as an Estrogen Receptor Probe

Y. Zhang, X. Xia, H. Feng, X. Lan; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

P252

[¹¹¹In]-DOTA-anti-MUC1 for SPECT applications, the production and quality control

B. Alirezapour¹, S. Abbas Abadi², I. Kertesz³, J. Mohammadnejad⁴, A. Jalilian¹, E. Maadi¹, M. Hashemizadeh¹, N. Soltani¹, S. Moradkhani¹; ¹Department of Radiopharmaceutical, Nuclear Science and Technology Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Faculty of pharmacy, University of Debrecen, Debrecen, HUNGARY, ³Department of Nuclear Medicine, University of Debrecen, Debrecen, HUNGARY, ⁴Department of Life Science Engineering, Faculty of New Sciences & Technologies, University of Tehran, Tehran, IRAN, ISLAMIC REPUBLIC OF.

P253

Myocardial perfusion in patients with severe hypercholesterolemia

L. Martirosyan^{1,2}, I. Sergienko³, A. Ansheles⁴, A. Popova⁵, K. Ivanov³, V. Sergienko⁵; ¹ Yaroslavl state medical Academy, Moskou, RUSSIAN FEDERATION, ²Russian Cardiology Research Complex., Russian Cardiology Research Complex. Moscow, RUSSIAN FEDERATION, ³ Russian Cardiology Research Complex., Russian Cardiology Research Complex. Moscow, RUSSIAN FEDERATION, ⁴Russian Cardiology Research Complex., Moskou, RUSSIAN FEDERATION, ⁵Russian Cardiology Research Complex., Russian Cardiology Research Complex. Moscow, RUSSIAN FEDERATION.

P254

Preparation of radionuclide labeled anti-microRNA-155 oligonucleotide and its role as a potential tumor imaging probe in multiple tumor bearing mice

L. Kang; Peking University First Hospital, Beijing, CHINA.

P14

Sunday, October 11, 2015

16:00 – 16:30

Radiopharmaceuticals & Radiochemistry: Antibodies & Peptides

P255

Influence of DOTA - Rituximab conjugates on their biodistribution in mice

U. Karczmarczyk, W. Wojdowska, E. Laszuk, M. Maurin, P. Garnuszek, R. Mikolajczak; Radioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, POLAND.

P256

Synthesis and radiolabeling of HYNIC-conjugated LIKKPF peptide with ¹⁸F-FDG for the detection of apoptosis

D. Beiki¹, S. Khoshbakht², S. Shahhosseini³, F. Kobarfard³, O. Sabzevari², M. Amini⁴; ¹Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Dpartment of Radiopharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Dpartment of Medicinal Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Dpartment of Medicinal Chemistry, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran, Tehran, IRAN, ISLAMIC REPUBLIC OF.

P257

Combined targeting of somatostatin receptor subtypes 2 and 5 with a novel ⁶⁸Ga-labelled somatostatin agonist

R. Mansi¹, G. P. Nicolas¹, K. A. Abid², E. Grouzmann², J. Watson³, D. Wild¹, M. Fani¹; ¹University of Basel Hospital, Basel, SWITZERLAND, ²University Hospital of Lausanne, Lausanne, SWITZERLAND, ³Somtheranostics, Epalinges, SWITZERLAND.

P258

Adaptive self-assembling dendrimers for theranostics: a proof of concept on angiogenesis

P. GARRIGUE, A. MOYON, X. LIU, C. LIU, P. ROCCHI, L. PENG, D. TAIEB, B. GUILLET; Aix-Marseille Université, Marseille, FRANCE.

P259

Radiolabeling of antibody for epitope of human carbonic anhydrase IX (IgG M75) by ⁶¹Cu and ⁶⁴Cu and its biological testing

A. Čepa^{1,2,3}, J. Ráliš², A. Pavelka⁴, L. Marešová⁴, M. Kleinová⁴, D. Seifert², I. Siegllová⁵, V. Král⁶, M. Poláček², O. Lebeda², M. Paurovová⁶, M. Lázníček¹; ¹Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Hradec Králové, CZECH REPUBLIC, ²Nuclear Physics Institute of the CAS, v. v. i., Řež, CZECH REPUBLIC, ³Institute for Clinical and Experimental Medicine, Prague, CZECH REPUBLIC, ⁴ÚJV Řež a. s., Řež, CZECH REPUBLIC, ⁵Institute of Molecular Genetics of the CAS, v. v. i., Prague, CZECH REPUBLIC, ⁶Faculty of Science, Charles University in Prague, Prague, CZECH REPUBLIC.

P260

Panitumumab Modified With Metal Chelating Polymers (MCPs) For Dual Labeling With ¹¹¹In and ¹⁷⁷Lu as a Potential Theranostic For Pancreatic Cancer

S. Aghevlian; University of Toronto, Toronto, ON, CANADA.

P261

Ga-68 NODAGA RGD: A PET radiopharmaceutical for integrin αvβ3 imaging

R. Vatsa¹, P. Bhusari², S. Kumar¹, G. Singh¹, S. Chakraborty³, A. Dash³, D. K. Dhawan², J. Shukla¹, B. R. Mittal¹; ¹Postgraduate Institute of Medical Education & Research, PGIMER, CHANDIGARH, INDIA, ²Panjab University, PU, CHANDIGARH, INDIA, ³Bhabha Atomic Research Centre, BARC, Mumbai, INDIA.

P262

Improving EGFR imaging by use of an anti-EGFRvIII monoclonal antibody: characterizations in an in vivo squamous cell carcinoma model

D. Spiegelberg¹, A. C. Mortensen¹, R. K. Selvaraju², J. Stenberg¹, A. Scott³, M. Nestor^{1,4}; ¹Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN, ²Preclinical PET Platform, Uppsala, SWEDEN, ³Ludwig Institute for Cancer Research, Olivia Newton-John Cancer Research Institute, and La Trobe University, Melbourne, AUSTRALIA, ⁴Department of Surgical Sciences, Academic hospital, Uppsala, SWEDEN.

P263

A neurotensin derivative with increased metabolic stability labeled with ^{99m}Tc for tumors imaging

M. Erfani, M. Shafiei; Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), P.O.Box: 14395-836, Tehran, IRAN, ISLAMIC REPUBLIC OF.

P15

Sunday, October 11, 2015

16:00 – 16:30

Radiopharmaceuticals & Radiochemistry: Radiopharmaceuticals

P264

⁶⁸Ga(DO3A-lysine) as a New PET Tracer for Biodistribution Study

C. Yang¹, P. Chandrasekharan², P. Padmanabhan¹, J. Carlstedt-Duke¹, B. Gulyás^{1,3}, C. Halldin^{4,3}; ¹Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, SINGAPORE, ²Singapore Bioimaging Consortium, Agency for Science Technology and Research, Singapore, SINGAPORE, ³Karolinska Institutet, Department of Clinical Neuroscience, S-171 76, Stockholm, SWEDEN, ⁴Nanyang Technological University, Singapore, SINGAPORE.

P265

A novel, specific PET-radiotracer for bacterial infections

S. M. Schneefeld¹, J. Thackeray¹, N. Murthy², J. P. Bankstahl¹, F. M. Bengel¹, G. Meyer¹, T. L. Ross¹; ¹Medical School Hannover, Hannover, GERMANY, ²University of California, Berkeley, CA, UNITED STATES.

P266

A Fully Automated Procedure for the GMP-Synthesis of ⁶⁸Ga-NODAGA-Exendin-4 Using a Cationic Purification Method

G. M. Franssen, M. Brom, S. M. A. Willekens, P. Laverman, C. M. van Rij, M. Gotthardt, O. C. Boerman; Radboud University Medical Center, Nijmegen, NETHERLANDS.

P267

Chelator-free ⁸⁹Zr-labeling of mesoporous silica nanoparticles with superb in vivo radiostability

F. Chen, S. Goel, H. F. Valdovinos, S. Shi, T. E. Barnhart, W. Cai; University of Wisconsin-Madison, MADISON, WI, UNITED STATES.

P268

Synthesis and biological evaluation of ⁶⁸Ga-DOTA-capsaicin as a imaging agent for MCF-7

J. Park¹, S. Lee¹, M. Hur¹, S. Yang¹, S. Kim², K. Yu³; ¹Korea Atomic Energy Research Institute, Jeongseup-Si, KOREA, REPUBLIC OF, ²Dongguk University-Gyeongju, Gyeongju, KOREA, REPUBLIC OF, ³Dongguk university-Seoul, Seoul, KOREA, REPUBLIC OF.

P269

Cation exchanged based post-processing of Ga-68 chloride: Comparison of three different SPE-cartridges on their suitability to DOTA-NOC, NODAGA-RGDfk and HBED-CC-PSMA.

V. Ladenbauer, J. Obermair, P. Lam, C. Artner; IASON GmbH, Graz, AUSTRIA.

P270

Synthesis of Gallium-HBED-CC-EDBE-Folate available PET diagnosis agent against folate receptors overexpressed in cancer cells

P. Choi¹, J. Park², D. Chang³, T. Kim², S. Lee⁴, S. Kim¹; ¹Dongguk University, Gyeongju, KOREA, REPUBLIC OF, ²Korea Atomic Energy Research, Jeongseup, KOREA, REPUBLIC OF, ³Sunchon University, Sunchon, KOREA, REPUBLIC OF, ⁴Daegu Gyeongbuk Institute of Science and Technology, Daegu, KOREA, REPUBLIC OF.

P271

Preparation of ⁶⁸Ga-DOTA peptides in a fully automated system using two generators sequentially connected

I. Vaccaro¹, F. Giurgola¹, S. Grugni¹, G. Tarullo¹, K. Marzo¹, A. Chiti²; ¹IRCCS Istituto Clinico Humanitas, Rozzano, ITALY, ²Humanitas University, Rozzano, ITALY.

P272

Good manufacturing practice in using an automatic module of synthesis for ⁶⁸Ga-labeled molecules

S. Migliari¹, G. Serrelli², O. Ortenzia², J. Šimeček³, C. Cidda¹, G. Baldari¹, M. Scarlattei¹, C. Ghetti², L. Ruffini¹; ¹Nuclear Medicine and Molecular Imaging Department, University Hospital of Parma, Parma, ITALY, ²Medical Physics Unit, University Hospital of Parma, Parma, ITALY, ³Scintomics GmbH, Fürstentfeldbruck, Germany, Fürstentfeldbruck, Germany, GERMANY.

P273

Evaluation of Zr-89 oxalate as a PET Tracer for Inflammation, Tumor and Rheumatoid Arthritis Model

J. Park, Y. Lee, J. Lee, R. Yoo, U. Shin, K. Lee, B. Kim, K. Kim, G. Ahn, J. Kim; Korea Institute of Radiological & Medical Sciences, Seoul, KOREA, REPUBLIC OF.

P274

Correct Procedures for the synthesis of Ga68 radiopharmaceuticals.

I. Baldazzi, Sr., G. Franchi, F. Trapasso, S. Tetti, M. Martini, C. Del Mastro, P. Ragni, A. Lenza, F. Scopinaro; Az. Osp. Sant' Andrea, Roma, ITALY.

P275

⁶⁸Ga-based radiopharmaceutical preparation using NaCl method: collected results and preliminary data on ethanol influence in labelling performances

M. Riondato, O. Ferrando, M. Gaeta, F. Montagnani, A. Ciarmiello; S. Andrea Hospital, La Spezia, ITALY.

P276

Synthesis and Evaluation of Novel [Cu-64] Labeled Dimeric c(RGD-ACH-K) Conjugates for Tumor PET Imaging

K. Lee, J. Park, J. Lee, U. Shin, G. An, S. Lim, B. Kim, J. Kim; Korea Institute of Radiological and Medical Sciences, Seoul, KOREA, REPUBLIC OF.

P277

(⁶⁸Ga) processing in the preparation of (⁶⁸Ga)-citrate

H. Kvaternik, C. Barowitsch, D. Hausberger, S. Kerschbaumer, R. M. Aigner; Medical University of Graz, Graz, AUSTRIA.

P278

Experimental implementation and proof of principle for a Radionuclidic Purity test solely based on half life measurement

T. Jørgensen, M. Jensen; Technical University of Denmark, Roskilde, DENMARK.

P279

GMP compatible synthesis, dosimetry and in vivo stability of the selective αvβ6 tracer [18F]IMAFIB for clinical use

M. Onega, C. Plisson, S. Ashworth, S. Lanzarone, J. Ramada-Magalhaes, S. Moz, N. Keat, J. Passchier; Imanova Limited, London, UNITED KINGDOM.

P280

Effects of chemotherapeutic agents on 18F-FDG uptake in various tumour cells: Implication for 18F-FDG PET

P. Ubl, X. Gao, F. Girschele, S. Birkmann, M. Hacker, G. Hamilton, S. Li; Medical University of Vienna, VIENNA, AUSTRIA.

P281

Radiosynthesis of the [18F]-FHBG and Uptake Study with Transfected Cells

M. Beaurain¹, A. Salabert¹, L. Vaysse¹, Q. Dardonville², V. Pottier², M. Alonso², I. Loubinoux¹, P. Payoux³, M. Tafani²; ¹Inserm UMR825, Toulouse, FRANCE, ²Radiopharmacy Department - CHU Toulouse, Toulouse, FRANCE, ³Nuclear Medicine Department, Toulouse, FRANCE.

P282

Promising chemical delivery system into the central nervous system of [18F]FLT for PET imaging studies of low-grade brain tumours.

F. Gourand¹, A. Henry², M. Ibazizène¹, M. Dhilly¹, C. Papamicaë², V. Levacher², L. Barré¹; ¹CEA/DSV/I2BM/UMR ISTCT 6301/LDM-TEP, Cycleron, Caen, FRANCE, ²Normandie Univ, COBRA, UMR 6014 et FR 3038; Univ Rouen; INSA Rouen; CNRS, IRCOF, Mont-Saint Aignan, FRANCE.

P283

Evaluation of [11C]EA10 to image GluN2B-containing NMDA receptor subunits

L. A. Wells¹, S. Kealey², O. Howes³, G. Henriksen⁴, J. Passchier¹, E. Arstad⁵; ¹Imanova Centre for Imaging Sciences, London, UNITED KINGDOM, ²Imperial College London, London, UNITED KINGDOM, ³Psychiatric Imaging, MRC Clinical Sciences Centre, London, UNITED KINGDOM, ⁴Norwegian Medical Cyclotron Centre and Institute of Basic Medical Sciences, University of Oslo, Oslo, NORWAY, ⁵Department of Chemistry, UCL, London, UNITED KINGDOM.

P284

Radiosynthesis and Evaluation of 2-[18F]Fluoroethyl 4-Nitrobenzyl Carbonate for Imaging Tumor Hypoxia with Positron Emission Tomography

Z. Zhang, J. Lau, N. Colpo, F. Bénard, K. Lin; BC Cancer Agency, Vancouver, BC, CANADA.

P285

A Comparison of [18F]fluorotetrafluoroborate with [124I]Iodide for imaging human sodium iodide symporter

S. Samnick¹, I. Israel¹, M. Schiller¹, M. Mix², A. Schirbel¹, A. Buck¹; ¹University of Wuerzburg, Wuerzburg, GERMANY, ²University of Freiburg, Freiburg, GERMANY.

P286

Automated GMP compatible synthesis of 3-[18F] Fluoro-5-[(pyridine-2-yl)ethynyl]benzonitrile ([18F] FPEB)

S. Hader; King's College London, London, UNITED KINGDOM.

P287

Implementation of Routine Production of [18F]-Fallypride on the TRASIS All-in-One Universal Synthesizer.

C. Marshall, K. Drandarov, S. H. Bukhari, D. Hardwick, V. Costanza, P. Llewelyn, K. Probst, A. Dabkowski; Cardiff University, CARDIFF, UNITED KINGDOM.

P288

Towards nucleophilic synthesis of alpha-[18F] Fluoromethyl-p-tyrosine

R. Krasikova¹, O. Kuznetsova¹, V. Orlovskaja¹, O. Fedorova¹, V. Maleev², Y. Belokon², A. Geolchanyan³, A. Saghyan³, L. Mu⁴, S. Ametamey⁴, R. Schibli⁴; ¹N.P.Bechtereva Institute of Human Brain Russian Academy of Science, St.-Petersburg, RUSSIAN FEDERATION, ²A.N. Nesmeyanov Institute of Organoelement Compounds Russian Academy of Science, Moscow, RUSSIAN FEDERATION, ³SPC Armibiotechnology NAS, Yerevan, ARMENIA, ⁴BIO, Paul Scherrer Institute, Villigen-PSI, SWITZERLAND.

P289

New Approach to Production of [18F]Flumazenil for Central Benzodiazepine Receptors Imaging by PET

N. Gomzina¹, D. Vaulina¹, M. Nasirzadeh²; ¹N.P.Bechtereva Institute of the Human Brain Russian Academy of Sciences (IHB RAS), St. Petersburg, RUSSIAN FEDERATION, ²Saint Petersburg State University, St. Petersburg, RUSSIAN FEDERATION.

P290

Use of Potassium tert-Butoxide in the Synthesis of [11C]Flumazenil, [11C]PK11195 and [11C]-(+)-DTBZ

S. F. Garcia-Arguello; Centro de Investigaciones Medico-Sanitarias (CIMES), Malaga, SPAIN.

P291

Direct nucleophilic synthesis of 18F-fluoroethylated arylbenzotriazole as a new potential PET probe for breast cancer imaging

C. L. Chen¹, G. Y. Li¹, F. C. Meng¹, R. S. Liu^{1,2}, H. E. Wang¹, V. V. Orlovskaja³, D. D. Vaulina³, O. F. Kuznetsova³, O. S. Fedorova³, R. N. Krasikova³; ¹Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, TAIWAN, ²National PET/Cyclotron Center, Veterans General Hospital, Taipei, TAIWAN, ³N.P. Bechtereva Institute of Human Brain Russian Academy of Science, St.-Petersburg, RUSSIAN FEDERATION.

P292

F-18 Radiolabelling of Chitosan-Based Nanoparticles and its Modelling Reaction

A. Lima Oubiña¹, T. Miklovicz¹, J. Varga¹, J. Borbély², P. Mikecz¹; ¹Department of Nuclear Medicine, University of Debrecen, Debrecen, HUNGARY, ²BBS NanoTech, Debrecen, HUNGARY.

P293

An efficient radiosynthesis of [18F]Fluoro-inositol derivatives dedicated to PET imaging

C. Collet^{1,2}, S. Schmitt^{3,2}, S. Lamandé-Langle^{3,2}, F. Chrétien^{3,2}, F. Maskali¹, S. Poussier^{1,2}, P. Marie^{1,2}, Y. Chapleur^{1,3,2}, G. Karcher^{1,2}; ¹Nancyclotep, Vandoeuvre les Nancy, FRANCE, ²Université de Lorraine, Vandoeuvre les Nancy, FRANCE, ³UMR 7565, Vandoeuvre les Nancy, FRANCE.

P294

18F-labeling and in vivo evaluation of PEG modified polystyrene micelles via PET imaging

J. M. Postema¹, L. Jennings², J. Thackeray³, J. Banksthal³, G. Waton², F. Schosseler², E. Mendes⁴, T. L. Ross¹; ¹Radiopharmaceutical Chemistry, Department of Nuclear Medicine, Hannover Medical School, Hannover, GERMANY, ²Institute Charles Sadron, CNRS-University of Strasbourg, Strassbourg, FRANCE, ³Preclinical Molecular Imaging, Department of Nuclear Medicine, Hannover Medical School, Hannover, GERMANY, ⁴Department of Chemical Engineering, Advanced Soft Matter, Delft University of Technology, Delft, NETHERLANDS.

P295

An adapted GMP-compliant production of [18F]FAZA on a cassette based synthesis unit for the detection of hypoxia using positron emission tomography (PET)

O. C. Neels, Y. Remde, U. Hennrich, K. Kopka; German Cancer Research Center, Heidelberg, GERMANY.

P296

The role of 64CuCl2 PET/CT scan in patients with outspreaded Hodgkin Lymphoma. Is the 64CuCl2 apt to plan a rescue radionuclide therapy?

E. Capasso, Jr.¹, S. Massidda², C. Meleddu¹; ¹U.O.C. Nuclear Medicine, Cagliari, ITALY, ²U.O.C. Hematology and Bone Marrow Transplantation, Cagliari, ITALY.

P16

Sunday, October 11, 2015

16:00 – 16:30

Radiopharmaceuticals & Radiochemistry: Radiopharmacy

P297

A specific fluorescein-combined media fill test for validation of aseptic radiopharmaceutical preparations and assessment of good radiopharmacy practice.

A. Chantry¹, C. Fanton D'andon¹, A. Gouillet¹, P. Garrigue^{2,1}, B. Guillet^{1,2}; ¹AP-HM, Marseille, FRANCE, ²Aix-Marseille Université, Marseille, FRANCE.

P298

Comparison between two compounds of exametazime produced by different laboratories for labeling of leukocytes

A. Almarcha Gimeno¹, L. Díaz Platas¹, M. Romero Otero¹, R. Díaz Exposito²; ¹Unidad de Radiofarmacia. Hospital Clínico Universitario de Valencia, Valencia, SPAIN, ²Servicio Medicina Nuclear. Hospital Clínico Universitario de Valencia, Valencia, SPAIN.

P299

Qualitative Determination of Human Antibodies Against Mouse Immunoglobulin (HAMA) Before the Administration of 99mTc-Scintimun® Using the MILLENNIA® QUIKLINE Kit

E. López, E. Ariza, F. Cuevas, M. Cardoso, Y. Santaella, P. Valderas, F. Martin; SAS, Algeciras, SPAIN.

P300

Application of Molecular Modelling to Elucidate Liver Uptakes of 99mTc-Labelled Quinolone Antibiotics

M. Salahinejad, M. Aboudzadeh; Nuclear Science and Technology Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF.

P301

Assessment of microbiological monitoring for the evaluation of GMP-compliance at a department of Nuclear Medicine and Molecular Imaging of the University Medical Center Groningen

M. Beugeling¹, F. Ekoume², H. J. Woerdenbag³, G. Luurtsema¹, M. N. Lub-de Hooge¹, D. J. Touw¹, S. M. Rubow⁴, H. H. Boersma¹; ¹University of Groningen, UMCG, Groningen, NETHERLANDS, ²Hôpital General de Yaoundé, Yaoundé, CAMEROON, ³University of Groningen, Department of Pharmaceutical Technology and Biopharmacy, Groningen, NETHERLANDS, ⁴University of Stellenbosch, Tygerberg Hospital, Department of Nuclear Medicine, Cape Town, SOUTH AFRICA.

P302

Labelling of leucocytes with ^{99m}Tc -HMPAO: a plasma gelled story

S. Bulcourt, E. Malek, M. Lamballais; Valenciennes Hospital, Valenciennes, FRANCE.

P303

Bacterial Endotoxin and Sterility Testing of Active Pharmacological Ingredients used in the production of different Fluorine-18, Gallium-68 and Lutetium-177 labeled Radiopharmaceuticals

A. Mitra, S. Lad, S. Kulkarni, M. G. R. Rajan; Medical Cyclotron Facility, Radiation Medicine Centre, BARC & BRIT, TMH Annexe, Parel, Mumbai, INDIA.

P304

In vitro stability study of 90 Yttrium-microsphere for the treatment of hepatocellular carcinoma

V. Ardisson, N. Lepreur, E. Garin; CLCC Eugène Marquis, Rennes, FRANCE.

P305

Quality control validation of 16β -[^{18}F]fluoro-5 α -dihydrotestosterone produced with the FlexLab radiosynthesiser

J. G. Chan, K. Young, U. Ackerman, H. Tochon-Danguy, A. Scott; Austin Health, HEIDELBERG VIC, AUSTRALIA.

P306

A Study of the Influence of Physicochemical Reaction Parameters on the Radiolabelling Efficiency and Stability of Two Types of ^{99m}Tc Radiolabelled Nanoparticles

C. Stefanescu^{1,2}, G. Dodi³, A. Cazacu⁴, C. M. Uritu⁵, M. Pinteala⁵, A. Timofti², V. Ghizdovat^{1,2}, I. C. Grierosu^{1,2}; ¹Department of Biophysics and Medical Physics, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, Iasi, ROMANIA, ²Department of Nuclear Medicine, "St. Spiridon" Hospital, Iasi, ROMANIA, ³Faculty of Chemical Engineering and Environmental Protection, "Gh. Asachi" Technical University, Iasi, ROMANIA, ⁴Department of Sciences, University of Agricultural Sciences and Veterinary Medicine, Iasi, ROMANIA, ⁵Advanced Research Centre in Bionanoconjugates and Biopolymers, "Petru Poni" Institute of Macromolecular Chemistry, Iasi, ROMANIA.

P307

Evaluation of in vivo and in vitro stability of Lu-177-DKFZ-617 for systemic radionuclide therapy in patients with castration resistant prostate cancer

M. Ocak¹, A. Aygun², N. Yeyin², E. Demirci³, E. Karayel², A. Araman¹, L. Kabasakal²; ¹Department of Pharmaceutical Technology, Pharmacy Faculty, Istanbul University, Istanbul, TURKEY, ²Department of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, TURKEY, ³Department of Nuclear Medicine, Sisli Etfal Training and Research Hospital, Istanbul, TURKEY.

P308

Qualitative and quantitative evaluation of a single eluate from two $^{68}\text{Ge}/^{68}\text{Ga}$ generators sequentially connected, without any pre-purification

I. Vaccaro¹, F. Giurgola¹, S. Grugni¹, G. Tarullo¹, K. Marzo¹, A. Chiti²; ¹IRCCS Istituto Clinico Humanitas, Rozzano, ITALY, ²Humanitas University, Rozzano, ITALY.

P309

^{99m}Tc -MAA preparation for radioembolization; from just-in-time to just-in-case

J. Prince, M. G. E. H. Lam, N. de Wit, R. R. de Roos, A. D. Barten - van Rijbroek, M. A. A. J. van den Bosch, G. C. Krijger; UMC Utrecht, Utrecht, NETHERLANDS.

P310

Labeling and quality control of a heterocyclic nitrogen containing side chain bisphosphonate with ^{99m}Tc as a skeletal imaging agent

M. Erfani, S. Shirmardi; Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), P.O.Box: 14395-836, Tehran, IRAN, ISLAMIC REPUBLIC OF.

P17

Monday, October 12, 2015

16:00 – 16:30

Radiopharmaceuticals & Radiochemistry: Miscellaneous

P311

Research to create a miniature generator of technetium-99m.

A. Rogov, V. Skuridin, E. Stasyuk, E. Nestwrov, E. Ilina; National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

P312

Cost Effective and Integrated Capture Systems for Radioactive Gases Generated During Automated C-11 and F-18 Radiopharmaceutical Synthesis.

D. H. R. Stimson, A. J. Pringle, D. Maillet, A. R. King, S. T. Nevin, T. K. Venkatachalam, D. C. Reutens, R. Bhalla; Centre for Advanced Imaging, the University of Queensland, St Lucia, QLD, AUSTRALIA.

P313

A New Model of Ge-68/Ga-68 Generator

M. Li, H. Chu, C. Lee, H. Chang; Institute of Nuclear Energy Research, Taoyuan, TAIWAN.

P314

Determination of the pH of the Radiopharmaceutical Products in Saline

J. Laine, T. Lipponen, K. Bergström; HUS Medical Imaging Center, Helsinki, FINLAND.

P315

Labelling of leukocytes with ¹⁸F-FDG: Quantification of radiation damage.

E. Miñana¹, D. Ramos², P. Campos¹, T. Martinez²; ¹Virgen de la Arrixaca Hospital, Murcia, SPAIN, ²Santa Lucia Hospital, Cartagena, SPAIN.

P316

Referential of radiopharmacy risks elaboration

A. VERREY, D. Martinez, C. Smadja; Hôpital Européen Georges Pompidou, Paris 15ème, FRANCE.

P318

A stable and remote ¹¹¹In-labeling of DTPA-DSPE long-circulating liposomes

T. van der Geest¹, D. Gerrits¹, G. M. Franssen¹, J. M. Metselaar^{2,3}, G. Storm^{2,4}, P. Laverman¹, O. C. Boerman¹; ¹Department of Radiology and Nuclear Medicine, Radboud university medical center, Nijmegen, NETHERLANDS, ²Department of Targeted Therapeutics, MIRA institute, University of Twente, Enschede, NETHERLANDS, ³Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH-Aachen University, Aachen, GERMANY, ⁴Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, NETHERLANDS.

P319

Methotrexate labeling with ^{99m}Tc - Preclinical studies

M. Papachristou¹, P. Bouziotis², G. Kastis³, S. Xanthopoulos², I. Datseris¹; ¹Nuclear Medicine Department-PET/CT, GHA „Evangelismos“, Athens, GREECE, ²Radiochemical Studies Laboratory, INRaSTES, NCSR „Demokritos“, Athens, GREECE, ³Research Center of Mathematics, Academy of Athens, Athens, GREECE.

P320

Effects of erlotinib therapy on [¹¹C]erlotinib kinetics

M. Yaqub, I. Bahce, E. F. Smit, O. S. Hoekstra, R. Boellaard, H. N. M. Hendrikse, A. A. Lammertsma; VU University Medical Center, Amsterdam, NETHERLANDS.

P321

Nanocolloid Radiopharmaceutical on the Based of Modified DTPA Labeled Technetium-99M

V. Chernov¹, A. Rogov², V. Skuridin², E. Stasyuk², E. Nestwrov², N. Varlamova², R. Zelchan³, V. Sadkin², E. Ilina², L. Larionova²; ¹FSBI, Tomsk, RUSSIAN FEDERATION, ²National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION, ³Cancer Research Institute of Siberian Branch of the Russian Academy of Medical Sciences, Tomsk, Tomsk, RUSSIAN FEDERATION.

P18

Monday, October 12, 2015

16:00 – 16:30

Radiopharmaceuticals & Radiochemistry: Radiopharmacokinetics & Drug Development

P317

How stable is stable?

L. Nics¹, A. Hahn¹, O. Langer¹, C. Vranka¹, F. Girschele¹, B. Steiner¹, R. Lanzemberger¹, K. H. Wagner², M. Hacker¹, W. Wadsak¹, M. Mitterhauser¹; ¹Medical University of Vienna, Vienna, AUSTRIA, ²University of Vienna, Vienna, AUSTRIA.

P19 Monday, October 12, 2015

16:00 – 16:30

**Radiopharmaceuticals & Radiochemistry:
Radiometals & New Targets**

P322

**QSPR study on the Complexation of Radiometals
with Bifunctional Coupling Agents for
Radiopharmaceuticals Applications**

*M. Salahinejad, M. Aboudzadeh; Nuclear Science and
Technology Research Institute, Tehran, IRAN, ISLAMIC
REPUBLIC OF.*

P323

**Selecting the best buffer for 68Ga labelling: a
theoretical molecular approach towards a rational
choice**

*M. I. Prata¹, S. Rodrigues²; ¹IBILI and ICNAS, Coimbra,
PORTUGAL, ²Coimbra Chemistry Centre UC, Coimbra,
PORTUGAL.*

P324

**Excitation function determination for 45Ti
production using 45Sc(p,n)45Ti reaction in low
energy cyclotrons**

*P. Costa¹, L. F. Metello², L. Cunha², R. R. Johnson³, W. Gelbart⁴,
J. Obermair⁵, B. Dietl⁵, R. Nausching⁵, C. Artners⁵, P. Lass⁶,
G. Currie⁷, S. Carmo⁸, F. Alves⁸, M. D. Naia⁹; ¹Nuclear Medicine
Department, ESTSP.IPP & CEMUC[®], Physics Department, ECT-
UTAD, Vila Nova de Gaia & Vila Real, PORTUGAL, ²Nuclear
Medicine Department, ESTSP.IPP & IsoPor SA, Vila Nova de
Gaia, PORTUGAL, ³Best Cyclotron Systems Inc, Vancouver,
BC, CANADA, ⁴Advanced Systems Design, Garden Bay, BC,
CANADA, ⁵IASON GmbH, Graz, AUSTRIA, ⁶Medical Faculty,
University of Gdansk, Gdansk, POLAND, ⁷School of Dentistry
and Health Sciences, Charles Sturt University, Wagga Wagga,
AUSTRALIA, ⁸Institute for Nuclear Sciences Applied to Health,
Univ. Coimbra, Coimbra, PORTUGAL, ⁹CEMUC[®] - Physics
Department, ECT-UTAD, Vila Real, PORTUGAL.*

P325

**Synthesis and Evaluation of metal phosphate as
column material for the ⁶⁸Ge/⁶⁸Ga generator**

*J. Park¹, J. Lee¹, M. Hur¹, S. Yang¹, S. Lee², S. Kim³; ¹Korea
Atomic Energy Research Institute, Jeongeup-Si, KOREA,
REPUBLIC OF, ²Daegu Gyeongbuk Institute of Science
& Technology, Daegu, KOREA, REPUBLIC OF, ³Dongguk
University-Gyeongju, Gyeongju-Si, KOREA, REPUBLIC OF.*

P326

**Titanium-45 as a Candidate for PET Imaging:
Cyclotron-Based Production & Functionalized-
Hydroxamate Column Separation & Purification**

*R. I. Price^{1,2}, R. W. Sheil¹, R. K. Scharli^{1,2}, S. Chan¹, P. Gibbons¹,
L. Morandea¹; ¹RAPID PET Labs, Sir Charles Gairdner
Hospital, Perth, AUSTRALIA, ²School of Physics, University of
WA, Perth, AUSTRALIA.*

P327

**Cyclotron production of 99mTc from highly enriched
100Mo**

*D. Pawlak, W. Wojdowska, J. L. Parus, I. Cieszykowska,
T. Janiak, K. Jerzyk, M. Mielcarski, T. Barcikowski, P. Garnuszek,
R. Mikołajczak; National Centre for Nuclear Research,
Otwock, POLAND.*

P328

**Development of a cell labelling technique using
zirconium-89 for inflammation imaging with positron
emission tomography (PET).**

*M. Fairclough¹, B. Ellis², G. Brown¹, H. Boutin¹, A. McMahon¹,
A. Gennari¹, A. Jones¹, C. Prenant¹; ¹University of Manchester,
Manchester, UNITED KINGDOM, ²Central Manchester
University Hospitals NHS Foundation trust, Manchester,
UNITED KINGDOM.*

P329

**Evaluation of Layered Double Hydroxide as a Drug
Delivery Carrier using Co-57**

*J. Park¹, J. Lee¹, T. Kim², J. Oh²; ¹Korea Atomic Energy Research
Institute, Jeongeup-Si, KOREA, REPUBLIC OF, ²Yonsei
University, Wonju, KOREA, REPUBLIC OF.*

P330

**Radiotherapy metabolic with 131I, a new promise for
cholangiocarcinoma treatment?**

*A. M. Abrantes^{1,2,3}, R. Teixo^{1,3}, A. F. Brito^{1,2,3}, A. I. Fernandes^{1,2,4},
A. C. Ribeiro¹, M. Laranjo^{1,2,3}, J. G. Tralhão^{1,2,5}, M. F. Botelho^{1,2,3};
¹Biophysics Unit, Faculty of Medicine, University of
Coimbra, Coimbra, PORTUGAL, ²Center of Investigation
on Environmental, Genetics and Oncobiology (CIMAGO),
Faculty of Medicine, Coimbra, PORTUGAL, ³CNC.IBILI, Faculty
of Medicine, University of Coimbra, Coimbra, PORTUGAL,
⁴Gastroenterology Department, CHUC, Coimbra, PORTUGAL,
⁵Surgical Department, Surgery A, CHUC, Coimbra,
PORTUGAL.*

P20 Monday, October 12, 2015

16:00 – 16:30

Cardiovascular System: Basic Science

P331

Synthesis of Novel 124I-Rhodamine: a Potential PET Myocardial Imaging Agent

I. Aljammaz, B. Alotaibi, S. Alyanbawi, F. Alrumayan, S. Okarvi; King Faisal Spec. Hosp. & Research Centre, Riyadh, SAUDI ARABIA.

P332

Effect of dipyridamole infused for myocardial perfusion imaging on blood glucose concentration: a preliminary study

A. Khorasanchi¹, M. Arabi¹, A. Akhavein², M. Eftekhari¹, H. Javadi³, M. Seyedabadi⁴, M. Assadi⁴; ¹Imam Hossein Hospital, Faculty of Medicine, Shahrood University of Medical Sciences, Shahrood, IRAN, ISLAMIC REPUBLIC OF, ²Islamic Azad University Tehran Medical Branch, TEHRAN, IRAN, ISLAMIC REPUBLIC OF, ³Golestan Research Center of Gastroenterology and Hepatology (GRCGH), Golestan University of Medical Sciences (GUOMS), Gorgan, IRAN, ISLAMIC REPUBLIC OF, ⁴The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, BUSHEHR, IRAN, ISLAMIC REPUBLIC OF.

P333

Measurement of concentration-dependent effect of sevoflurane on myocardial oxygen consumption using 11C acetate PET in rats

K. Matsunaga¹, T. Watabe¹, A. Nakae², H. Kang², Y. Kanai³, K. Isohashi¹, H. Kato¹, E. Shimosegawa^{1,3}, J. Hatazawa¹; ¹Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Suita, JAPAN, ²Department of Anesthesiology and Intensive Care, Osaka University Graduate School of Medicine, Suita, JAPAN, ³Department of Molecular Imaging in Medicine, Osaka University Graduate School of Medicine, Suita, JAPAN.

P334

Myocardial Insulin Resistant under Hyperinsulinemic-Euglycemic Clamp in a Rat Model

K. Fukushima^{1,2}, P. Arias¹, H. Wakabayashi¹, T. Shinaji^{1,3}, R. Werner^{1,3}, H. Pelzer¹, T. Higuchi^{1,3}; ¹Würzburg Univ, Würzburg, GERMANY, ²Hyogo College of Medicine, Hyogo, JAPAN, ³Comprehensive Heart Failure Center, Würzburg, GERMANY.

P21 Monday, October 12, 2015

16:00 – 16:30

Cardiovascular System: Clinical Science – Perfusion, Metabolism and Receptors

P336

Higher Event Rate in Patients with Known CAD Despite a Normal Myocardial Perfusion Scan

M. u. Zaman¹, N. Fatima², U. Zaman³, A. Zaman³, R. Zaman³; ¹AKUH, Karachi, PAKISTAN, ²Dr Ziauddin Hospital, Karachi, PAKISTAN, ³Dow University of Health Sciences (DUHS), Karachi, PAKISTAN.

P337

High Negative Predictive Value of Workload ≥ 7 METS on Exercise Testing in Patients with Normal Gated Myocardial Perfusion Imaging: Was Imaging Really Required?

M. u. Zaman^{1,2}, N. Fatima^{2,3}, U. Zaman⁴, A. Zaman⁴, R. Tahseen⁴; ¹AKUH, Karachi, PAKISTAN, ²Karachi Institute of Heart Diseases (KIHD), Karachi, PAKISTAN, ³Dr Ziauddin Hospital, Karachi, PAKISTAN, ⁴Dow University of Health Sciences (DUHS), Karachi, PAKISTAN.

P338

Temporal Trends in Results of 9170 Myocardial Perfusion Imaging Studies (2004 to 2013)

N. Fatima^{1,2}, M. u. Zaman^{3,2}, U. Zaman⁴, A. Zaman⁴, R. Tahseen⁴; ¹Department of Nuclear Medicine, Dr Ziauddin Medical University, Karachi, PAKISTAN, ²Karachi Institute of Heart Diseases (KIHD), Karachi, PAKISTAN, ³AKUH, Karachi, PAKISTAN, ⁴Dow University of Health Sciences (DUHS), Karachi, PAKISTAN.

P339

Comparison of hemodynamic effects and negative predictive value of normal adenosine gated myocardial perfusion scan with and without caffeine abstinence

N. Fatima^{1,2}, M. u. Zaman^{3,2}; ¹Department of Nuclear Medicine, Dr Ziauddin Medical University, Karachi, PAKISTAN, ²Karachi Institute of Heart Diseases (KIHD), Karachi, PAKISTAN, ³AKUH, Karachi, PAKISTAN.

P341

Direct Voxel-by-Voxel Comparison of Tomographic Images from Nuclear Cardiology

J. Trnka, A. Fikrlé, D. Zogala; General University Hospital, Prague, CZECH REPUBLIC.

P342

A Useful and Easy to Develop Combined Stress Test for Myocardial Perfusion Imaging: Regadenoson and Isometric Exercise, Preliminary Results.

I. Janvier, Jr.^{1,2}; ¹CHU Bordeaux, Bordeaux, FRANCE, ²CHU Nancy, Nancy, FRANCE.

P343

Myocardial perfusion imaging pattern in patients with intermediate and significant coronary artery stenosis

K. W. Zavadovsky^{1,2}, M. O. Gulya^{1,2}, V. V. Saushkin¹, Y. V. Saushkina^{1,2}, Y. B. Lishmanov^{2,1}; ¹Federal State Budgetary Scientific Institution „Research Institute for Cardiology“, Tomsk, RUSSIAN FEDERATION, ²National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

P344

A new approach to assessment of myocardial perfusion in patients with hypercholesterolemia according to the single-photon emission computed tomography

L. Martirosyan, Doctor, I. Sergienko, A. Ansheles, A. Popova, K. Ivanov, V. Sergienko; FGBU RC NPC MH RF, Moskou, RUSSIAN FEDERATION.

P345

Interchangeability of cardiac volumetric and phase analysis parameters between two software (CardioRepo and Heart Function View)

T. Kudo, R. Ideguchi, M. Uetani, Y. Koide, K. Maemura; Nagasaki University, Nagasaki, JAPAN.

P346

Radionuclide assessment of myocardial flow reserve in patients with multivessel coronary artery disease

K. W. Zavadovsky^{1,2}, A. Mochula¹, S. Andreev¹, Y. Lishmanov^{2,1}; ¹Federal State Budgetary Scientific Institution „Research Institute for Cardiology“, Tomsk, RUSSIAN FEDERATION, ²National Research Tomsk Polytechnic University, Russian Federation, Tomsk, RUSSIAN FEDERATION.

P347

Side Effects of Adenosine as a Pharmacologic Stress Agent for Myocardial Perfusion Scan in a local setup

H. Amer; King Abdulaziz Hospital National Guards Health Affairs, Al Ahsa, SAUDI ARABIA.

P348

Prediction of occult coronary artery disease in patients with normal myocardial perfusion scintigraphy using myocardial perfusion reserve on dynamic thallium-201 single-photon emission computed tomography with a semiconductor gamma camera

S. Shiraishi¹, N. Tsuda¹, F. Sakamoto¹, M. Yoshida², S. Tomiguchi¹, Y. Yamashita¹; ¹Kumamoto University, Kumamoto City, JAPAN, ²Amakusa medical center, Hondo City, JAPAN.

P349

Large myocardial injury attenuates a response to steroid therapy in patients with cardiac sarcoidosis

M. Momose¹, K. Fukushima¹, C. Kondo¹, N. Serizawa², A. Suzuki², K. Abe¹, N. Hagiwara², S. Sakai¹; ¹Department of Diagnostic Imaging and Nuclear Medicine, Tokyo Women's Medical University, Tokyo, JAPAN, ²Department of Cardiology, Tokyo Women's Medical University, Tokyo, JAPAN.

P350

Visualization of Acute Myocardial Infarction of Right Ventricle Free Wall after Cardiac Surgery by Gated SPECT with Phase Images

E. N. Ostroumov¹, E. D. Kotina², V. A. Ploskikh², A. V. Babin², A. S. Ivanov¹, A. V. Rodionov¹, O. M. Mas¹; ¹Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow, RUSSIAN FEDERATION, ²Saint-Petersburg State University, Saint-Petersburg, RUSSIAN FEDERATION.

P351

Is increased septal perfusion an indicator of asymmetrical septal hypertrophy?

S. Ozdemir¹, Y. Tan¹, E. Gazi², F. Celik¹; ¹Cakkale Onsekiz Mart University, Faculty of Medicine. Department of Nuclear Medicine, Canakkale, TURKEY, ²Canakkale Onsekiz Mart University, Faculty of Medicine. Department of Cardiology, Canakkale, TURKEY.

P353

Added value of coronary calcium scoring as part of myocardial perfusion scan

A. Notghi, S. Tomas Hernandez, J. O'Brien; Sanwell and West Birmingham Hospitals NHS Trust, Birmingham, UNITED KINGDOM.

P354

Myocardial perfusion scintigraphy in patients undergoing cardiac rehabilitation

S. Rizkallal Monzon¹, B. Theillac², B. Navarro Martinez², J. Castro Beiras², M. Martinez Gomez²; ¹Hospital Universitario La Paz, Madrid, SPAIN, ²Hospital Universitario Ramon y Cajal, Madrid, SPAIN.

P355

Clinical Impact of Myocardial Perfusion Scintigraphy in Patients with Previous Percutaneous Coronary Intervention

S. Czibor, M. Moravszki, K. Buga, M. Toth, R. Joba, I. Szilvasi; Hungarian Defence Forces Medical Centre, Dept. of Nuclear Medicine, Budapest, HUNGARY.

P356

Value of ECG-gated study during dipyridamole stress in myocardial perfusion PET

K. Nakagawa¹, S. Onodera², T. Uchida², Y. Ozaki², H. Henmi², Y. Uchino²; ¹Tokyo Seaside Clinic, Tokyo, JAPAN, ²Chiba Ryougo Center, Chiba, JAPAN.

P357

The Value of Semiquantitative Analysis in Myocardial Perfusion Imaging using Multifocal Collimator SPECT/CT: IQ-SPECT

M. Trogrlic, M. Medvedec, S. Tezak; University Hospital Centre Zagreb, Zagreb, CROATIA.

P358

What is the impact of apparently minimal dipyridamole response to the accuracy of myocardial perfusion scintigraphy?

A. Doulmas¹, I. Iakovou¹, V. Mpalaris¹, D. Mpountas², V. Athanasiou¹, D. Katsaboukas¹, S. Georga¹, K. Badiavas¹, D. Lo Presti¹; ¹Academic Nuclear Medicine dpt, Papageorgiou hsp, Thessaloniki, GREECE, ²Nuclear medicine dpt „Hippokrates“, Thessaloniki, GREECE.

P359

Splenic switch-off in Rb82 myocardial perfusion imaging: an indication of adequate vasodilatation?

M. J. Memmott, P. Arumugam, C. M. Tonge; Central Manchester University Hospitals NHS Foundation Trust, Manchester, UNITED KINGDOM.

P360

One year outcome of the myocardial infarcted areas seen immediately post primary percutaneous transluminal coronary angioplasty (PTCA)

A. Doulmas¹, T. Christoforidis¹, I. Iakovou¹, V. Mpalaris¹, D. Mpountas², D. Katsaboukas¹, V. Athanasiou¹, S. Georga¹, D. Lo Presti¹, N. Karatzas¹; ¹Academic Nuclear Medicine dpt, Papageorgiou hsp, Thessaloniki, GREECE, ²Nuclear medicine dpt „Hippokrates“, Thessaloniki, GREECE.

P361

Does observer-dependence influence the reliability of supine/prone stress-only MPI with cardiac dedicated CZT scanner?

S. Osiecki¹, S. Piszczek¹, P. J. Kwasiborski², A. Mazurek¹, M. Dziuk¹; ¹Military Institute of Medicine, Warsaw, POLAND, ²Medical University of Warsaw, Warsaw, POLAND.

P362

Myocardial blood flow quantification with 82-Rubidium PET/CT for the diagnosis of cardiac sarcoidosis

Q. Gillebert¹, R. Chequer¹, R. Ben Azzouna¹, S. Leygnac¹, N. Mikail¹, F. Hyafil¹, C. Chapelon-Albric², B. Crestani³, D. Le Guludec¹, F. Rouzet¹; ¹Department of Nuclear Medicine, Bichat University Hospital, Département Hospitalo-Universitaire FIRE, Assistance Publique-Hôpitaux de Paris, University Paris Diderot-Paris 7, Paris, FRANCE, ²Department of Internal Medicine II, CHU Pitié Salpêtrière, University Pierre et Marie Curie, Assistance Publique-Hôpitaux de Paris, Paris, FRANCE, ³Department of Pulmonology, Bichat University Hospital, Assistance Publique-Hôpitaux de Paris, University Paris Diderot-Paris 7, Paris, FRANCE.

P363

Impact of prone-position acquisition of 123I-MIBG cardiac imaging on heart-to-mediastinum ratio

T. Pellegrino¹, V. Piscopo², A. Boemio², R. Carotenuto², B. Russo², S. Pellegrino², G. De Matteis², A. Cuocolo²; ¹Institute of Biostructures and Bioimages, Naples, ITALY, ²University of Naples - Federico II, Naples, ITALY.

P364

Preliminary report of long term follow-up with myocardial perfusion scan in breast cancer patients after external beam radiation therapy.

M. Eftekhari¹, F. Kalantari¹, M. Abbasi², S. Farzanefer², A. Fard-Esfahani¹, B. Fallahi¹, D. Beiki¹, A. Hassanzadeh-Rad¹, A. Emami-Ardekani¹; ¹research center for nuclear medicine, Tehran university of medical sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Nuclear Medicine Department, Vali-asr Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

P365

Effect of Low Dose CT Attenuation Correction in the Incidence of Ischemia During Myocardial Perfusion Scintigraphy

T. Pipikos¹, F. Vlachou¹, A. Nikaki¹, L. Koletti¹, K. Gogos², K. Dalianis², V. Prassopoulos¹; ¹Nuclear Medicine Department Hygeia SA, Athens, Marousi, GREECE, ²Medical Physics Department „Hygeia S.A., Athens, Marousi, GREECE.

P366

Regadenoson safety and tolerability in myocardial perfusion imaging

M. Catalano, G. Annunziata, A. Sasso, R. Gottilla, D. Scala, V. Ippolito, I. Valenti; AORN, Naples, ITALY.

P367

Adenosine stress Myocardial Perfusion Scintigraphy and Adenosine stress echocardiography in post arterial switch operation patients: A mid-term follow up.

K. Kumar, S. G. Roy, C. D. Patel, S. Ramakrishnan, R. Kumar, A. K. Bisoi; All India Institute Of Medical Sciences, New Delhi, INDIA.

P368

Calculation of left ventricular ejection fraction using cardiac gated parametric blood volume images from a dynamic 150-water PET/CT scan

J. Nordström, T. Kero, C. Widström, J. Sörensen, M. Lubberink; Department of Surgical Sciences, Radiology, Uppsala, SWEDEN.

P369

Perfusion Vector - A New Method to Quantify Myocardial Perfusion Scintigraphy Images

M. Senneby¹, D. Minarik², P. Wollmer¹, L. Edenbrandt¹, K. Sjöstrand³, E. Trägårdh¹; ¹Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund University, Malmö, Sweden, Malmö, SWEDEN, ²Radiation Physics, Skåne University Hospital, Lund University, Malmö, Sweden, Malmö, SWEDEN, ³Informatics and Mathematical Modelling, Technical University of Denmark, Copenhagen, Denmark, Malmö, SWEDEN.

P370

Is Data-Driven Cardiac Gating Possible with REGAT Software Applied to SPECT Myocardial Perfusion Imaging Acquired with Discovery NM 530c?

D. Daou^{1,2}, R. Sabbah³, H. Bouladhour³, C. Coaguila⁴; ¹Cochin Hospital, APHP, Paris, FRANCE, ²EA 7334 REMES, Université Paris-Diderot, Sorbonne Paris-Cité, Paris, AUSTRIA, ³CHU Jean Minjot, Besançon, FRANCE, ⁴Centre Hospitalier de Bigorre, Tarbes, FRANCE.

P371

Tetrofosmin-Tc-99m Right Ventricular to Left Ventricular Uptake Ratio as a New Surrogate Marker of Subclinical Pulmonary Arterial Hypertension in Rheumatoid Arthritis

T. S. Vieira, M. Bernardes, E. Martins, V. Alves, A. Sá Pinto, A. Fernandes, A. Oliveira, T. Faria, M. Perez, J. G. Pereira; Centro Hospitalar de São João, Porto, PORTUGAL.

P372

Does MPI with CZT cardiac gamma camera show significant abnormalities in presence of intermediately stenosed coronaries with normal adenosine/regadenoson FFR - preliminary results

S. Piszczek, K. Tkaczewski, A. Mazurek, S. Osiecki, M. Dziuk; Military Institute of Medicine, Warsaw, Szaserów Street 128, POLAND.

P373

Cardiac 13N-Ammonia PET in Left Ventricular Systolic Dysfunction without Obstructive Coronary Artery Disease

A. Monroy-Gonzalez¹, L. Juarez-Orozco¹, E. Berrios-Barcenas², E. Flores-Gonzalez², R. Cruz-Mendoza², R. Tio¹, R. Slart^{1,3}, R. Dierckx¹, E. Alexanderson^{2,4}; ¹University Medical Center Groningen, Groningen, NETHERLANDS, ²Instituto Nacional de Cardiología „Ignacio Chavez“, Mexico City, MEXICO, ³University of Twente, Enschede, NETHERLANDS, ⁴Unidad PET/CT UNAM, Mexico City, MEXICO.

P374

Long-term Follow-up in Hypertensive Patients With Normal Stress Myocardial Perfusion Imaging: a Parametric Analysis

C. Nappi¹, E. Zampella¹, R. Assante¹, R. Green¹, N. Frega¹, D. D'Arienzo¹, G. De Matteis¹, S. Daniele², W. Acampa², M. Petretta³, A. Cuocolo¹; ¹Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, ITALY, ²Institute of Biostructure and Bioimaging, National Council of Research, Naples, ITALY, ³Department of Translational Medical Sciences, University of Naples 'Federico II', Naples, ITALY.

P375

Evaluation of myocardial blood flow in patients with myocardial bridging: A 13N-ammonia PET study.

A. Monroy-Gonzalez¹, L. Juarez-Orozco¹, E. Berrios-Barcenas², C. Gonzalez-Padilla², M. Martinez-Aguilar², G. Guinto-Nishimura², R. Dierckx¹, R. Tio¹, R. H. J. A. Slart^{1,3}, E. Alexanderson^{2,4}; ¹University Medical Center Groningen, Groningen, NETHERLANDS, ²National Institute of Cardiology, Mexico City, MEXICO, ³University of Twente, Enschede, NETHERLANDS, ⁴Unidad PET/CT UNAM, Mexico City, MEXICO.

P22 Monday, October 12, 2015

16:00 – 16:30

**Cardiovascular System: Clinical Science –
Plaque and Vascular Imaging**

P376

Prognostic value of cardiac gated SPECT combined with coronary calcium score in patients with end-stage kidney disease

M. Kamínek^{1,2}, M. Havel¹, I. Metelkova¹, M. Budikova¹, L. Henzlova¹, P. Koranda¹, J. Zadrazil¹, V. Kinc²; ¹Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, CZECH REPUBLIC, ²International Clinical Research Center, Center of Molecular Imaging, St. Anne's University Hospital, Masaryk University, Brno, CZECH REPUBLIC.

P377

The index of the maximum accumulation 99mTc-DPD in the myocardium of patients with transthyretin (TTR) cardiac amyloidosis and of older people without known heart disease

M. Buncová, A. Čepa, M. Kubánek, A. Krebsová; Institute for Clinical and Experimental Medicine, Prague, CZECH REPUBLIC.

P378

The prognostic value of baseline 18F-FDG PET/CT in steroid-naïve large-vessel vasculitis: introduction of volume-based parameters

L. Dellavedova, L. S. Maffioli; AO Ospedale Civile di Legnano, Legnano, ITALY.

P379

[18F]-FDG PET/CT imaging for detection of the inflammation in the calcified atherosclerotic plaques

D. V. Ryzhkova, D. A. Pavlova; North-Western Federal Medical Research Centre, St. Petersburg, RUSSIAN FEDERATION.

P380

Influence of the peptide receptor radionuclide therapy (PRRT) on the inflammatory activity in atherosclerotic plaques based on the initial 68Ga-DOTA-TATE (DOTA) uptake.

M. J. Zacherl¹, A. Todica¹, G. Rubinstein¹, P. Bartenstein¹, M. Hacker², S. Lehner¹; ¹University of Munich, Munich, GERMANY, ²Medical University of Vienna, Vienna, AUSTRIA.

P381

Feasibility of Annexin A5 for ex vivo imaging of human fresh and frozen atherosclerotic plaques

S. A. de Boer¹, J. van Hoek^{2,3}, D. J. Mulder¹, H. J. de Haas², N. A. Jager⁴, J. G. W. Kosterink³, C. J. Zeebregts⁵, C. P. M. Reutelingsperger⁶, P. H. Elsinga², R. H. J. A. Slart^{2,7}, H. H. Boersma^{2,3}; ¹Department of Vascular Medicine, University Medical Center Groningen, University of Groningen, Groningen, NETHERLANDS, ²Department of Nuclear Medicine, University Medical Center Groningen, University of Groningen, Groningen, NETHERLANDS, ³Department of Clinical and Hospital Pharmacy, University Medical Center Groningen, University of Groningen, Groningen, NETHERLANDS, ⁴Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, NETHERLANDS, ⁵Division of Vascular Surgery, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, NETHERLANDS, ⁶Department of Biochemistry, University of Maastricht, Maastricht, NETHERLANDS, ⁷Faculty of Science and Technology, Biomedical Photonic Imaging, University of Twente, Enschede, NETHERLANDS.

P382

Quantitative assessment of intermediate stenosis of coronary arteries by single photon emission computed tomography with attenuation correction compared fractional flow reserve

V. Solomyanny; Russian cardiology research and production complex, Moscow, RUSSIAN FEDERATION.

P383

18F-FDG uptake in main arterial branches of patients with large vessel vasculitis: visual and semiquantitative analysis.

M. Castellani¹, M. Vadrucchi¹, L. Florimonte¹, M. Caronni², E. Orunesu¹, R. Benti¹; ¹Fondazione Irccs Ca'granda Ospedale Maggiore Policlinico Nuclear Medicine Department, Milan, ITALY, ²Fondazione Irccs Ca'granda Ospedale Maggiore Policlinico Referral Center For Systemic Autoimmune Diseases, Milan, ITALY.

P384

18F-FDG-PET/CT imaging in Giant Cell Arteritis: Are we still unable to "light up" temporal arteries?

Z. Rehak¹, J. Vasina¹, J. Ptacek², P. Nemec³, Z. Fojtik⁴; ¹Masaryk Memorial Cancer Inst., Brno, CZECH REPUBLIC, ²University Hospital, Olomouc, CZECH REPUBLIC, ³St. Anne's University Hospital, Brno, CZECH REPUBLIC, ⁴University Hospital, Brno, CZECH REPUBLIC.

P385

Identification of complicated carotid plaques by adding functional FDG-PET imaging to morphological characteristics on CT angiography

N. Mikail¹, F. Hyafil¹, M. Mazighi², E. Meseguer³, C. Guidoux³, L. Cabrejo³, P. Lavallée³, K. Benali¹, F. Rouzet¹, D. Le Guludec¹, G. Lesèche⁴, P. Amarenco³; ¹Bichat University Hospital, Department of Nuclear Medicine, PARIS, FRANCE, ²Lariboisière University Hospital, Department of Neurology, PARIS, FRANCE, ³Bichat University Hospital, Department of Neurology, PARIS, FRANCE, ⁴Bichat University Hospital, Department of Vascular Surgery, PARIS, FRANCE.

P386

[18F]-Sodium Fluoride Uptake in Takayasu Arteritis

E. Alexanderson^{1,2}, A. Monroy-Gonzalez³, L. Juarez-Orozco³, R. Tio³, A. W. J. M. Glaudemans³, E. Estrada⁴, O. Garcia⁴, A. Meave¹, R. H. J. A. Slart^{3,5}, M. E. Soto-Lopez⁵; ¹National Institute of Cardiology, Mexico City, MEXICO, ²Unidad PET/CT UNAM, Mexico City, MEXICO, ³University Medical Center Groningen, Groningen, NETHERLANDS, ⁴National Institute of Cancer, Mexico City, MEXICO, ⁵University of Twente, Enschede, NETHERLANDS.

P23

Monday, October 12, 2015

16:00 – 16:30

Cardiovascular System: Imaging Systems

P387

Radionuclide evaluation of cardiac function and dyssynchrony in children with idiopathic ventricular tachycardia

K. W. Zavadovsky^{1,2}, V. Saushkin¹, Y. Lishmanov^{1,2}; ¹Federal State Budgetary Scientific Institution «Research Institute for Cardiology», Tomsk, RUSSIAN FEDERATION, ²National Research Tomsk Polytechnic University, Tomsk, Russian Federation, Tomsk, RUSSIAN FEDERATION.

P388

The utility of 99mTc-Pyrophosphate SPECT in diagnosis of latent myocarditis in patients with atrial fibrillation.

S. Sazonova^{1,2}, Y. Ilyushenkova^{1,2}, R. Batalov¹, Y. Rogovskaya¹, Y. Lishmanov^{1,2}; ¹Institute of Cardiology, Tomsk, RUSSIAN FEDERATION, ²National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

P389

Interpretation of myocardial perfusion SPECT with CT-based attenuation correction

A. Ansheles, L. Martirosyan, I. Sergienko, V. Sergienko; Russian Cardiology Research Center, Moscow, RUSSIAN FEDERATION.

P390

the efficacy of myocardial perfusion image morphing combined with computed tomography coronary angiography in the diagnosis of silent myocardial ischemia

C. Chang, W. Xie, B. Lei, L. Wang, R. Li, Z. Zheng, s. yang; Shanghai Chest Hospital, Shanghai, CHINA.

P391

99mTc-HMPAO labeled leukocyte SPECT/CT in evaluation of cardiac device infection

M. Kostkiewicz, K. Holcman, W. Szot, B. Malecka; Intitute of Cardiology, Jagiellonian University, Hospital John Paul II, KRAKOW, POLAND.

P392

Dual radionuclide myocardial perfusion SPECT may be planned with much lower radiation doses on CZT cameras

V. Roch^{1,2}, L. Imbert^{1,2,3}, W. Djaballah^{1,2}, M. Perrin^{1,2}, A. Verger^{1,2}, H. Boutley^{1,2}, G. Karcher^{1,2,3}, P. Marie^{1,2,4}; ¹Chu Nancy Hopital Brabois Adultes, Vandoeuvre-Lès-Nancy, FRANCE, ²Nancyclotep experimental imaging platform, Nancy, FRANCE, ³CRAN, UMR 7039, Université de Lorraine - CNRS, Vandoeuvre-lès-Nancy, FRANCE, ⁴INSERM, U1116, Nancy, FRANCE.

P393

Evaluation of simultaneous Tc-99m and I-123 dual-isotope SPECT imaging using cardiac CZT camera

T. Niimi¹, M. Sugimoto¹, M. Nanasato¹, H. Maeda²; ¹Nagoya Daini Red Cross Hospital, NAGOYA, JAPAN, ²Nagoya University, NAGOYA, JAPAN.

P394

Optimization of radioactive dose for dipyridamole and exercise myocardial perfusion Gated-SPECT.

F. Ticconi¹, A. Nieri¹, M. Bauckneht¹, G. Ferrarazzo¹, F. Fiz¹, M. Pennone¹, S. Morbelli¹, F. Bongioanni¹, C. Marini², G. Sambuceti¹; ¹Nuclear Medicine, IRCCS AUO San Martino IST, Genova, ITALY, ²Institute Of Bioimaging and Molecular Physiology, CNR, Milan, Genoa Section, Genova, ITALY.

P395

Reference values for right ventricular and lung uptake in relation to left ventricular uptake in 99mTc-tetrofosmin myocardial perfusion SPECT/CT imaging

T. M. Laitinen¹, A. Corovai^{1,2}, H. Hämäläinen^{1,2}, T. Laitinen^{1,2}; ¹Kuopio University Hospital, Kuopio, FINLAND, ²University of Eastern Finland, Kuopio, FINLAND.

P396

Comparison of Phase analysis among three kinds of soft-ware (QGS, ETB and Heart function view) in diagnosing ischemic heart disease

S. Nagamachi, MD¹, H. Onizuka, MD², R. Nishii, MD¹, Y. Mizutani, MD¹, T. Hirai, MD¹, K. Kitamura, MD³;
¹Department of Radiology, Miyazaki University, Miyazaki, JAPAN, ²Department of 1st Internal Medicine, Miyazaki University, Miyazaki, JAPAN, ³Department of 1st Internal Medicine, Miyazaki University, Miyazaki, JAPAN.

P397

Assessment of left ventricular function with a fast low-dose recording protocol planned on a semi-conductor gamma-camera

M. Claudin, Sr., W. Djaballah, Sr., L. Imbert, Sr., N. Veran, Sr., S. Poussier, Sr., V. Roch, G. Karcher, Sr., P. Marie, Sr.; Centre hospitalo-universitaire de Nancy, Vandoeuvre-les-Nancy, FRANCE.

P398

Long-term survival of patients with manifested coronary artery disease with and without diabetes undergoing myocardial viability assessment.

G. Rendl, P. Keinrath, K. Krommes, G. Barth, J. Holzmannhofer, C. Pirich; Department of Nuclear Medicine and Endocrinology, Paracelsus Medical University Salzburg, Salzburg, AUSTRIA.

P399

Is CMR reproducible enough to replace Gated Blood Pool SPECT for the follow-up of RVEF?

T. Giraudmailet¹, F. Mokrane², C. Zadro², H. Rousseau², L. Dercle³; ¹CHU Toulouse, Toulouse, FRANCE, ²CHU Toulouse, Toulouse, FRANCE, ³Gustave Roussy, Villejuif, FRANCE.

P400

How the change in time interval between 99mTc-sestamibi injection and image acquisition may effect on quantitative data of gated SPECT myocardial perfusion imaging at stress phases

M. Haghighatafshar¹, S. Entezarmahdi², S. Mortazavi¹, F. Khajerahimi¹; ¹Nuclear Medicine Department, Shiraz University of Medical Science, Shiraz, IRAN, ISLAMIC REPUBLIC OF, ²Radiation Medicine Engineering Department, Shahid Beheshti University, Tehran, IRAN, ISLAMIC REPUBLIC OF.

P401

Would SPECT/CT be a must for attenuation correction in gated-SPECT myocardial perfusion imaging?

L. Ali¹, A. Al-Saffar¹, I. Loutfi²; ¹Faculty of Allied Health Sciences, Kuwait University, Kuwait, KUWAIT, ²Faculty of Medicine, Kuwait University, Kuwait, KUWAIT.

P24

Monday, October 12, 2015

16:00 – 16:30

Cardiovascular System: Miscellaneous

P402

Frequent incidental CT findings during Rubidium-82 myocardial perfusion PET

J. A. van der Heide, J. Esser, A. M. van den Berk, E. A. de Vrey, B. J. G. L. de Smet, J. M. H. de Klerk; Meander Medical Centre, Amersfoort, NETHERLANDS.

P403

The Value of Transient Ischemic Dilatation after Coronary Revascularization

S. S. Gültekin¹, M. Sadiç², M. Bilgin³, E. Yeter³, G. Koca², S. Açıkel³, M. Korkmaz²; ¹Hacettepe University, Kastamonu School of Medicine and Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, TURKEY, ²Ankara Training and Research Hospital, Ankara, TURKEY, ³Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, TURKEY.

P404

Usefulness and safety of adenosine stress myocardial perfusion SPECT for patients with "inactive" bronchial asthma.

T. Kasai¹, M. Aiga¹, Y. Iwasaki¹, K. Oshima¹, Y. Sasaki¹, Y. Fujita¹, N. Tanaka¹, A. Yamashina²; ¹Tokyo Medical University Hachioji Medical Center, Tokyo, JAPAN, ²Tokyo Medical University, Tokyo, JAPAN.

P405

Contraction synchronicity and work measured in patients with coronary artery disease

T. Niimi¹, M. Nanasato¹, H. Maeda²; ¹Nagoya Daini Red Cross Hospital, NAGOYA, JAPAN, ²Nagoya University, NAGOYA, JAPAN.

P406

Effect of Methamphetamine on perfusion and functional indices of the left ventricle using gated myocardial perfusion SPECT

V. Dabbagh, B. Dadpour, R. Afshari, S. Mohajeri; Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

P407

Activity of cardiac sympathetic nervous system in patients with atrial fibrillation before and after catheter ablation

B. Chrapko, M. Pachowicz, A. Głowniak, A. Nocur, M. Wójcik, A. Wysokiński; Medical University of Lublin, LUBLIN, POLAND.

P408

Usefulness of 18F-FDG PET-CT for Diagnosis of Cardiac Device Infection

A. Jiménez-Ballvé¹, M. J. Pérez-Castejón¹, M. Martínez de Bourio¹, C. Sánchez-Enrique², I. Vilacosta², L. Lapeña Gutiérrez^{1,3}, E. Cala Zuluaga¹, D. Vivas², J. L. Carreras-Delgado^{1,3}; ¹Nuclear Medicine Department, Hospital Clinico San Carlos, Madrid, SPAIN, ²Cardiology Department, Hospital Clinico San Carlos, Madrid, SPAIN, ³Universidad Complutense, Madrid, SPAIN.

P409

Cardiac 99mTc-DPD uptake in subjects with Glu89Gln transthyretin gene mutation: is it the earliest sign of disease development?

F. Minutoli¹, A. Mazzeo¹, G. Di Bella¹, A. Sindoni², L. Gentile¹, G. Vita¹, S. Baldari¹; ¹University of Messina, Messina, ITALY, ²AOU „Policlinico P. Giaccone“, Palermo, ITALY.

P410

The prognostic role of Fetuin-A serum levels in patients with Coronary Artery Disease. Corellation with myocardium scintigraphy.

A. Zissimopoulos¹, A. Psomiadou², L. Baloka², E. Karathanos¹, A. Thomaidou³; ¹Nuclear Medicine Department, Democritus University of Thrace, Alexandroupolis, GREECE, ²School of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, GREECE, ³Cardiology Clinic, Univ. Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, GREECE.

P411

Continued validation of metallic artefact reduction (MAR) algorithms for reducing the likelihood of false positive cardiac implantable device infection (CIED) investigations

M. J. Memmott, J. M. James, F. Z. Ahmed; Central Manchester University Hospitals NHS Foundation Trust, Manchester, UNITED KINGDOM.

P412

Correlation of QRS complex duration in 12-lead electrocardiography and cardiac systolic asynchrony assessed by gated SPECT myocardial perfusion imaging

M. Pachowicz, MD, K. Kosecka, A. Kocun, M. Zarobkiewicz, A. Roszkowska, L. Swierszcz, M. Belz, MD, B. Chrapko, MD PhD; Medical University of Lublin, Lublin, POLAND.

P413

Equilibrium Isotopic Ventriculography in the Diagnosis and Follow-Up of Patients with Drugs Induced Cardiotoxicity

J. Orozco-Cortés¹, I. Casáns-Tormo¹, R. Díaz-Expósito¹, S. Prado-Wohlwend¹, H. Bowles-Antelo¹, B. Bermejo-de las Heras², M. Romero-Otero¹; ¹Nuclear Medicine. Hospital Clinico Universitario, Valencia, SPAIN, ²Oncology. Hospital Clinico Universitario, Valencia, SPAIN.

P414

Improvement in myocardial perfusion induced by subendocardial stem cell injection in patients with advanced heart failure

L. Lezaic¹, A. Socan¹, P. Kolenc Peitl¹, G. Poglajen¹, M. Sever¹, F. Haddad², B. Vrtovec¹; ¹Klinicni center Ljubljana, LJUBLJANA, SLOVENIA, ²Stanford University Medical Center, LJUBLJANA, CA, UNITED STATES.

P415

Evaluation of early changes in left ventricular volumes in women with breast cancer treated with adjuvant trastuzumab

C. Haase, B. Zerahn, A. Polk, D. Nielsen; Herlev Hospital, Herlev, DENMARK.

P416

Effects of anthracycline and trastuzumab chemotherapy on diastolic function and mechanical synchrony

V. M. Alves, T. Vieira, A. Oliveira, A. Fernandes, A. Pinto, T. Faria, B. Perez, J. Pereira; São João Hospital Centre, Porto, PORTUGAL.

P417

Association between body mass index and left ventricular mechanical dyssynchrony in patients with chronic kidney disease

V. M. Alves, A. Fernandes, T. Vieira, A. Oliveira, A. Pinto, T. Faria, B. Perez, J. Pereira; São João Hospital Centre, Porto, PORTUGAL.

P418

Post-stress worsening of LV mechanical dyssynchrony is more frequent in CAD patients but has low diagnostic accuracy

Y. Chang, C. Hsu; Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, TAIWAN.

P25 Monday, October 12, 2015

16:00 – 16:30

Neurosciences: Basic Science

P419

Test-retest reproducibility of adenosine A1 receptor imaging in rats, using microPET, the tracer 11C-MPDX, repeated arterial blood sampling and kinetic modeling

J. W. A. Sijbesma¹, X. Zhou¹, J. Doorduyn¹, M. Houwertjes², C. Kwizera¹, B. Maas¹, P. Meerlo³, R. A. J. O. Dierckx¹, R. H. J. A. Slart¹, P. H. Elsinga¹, A. Van Waarde¹; ¹University of Groningen, University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, GRONINGEN, NETHERLANDS, ²University of Groningen, University Medical Center Groningen, Department of Anesthesiology, GRONINGEN, NETHERLANDS, ³University of Groningen, Department of Behavioral Physiology, GRONINGEN, NETHERLANDS.

P420

Effect of mTOR inhibition on epileptogenesis in the rat epilepsy model

A. Cullier¹, F. Maskali¹, A. Clement¹, S. Poussier¹, G. Karcher, Pr.¹, P. Marie, Pr.¹, E. Raffo²; ¹Gie-Nancyclotep, Vandoeuvre-Les-Nancy, FRANCE, ²Neuropediatrics Departement, Hospital Of Brabois, Vandoeuvre-Les-Nancy, FRANCE.

P421

Are there gender differences in P-glycoprotein function at the rat blood-brain barrier ?

S. MARIE, G. POTTIER, S. GOUTAL, S. AUVITY, I. BUVAT, R. BOISGARD, F. DOLLE, F. CAILLE, N. TOURNIER; IMIV, UMR 1023 Inserm/CEA/Université Paris Sud - ERL 9218 CNRS, CEA, DSV, I2BM, Service Hospitalier Frédéric Joliot, Orsay, F-91401, FRANCE.

P422

A [¹¹C]preladenant PET study of Striatal adenosine A_{2A} receptor occupancy by KW-6002 in rats

X. Zhou, P. Elsinga, R. Dierckx, E. de Vries; University Medical Center Groningen, Groningen, NETHERLANDS.

P423

Comparing 123I-Ioflupane (DatScan) SPECT using LEHR and Fan-Beam Collimators - an Initial Investigation into Clinical Impact

H. A. Williams, G. Al-Bahrani, J. James; Nuclear Medicine, Manchester, UNITED KINGDOM.

P424

Revealing asymmetric activations in the auditory cortex in rats with FDG PET

M. Mamach^{1,2}, G. Berding^{1,2}, J. P. Bankstahl¹, F. M. Bengel¹, S. Kurt^{1,2}; ¹Medical School, Hannover, GERMANY, ²Cluster of Excellence „Hearing4All“, Oldenburg, GERMANY.

P425

Metabolic and Neurovascular Coupling in brain SPECT and PET of patients with epilepsy and normal 3T MRI.

E. N. I. Itikawa^{1,2}, D. K. S. Sonvenso^{1,3}, L. A. S. Santos^{1,3}, M. K. Kato^{1,3}, F. A. P. Pitella^{1,3}, C. E. P. B. Baltazar^{1,4}, A. C. T. Trevisan^{1,2}, V. A. J. Junior^{1,3,5}, L. W. A. Wichert-Ana^{1,2,3}; ¹Ribeirão Preto School of Medicine, Ribeirão Preto, BRAZIL, ²Post-Graduation Program Interunits Bioengineering EESC/FMRP/IQSC-USP, São Carlos, BRAZIL, ³Postgraduation Program in Internal Medicine, Ribeirão Preto, BRAZIL, ⁴Faculty of Philosophy, Sciences and Literature of Ribeirão Preto, Ribeirão Preto, Ribeirão Preto, BRAZIL, ⁵Department of Neurology, Ribeirão Preto, BRAZIL.

P426

Quantification of GABA-A receptor binding in the auditory system of rats using F-18-Flumazenil PET

M. Mamach^{1,2}, G. Berding^{1,2}, J. P. Bankstahl¹, T. L. Ross¹, F. M. Bengel¹, S. Kurt^{1,2}; ¹Medical School, Hannover, GERMANY, ²Cluster of Excellence „Hearing4All“, Oldenburg, GERMANY.

P427

Quantification of 5HT_{2A}-Receptors in the Human Brain with [18F]MHMZ

V. Kramer¹, M. Herth², E. Hernandez³, C. Juri⁴, R. Pruzzo³, F. Rösch⁵, H. Amaral¹; ¹PositronPharma SA, Santiago de Chile, CHILE, ²University of Copenhagen, Copenhagen, DENMARK, ³Nuclear Medicine and PET/CT Center FALP, Santiago de Chile, CHILE, ⁴Universidad Catolica, Santiago de Chile, CHILE, ⁵Johannes Gutenberg-Universität Mainz, Mainz, GERMANY.

P26 Monday, October 12, 2015

16:00 – 16:30

Neurosciences: Dementia

P428

Introducing the Glucose Metabolism to Amyloid Deposition Ratio Image

K. Ishii¹, R. Takahashi², Y. Wakabayashi¹, C. Hosokawa¹, H. Kaida¹, T. Murakami¹; ¹Kinki University, Osakasayama, JAPAN, ²Hyogo Prefectural Rehabilitation Hospital at Nishi-Harima, Tatsuno, JAPAN.

P429

The brain SPECT perfusion rating using Neurogam program for diagnostics of early onset Alzheimer disease

R. Pichova¹, A. Bartos², O. Samokhvalova², J. Kotoucova², D. Ripova³; ¹Charles University Prague, 3rd Medical Faculty, CZECH REPUBLIC, ²Charles University Prague, 3rd Medical Faculty, National Institute of Mental, CZECH REPUBLIC, ³Charles University Prague, National Institute of Mental Health, CZECH REPUBLIC.

P430

SUVratio(SUVr)-independent semiquantification of brain amyloidosis: a software-aided integration of visual and quantitative analyses.

S. Morbelli¹, F. Nobili², F. Sensi³, U. Guerra⁴, L. Rei³, I. Bossert¹, A. Chincarini for the ADN³; ¹Nuclear Medicine Unit, IRCCS AOU San Martino - IST, Genoa, ITALY, ²Department of Neurology, IRCCS AOU San Martino - IST, University of Genoa, Genoa, ITALY, ³National Institute for Nuclear Physics (INFN), Genoa, ITALY, ⁴Nuclear Medicine Unit, Fondazione Poliambulanza, Brescia, ITALY.

P431

18F-FDG PET/CT: A New Tool to Evaluate the Interaction between Cognitive Reserve (CR) and CSF-Biomarkers in Alzheimer Disease (AD) Patients.

E. Carapelle, S. Modoni, G. Rotondo, L. Specchio; OSPEDALI RIUNITI, FOGGIA, ITALY.

P432

Different patterns of brain glucose consumption related to the age of onset in Alzheimer's disease

A. Chiaravalloti¹, D. Di Biagio¹, R. Danieli¹, B. Di Pietro¹, G. Koch², A. Martorana², P. Abbatiello¹, O. Schillaci¹; ¹Department of Biomedicine and Prevention, University Tor Vergata, Rome, ITALY, ²Department of Neurosciences, University Tor Vergata, Rome, ITALY.

P433

The impact of education on FDG PET single subject analysis for Alzheimer's dementia diagnosis

I. Mainta, G. Amzalag, O. Ratib, G. B. Frisoni, V. Garibotto; University Hospital of Geneva, GENEVE, SWITZERLAND.

P434

Proposal of a Method to Estimate Normal Threshold Values of Summed Z-scores in the Specified Regions for Z Sum Analysis for Diagnosing Alzheimer's Disease with Voxel-based Control Database of I-123 IMP SPECT

N. Shuke¹, C. Miyazaki¹, A. Ando¹, T. Onishi¹, K. Saito¹, J. Sato², A. Okizaki², K. Nishikawa³; ¹Kushiro Kojinkai Memorial Hospital, Kushiro, JAPAN, ²Asahikawa Medical College, Asahikawa, JAPAN, ³Imaging Information Technology Center, Nihon Medi-Physics Co., Ltd., Osaka, JAPAN.

P435

Correlation between brain perfusion SPECT and neuropsychological test in the diagnosis of dementia

M. J. Ibáñez Ibáñez¹, L. Mohamed Salem¹, M. V. Godoy Bravo¹, L. F. Álvarez Nieto¹, R. Reyes Marlés¹, M. I. Castellón Sánchez¹, L. Frutos Esteban¹, J. L. Navarro Fernández¹, J. Marín Muñoz², C. Antúnez Almagro², M. A. Claver Valderas¹; ¹Servicio de Medicina Nuclear, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN, ²Unidad de Demencias, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN.

P436

¹¹C-PIB Retention Patterns in Amnesic and Nonamnesic Mild Cognitive Impairment Patients. Comparison with 18F- FDG PET/CT

Z. Bravo- Ferrer, J. Jiménez-Bonilla, M. De Arcocha-Torres, I. Banzo, I. Martínez-Rodríguez, R. Quirce, C. Lavado-Pérez, J. L. López-Defilló, M. Jiménez-Alonso, D. Meza-Escobar, F. Gómez-de la Fuente, J. M. Carril; Nuclear Medicine. Molecular Imaging Group (IDIVAL). Marqués de Valdecilla University Hospital. University of Cantabria, Santander, SPAIN.

P437

Hypometabolism in posterior and temporal areas of the brain is associated with cognitive decline in Parkinson's disease

F. Demailly¹, C. Tard², P. Lenfant¹, F. Semah¹, C. Moreau³, K. Dujardin³; ¹Service De Médecine Nucléaire, CHRU Lille, Lille, FRANCE, ²Service de Neurophysiologie, CHRU Lille, Lille, FRANCE, ³Service de Neurologie et pathologie du mouvement, CHRU Lille, Lille, FRANCE.

P438

Role of Tc-99m HMPAO brain SPECT in the differential diagnosis of vascular and other dementias

A. T. Golubic¹, R. Petrovic¹, T. Samardzic¹, N. Klepac², F. Borovecki²; ¹Department of Nuclear Medicine and Radiation Protection, University Hospital Center Zagreb, Zagreb, CROATIA, ²Clinical Department of Neurology, University Hospital Center Zagreb, Zagreb, CROATIA.

P439

Brain perfusion differences between early and late onset Alzheimer's disease.

V. Valotassiou¹, J. Papatriantafyllou², N. Sifakis³, C. Tzavara¹, S. Alexiou¹, I. Tsougos¹, D. Psimadas¹, A. Ziaka¹, E. Baniora¹, P. Georgoulis¹; ¹Department of Nuclear Medicine, University Hospital of Larissa, Larissa, GREECE, ²Memory & Cognitive Disorders Clinic, Neurology Dpt., "G. Gennimatas" Hospital, Athens, GREECE, ³Nuclear Medicine Dpt, "Alexandra" University Hospital, Athens, GREECE.

P440

FDG-PET study of psychophysiological mechanisms of aggression in patients with vascular dementia.

J. Khomenko, D. Susin, G. Kataeva, T. Reznikova, N. Seliverstova, B. Lipovetsky; N.P.Bechtereva Institute of the Human Brain, RAS, St.Peterburg, RUSSIAN FEDERATION.

P441

Diagnostic value of regional myocardial adrenergic imaging using 123I-MIBG compared to SPECT-HMPAO perfusion and cerebrospinal fluid biomarkers to differentiate Lowy Body Dementia and Alzheimer Disease.

F. Hamza¹, I. Jarak¹, W. Amouri¹, F. Kallel¹, N. Bouzidi², S. Charfeddine¹, E. Turki², M. Maaloul¹, C. Mhiri², F. Guermazi¹; ¹Nuclear Medicine Departement, Habib Bourguiba Hospital, Sfax, TUNISIA, ²Departement of Neurology, Habib Bourguiba Hospital, Sfax, TUNISIA.

P442

FDG-PET in the evaluation of brain metabolic changes induced by Cognitive stimulation in aMCI subjects

E. Giovannini, E. Borsò, F. Benso, E. Carabelli, M. Del Sette, A. Ciarmiello; Sant'Andrea Hospital, La Spezia, ITALY.

P443

Graph-theoretical analysis for comparison of functional brain networks between very early Alzheimer's disease and healthy volunteers

H. Matsuda, E. Imabayashi, J. Rokicki, N. Maikusa; National Center of Neurology and Psychiatry, Kodaira, JAPAN.

P445

Pilot data on 11C-PiB PET in major depressive disorder

E. Imabayashi¹, H. Baba², H. Matsuda¹, I. Kuji³; ¹National Center of Neurology and Psychiatry, TOKYO, JAPAN, ²Juntendo University, TOKYO, JAPAN, ³Saitama International Center, Saitama Medical University, SAITAMA, JAPAN.

P446

Impact of PET Brain Imaging Using F18-FDG and F18-FLORBETAPIR In Patients With Cognitive Impairment

C. Gamez-Cenzano¹, J. J. Robles-Barba¹, L. Rodriguez-Bel¹, J. Gascon-Bayarri², M. Cortes-Romera¹, A. Sabate-Llobera¹, L. M. Gracia-Sanchez¹, I. Romero-Zayas¹, M. Roca-Engronyat¹, J. L. Vercher-Conejero¹, C. Majos-Torro¹, C. Soriano-Mas³, C. Aguilera-Grijalvo¹, I. Rico-Pons⁴, R. Reñe-Ramirez⁴; ¹Idi-Hospital De Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ²Neurología-Hospital de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ³Hospital de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ⁴Neurologia-Hospital de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN.

P27

Monday, October 12, 2015

16:00 – 16:30

Neurosciences: Psychiatry

P447

A comparative analysis of SERT function in neuropsychiatric disorders

S. Nikolaus, H. Müller, H. Hautzel; University Hospital Düsseldorf, DÜSSELDORF, GERMANY.

P448

Anxiety disorder, major depression, bipolar disorder and schizophrenia show different patterns of 5-HT1A receptor dysfunction

S. Nikolaus, H. Müller, H. Hautzel; University Hospital Düsseldorf, DÜSSELDORF, GERMANY.

P449

Different patterns of 5-HT2A receptor dysfunction in anxiety disorder, major depression, bipolar disorder and schizophrenia

S. Nikolaus, H. Hautzel, H. Müller; University Hospital Düsseldorf, DÜSSELDORF, GERMANY.

P450

Brain perfusion single photon emission computed tomography (SPECT) in patients with attention-deficit/hyperactivity disorder (ADHD) using 99mTc-ECD: a report of three cases and review of the literature

M. Taghizadeh Asl¹, F. Yousefi², R. Nemati³, M. Assadi²; ¹Department of Nuclear Medicine, Kasra Hospital, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, BUSHEHR, IRAN, ISLAMIC REPUBLIC OF, ³Department of Neurology, Bushehr Medical University Hospital, Bushehr University of Medical Sciences, BUSHEHR, IRAN, ISLAMIC REPUBLIC OF.

P451

Our institutional pictorial essay on brain perfusion SPECT in various neuro-psychiatric disorders and intoxication: Though practical, it is not very commonly used

M. Taghizadeh Asl¹, R. Nemat², M. Assadi³; ¹Department of Nuclear Medicine, Kasra Hospital, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Department of Neurology, Bushehr Medical University Hospital, Bushehr University of Medical Sciences, BUSHEHR, IRAN, ISLAMIC REPUBLIC OF, ³The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, BUSHEHR, IRAN, ISLAMIC REPUBLIC OF.

P452

Evaluating the brain status of serotonin transporters in depression-like rat model using 4-[18F]-ADAM/animal PET

C. Cheng¹, K. Ma², S. Lu^{1,3}, C. Shiue¹, W. Huang⁴; ¹Department of Nuclear Medicine, Tri-Service General Hospital, National Defense Medical Center, TAIPEI, TAIWAN, ²Department of Biology and Anatomy, National Defense Medical Center, TAIPEI, TAIWAN, ³Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, TAIWAN, ⁴Departments of nuclear medicine and medical research, Changhua Christian Hospital, CHANGHUA, TAIWAN.

P453

SPECT scanning of brainstem serotonin transporter availability reveals association with circulating inflammatory tumour necrosis factor

R. Krishnadas¹, A. Nico², J. Sassarini³, N. Puri², S. Pimlott², D. Hadley², I. McInnes³, J. Cavanagh¹; ¹Sackler Institute of Psychobiological Research, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UNITED KINGDOM, ²NHS Greater Glasgow & Clyde, Glasgow, UNITED KINGDOM, ³University of Glasgow, Glasgow, UNITED KINGDOM.

P454

Resting-state Functional Connectivity in Social Anxiety Disorder Compared to Healthy Controls and the Effect of Pharmacotherapy

A. G. G. Doruyter¹, C. Lochner¹, P. Dupont², D. Stein¹, J. Warwick¹; ¹Stellenbosch University, Cape Town, SOUTH AFRICA, ²Katholieke Universiteit Leuven, Leuven, BELGIUM.

P28

Monday, October 12, 2015

16:00 – 16:30

Neurosciences: Neurodegeneration

P456

Imaging Mutant Huntingtin Aggregates: Development of Potential PET Ligands

C. J. Brown¹, M. Prime¹, D. Clark-Frew¹, S. Schaert², J. Häggkvist³, C. Halldin³, V. Stepanov³, A. Varrone³, K. Varnäs³, M. Svedberg³, I. Munoz-Sanjuan⁴, V. Khetarpal⁴, J. Bard⁴, J. Wityak⁴, C. Dominguez⁴; ¹Evotec UK Ltd, Abingdon, UNITED KINGDOM, ²Evotec AG, Hamburg, GERMANY, ³Karolinska Institutet, Stockholm, SWEDEN, ⁴CHDI, Los Angeles, CA, UNITED STATES.

P457

The comparison of I-123-ioflupane dopamine transporter imaging with I-123-MIBG cardiac imaging in Parkinson's disease and Lewy body disease

M. Momose; Matsumoto Medical Center, Matsumoto, JAPAN.

P458

Functional correlates of cerebrospinal fluid levels of lactate dehydrogenase in Alzheimer's Disease: a 18F FDG PET/CT study.

A. Chiaravalloti¹, M. Pierantozzi², C. Liguori², C. Di Russo¹, A. Fiorentini¹, R. Catalano¹, S. Pizzi¹, O. Schillaci¹; ¹Department of Biomedicine and Prevention, University Tor Vergata, Rome, ITALY, ²Department of Neurosciences, University Tor Vergata, Rome, ITALY.

P459

Is amyloid deposition related to the age of onset of Alzheimer disease?

A. Chiaravalloti¹, A. Lacanfora¹, R. Danieli¹, A. Fiorentini¹, L. Cravello², F. Di Iulio², C. Caltagirone², O. Schillaci¹; ¹Department of Biomedicine and Prevention, University Tor Vergata, Rome, ITALY, ²IRCCS Santa Lucia, Rome, ITALY.

P460

Initial experience of the dopamine transporter SPECT in three pediatric patients with rare neurodegenerative disorder

I. Mochida, K. Matsunaga, S. Watanabe, K. Isohashi, T. Watabe, M. Tatsumi, H. Kato, E. Shimosegawa, J. Hatazawa; Osaka University Graduate School of Medicine, Suita-shi, Osaka, JAPAN.

P461

Investigating the co-grafted effects of porcine ventral mesencephalic tissue and mesenchymal stem cells in Parkinson's disease rat model using [18F]-FDOPA/ animal PET

K. Ma¹, T. Liu¹, Y. Jhao¹, S. Weng¹, K. Tzen², R. Yen², W. Huang³;
¹Department of Biology and Anatomy, National Defense Medical Center, TAIPEI, TAIWAN, ²Department of Nuclear Medicine, National Taiwan University Hospital, TAIPEI, TAIWAN, ³Departments of nuclear medicine and medical research, Changhua Christian Hospital, CHANGHUA, TAIWAN.

P462

Cerebral cortex glucose metabolism correlates with the MRS findings in white matter in HIV positive patients

E. Gromova, J. Khomenko, G. Kataeva, A. Bogdan, I. Kotomin; N.P.Bechtereva Institute of the Human Brain, RAS, St.Peterburg, RUSSIAN FEDERATION.

P463

Effect of mTOR inhibition on epileptogenesis in the rat epilepsy model

A. Cullier^{1,2}, F. Maskali¹, A. Clement¹, S. Poussier¹, G. Karcher¹, P. Marie¹, E. Raffo³; ¹Gie-Nancyclotep, Vandoeuvre-Les-Nancy, FRANCE, ²hospital of brabois, Vandoeuvre les nancy, FRANCE, ³hospital of brabois, Vandoeuvre-Les-Nancy, FRANCE.

P464

The influence of gender on brain perfusion in patients with Alzheimer's disease.

V. Valotassiou¹, J. Papatriantafyllou², N. Sifakis³, C. Tzavara¹, I. Tsougos¹, S. Alexiou¹, D. Psimadas¹, E. Baniora¹, A. Ziaka¹, P. Georgoulis¹; ¹Department of Nuclear Medicine, University Hospital of Larissa, Larissa, GREECE, ²Memory & Cognitive Disorders Clinic, Neurology Dpt., "G. Gennimatas" Hospital, Athens, GREECE, ³Nuclear Medicine Dpt, "Alexandra" University Hospital, Athens, GREECE.

P465

Application of CT based spatial normalization by DARTEL to quantitative assessment of 123I-FP-CIT SPECT.

K. Yokoyama, E. Imabayashi, H. Matsuda; National Center of Neurology and Psychiatry, Kodaira, JAPAN.

P29

Monday, October 12, 2015

16:00 – 16:30

Neurosciences: Movement Disorders

P466

Is Dynamic [11C]Raclopride PET Scanning needed to Distinguish Patients from Healthy Controls?

P. Gykiere, N. Van Laeken, A. Dobbeleir, F. De Vos, I. Goethals; University Hospital Ghent, Ghent, BELGIUM.

P467

Relationship between dopamine deficit and the expression of depressive behavior resulting from alteration serotonin system

M. Lee¹, Y. Ryu², J. Choi², W. Cho³, I. Hyun¹; ¹Inha University Hospital, Incheon, KOREA, REPUBLIC OF, ²Yonsei University, Gangnam Severance Hospital, Seoul, KOREA, REPUBLIC OF, ³Yonsei University College of Medicine, Wonju, KOREA, REPUBLIC OF.

P468

123-I-MIBG cardiac scintigraphy quantitative analysis in Parkinson's disease (PD) and Parkinsonism (P) differential diagnosis: a classification tree (CIT) classifier additional contribute.

S. Nuvoli¹, B. Palumbo², M. L. Fravolini³, B. Piras¹, G. Dachena¹, S. Cascianelli², A. Spanu¹, G. Madeddu¹; ¹Unit of Nuclear Medicine, University of Sassari, Sassari, ITALY, ²Section of Nuclear Medicine, Dept of Surgical and Biomedical Sciences. University of Perugia, Perugia, ITALY, ³Dept of Engineering, University of Perugia, Perugia, ITALY.

P469

Contribution of cardiac 123-I metaiodobenzylguanidine (MIBG) scintigraphy of combined whit FP-CIT SPECT in the differential diagnosis of the Parkinson disease and atypical parkinsonian syndromes.

G. Martinez Pimienta, R. Gomez Llopico, M. Bajén, A. Benitez Segura, O. Puig, J. Rojas Camacho, M. Boya-Roman, J. Rodríguez-Rubio, E. Noriega, J. Mora; Hospital Universitario de Bellvitge, Barcelona, SPAIN.

P470

Correlation between tracer injection latency and seizure duration with the accuracy in detection of epileptogenic zone by SPECT and SISCOM

M. Suarez-Piñera¹, A. Mestre-Fusco¹, S. Medrano², M. Ley³, G. Conesa⁴, R. Rodrigo³; ¹Hospital del Mar Barcelona. Nuclear Medicine Department, Barcelona, SPAIN, ²Hospital del Mar Barcelona. Neuroradiology Department, Barcelona, SPAIN, ³Hospital del Mar Barcelona. Epilepsy Unit. Neurology Department, Barcelona, SPAIN, ⁴Hospital del Mar Barcelona. Neurosurgery Department, Barcelona, SPAIN.

P471

Importance of different modalities (SPECT/CT, MRI) in the quantitative assessment of DaTscan findings

S. Szekeres¹, N. Kovacs², G. Perlaki³, G. Orsi³, L. Papp⁴, B. Suha⁵, E. Schmidt¹, K. Zambo¹; ¹University of Pecs Department of Nuclear Medicine, PECS, HUNGARY, ²University of Pecs Department of Neurology, PECS, HUNGARY, ³MTA-PTE Clinical Neuroscience MRI Research Group, PECS, HUNGARY, ⁴Mediso GmbH, Budapest, HUNGARY, ⁵University of Pecs Medical Faculty, PECS, HUNGARY.

P472

Exploring the feasibility and potential advantages of applying CT-based attenuation correction in 123I-FPCIT and 123I-IBZM SPECT studies. Our first experience

K. Badiavas, I. Iakovou, V. Athanasiou, K. Mihailos; Nuclear Medicine Department, Aristotle University, „Papageorgiou“ General Hospital, Thessaloniki, GREECE.

P473

The clinical usefulness of I-123-lobflupane SPECT (DaTscan) in patients with equivocal diagnosis of Parkinson's disease

S. Czibor¹, D. Nagy¹, M. Moravszki¹, L. Duffek¹, E. Takacs², E. Kalameny³, Z. Szeplaki⁴, A. Takats⁴, I. Szilvasi¹; ¹Hungarian Defence Forces Medical Centre, Dept. of Nuclear Medicine, Budapest, HUNGARY, ²Semmelweis University, Dept. of Nuclear Medicine, Budapest, HUNGARY, ³Hungarian Defence Forces Medical Centre, Dept. of Neurology, Budapest, HUNGARY, ⁴Semmelweis University, Dept. of Neurology, Budapest, HUNGARY.

P474

Diagnostic value of MIBG cardiac scintigraphy for the diagnosis of Parkinson disease.

M. Abbasi¹, A. Tafakhori²; ¹Department of Nuclear Medicine, Vali-e-asr Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Department of Neurology, Imam-komeini Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

P475

Absolute quantitative evaluation of 123I-FP-CIT: is it possible?

F. Scalorbi¹, S. Bressan², S. Favaretto³, S. Berti¹, S. Pompanin³, A. Cagnin³, A. Antonini³, C. Gabelli⁴, P. Zucchetta¹, F. Bui¹, D. Cecchin¹; ¹Department of Nuclear Medicine of Padova, Padova, ITALY, ²Hospital of Padova, Padova, ITALY, ³Department of Neurology of Padova, Padova, ITALY, ⁴Centro regionale per la cura dell'invecchiamento cerebrale, Padova, ITALY.

P476

Cut-off values to diagnose Parkinson's disease by means of 123I-FP-CIT brain SPECT semiquantitative data as evaluated by Classification Tree algorithm

B. Palumbo¹, S. Cascianelli², I. Sabalich¹, A. Santonicola¹, T. Buresta¹, M. L. Fravolini², N. Tambasco³, S. Nuvoli⁴, A. Spanu⁴, G. Madeddu⁴; ¹Department of Surgical and Biomedical Sciences- Nuclear Medicine and Health Physics- University of Perugia, PERUGIA, ITALY, ²Department of Engineering-University of Perugia, PERUGIA, ITALY, ³Unit of Neurology, Department of Medicine, Perugia University Hospital, PERUGIA, ITALY, ⁴Unit of Nuclear Medicine, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, ITALY.

P477

Evaluation of 99mTc-TRODAT-1 SPECT in the diagnosis of Parkinson's disease and its differentiation from the other types of parkinsonism syndroms - A pilot study

D. Beiki¹, A. Esmaili¹, B. Fallahi¹, S. Oveisgharan², H. Noorollahi-Moghaddam³, M. Erfani⁴, A. Tafakhori⁵, M. Rohani⁶, A. Fard-Esfahani¹, A. Emami-Ardekani¹, M. Eftekhari¹; ¹Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Department of Neurology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Shariati Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Radiation Application Research School, Nuclear Science and Technology Research Institute, Atomic Energy Organization of Iran, Tehran, Iran, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁵Department of Neurology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁶Department of Neurology, School of Medicine, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

P478

123I-MIBG cardiac scintigraphy in discriminating Parkinson's disease (PD) from vascular parkinsonism (VP) using Classification tree (CIT) classifier together with conventional quantitative analysis.

S. Nuvoli¹, A. Spanu¹, B. Palumbo², M. L. Fravolini³, G. Dachena¹, B. Piras¹, G. Madeddu¹; ¹Nuclear Medicine Unit; University of Sassari, Sassari, ITALY, ²Section of Nuclear Medicine, Dept of Surgical and Biomedical Sciences. University of Perugia, Perugia, ITALY, ³Dept of Engineering University of Perugia, Perugia, ITALY.

P479

Importance of myocardial MIBG scintigraphy in differentiating idiopathic Parkinson's disease from other neurodegenerative diseases

R. Petrovic¹, A. T. Golubic¹, T. Samardzic¹, N. Klepac², S. Telarovic², S. Tezak¹; ¹Department of Nuclear Medicine and Radiation Protection, University Hospital Center Zagreb, Zagreb, CROATIA, ²Clinical Neurology Department, University Hospital Center Zagreb, Zagreb, CROATIA.

P480

Correlation among freezing of gait, falls and dopaminergic dysfunction in Parkinson's disease: evidences of a five years follow-up.

F. Guidoccio¹, R. Ceravolo², G. Puccini¹, D. Frosini², G. Manca¹, U. Bonuccelli², I. Paglianiti¹, D. Volterrani¹; ¹Regional Center of Nuclear Medicine, University of Pisa, PISA, ITALY, ²Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa, PISA, ITALY.

P481

99mTc-TRODAT-1 SPECT in the evaluation of Parkinson's disease progression and severity.

A. Damian¹, C. Pascovich¹, D. Muñoz¹, M. Langhain¹, I. Amorin², A. Lescano², R. Buzo², R. Ferrando¹; ¹Nuclear Medicine Centre, Clinical Hospital, University of the Republic, Montevideo, URUGUAY, ²Neurology Institute, Clinical Hospital, University of the Republic, Montevideo, URUGUAY.

P482

Pupillometry and I-123-DaTSCAN imaging in Parkinson's disease-a comparative study.

G. Gerasimou¹, E. Giza², S. Bonstanjioloulou², Z. Katsarou³, E. Moravidis¹, E. Papanastasiou¹, P. Ioannidis¹, A. Gotzamani-Psarrakou¹; ¹AHEPA University Hospital, THESSALONIKI, GREECE, ²Papanikolaou Hospital, THESSALONIKI, GREECE, ³Hippokration Hospital, THESSALONIKI, GREECE.

P483

Difference in striatal dopamine transporter availability and psychiatric symptoms in Parkinson's disease subtypes: ¹²³I-FP-CIT SPECT results

F. Cocciolillo¹, D. Di Giuda¹, S. Annunziata¹, V. Scolozzi¹, F. Bove², M. G. Vita², C. Piano², D. Fortini¹, A. R. Bentivoglio², G. Camardese³, A. Giordano¹; ¹Nuclear Medicine Institute, Università Cattolica del Sacro Cuore, Roma, ITALY, ²Neurology Institute, Università Cattolica del Sacro Cuore, Roma, ITALY, ³Psychiatric and Psychology Institute, Università Cattolica del Sacro Cuore, Roma, ITALY.

P484

The significance of the posterior part of the putamen in I-123-FP-CIT SPECT scanning and the early diagnosis of Parkinson's disease.

G. Gerasimou¹, E. Papanastasiou¹, E. Moravidis¹, Z. Katsarou², P. Ioannidis¹, M. Arnaoutoglou¹, N. Grigoriadis¹, T. Tegos¹, G. Liaros¹, M. Gkirkoudis¹, A. Vasileiadis¹, S. Bonstanjiopoulou³, A. Gotzamani-Psarrakou¹; ¹AHEPA University Hospital, THESSALONIKI, GREECE, ²Hippokration Hospital, THESSALONIKI, GREECE, ³Papanikolaou Hospital, THESSALONIKI, GREECE.

P30

Monday, October 12, 2015

16:00 – 16:30

Neurosciences: Data Analysis & Quantification

P485

In vivo quantification of the [11C]-DASB binding in the normal canine brain using Positron Emission Tomography

O. Taylor¹, N. Van Laeken², F. De Vos², I. Polis¹, T. Bosmans¹, I. Goethals³, R. Achten³, A. Dobbeleir³, E. Vandermeulen¹, C. Baeken³, J. Saunders¹, K. Peremans¹; ¹University of Ghent (Faculty of Veterinary Medicine), Merelbeke, BELGIUM, ²University of Ghent (Faculty of Pharmaceutical Sciences), Ghent, BELGIUM, ³Ghent University Hospital, Ghent, BELGIUM.

P486

Automated PET-only quantification of amyloid deposition with adaptive template and amyloid-specific region-of-interest

G. Akamatsu^{1,2}, Y. Ikari¹, A. Ohnishi¹, T. Nishio¹, H. Nishida¹, K. Aita¹, Y. Yamamoto³, M. Sasaki¹, M. Sasaki², M. Senda¹; ¹Institute of Biomedical Research and Innovation, Kobe, JAPAN, ²Kyushu University, Fukuoka, JAPAN, ³Kobe University, Kobe, JAPAN.

P487

Fully Parametric Imaging for Reversible Tracer of FLT within Reasonable Time

N. Kudomi, A. Nishiyama, Y. Maeda, T. Hatakeyama, Y. Yamamoto, Y. Nishiyama; Faculty Of Medicine, Kagawa University, KAGAWA, JAPAN.

P488

Comparison with cerebral blood volume on 15Ogas-PET/CT in patients with chronic cerebrovascular disease

N. Morita, A. Shimizu, Y. Terakawa, K. Kajimoto, T. Uehara, D. Maruyama, J. Nakagawara, H. Iida; National Cerebral and Cardiovascular Center, Suita, JAPAN.

P489

Evaluation of increasing cerebral blood volume on 15Ogas-PET/CT in patients with severe ischemic cerebrovascular disease

N. Morita, A. Shimizu, Y. Terakawa, K. Kajimoto, T. Uehara, D. Maruyama, J. Nakagawara, H. Iida; National Cerebral and Cardiovascular Center, Suita, JAPAN.

P490

Deformable registration for 18F-florbetapir PET quantification

L. Sibille, C. Hutton, J. Declerck; Siemens Molecular Imaging, Oxford, UNITED KINGDOM.

P491

Total Metabolic Index; Inter-Rater Variability in Quantifying Cerebral Hemispheric Glucose Metabolism in the Course of Treatment of Glioma

E. A. Segtnan¹, P. Grupe¹, J. O. Jarden², S. B. Christlieb¹, J. E. Pedersen¹, C. Constantinescu¹, O. Gerke¹, S. Houshmand³, S. Hess¹, A. Alavi³, P. F. Højlund-Carlson¹; ¹Dept. of Nuclear Medicine, Odense University Hospital, Odense, DENMARK, ²Dept. of Neurology, Herlev University Hospital, Copenhagen, DENMARK, ³Division of Nuclear Medicine, University of Pennsylvania, Philadelphia, PA, UNITED STATES.

P493

Efficiency Changes of Cerebral Blood Flow Network in Response to Hypercapnia Show Early Abnormal Status in Mild Cognitive Impairment: a Graph Analysis Study

C. Sánchez Catsús¹, G. Sanabria-Díaz², R. Dierckx³, L. Melie-García²; ¹CIREN, Havana, CUBA, ²Cuban Neuroscience Center, Havana, CUBA, ³Department of Nuclear Medicine & Molecular Imaging, Medical Imaging Center, University Medical Center, Groningen, NETHERLANDS.

P494

Attenuation correction by CT can improve detectability of lesions by voxel based statistical analysis of brain SPECT

H. Kato¹, E. Shimosegawa¹, K. Fujino², J. Hatazawa¹; ¹Osaka University Graduate School of Medicine, Osaka, JAPAN, ²Osaka University Medical Hospital, Osaka, JAPAN.

P495

Detection of Regional Cerebral Blood Flow disturbance with the assistance of statistical parametric mapping (SPM): a 99mTc-ECD brain perfusion SPECT study in Alzheimer's and Multiple Sclerosis diseases

N. Chabi¹, M. Taghizadeh Asl², M. Assadi¹; ¹The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, BUSHEHR, IRAN, ISLAMIC REPUBLIC OF, ²Department of Nuclear Medicine, Kasra Hospital, BUSHEHR, IRAN, ISLAMIC REPUBLIC OF.

P496

Machine learning model targeting 11C-PiB PET images in diagnosis of Alzheimer's Disease

Z. Huang¹, X. Shu², J. Jiang², Y. Guan¹; ¹Huashan Hospital, Fudan University, Shanghai, CHINA, ²Institute of Biomedical Engineering, School of Communication and Information Technology, Shanghai University, Shanghai, CHINA.

P497

Quantitative comparison between different methods for measurement Dopamine Transporters (DAT): An assessment of the accuracy and precision in DAT-SPECT images.

L. Alexandre-Santos¹, E. N. Itikawa², D. K. Sonvenso¹, A. C. Trevisan², M. Kato¹, F. A. Pitella¹, C. E. P. Baltazar¹, E. R. Moraes³, O. Baffa³, L. Wichert-Ana^{1,2}; ¹Ribeirão Preto School of Medicine - University of São Paulo, Ribeirão Preto, BRAZIL, ²Bioengineering Post Graduation Programme - São Carlos School of Engineering - University of São Paulo, São Carlos, BRAZIL, ³Faculty of Philosophy, Sciences and Letters at. Ribeirão Preto, Ribeirão Preto, BRAZIL.

P498

Distribution of the Dopamine Transporter (DAT) in the nigro-striatal pathway examined in vivo with [18F]FE-PE2I and high-resolution PET.

P. Fazio¹, Z. Cselényi^{1,2}, C. Halldin¹, L. Farde^{1,2}, A. Varrone¹; ¹Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm, SWEDEN, ²AstraZeneca Translational Science Centre at Karolinska Institutet, Stockholm, SWEDEN.

P499

Evaluation of the uniform attenuation correction in ictal SPECT images in Frontal Lobe Epilepsy: A quantitative approach through SPM.

L. Alexandre-Santos¹, H. T. Amaral-Silva¹, E. N. Itikawa², D. Sonvenso¹, A. C. Trevisan², T. R. Velasco¹, F. A. Pitella¹, V. Alexandre, Jr.¹, M. Kato¹, L. Wichert-Ana^{1,2}; ¹Ribeirão Preto School of Medicine - University of São Paulo, Ribeirão Preto, BRAZIL, ²Bioengineering Post Graduation Programme - São Carlos School of Engineering - University of São Paulo, São Carlos, BRAZIL.

P500

Standardization of normative data as reference data' in a single institute for the qualitative and quantitative DaTSCAN evaluation

G. S. Limouris¹, E. Konstantinidis², N. Triantafyllou², M. Paphiti³, I. Valais⁴, G. Paraskevas², E. Kapaki²; ¹Nuclear Medicine Div, I Radiology Dept, 'Aretaieion' Hosp, Athens Univ Medical Faculty, Athens, GREECE, ²Neurologic Clinic, 'Aeginiteion' Hospital, Athens Univ Medical Faculty, Athens, GREECE, ³Nuclear Medicine Dept, Royal Sussex County Hosp, Brighton, UNITED KINGDOM, ⁴Bioengineering Dept, TEI Athens, Athens, GREECE.

P501

Comparison of an Atlas-based Method of DaTscanTM Quantification to Manual Volume of Interest Definition

A. S. Nelson, A. Pilla, M. Horvat, J. W. Piper; MIM Software, Cleveland, OH, UNITED STATES.

P31

Monday, October 12, 2015

16:00 – 16:30

Neurosciences: Miscellaneous

P502

Application of PET, MRI and invasive EEG in patients with drug-resistant epilepsy

I. Kostadinova¹, K. Minkin², P. Dimova², D. Zlatareva³, V. Hadjiiska¹; ¹Clinic of nuclear medicine, Medical University, Sofia, BULGARIA, ²Clinic of neurosurgery, Medical University, Sofia, BULGARIA, ³Clinic of radiology, Medical University, Sofia, BULGARIA.

P503

Functional/Anatomic Brain Volume Mismatch Can Serve as a Predictive Parameter for Post Stroke Patient's Candidacy for Hyperbaric Oxygen Therapy

H. Golan¹, B. Makogon², O. Volkov³, Y. Smolyakov⁴, E. Ben-Jacob⁵, R. Boussi-Gross⁶, S. Efrati⁶; ¹Nuclear Medicine, Assaf Harofeh Medical Center, Beer Yaakov, ISRAEL, ²Radiology, Assaf Harofeh Medical Center, Beer Yaakov, ISRAEL, ³Assaf Harofeh Medical Center, Beer Yaakov, ISRAEL, ⁴Department of Medical Physics and Informatics, Chita State Medical Academy, Chita, RUSSIAN FEDERATION, ⁵The Raymond and Beverly Sackler Faculty of Exact Sciences, School of Physics and Astronomy, Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, ISRAEL, ⁶Hyperbaric Medicine Institute, Research and Development Unit, Assaf Harofeh Medical Center, Beer Yaakov, ISRAEL.

P504

Calorie consumption and brain glucose metabolism in the patients with chronic severe brain injury - A study using brain 18F-FDGPET -

Y. Uchino; Chiba Ryogo Center, CHIBA CITY, JAPAN.

P505

99mTc-ECD brain perfusion SPECT imaging for assessment of the effect of hyperbaric oxygen therapy on secondary progressive multiple sclerosis patients with a moderate to severe stage of disease

M. Taghizadeh Asl¹, R. Nemati², M. Assadi³; ¹Department of Nuclear Medicine, Kasra Hospital, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Department of Neurology, Bushehr Medical University Hospital, Bushehr University of Medical Sciences, BUSHEHR, IRAN, ISLAMIC REPUBLIC OF, ³The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, BUSHEHR, IRAN, ISLAMIC REPUBLIC OF.

P506

Comparison of diagnostic value of brain perfusion SPECT with CT scan, EEG and MRI modalities in pediatric seizure setting

A. Shirkani¹, M. Taghizadeh Asl², F. Hafezi¹, R. Nemati³, M. Assadi⁴; ¹Department of Pediatrics, Faculty of Medicine, Bushehr University of Medical Sciences, BUSHEHR, IRAN, ISLAMIC REPUBLIC OF, ²Department of Nuclear Medicine, Kasra Hospital, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Department of Neurology, Bushehr Medical University Hospital, Bushehr University of Medical Sciences, BUSHEHR, IRAN, ISLAMIC REPUBLIC OF, ⁴The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, BUSHEHR, IRAN, ISLAMIC REPUBLIC OF.

P507

Plaque Inflammation Imaging in severe carotid stenosis and recurrent cerebral ischemia/strokes.

A. SINHA, V. sharma, S. Kapur, S. Pillai, D. Teh; National University Hospital, SINGAPORE, SINGAPORE.

P508

Value of the ictal and interictal Perfusion-SPECT in the localization of the epileptic focus in drug-resistant epilepsy

M. Boya-Román¹, O. Puig¹, R. Julio¹, J. Rojas¹, I. Gil¹, P. Saldaña², G. Plans¹, J. Miró¹, J. Mora¹; ¹Hospital Universitari de Bellvitge-IDIBELL, Barcelona, SPAIN, ²Institut Català d'Oncologia, Barcelona, SPAIN.

P509

Three Months Follow-Up of Mild Traumatic Brain Injury in Rats: A Combined [18F]FDG and [11C] PK11195 PET Study

*D. Vázquez García¹, A. Otte², R. A. J. O. Dierckx¹, J. Doorduyn¹;
¹University Medical Center Groningen, Groningen, NETHERLANDS, ²Offenburg University of Applied Sciences, Offenburg, GERMANY.*

P510

Baseline Right Hemispheric Metabolic Activity Predicts Improvement in Aphasia Severity and Visual Attention Tasks in Persons with Aphasia Treated with a Cholinergic Agent

*A. L. Gutiérrez Cardo¹, N. Roé Vellvé¹, F. Alfaro Rubio¹, G. Dávila², M. J. Torres-Prioris², M. L. Berthier²;
¹Fundación General de la Universidad de Málaga, Málaga, SPAIN, ²Universidad de Málaga, Málaga, SPAIN.*

P511

^{99m}Tc-HMPAO Brain SPECT in Rabbits: Preliminary Results on CBF Variation by Different Anaesthetic Drugs

*M. Longo¹, C. Pettinato², D. De Zani¹, G. Ravasio¹, M. Di Giancamillo¹, D. Zani¹;
¹DIVET, University of Milano, Milano, ITALY, ²Medical Physics Unit, Bologna, ITALY.*

P512

The potential role of [18F]-FDOPA PET/CT in proton treatment planning for glioblastoma: preliminary experience.

*D. Donner¹, D. Amelio², S. Agostini¹, G. Carbone¹, A. Palucci¹, S. Vennarini², U. Rozzanigo³, M. Erini¹, E. Bagatin¹, M. Amichetti², M. Recla³, F. Chierichetti¹;
¹Nuclear Medicine Dpt - S. Chiara Hospital - APSS, TRENTO, ITALY, ²Proton Center - APSS, TRENTO, ITALY, ³Radiology Dpt - S. Chiara Hospital - APSS, TRENTO, ITALY.*

P513

Cisternoscintigraphy in cerebrospinal fluid fistula and intracranial hypotension syndrome

M. Castrillon; Sergas, Vigo, SPAIN.

P32

Monday, October 12, 2015

16:00 – 16:30

Basic Oncology: Miscellaneous

P514

Characterization of 18F-DOPA-Uptake in Various Tumour Cells: Implication for the 18F-DOPA PET

*M. Delivuk, P. Ubl, F. Girschele, M. Hacker, G. Hamilton, S. Li;
Medical University of Vienna, VIENNA, AUSTRIA.*

P515

Intraobserver variability in gross tumor volume delineation on PET/CT workstation and Eclipse™ radiation therapy planning system of head and neck cancers

S. Sediene, I. Kulakiene, V. Rudzianskas; Lithuanian Hospital of Health science Kauno clinics, Kaunas, LITHUANIA.

P516

Development and characterization of microspheres contained with different polymers for hepatoma therapy

P. Chiang, C. Peng, Y. Chu, T. Luo; Institute of Nuclear Energy Research, Taoyuan, TAIWAN.

P33

Monday, October 12, 2015

16:00 – 16:30

Clinical Oncology: Thyroid – Malignant

P517

The prognostic impact of FDG PET/CT imaging in the early postoperative work-up of differentiated thyroid carcinoma patients with elevated Thyroglobulin levels

G. Ucmak, B. Demirel, B. E. Akkas, A. K. Fidan; Ankara Oncology Research and Training Hospital Department of Nuclear Medicine, Ankara, TURKEY.

P518

The Role of Postoperative Diagnostic I123 SPECT-CT in Low and Intermediate Risk Profile Patients with Differentiated Thyroid Carcinoma

O. Bessolova, O. Perfileva, Y. Kizhaev, V. Vidioukov, N. Vyrenkova; Russian Medical Academy of Postgraduate Education, Moscow, RUSSIAN FEDERATION.

P519

The clinical significance of thyroid incidentaloma on FDG-PET/CT - one centre's experience

P. Martineau, M. Pelletier-Galarneau, W. Zeng, X. Pham; The Ottawa Hospital, Ottawa, ON, CANADA.

P520

Role of 18F-FDG-PET/CT Scan in the Follow-Up of Patients with Differentiated Thyroid Carcinoma. Significance of Thyroglobulin and Anti-Thyroglobulin Antibody Levels

F. S. Zelaya Reinquet, J. M. Nogueiras Alonso, D. Ruiz Hernández, C. Castillo Berrio, M. A. Castrillón Sánchez, A. Serena Puig, L. Campos Villarino, R. Guitián Iglesias; Hospital Do Meixoneiro, VIGO, SPAIN.

P521

Predictors of malignancy in thyroid incidentalomas seen on 18F-FDG PET/CT scanning in patients not known to have thyroid cancer

H. Nasr^{1,2}; ¹Prince Sultan Military Medical City, Riyadh, SAUDI ARABIA, ²Kasr El-Aini Cairo University Hospital, Nuclear Medicine Unit, Cairo, EGYPT.

P522

99mTc-Methoxy-isobutyl-isonitrile (MIBI) Scintigraphy is an useful and cost-effective tool for assessing the risk of malignancy in thyroid nodules with indeterminate fine needle cytology (FNAC)

A. Campenni¹, L. Giovanella², S. Giovinazzo³, F. Di Mauro¹, S. Pignata¹, M. Mure¹, M. Stipo¹, M. Siracusa¹, M. Ruggeri³, S. Baldari¹; ¹Nuclear Medicine Unit of Messina, Messina, ITALY, ²Nuclear Medicine and PET/CT Centre, Oncology Institute of Southern Switzerland - Bellinzona, Switzerland., Bellinzona, SWITZERLAND, ³Endocrinology Unit, University of Messina, Messina, ITALY.

P524

⁶⁸Ga-DOTATATE-PET in MTC patients with elevated calcitonin but normal radiological examination.

Z. Wygoda, D. Handkiewicz-Junak; Centre of Oncology - MSC Institute, GLIWICE, POLAND.

P525

¹³¹I SPECT/CT in differentiating neck iodine fixing foci in patients with differentiated thyroid carcinoma (DTC).

A. Spanu, I. Gelo, L. Mele, S. Contu, B. Piras, S. Nuvoli, G. Madeddu; Unit of Nuclear Medicine, University of Sassari, Sassari, ITALY.

P526

Successful slowing of tumour growth by sequential use of different tyrosine kinase inhibitors in a patient with poorly differentiated follicular thyroid carcinoma

A. Becherer, T. G. Böhler, W. Furlan, A. A. Hofmann, F. Karakolcu, H. Wiederin; Academic Teaching Hospital Feldkirch, Feldkirch, AUSTRIA.

P527

Prognostic value of CEA and Calcitonin compared to image-based monitoring of MTC patients undergoing TKI treatment

R. A. Werner^{1,2}, C. Bluemel¹, D. Muegge³, T. Higuchi^{1,2}, J. S. Schmid¹, C. Reiners¹, K. Herrmann^{1,4}, A. K. Buck¹, C. Lapa¹; ¹Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY, ²Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, GERMANY, ³Institute of Psychology, University of Innsbruck, Innsbruck, AUSTRIA, ⁴Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, UNITED STATES.

P528

Incremental Value of SPECT/CT Over Planar Imaging in Recombinant TSH I-131 Scanning of Follow up Patients

M. Al Janabi, Sr.; Mediclinic City Hospital, Dubai, UNITED ARAB EMIRATES.

P529

Thyroid cancer in patients with hyperthyroidism

S. Choukry, G. Cherkaoui Salhi, s. taleb, A. Guinsi; IBN ROCHD UNIVERSITY HOSPITAL, Casablanca, MOROCCO.

P530

Effectiveness of aromatherapy on Physiology and Psychology in patients undergoing I-131 ablation with differentiated thyroid cancer.-Using Physiological and Sensory evaluation-

M. Nakayama¹, A. Okizaki¹, S. Ishitoya¹, T. Uno², T. Suzuki², Y. Mikami², J. Sato², K. Takahashi¹; ¹Asahikawa Medical University, ASAHIKAWA, HOKKAIDO, JAPAN, ²Asahikawa Medical University Hospital, ASAHIKAWA, HOKKAIDO, JAPAN.

P531

Lung metastasis from differentiated thyroid carcinoma: Characteristics and prognosis factors

A. Ezzine^{1,2}, M. Ben Fredj^{1,2}, C. Jabeur¹, S. Melki^{1,2}, R. Sfar¹, M. Guezguez¹; ¹Nuclear medicine department, Sousse, TUNISIA, ²99/UR/08-64, faculty of Medicine Sousse, University of Sousse, Sousse, TUNISIA.

P532

Pre-therapy I-131 uptake value as a prediction method for metastatic lymph node status in patients with differentiated thyroid carcinoma

G. Ege Aktas, S. Soyuluoglu Demir, F. Ustun, A. Sarikaya, G. Durmus Altun; Trakya University Medical Faculty Hospital Nuclear Medicine Department, Edirne, TURKEY.

P533

The 18F-FDG-PET/CT for localization of tumor foci in patients with elevated thyroglobulin antibodies

J. M. Nogueiras Alonso, F. Zelaya Reinquet, D. M. Ruiz Hernández, C. Castillo Berrio, M. A. Castrillón Sánchez, L. Campos Villarino, A. Serena Puig, R. Guitián Iglesias; Hospital Do Meixoneiro, VIGO, SPAIN.

P534

Incidental Findings of Hypermetabolic Thyroid Lesions in PET-CT Studies and Their Clinical Significance

D. Villasboas-Roscioles, Jr, A. García-Burillo, MD, C. Zafón Llopis, MD, M. Salcedo-Pujantell, Jr, M. Velasco Nuño, Jr, J. Monturiol Duran, Jr, J. Castell-Conesa, MD; Hospital Universitari Vall d'Hebron, Barcelona, SPAIN.

P535

Primary mucoepidermoid carcinoma and sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid gland: a report of two cases, one with aggressive clinical course and other with good prognosis

P. Petranović Ovčariček¹, M. Franceschi¹, T. Jukić¹, N. Dabelić¹, B. Krušlin², Z. Kusić¹; ¹University Hospital Center „Sestre milosrdnice“, Department of Oncology and Nuclear medicine, Zagreb, CROATIA, ²University Hospital Center „Sestre milosrdnice“, Department of Pathology „Ljudevit Jurak“, Zagreb, CROATIA.

P536

Evaluation of factors effecting health-related quality of life, levels of anxiety and depression in patients with thyroid cancer

G. Ucmak¹, D. H. Yalvac², B. E. Akkas¹; ¹Ankara Oncology Research and Training Hospital Department of Nuclear Medicine, Ankara, TURKEY, ²Ankara Oncology Research and Training Hospital Department of Psychiatry, Ankara, TURKEY.

P537

Descriptive study of 1855 patients with differentiated thyroid carcinoma treated in the period 1998-2012 in 11 hospitals of Catalonia

A. García-Burillo¹, D. Villasboas¹, C. Zafón¹, J. González², M. Ysamat², J. Castell¹; ¹Hospital General Universitari Vall d'Hebron, BARCELONA, SPAIN, ²Mutua de Terrassa, Terrassa, SPAIN.

P538

Correlation Between Day 3 and Day 5 Blood Test Results After Thyrotropin Alfa (Thyrogen) Injection In Differentiated Thyroid Cancer Patients

S. Sager, Dr, C. Nisli, O. E. Sahin, R. Akyel, B. Rezavi, J. Nemetyazar, E. Kaymakci, B. Vatankulu, M. Halac, H. Sayman, I. Uslu, K. Sönmezoglu; Istanbul University, Cerrahpasa Medical School, Istanbul, TURKEY.

P539

Vesicular cancer on ectopic lingual thyroid (In a case report and literature review)

S. Choukry, G. Cherkaoui Salhi, s. taleb, a. Guinsi; IBN ROCHD UNIVERSITY HOSPITAL, Casablanca, MOROCCO.

P540

Familial Forms of Papillary Thyroid Carcinoma: a Case Report

S. Kusacic Kuna¹, J. Filipovic², G. Horvatic Herceg¹, T. Samardzic¹, M. Despot¹, D. Huic¹; ¹Clin. Dept of Nucl Med, University Hospital Centre Zagreb, Zagreb, CROATIA, ²Department of Nuclear Medicine, General Hospital Pula, Croatia, Zagreb, CROATIA.

P541

Correlation of perceived social support with psychological distress and the levels of anxiety and depression in differentiated thyroid cancer patients before hospitalization for radioiodine therapy

G. Ucmak¹, B. E. Akkas¹, D. H. Yalvac², I. Ozer², O. Yuncu², A. Caykoylu²; ¹Ankara Oncology Research and Training Hospital Department of Nuclear Medicine, Ankara, TURKEY, ²Ankara Oncology Research and Training Hospital Department of Psychiatry, Ankara, TURKEY.

P542

Not all DTC patients with N positive disease deserve the attribution “high risk”. Contribution of the MSDS trial.

A. Vrachimis, C. Wenning, B. Riemann; University Hospital Muenster, Muenster, GERMANY.

P543

“High stimulated thyroglobulin on first follow up in differentiated thyroid cancer patients is really worrisome?”

M. Gupta, Jr.; RAJIV GANDHI CANCER INSTITUTE AND RESEARCH CENTRE, DELHI, INDIA.

P544

Radiation dose rate of I-131 in patients with differentiated thyroid carcinoma; effect of administrated activity, admission number and TSH level on retention curve

M. Moslehi¹, A. Mahmoud Pashazadeh², M. Assad²;
¹Department of Nuclear Medicine, Seyedoshohada Hospital, Isfahan University of Medical Sciences, Isfahan, IRAN, ISLAMIC REPUBLIC OF, ²The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, BUSHEHR, IRAN, ISLAMIC REPUBLIC OF.

P545

Predictive factors for the outcome of I-131 1110MBq ablation therapy in the patients with differentiated thyroid cancer: urinary iodine, serum thyroglobulin, and uptake to thyroid bed

S. Ito¹, S. Iwano¹, K. Kato², S. Naganawa¹; ¹Department of Radiology, Nagoya University Graduate School of Medicine, Nagoya, JAPAN, ²Department of Radiological and Medical Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, JAPAN.

P34

Monday, October 12, 2015

16:00 – 16:30

Clinical Oncology: Brain

P546

Correlation of Standardized Uptake Value Derived Indices with Tumoral Aggressiveness of Gliomas in Static 18F-FDOPA PET: Use in Clinical Practice.

I. Janvier, Jr., A. Verger; CHU Nancy, Nancy, FRANCE.

P547

Role of ¹¹C-Methionine PET for the Molecular Characterization of Primary Brain Tumours Eligible for Surgery.

E. Lopci, M. Riva, L. Bello, L. Olivari, F. Raneri, M. Rodari, A. Chiti; Humanitas Clinical and Research Hospital, Rozzano (Milano), ITALY.

P548

Comparison of PET/CT and Difusion/Perfusion Weighted Magnetic Resonance Imaging Findings in Malignant Brain Tumors

M. Sipahi; Bakirkoy Dr. Sadi Konuk Education And Research Hospital, Istanbul, TURKEY.

P549

Correlation of 4β-[Methyl-¹¹C]-Thiothymidine Uptake with Ki-67 Immunohistochemistry in Patients with Newly Diagnosed and Recurrent Gliomas: Comparison with ¹¹C-Methionine Uptake

Y. Yamamoto¹, K. Tanaka¹, H. Yamamoto¹, N. Kudomi¹, T. Hatakeyama¹, J. Toyohara², Y. Nishiyama¹; ¹Kagawa University, Kagawa, JAPAN, ²Tokyo Metropolitan Institute of Gerontology, Tokyo, JAPAN.

P550

PET/CT Using [¹¹C]Methionine in Differential Diagnosis of Intramedullary Tumors from Non-neoplastic Spinal Cord Lesions

T. Skvortsova, Z. Savintseva, L. Prakhova, D. Zakhs, S. Medvedev; N. P. Bechtereva Institute of the Human Brain of Russian Academy of Sciences, Saint-Petersburg, RUSSIAN FEDERATION.

P551

FET PET in the evaluation of indeterminate brain lesions on MRI: differentiating glioma from other non-neoplastic causes

D. L. Chan, G. P. Schembri, M. Back, D. L. Bailey, P. J. Roach, H. Wheeler, R. Cook, J. Parkinson, A. Lee, D. Jayamanne, J. Drummond, E. Hsiao; Royal North Shore Hospital, St Leonards, AUSTRALIA.

P552

Use of ¹¹C-methionine PET for the immunohistochemistry characterization of gliomas

A. Mestre-Fusco¹, F. Alameda², M. Suárez-Piñera¹, S. Moja³, M. Martínez-García⁴, G. Conesa⁵; Neurooncology PSMar Group; ¹Nuclear Medicine department. Hospital del Mar. Parc de Salut Mar, Barcelona, SPAIN, ²Pathology department. Hospital del Mar. Parc de Salut Mar, Barcelona, SPAIN, ³Institute of Medical Research IMIM. PRBB, Barcelona, SPAIN, ⁴Neurooncology department. Hospital del Mar. Parc de Salut Mar, Barcelona, SPAIN, ⁵Neurosurgery department. Hospital del Mar. Parc de Salut Mar, Barcelona, SPAIN.

P553

¹⁸F-fluorocholine PET/CT in the assessment of brain primary tumors

A. Montes¹, A. Fernandez¹, V. Camacho¹, J. Craven-Bartle², C. De Quintana³, O. Gallego⁴, R. Jaller¹, A. Flotats¹, M. Estorch¹, D. Lopez¹, I. Carri¹; ¹Nuclear Medicine Department. Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN, ²Radiation Oncology Department. Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN, ³Neurosurgery Department. Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN, ⁴Oncology Department. Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN.

P554

Differentiation of Pseudoprogress and Actual Progress in Glioblastoma Multiforme by Textural Inhomogeneity Parameters in [18F]-Fluoroethyltyrosine PET

Z. Khurshid¹, S. Kebir², U. Herrlinger³, L. Papp³, N. Zsótér³, F. Gaertner¹, M. Essler¹, R. Bundschuh¹; ¹Department of Nuclear Medicine, Uniklinikum Bonn, Bonn, GERMANY, ²Center for Neuro-oncology, Department of Neurology, Uniklinikum Bonn, Bonn, GERMANY, ³Mediso Medical Imaging Systems, Budapest, HUNGARY.

P555

Usefulness of Preoperative Dual-Phase thallium-201 SPECT and Imaging Fusion with SPECT and MRI in Predicting Histopathology of Meningiomas and Hemangioblastomas

A. Abe¹, S. Abe², S. Oya¹, T. Matsui¹; ¹Saitama Medical University, Kawagoe, JAPAN, ²Mitsui Memorial Hospital, Tokyo, JAPAN.

P35

Monday, October 12, 2015

16:00 – 16:30

Clinical Oncology: Head & Neck

P556

FDG PET/CT and MRI in oral cavity carcinomas: anatomical considerations

H. Munechika, T. Saginoya, Y. Miura, S. Takekawa, K. Seto, K. Watanabe; Southern Tohoku General Hospital, KORIYAMA, JAPAN.

P557

Semi-quantitative analysis of FDG-PET/CT images to assess residual nodal disease in patients with squamous cell carcinoma of the head and neck (HNSCC) after (chemo)radiotherapy (CRT): can it improve accuracy and prognostic value?

N. Helsen^{1,2}, T. Van den Wyngaert^{1,2}, L. Carp^{1,2}, D. Van den Weyngaert^{1,3}, S. Stroobants^{1,2}; ¹University of Antwerp, Wilrijk (Antwerp), BELGIUM, ²Antwerp University Hospital, Edegem, BELGIUM, ³Middelheim hospital, Antwerp, BELGIUM.

P558

Meta-analysis of 18F-FDG PET/CT for diagnosis of residual/recurrent nasopharyngeal carcinoma after radiotherapy

H. Zhou, Y. Zhou, L. Li; West China Hospital, Chengdu, CHINA.

P559

Diagnostic performance of time-of-flight system to detect neck small lymph node using 18F-FDG PET/CT

H. Saito, A. Yamane, S. Imai, E. Orita, K. Hakozaiki, K. Akiyama, K. Ishihara, S. Kumita; Nippon Medical School, Bunkyo-ku, Tokyo, JAPAN.

P560

Texture analysis of pre-treatment 18F-FDG PET/CT images predicts for overall and recurrence-free survival of patients with locoregional advanced nasopharyngeal carcinoma after concurrent chemoradiotherapy

S. Chan¹, K. Chang², C. Lin², T. Yen²; ¹Keelung Chang Gung Memorial Hospital, Keelung, TAIWAN, ²Linkou Chang Gung Memorial Hospital, Taoyuan, TAIWAN.

P561

A Comparative Study of FDG PET/CT and MRI in Clinical/Pathological T4-stage Buccal Squamous Cell Carcinoma

C. Lo¹, P. Kao^{1,2}, J. Weng¹; ¹Chung Shan Medical University Hospital, Taichung, TAIWAN, ²Chung Shan Medical University, School of Medicine, TAIWAN.

P562

Clinical value of SPECT/CT for evaluation of bone metastasis in patients with head and neck cancer

P. Arican, B. Okudan Tekin, R. Şefizade, S. Naldöken; Ankara Numune Education and Research Hospital, Ankara, TURKEY.

P563

Prognostic value of pre-treatment 18F-FDG PET/CT volumetric parameters in patients with locally advanced larynx carcinoma treated with concurrent chemo-radiotherapy

G. Paone, V. Espeli, F. Martucci, L. Ceriani, A. Richetti, L. Giovanella; Oncology Institute of Southern Switzerland, Bellinzona, SWITZERLAND.

P564

SPECT-CT in Patients with Parathyroid and Thyroid Comorbidities

O. Bessolova, O. Perfilova, Y. Kizhaev, V. Vidioukov; Russian Medical Academy of Postgraduate Education, Moscow, RUSSIAN FEDERATION.

P565

Diagnostic accuracy of F-18 FDG PET/CT performed after radiation therapy in patients with head and neck cancer

W. Choi¹, E. Han², W. Lee³, Y. Park¹; ¹St. Vincent's Hospital, College of Medicine, The Catholic University Of Korea, Suwon, KOREA, REPUBLIC OF, ²Deajeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Deajeon, KOREA, REPUBLIC OF, ³Chungbuk National University Hospital, Cheongju, KOREA, REPUBLIC OF.

P566

Intra-operative lymphatic mapping and sentinel node biopsy in laryngeal carcinoma: preliminary results

R. Sadeghi¹, E. Khadivi², M. Daghighi², K. Khazaeni², V. Dabbagh Kakhki¹, L. Zarifmahmoudi¹; ¹Nuclear Medicine Research Center, Mashhad University of Medical Sciences, MASHHAD, IRAN, ISLAMIC REPUBLIC OF, ²Sinus and Surgical Endoscopic Research Center, Mashhad University of Medical Sciences, MASHHAD, IRAN, ISLAMIC REPUBLIC OF.

P567

Juvenilenasopharyngeal angiofibromas - in vitro and in vivo examinations of somatostatin receptors expression.

J. Kunikowska¹, W. Kukwa², A. Cyran-Chlebicka², D. Pawlak³, R. Matyskiel¹, & Koperski⁴, Z. Gronkiewicz², B. Górnicka⁵, L. Królicki¹; ¹Nuclear Medicine Department, Medical University of Warsaw, Warsaw, POLAND, ²Department of Otorhinolaryngology, Czerniakowski Hospital, Medical University of Warsaw, Warsaw, POLAND, ³Radioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, POLAND, ⁴Department of Pathology, Medical University of Warsaw, Warsaw, POLAND, ⁵Department of Pathology, Medical University of Warsaw, Warsaw, POLAND.

P568

Value of 18F-FDG PET/TC in the Evaluation of Treatment Response in Head and Neck Cancer

M. Salcedo-Pujantell, C. Lorenzo-Bosquet, MD, G. Cuberas-Barrós, S. Siurana-Montilva, MD, A. Rovira-Cañellas, MD, J. Castell-Conesa, MD; Hospital Universitari de Vall d'Hebronn, Barcelona, SPAIN.

P569

Are contouring time and multimodality imaging prognostic factors for radiation therapy of advanced head and neck cancer?

M. Schmuecking¹, O. Elicin², B. Bojaxhiu², R. Bigler², J. Tille², S. Fankhauser², H. Thöny³, B. Klaeser⁴, A. Geretschlager⁵; ¹Strahlenzentrum Hamburg/CyberKnife Center Hamburg, Hamburg, GERMANY, ²Inselspital Bern, Dept. of Radiation Oncology, Bern, SWITZERLAND, ³Inselspital Bern, Dept. of Radiology, Bern, SWITZERLAND, ⁴Inselspital Bern, Dept. of Nuclear Medicine, Bern, SWITZERLAND, ⁵St. Clara Spital Basel, Dept. of Radiation Oncology, Basel, SWITZERLAND.

P570

Impact of 18F FDG PET CT on Initial Management of Patients Presenting with Secondaries in Neck from an Unknown Primary

M. Sarma, P. Subramanyam, P. Sundaram; Dept. Of Nuclear Medicine And Pet Ct, Amrita Institute Of Medical Sciences And Research Centre (Amrita Vishwa Vidyapeetham), Cochin, INDIA.

P571

Analysis of 18F-FDG PET/CT parameters in patients with head and neck soft tissue sarcoma

S. Baek, D. Yoon, E. Yun, Y. Seo, K. Lim, J. Kim; Kangdong Seong-Sim Hospital, Hallym University College of Medicine, Seoul, KOREA, REPUBLIC OF.

P572

Soft Tissue Sarcoma of the Head and Neck: CT, MRI, and FDG-PET/CT Imaging Findings

S. Baek, D. Yoon, J. Kim; Kangdong Seong-Sim Hospital, Hallym University College of Medicine, Seoul, KOREA, REPUBLIC OF.

P36

Monday, October 12, 2015

16:00 – 16:30

Clinical Oncology: Breast

P573

Diagnosis of distant recurrent breast cancer: head-to-head comparisons of FDG-PET/CT, contrast enhanced CT, and bone scintigraphy

M. G. Hildebrandt¹, O. Gerke¹, C. Baun¹, K. Falch¹, J. Ansholm¹, Z. Farahani¹, L. Larsen¹, S. Duvnjak¹, K. Soe¹, A. B. Jylling¹, M. Ewertz¹, A. Alavi², P. Hoiland-Carlsen¹; ¹Odense University Hospital, Odense, DENMARK, ²University of Pennsylvania, Philadelphia, PA, UNITED STATES.

P574

Visualization of internal mammary sentinel lymph nodes in patients with breast cancer - the corn stone for radiotherapy planning.

S. N. Novikov, S. Kanaev, P. Krzhivitsky; N.N. Petrov Institute Oncology, St Petersburg, RUSSIAN FEDERATION.

P575

Role of MUGA scan in diagnosis of the effect of trastuzumab (Herceptin) on global and segmental left ventricular ejection fraction in patients with breast cancer

S. M. W. Yassin¹, K. Salman¹, A. Mostafa¹, M. Abd El Kareem², W. Mohamerd¹, A. Abd El Samee², Y. Mohamed², E. Abo El-Naga¹, S. Abd El Razek³; ¹King Abdulla Medical City (KAMC), Jeddah, SAUDI ARABIA, ²Cairo University, Cairo, EGYPT, ³Assuit University, Assuit, EGYPT.

P576

Therapy Response Evaluation of Patients with Locally Advanced and Metastatic Breast Cancer: Comparison of Anatomic and Metabolic Criteria for Early and Accurate Response Assessment

B. Gunalp¹, M. Erdogan², S. Ince¹, E. Balkan¹, E. Alagoz¹, A. Ayan¹, N. Arslan¹; ¹Gulhane Military Medical Academy and Medical Faculty, ANKARA, TURKEY, ²Diskapi Yildirim Beyazit Egitim ve Arastirma Hastanesi,, ANKARA, TURKEY.

P577

Prognostic Value of Semiquantitative Tumor Uptake on Tc-99m Sestamibi Breast-Specific Gamma Imaging in Invasive Ductal Breast Cancer

S. Jang¹, H. Yoon², Y. Kim³, B. Kim²; ¹Dep. nuclear medicine, Sheikh Khalifa Specialty Hospital, Ras al Khaimah, UNITED ARAB EMIRATES, ²Dep. nuclear medicine, Ewha Womans University School of Medicine, Seoul, KOREA, REPUBLIC OF, ³Ewha Womans University School of Medicine, Seoul, KOREA, REPUBLIC OF.

P578

Breast cancer patients with bone metastases reveled by FDG-PET showed worse long-term survival than those reveled only by bone scan.

Y. Huang, P. Lee, M. Liu; Koo-Foundation, Sun Yat-Sen Cancer Center, Taipei, TAIWAN.

P579

Comparison of FDG PET/CT and bone scan for diagnosis of metastatic bone involvement in breast carcinoma patients: A retrospective analysis

B. Yazici, A. Oral, Z. Ozcan; Ege University Medical Faculty Deparment of Nuclear Medicine, Izmir, TURKEY.

P580

Pathological Correlation of Mild Focal Uptake on the Tc-99m MIBI Breast specific gamma camera imaging.

S. Yoon; Dankook University College of Medicine, Cheil General Hospital, Women's Cancer Center, Seoul, KOREA, REPUBLIC OF.

P581

Contralateral axillary sentinel lymph node in breast cancer patients: an uncommon lymphatic drainage

T. Tanaka, S. Sato, R. Inai, A. Tada, S. Kanazawa; Department of Radiology, Okayama University Hospital, Okayama, JAPAN.

P582

Comparison of Subareolar Injection Lymphoscintigraphy with the 1 Day and the 2 Day Protocol for the Detection of Sentinel Lymph Nodes in Patients with Breast Cancer

E. Lee, J. Seok; Department of Nuclear Medicine, Chung-Ang University, College of Medicine, Seoul, KOREA, REPUBLIC OF.

P583

Comparison of the Efficiency for Tc-99m Tin-Colloid and Tc-99m Phytate in Sentinel Node Detection in Breast Cancer Patients

E. Lee, J. Seok; Department of Nuclear Medicine, Chung-Ang University, College of Medicine, Seoul, KOREA, REPUBLIC OF.

P584

The addictional value of 18F-FDG PET/CT in pre and post-operative setting in patients with locally advanced breast cancer

L. Evangelista, A. Cervino, S. Michieletto, T. Saibene, E. Bezzon, F. Pomerri, F. Bozza, C. Ghiotto, G. Saladini; Istituto Oncologico Veneto I.R.C.C.S., PADOVA, ITALY.

P585

Impact of radioguided occult lesion localization plus sentinel node biopsy after neoadjuvant chemotherapy in breast cancer.

I. Cepedello Boiso, M. Ureña Lara, J. Jiménez Anula, C. Ramírez Tortosa, J. Díaz Alarcón; Complejo Hospitalario de Jaén, Jaén, SPAIN.

P586

Reliable I-125 seed localization after neo-adjuvant chemotherapy to identify breast lesions in combination with sentinel node biopsy

D. Koopman^{1,2}, D. Lots¹, A. B. Francken³, H. Arkies¹, P. L. Jager¹, C. H. Slump², J. A. van Dalen⁴; ¹Isala, department of Nuclear Medicine, Zwolle, NETHERLANDS, ²MIRA Institute for Biomedical Technology and Technical Medicine, Enschede, NETHERLANDS, ³Isala, department of Surgery, Zwolle, NETHERLANDS, ⁴Isala, department of Medical Physics, Zwolle, NETHERLANDS.

P587

18F-FDG PET/CT is a prognostic bio-marker in patients affected by bone metastases from breast cancer. Comparison with 18F-NaF-PET/CT.

A. Piccardo¹, M. Massollo¹, V. Altrinetti¹, S. Morbelli², F. Bongioanni², M. Iacozzi¹, G. Sambuceti², A. Gennari³, R. Gonella⁴, M. Puntoni⁵, A. Decensi³, M. Cabria¹; ¹Nuclear Medicine Unit E.O Ospedali Galliera, Genoa, ITALY, ²Nuclear Medicine Unit San Martino IST, Genoa, ITALY, ³Oncology Unit E.O Ospedali Galliera, Genoa, ITALY, ⁴Department of Internal Medicine San Martino IST, Genoa, ITALY, ⁵Clinical Trial Research Unit, Galliera Hospital, Genoa, ITALY.

P588

18F-Fluoroestradiol positron emission tomography in breast cancer patients: systematic review of the literature & meta-analysis

L. Evangelista¹, M. Dieci¹, A. Cervino¹, G. Saladini¹, P. Conte^{1,2}, V. Guarneri^{1,2}; ¹Istituto Oncologico Veneto I.R.C.C.S., PADOVA, ITALY, ²University of Padua, Padova, ITALY.

P589

The Value of Molecular Breast Imaging in the Initial Work-up of Women with Proven Breast Cancer Scheduled for Breast Conserving Therapy

A. Collarino^{1,2,3}, L. M. Pereira Arias-Bouda^{2,3}, F. Smit^{2,3}, P. Neijenhuis⁴, L. M. H. Wijers⁵, A. F. Van der Hoeven³, K. Hofkes-Fillekes⁵, A. Zeilemaker⁴, R. A. Valdés Olmos²; ¹Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Roma, ITALY, ²Department of Nuclear Medicine, Leiden University Medical Center, Leiden, NETHERLANDS, ³Department of Nuclear Medicine, Alrijne Hospital, Leiderdorp, NETHERLANDS, ⁴Department of Surgery, Alrijne Hospital, Leiderdorp, NETHERLANDS, ⁵Department of Radiology, Alrijne Hospital, Leiderdorp, NETHERLANDS.

P590

Diagnostic value of 99mTc-bombesin scintigraphy for differentiation of malignant from benign breast lesions

K. Aryana, F. Shariati, A. Fattahi, A. Azarian; Mashhad university of medical sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

P591

Predictive and Prognostic Value of FDG-PET/CT Imaging and Different Response Evaluation Criteria after Primary Systemic Therapy of Breast Cancer

T. Tokes¹, K. Kajáry², G. Szentmártoni³, Z. Lengyel², T. Györke⁴, L. Torgyík³, K. Somlai⁵, A. Tőkés⁶, J. Kulka⁷, M. Dank⁸; ¹Semmelweis University, Budapest, HUNGARY, ²Pozitron PET/CT Center, Budapest, HUNGARY, ³Semmelweis University, 1st Dept. of Medicine, Oncological Division, Budapest, HUNGARY, ⁴Semmelweis University Department of Nuclear Medicine and Scanomed Ltd, Budapest, Budapest, HUNGARY, ⁵Surgical Division of the St Margaret Hospital, Budapest, HUNGARY, ⁶MTA-SE Tumor Progression Research Group, 2nd Department of Pathology, Budapest, HUNGARY, ⁷Semmelweis University 2nd Department of Pathology, Budapest, HUNGARY, ⁸Semmelweis University, 1st Dept. of Internal Medicine, Oncological Division, Budapest, HUNGARY.

P592

Can 18F FDG PET/CT be a new tool in the prognostic armamentarium of carcinoma breast ? Correlating 18F FDG uptake values with histopathological markers in primary breast cancer

M. Ravina^{1,2}, M. Chauhan², M. Jacob², A. Pandit², N. Sancheti²; ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, INDIA, ²Army Hospital Research and Referral, New Delhi, INDIA.

P593

Clinical utility of 18F-FDG PET/CT scan in younger than 40 years breast cancer patients

R. V. PARGHANE, Sr., R. Phulsunga, Jr, K. Agrewal, Sr., B. Mittal, Prof., A. Bhattacharya, Prof., A. Sood, Consultant; PGIMER, CHANDIGARH, INDIA.

P594

[18F]FDG-PET/CT results predict outcome in breast cancer

M. Sollini¹, B. Zangheri¹, L. Calabrese¹, M. Di Paolo², A. Versari², M. Gasparini¹; ¹IRCCS; MultiMedica, Sesto San Giovanni, ITALY, ²Santa Maria Nuova Hospital IRCCS, Reggio Emilia, Reggio Emilia, ITALY.

P595

Quantification of Dual Time Point FDG-PET/CT in Bone Lesions in Breast Cancer Recurrence

J. A. Hansen¹, M. G. Hildebrandt¹, O. Gerke¹, C. Baun¹, K. Falch¹, S. Duvnjak², A. Alavi³, P. F. Høilund-Carlson¹; ¹Department of Nuclear Medicine, Odense University Hospital, Odense C, DENMARK, ²Department of Radiology, Odense University Hospital, Odense C, DENMARK, ³Division of Nuclear Medicine, University of Pennsylvania, Philadelphia, PA, UNITED STATES.

P596

Effectiveness and cost-effectiveness analysis of radical axillar lymphadenectomy after a positive sentinel node in breast cancer

P. Serra-Arbeloa, Á. O. Rabines-Juárez, F. Domínguez-Cunchillos, C. de Miguel-Medina, C. Artieda-Soto; Complejo Hospitalario de Navarra, Pamplona, SPAIN.

P597

Defining the nodal status in the initial staging of patients with locally advanced breast cancer: Where must PET/CT stand?

B. E. Akkas, B. Demirel, G. Ucmak, S. Demirtas; Ankara Oncology Research and Training Hospital Department of Nuclear Medicine, Ankara, TURKEY.

P598

Diagnosing bone metastasis in recurrent breast cancer: dual time FDG-PET/CT compared to contrast enhanced CT and bone scintigraphy

M. G. Hildebrandt¹, J. Ansholm¹, O. Gerke¹, C. Baun¹, K. Falch¹, Z. Farahani¹, S. Duvnjak¹, L. Larsen¹, I. Buskevica¹, S. Bektas¹, A. Alavi², P. Hoiland-Carlsen¹; ¹Odense University Hospital, Odense, DENMARK, ²University of Pennsylvania, Philadelphia, PA, UNITED STATES.

P599

18F-FDG PET/CT is most cost-effective for screening distant metastases in stage II/III breast cancer patients

S. C. Teixeira, A. Miquel Cases, R. A. Valdes Olmos, E. J. T. Rutgers, W. van Harten; Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS.

P600

Sentinel lymph node biopsy in breast cancer in patients with previous breast surgery

J. Orozco-Cortés¹, R. Díaz-Expósito¹, I. Casáns-Tormo¹, S. Prado-Wohlwend¹, H. Bowles-Antelo¹, A. Caballero-Garate², A. Almarcha-Gimeno³; ¹Hospital Clínico Universitario. Servicio de Medicina Nuclear, Valencia, SPAIN, ²Hospital Clínico Universitario. Servicio de Cirugía General, Valencia, SPAIN, ³Hospital Clínico Universitario. Unidad de Radiofarmacia, Valencia, SPAIN.

P601

Combined use of portable gammacamera and mammography for the margin delimitation in Radioguided Occult Lesion Localization (ROLL) in breast cancer.

H. Rodriguez, L. Marbello, P. Abreu, M. Reyes, D. Balaguer, E. Caballero, T. Mut, C. Plancha; University Hospital Dr. Peset, Valencia, SPAIN.

P602

Analysis of the metabolic heterogeneity of breast tumors with FDG-PET/CT

B. Farkas; University of Debrecen, Debrecen, HUNGARY.

P603

FDG-PET/CT versus CT in local recurrent breast cancer and the standardized uptake value in local and distant recurrent breast cancer

C. B. Petersen¹, M. G. Hildebrandt¹, J. A. Hansen¹, C. Baun¹, K. Falch¹, O. Gerke¹, A. B. Jylling¹, A. Alavi², P. F. Høilund-Carlsen¹; ¹Odense University Hospital, Odense C, DENMARK, ²University of Pennsylvania, Philadelphia, PA, UNITED STATES.

P604

Preliminary findings of our institute on initial staging of breast cancer with FDG-18 PET/CT

T. ÇAKIR, E. ABAMOR, A. ÇAKIR, P. BASIM, C. GEZEN, M. EVREN, T. ATASEVER; MEDIPOL UNIVERSITY, ISTANBUL, TURKEY.

P605

Is 18F-FDG uptake and apparent diffusion coefficient obtained from diffusion weighted magnetic resonance imaging correlate on the primary tumour of breast carcinoma?

A. Ozen, T. Sayin, S. Altinay, A. Celik, O. Ekmekcioglu, E. Bastug, A. Muhammedoglu, R. Albayrak; Bagcilar Training and Research Hospital, Istanbul, TURKEY.

P606

The Contribution of FDG PET/CT in Diagnosis and Staging of Breast Cancer

E. Arslan¹, T. Çermik¹, F. Can Trabulus², E. Kelten Talu³, S. Tuter Basaran⁴; ¹Istanbul Research And Educational Hospital Clinic Of Nuclear Medicine, Istanbul, TURKEY, ²Istanbul Research And Educational Hospital Clinic Of General Surgery, Istanbul, TURKEY, ³Istanbul Research And Educational Hospital Clinic Of Pathology, Istanbul, TURKEY, ⁴Istanbul Haseki Research And Educational Hospital Clinic Of Pathology, Istanbul, TURKEY.

P607

Relationship between primary tumor FDG SUVmax, histologic grade, receptor and C-erbB2 status and value in breast Cancer

E. Arslan¹, T. Çermik¹, F. Can Trabulus², E. Kelten Talu³, S. Tuter Basaran⁴; ¹Istanbul Research And Educational Hospital Clinic Of Nuclear Medicine, Istanbul, TURKEY, ²Istanbul Research And Educational Hospital Clinic Of General Surgery, Istanbul, TURKEY, ³Istanbul Research And Educational Hospital Clinic Of Pathology, Istanbul, TURKEY, ⁴Istanbul Haseki Research And Educational Hospital Clinic Of Pathology, Istanbul, TURKEY.

P608

Comparison between 18F-FDG uptake pattern and apparent diffusion coefficient value obtained from diffusion weighted magnetic resonance imaging on the detection of primary tumour and axillary metastases in breast carcinoma

A. Ozen, T. Sayin, O. Ekmekcioglu, S. Altinay, E. Bastug, A. Muhammedoglu, A. Celik, R. Albayrak; Bagcilar Training and Research Hospital, Istanbul, TURKEY.

P609

Accuracy of 18F-FDG-PET/CT in staging, restaging, and treatment response in patients with male breast cancer

B. Vatankulu¹, S. Kuyumcu², P. Ç. Kocaeli¹, E. G. Işık², S. Asa¹, S. Sağer¹, M. Halaç¹, C. Türkmen², K. Sönmezoğlu¹; ¹Istanbul University Cerrahpaşa Medical Faculty, Istanbul, TURKEY, ²Istanbul University Istanbul Medical Faculty, Istanbul, TURKEY.

P37

Monday, October 12, 2015

16:00 – 16:30

Clinical Oncology: Lung

P610

Evaluation of 18F-FDG PET/CT and low-dose CT performance in diagnosing lymph node metastases among NSCLC patients.

J. Teodorczyk¹, B. Brockhuis¹, G. Romanowicz¹, W. Cytawa¹, I. Wenzel¹, J. Kozłowska¹, L. Cunha^{2,3}, A. Silva³, L. Metello^{2,3}, P. Lass^{1,4}; ¹Department of Nuclear Medicine, Medical University of Gdansk, Gdansk, POLAND, ²Department of Nuclear Medicine, ESTSPIPP, Porto, PORTUGAL, ³Department of Nuclear Medicine, IsoPor SA, Porto, PORTUGAL, ⁴Division of Molecular Spectroscopy, Institute of Experimental Physics, University of Gdansk, Gdansk, POLAND.

P611

The value of different 18 F-FDG PET/CT baseline measurements in predicting response to chemo-radiotherapy in advanced NSCLC

H. N. M. Abdelwahab¹, Y. G. Abdelhafez², R. A. Amin¹, A. O. Azab¹, S. El-Refaei¹; ¹Cairo University, Cairo, EGYPT, ²South Egypt Cancer Institute, Assiut, EGYPT.

P612

Dual-phase F-18 FDG PET diagnosis of pulmonary adenocarcinoma smaller than 3 cm

K. Hayasaka¹, T. Nishihashi², H. Inoue¹, T. Saitoh¹, Y. Shiraishi¹, K. Yoshimori¹, H. Gotoh¹; ¹Fukuyuujii Hoospital, Tokyo, JAPAN, ²Nagoya Graduate Scholl of Medicine, Nagoya, JAPAN.

P613

Role of F-18 FDG PET in the differential diagnosis between mediastinal malignant lymphoma and thymic epithelial tumors

T. Yamane, A. Seto, I. Matsunari, I. Kuji; Saitama International Medical Center, Saitama Medical University, Hidaka, JAPAN.

P614

Whole-Body Bone Scintigraphy and Serum Concentration of Bone Resorption Marker in Patients with Lung Cancer

J. Weissensteiner¹, E. Babusikova²; ¹Department of Nuclear Medicine, Hospital Poprad, SLOVAKIA, ²Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin, Department of Medical Biochemistry, Martin, SLOVAKIA.

P615

NSCLC: Comparison of PET-CT and contrast enhanced CT in mediastinal staging and PET-CT diagnosis of lung cancer recurrence-impact on patient management

N. Beslic, A. Sadija, T. Cerić, R. Milardović, S. Cerić, A. Beganović, S. Kristić; University Clinical Center, Sarajevo, BOSNIA AND HERZEGOVINA.

P616

Prognostic Value of Early Response Assessment Using FDG PET/CT in Chemotherapy-Treated Patients with Non-Small Cell Lung Cancer

E. Han¹, W. Lee², W. Choi³, S. Kim⁴; ¹Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Daejeon, KOREA, REPUBLIC OF, ²College of Medicine, Chungbuk National University, Cheongju, KOREA, REPUBLIC OF, ³St. Vincent Hospital, College of Medicine, The Catholic University of Korea, Suwon, KOREA, REPUBLIC OF, ⁴Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, KOREA, REPUBLIC OF.

P617

Surprising 18F-FDG PET/CT scan findings in patient with elevated CA125

A. Mazurek^{1,2}, M. Dziuk^{1,2}, E. Witkowska-Patena¹, S. Piszczek^{1,2}, A. Gizewska^{1,2}; ¹Military Institute of Medicine, Department of Nuclear Medicine, Warsaw, POLAND, ²Affidea Masovian PET/CT Center., Warsaw, POLAND.

P618

The diagnostic value of 18FDG-PET/CT and DWI for the detection of mediastinal nodal metastasis in lung cancer: Which is better?

G. Shen, Z. Jia, H. Deng, A. Kuang; West China Hospital of Sichuan University, Chengdu, CHINA.

P619

Correlation of [¹⁸F]FDG Uptake with Clinical and Laboratory Parameters in Patients with Lung Cancer.

M. Boudali¹, E. Skoura², S. Michopoulou², I. E. Datsis¹, K. N. Syrigos³; ¹Evangelismos General Hospital, Athens, GREECE, ²UCLH, London, UNITED KINGDOM, ³Oncology Unit GPP, University of Athens, School of Medicine, Athens, GREECE.

P620

PET/CT imaging artifacts after talc pleurodesis – a clinical case.

Z. Dancheva, P. Bochev, B. Chaushev, T. Yordanova, A. Klisarova; St Marina University Hospital, Varna, BULGARIA.

P621

The metabolic change of dual-time-point ¹⁸F-FDG PET/CT in patients with suspected of having lung cancer

J. Lee¹, S. Jang¹, J. Lee², E. Kim², H. Jeong², J. Rho³, S. Cho⁴; ¹Department of Nuclear Medicine, CHA Bundang Medical Center CHA University, Seongnam, KOREA, REPUBLIC OF, ²Department of Internal Medicine, CHA Bundang Medical Center CHA University, Seongnam, KOREA, REPUBLIC OF, ³Department of Radiology, CHA Bundang Medical Center CHA University, Seongnam, KOREA, REPUBLIC OF, ⁴Department of Pathology, CHA Bundang Medical Center CHA University, Seongnam, KOREA, REPUBLIC OF.

P622

Prognostic Significance of Changes of Volumetric Metabolic Parameters in ¹⁸F-FDG PET/CT During and After Radiotherapy in Stage III Non-Small Cell Lung Cancer

N. Chiu, W. Su, H. Guo, B. Lee, H. Chen; National Cheng Kung University Hospital, Tainan, TAIWAN.

P623

Maximum standardized uptake value cutoff point of the lymph nodes metastases in NSCLC detected by FDG-PET/CT – a prognostic value

N. Georgieva¹, Z. Dancheva², P. Bochev², B. Chaushev², T. Yordanova², A. Klisarova², K. Peeva³; ¹Department of Physics, Biophysics, Roentgenology and Radiology Medical Faculty, Trakia University, Stara Zagora, BULGARIA, ²Nuclear Medicine Department, St. Marina University Hospital, Varna, BULGARIA, ³Department of Social Medicine and Health Management, Medical Faculty, Trakia University, Stara Zagora, BULGARIA.

P624

Value of Tc99m-Thyrosine-Octreotide in characterization of lung masses

B. Mahmoudian¹, S. D. Oskoei¹, M. Nazemiyeh², R. Javadrashid³; ¹Division of Nuclear Medicine, Imam Reza Hospital, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF, ²Tuberculosis and Lung Research Center, Imam Reza Hospital, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF, ³Department of Radiology, Imam Reza Hospital, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF.

P625

Self-pleural in culture of autologous tumor cells from human lung adenocarcinoma by ¹⁸F-FDG imaging and chemotherapy drug sensitivity

L. Chen, C. Liu, J. Cao, J. Lou, J. Jiang, W. Xie, S. Yang; Shanghai Chest Hospital, Shanghai, CHINA.

P626

Which factors are affecting development of the axillary metastasis in lung cancer?

F. USTUN, G. Durmuş Altun; Trakya University Medical Faculty, Edirne, TURKEY.

P627

Impact of Optimal Respiratory Gated Positron Emission Tomography on Characterisation of Intra-Tumour Heterogeneity in Lung Cancer Patients

W. Grootjans¹, F. Tixier², C. S. van der Vos¹, D. Vriens³, C. Cheze-le Rest², J. Bussink¹, W. J. G. Oyen¹, L. F. de Geus-Oei³, D. Visvikis⁴, E. P. Visser¹; ¹Radboud university medical center, Nijmegen, NETHERLANDS, ²University Hospital Poitiers, Poitiers, FRANCE, ³Leiden University Medical Center, Leiden, NETHERLANDS, ⁴INSERM, UMR1101, LaTIM, University of Brest, Brest, FRANCE.

P628

The Diagnostic Accuracy of PET/CT in the Evaluation of Pulmonary Mass Lesions in a Tuberculosis-Endemic Area

R. du Toit, E. M. Iruen, J. A. Shaw, F. von Groote-Bidlingmaier, J. M. Warwick, C. F. N. Koegelenberg; Stellenbosch University, Cape Town, SOUTH AFRICA.

P629

Estimating the probability of malignancy in patients with solitary pulmonary nodules

R. Tian, C. Jiang, N. Hou, M. Su, F. Li; West China Hospital, Sichuan University, Chengdu, CHINA.

P630

Is There Any Correlation Between Serum Osteopontin, CEA Levels, and FDG Uptake in Bone Metastasis in Lung Cancer?

A. K. Ayan¹, B. Erdemci², E. Orsal³, Z. Bayraktutan⁴, E. Akpınar⁵, A. Topcu⁵, M. Turkel⁶, B. Seven⁷; ¹Ataturk University School of Medicine Department of Nuclear Medicine, Erzurum, TURKEY, ²Ataturk University School of Medicine Department of Radiation Oncology, Erzurum, TURKEY, ³Istanbul Medeniyet University School of Medicine Department of Nuclear Medicine, Istanbul, TURKEY, ⁴Erzurum Regional Training and Research Hospital, Department of Biochemistry, Erzurum, TURKEY, ⁵Ataturk University School of Medicine Department of Pharmacology, Erzurum, TURKEY, ⁶Ataturk University School of Medicine Department of Internal Medicine, Erzurum, TURKEY, ⁷Mevlana University School of Medicine Department of Nuclear Medicine, Konya, TURKEY.

P631

Lung cancer versus chronic inflammation: can we differentiate the two on F-18 FDG PET/CT?

H. Kim¹, I. Yoo¹, H. Park¹, Y. Lee¹, S. Park¹, H. Sohn², S. Kim¹, Y. Park³; ¹Seoul St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, KOREA, REPUBLIC OF, ²Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, KOREA, REPUBLIC OF, ³St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, KOREA, REPUBLIC OF.

P632

Cost-Effectiveness of 18F-FDG PET-CT for preoperative restaging in patients with non-small cells lung cancer IIIA after neoadjuvant therapy

W. Valdés, A. Ramírez, E. Morillo, T. Aroui, N. Testart, E. Triviño, A. Rodríguez-Fernández, J. Llamas-Elvira; H.VIRGEN DE LAS NIEVES, GRANADA, SPAIN.

P633

The Value of the quantitative volumetric metabolic measurements with F-18 FDG PET-CT in patients with solitary pulmonary nodules.

D. Yüksel¹, T. Şengöz¹, O. Yaylalı¹, H. Aslan¹, F. Bir²; ¹Pamukkale University, Medical Faculty, Dept. of Nuclear Medicine, Denizli, TURKEY, ²Pamukkale University, Medical Faculty, Dept. of Pathology, Denizli, TURKEY.

P634

FDG-PET/CT in thymic epithelial tumors: correlation with the WHO classification and the tumor stage

M. Ishibashi, Y. Tanabe, S. Fujii, Y. Ohta, T. Ogawa; Division of Radiology, Department of Pathophysiological and Therapeutic Science, Faculty of Medicine, Tottori University, Yonago, JAPAN.

P635

Solitary Pulmonary Nodule (SPN) investigation with FDG-PET/CT

F. Vlachou¹, V. Filippi¹, A. Nikaki¹, D. Savvidou¹, P. Kosmidis², K. Iliadis³, T. Pipikos¹, K. Gogos⁴, K. Dalianis⁴, I. Andreou¹, R. Efthymiadou¹, V. Prassopoulos¹; ¹PET/CT Department, Hygeia S.A., Athens, Marousi, GREECE, ²2nd Internal Medicine - Oncology Clinic Hygeia SA, Athens, Marousi, GREECE, ³Thoracic Surgery Clinic Hygeia SA, Athens, Marousi, GREECE, ⁴Medical Physics Department, Hygeia S.A., Athens, Marousi, GREECE.

P636

The evaluation of clinical usefulness of continuous bed motion scanning in positron emission tomography in diagnosis of patients with subsolid pulmonary nodule

M. Endo, K. Asakura, T. Aramaki, E. Bekku, R. Sato, K. Yoza; Shizuoka cancer center, Shizuoka, JAPAN.

P637

Efficacy of SUVmax and SUVpeak to predict distant metastasis of non-small cell lung cancer before treatment

S. Toubaru¹, S. Ohashi¹, Y. Tachibana¹, M. Hasebe¹, K. Tanimoto¹, M. Zhang¹, N. Yamamoto¹, M. Nakajima¹, M. Karube¹, T. Obata¹, T. Saga¹, Y. Ando¹, K. Yoshikawa², T. Kamada¹; ¹National Institute of Radiological Sciences, Chiba, JAPAN, ²Tokyo Bay Advanced Imaging & Radiation Oncology Clinic MAKUHARI, Chiba, JAPAN.

P638

Role of 18FDG-PET/CT semiquantitative parameters in the evaluation of therapy response in patients affected by recurrent pleural mesothelioma

A. Di Palo, A. Niccoli Asabella, C. Altini, A. Notaristefano, C. Ferrari, G. Rubini; Nuclear Medicine Unit, D.I.M., University of Bari, ITALY, Bari, ITALY.

P639

Assessment of the influence of several clinical, surgical and pathologic variables in bronchogenic carcinoma increasing stage from diagnostic PET/CT to reparative surgery.

E. Rodríguez Pelayo, E. Castillo Gallo, J. García Satué, B. De Olaiz Navarro, J. Aramburu González, M. Balsa Bretón, C. Paniagua Correa, M. Castillejos Rodríguez, F. Penín González; Hospital Universitario de Getafe, Madrid, SPAIN.

P640

Is Molecular Remission as Detected by 18F-FDG PET/CT and Regression Grade After Neoadjuvant Treatment in the Primary Tumor and the Involved Mediastinal Lymph Nodes a Prognostic Factor in Patients With NSCLC Stage III?

M. Schmuecking¹, R. P. Baum², N. D. Klass³, E. Fritz³, S. C. Schaefer⁴, N. Presselt⁵, B. Hokscho⁶, K. M. Mueller⁷, T. G. Wendt⁸, B. Klaeser⁹, R. Bonnet¹⁰; ¹Strahlenzentrum Hamburg/CyberKnife Center Hamburg, Hamburg, GERMANY, ²Zentralklinik Bad Berka, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Bad Berka, GERMANY, ³Inselspital Bern, Dept. of Radiation Oncology, Bern, SWITZERLAND, ⁴University of Bern, Institute of Pathology, Bern, SWITZERLAND, ⁵Zentralklinik Bad Berka, Dept. of Thoracic Surgery, Bad Berka, GERMANY, ⁶Inselspital Bern, Dept. of Thoracic Surgery, Bern, SWITZERLAND, ⁷University of Münster, Institute of Pathology, Münster, GERMANY, ⁸University of Jena, Dept. of Radiation Oncology, Jena, GERMANY, ⁹Inselspital Bern, Dept. of Nuclear Medicine, Bern, SWITZERLAND, ¹⁰Zentralklinik Bad Berka, Dept. of Pneumology, Bad Berka, GERMANY.

P641

Study of FDG PET/CT in detecting mediastinal and hilar/interlobar lymph nodes metastases of non-small cell lung cancer

Q. Xue, Z. Yao; Beijing Hospital, Beijing, CHINA.

P642

Is there a role for 18F-FDG PET/CT to differentiate benign from malignant form of solitary fibrous tumors of the pleura?

D. Familiari¹, M. Migliore², A. Missiato³, S. Russo¹, A. Ruggeri¹, E. Potenza³, M. C. Fornito¹; ¹Nuclear Medicine Department/ PET-CT center - A.R.N.A.S. Garibaldi, Catania, ITALY, ²Thoracic Sugery Department - Azienda Ospedaliera Universitaria "Policlinico- Vittorio Emanuele", Catania, ITALY, ³Thoracic Sugery Department - A.R.N.A.S. Garibaldi, Catania, ITALY.

P643

Positron Emission Tomography CT to differentiate tumour recurrence and radiation-induced pulmonary fibrosis after stereotactic body radiation therapy

G. Capriotti¹, S. Di Traglia¹, A. Covello¹, P. Pizzichini¹, D. Prosperi¹, M. Tuccimei¹, R. Maurizi Enrici², M. Osti², F. Scopinaro¹; ¹Sapienza University of Rome, Nuclear Medicine Unit, Sant'Andrea Hospital, ROME, ITALY, ²Sapienza University of Rome, Sant'Andrea Hospital, ROME, ITALY.

P644

Predictive value of early dynamic and static FDG PET / CT findings in evaluation of primary lung lesions

B. Vatankulu¹, S. Bakan², O. E. Şahin¹, S. Sağer¹, M. Halaç¹, H. B. Sayman³, K. Sönmezoğlu¹; ¹Istanbul University Cerrahpaşa Medical Faculty Department of Nuclear Medicine, İstanbul, TURKEY, ²Istanbul University Cerrahpaşa Medical Faculty Department of Radiology, İstanbul, TURKEY, ³Istanbul University Cerrahpaşa Medical Faculty Department of Nuclear Medicine, İstanbul, TURKEY.

P645

Correlation of F-18 FDG PET-CT based on metabolic volumetric parameters with survival in patients with non-small cell lung carcinoma

M. Kula¹, E. Kocaagaoglu¹, U. Abdulrezzak¹, H. Karaca², Ö. Onal³, A. Tutus¹, Y. Kose Kurt¹; ¹Erciyes University, School of Medicine, Department of Nuclear Medicine, Kayseri, TURKEY, ²Erciyes University, School of Medicine, Department of Clinical Oncology, Kayseri, TURKEY, ³Erciyes University, School of Medicine, Department of Cardiovascular Surgery, Kayseri, TURKEY.

P38

Monday, October 12, 2015

16:00 – 16:30

**Clinical Oncology:
Liver, Upper GI & Pancreatic Cancer**

P646

Value of 18F-FDG PET/CT in the Staging of Gastric Carcinoma

L. Mena Bares, V. González Cosano, E. Carmona Asenjo, M. Pleguezuelo Navarro, F. Maza Muret, V. Guiote Moreno, E. Moreno Ortega, J. Vallejo Casas; Hospital Universitario Reina Sofía, Córdoba, SPAIN.

P647

Delayed FDG image obtained 90 min after injection gives incremental information which correlates histopathological data; Analysis with surgically resected pancreatic cancer

T. Kudo¹, R. Ideguchi¹, M. Uetani¹, A. Nanashima², T. Nagayasu¹; ¹Nagasaki University, Nagasaki, JAPAN, ²University of Miyazaki, Miyazaki, JAPAN.

P648

The diagnostic performance of FDG-PET/CT versus conventional imaging modalities in the evaluation of treatment response following ablation therapy for colorectal liver metastases: a meta-analysis

M. Samim¹, Q. I. Molenaar¹, M. F. J. Seesing¹, M. A. A. J. van den Bosch¹, T. J. M. Ruers², I. H. M. Borel Rinkes¹, R. van Hillegersberg¹, M. G. E. H. Lam¹, H. M. Verkooijen¹; ¹University Medical Center Utrecht, Utrecht, NETHERLANDS, ²Dutch Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, NETHERLANDS.

P649

Respiratory gated 18F-FDG-PET/CT improves quantification of metabolic parameters and their correlation with overall survival in patients with pancreatic ductal adenocarcinoma

D. Withaar, W. Grootjans, J. Hermans, K. Van Laarhoven, L. De Geus-Oei, M. Gotthardt, E. Aarntzen; Radboudumc, Nijmegen, NETHERLANDS.

P650

18F-FDG PET/CT findings in a patient with Cowden's syndrome

K. Öksüzöğlü¹, T. Öneş¹, H. T. İlçe², F. Dede¹, H. T. Turoğlu¹, S. İnanır¹, T. Y. Erdil¹; ¹S.B. Marmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesi, Nükleer Tıp AD, İstanbul, TURKEY, ²Sakarya Üniversitesi Eğitim ve Araştırma Hastanesi, Nükleer Tıp AD, Sakarya, TURKEY.

P651

Better accuracy of SPECT/CT in determination of liver hemangioma in patients with malignant tumor

M. Prpic¹, Z. Kusic²; ¹University Hospital Centre "Sestre Milosrdnice", Zagreb, CROATIA, ²University Hospital Centre "Sestre Milosrdnice", Zagreb, CROATIA.

P652

Metabolic FDG superscan in a patient with gastric adenocarcinoma: A rare finding in PET/CT imaging

B. E. Akkas, S. Demirtas, B. Demirel, G. Ucmak; Ankara Oncology Research and Training Hospital Department of Nuclear Medicine, Ankara, TURKEY.

P653

Efficacy of 18F-FDG-PET/CT for detection of suspected recurrence in post treatment follow-up of patients with carcinoma gall bladder, in a North Indian population-a pilot study.

M. Ravina, S. Gambhir, A. Prashanth, S. Barai, N. Kumar, D. Singh; Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, INDIA.

P654

Hepatic Epithelioid Hemangioendothelioma on FDG PET/CT

K. Oksuzoglu, R. Maleki, S. Inanir; Marmara University School of Medicine, Department of Nuclear Medicine, Istanbul, TURKEY.

P655

Metabolic response assessment on 18F-FDG PET/CT with delta SUVmax, and its utility in predicting histological response following neoadjuvant chemoradiotherapy in patients with oesophageal cancer.

N. Ahmed, G. Avery, A. Razack, T. Goldstone, R. Roy, M. Hingorani, J. Cooke; Hull and East Yorkshire Hospitals NHS Trust, Hull, UNITED KINGDOM.

P39

Tuesday, October 13, 2015

16:00 – 16:30

Clinical Oncology: Neuroendocrine Tumours

P656

Additional value of the quantitative measurements of the therapeutic effect in patients with somatostatin expressing tumors using 99mTc-Tectrotyde

I. Kostadinova¹, A. Demirev¹, J. Mihailova², V. Hadjiiska¹; ¹Clinic of nuclear medicine, Sofia, BULGARIA, ²Clinic of medical oncology, Sofia, BULGARIA.

P657

A retrospective comparison between 68Ga-DOTA-TOC and 18F-DOPA PET/CT in metastatic extra-adrenal paraganglioma

A. Kroiss¹, B. L. Shulkin², C. Uprimny¹, T. Jazbec¹, A. Frech¹, G. M. Sprinzl³, G. Gastl¹, C. Thomé¹, G. Fraedrich¹, I. J. Virgolini¹; ¹Medical University Innsbruck, Innsbruck, AUSTRIA, ²Radiological Sciences, St. Jude Children's Research Hospital, Memphis, TN, UNITED STATES, ³State Clinic St. Poelten, St. Poelten, AUSTRIA.

P658

Oncogenic osteomalacia: Role of 68Ga DOTA-NOC PET/CT scan in identifying the culprit lesion and its management

S. Gambhir, D. Singh, M. Ravina, S. Barai, A. Prashanth, N. Kumar; Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, INDIA.

P659

Utility of Ga-68 DOTANOC PET CT in evaluation of unusual or rare neuroendocrine tumors: Single institutional experience

A. Pruthi, P. Pankaj, R. Verma, A. Jain, E. S. Belho, H. Mahajan; Sir Ganga Ram Hospital and Research Centre, New Delhi, INDIA.

P660

Comparison between 18FDG-PET/CT scan and Tc-99mHYNIC-[D-Phe1,Tyr3-Octreotide (Tektrotyd) scintigraphy in patients with neuroendocrine tumor (NET).

I. Navales Mateu, M. Simó Perdigó, M. Salcedo Pujantell, M. Barios Profitos, A. Garcia Burillo, J. Capdevila Castellón, J. Monturiol Duran, M. Velasco Nuño, J. Castell Conesa; Hospital Universitari Vall d'Hebron, Barcelona, SPAIN.

P661

Impact of SPECT/CT 99mTc-EDDA/ HYNIC-TOC in the diagnosis and the extension of neuroendocrine tumors

S. E. Bouyoucef, M. Habbeche, S. Rahabi, A. Talbi, B. Abdi, S. Bellabas, A. Amimour; Department of Nuclear Medicine CHU Bab El Oued, Algiers, ALGERIA.

P662

Comparison of Early and Late SUVmax Values of Somatostatin Receptor Positive Lesions in Ga-68 DOTATATE PET/CT Images

J. Nematyazar, S. Sager, O. Erdem Sahin, B. Razavi, R. Akyel, B. Vatankulu, E. Kaymak, M. Halac, H. Sayman, I. Uslu, K. Sonmezoglu; 1Department of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, TURKEY.

P663

Analysis of carbidopa premedication in patients with neuroendocrine tumors before a 18F-DOPA PET-CT study

A. Ramírez, E. Morillo, W. Valdés, N. Testart, E. Triviño, T. Aroui, A. Rodriguez-Fernandez, J. Llamas-Elvira; H.VIRGEN DE LAS NIEVES, GRANADA, SPAIN.

P664

Comparative evaluation of somatostatin receptor scintigraphy using Tc-99m and In-111 labelled somatostatin analogues

I. Szilvási¹, Z. Varga², R. Jóna¹, K. Buga¹, K. Bús², E. Takács², G. Dabas²; ¹Hungarian Defense Forces Medical Centre, Budapest, HUNGARY, ²Semmelweis University, Budapest, HUNGARY.

P665

Ga-68 DOTANOC PET/CT for Neuroendocrine Tumours: Experience at Western Cape Academic PET/CT Centre

A. G. G. Doruyster, A. Ellmann, S. M. Rubow; Stellenbosch University, Cape Town, SOUTH AFRICA.

P666

GLP-1 receptor scintigraphy as a potential tool in the detection of neuroendocrine malignancies.

A. Sowa-Staszczak, A. Stefańska, M. Buziak-Bereza, M. Trofimiuk-Muldner, M. Kołodziej, A. Hubalewska-Dydejczyk; Nuclear Medicine Unit, Endocrinology Department, University Hospital Krakow, Krakow, POLAND.

P667

Focally increased activity in the pancreas on In-111 Octreotide scan – can it be a physiologic variant?

Z. Kováčová¹, D. Zogala¹, A. Pudlač², J. Kubinyi¹; ¹Institute of Nuclear Medicine, First Faculty of Medicine, Charles University in Prague, Prague, CZECH REPUBLIC, ²Department of Radiology, First Faculty of Medicine, Charles University in Prague, Prague, CZECH REPUBLIC.

P668

Effect of I-131 MIBG Thyroid Uptake on Thyroid Function Tests

A. Hassanzadeh-Rad, S. Katal, D. Beiki, A. Fard-Esfahani, A. Emami-Ardekani, B. Fallahi, M. Eftekhari; Research Center for Nuclear Medicine, Shariati Hospital, Tehran, IRAN, ISLAMIC REPUBLIC OF.

P669

Contribution of Ki67 proliferation index and 111In-Pentetreotide somatostatin receptor scintigraphy in Neuroendocrine Tumors

G. Muñoz Garcia¹, J. Muñoz Iglesias¹, C. Penín Corderi², R. Guitián Iglesias¹; ¹Nuclear Medicine Department. Complejo Hospitalario Universitario de Ourense, Ourense, SPAIN, ²Pathology Department. Complejo Hospitalario Universitario de Ourense, Ourense, SPAIN.

P670

The diagnostic use of a 2 day protocol in Somatostatin Receptor Scintigraphy using 99mTc-HYNIC-TOC. Preliminary Results.

P. Z. Stavrou, C. Giannopoulou, E. Persakis, K. Kouvelis, M. Papachristou, E. Vontzou, I. Datseris; Evangelismos Hospital, Athens, GREECE.

P671

Correlation between Tumor Volume Defined by 68Ga-DOTANOC PET/CT scan and Maximum Standardized Uptake Value Variation (Δ SUVmax) after Peptide Receptor Radionuclide Therapy (PRRNT)

L. Sobral Violante¹, I. Sampaio¹, J. Teixeira¹, A. Santos¹, A. Duarte², F. Lopes¹, L. Costa¹, O. Soares¹, I. Paula¹, H. Duarte¹;
¹Instituto Português de Oncologia, Porto, PORTUGAL,
²Instituto Politécnico de Bragança, Bragança, PORTUGAL.

P672

[68Ga]DOTANOC PET: sex specific differences and influence of diabetes and usage of proton pump inhibitors

A. Leisser, W. Wadsak, M. Mayerhoefer, M. Mitterhauser, G. Karanikas, M. Hacker, A. R. Haug; Medical University of Vienna, Vienna, AUSTRIA.

P673

Predictors of FDG-F18 PET Positivity in Neuroendocrine Tumours

R. Silva¹, L. Pires¹, R. Ferreira¹, A. Moreira¹, P. Lapa¹, G. Costa¹, J. Pedrosa de Lima²; ¹Serviço de Medicina Nuclear do Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL,
²Instituto de Ciências Nucleares Aplicadas à Saúde, Coimbra, PORTUGAL.

P674

Characterizing 68Ga-DOTA-peptide uptake in uncinate process of pancreas: normality versus Pathology

A. Kasat, C. Goh, H. Li, X. Yan; Singapore general Hospital, Singapore, SINGAPORE.

P675

The role of 68Ga-DOTA-NOC PET/CT as first step examination in cases with suspected Neuroendocrine Tumors (NET) based on clinical, biochemical and radiologic data

L. M. P. Pires, R. Silva, J. Álbán, M. Silva, A. Moreira, G. Costa, J. P. Lima; Centro Hospitalário e Universitário de Coimbra, Coimbra, PORTUGAL.

P676

Interest of 68Ga DOTATOC-PET-CT compared to 111In-DTPA-octreotide scintigraphy to detect pancreas and duodenum neuroendocrine tumors in patients with MEN-1: preliminary results.

C. Morgat^{1,2,3}, F. Vélayoudom-Céphise⁴, P. Schwartz¹, M. Nunes⁴, J. Schulz^{2,3}, J. Mazère^{1,2,3}, M. Guyot¹, D. Gaye⁴, E. Hindié^{1,2,3}, A. Tabarin⁴, P. Fernandez^{1,2,3}; ¹Service de Médecine Nucléaire, CHU de Bordeaux, Pessac, FRANCE, ²Univ Bordeaux, INCIA UMR-CNRS 5287, F-33400 Talence, FRANCE, ³CNRS, INCIA UMR 5287, F-33400 Talence, FRANCE, ⁴Service d'Endocrinologie, CHU de Bordeaux, Pessac, FRANCE.

P40

Tuesday, October 13, 2015

16:00 – 16:30

Clinical Oncology: Colorectal Cancer

P677

Added value of dual time point 18F-FDG PET/CT scanning in detection of local recurrence in rectal cancer

H. R. Farghaly^{1,2}, H. A. Nasr^{1,3}, A. Al Qarni¹; ¹Radiology Department, Prince Sultan Military Medical City, Riyadh, SAUDI ARABIA, ²Nuclear Medicine Unit, Assiut University, Assiut, EGYPT, ³Nuclear Medicine Unit, Cairo University, Cairo, EGYPT.

P678

Evaluation of recurrent disease in the re-staging of colorectal cancer by 18F FDG PET/CT: can CEA and CA 19.9 help in patient selection?

A. Chiaravalloti, A. Fiorentini, D. Rinino, L. Travascio, R. Danieli, A. Lacanfora, E. Palombo, D. Di Biagio, O. Schillaci; Department of Biomedicine and Prevention, University Tor Vergata, Rome, ITALY.

P679

Value of FDG PET/CT in the assessment of patients with colon cancer comparing to stand-alone CT

K. Akbari¹, S. Haim², K. Emmanuel³, W. Zaglmair³, C. Pirich⁴, F. Fellner¹, W. Langsteger², M. Beheshti²; ¹Radiology, General Hospital Linz, Linz, AUSTRIA, ²PET-CT Center Linz, St. Vincent's Hospital, Linz, AUSTRIA, ³GI-Cancer Center, St. Vincent's Hospital, Linz, AUSTRIA, ⁴Nuclear Medicine & Endocrinology, Paracelsus Medical University, Salzburg, AUSTRIA.

P680

18F-FDG PET/CT in rectal cancer preoperative staging: improved detection of metastases and 2° unsuspected tumour

N. Testart, A. Rodríguez-Fernández, T. Aroui-Luquin, R. Sánchez-Sánchez, M. Gómez-Río, E. Triviño-Ibáñez, A. Medina-Benítez, R. Conde-Muiño, J. Llamas-Elvira; Complejo Hospitalario Universitario De Granada, Granada, SPAIN.

P681

18F-FDG PET-CT Predicting Pathological Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer

D. Sanchez Fuentes, S. Pedraza Fernandez, S. Ruiz Solis, A. Hernandez Martinez, P. Sarandeses Fernandez, A. Gomez Grande, M. Perez-Escutia, J. Estenoz Alfaro; Hospital Universitario 12 De Octubre, Madrid, SPAIN.

P682

Correlation Between Carcinoembryonic Antigen, Standard Uptake Value and Metabolic Volume in F-18 FDG PET/CT Positive Patients With Proven Recurrent Colorectal Carcinoma

E. G. Matovina, J. Mihailovic, D. Srbovan; Oncology institute of Vojvodina, Novi Sad, SERBIA.

P683

Incidentally detected increased 11C-Choline uptake in bowel and histopathological correlation.

E. Tabacchi, P. Ghedini, P. Castellucci, I. Grassi, S. Cambioli, S. Fanti; S. Orsola-Malpighi Hospital - University of Bologna, Bologna, ITALY.

P684

Contribution of FDG PET/CT for re-staging in patients with colorectal cancer having suspicious radiological findings and/or elevated serum tm marker levels.

M. YÜKSEL, M. T. Yanmaz, H. Akyol, M. A. Aydın, E. Ziyilan, T. Ipek, E. Eyüpoglu; Kemerburgaz University, Medical Faculty, ISTANBUL, TURKEY.

P41

Tuesday, October 13, 2015

16:00 – 16:30

Clinical Oncology: Urogenital

P685

11C-Choline PET/CT in Prostate Cancer Patients with Biochemical Recurrence

D. M. Pursanova¹, I. P. Aslanidis¹, O. V. Mukhortova¹, A. S. Rumyantsev¹, O. B. Karyakin², V. A. Biryukov², V. I. Shirokorad³; ¹Bakoulev Scientific Center for Cardiovascular Surgery, Moscow, RUSSIAN FEDERATION, ²A.Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre, Obninsk, RUSSIAN FEDERATION, ³Moscow City Oncology Hospital №62, Moscow, RUSSIAN FEDERATION.

P686

Diuretic FDG PET/CT and diffusion weighted MR imaging for urothelial carcinoma: capability for prediction of pathological characteristics and prognosis

M. Nogami¹, H. Iwasa², K. Miyatake², S. Kohsaki², K. Ohgi², M. Nishimori², T. Yamagami², D. Takenaka¹, S. Adachi¹; ¹Hyogo Cancer Center, Akashi, JAPAN, ²Kochi Medical School, Kochi University, Nankoku, JAPAN.

P687

68Ga-PSMA-11 dynamic PET/CT in the diagnostics of primary prostate cancer

C. Sachpekidis¹, M. Eder², K. Kopka², W. Mier³, B. A. Hadaschik⁴, U. Haberkorn³, A. Dimitrakopoulou-Strauss¹; ¹Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, GERMANY, ²Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, GERMANY, ³Division of Nuclear Medicine, University of Heidelberg, Heidelberg, GERMANY, ⁴Urology Clinic, University of Heidelberg, Heidelberg, GERMANY.

P688

68Ga-PSMA-11 dynamic PET/CT in biochemical relapse of prostate cancer

C. Sachpekidis¹, M. Eder², K. Kopka², W. Mier³, B. A. Hadaschik⁴, A. Dimitrakopoulou-Strauss¹; ¹Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, GREECE, ²Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, GREECE, ³Division of Nuclear Medicine, University of Heidelberg, Heidelberg, GREECE, ⁴Urology Clinic, University of Heidelberg, Heidelberg, GREECE.

P689

Radiolabeled somatostatin analogs for diagnosis and treatment of patients with advanced urothelial carcinoma

M. Rodrigues¹, L. Scarpa¹, D. Kendler¹, C. Uprimny¹, B. Nilica¹, S. Buxbaum¹, G. Gast², I. Virgolini¹; ¹Department of Nuclear Medicine, Medical University, Innsbruck, AUSTRIA, ²Department of Internal Medicine, Division of Haematology and Oncology, Medical University, Innsbruck, AUSTRIA.

P690

Correlation of serum PSA levels with 68Ga-PSMA tumor SUV in patients with primary and metastatic prostate cancer

S. Lütje¹, B. Gomez¹, S. Heskamp², R. Reichel¹, A. Bockisch¹, O. C. Boerman², A. Wetter³, T. D. Poeppel¹; ¹Clinic for Nuclear Medicine, University Hospital Essen, Essen, GERMANY, ²Department of Radiology and Nuclear Medicine, Radboud university medical center, Nijmegen, NETHERLANDS, ³Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, GERMANY.

P691

Renal cell carcinoma: clinical and prognostic value of FDG-PET/CT after surgery

P. Alongi¹, M. Picchio¹, M. Spallino², L. Gianolli¹, G. Saladini³, L. Evangelista³; ¹IRCCS San Raffaele Scientific Institute, Milano, ITALY, ²University of Milano-Bicocca, Milano, ITALY, ³Veneto Institute of Oncology, Padova, ITALY.

P692

Optimising 18F-Choline PET-CT acquisition protocol in prostate cancer

L. Mohamed Salem, Sr.¹, M. Ibañez Ibañez¹, L. Álvarez Nieto¹, V. Godoy Bravo¹, R. Reyes Marles¹, L. Frutos Esteban¹, J. Navarro Fernandez¹, M. Castellón Sanchez¹, P. Nicolas Ruiz¹, M. Claver Valderas¹, B. Miñana López², A. Rosino Sánchez², P. López Cubillana¹, A. Montellano Fenoy¹, M. Roldan Rubio¹; ¹Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN, ²Hospital Universitario Morales Meseguer, Murcia, SPAIN.

P693

Clinical efficacy of PET/CT using 68Ga-DOTATOC for restaging in renal cell carcinoma

Y. Nakamoto, K. Sano, T. Ishimori, K. Togashi; Kyoto University Graduate School of Medicine, Kyoto, JAPAN.

P694

[⁶⁸Ga]PSMA-HBED uptake in sympathetic ganglia - A potential pitfall in scan interpretation

G. Kanthan, E. Hsiao, D. Chan, J. Drummond, G. Schembri; Royal North Shore Hospital, St Leonards, AUSTRALIA.

P695

Impact of 18F-choline PET-CT on management of patients with biochemical recurrence of prostate cancer

A. R. Teagle, A. Robinson, A. Nikapota, F. McKinna, S. Dizdarevic; Brighton and Sussex University Hospitals NHS Trust, Brighton, UNITED KINGDOM.

P696

Preoperative Staging of Urinary Bladder Carcinoma by F-18 FDG PET/CT Using a Novel Protocol – A Prospective Study

Y. C. Lin, S. C. Tsai, J. Y. Li, W. Y. Lin; Taichung Veterans Hospital, Taichung, TAIWAN.

P697

First Clinical Experience Using a Cold Kit Based 68Ga-PSMA PET/CT for Recurrence Detection of Prostate Cancer

C. Artigas, Z. Wimana, G. Ghanem, B. Vanderlinden, P. Flamen; Institut Jules Bordet, Brussels, BELGIUM.

P698

¹¹C-Methionine PET-CT for imaging of prostate cancer: preliminary results.

B. Padovano¹, A. Lorenzoni¹, A. Alessi¹, N. Bedini², S. Morlino², C. Pascali¹, C. Cucchi¹, G. Serafini¹, R. Valdagni², F. Crippa¹; ¹Nuclear Medicine - PET Unit - Fondazione IRCSS Istituto Nazionale Tumori, Milan, ITALY, ²Radiotherapy Unit - Fondazione IRCSS Istituto Nazionale Tumori, Milan, ITALY.

P699

Cu-64 PSMA PET in Prostate Cancer

S. Mirzaei¹, B. Grubmueller², E. Capasso³, P. Knoll¹, A. Floth⁴, C. Meleddu³, S. Shariat², H. Klingler⁴; ¹Institute of Nuclear Medicine with PET-Center, Wilhelminenspital, Vienna, AUSTRIA, ²Department of Urology, Medical University of Vienna, Vienna, AUSTRIA, ³U.O.C. Nuclear Medicine, Regional Oncological Hospital, Cagliari, AUSTRIA, ⁴Department of Urology, Wilhelminenspital, Vienna, AUSTRIA.

P700

Role of PET/CT with 18F-FDG in the staging of patients with localized or locally advanced bladder and urinary tract cancer

J. Duch, A. Montes, A. Domenech, C. Achury, G. Alfonso, G. Anguera, P. Maroto, I. Carrió; Hospital de la Santa Creu i Sant Pau, Barcelona, Barcelona, SPAIN.

P701

¹⁸F-Fluorocholine PET/CT acquisition protocol in prostate cancer: the role of early acquisition of the pelvis in lesion detection rate

S. Capitanio, A. Gerali, G. Virotta, R. Rota, L. Madaschi, A. Bruno; Nuclear medicine Dept., A.O. Papa Giovanni XXIII, Bergamo, ITALY.

P702

"Interpretation of ¹¹C-choline PET/TC for the diagnosis of local relapse (LR) in radically treated prostate cancer (PCa)"

A. Matti¹, G. M. Lima¹, L. Zanoni¹, C. Pultrone², R. Schiavina², F. Lodi¹, S. Fanti¹, C. Nanni¹; ¹S.Orsola-Malpighi Hospital, Nuclear Medicine Department, Bologna, ITALY, ²S.Orsola-Malpighi Hospital, Urology Department, Bologna, ITALY.

P703

The predictive value of ¹⁸F-Methilcholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate

P. Caroli, U. De Giorgi, L. Fantini, A. Moretti, R. Galassi, V. Conteduca, C. Lolli, G. Schepisi, E. Scarpi, D. Amadori, G. Paganelli, F. Matteucci; IRCCS IRST, Meldola, ITALY.

P704

Incidental findings in ¹⁸F-choline PET/CT scans (FC) : an update on our series of 759 patients studied for prostate cancer (PC)

M. Rensi, F. Giacomuzzi, D. Capobianco, F. Di Gregorio, G. Ferretti, M. Povolato, O. Geatti; University Hospital SMM, Udine, ITALY.

P705

Correlation Between GRP Receptor Expression and Pathological and Clinical Characteristics in Radical Prostatectomy Specimens

I. L. Bakker, G. J. L. H. van Leenders, E. de Blois, M. Busstra, A. C. Fröberg, W. M. van Weerden, M. de Jong; Erasmus MC, Rotterdam, NETHERLANDS.

P706

Correlation between detectability with ¹⁸F-Choline PET/CT in biochemical relapse after therapy and the risk parameters at initial diagnosis with prostate cancer

J. J. Robles-Barba¹, C. Gámez-Cenzano¹, J. L. Vercher-Conejero¹, A. Sabaté-Llobera¹, M. Cortés-Romera¹, L. Rodríguez-Bel¹, L. M. Gràcia-Sánchez¹, I. Romero-Zayas², M. Roca-Engronyat³, E. M. Merino-Serra⁴, A. M. Ferrer-Artola⁵, A. Ferrer-González⁶, J. Pera-Fábregas⁷, A. Arellano-Tolivar⁸, J. F. Suárez-Navo⁶; ¹PET-CT Unit, Institut de Diagnòstic per la Imatge (IDI). Bellvitge Hospital, L'Hospitalet de Llobregat, SPAIN, ²Radiofarmacia, Institut de Diagnòstic per la Imatge (IDI). Bellvitge Hospital, L'Hospitalet de Llobregat, SPAIN, ³Radiofarmacia. Bellvitge Hospital, L'Hospitalet de Llobregat, SPAIN, ⁴Servicio de Radiología. Institut de Diagnòstic per la Imatge (IDI). Bellvitge Hospital, L'Hospitalet de Llobregat, SPAIN, ⁵Farnacia. Bellvitge Hospital, L'Hospitalet de Llobregat, SPAIN, ⁶Unidad Funcional de Próstata. Bellvitge Hospital, L'Hospitalet de Llobregat, SPAIN, ⁷Braquiterapia. Institut Català d'Oncologia, L'Hospitalet de Llobregat, SPAIN, ⁸Oncología Radioterápica. Institut Català d'Oncologia, Badalona, SPAIN.

P707

The diagnostic value of PET/CT imaging with the ⁶⁸Ga-labelled PSMA ligand HBED-CC in the diagnosis of prostate cancer

E. Akdemir¹, M. Tuncel¹, M. Ç. Tuncali¹, C. Y. Bilen², F. Akyol³, D. Baydar⁴, H. Özen²; ¹Hacettepe University, Department of Nuclear Medicine, ANKARA, TURKEY, ²Hacettepe University, Department of Urology, ANKARA, TURKEY, ³Hacettepe University, Department of Radiation Oncology, ANKARA, TURKEY, ⁴Hacettepe University, Department of Pathology, ANKARA, TURKEY.

P708

Lung uptake of Fluorine-18 Fluoroethyl-Choline PET-CT in patients with recurrent prostate cancer: a first retrospective analysis.

D. A. Pizzuto¹, C. Caldarella¹, S. Annunziata¹, F. P. Ieria¹, M. A. Isgrò², A. Del Ciello³, V. Rufini¹, A. Giordano¹; ¹Institute of Nuclear Medicine, Department of Radiological Sciences. Catholic University of Sacred Heart, Rome, ITALY, ²Institute of General Pathology. Catholic University of Sacred Heart, Rome, ITALY, ³Institute of Radiology, Department of Radiological Sciences. Catholic University of Sacred Heart, Rome, ITALY.

P709

18F-FACBC PET/CT for the detection of recurrence in patients radically treated for prostate cancer with biochemical relapse: preliminary accuracy data.

L. Zanoni¹, R. Schiavina², C. Pultrone², C. Pettinato¹, C. Fonti¹, S. Semini¹, S. Boschi¹, M. Ferrari³, P. Rigatti³, E. Brunocilla², G. Martorana², S. Fanti¹, C. Nanni¹; ¹Nuclear Medicine, University Hospital Sant'Orsola-Malpighi, Bologna, ITALY, ²Urology, University Hospital Sant'Orsola-Malpighi, Bologna, ITALY, ³Urology, Italian Institute for auxology, Capitanio Hospital, Milan, ITALY.

P710

18F-Choline PET/CT and prostatic gland/fossae recurrence: what can help to identify the local recurrence of disease?

L. Evangelista¹, M. Cimitan², M. Hodolic³, T. Baseric², A. Cervino¹, J. Fettich³, G. Saladini¹, E. Borsatti²; ¹Istituto Oncologico Veneto I.R.C.C.S., PADOVA, ITALY, ²IRCCS National Cancer Institute (CRO), Aviano, ITALY, ³University Medical Center Ljubljana, Ljubljana, SLOVENIA.

P42

Tuesday, October 13, 2015

16:00 – 16:30

Clinical Oncology: Gynaecological

P711

Sentinel Node in Endometrial Cancer. Our Experience

C. Escabias del Pozo, I. Santos Gomez, M. Diestro Tejeda, S. Rodado Marina, M. Coronado Poggio, M. Orduña Diez, M. Marin Ferrer; Hospital Universitario La Paz, Madrid, SPAIN.

P713

Dual-time FDG-PET/CT imaging in suspected ovarian cancer

M. H. Vilstrup¹, G. Neumann², J. T. Asmussen³, O. Gerke¹, A. Alavi⁴, P. Høilund-Carlsen¹; ¹Department of Nuclear Medicine, Odense University Hospital, Odense C, DENMARK, ²Department of Obstetrics and Gynecology, Odense University Hospital, Odense C, DENMARK, ³Department of Radiology, Odense University Hospital, Odense C, DENMARK, ⁴Division of Nuclear Medicine, Department of Radiology, University of Pennsylvania, Philadelphia, PA, UNITED STATES.

P714

Neoadjuvant treatment in advanced cervical cancer: can 18F-FDG PET/CT be predictive of response?

P. Mapelli¹, F. Fallanca¹, A. Bergamini², A. Dell'Acqua², G. Mangili², E. Rabaioni², E. Incerti¹, M. Candiani², L. Gianolli¹, M. Picchio¹; ¹Nuclear Medicine Unit, IRCCS San Raffaele Scientific Institute, Milano, ITALY, ²Gynecology Department, San Raffaele Scientific Institute, Milano, ITALY.

P715

Is multimodality, multiparametric MRI complementary or superfluous to PET-CT in the management of Pelvic malignancies?

S. Raja^{1,2}, M. S. Qureshi², S. George³, A. S. Aldosary²; ¹Baylor College of Medicine, Bellaire, TX, UNITED STATES, ²KFMC, Riyadh, SAUDI ARABIA, ³Johns Hopkins Aramco Healthcare, Dhahran, SAUDI ARABIA.

P716

Impact of PET-CT on the follow-up of patients with cervical and ovarian cancers

S. Carrilho Vaz, Â. Silva, R. Sousa, T. C. Ferreira, P. Ratão, A. Daniel, I. P. Carvalho, F. Brandão, L. Salgado; Portuguese Institute of Oncology – Lisbon Center, Lisbon, PORTUGAL.

P717

18F-FDG PET-CT in Ovarian Cancer: Can We Identify the More Aggressive Histologies?

B. González García¹, M. E. Bellón Guardia², M. P. Talavera Rubio², A. M. Palomar Muñoz², A. M. García Vicente², G. A. Jiménez Londoño², J. M. Cordero García², V. M. Poblete García², A. M. Soriano Castrejón²; ¹Hospital General Universitario Ciudad Real, Ciudad Real, SPAIN, ²SESCAM, Ciudad Real, SPAIN.

P718

Accuracy of 18F-FDG-PET/CT in the Assessment of Incidental Suspicious Ovarian Masses. Advantages and Limitations of a Powerful Imaging Technique.

A. Mari-Hualde¹, D. Zamudio¹, P. Pilkinton¹, T. Castellanos², S. Alonso², L. Chiva², J. Alonso¹; ¹ITSS. MD Anderson Cancer Center Madrid, Madrid, SPAIN, ²MD Anderson Cancer Center Madrid, Madrid, SPAIN.

P719

F-18 FDG PET-CT in restaging of patients with cervical cancer: - experience at a tertiary care hospital

T. K. Jain, R. K. Basher, B. R. Mitta, J. Shukla, A. Bhattacharya, V. Suri, N. Kumar, S. Kumar; PGIMER, Chandigarh, INDIA, Chandigarh, INDIA, INDIA.

P43 Tuesday, October 13, 2015

16:00 – 16:30

Clinical Oncology: Lymphoma

P720

ΔSUV Reduction versus Deauville Visual criteria in Follicular Lymphoma evaluated with 18F-FDG PET/CT

M. Cozar Santiago¹, J. Garcia Garzon², R. Sanz Llorens¹, M. Moragas Solanes², C. Villegas Cardos³, M. Sanchez Delgado³, J. Aguilar Barrios¹, R. Sanchez Jurado¹, J. Ferrer Rebolledo¹; ¹Eresa-General University Hospital, Valencia, SPAIN, ²Cetir-Esplugues PET/CT Unit, Barcelona, Spain, ³Hematology General University Hospital, Valencia, SPAIN.

P721

Could the ratio between lesion and liver SUVmax (rPET) be a prognostic factor in patients with Hodgkin Lymphoma undergoing interim FDG-PET/CT? A retrospective study.

S. Annunziata¹, A. Cuccaro², M. Calcagni¹, L. Indovina³, S. Hohaus², A. Giordano¹, V. Rufini¹; ¹Institute of Nuclear Medicine - Università Cattolica del Sacro Cuore, Rome, ITALY, ²Institute of Hematology - Università Cattolica del Sacro Cuore, Rome, ITALY, ³Institute of Medical Physics - Università Cattolica del Sacro Cuore, Rome, ITALY.

P722

Utility of 18F-FDG-PET/CT for bone assessment in the initial staging of patients diagnosed of Hodgkin's lymphoma.

M. Fernández Rodríguez, E. Rodríguez Pelayo, M. L. Castillejos Rodríguez, C. Sandoval Moreno, M. A. Balsa Bretón, M. P. García Alonso, C. Paniagua Correa, A. Ortega Valle, F. J. Penín González; Hospital Universitario de Getafe, Getafe, SPAIN.

P723

FDG-PET/CT in intravascular large B-cell lymphoma: evaluation of diffuse splenic and bone marrow uptake as predictive factors of hemophagocytic syndrome

T. Kinjo, K. Nakatani, K. Yoshino, K. Kitaguchi, T. Koyama; Kurashiki Central Hospital, Kurashiki, JAPAN.

P724

[18F]FDG-PET/CT in extranodal lymphoma

M. Sollini, B. Zangheri, L. Calabrese, M. Gasparini; IRCCS MultiMedica, Sesto San Giovanni, ITALY.

P725

FDG PET/CT Can Reliably Determine Bone Marrow Involvement in Diffuse Large B Cell Lymphoma but not in Follicular Lymphoma

A. R. Teagle¹, H. Barton¹, E. Charles-Edwards¹, S. Dizdarevic¹, T. Chevassut^{2,1}; ¹Brighton and Sussex University Hospitals NHS Trust, Brighton, East Sussex, UNITED KINGDOM, ²Brighton and Sussex Medical School, Brighton, East Sussex, UNITED KINGDOM.

P726

The Liver as Reference Organ for Quantification of 18F-FDG Uptake in Lymphoma

C. N. Strandholdt¹, O. Gerke¹, J. T. Friis¹, T. S. Larsen², K. J. Mylam³, P. F. Høilund-Carlson¹; ¹Dept. of Nuclear Medicine, Odense University Hospital, Odense C, DENMARK, ²Dept. of Haematology, Odense University Hospital, Odense C, DENMARK, ³Dept. of Medicine, Vejle Hospital, Vejle, DENMARK.

P727

The Utility Of 18F-FDG PET/CT In Evaluation Of Bone Marrow Involvement In Non-Hodgkin's Lymphoma Patients

D. Vassileva¹, B. Spassov¹, I. Kostadinova², M. Guenova¹; ¹Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, BULGARIA, ²University Hospital Alexandrovska, Sofia, BULGARIA.

P728

Recognition of Graft-Versus-Host-Disease by Semi-Quantitative Analysis of Lung Parenchyma at FDG PET/CT images.

F. Fizi¹, F. Bongioanni¹, M. Pennone², I. Calamia¹, A. Bacigalupo³, C. Marini⁴, S. Morbelli², G. Sambuceti¹; ¹Nuclear Medicine Unit, Department of Health Sciences, University of Genoa, Genoa, ITALY, ²Nuclear Medicine Unit, IRCCS San Martino - IST, Genoa, ITALY, ³Hematology and Bone Marrow Transplantation Unit, IRCCS San Martino - IST, Genoa, ITALY, ⁴CNR-IBFM, Milano, ITALY.

P729

Revised Criteria for 18F-FDG-PET Bone-marrow Evaluation in Lymphoma-staging: High Diagnostic Accuracy in selected patients

E. Orunesu¹, M. Longo², L. Florimonte¹, M. Castellani¹, F. Zito¹, C. Canzi¹, F. Voltini¹, M. Goldaniga³, R. Benti¹, A. Cortelezzi¹; ¹Department of Nuclear Medicine, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, MILAN, ITALY, ²Nuclear Medicine Residency, University of Milan, Unit of Nuclear Medicine, San Paolo Hospital, MILAN, ITALY, ³Oncohaematology Division, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, MILAN, ITALY.

P730

18F-FDG-PET/CT in the evaluation of patients with follicular lymphoma

R. Fonti¹, B. Salvatore¹, A. De Renzo², S. Pellegrino³, C. Cerchione², M. Monti², C. Cimmino², F. Pane², L. Pace⁴, S. Del Vecchio³; ¹Institute of Biostructures and Bioimages-CNR, NAPLES, ITALY, ²Haematology Division, University "Federico II", NAPLES, ITALY, ³Department of Advanced Biomedical Sciences, University "Federico II", NAPLES, ITALY, ⁴Department of Medicine and Surgery, University of Salerno, SALERNO, ITALY.

P731

Staging and Indices measured with 18F-FDG PET/CT as a predictor of survival in Non-hodgkin's lymphoma

B. Dirlik Serim¹, E. Umit², F. Ustun³, B. Tokuç⁴, M. Demir², G. Durmus Altun³; ¹Istanbul Medicine Faculty, Nuclear Medicine Department, Istanbul, TURKEY, ²Trakya University Medicine Faculty, Hematology Department, Edirne, TURKEY, ³Trakya University Medicine Faculty, Nuclear Medicine Department, Edirne, TURKEY, ⁴Trakya University Medicine Faculty, Department of Public Health, Edirne, TURKEY.

P732

Delayed-time-point [18F]-FDG-PET in MALT lymphoma: is [18F]-FDG-PET better than its reputation?

M. Mayerhoefer, C. Giraudo, D. Senn, M. Hartenbach, M. Raderer; Medical University of Vienna, Vienna, AUSTRIA.

P733

FDG-PET in aggressive non Hodgkin lymphoma: the prognostic value of interim evaluation

L. Aloj¹, F. Frigeri², C. Caracò¹, S. Crisci², R. Farese³, F. Ibello¹, A. Morisco³, G. Capobianco², F. Volzone², A. Pinto², S. Lastoria¹; ¹SC Medicina Nucleare, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, Napoli, ITALY, ²SC Ematologia, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, Napoli, ITALY, ³Centro Ricerche Oncologiche Mercogliano, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, Mercogliano (AV), ITALY.

P734

Prolonged effect of chemotherapy on FDG uptake of the normal bone marrow in patients with malignant lymphoma

G. S. Alobthani¹, T. Morita¹, K. Isohashi¹, H. Kato¹, M. Tatsumi¹, E. Shimosegawa², J. Hatazawa¹; ¹Department of Nuclear Medicine and Tracer kinetic, Graduate School of Medicine, Osaka University, Osaka, JAPAN, ²Department of Molecular Imaging in Medicine, Graduate School of Medicine, Osaka University, Osaka, JAPAN.

P735

Predictive value of F-18 FDG PET/CT quantification parameters for progression-free survival in patients with B-cell lymphoma

W. He, W. Zhai, W. Yu; Huadong Hospital, Shanghai, CHINA.

P44

Tuesday, October 13, 2015

16:00 – 16:30

Clinical Oncology: Leukaemia & Myeloma

P736

Is there any complementary role of F-18 NaF PET/CT in detecting of osseous involvement of Multiple Myeloma?: A comparative study for F-18 FDG PET/CT and F-18 FDG NaF PET/CT

I. Ak Sivriköz¹, H. Onner¹, O. Akay²; ¹Esogu School Of Medicine, Department Of Nuclear Medicine, Eskisehir, TURKEY, ²Esogu School Of Medicine, Department Of Hematology, Eskisehir, TURKEY.

P737

Bone marrow plasma cell infiltration rate is higher in multiple myeloma patients with pathological 18F-FDG PET/CT than in patients with normal scans

C. Sachpekidis¹, E. K. Mai², J. Hillengass², H. Goldschmidt², U. Haberkorn³, A. Dimitrakopoulou-Strauss¹; ¹Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, GERMANY, ²Medical Clinic V, University of Heidelberg, Heidelberg, GERMANY, ³Division of Nuclear Medicine, University of Heidelberg, Heidelberg, GERMANY.

P738

Correlation of 18F-FDG SUVs derived from reference bone marrow with recognized prognostic laboratory parameters in multiple myeloma

C. Sachpekidis¹, E. K. Mai², J. Hillengass², H. Goldschmidt², U. Haberkorn³, A. Dimitrakopoulou-Strauss¹; ¹Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, GERMANY, ²Medical Clinic V, University of Heidelberg, Heidelberg, GERMANY, ³Division of Nuclear Medicine, University of Heidelberg, Heidelberg, GERMANY.

P739

Italian Interpretation Criteria for FDG PET/CT in Multiple Myeloma(MM)

C. Nanni¹, A. Versari², A. Bianchi³, M. Rensi⁴, M. Bello⁵, S. Chauvie³, E. Zamagni¹, M. Cavo¹, S. Fanti¹; ¹Aou S.orsola-Malpighi, Bologna, ITALY, ²S.maria Nuova Irccs, Reggio Emilia, ITALY, ³Aso S. Croce E Carle, Cuneo, Italy, ⁴Aou S.maria Della Misericordia, Udine, ITALY, ⁵Ao Citta' Della Salute E Della Scienza, Torino, ITALY.

P740

Application of PET-CT for Evaluation of the Therapeutic Effect in Patients with Multiple Myeloma

M. B. Garcheva-Tsacheva¹, B. Spassov², D. Vassileva³; ¹Medical University, Sofia, BULGARIA, ²Department of Clinical Hematology, Specialized Hospital for Active Therapy of Haematological diseases, Sofia, BULGARIA, ³Department of Nuclear Medicine, Specialized Hospital for Active Therapy of Haematological diseases, Sofia, BULGARIA.

P741

FDG PET/CT correlates better than the percent bone marrow infiltration with the status of active disease in patients with Multiple Myeloma

G. Ucmak, B. E. Akkas, B. B. Demirel, S. Demirtas; Ankara Oncology Research and Training Hospital Department of Nuclear Medicine, Ankara, TURKEY.

P742

Combined Use Of PET/CT And Serum Beta-2-Microglobulin In Patients With Multiple Myeloma

D. Vassileva¹, B. Spassov¹, M. Garcheva²; ¹Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, BULGARIA, ²University Hospital Alexandrovska, Sofia, BULGARIA.

P743

Diagnostics of multiple myeloma using FET PET/CT - feasibility study.

B. Malkowski¹, A. Jurczyszyn², R. Lopatto¹, M. Wrobel¹, M. Olejniczak¹, J. Czyz³; ¹Oncology Centre, Bydgoszcz, POLAND, ²Hematology Clinic, JU, Krakow, POLAND, ³University Hospital, Bydgoszcz, POLAND.

P744

Possibility of the early assessment of treatment effectiveness in multiple myeloma by FET PET/CT - initial results.

B. Małkowski¹, R. Lopatto¹, M. Wróbel¹, M. Olejniczak¹, A. Jurczyszyn², J. Czyz³; ¹Oncology Centre Bydgoszcz, Bydgoszcz, POLAND, ²Haematology Clinic Jagiellonian University, Kraków, POLAND, ³Haematology Clinic CM NC University, Bydgoszcz, POLAND.

P745

Diagnostic value of F-18 FDG PET-CT imaging in multiple myeloma

F. Canbaz¹, Y. Usta¹, O. Yapici¹, M. Turgut²; ¹Ondokuz Mayıs University Hospital, Faculty of Medicine, Nuclear Medicine Dept., Kurupelit / Samsun, TURKEY, ²Ondokuz Mayıs University Hospital, Faculty of Medicine, Hematology Dept., Kurupelit / Samsun, TURKEY.

P746

Discrepancies in detection of Myeloma's bone lesions between PET and CT components in 18F-FDG PET/CT studies.

L. F. León Ramírez, C. González Roiz, A. Ortega Candil, C. Rodríguez Rey, A. Serrano Palacio, C. Riola Parada, R. Couto Caro, J. L. Carreras Delgado; Hospital Clinico San Carlos, Madrid, SPAIN.

P45

Tuesday, October 13, 2015

16:00 – 16:30

Clinical Oncology: Bone

P747

Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and PSA in prostate cancer patients receiving radium-223 dichloride therapy.

Y. Nakagami, D. Kano, M. Kusumoto; National Cancer Center, Chiba, JAPAN.

P748

Automatic bone scan index for therapy response assessment of radium-223-dichloride (Ra-223) therapy in advanced prostate cancer

M. Sakretz, J. Kurth, S. M. Schwarzenböck, B. J. Krause, M. Heuschkel; Rostock University Medical Center, Department of Nuclear Medicine, Rostock, GERMANY.

P46 Tuesday, October 13, 2015

16:00 – 16:30

Clinical Oncology: Melanoma

P749

Benefits of performing ultrasound and US-guided FNAC in melanoma patient scheduled for sentinel lymph node biopsy

G. Horvatic Herceg¹, I. Bracic¹, M. Kralik², D. Herceg³, S. Kusacic-Kuna¹, J. Antulov⁴; ¹Clinical department of nuclear medicine and radiation protection, University Hospital Center Zagreb, Zagreb, CROATIA, ²Department of radiology, University Hospital Center Zagreb, Zagreb, CROATIA, ³Department of Medical Oncology, University Hospital Center Zagreb, Zagreb, CROATIA, ⁴Clinical department of histopathology, University Hospital Center Zagreb, Zagreb, CROATIA.

P750

Sentinel Lymph Node Biopsy for Melanoma: our Experience

E. M. Triviño-Ibáñez, N. Testart, J. M. Ruiz-López, R. Sánchez-Sánchez, J. M. Llamas-Elvira; Virgen de las Nieves University Hospital, Granada, SPAIN.

P47 Tuesday, October 13, 2015

16:00 – 16:30

Clinical Oncology: Imaging Guided Surgery (including Sentinel Lymph Node)

P751

"SPECTacles" for surgeons: SECT-CT visualization of axillary sentinel lymph nodes in patients with breast cancer - obligatory step of surgery planning

P. Krzhivitskiy, S. Kanaev, S. N. Novikov, P. Krivorotko, L. Jukova; N.N. Petrov Institute Oncology, St Petersburg, RUSSIAN FEDERATION.

P752

Sentinel node biopsy in head and neck tumors. Validation results

M. Bellón Guardia¹, M. Talavera Rubio¹, A. Palomar Muñoz¹, R. Galan Hernandez², L. Gonzalez Lopez³, B. González García¹, V. Poblete Garcia¹, F. Pena Pardo¹, A. Soriano Castrejon¹; ¹Servicio de Medicina Nuclear. Hospital General Universitario, Ciudad Real, SPAIN, ²Servicio de Cirugía maxilofacial. Hospital General Universitario, Ciudad Real, SPAIN, ³Servicio de Anatomía Patológica. Hospital General Universitario, Ciudad Real, SPAIN.

P753

The clinical impact of selective axillary dissection after lymphoscintigraphy axillary reverse mapping to reduce breast-cancer related lymphedema : long term results of a preliminary study

M. Maccauro¹, M. Gennaro², A. Lorenzoni¹, G. Aliberti¹, C. Sigari³, L. Bedodi³, M. Castellani¹, E. Seregni¹, R. Agresti², A. Caraceni³, M. Greco², F. Crippa¹; ¹Nuclear Medicine Unit, Department of Diagnostic Imaging and Radioterapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Milan, ITALY, ²Breast Unit, Department of Oncological Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Milan, ITALY, ³Department of Rehabilitation and Palliative Care, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Milan, ITALY.

P754

Contribution of SPECT/CT imaging to radioguided sentinel lymph node biopsy in melanoma

J. Villanueva Curto, A. Cobo Rodriguez, A. Sainz-Esteban, C. Gamazo Laherrán, M. González Selma, M. Ruiz Gómez, M. Alonso Rodríguez, R. Olmos García; HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID, Valladolid, SPAIN.

P755

Review of breast cancer sentinel node scintigraphy at Hospital da Luz - 2009-2013

V. Sousa, T. Cunha, C. Loewenthal, M. Vieira; Hospital da Luz, 1500-650, PORTUGAL.

P756

Utility of sentinel lymph node biopsy in vulvar cancer.

A. SAINZ-ESTEBAN, A. Cobo Rodríguez, J. Villanueva Curto, C. Gamazo Laherrán, M. González Selma, M. Ruiz Gómez, M. Alonso Rodríguez, R. Olmos García; Hospital Clínico Universitario de Valladolid, VALLADOLID, SPAIN.

P757

Comparative evaluation of 99mTc-Al2O3 and 99mTc-fiat nanocolloids for sentinel lymph nodes visualization in patients with cervical cancer

I. Sinilkin^{1,2}, V. Chernov^{1,2}, A. Chernyshova¹, L. Kolomiets¹, A. Titskaya^{1,2}, R. Zeltchan^{1,2}, O. Bragina², A. Lyapunov¹, V. Skuridin²; ¹Tomsk Cancer Research Institute, Tomsk, RUSSIAN FEDERATION, ²Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

P758

Comparative evaluation of 99mTc-Al₂O₃ and 99mTc-fiat nanocolloids for sentinel lymph nodes visualization in patients with cancer of larynx and hypopharynx

V. Chernov^{1,2}, I. Sinilkin^{1,2}, E. Choyzonov^{1,2}, S. Chijevskaya¹, A. Titskaya^{1,2}, R. Zeltchan^{1,2}, O. Bragina², A. Lyapunov¹, V. Skuridin²; ¹Tomsk Cancer Research Institute, Tomsk, RUSSIAN FEDERATION, ²Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

P759

Axillary lymph node biopsy: standard radioisotopic technique with 99mTc-nanocolloid versus new magnetic tracers.

C. Castillo-Berrio, M. Castrillón, F. Zelaya, D. Ruiz, F. Loira, J. M. Nogueiras, A. López, A. Serena, L. Campos; Meixoeiro University Hospital, Vigo, SPAIN.

P760

Clinical Impact of the Implementation of Radioguided Localization of Non-Palpable Breast Tumors

C. Sandoval Moreno, M. A. Balsa Breton, P. Garcia Alonso, E. Rodriguez Pelayo, M. Fernandez Rodriguez, L. Castillejos Rodriguez, A. Ortega Valle, C. Paniagua Correa, F. J. Penin Gonzalez; Hospital Universitario De Getafe, Madrid, SPAIN.

P761

Validation of selective sentinel node biopsy in patients with adenocarcinoma of the prostate with high-intermediate and high-risk

V. Vera Pinto, P. Bello Arques, C. Igua Sáenz, P. Borrelli, P. Olivan Sasot, J. Vercher Conejero, J. Loaiza Góngora, P. Sopena Novales, C. Ruiz-Llorca; Hospital Universitario y Politécnico La Fe, Valencia, SPAIN.

P762

Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients with initial axillary node metastasis

N. Testart, A. C. Rebollo-Aguirre, R. Sánchez-Sánchez, T. Aroui, E. M. Triviño-Ibáñez, J. García-García, S. Menjón-Beltrán, J. M. Llamas-Elvira; Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

P763

Sentinel lymph node biopsy in vulvar cancer. Our experience after five years

J. Muñoz Iglesias¹, G. Muñoz García¹, B. Couso Cambeiro², J. Doval Conde², R. Guitián Iglesias¹; ¹Nuclear Medicine Department. Complejo Hospitalario Universitario de Ourense, Ourense, SPAIN, ²Gynecology and Obstetrics Department. Complejo Hospitalario Universitario de Ourense, Ourense, SPAIN.

P764

Sentinel lymph node biopsy and neoadjuvant chemotherapy in breast cancer patients: a single institution experience.

A. C. Rebollo-Aguirre, N. Testart, R. Sánchez-Sánchez, T. Aroui, E. Triviño-Ibáñez, J. García-García, S. Menjón-Beltrán, J. M. Llamas-Elvira; Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

P765

Cervix Cancer: our Experience Using Lymphatic Mapping and Sentinel Node Biopsy

P. Olivan Sasot, P. Borrelli, C. Igua Sáenz, V. Vera Pinto, P. Bello Arqués, J. Loaiza Góngora, C. Ruiz Llorca, A. Repetto; Hospital La Fe, Valencia, SPAIN.

P766

Feasibility of 3D-image guided resection of neuroendocrine tumours

C. Bluemel, M. Gasser, M. Fassnacht, R. A. Werner, A. K. Buck, K. Herrmann; Universitätsklinikum Würzburg, Würzburg, GERMANY.

P767

Sentinel lymph node biopsy in patients with locally advanced breast cancer with negative axilla after chemotherapy

P. Olivan Sasot, P. Borrelli, C. Igua Sáenz, V. Vera Pinto, P. Bello Arqués, J. Loaiza Góngora, C. Ruiz Llorca, P. Sopena; Hospital La Fe, Valencia, SPAIN.

P768

Differences in clinical-biological characteristics and SLN detectability in different age-groups of breast cancer patients

S. M. Nieves Maldonado, S. Argibay Vazquez, M. Garrido Pumar, V. Pubul Nuñez, J. Cortes Hernandez, A. Ruibal Morell; Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, SPAIN.

P769

ROLL technique application for Minimally-Invasive Radioguided Parathyroidectomy (MIRP) in Hyperparathyroidism (HPT)

I. Santi¹, P. Carcoforo², G. Trasforini³, S. Panareo¹, C. Cittanti¹, C. Peterle¹, V. de Cristofaro¹, E. Degli Uberti³, L. Feggi¹; ¹Sant'Anna University Hospital, Nuclear Medicine Unit, Department of Diagnostic Imaging and Laboratory Medicine, Ferrara, ITALY, ²Sant'Anna University Hospital, Breast and Radioguided Surgery Unit, Surgical Department, Ferrara, ITALY, ³Sant'Anna University Hospital, Endocrinology Unit, Department of Medical Sciences, Ferrara, ITALY.

P770

Improving the sensitivity of sentinel node biopsies in malignant melanoma of the head and neck using a handheld gamma camera

S. Schneider-Burrus, A. Pokrywka; Charité Universitätsmedizin, Berlin, GERMANY.

P48

Tuesday, October 13, 2015

16:00 – 16:30

Clinical Oncology: External Beam Radiation Therapy Planning

P771

An Automatic Method for PET Delineation of Cervical Tumors

A. Stefano^{1,2}, S. Vitabile³, G. Russo¹, F. Marletta⁴, C. D'Arrigo⁴, D. D'Urso¹, O. Gambino², R. Pirrone², E. Ardizzone², M. C. Gilardi¹, M. Ippolito⁴; ¹IBFM-CNR, Cefalù, ITALY, ²DICGIM, University of Palermo, Palermo, ITALY, ³DIBIMED, Palermo, ITALY, ⁴Cannizzaro Hospital, Catania, ITALY.

P772

The usefulness of intratumoral metabolic heterogeneity in selecting patients for radiotherapy dose-escalation

S. Kang¹, H. Kim¹, K. Park², G. Jeong¹, H. Park¹, J. Kim², J. Min¹, H. Song², H. Bom¹, S. Kwon¹; ¹Chonnam National University Hwasun Hospital, Hwasun-Gun, KOREA, REPUBLIC OF, ²Chonnam National University Hospital, Gwang-ju, KOREA, REPUBLIC OF.

P49

Tuesday, October 13, 2015

16:00 – 16:30

Clinical Oncology: Therapy Response Assessment

P773

Tumor FDG-Metabolic Values to Predict Pathological Response After Neoadjuvant Chemoradiotherapy in Patients with Resectable Locally Advanced Esophageal Cancer

K. Itoh¹, T. Kitsukawa², H. Takahashi³, M. Myoujin⁴, T. Oishi⁵, T. Takenouchi⁵, S. Watanabe¹, K. Kanegae¹, M. Hosokawa²; ¹Keiyukai Sapporo Hospital, Radiological Imaging Center, Sapporo, JAPAN, ²Keiyukai Sapporo Hospital, Department of Digestive Surgery, Sapporo, JAPAN, ³Keiyukai Sapporo 2nd Hospital, Department of Internal Medicine, Sapporo, JAPAN, ⁴Keiyukai Sapporo Hospital, Department of Radiotherapy, Sapporo, JAPAN, ⁵Keiyukai Sapporo Hospital, Department of Clinical Pathology, Sapporo, JAPAN.

P774

PET/CT Reconstruction and Its Impact on Quantitative Image Analysis

G. Kuhnert¹, R. Boellaard², D. Kahramann¹, M. Scheffler¹, J. Wolf¹, M. Dietlein¹, A. Drzezga¹, C. Kobe¹; ¹University Hospital of Cologne, Cologne, GERMANY, ²VU University Medical Centre, Amsterdam, NETHERLANDS.

P775

Texture analysis for tumor hypoxia visualized by FMISO PET/CT during radiation therapy

M. Hosono, I. Tachibana, Y. Nishimura, K. Hanaoka, S. Kanamori, K. Nakamatsu, K. Ishikawa, K. Sakaguchi; Kinki University Faculty of Medicine, Osaka-Sayama, JAPAN.

P776

PERCIST versus RECIST versus Visual PET assessment for the evaluation of response by PET/c.e.CT to chemoradiation neoadjuvant therapy in patients with locally advanced esophageal cancer

A. Cervino¹, L. Evangelista¹, E. Scagliori¹, R. Alfieri¹, V. Sileni Chiarion¹, S. Galuppo¹, A. Ruol², F. Pomerri³, G. Saladini¹; ¹Istituto Oncologico Veneto I.R.C.C.S., PADOVA, ITALY, ²Hospital of Padua, PADOVA, ITALY, ³University of Padua, PADOVA, ITALY.

P777

Heterogeneity of Metabolic Parameters and Impact on Early Response Evaluation with FDG PET/CT in Patients with Metastatic Colorectal Cancer treated with Cetuximab Monotherapy

E. J. van Helden, O. S. Hoekstra, R. Boellaard, H. M. W. Verheul, C. W. Menke-van der Houven van Oordt; VU Medical Center, Amsterdam, NETHERLANDS.

P778

Therapeutic response assessment of bone metastatic prostate carcinoma treated by abiraterone using x-SPECT QUANT® : a feasibility study.

R. de Laroche, P. Robin, P. Le Roux, J. Malhaire, D. Bourhis, P. Salaun, R. Abgral; University Hospital of Brest, Brest, FRANCE.

P779

Evaluation of Platinum-based Therapy Response in Non-Small Cell Lung Cancer

M. Ippolito¹, A. Stefano^{2,3}, G. Russo², S. Gieri², S. Cosentino¹, G. Murè¹, S. Baldari¹, M. G. Sabini¹, F. Fraggetta¹, S. Vitabile⁴, M. C. Gilardi², G. Banna¹; ¹Cannizzaro Hospital, CATANIA, ITALY; ²IBFM CNR - LATO, Cefalù, ITALY; ³DICGIM, University of Palermo, Palermo, ITALY; ⁴DIBIMED, Palermo, ITALY.

P780

18F-FLT PET/CT as a surrogate biomarker for synergy quantification in EGFR targeted combination therapy of NSCLC

F. Iommelli¹, V. De Rosa¹, M. Monti², M. Panico¹, R. Fonti¹, S. Del Vecchio²; ¹Institute of Biostructures and Bioimages, National Research Council, Naples, ITALY; ²Department of Advanced Biomedical Sciences, University "Federico II", Naples, ITALY.

P781

The role of 18F-FDG PET-CT for evaluation of radiotherapy response in lumbar and sacrococcygeal spine chordoma

S. Cambioli¹, C. Nanni¹, P. Ghedini¹, L. Zanon¹, E. Tabacchi¹, A. Svirydenka¹, S. Diodato¹, S. Bandiera², S. Fanti¹; ¹Nuclear Medicine Department, University Hospital S.Orsola-Malpighi, Bologna, ITALY; ²Department of Oncological and Degenerative Spine Surgery, Rizzoli Orthopedic Institute, Bologna, ITALY.

P782

The response of metastatic lesions in renal cell carcinoma to tyrosine kinase inhibitors evaluated by F-18 FDG PET/CT

O. Yaylali, D. Yuksel, G. G. Dogu, T. Sengoz, A. Yaren; Pamukkale University, Denizli, TURKEY.

P50

Tuesday, October 13, 2015

16:00 – 16:30

Clinical Oncology: Miscellaneous

P783

The clinical value of FDG-PET/CT in common cancers: Actual use compared with literature-based recommendations

P. F. Høilund-Carlsen¹, H. Petersen¹, P. C. Holdgaard², P. H. Madsen³, L. M. Knudsen⁴, D. Gad⁵, A. E. Gravergaard⁵, M. Rohde⁶, B. Engelmann⁷, D. Theilmann-Jørgensen⁸, J. B. Christensen⁹, A. Johansen¹; ¹Dept. of Nuclear Medicine, Odense University Hospital, Odense C, DENMARK; ²Dept. of Nuclear Medicine, Vejle Hospital, Vejle, DENMARK; ³Dept. of Medicine, Vejle Hospital, Vejle, DENMARK; ⁴Dept. of Haematology, Odense University Hospital, Odense C, DENMARK; ⁵Dept. of Plastic Surgery, Odense University Hospital, Odense C, DENMARK; ⁶Dept. of ORL Head & Neck Surgery, Odense University Hospital, Odense C, DENMARK; ⁷Dept. of Internal Medicine, Næstved Hospital, Næstved, DENMARK; ⁸Dept. of Gynaecology and Obstetrics, Aabenraa Hospital, Aabenraa, DENMARK; ⁹Dept. of Quality and Research, Odense University Hospital, Odense C, DENMARK.

P784

Diagnostic value of 18F-FDG PET/CT in whole body cancer screening

Y. Sone¹, M. Abe¹, C. Arakawa¹, I. Kato², A. Sobajima², T. Kawachi², I. Takeda³, T. Kumada³; ¹Department of Radiology, Ogaki Municipal Hospital, Ogaki, JAPAN; ²Department of Radiological Technology, Ogaki Municipal Hospital, Ogaki, JAPAN; ³Health Management Center, Ogaki Municipal Hospital, Ogaki, JAPAN.

P785

Cost-Utility Analysis for Improved Decision Making in Method Comparison PET Studies: an Example in Lymph Node Staging of Prostate Cancer

O. Gerke, M. H. Poulsen, P. Høilund-Carlsen; Odense University Hospital, Odense C, DENMARK.

P786

18-F-FDG-PET/CT Value in the Therapeutic Management of Unknown Primary

M. B. Garcheva-Tsacheva, Sr.¹, V. Hadzhiyska¹, Z. Mihaylova²; ¹Medical University, Sofia, BULGARIA; ²Military Medical Academy, Sofia, BULGARIA.

P787

Barriers and Facilitators to Doctors' Engagement with the National PET CT Clinical Audit Programme

P. Ross¹, J. Hubert², M. Saunders³, W. L. Wong⁴; ¹Birkbeck University of London, London, UNITED KINGDOM, ²NHS South West Commissioning Group Englang, Bristol, UNITED KINGDOM, ³Alliance Medical Molecular Imaging, London, UNITED KINGDOM, ⁴Mount Vernon Hospital, Northwood, UNITED KINGDOM.

P788

Does 18F-FDG PET-CT field of view that includes vertex have an impact on oncological patients management

Y. E. Ramirez, I. Santos, A. Martinez, S. Rodado, I. Hernandez, C. Escabias, M. Coronado; Hospital Universitario La Paz, Madrid, SPAIN.

P789

The Evaluation of Dual-time-point F-18 FDG PET/CT and chest CT for the prediction of the WHO grade in thymic epithelial neoplasms

T. Shinya¹, Y. Otomi¹, T. Tanaka², R. Inai², S. Kanazawa², M. Harada¹; ¹Tokushima university graduate school, Tokushima-city, JAPAN, ²Okayama university hospital, Okayama-city, JAPAN.

P790

Physiological joint pitfall and misinterpretation of PET/CT DOPA Scan

A. Cervino, L. Evangelista, M. Burei, P. Reccia, G. Saladini; Istituto Oncologico Veneto I.R.C.C.S., PADOVA, ITALY.

P791

FDGPET/CT for Pseudomyxoma Peritonei (PMP) and other peritoneal malignancies: Diagnostic features and prognostic consideration

K. Kubota, M. Morooka, M. Okasaki, M. Kameyama, Y. Miyata, R. Minamimoto, Y. Goda, H. Yano; National Center for Global Health and Medicine, TOKYO, JAPAN.

P792

The utility of 18F-FDG PET/CT in patients with carcinoma of unknown primary.

A. Sowa-Staszczak, M. Kołodziej, M. Buziak-Bereza, M. Trófiński, A. Stefańska, A. Hubalewska-Dydejczyk; Nuclear Medicine Unit, Endocrinology Department, University Hospital Krakow, Krakow, POLAND.

P793

(18) F-FDG PET-TC imaging in the detection of primary tumors in patients with metastatic carcinoma of unknown primary origin: a multicentric study

M. Rossi¹, A. Romeo², M. Della Porta¹, F. Malvaldi¹, D. Bacciardi¹, S. Stefanini¹, R. Pratali¹, N. Mazzuca¹; ¹U.O. medicina nucleare, USL 6 di Livorno, Livorno, ITALY, ²U.O. medicina nucleare, Ospedale Maggiore, Bologna, ITALY.

P794

Time-dependent reduction of liver 18 FDG activity in the dual-phase 18 FDG PET/CT study.

O. Kupik, M. Tuncel, P. Kiratli, B. Erbas; Hacettepe University, Ankara, TURKEY.

P51

Tuesday, October 13, 2015

16:00 – 16:30

Radionuclide Therapy & Dosimetry: MIBG & Peptides Therapy

P795

Peptide Receptor Radionuclide Therapy with Lu-177 DOTATATE in patients with somatostatin receptor positive tumours

K. Kamaleshwaran, n. sudhakar, s. paulvannan, m. vysakh, A. shinto; Kovai medical center and hospital limited, Coimbatore, INDIA.

P796

Early side effects of radio ligand therapy with 177-Lutetium-PSMA of metastatic castrate-resistant prostate cancer

H. Ahmadzadehfar¹, A. Yordanova¹, S. Kürpig¹, E. Eppard¹, F. Gärtner¹, S. Rogenhofer², M. Essler¹; ¹University Hospital Bonn, Department of Nuclear Medicine, Bonn, GERMANY, ²University Hospital Bonn, Department of Urology, Bonn, GERMANY.

P797

The clinical efficacy and effectiveness of the Lu-177 DOTATATE therapy

E. Acar, H. Durak, G. Çapa Kaya; Dokuz Eylül University, School of Medicine, Department of Nuclear Medicine, İzmir, TURKEY.

P798

Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-dotatate is an active treatment in advanced bronchial carcinoids: prognostic role of TTF1 and FDG-PET.

A. Ianniello, M. Sansovini, S. Severi, S. Nicolini, V. Lanzetta, K. Massri, F. Matteucci, P. Caroli, A. Bongiovanni, M. Monti, V. D'Errico, G. Paganelli; IRCCS IRST of Meldola, Meldola, ITALY.

P799

The clinical efficacy and effectiveness of the Y-90 radioembolization therapy for the treatment of liver malignancies

E. Acar¹, G. Çapa Kaya¹, A. Gülcü², H. Durak¹; ¹Dokuz Eylül University, School of Medicine, Department of Nuclear Medicine, İzmir, TURKEY, ²Dokuz Eylül University, School of Medicine, Department of Radiology, İzmir, TURKEY.

P800

Assessment of Response with Evaluation of Renal Toxicity in Patients Receiving ¹⁷⁷Lu-DOTA-(Tyr3)-octreotate Therapy in a Tertiary Care Centre in Mumbai, India

T. Bharadwaj¹, H. Rathore¹, H. Shah¹, P. Aland¹, B. Jois Ks¹, S. Ghosh¹, P. Singh², P. Chandrak³, P. Chaudhuri¹, L. Reddy¹, P. Kumar¹, S. Patro¹, V. Lele¹; ¹Jaslok Hospital and Research Centre, Mumbai, INDIA, ²K.E.M Hospital, Mumbai, INDIA, ³Tata Memorial Hospital, Mumbai, INDIA.

P801

Peptide receptor radionuclide therapy of neuroendocrine tumours with ¹⁷⁷Lu-octreotate: first experience in a French Canadian centre

M. Del Prete, F. A. Buteau, J. M. Beaugregard; Université Laval, Quebec City, QC, CANADA.

P802

Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Metastatic Neuroendocrine Tumors: How Effective and Safe Are They?

T. Liotsou, A. P. Stefanoyiannis, S. N. Chatziioannou; 2nd Department of Radiology, Nuclear Medicine Section, National and Kapodistrian University of Athens, Athens, GREECE.

P803

Efficacy and and long-term tolerability of ¹⁷⁷Lu-DOTATATE treatment

J. Svensson¹, A. Elf², R. Rossi Norrlund³, V. Johansson², B. Wängberg², P. Bernhardt⁴; ¹Department of Oncology, The Sahlgrenska Academy, Sahlgrenska University Hospital, Göteborg, SWEDEN, ²Department of Surgery, The Sahlgrenska Academy, Sahlgrenska University Hospital, Göteborg, SWEDEN, ³Department of Radiology, The Sahlgrenska Academy, Sahlgrenska University Hospital, Göteborg, SWEDEN, ⁴Department of Radiation Physics, The Sahlgrenska Academy, Sahlgrenska University Hospital, Göteborg, SWEDEN.

P52

Tuesday, October 13, 2015

16:00 – 16:30

Radionuclide Therapy & Dosimetry: Thyroid

P804

Effect of application of prophylactic central compartment lymph node dissection to radioiodine ablation doses in patients with papillary thyroid carcinoma.

C. Soydal, E. Ozkan, N. O. Kucuk, K. M. Kir; Tip Fakultesi, Ankara, TURKEY.

P805

Radioiodine therapy outcome in older patients with thyreotoxicosis caused by Graves' disease : our experience

M. Yaneva; UMBAL St.George Plovdiv, PLOVDIV, BULGARIA.

P806

^{99m}Tc-HYNIC Octreotide and F-18 FDG PET-CT in differentiated thyroid cancer patients with raised thyroglobulin levels and negative ¹³¹I whole-body scans

K. Kamaleshwaran, n. sudhakar, m. vysakh, A. shinto; Kovai medical center and hospital limited, Coimbatore, INDIA.

P807

Thymic involution after radioiodine therapy for Graves' disease

M. Jinguji¹, M. Nakajo¹, M. Nakajo¹, Y. Nakabeppu¹, C. Koriyama², T. Yoshiura¹; ¹Department of Radiology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, JAPAN, ²Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, JAPAN.

P808

First experience of treatment of thyroid cancer with high-ablative dose of I-131

R. Alimanovic-Alagic¹, A. Skopljak-Beganovic², E. Elma Kucukalic-Selimovic¹; ¹University Clinical Centre Sarajevo, Clinic of Nuclear Medicine, Sarajevo, BOSNIA AND HERZEGOVINA, ²University Clinical Centre Sarajevo, Department of Medical Physics and Radiation Safety, Sarajevo, BOSNIA AND HERZEGOVINA.

P809

Radioiodine Retreatment or Wait for a Limited Time in Patients with Differentiated Thyroid Carcinoma with Negative Thyroglobulin and Antithyroglobulin, but Remained Thyroid Residue after Post-Surgery Radioiodine Ablative Therapy?

A. Fard-Esfahani, B. Fallahi, A. Emami-Ardekani, S. Sahari, D. Beiki, M. Abedi, A. Hassanzadeh-Rad, M. Eftekhari; Tehran University of Medical Sciences, Research Center for Nuclear Medicine, Tehran, IRAN, ISLAMIC REPUBLIC OF.

P810

Risk Factors for Persistent Disease in Papillary Thyroid Carcinoma with Lymph Node Metastasis

A. Oral¹, B. Yazici¹, A. Akgun¹, H. Hassoy², Z. Ozcan¹; ¹Ege University, Faculty of Medicine, Department of Nuclear Medicine, Izmir, TURKEY, ²Ege University, Faculty of Medicine, Department of Public Health, Izmir, TURKEY.

P811

Clinical impact of circulating anti-thyroglobulin autoantibodies on the prediction of recurrence in patients with differentiated thyroid cancer after first remnant ablation

G. Shen, S. Hu, A. Kuang; West China Hospital of Sichuan University, Chengdu, CHINA.

P812

J-131 Therapy of Autonomously Functioning Thyroid Adenoma: the Outcome of Our 20 Years Experience

Z. Petrovski; Department Of Nuclear Medicine Clinical Hospital - Bitola, Bitola, MACEDONIA, The Former Yugoslav Republic Of.

P813

Evaluation of ablation of thyroid remnants with 1850MBq iodine-131 in patients with thyroid cancer

J. Kawabe, S. Higashiyama, K. Kotani, A. Yoshida, S. Shiomi; Graduate School of Medicine, Osaka City University, Osaka City, JAPAN.

P814

Radioiodine scan feature [multifocal versus unifocal pattern] as the determinant for radioiodine ablative treatment dose in patients of Differentiated Thyroid Carcinoma

P. Singh^{1,2}, S. Basu², R. Asopa², M. Rajan²; ¹Seth G.S. and K.E.M. Hospital, Mumbai, INDIA, ²Radiation Medicine Centre, BARC, Mumbai, INDIA.

P815

Radioiodine treatment of Grave's disease despite history of iodine allergy

I. G. E. El Bez, N. Bechir, I. Meddeb, I. Yeddes, K. Trabelsi, H. Boutruigua, L. Zaabar, D. Ben Sellem, B. Letaief, I. Slim, A. Mhiri, M. Ben Slimene, M. Ben Slimene; Institut Salah Azaiez, Tunis, TUNISIA.

P816

Evaluation of the expression of ADAMTS-3, -4 and -15 genes in parotid and submandibular salivary glands after RAI therapy

M. Sadic¹, H. I. Atilgan², S. O. Halacli³, K. Demircan⁴, M. Korkmaz¹; ¹Ministry of Health Ankara Training and Research Hospital, ANKARA, TURKEY, ²Division of Nuclear Medicine, Ministry of Health, Kahramanmaraş Necip Fazıl City Hospital, Kahramanmaraş, TURKEY, ³Hacettepe University, School of Medicine, Department of Molecular Biology, ANKARA, TURKEY, ⁴Turgut Ozal University, School of Medicine, Department of Molecular Biology, ANKARA, TURKEY.

P817

Treatment of hyperthyroidism with iodine-131: Experience of nuclear medicine department at the salah azaiez Institute in Tunis

I. G. E. El Bez, N. Bechir, K. Trabelsi, H. Boutruigua, I. Slim, I. Yeddes, L. Zaabar, I. Meddeb, D. Ben Sellem, B. Ltaief, A. Mhiri, M. Ben Slimene; Institut Salah Azaiez, Tunis, TUNISIA.

P818

Comparison between low and high radioactive iodine (131I) ablation dose in patients with low risk of papillary thyroid cancer

I. G. E. El Bez, I. Slim, T. Ben Ghachem, I. Yeddes, I. Meddeb, L. Zaabar, D. Ben Sellem, B. Ltaief, A. Mhiri, M. Ben Slimene; Institut Salah Azaiez, Tunis, TUNISIA.

P819

Hürthle cell Carcinoma of the thyroid gland presenting a favorable outcome (about 2 cases)

S. Taleb, G. Cherkaoui Salhi, S. Choukry, M. Ait Idir, A. Guensi; Nuclear Medicine Department, Casablanca, MOROCCO.

P820

Effectiveness of total remnant ablation with single therapeutic dose of radioiodine in patients with thyroid cancer after initial surgery

E. Takacsova, R. Králik, J. Kausitz; St. Elisabeth Cancer Institute, BRATISLAVA, SLOVAKIA.

P821

Patients (Pts) with Differentiated Cancer Thyroid (DTC): prognostic value of Serum Thyroglobulin (Tg0) at the time of the first Ablative Radioiodine Treatment (RAI) and follow up with 131I Whole Body Scan (WBS)

L. Bertolazzi, V. Barbetti, L. Di Ciolo, C. Cananzi, M. Gaffuri, G. Agnese, C. Motta, E. Piccardo, P. Moresco; Azienda Ospedaliera Santa Corona, PIETRA LIGURE (SV), ITALY.

P822

Assessment of prognosis in differentiated thyroid carcinoma patients showing detectable thyroglobulin level 6 months after therapy based on radioactive iodine whole body scan results (A preliminary report)

B. Fallahi, A. Fard-Esfahani, N. Ahmadpour, D. Beiki, A. Emami-Ardekani, M. Eftekhari, S. Farzanefar, S. Izadyar; Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

P823

Epidemiological analysis of patients referred to nuclear medicine consultation for therapeutic evaluation

M. J. Ibáñez Ibáñez, M. V. Godoy Bravo, L. F. Álvarez Nieto, R. Reyes Marlés, M. I. Castellón Sánchez, F. Nicolás Ruiz, L. Mohamed Salem, L. Frutos Esteban, J. L. Navarro Fernández, M. A. Claver Valderas; Servicio de Medicina Nuclear. Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN.

P824

Revaluation of risk of recurrence in patients with differentiated thyroid cancer depending on their initial response to treatment

L. F. Cáncer Garza, M. Delgado, A. Andrés, L. Tardin, S. Ayala, P. Razola, M. López, V. Cardona, E. Prats; Hospital Clínico Universitario Lozano Blesa, Zaragoza, SPAIN.

P825

Follicular thyroid carcinoma in Morocco : predictive factors of distant metastasis

S. Taleb, G. Cherkaoui Salhi, S. Choukry, M. Ait Idir, A. Guensi; Nuclear Medicine Department, Casablanca, MOROCCO.

P826

Influence of coexistence of Hashimoto's disease on the prognosis of patients with differentiated thyroid cancer. A retrospective study

D. Papadoulis, L. Iordanidou, E. Doika, C. Petropoulos, E. Matselas, E. Trivizaki; Metaxa Cancer Hospital, Piraeus, GREECE.

P827

Iodine 131 uptake in lactating breasts

P. Martineau, W. Zeng; The Ottawa Hospital, Ottawa, ON, CANADA.

P828

Feasibility of Blood Dosimetry Estimation by Remote-Measurement System in DTC Patients with High Dose Radioiodine Therapy.

Y. Chen, Y. Lai, Q. Chang, M. Chung, P. Hsiao, H. Chen, F. Chiang; Kaohsiung Medical University Hospital; Kaohsiung Medical University, Kaohsiung, TAIWAN.

P829

Advantages of thyroidal therapy uptake calculation with 2D-diagnostic imaging

R. Ringler, M. Stich, K. Schuller; Technische Hochschule Amberg-Weiden, Weiden, GERMANY.

P830

Thyroidal diagnostics need optimized collimation and segmentation within 2D-imaging

R. Ringler, J. Vogt, S. Seemann, M. Stich; Technische Hochschule Amberg-Weiden, Weiden, GERMANY.

P831

Exposition Rates of Thyroid Cancer Patients Treated with Radioiodine. Differences Between Endogenous and Exogenous Stimulation

J. Rodríguez-Rubio Corona¹, E. Noriega Álvarez¹, O. Puig¹, G. Martínez Pimienta¹, J. Rojas Camacho¹, M. Boya-Román¹, P. Saldaña Gutiérrez², I. Romero-Zayas³, A. Rodríguez-Gasén¹; ¹Hospital Universitari de Bellvitge, Barcelona, SPAIN, ²Medical Physics and Radiation Protection Department, Instituto Catalán de Oncología, L'Hospitalet de Llobregat, SPAIN, ³IDI-PET Unit, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, SPAIN.

P53 Tuesday, October 13, 2015

16:00 – 16:30

Radionuclide Therapy & Dosimetry: Bone Metastases – Pain Palliation

P832

Hematotoxicity and non-hematological adverse events of Ra-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases

H. Ahmadzadehfar¹, K. Azgomi¹, S. Rogenhofer², R. Bundschuh¹, S. Kürpig¹, L. Thomas¹, M. Essler¹; ¹University Hospital Bonn, Department of Nuclear Medicine, Bonn, GERMANY; ²University Hospital Bonn, Department of Urology, Bonn, GERMANY.

P833

Therapeutic response of Sm-153 EDTMP treatment in breast cancer with painful bone metastases

M. Elzahry¹, H. Sinzinger², B. Palumbo³; ¹Faculty of Medicine-Department of Clinical Oncology and Nuclear Medicine, South Valley University, EGYPT; ²Faculty of Medicine, ISOTOPIX- Institute for Nuclear Medicine, Vienna, AUSTRIA; ³Department of Surgical, Radiological and Odontostomatological Sciences, Nuclear Medicine Section, University of Perugia, ITALY.

P834

Radium-223 therapy in metastatic castration resistant prostate cancer: South Central England single centre early experience

h. chorfi, F. sundram; Southampton general hospital, southampton, UNITED KINGDOM.

P835

Radiopharmaceutical therapy for palliation of bone pain from osseous Metastases: what about beta Therapy in prostate cancer?

T. Ben Ghachem¹, A. Mhiri¹, I. Slim¹, I. Yeddes¹, I. Elbez¹, I. Meddeb¹, A. Sellem², H. Hammami², M. F. Ben Slimène¹; ¹Nuclear Medicine department; Salah Azaiez Institute, Tunis, TUNISIA; ²Nuclear Medicine department; Military Hospital, Tunis, TUNISIA.

P836

Bone metastases in patients with differentiated thyroid carcinoma: clinical features and outcome (medullary carcinoma excluded)

G. Cherkaoui Salhi¹, S. Taleb¹, S. Choukry¹, M. Aitidir², A. Guensi¹; ¹Ibn Rochd University Hospital, Casablanca, MOROCCO; ²Mohamed Iv University Hospital, Marrakech, MOROCCO.

P837

Roll of different XCAT phantom BMIs in dosimetry for 153Sm-EDTMP bone pain palliation

M. Fallahpoor, S. Farzanefar, S. Heydarinejad, M. Abbasi; Department of Nuclear Medicine, Vali-e-asr Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

P838

Role of EDTMP-Samarium in the management of Bone metastasis:

S. E. Bouyoucef, B. Abdi, R. Drahmoune, A. Talbi, S. Rahabi, M. Habbeche; Department of Nuclear Medicine CHU Bab El Oued, Algiers, ALGERIA.

P839

223Ra Therapy: A Successful Patient Outcome

K. Gannon, R. Cornhill, R. Gunasekera, K. Tarver; Barking, Havering and Redbridge University Hospitals Trust, Romford, UNITED KINGDOM.

P840

Early experience with 223Ra-dichloride treatment of prostate cancer patients with multiple bone metastases

O. Sántha, J. Szegedi, I. Garai; Scanomed Ltd., Debrecen, HUNGARY.

P54 Tuesday, October 13, 2015

16:00 – 16:30

Radionuclide Therapy & Dosimetry: Local Radionuclide Treatment

P841

Biological Therapy and Radiosynoviorthesis in Patients with Rheumatoid Arthritis

M. Szentesi, Z. Nagy, P. Géher, I. Nagy; Budai Irgalmasrendi Kórház, BUDAPEST, HUNGARY.

P842

Trans Arterial Radio Embolization (TARE) In The Management Of Intractable Hypoglycemia In Malignant Insulinoma

M. Menga¹, M. Zotta², A. Codegone¹, E. Richetta¹, A. Piovesan³, E. Arvat³, R. E. Pellerito¹; ¹Nuclear Medicine - A.O. Ordine Mauriziano, Turin, ITALY; ²Nuclear Medicine - A.O.U. Città della Salute e della Scienza, Turin, ITALY; ³Oncological Endocrinology - A.O.U. Città della Salute e della Scienza, Turin, ITALY.

P843

Radioembolization with Y-90 resin microspheres for intrahepatic cholangiocellular carcinoma: Prognostic factors.

C. Soydal, N. O. Kucuk, S. Bilgic, E. Ibis; Tip Fakultesi, Ankara, TURKEY.

P844

177Lu-labeled hydroxyapatite (Lu-177 HA) in Radiosynovectomy of knee joints due to Rheumatoid arthritis.

K. Kamaleshwaran, S. Thirumalaisamy, V. Rajamani, E. Radhakrishnan, A. shinto; Kovai medical center and hospital limited, Coimbatore, INDIA.

P846

Evaluation of the delivered activity of yttrium-90 resin microspheres with sterile water and 5% dextrose (D5W) as application agents

H. Ahmadzadehfar¹, C. Meyer², C. Pieper², R. Bundschuh³, M. Muckle³, F. Gärtner³, H. Schild², M. Essler³; ¹University Hospital Bonn, BONN, GERMANY, ²University Hospital Bonn Department of Radiology, BONN, GERMANY, ³University Hospital Bonn Department of Nuclear Medicine, BONN, GERMANY.

P847

First ever use of Peptide Receptor Radionuclide Therapy (PRRT) with the Radiolabeled Somatostatin Analog (177Lu-DOTATATE) in metastasized neuroendocrine tumors (NETs) in a Spanish Public Hospital. Our experience in the first year.

I. Plaza de las Heras, C. Field Galán, R. de Teresa Herrera, A. Prieto Soriano, B. Rodriguez Alfonso, J. Cardona Arboniés, J. Aller Pardo, M. Mitjavila Casanovas; University Hospital Puerta de Hierro, Majadahonda, SPAIN.

P848

Radioembolization of primary and / or metastatic hepatic tumors with 90-yttrium microspheres: our experience.

R. De Teresa Herrera, I. Plaza De Las Heras, C. Field Galan, M. Beresova, J. Cardona Arbonies, A. Prieto Soriano, S. Mendez Alonso, S. Mendez Alonso, M. Mitjavila Casanovas; Hospital Universitario Puerta De Hierro, Majadahonda, Madrid, SPAIN.

P849

Resin-Based 90 Yttrium Radioembolization Of Liver Tumors: The Three First Cases Performed In Lebanon.

F. Chehade, J. Daher, F. Kamar, C. Tayar, M. Ghosn, B. Mourani, K. Yammine; Clemenceau Medical Center, Beirut, LEBANON.

P850

Clinical efficacy of radiosynoviorthesis in finger joint systemic arthritis.

I. Iakovou, K. Badiavas, A. Doulas, V. Mpalaris, S. Tosounoglou, D. Kotrotsios, V. Athanasiou, D. Katsaboukas, S. Georga, D. Lo Presti, G. Arsos; Academic Nuclear Medicine dpt, Papageorgiou hsp, THESSALONIKI, GREECE.

P851

The impact of isotope intra-articular distribution and extra-articular leakage on the clinical outcome of radiosynoviorthesis (RS) of the knee.

I. Iakovou, A. Doulas, K. Badiavas, V. Mpalaris, S. Tosounoglou, D. Kotrotsios, V. Athanasiou, D. Katsaboukas, S. Georga, D. Lo Presti, G. Arsos; Academic Nuclear Medicine dpt, Papageorgiou hsp, THESSALONIKI, GREECE.

P852

Radioisotope synoviorthesis in paediatric and adolescent patients with haemophilia

A. Martínez-Estève, R. Álvarez-Pérez, J. Tirado-Hospital, R. García-Jiménez, R. Núñez-Vázquez, I. Borrego-Dorado; Virgen del Rocío University Hospital, Seville, SPAIN.

P853

Safety and efficacy of transarterial Y-90 radioembolisation for liver metastases of neuroendocrine tumours

G. Boni¹, I. Bargellini², M. Tredici³, s. mazzarri³, A. Farnesi⁴, S. Chiacchio³, A. C. Traino⁵, G. Manca¹, F. Guidoccio³, R. Cioni², C. Bartolozzi², S. Ricci⁶, D. Volterrani³; ¹Regional Center Of Nuclear Medicine, University Hospital Of Pisa, pisa, ITALY, ²Department of Radiology, Vascular and Interventional Radiology, University Hospital Of Pisa, pisa, ITALY, ³Regional Center Of Nuclear Medicine, University Hospital Of Pisa, pisa, ITALY, ⁴Division of Oncology, Hospital of Pisa, pisa, ITALY, ⁵Health Physics Unit, Section of Medical Physics, University Hospital, Pisa, Italy, pisa, ITALY, ⁶Division of Oncology, University Hospital of Pisa, pisa, ITALY.

P854

Safety and efficacy of selective internal radiotherapy with Y-90 glass-microspheres in patients with progressive hepatocellular carcinoma (HCC) after failure of transarterial chemoembolization (TACE)

A. P. Bellendorf¹, S. P. Müller¹, A. Bockisch¹, S. Ezziddin², J. Nagarajah³, J. Best⁴, J. Schelhorn⁵, T. D. Poeppel¹, A. Sabet¹; ¹University Hospital Essen, Germany, Department of Nuclear Medicine, Essen, GERMANY, ²Saarland University Homburg, Germany, Department of Nuclear Medicine, Homburg, GERMANY, ³Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES, ⁴University Hospital Essen, Germany, Department of Internal Medicine and Gastroenterology, Essen, GERMANY, ⁵University Hospital Essen, Germany, Institute for Diagnostic and Interventional Radiology and Neuroradiology, Essen, GERMANY.

P855

Radiosynovectomy application after arthroscopic surgery on the hip joint

H. I. Atilgan¹, M. Sadic², H. Ozsoy³, G. Koca², A. Ozsoy⁴, M. Korkmaz²; ¹Kahramanmaras Necip Fazıl City Hospital, Department of Nuclear Medicine, Kahramanmaras, TURKEY, ²Ministry of Health Ankara Training and Research Hospital, ANKARA, TURKEY, ³Memorial Ankara Hospital, Department of Orthopedics and Traumatology, ANKARA, TURKEY, ⁴Ministry of Health Ankara Numune Training and Research Hospital, Clinic of Radiology, ANKARA, TURKEY.

P856

Phase I Clinical Experience of Post-Radioembolization Yttrium-90 Imaging Using Next Generation Digital PET/CT

C. L. Wright¹, J. Zhang¹, K. Binzel¹, E. J. Wuthrick¹, P. Maniawski², M. V. Knopp¹; ¹The Ohio State University, Columbus, OH, UNITED STATES, ²Philips Healthcare, Cleveland, OH, UNITED STATES.

P55

Tuesday, October 13, 2015

16:00 – 16:30

Radionuclide Therapy & Dosimetry: Data Collection Methods & Pharmacokinetics

P857

Image Quality Parameters and Quantification Issues with Y-90 Bremsstrahlung SPECT/CT

S. Beykan, M. Lassmann, S. Schlögl; Department of Nuclear Medicine, University of Würzburg, Würzburg, GERMANY.

P858

Radiation dose estimate from patients undergoing 18F-FDG scanning: implications for the general public and nuclear medicine technicians

B. Liu, R. Tian; Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, CHINA.

P859

The Importance of Treatment Planning in Radiopharmaceutical Therapy According to Human Data of 153Sm-EDTMP

M. Meftahi^{1,2}, A. Bahrami Samani², I. Jabbari¹, T. Hoseinnejad³; ¹University of Isfahan, Isfahan, IRAN, ISLAMIC REPUBLIC OF, ²Nuclear Science and Technology Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Mashhad University of Medical Science, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

P860

Absolute SPECT/CT calibration for dosimetry in 177Lu targeted radionuclide therapy

F. Fioroni, E. Grassi, V. Ferri, S. Marco Antonio, F. Angelina, A. Versari, M. Iori; IRCCS-ASMN, Reggio Emilia, ITALY.

P861

Comparison of Geant4 and MCNPX Monte Carlo systems in the calculation of voxel S values for the therapeutic radionuclides 90Y, 111In, 177Lu and 131I

L. Auditore¹, E. Amato¹, A. Italiano², F. Minutoli¹, A. Campenni¹, S. Baldari¹; ¹University of Messina, MESSINA, ITALY, ²Istituto Nazionale di Fisica Nucleare, MESSINA, ITALY.

P56

Tuesday, October 13, 2015

16:00 – 16:30

Radionuclide Therapy & Dosimetry: Preclinical and Clinical Dosimetry & Radiobiology

P862

Pre-therapy Initial Dosimetry Results of Lu-177-DOTA-617-PSMA In Castration Resistant Prostate Cancer

M. M. Abuqbeitah, N. Yeyin, A. Aygün, E. Demirci, M. Ocak, M. Demir, L. Kabasakal; Istanbul University, Istanbul, TURKEY.

P863

Influence of syringe residual activity (SRA) on effective dose (ED) estimates from myocardial perfusion imaging (MPI) exams

F. A. A. de Jonge, S. Valente, T. C. Ferreira; Hospital Lusíadas Lisboa, Lisbon, PORTUGAL.

P864

Revised dose calculations for 99mTc-pertechnetate used for diagnostic nuclear medicine procedures in adults

M. Andersson¹, L. Johansson², D. Minarik¹, S. Mattsson¹, S. Leide Svegborn¹; ¹Medical Radiation Physics, Malmö, SWEDEN, ²Department of Radiation Sciences, Umeå, SWEDEN.

P865

Partial volume effect restoration in dose volume histograms for Y-90 dosimetry: a proof of concept

M. Sanchez-Garcia¹, P. Buyssens², I. Gardin³, R. Lebtahi¹, A. Dieudonné¹; ¹Department of Nuclear Medicine, Beaujon Hospital, Assistance Publique-Hôpitaux de Paris (APHP) & INSERM U1149, Clichy, FRANCE, ²QuantIF – LITIS [EA 4108], Rouen, FRANCE, ³Department of Nuclear Medicine, Henri Becquerel Cancer Center and Rouen University Hospital, & QuantIF – LITIS [EA 4108], Rouen, FRANCE.

P866

Automatic image segmentation for 3D dosimetry in Lu177-DOTATATE PRRT using a robust cluster algorithm on dynamic SPECT data

L. Vomacka, A. Delker, A. Gosewisch, E. Mille, H. Ilhan, F. J. Gildehaus, P. Bartenstein, G. Böning; Ludwig-Maximilian-University of Munich, Munich, GERMANY.

P867

Estimation of local photon dose to active bone marrow in Lu-177 PSMA PRRT therapy using patient-specific Monte Carlo simulations

A. Gosewisch¹, A. Delker¹, L. Vomacka¹, W. P. Fendler¹, A. Brunegrat¹, F. J. Gildehaus¹, A. Mairan², K. Parodi³, P. A. Bartenstein¹, G. Böning¹; ¹University Hospital Munich, Munich, GERMANY, ²National Centre for Oncological Treatment, Pavia, ITALY, ³Ludwig-Maximilians University Munich, Munich, GERMANY.

P868

Partition model for accurate radiation therapy with yttrium-90 Glass microspheres in hepatocellular carcinoma.

S. Adib, M. Monteiro, S. Gnesin, P. Bize, A. Denys, J. Prior, A. Boubaker; CHUV, Lausanne, SWITZERLAND.

P57

Tuesday, October 13, 2015

16:00 – 16:30

Radionuclide Therapy & Dosimetry: Miscellaneous

P870

Radiation Protection Challenges When Treating Dialysis Patients With I-131

S. Gould, R. Fernandez, J. Robinson, P. Geraghty, C. Mills, H. Mohan; Guy's and St Thomas' NHS Foundation Trust, London, UNITED KINGDOM.

P871

Single-cell dosimetry: effect of cell geometry on cellular S-values

N. Falzone^{1,2}, J. M. Fernández-Varea³, G. Flux⁴, K. A. Vallis¹; ¹University of Oxford, Oxford, UNITED KINGDOM, ²Tshwane University of Technology, Department of Biomedical Science, Pretoria, SOUTH AFRICA, ³Universitat de Barcelona, Facultat de Física (ECM and ICC), Barcelona, SPAIN, ⁴Royal Marsden NHSFT, Physics Department, UNITED KINGDOM.

P872

A 3D Printed Anthropomorphic Phantom for Validating Quantitative SIRT Imaging in Multicentre Trials

J. Gear¹, C. Cummings², M. Tapner³, G. Flux¹; ¹Royal Marsden NHSFT, Sutton, UNITED KINGDOM, ²Institute of Cancer Research, Sutton, UNITED KINGDOM, ³SIRTEX, North Sydney, AUSTRALIA.

P58

Tuesday, October 13, 2015

16:00 – 16:30

Conventional & Specialised Nuclear Medicine: Urology

P873

Application of a dual nuclear medicine protocol in patients with urolithiasis.

V. Hadzhiyska¹, T. Petrov¹, I. Kostadinova¹, V. Marianovski², B. Mladenov², Y. Asenov³; ¹University Hospital Alexandrovska, Sofia, BULGARIA, ²University Multiprofile Hospital for Active Treatment and Emergency Medicine "N.I. Pirogov", Sofia, BULGARIA, ³University Hospital "Tsaritsa Yoanna", Sofia, BULGARIA.

P874

Extracellular volume (ECV) assessment by Cr-51-EDTA plasma clearance and bioimpedance spectrometry (BIS) : a comparison study

G. Arsos¹, D. Katsampoukas¹, C. Sachpekidis², E. Manou³, K. Lazaridis¹, E. Mitsopoulos³; ¹3rd Dept of Nuclear Medicine, Aristotle University of Thessaloniki Medical School, Papageorgiou Hospital, Thessaloniki, GREECE, ²Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, GERMANY, ³Dept of Nephrology, Papageorgiou Hospital, Thessaloniki, GREECE.

P875

Extracellular volume (ECV) may not represent a major improvement in glomerular filtration rate (GFR) normalization compared to body surface area (BSA)

G. Arsos¹, C. Sachpekidis², D. Katsampoukas¹, E. Manou³, K. Lazaridis¹, E. Mitsopoulos³; ¹3rd Dept of Nuclear Medicine, Aristotle University of Thessaloniki Medical School, Papageorgiou Hospital, THESSALONIKI, GREECE, ²Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, GERMANY, ³Dept of Nephrology, Papageorgiou Hospital, THESSALONIKI, GREECE.

P876

Diuretic Renography in Seated Position F+10(sp) for Post-Emergency Clinical Management in PerCutaneous Nephrostomy.

G. Tartaglione¹, M. Vittori², A. Cina³, M. Pagan¹, A. D'Addessi², P. F. Bassi²; ¹Nuclear Medicine, Cristo Re Hospital, Rome, ITALY, ²Urology, Catholic University of the Sacred Heart, Rome, ITALY, ³Radiology, Catholic University of the Sacred Heart, Rome, ITALY.

P877

A new quantitative index for baseline renal transplant scintigraphy with Tc-99m DTPA in evaluation of delayed graft function and prediction of 1-year graft function

B. Yazici¹, A. Oral¹, C. Gokalp², A. Akgün¹, H. Toz²; ¹Ege University Medical Faculty Department of Nuclear Medicine, Izmir, TURKEY, ²Ege University Medical Faculty Department of Internal Medicine Division of Nephrology, Izmir, TURKEY.

P878

Correction of Differential Renal Function for Asymmetric Renal Area Ratio in Unilateral Hydronephrosis

G. Ege Aktas, A. Sarikaya; Trakya University Medical Faculty Department of Nuclear Medicine, Edirne, TURKEY.

P879

The evaluation of inter- and intraobserver variability of 99mTc-Dimercaptosuccinic acid SPECT renal scintigraphy

U. Can, G. Durmus Altun; Trakya University Medical Faculty, Edirne, TURKEY.

P880

Clinical Value of Cystatin C and Beta-trace Protein in Glomerular Filtration Rate in Chronic Renal Disease Adult Cases With Different Degree Renal Function Disorder: Comparison by The 99mTc-DTPA Plasma Sample Method

F. Aydin, E. Surer Budak, S. Demirelli, A. Oner, G. Suleymanlar, H. Akbas, F. Davran, S. Bozkurt, F. Gungor; Akdeniz University, Antalya, TURKEY.

P881

"Hot Kidney" Artifact on Bone Scan: Incidence and Approach to Quantification

A. K. Kondakov¹, D. S. Kharina^{1,2}, E. A. Servuli^{1,2}, I. A. Znamenskiy^{2,1}; ¹Pirogov RNRMU, Moscow, RUSSIAN FEDERATION, ²CCH RAS, Moscow, RUSSIAN FEDERATION.

P883

Diagnostic and Prediction Accuracy of GFR Prediction Equations in Comparison with 51Cr-EDTA

V. Ptacnik, J. Kubinyi, H. Jiskrova, D. Skibova, R. Rysava, V. Tesar, M. Samal; Charles University Prague, Prague, CZECH REPUBLIC.

P59

Tuesday, October 13, 2015

16:00 – 16:30

Conventional & Specialised Nuclear Medicine: Thyroid – Benign

P884

Recombinant Human Thyrotropin Stimulation Before ¹³¹I Therapy in Toxic Multinodular Goiter with Low Radioactive Iodine Uptake

M. Azorín-Belda, A. Martínez-Caballero, G. C. Figueroa-Ardila, C. A. Gómez-Jaramillo, J. Verdú-Rico, J. I. Dolado-Ardid, M. Antón-Leal, M. Martínez-Ramírez; Hospital Universitario San Juan de Alicante, Alicante, SPAIN.

P885

Correlation between autoimmunthyroid diseases and Vitamin D deficiency in a German population

C. Körber, N. Körber-Hafner; Nuclear Medicine Fulda, Fulda, GERMANY.

P886

Comparison of planar and tomographic methods for calculating thyroid volumes in cats and dogs

R. P. Jóna¹, G. Dabasi¹, A. Polyák², Z. Pöstényi², J. Thuroczy³, K. Bús¹, L. Jorgov¹, L. Balogh²; ¹Dept. of Nuclear Medicine, Semmelweis University, Budapest, HUNGARY, ²National "F.J.C." Research Institute for Radiobiology and Radiohygiene (NRIRR), Budapest, HUNGARY, ³Veterinary Faculty, Szent Istvan University, Budapest, HUNGARY.

P887

Detection of papillary carcinoma in patients with chronic nodular autoimmune thyroiditis

K. Zaplatnikov¹, V. Soukhov²; ¹MAZ Clinic for Nuclear Medicine, Nürnberg, GERMANY, ²Military Medical Academy, ST. PETERSBURG, RUSSIAN FEDERATION.

P888

Factors Influencing the Length of Remission Period in Patients with Graves' Disease

D. Šfiligoj¹, S. Gaberšček¹, P. Jaki Mekjavič², K. Zaletel¹, E. Pirnat¹; ¹University Medical Centre Ljubljana, Department of Nuclear Medicine, Ljubljana, SLOVENIA, ²University Medical Centre Ljubljana, Eye Hospital, Ljubljana, SLOVENIA.

P889

Late single uptake measurement for accurate absorbed dose calculations in I-131 treatments of hyperthyroidism

K. S. Andreasson¹, J. Svensson^{2,3}, F. Henriksson^{2,3}, P. Bernhardt^{4,3}; ¹Sahlgrenska University Hospital, Departments of Medical Physics & Biomedical Engineering, Gothenburg, SWEDEN, ²Sahlgrenska University Hospital, Department of Oncology, Gothenburg, SWEDEN, ³The Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN, ⁴Sahlgrenska University Hospital, Department of Radiation Physics, Gothenburg, SWEDEN.

P890

Patients with Different Types of Hypothyroidism have Different Biochemical Characteristics in Spite of Normal Thyrotropin Levels and Similar Weekly Dose of L-Thyroxine

S. Gaberscek^{1,2}, B. Samec², G. Setnikar², E. Pirnat¹, K. Zaletel¹; ¹Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, ²Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA.

P891

Patients Treated for Central Hypothyroidism have Different Biochemical Characteristics than Patients Adequately Treated for Hypothyroid Hashimoto's Thyroiditis

S. Gaberscek^{1,2}, G. Setnikar², B. Samec², T. Kocjan^{3,2}, E. Pirnat¹, K. Zaletel¹; ¹Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, ²Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA, ³Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana, SLOVENIA.

P892

The Role of Colour Flow Doppler Sonography in the Evaluation of Autonomous Thyroid Nodule Activity

K. Zaletel¹, M. Jakič², M. Jager², E. Pirnat¹, S. Gaberšček^{1,2}; ¹University Medical Centre Ljubljana, Ljubljana, SLOVENIA, ²University of Ljubljana, Ljubljana, SLOVENIA.

P893

Predictors of outcome in radioiodine treatment of Graves' disease

M. Silva¹, L. Cardoso², R. Silva¹, L. Pires¹, F. Rodríguez¹, N. Vicente², P. Lapa¹, G. Costa¹, F. Carrilho², J. Pedroso de Lima¹; ¹Serviço de Medicina Nuclear do Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, ²Serviço de Endocrinologia, Diabetes e Metabolismo do Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL.

P894

Prevalence of normal TSH levels in patients with thyroid autonomy detected by thyroid scintigraphy.

G. Treglia¹, P. Trimboli², F. Verburg³, M. Luster⁴, L. Giovanella^{1,2}; ¹Department of Nuclear Medicine, Oncology Institute of Southern Switzerland, Bellinzona and Lugano, SWITZERLAND, ²Thyroid Center, Ente Ospedaliero Cantonale, Bellinzona and Lugano, SWITZERLAND, ³Department of Nuclear Medicine, University Hospital of Aachen, Aachen, GERMANY, ⁴Department of Nuclear Medicine, University Hospital of Marburg, Marburg, GERMANY.

P895

The role of combined single-isotope dual-phase scintigraphy with ^{99m}Tc-tetrofosmin with SPECT technique in minimal invasive parathyroidectomy

M. Yaneva, A. Botushanova; UMBAL St. George Plovdiv, Plovdiv, BULGARIA.

P896

Subacute Thyroiditis Management and Follow-up with use dual scintigraphy modality

V. Soukhov¹, K. Zaplatnikov²; ¹Military Medical Academy, St. Petersburg, RUSSIAN FEDERATION, ²MAZ Clinic for Nuclear Medicine, Nürnberg, GERMANY.

P897

Clinical Value of I-131 SPECT/CT over planar imaging in Detecting Metastases in Patients with Differentiated Thyroid Carcinoma

W. Yao, Y. Wang, N. Chiu, C. Hung; College of Medicine, National Cheng Kung University, TAINAN, TAIWAN.

P898

Evaluation of Radioiodine Therapy with an Adapted Dosimetric Approach in Patients with Hyperthyroidism

A. Fernandes¹, T. Faria¹, P. Coelho¹, J. Casalta-Lopes^{2,3}, A. Oliveira¹, V. Alves¹, A. Pinto¹, M. Pérez¹, T. Vieira¹, J. Pereira¹; ¹Centro Hospitalar São João, Porto, PORTUGAL, ²Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, ³Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL.

P899

Middle-Term Outcome and safety of hyperthyroid patients treated with calculated activity of radioiodine

A. Campenni¹, E. Amato¹, M. Murè¹, F. Di Mauro¹, M. Stipo¹, G. Cabbanè¹, V. Gangemi¹, M. Bertia¹, M. Cucinotta¹, M. Ruggeri², S. Baldari¹; ¹Nuclear Medicine Unit of Messina, Messina, ITALY, ²Department of Clinical and Experimental Medicine, Endocrinology Section, University of Messina, Italy, Messina, ITALY.

P900

Predictive value of pyramidal lobe, % thyroid uptake and age for ablation outcome after 15 mCi fixed dose of radioiodine-131 in Graves' disease

M. u. Zaman¹, N. Fatima², U. Zaman³, Z. Sajjad¹, A. Zaman³, R. Tahseen³; ¹AKUH, Karachi, PAKISTAN, ²Dr Ziauddin Hospital, Karachi, PAKISTAN, ³Dow University of Health Sciences (DUHS), Karachi, PAKISTAN.

P901

99mTc-MIBI SPECT/CT in patients with hyperparathyroidism and the relationship between uptake ratio and serum PTH, calcium as well as volume of lesion

Z. Cheng, S. Zou, X. Zhu; Department of Nuclear Medicine & PET, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

P60

Tuesday, October 13, 2015

16:00 – 16:30

Conventional & Specialised Nuclear Medicine: Paediatric Uronephrology

P902

Contribution of diuretic renal scintigraphy with 99mTc-MAG-2 to surgical indication in infants with antenatal hydronephrosis.

C. Gamazo Laherrán, J. Villanueva Curto, A. Cobo Rodriguez, A. Sainz-Esteban, M. González Selma, M. Ruiz Gómez, R. Olmos García; Hospital Clinico Universitario De Valladolid, Valladolid, SPAIN.

P903

Preliminary Validation of Blood-Pool Compensation Method for Assessment of Relative Renal Uptake in Children

M. Samal¹, A. Brink², M. J. Wesolowski³, C. A. Wesolowski³; ¹Charles University Prague, Prague, CZECH REPUBLIC, ²Red Cross War Memorial Children's Hospital, Cape Town, SOUTH AFRICA, ³University of Saskatchewan, Saskatoon, SK, CANADA.

P904

Importance of Vesicoureteral Reflux Detected During Routine 99mTc-MAG3 Renal Scintigraphy in Pediatric Patients

N. C. M. Gulaldi, N. Altun Yologlu, S. Ozyurt; Department of Nuclear Medicine, Dr. Sami Ulus Maternity and Children's Health and Diseases Training and Research Hospital, ANKARA, TURKEY.

P905

Invalidity of Gates method to assess renal function in children

V. Markovic^{1,2}, D. Eterovic^{1,2}, A. Punda^{1,2}, Z. Antunovic³; ¹University Hospital Split, Split, CROATIA, ²School of Medicine, University of Split, Split, CROATIA, ³Department of Physics, Faculty of Science, University of Split, Split, CROATIA.

P906

Impact of 99mTc-DMSA scan during acute phase of pyelonephritis

S. E. Bouyoucef, M. Habbeche, S. Benadda, A. Bellabes, B. Abdi, K. Chentli, A. Khelifa; Department of Nuclear Medicine CHU Bab El Oued, Algiers, ALGERIA.

P907

The Four Year Experience of Congenital Hydronephrosis in the Single Centre of Nuclear Medicine from the North-Eastern Region of Romania

I. C. Grierosu, Sr.^{1,2}, M. Starcea^{3,2}, M. Munteanu³, R. Russu³, A. Rotaru³, A. Statescu¹, R. Gherasim¹, S. Atudosie², V. Ghizdovat^{1,2}, I. Miron^{3,2}, C. Stefanescu^{1,2}; ¹Emergency Clinical Hospital Sf. Spiridon, Iasi, ROMANIA, ²Faculty of Medicine, Iasi, ROMANIA, ³Emergency Hospital for Children Sf. Maria, Iasi, ROMANIA.

P908

Study of association of lesion and ambulation level with kidney dysfunction in spina bifida

E. Ozgonenel¹, L. Ozgonenel², I. Karalok³; ¹Istanbul Bilim University Department of Nuclear Medicine, Istanbul, TURKEY, ²Istanbul Bilim University Department of Physical Therapy and Rehabilitation, Istanbul, TURKEY, ³Istanbul Bilim University Department of Radiology, Istanbul, TURKEY.

P909

Diagnostic Accuracy of Tc-99m DMSA Scintigraphy and Renal Ultrasonography in Children with Spina Bifida During Long Term Follow up

E. Ozgonenel¹, I. Karalok², & Alatas³, E. Ceylan Günay¹, L. Özgönenel⁴, P. Gün Atak⁵, B. Yazıcı⁶, K. Özel⁷; ¹Istanbul Bilim University Department of Nuclear Medicine, Istanbul, TURKEY, ²Istanbul Bilim University Department of Radiology, Istanbul, TURKEY, ³Istanbul Bilim University Department of Neurosurgery, Istanbul, TURKEY, ⁴Istanbul Bilim University Department of Physical Therapy and Rehabilitation, Istanbul, TURKEY, ⁵Istanbul Bilim University Department of Biochemistry, Istanbul, TURKEY, ⁶Istanbul Bilim University Department of Pediatrics, Istanbul, TURKEY, ⁷Istanbul Bilim University Department of Pediatric Surgery, Istanbul, TURKEY.

P61

Tuesday, October 13, 2015

16:00 – 16:30

Conventional & Specialised Nuclear Medicine: Bone & Joint

P910

Title: Does the Differences in Hydration Influence the Image Quality in 99mTc-MDP Bone Scintigraphy?

N. Hosseinifar¹, M. Hosntalab¹, M. Eftekhari², F. Babapour Mofrad¹, P. Geramifar²; ¹Islamic Azad University Science and Research Branch, Faculty of Engineering, Tehran, Iran, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Research Center For Nuclear Medicine, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

P911

Improved therapy response assessment in patients with bone metastases of prostate cancer using an expert system for bone scan interpretation

F. Päsler¹, G. Berding¹, A. Namazian¹, F. Wilke², A. Böker³, L. Geworski², M. Kuczyk³, F. Bengel¹, I. Peters³; ¹Dpt. for Nuclear Medicine, MHH, Hannover, GERMANY, ²Dpt. of Medical Physics and Radiation Protection, MHH, Hannover, GERMANY, ³Dpt. for Urology, MHH, Hannover, GERMANY.

P912

Validation of the Imaging Biomarker Bone Scan Index – Influence of Image Quality on Reproducibility

R. Kaboteh¹, A. Anand², L. Bath¹, A. Bjartell², L. Edenbrandt¹; ¹Sahlgrenska University Hospital, Gothenburg, SWEDEN, ²Division of Urological Cancer, Lund University, Malmö, SWEDEN.

P913

Feasibility of bone scan index for the diagnosis and follow-up of medication-related osteonecrosis of the jaw

S. Watanabe, K. Nakajima, H. Yaegashi, A. Mizokami, N. Noguchi, S. Kawashiri, M. Inokuchi, S. Kinuya; Kanazawa University Hospital, Kanazawa-city, JAPAN.

P914

Are the patients who observed as definitely benign in planar bone scintigraphy actually benign? The value of SPECT/CT

P. Arıcan, B. Okudan Tekin, R. Şefizade, S. Naldöken; Ankara Numune Education and Research Hospital, Ankara, TURKEY.

P915

Sacral Insufficiency Fractures in Oncologic Patients Revealed by Bone Scan and SPECT/CT

O. Lapina, S. Tiskecivius, M. Stalnionis; National Cancer Institute, Vilnius, LITHUANIA.

P916

Role of bone scintigraphy in the early detection of fatigue fractures

H. Boudriga, I. Yeddes, I. Meddeb, I. El Bez, A. Mhiri, M. Ben Slimène; Salah Azaiez Institut, Tunis, TUNISIA.

P917

A new area for F-18 NaF PET/CT: Avascular Necrosis of the Femoral Head as a benign disease

I. Ak Sivriköz¹, H. Onner¹, N. Kose²; ¹Esogü School Of Medicine Department Of Nuclear Medicine, Eskişehir, TURKEY, ²Esogü School Of Medicine Department Of Orthopedic Surgery, Eskişehir, TURKEY.

P918

Evaluation of sternoclavicular hyperostosis in 20 patients: preliminary study

B. Celik¹, F. Canbaz², Y. Bilgin Büyükkarabacak¹, A. Taslak Sengül¹, Z. Pelin Sürücü¹, A. Başoğlu¹; ¹Ondokuz Mayıs University Hospital, Faculty of Medicine, Thoracic Surgery Dept., KURUPELİT / SAMSUN, TURKEY, ²Ondokuz Mayıs University Hospital, Faculty of Medicine, Nuclear Medicine Dept., KURUPELİT / SAMSUN, TURKEY.

P919

Semiquantitative analysis of bone SPECT studies in the detection of active sacroiliitis

A. Kokkini, G. Koniaris, A. Zafirakis, K. Athanasiou, D. Kassimos, J. Koutsikos; 401 General Military Hospital, ATHENS, GREECE.

P920

Bone scintigraphy, DAS 28 score and biochemical parameters in patients with Rheumatoid Arthritis

S. Karacavus¹, M. Ucar², M. F. Gecer³, O. Balbaloglu², O. Nas⁴, U. Sarp⁴; ¹Bozok University, School of Medicine, Department of Nuclear Medicine, Yozgat, TURKEY, ²Bozok University, School of Medicine, Department of Physical Medicine and Rehabilitation, Yozgat, TURKEY, ³Yozgat State Hospital, Department of Nuclear Medicine, Yozgat, TURKEY, ⁴Yozgat State Hospital, Department of Physical Medicine and Rehabilitation, Yozgat, TURKEY.

P921

Interest of SPECT/CT hybrid imaging in the management of McCune-Albright syndrome

A. Matrane, M. Bsiss, S. Hiroual, S. Bennani Doubli; Mohammed VI University Hospital, Marrakech, MOROCCO.

P922

Value of quantitative 3 - phase bone scintigraphy in the assessment of hip and knee endoprosthesis

C. C. Schiller, F. Fitz, S. Haim, H. Söser, J. Hochreiter, W. Langsteger, M. Beheshti; Nuclear Medicine & Endocrinology, St. Vincent's Hospital, LINZ, AUSTRIA.

P923

Scintigraphy studies for the evaluation of painful hip and knee prosthetic joints

J. A. Sequeira¹, J. G. Santos¹, A. Prata¹, S. Carmona¹, J. Salreta², M. Tapadinhas², A. I. Santos¹; ¹Hospital Garcia de Orta - Serviço de Medicina Nuclear, Almada, PORTUGAL, ²Hospital Garcia de Orta - Serviço de Ortopedia, Almada, PORTUGAL.

P924

Does bone scintigraphy keeps a place in para-articular osteoma?

D. Ben Sellem, L. Zaabar, B. Dhaouadi, B. Letaief, M. F. Ben Slimene; Nuclear Medicine Department, Salah Azaiez Institute, Tunis, TUNISIA.

P925

FDG-PET/CT of bone lesions

Y. Otomi¹, H. Otsuka², T. Shinya¹, K. Terazawa¹, M. Kubo¹, M. Harada¹; ¹Tokushima University Hospital, Tokushima, JAPAN, ²Tokushima University, Tokushima, JAPAN.

P926

Role of F18 Bone Scan in metastatic workup of Primary Bone tumors

H. B. Sr., V. Pawar, S. C. H; BGS Global Hospital, Bangalore, INDIA.

P927

SPECT-CT with 99mTc-MIBI in patients with recurrent malignant soft tissue sarcomas: is it important for radiotherapy planning and monitoring of its efficacy.

S. Kanaev, S. N. Novikov, P. Krzhivitskiy, G. Gafton; N.N. Petrov Institute Oncology, St Petersburg, RUSSIAN FEDERATION.

P928

Follow-up in patients with Ewing sarcoma: value of an imaging protocol including FDG-PET(-CT) and MRI for recurrence detection

M. Heinemann¹, A. Ranft¹, H. Jürgens¹, T. Langer², V. Vieth¹, M. Schäfers¹, M. Weckesser¹, L. Stegger¹, U. Dirksen¹; ¹University Hospital Münster, Münster, GERMANY, ²University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, GERMANY.

P929

Disappearing Bone Disease (Gorham's Disease) demonstrated on SPECT/CT imaging

A. Atabaki^{1,2}, R. Mansberg²; ¹Westmead Hospital, Sydney, NSW, AUSTRALIA, ²Concord Hospital, Sydney, NSW, AUSTRALIA.

P930

Prominent thallium-201 uptake of giant cell tumor of bone : comparison with osteosarcoma

R. Inai¹, S. Takayoshi², T. Tanaka¹, Y. Tsuboi¹, S. Norikane¹, K. Kojima¹, A. Tada¹, T. Kunisada¹, S. Sato¹, T. Ozaki¹, S. Kanazawa¹; ¹Okayama university hospital, Okayama, JAPAN, ²Tokushima university hospital, Tokushima, JAPAN.

P931

Inclusion of Trabecular Bone Score (TBS) in Risk Assement of Fragility Fracture in Postmenopausal Women

B. Perez Lopez, R. Ruano Perez, L. G. Diaz Gonzalez, M. E. Martin Gomez, E. Martin Gomez, M. P. Tamayo Alonso, F. Gomez Caminero Lopez, P. Garcia-Talavera San Miguel, J. Del Pino Montes, T. Carranco; Hospital Universitario Clinico De Salamanca, Salamanca, SPAIN.

P932

Bone Mineral Density in Patients Treated with Antipsychotics

A. Cengiz¹, V. Altinyazar², B. G. Manoğlu², F. Vahapoğlu², O. Kocabaş², I. Kurt Ömürlü³, Y. Yürekli¹; ¹Adnan Menderes University, Medical School, Department of Nuclear Medicine, Aydin, TURKEY, ²Adnan Menderes University, Medical School, Department of Psychiatry, Aydin, TURKEY, ³Adnan Menderes University, Medical School, Department of Biostatistics, Aydin, TURKEY.

P933

Knowledge Challenge: Garlet Sign on DXA Scan

N. Fatima¹, M. u. Zaman²; ¹Department of Nuclear Medicine, Dr Ziauddin Medical University, Karachi, PAKISTAN, ²AKUH, Karachi, PAKISTAN.

P62

Tuesday, October 13, 2015

16:00 – 16:30

Conventional & Specialised Nuclear Medicine: Infection & Inflammation

P934

FDG PET/CT in left ventricular assist device infection

D. Grigolato, M. Zuffante, E. Carmagnani, M. Cucca, E. Concia, M. Ferdeghini; Azienda Ospedaliera di Verona, VERONA, ITALY.

P935

Diagnosis value of 18F-FDG PET/CT with myocardial suppression in the detection of cardiovascular implantable electronic device infections

U. Granados, D. Fuster, J. Pericas, S. Ninot, J. Tolosana, A. Moreno, C. Falces, J. Miro, F. Lomeña; Hospital Clínic, Barcelona, SPAIN.

P936

Diagnostic value of 18FDG PET imaging patients with clinical suspicion of vasculitis

E. Piekarski, F. Hyafil, N. Mikail, B. Mahida, J. Slama, E. Blanchet, J. Calais, H. Regaieg, R. De Paola Chequer, F. Rouzet, D. Le Guludec, K. BenAli; Bichat's hospital, Paris, FRANCE.

P937

FDG-PET in suspected infection versus loosening of Orthopedic Fixation Device (rods, plates, screws, and wire loops) – correlation with cultures.

S. Raja^{1,2}, N. Alnakshabandi², S. George³, M. AlHarbi², R. Sergey²; ¹Baylor College of Medicine, Bellaire, TX, UNITED STATES, ²KFMC, Riyadh, SAUDI ARABIA, ³Johns Hopkins Aramco Healthcare, Dhahran, SAUDI ARABIA.

P938

FDG PET/CT and WBC scan in vascular graft infection

M. Pacilio, C. Lauri, F. Trapasso, I. Baldazzi, D. Proserpi, A. Lenza, C. Tirrotti, M. Taurino, F. Scopinaro, A. Signore; Università Sapienza Roma, Rome, ITALY.

P939

Assessment of the Diagnostic Performance of Quantitative FDG-PET/CT Parameters in the Detection of Vascular Graft Infection

S. Houshmand¹, A. Salavati¹, M. Sadiq², K. T. Pedersen³, A. Alavi¹, P. F. Høilund-Carlsen³, S. Hess³; ¹University of Pennsylvania, Philadelphia, PA, UNITED STATES, ²Ankara Training and Research Hospital, Ankara, TURKEY, ³Odense University Hospital, Odense, DENMARK.

P940

Usefulness of (18)F-FDG PET/CT in the infections of peritoneal catheter

S. SANFILIPPO, A. Sviridenko, P. Ghedini, P. Castellucci, R. Bonfiglioli, S. Diodato, S. Cambioli, S. Fanti; Azienda ospedaliero-universitaria S.Orsola-Malpighi, Bologna, ITALY.

P941

Fever of Unknown Origin (FUO). Utility of 18F-FDG PET-CT.

C. Riola-Parada¹, M. N. Cabrera-Martín², O. Salsidua-Arroyo¹, M. Pedrera-Canal¹, M. Martínez-de-Bourio¹, E. Cala-Zuluaga¹, L. Lapeña-Gutierrez², R. Couto-Caro¹, J. L. Carreras-Delgado²; ¹Nuclear Medicine Department. Hospital Clínico San Carlos, Madrid, SPAIN, ²Nuclear Medicine Department. Hospital Clínico San Carlos. Universidad Complutense, Madrid, SPAIN.

P942

The Clinical Value of FDG-PET/CT in Bacteraemia of Unknown Origin: A Retrospective Study

M. B. Brøndserud¹, S. Hess¹, A. H. D. Johansen¹, C. Pedersen², P. F. Høilund-Carlsen¹; ¹Dept. of Nuclear Medicine, Odense University Hospital, Odense, DENMARK, ²Dept. of Infectious Diseases, Odense University Hospital, Odense, DENMARK.

P943

Comparison of 18F-FDG-PET/CT and 99mTc-HMPAO-labelled-leukocyte SPECT/CT in the evaluation of patients with fever

G. Cusato¹, P. Ferro¹, S. Fiorino¹, M. Spallino¹, C. E. Popescu², R. Sara², M. Milella², G. Cabrin², C. Rossetti²; ¹Università Milano-Bicocca, Milano, ITALY, ²Ospedale Niguarda, Milano, ITALY.

P944

Complementary roles of retrospectively co-registered PET and MR in evaluation of suspected osteomyelitis of foot.

S. Raja^{1,2}, N. Alnakshabandi², S. George³, M. AlHarbi², S. Romyantsev²; ¹Baylor College of Medicine, Bellaire, TX, UNITED STATES, ²KFMC, Riyadh, SAUDI ARABIA, ³Johns Hopkins Aramco Healthcare, Dhahran, SAUDI ARABIA.

P945

SPECT/CT value in the diagnosis of diabetic foot infections by ^{99m}Tc-HMPAO-labeled leucocyte scan

S. Georga¹, C. Manes², D. Lo-Presti¹, V. Mpalaris¹, I. Tsavdaridis², I. Iakovou¹, D. Katsaboukas¹, V. Athanasiou¹, K. Badiavas¹, A. Doulmas¹, G. Arsos¹; ¹3rd Dept of Nuclear Medicine, Aristotle University Medical School, Papageorgiou Hospital, THESSALONIKI, GREECE, ²Diabetes Center, Papageorgiou Hospital, THESSALONIKI, GREECE.

P946

^{99m}Tc-HMPAO white blood cell labelled scintigraphy in patient with osteosynthesis material and inter-observer reproducibility

E. Noriega, M. Bajén Lázaro, A. Benítez Segura, A. Rodríguez-Gasén, P. Saldaña, O. Puig Calvo, G. Martínez Pimienta, M. Boya Román, J. Mora Salvadó; Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat (BARCELONA), SPAIN.

P947

Contribution of labelled leukocytes scintigraphy with decay correction at 8 or 24 hours in the diagnosis of osteoarticular infection

J. Rodríguez-Rubio Corona¹, E. Noriega Álvarez¹, I. Gil Viciano¹, A. Rodríguez-Gasén¹, A. Benítez-Segura¹, I. Romero-Zayas², G. Martínez-Pimienta¹, M. Boya-Román¹, M. Roca Engronyat¹; ¹Nuclear Medicine Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat (Barcelona), SPAIN, ²IDI-PET Unit, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat (Barcelona), SPAIN.

P948

Effectiveness of 18F-FDG PET/CT in patients with suspected residual spinal infection, with or without surgical device : a prospective 30 case study.

A. Dutertre; Chu Bordeaux, Bordeaux, FRANCE.

P949

The role of 18 F-FDG PET/CT in HIV positive patients.

R. Bonfiglioli, T. Graziani, F. Ceci, S. Sanfilippo, L. Zaroni, C. Pettinato, M. Bartoletti, P. Viale, C. Nanni, P. Castellucci, S. Fanti; Azienda ospedaliero-universitaria S.Orsola-Malpighi, BOLOGNA, ITALY.

P950

FDG PET/CT in pulmonary aspergillosis

D. Grigolato, M. Zuffante, M. Cucca, E. Carmagnani, E. Concia, M. Ferdeghini; Azienda Ospedaliera di Verona, VERONA, ITALY.

P951

FDG-PET/CT in ANCA Associated Vasculitis: An Exploratory Pilot Study

S. Hess^{1,2}, M. J. Velandar³, P. F. Høilund-Carlsen^{1,2}, H. Laustrop⁴; ¹Dept. of Nuclear Medicine, Odense University Hospital, Odense, DENMARK, ²Institute of Clinical Research, University of Southern Denmark, Odense, DENMARK, ³Department of Internal Medicine, Section of Rheumatology, Odense University Hospital - Svendborg Hospital, Odense, DENMARK, ⁴Dept. of Rheumatology, Odense University Hospital, Odense, DENMARK.

P952

The role of 18F-FDG PET/CT combined with MRI in the diagnosis and follow-up of the retroperitoneal fibrosis and vasculitis in a 14year-old girl

D. Chroustova¹, J. Jahoda¹, M. Kyncp², J. Trnka¹, P. Dolezalova¹, J. Kubinyi¹; ¹General University Hospital and 1st Faculty of Medicine Charles University, PRAGUE 2, CZECH REPUBLIC, ²Hospital Motol and 2nd Faculty of Medicine Charles University, PRAGUE 5, CZECH REPUBLIC.

P953

Long fasting with HNF is effective in inhibiting myocardial 18FDG uptake for evaluating cardiac sarcoidosis or endocarditis

P. VIAU, G. Nivaggioni, R. Capet, M. Razzouk-Cadet; University Hospital Archet, Nice, FRANCE.

P954

The role of 18F-FDG PET/CT in clinical management of patient with spondylodiscitis

N. Prandini¹, L. Massi¹, A. Bedini², S. Taralli¹, A. Franceschetto¹, A. Casolo¹, S. Zona², C. Mussini²; ¹Nuclear Medicine University Hospital, Modena, ITALY, ²Infectious Disease Clinic, University, Modena, ITALY.

P63

Tuesday, October 13, 2015

16:00 – 16:30

Conventional & Specialised Nuclear Medicine: General & Miscellaneous

P955

Comparison of Prognostic Value Between NP-59 Adrenal Scintigraphy and Adrenal Venous Sampling in Primary Aldosteronism Patients After Adrenalectomy

C. Lu, V. Wu, C. Chang, K. Wu, TAIPAI Study Group, R. Yen; National Taiwan University Hospital, Taipei, TAIWAN.

P956

Transport capacity of lymphatic system of lower extremities in patients with diabetes

O. Lang^{1,2}, V. Prymkova², I. Kunikova¹, H. Krizova¹, H. Balon¹;
¹Charles Univ, Prague 10, CZECH REPUBLIC, ²District Hosp, Pribram, CZECH REPUBLIC.

P957

The effect of age on indices of quantitative lymphoscintigraphy (LS)

G. Arsos¹, D. Dionysiou², C. Sachpekidis³, K. Michailos¹, E. Demiri²; ¹3rd Dept of Nuclear Medicine, Aristotle University of Thessaloniki Medical School, Papageorgiou Hospital, THESSALONIKI, GREECE, ²Plastic Surgery Clinic, Aristotle University of Thessaloniki Medical School, Papageorgiou Hospital, THESSALONIKI, GREECE, ³Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, GERMANY.

P958

Accuracy of 99mTc-Sestamibi Molecular Breast Imaging Guided Needle Biopsy Using a Stereotactic Lesion Localisation System

A. Collarino^{1,2,3}, L. M. Pereira Arias-Bouda^{2,3}, F. Smit², P. Neijenhuis⁴, L. M. H. Wijers⁵, A. F. Van der Hoeven³, K. Hofkes-Fillekes⁵, A. Zeillemaker⁴, R. A. Valdés Olmos²;
¹Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Roma, ITALY, ²Department of Nuclear Medicine, Leiden University Medical Center, Leiden, NETHERLANDS, ³Department of Nuclear Medicine, Alrijne Hospital, Leiderdorp, NETHERLANDS, ⁴Department of Surgery, Alrijne Hospital, Leiderdorp, NETHERLANDS, ⁵Department of Radiology, Alrijne Hospital, Leiderdorp, NETHERLANDS.

P959

The hidden sentinel node in breast cancer: reevaluating the role of SPECT/CT and tracer reinjection

B. Pouw, D. Hellingman, M. Kieft, W. V. Vogel, E. J. T. Rutgers, M. P. M. Stokkel, R. A. Valdés Olmos; Netherlands Cancer Institute, Amsterdam, NETHERLANDS.

P960

SPECT/CT Imaging: Clinical Utility in Lymphoscintigraphy for Sentinel Node Mapping in Patients with Melanoma .

J. Rodriguez Alban, A. Albuquerque, M. Silva, L. Pires, P. Lapa, A. Moreira, R. Vieira, A. Figueiredo, G. Costa, J. Pedroso De Lima; Chuc, Coimbra, PORTUGAL.

P961

Potential role of Lymphangioscintigraphy in anticipating results of Lymphatic-Venous Anastomoses: Clinical and Imaging Patterns

E. Cracco¹, A. Busetto², A. Bonazza¹, F. Dei Rossi¹, M. Gallan¹, R. Mameli¹, M. Rizzo², M. Siculo²; ¹Division of Nuclear Medicine, Ospedale dell'Angelo, Mestre, ITALY, ²Division of Surgery, Ospedale dell'Angelo, Mestre, ITALY.

P963

Scintigraphy is a Validated Method for in vivo Evaluation of Drug Delivery to Gastrointestinal System

B. E. Akkas¹, L. Guner², A. Celkan³, F. Acarturk³, F. Tugcu Demiroz³, N. Gokcora⁴; ¹Ankara Oncology Research and Training Hospital Department of Nuclear Medicine, Ankara, TURKEY, ²Acibadem Hospital Department of Nuclear Medicine, Istanbul, TURKEY, ³Gazi University Faculty of Pharmacy, Department of Pharmaceutical Technology, Ankara, TURKEY, ⁴Gazi University Faculty of Medicine, Department of Nuclear Medicine, Ankara, TURKEY.

P964

Scintigraphic evaluation of pyloroplasty role in Ivor-Lewis esophagectomy

M. Zuffante, L. Gobbi, L. Pavanello, S. Giacomuzzi, J. Weindelmayer, F. Longo, E. Carmagnani, M. Cucca, D. Grigolato, G. de Manzoni, M. Ferdeghini; AOUI, Verona, ITALY.

P965

Gastric Motility SPECT/CT with Tc99m labelled standard quality food (SQF)

I. Garai¹, A. Forgács¹, K. Kukuts¹, S. Barna¹, G. Opposits², S. A. Kiss², M. Emri², Z. Csiki³; ¹ScanoMed Ltd., Debrecen, HUNGARY, ²Institute of Nuclear Medicine, University of Debrecen, Debrecen, HUNGARY, ³Institute of Internal Medicine, University of Debrecen, Debrecen, HUNGARY.

P966

Diagnostic accuracy of 123I-MIBG SPECT-CT using semi-quantitative analysis in patients with adrenal pheochromocytoma

Y. Sugihara, Y. Fukushima, S. Kumita; Nippon Medical School Hospital, Tokyo, JAPAN.

P967

The value of parathyroid hormon determination in fine needle aspiration washout fluid in patients with negative or equivocal scintigraphic findings

S. Ince, H. San, M. O. Emer, E. Alagoz, A. Ayan, K. Okuyucu, B. Gunalp, A. O. Karacalioglu, N. Arslan; Gülhane Military Medical Academy, Ankara, TURKEY.

P969

Psychiatric symptoms in a patient with parathyroid adenoma: diagnostic role of sestamibi scintigraphy.

M. Finessi¹, A. Pia², V. Podio¹, A. Barberi³, P. Moretto⁴, V. Marci⁵, T. Angusti¹; ¹Nuclear Medicine, San Luigi Hospital, University of Turin, Orbassano, ITALY, ²Internal Medicine, San Luigi Hospital, University of Turin, Orbassano, ITALY, ³Psychiatry, San Luigi Hospital, University of Turin, Orbassano, ITALY, ⁴Radiology, San Luigi Hospital, University of Turin, Orbassano, ITALY, ⁵Division of Pathology, San Luigi Hospital, University of Turin, Orbassano, ITALY.

P970

^{99m}Tc-MIBI dual phase planar and SPECT CT scanning in diagnosis of hyperparathyroidism in patients with MEN 1

M. Castellon Sanchez, M. Godoy Bravo, M. Balsalobre Salmeron, L. Alvarez Nieto, M. Ibáñez Ibáñez, J. Rodriguez Gonzalez, F. Nicolás Ruiz, L. Mohamed Salem, R. Reyes Marlés, M. Claver Valderas; Nuclear Medicine department, Hospital universitario clínico Virgen de la Arrixaca, Murcia, SPAIN.

P971

Lung Ventilation/Perfusion SPECT feasibility and interobserver concordance in patients with suspected pulmonary embolism

D. Balaguer, L. Marbello, H. Rodríguez, P. Abreu, D. Reyes, T. Mut, C. Plancha, E. Caballero; Dr. Peset Hospital, Valencia, SPAIN.

P972

Body fat changes in HIV patients on highly active antiretroviral therapy (HAART): a longitudinal DEXA study.

G. Madeddu¹, A. Spanu², P. Solinas², G. M. Calia¹, C. Lovigu¹, M. Mannazzu¹, P. Bagella¹, S. Nuvoli², M. S. Mura¹, G. Madeddu²; ¹Unit of Infection Disease, University of Sassari, Sassari, ITALY, ²Unit of Nuclear Medicine, University of Sassari, Sassari, ITALY.

P973

Extravasation of Radiopharmaceuticals: Which Action Is Required? A Systematic Review

J. A. J. van der Pol, F. M. Mottaghy, S. Vöö; Maastricht University Medical Center, Maastricht, NETHERLANDS.

P974

Nuclear medicine in veterinary practice: preliminary experiences at Az. Polo Veterinario di Lodi

D. De Zani¹, C. Pettinato², M. Longo¹, G. Ravasio¹, M. Di Giancamillo¹, D. Zani¹; ¹DIVET, University of Milano, Milano, ITALY, ²Medical Physics Unit, Bologna, ITALY.

P975

¹⁸F-FDG PET/CT Contribution in Characterization of Malignancy of Brain Tumors

L. F. León Ramírez, M. Martinez de Bourio, M. N. Cabrera Martin, C. Gonzalez Roiz, A. Ortega Candil, M. J. Pérez Castejón, E. Cala Zuluaga, M. Pedrera Canal, A. Jiménez Ballvé, J. L. Carreras Delgado; Hospital Clinico San Carlos, Madrid, SPAIN.

P976

Added value of SPECT/CT to Technetium ^{99m}-labeled red blood cells scintigraphy in small bowel bleeding

W. Amouri, F. Hamza, I. Jardak, H. Charfi, M. Maaloul, F. Kallel, S. Charfeddine, F. Guermazi; Habib Bourguiba Hospital, Sfax, TUNISIA.

P977

Lung perfusion scintigraphy with SPECT-CT for diagnosis of pulmonary embolism.

A. Tzonevska¹, M. Shindov¹, M. Yaneva²; ¹National Center of Oncology, Sofia, BULGARIA, ²University Hospital "St.Georgi", Plovdiv, BULGARIA.

P978

Impact of Fluorodeoxyglucose-PET scan in characterizing pleural effusions (massive/submassive) in non-oncologic patients

M. Simo, J. Monturiol, M. Velasco, I. Navales, M. Barios, J. Castell; Hospital Universitario Vall Hebron Barcelona, Barcelona, SPAIN.

P979

Determining prognosis using lower limb perfusion SPECT-CT in patients with arteriosclerosis obliterans

H. Hashimoto; Department of Radiology, Nippon Medical School, Tokyo, JAPAN.

P980

Is diffuse increased FDG uptake in renal parenchyma associated with impaired renal dysfunction?

N. Hayakawa, Y. Nakamoto, T. Ishimori, K. Togashi; Kyoto University Graduate School of Medicine, Kyoto, JAPAN.

P981

Evaluation of preventive effect of dexpanthenol in radiation injury by lung perfusion scintigraphy

Z. Koç¹, E. İn¹, Ö. Üçer¹, I. Karslıoğlu², S. Canpolat³; ¹Firat University Hospital, Elazig, TURKEY, ²Medical Park Hospital, Elazig, TURKEY, ³Firat University, Elazig, TURKEY.

P982

Application of combined nuclear medicine protocol including Whole Body Bone Scintigraphy and Single Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) of the pelvis for the initial staging of prostate cancer

V. Hadzhiyska¹, T. Petrov¹, I. Kostadinova¹, V. Mariyanovski², D. Zlatareva¹, M. Garcheva-Tsacheva¹; ¹University Hospital Alexandrovska, Sofia, BULGARIA, ²Pirogov Hospital, Sofia, BULGARIA.

P984

Tc99m tagged RBCs venography with additional abdominal/pelvic SPECTCT in diagnosis of Iliac venous compression (May-Thurner syndrome).

Y. Chen, C. Lin, D. Wu, C. Chiu; Kaohsiung Medical University Hospital, Kaohsiung, TAIWAN.

P985

Prognostic impact of deep-inspiratory breath-hold pulmonary perfusion SPECT-CT in patients with pulmonary thromboembolism

Y. Fukushima, S. Kumita, H. Hashimoto, Y. Sugihara; Nippon Medical School Hospital, Tokyo, JAPAN.

P986

Physiological uptake of the uncinate process of the pancreas: incidence of this potential pitfall in a retrospective study fo 220 patients.

J. Pinaquy, Sr., P. Schwartz, L. Bordenave; CHU BORDEAUX, Bordeaux, FRANCE.

P987

IMP and MIBG scintigraphy as an index comparable to the core symptoms for a diagnosis of dementia with Lewy bodies?

F. Sakamoto¹, S. Shiraishi¹, N. Tsuda¹, H. Yuki¹, T. Namimoto¹, M. Kitajima¹, M. Hashimoto², S. Tomiguchi³, M. Ikeda², Y. Yamashita⁴; ¹Diagnostic Radiology Graduate School of Life Sciences Kumamoto University, kumamoto, JAPAN, ²Department of Neuropsychiatry, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Japan, kumamoto, JAPAN, ³Department of Diagnostic Medical Imaging, School of Health Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan, kumamoto, JAPAN, ⁴Department of Diagnostic Radiology, Graduate School of Life Sciences, Kumamoto University, kumamoto, JAPAN.

P988

Assessment of vascular reserve state with brain SPECT in asymptomatic patients with steno-occlusive lesion in Brain MRA

S. OH¹, J. Han², M. Cha³, S. Pyun³, J. Lee¹; ¹Department of Nuclear Medicine, National Police Hospital, Seoul, KOREA, REPUBLIC OF, ²Department of Nuclear Medicine, National Police HospitalGapyeong Public Health Center, Gapyeong, KOREA, REPUBLIC OF, ³Department of Neurology, National Police Hospital, Seoul, KOREA, REPUBLIC OF.

TECHNOLOGIST POSTERS

TP01 Tuesday, October 13, 2015

08:00 – 09:30

Technologist Poster Session 1

TP001

Radiosynovectomy as a Primary Modality of Treatment for Diffuse Pigmented Villonodular Synovitis of Elbow joint treated with Rhenium-188 labelled Tin-Colloid.

K. Kamaleshwaran, L. Babu, b. krishnan, m. mallia, A. shinto; Kovai medical center and hospital limited, Coimbatore, INDIA.

TP002

Comparison Between Left Ventricular Function Parameters as Measured on 8- Versus 16-Frame ECG-Gated $^{13}\text{NH}_3$ Myocardial Perfusion PET Studies

N. J. Hoogvorst; Medical Center Alkmaar, Alkmaar, NETHERLANDS.

TP003

Renal Parenchymal Analysis: $^{99\text{mTc}}$ -MAG3 'v' $^{99\text{mTc}}$ -DMSA

T. De Sousa, D. Bailey; Guy's and St. Thomas' NHS Foundation Trust, London, UNITED KINGDOM.

TP004

Influence of attenuation correction in the MPI image reconstructed by the Evolution for Cardiac™ software

D. F. F. Ribeiro¹, J. Vilaça¹, C. Nunes¹, L. Freire¹, M. Pinheiro¹, G. Cantinho², E. Carolino¹, E. Sousa¹; ¹Escola Superior de Tecnologia da Saúde de Lisboa, Lisbon, PORTUGAL, ²Atomimedical, Laboratório de Medicina Nuclear, Lisbon, PORTUGAL.

TP005

Influence of geometry on the measurement of an alpha emitter radionuclide, Ra-223.

K. Thongklam, P. Charoenphun; Division of Nuclear Medicine, Ramathibodi hospital, Mahidol University, Bangkok, THAILAND.

TP006

Patient satisfaction in The Department of Nuclear Medicine and PET-Centre, Aarhus University Hospital, Denmark

A. Dysterdich, V. Larsen, L. Pedersen; Aarhus Universitetshospital, Aarhus, DENMARK.

TP007

Technologist radiation exposure performing PET/CT using F18-FDG automatic dispenser

M. I. Larg, C. Pestean, M. Crisan, E. Barbus, D. Piciu; Ion Chiricuta Institute of Oncology, Cluj-Napoca, ROMANIA.

TP008

Studies on measurement of thyroid uptake rate on I-131 scintigraphy images

Y. Koshiba¹, S. Abe², S. Tsuchiya¹, N. Fujita², T. Odagawa¹, K. Kato¹; ¹Nagoya University Graduate School of Medicine, Nagoya-shi, JAPAN, ²Nagoya University Hospital, Nagoya-shi, JAPAN.

TP009

Semi-quantitative ^{18}F -NaF PET/CT in the assessment of bone mineral density (BMD): Comparison with dual-energy X-Ray Absorptiometry (DXA)

S. Haim¹, F. Fitzal², B. Saboury³, A. Alavi³, C. Schiller¹, W. Langsteiger¹, M. Beheshti¹; ¹Nuclear Medicine & Endocrinology, St. Vincent's Hospital, Linz, AUSTRIA, ²Breast Cancer Center, St. Vincent's Hospital, Linz, AUSTRIA, ³Division of Nuclear Medicine, University of Pennsylvania, Philadelphia, PA, UNITED STATES.

TP010

Implementation of new Hidex automatic gamma counter

S. M. Virtaniemi, J. Laine, K. Bergström; Helsinki University Central Hospital, HUS, FINLAND.

TP011

Enhanced Myocardial Glucose Uptake During Viability Assessment Using Modified Niacin Induced Protocol 2-[^{18}F] Fluoro-2-Deoxy-D-Glucose (^{18}F -FDG) Positron Emission Tomography/Computed Tomography (PET/CT).

M. Che Nordin¹, A. Nordin¹, F. Ahmad Saad¹, H. Abdul Razak²; ¹Universiti Putra Malaysia (UPM), Serdang, MALAYSIA, ²Universiti Teknologi Mara (UiTM), Puncak Alam, MALAYSIA.

TP012

Possible sources of artificial focal ^{18}F -FDG accumulations in the lung tissue without corresponding morphological CT changes

T. K. Lehnskov, T. A. Roholm, U. Tøllneruphuus; Bispebjerg and Frederiksberg Hospital, Copenhagen, DENMARK.

TP013

Evaluation of therapeutic response to ¹³¹I in the treatment of hyperthyroidism

A. C. C. Caetano¹, A. P. S. Leite¹, J. I. R. Madrid², J. S. Vicente², E. Carolino¹, L. Vieira¹; ¹Escola Superior de Tecnologia da Saúde de Lisboa, IPL, Lisboa, PORTUGAL, ²Hospital Infanta Cristina, Badajoz, SPAIN.

TP014

Standardization analysis protocol proposal for isotopic ventriculography

P. Borrelli¹, J. Loaiza Góngora¹, J. Vercher-Conejero¹, C. Ruiz Llorca¹, C. Igua Sáenz¹, D. Hervás Marín², C. Olivas Arroyo¹, V. Vera Pinto¹, P. Olivan Sasot¹, P. Bello Arqués¹; ¹Hospital Universitario y Politécnico La Fe, Valencia, SPAIN, ²Instituto Investigación del Hospital Universitario y Politécnico La Fe, Valencia, SPAIN.

TP015

Surface contamination from ^{99m}Tc -Technegas aerosols in the SPECT/CT room after lung ventilation.

S. D. Lind, R. S. Olsen, I. L. Rasmussen, M. Lonsdale; Department of Clinical Physiology & Nuclear Medicine, Bispebjerg and Frederiksberg University Hospital, København NV, DENMARK.

TP016

Clinical classification versus semiquantification with adapted reference values for ¹²³I-FP-CIT SPECT in a Nuclear Medicine Department

D. Silva¹, M. Queiroga¹, M. Elias¹, J. Serrano², J. Madrid², E. Carolino¹, E. Sousa¹; ¹Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisbon, PORTUGAL, ²Nuclear Medicine Department, Hospital Infanta Cristina, Badajoz, Spain, Badajoz, SPAIN.

TP017

Elution features of sorptive generators technetium-^{99m}.

A. Rogov, V. Skuridin, E. Stasyuk, N. Varlamova, E. Nestwrov, V. Sadkin, L. Larionova, E. Ilina; National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

TP018

The Evaluation of External Dose Measurements in Children and Adolescent Patients Receiving Radioiodine Therapy for Well-Differentiated Thyroid Cancer

N. Edis, A. Ogretici, M. O. Tamam, M. Mulazimoglu; Okmeydanı Training and Research Hospital, Istanbul, TURKEY.

TP019

Radiotherapy Planning in PET/CT: The Process and Challenges

S. A. Summers, A. Ribeiro; The Royal Marsden NHS Hospital, Sutton, UNITED KINGDOM.

TP020

Comparative study on recovery coefficients of SPECT-CT

S. Tsuchiya¹, S. Abe², N. Fujita², Y. Sakuragi², Y. Koshiba¹, T. Odagawa¹, K. Kato¹; ¹Nagoya University Graduate School of Medicine, Nagoya, JAPAN, ²Nagoya University Hospital, Nagoya, JAPAN.

TP021

Practical consequences of new indications for sentinel node procedures in breast cancer: evaluating the role of SPECT/CT and tracer reinjection

M. Kieft, B. Pouw, D. Hellingman, W. V. Vogel, M. P. M. Stokkel; NKI-AVL, Amsterdam, NETHERLANDS.

TP022

Non-invasive quantification of the regional cerebral blood flow using I-¹²³ IMP SPECT and phase contrast MRA; preliminary study of combination and revisit of the matured technologies.

S. Mano, M. Tadokoro, S. Shirakawa, M. Ishiguro, H. Toyama; Fujita Health University, Toyoake City, JAPAN.

TP023

Dynamic F18-FDG studies with a dedicated breast-PET: Preliminary results.

R. Sanchez Jurado¹, J. Ferrer Rebollada¹, B. Kundu², S. Majewski², X. Zhang³, Y. Li³, A. González⁴, M. Garcia¹; ¹ERESA, VALENCIA, SPAIN, ²Radiology and Medical Imaging, University of Virginia, Virginia, VA, UNITED STATES, ³Beijing Institute of Technology, Beijing, CHINA, ⁴Institute for Instrumentation in Molecular Imaging, VALENCIA, SPAIN.

TP024

A Case Report: Suitability of Measuring Kidney Depth with Assessment of GFR Using ^{99m}Tc-DTPA in Ectopic Kidney and Pediatric Patients.

J. CHOI; Asan Medical Center, SEOUL, KOREA, REPUBLIC OF.

TP025

Planar Scintigraphy vs SPECT/CT in The Visualisation of Sentinel Node(s) for Patients with Vulvar Carcinoma

M. Brom-Attard, E. Mijnheere, M. Janssen; Radboud University Nijmegen Medical Centre, Nijmegen, NETHERLANDS.

TP026

Evaluation of a rhodamine-angiotensin conjugate as a potential breast cancer imaging agent

S. Okarvi, I. Jammaz; King Faisal Specialist Hospital & Research Centre, Riyadh, SAUDI ARABIA.

TP02

Tuesday, October 13, 2015

08:00 – 09:30

Technologist Poster Session 2

TP027

A new amyloid imaging probe 125I-EISB in PET/SPECT imaging of amyloid was developed for both brain and whole body for clinical use

S. Tsukimoto; Kumamoto University, Kumamoto, JAPAN.

TP028

Influence of Nuclear Medicine Technologists' professional experience and visual function in the Myocardial Perfusion Gated-SPECT semi-automatic processing

A. S. Reimão¹, F. Nascimento², E. Carolino³, J. Pereira⁴, M. Nobre², I. Poças², L. Vieira⁵; ¹Nuclear Medicine Scientific Area, Lisbon School of Health Technology – Lisbon Polytechnic Institute (ESTeSL-IPL), Lisbon, PORTUGAL & Brighton and Sussex University Hospitals NHS Trust, Brighton, UNITED KINGDOM, ²Orthoptics Scientific Area, ESTeSL-IPL, Lisbon, PORTUGAL, ³Mathematics Scientific Area, ESTeSL-IPL, Lisbon, PORTUGAL, ⁴Nuclear Medicine Scientific Area, ESTeSL-IPL, Lisbon, PORTUGAL, ⁵Nuclear Medicine Scientific Area, ESTeSL-IPL & Instituto de Biofísica e Engenharia Biomédica, Faculdade de Ciências da Universidade de Lisboa, Lisbon, PORTUGAL.

TP029

I131 Effective Half-Life in Well Differentiated Thyroid Cancer Patients

S. Saengsuda; Rajavithi hospital, Bangkok, THAILAND.

TP030

Optimizing the azeotropic drying of 18F-way to improve 18F-Fluorocholine radiochemical yields!

H. Hassan¹, S. Abu Bakar², K. Che A. Halim², J. Idris², A. Nordin¹; ¹Universiti Putra Malaysia, Serdang, Selangor, MALAYSIA, ²National Cancer Institute, Putrajaya, MALAYSIA.

TP031

The Radiation Dose Received by the Staff Responsible for the Collection and Transport of the Radioactive Waste

N. Edis, A. Ogretici, M. O. Tamam, M. Mulazimoglu; Okmeydanı Training and Research Hospital, Istanbul, TURKEY.

TP032

Additional findings above skull base on 18F-FDG PETCT: the usefulness of imaging from vertex

N. Gulliver, A. Almeida, N. Mulholland, G. Vivian, A. Eccles; King's College Hospital, London, UNITED KINGDOM.

TP033

Technologist Radiation Exposure in Routine Clinical Practice with I-131 Administration for Ablation of Thyroid Cancer

A. Ergulen, F. Ustun, O. N. Yigitbasi, G. Durmus-Altun; Trakya University Medical Faculty, EDIRNE, TURKEY.

TP034

Comparison of capability of diagnosis supporting system between two different gamma cameras for bone scintigraphic images in diagnosing bone metastasis of cancer

K. Shimizu¹, M. Hino¹, K. Matsumoto², S. Yamamoto³; ¹Kobe City Medical Center General Hospital, Kobe, JAPAN, ²Kyoto College of Medical Science, Nantan, JAPAN, ³Nagoya University Graduate School of Medicine, Nagoya, JAPAN.

TP035

Dosimetric analysis of Lu-177-DOTA-Rituximab in patients of relapsed/refractory Non-Hodgkin's Lymphoma

M. P. Yadav, S. Singla, P. Thakral, S. Ballal, S. K. Gupta, C. Bal, A. Malhotra; All India Institute of Medical Sciences, New Delhi, INDIA.

TP036

Validation of an in-house media-fill on radiopharmaceuticals compared to ready-to-use kits: a cost-effective procedure fitted on each nuclear medicine needs

M. Di Franco¹, S. Valfre², T. Scotognella³, T. Angusti¹, D. Ielo¹, V. Podio¹; ¹Ospedale San Luigi Gonzaga, Orbassano (TO), ITALY, ²Università degli Studi, Torino, ITALY, ³Policlinico Agostino Gemelli, Roma, ITALY.

TP037

Myocardial Perfusion Radiopharmaceuticals and Imaging in SPECT and PET

R. Adães¹, E. Pereira², M. Fernandes², E. Sousa¹; ¹Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisbon, PORTUGAL, ²Nuclearmed - Instituto de Medicina Nuclear, Lisbon, PORTUGAL.

TP038

Evaluation of the quality of neuroimaging features as Alzheimer's Disease biomarkers

F. Lucena¹, T. F. Vaz¹, J. Pé-Leve², A. S. Ribeiro³, L. Lacerda⁴, N. Silva⁵, D. Nutt³, J. McGonigle³, H. A. Ferreira²; ¹Institute of Biophysics and Biomedical Engineering of the Faculty of Sciences of the University of Lisbon / Lisbon School of Health Technology of the Polytechnic Institute of Lisbon, Lisbon, PORTUGAL, ²Institute of Biophysics and Biomedical Engineering of the Faculty of Sciences of the University of Lisbon, Lisbon, PORTUGAL, ³Centre for Neuropsychopharmacology, Division of Brain Sciences, Department of Medicine, Imperial College London, London, UNITED KINGDOM, ⁴Centre for Neuroimaging Sciences, Institute of Psychiatry, King's College London, London, UNITED KINGDOM, ⁵Institute of Neuroscience and Medicine 4, Forschungszentrum Jülich GmbH, Jülich, GERMANY.

TP039

Qualitative and quantitative analysis of 123I-DaTSCAN SPECT in the diagnosis of Parkinson's diseases: body-contouring versus circular orbit acquisition

A. Palmieri¹, A. Zocco²; ¹Santa Maria Nuova Hospital, Reggio Emilia, ITALY, ²Universita' Di Modena E Reggio Emilia, Modena, ITALY.

TP040

Influence of disposable materials in 99mTc-MAG3 radiolabelling

M. Menzaghi, R. Lucianini; Ospedale di Circolo, VARESE, ITALY.

TP041

Intraobserver and interobserver variation of myocardial perfusion SPECT results related to repeated reconstructions

M. Kraft, T. Koivumäki, M. Hakulinen, M. Kokkonen, A. Leinonen, T. Laitinen; Kuopio University Hospital, Kuopio, FINLAND.

TP042

Influence of Reconstruction Parameters for FBP in Semiquantification of Brain Studies with 123I-FPCIT

F. Alves¹, R. Adães², C. Fortes², E. V. Sousa²; ¹Alliance Medical, London, UNITED KINGDOM, ²Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisbon, PORTUGAL.

TP043

Half-time oncologic bone scintigraphy imaging in patients with prostate and breast cancer

S. J. C. Serém¹, M. I. Gomes¹, W. Grootjans², W. J. M. van den Broek², E. P. Mijneheer², B. F. Bulten², L. Heijmen², R. Hermesen²; ¹Coimbra Health School, Polytechnic Institute of Coimbra, Coimbra, PORTUGAL, ²Radboud University Medical Center, Nijmegen, NETHERLANDS.

TP044

Albumin macroaggregates (MAA) kit fractionation for labeling with 99mTc: temperature and storage time influence in quality parameters

S. F. C. Mendes, B. F. Oliveira, A. G. F. Ramos, F. Lucena; Escola Superior de Tecnologias da Saúde, IPL, Lisboa, PORTUGAL.

TP045

The Study on Effect of the Image Applying to Breast Implants in Breast Specific Gamma Imaging

J. Lee¹, H. Lee², J. Kim³, H. Park⁴; ¹Graduate school of Public Health, Yonsei University, Seoul, KOREA, REPUBLIC OF, ²Department of Nuclear Medicine, Konkuk University Medical Center, Seoul, KOREA, REPUBLIC OF, ³Department of Nuclear Medicine, Seoul Medical Center, Seoul, KOREA, REPUBLIC OF, ⁴Shingu College, Seongnam, KOREA, REPUBLIC OF.

TP046

Biodistribution Assessment of Sodium Pamidronate and Methylene Diphosphonate for Rats Bone Scintigraphy Images

T. S. C. Camozzato, Sr.¹, A. Z. P. De Souza², M. Tizon¹, S. J. Garcia¹, V. F. Dutra¹, T. G. Costa¹; ¹Instituto Federal de Educação, Ciência e Tecnologia de Santa Catarina, Florianópolis, BRAZIL, ²Universidade Federal de Santa Catarina, Florianópolis, BRAZIL.

TP047

Implementation of a New Reference values's Database for Semiquantification in 123I-FP-CIT Brain Single Photon Emission Tomography

M. Queiroga¹, D. Silva¹, M. Elias¹, J. Serrano², J. Madrid², E. Carolino¹, E. Sousa¹; ¹Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisbon, PORTUGAL, ²Nuclear Medicine Department, Hospital Infanta Cristina, Badajoz, Spain, Badajoz, SPAIN.

TP048

ASTRIM® Software Implementation - Complying with the Italian Current Regulations - for the Radiolabelling of Therapeutic Radiopharmaceuticals: the Role of Nuclear Medicine Technicians

N. Bartolini, G. Di Guilmi, G. Marchi, M. Casi, F. De Lauro, M. Bartolomei; Nuclear Medicine Unit M. Bufalini Hospital, Cesena, ITALY.

TP049

5-HT1A agonist and antagonist PET radiopharmaceuticals bind differently to receptors in Alzheimer's disease: a postmortem study

B. Vidal¹, J. Sebti¹, M. Verdurand¹, S. Fieux¹, N. Streichenberger¹, T. Billard², A. Newman-Tancredi³, L. Zimmer¹; ¹Université Claude Bernard Lyon 1, Lyon, FRANCE, ²CNRS, Lyon, FRANCE, ³Neurolix, Dana Point, CA, UNITED STATES.

TP050

Introduction of a new Gallium-68 (Ga-68) DOTATATE synthesis module: a retrospective evaluation of GMP qualification and validation, radiation hygiene and organizational planning.

S. Baank, L. de Wit-van Veen, M. Jonker, E. Aalbersberg; Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS.

TP051

Nuclear Medicine/PET/CT Research: The role of a technologist/radiographer

A. S. F. Ribeiro, S. Summers; Royal Marsden Hospital, Sutton, UNITED KINGDOM.

TP03

Tuesday, October 13, 2015

08:00 – 09:30

Technologist Poster Session 3

TP052

The use of non-attenuation corrected PET images in the assessment of cardiac implantable electronic device infections

C. Abreu¹, J. O'Doherty¹, A. Corrigan², S. Barrington¹, J. John¹; ¹PET Imaging Centre, King's College London, King's Health Partners, St Thomas' Hospital, London, UNITED KINGDOM, ²Department of Radiology, Maidstone Hospital, Maidstone and Tunbridge Wells NHS Trust, Kent, UNITED KINGDOM.

TP053

Performance of image evaluation due to the difference in the acquisition time using multifocal collimator with 99mTc myocardial SPECT: Evidence from a phantom study

Y. Banno¹, M. Onoguchi¹, K. Nakajima², S. Matsuo²; ¹Department of Quantum Medical Technology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, JAPAN, ²Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, JAPAN.

TP054

64Cu-ATSM PET studies: Are radiation protection restrictions required for patients after scan?

S. Pereira, E. Woods, J. John, A. Jacob, C. Abreu, L. Alves, L. Pike; PET Imaging Centre, St Thomas' Hospital, King's College London, London, UNITED KINGDOM.

TP055

The Comparison of Lesion Localization Methods in Breast Lymphoscintigraphy

Y. Joonho, H. Gunchul; Samsung Medical Center, Seoul, KOREA, REPUBLIC OF.

TP056

Clinical application of breath-hold PET/CT to improve quantitation of the NSCLC

W. Huang¹, S. Tasi¹, T. Pan², J. Tseng¹, K. Lin¹, T. Yen¹; ¹Molecular Imaging Center and Department of Nuclear Medicine, Chang Gung Memorial Hospital, Taoyuan, TAIWAN, ²Department of Imaging Physics, The University of Texas M.D. Anderson Cancer Center, Houston, TX, UNITED STATES.

TP057

The Correlation of PSA and PSA kinetics to 11C-Choline Positron Emission Tomography/Computerized Tomography for recurrent Prostate Cancer after Radical Prostatectomy

L. G. Jordan, III, G. Dimonte, M. L. Burton, R. Haloi, L. J. Rangel, J. C. Hung, B. J. Davis, M. A. Nathan, E. D. Kwon, R. J. Karnes; Mayo Clinic, Rochester, MN, UNITED STATES.

TP058

FCH for detection of parathyroid adenomas in Tc-99m-sestamibi negative patients

B. M. de Jong, M. Postma, S. J. Eelkman Rooda, J. P. Esser, J. M. H. de Klerk; Meander Medisch Centrum, Amersfoort, NETHERLANDS.

TP059

Positioning of the arms is essential in reducing artefacts in PET/CT-scans

B. Christensen, P. C. Holdgaard, MD; Vejle Hospital, part of Lillebaelt Hospital, Vejle, DENMARK.

TP060

Fast or Food: a Study on Cardiac FDG Preparation Effectiveness

A. Almeida, N. Gulliver, G. Vivian, A. Eccles, N. Mulholland, B. Corcoran; King's College Hospital NHS Foundation Trust, London, UNITED KINGDOM.

TP061

Evaluation on Artifacts by Bone Cement of PVP Performed Patients and Usefulness of CT Correction in SPECT/CT Examinations

J. Kim¹, H. Park², J. Lee³, H. Son¹, S. Park¹; ¹Seoul Medical Center, Seoul, KOREA, REPUBLIC OF, ²Shingu College, Seongnam-si, KOREA, REPUBLIC OF, ³Graduate School of Public Health, Yonsei University, Seoul, KOREA, REPUBLIC OF.

TP062

Whole body bone SPECT: aspects of methodology

K. Kukuts, I. Fordzyun, A. Forgács, S. Barna, I. Garai; Scanomed Ltd., Debrecen, HUNGARY.

TP063

Evaluation of 68Ge-68Ga Generator and Synthesis Module efficiency in the procedure of 68Ga-DOTATOC labelling

L. Pavanello, F. Sciume, M. Zuffante, D. Grigolato, E. Carmagnani, M. Ferdeghini; Nuclear Medicine AOUI, Verona, ITALY.

TP064

The devil is in the details.... Radioactive Waste disposal changes

C. Vroonland, M. Sonneborn, L. Janssen-Pinkse; Antonie van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS.

TP065

Static Myocardial Perfusion Imaging using denoised dynamic Rb-82 PET/CT scans

M. N. M. Petersen, C. M. Hoff, H. J. Harms, K. Bouchelouche, J. Sørensen, L. P. Tolbod; Dept. Nuclear Medicine & PET-Centre, Aarhus University Hospital, Aarhus N, DENMARK.

TP066

RubiShort: Reducing scan time in 82Rb heart scans to minimize movements artifacts

J. Madsen, K. J. Vraa, H. J. Harms, K. Bouchelouche, J. Frøkiær, J. Sørensen, L. P. Tolbod; Dept. Nuclear Medicine & PET-Centre, Aarhus University Hospital, Aarhus N, DENMARK.

TP067

Comparison of absolute myocardial blood flow with 13N-NH3 cardiac PET determined by different compartmental models and softwares

B. Olsson¹, S. Akil¹, F. Hedeer¹, H. Engblom¹, C. Hindorf²; ¹Clinical Physiology and Nuclear medicine, LUND, SWEDEN, ²Radiation Physics, LUND, SWEDEN.

TP068

Assessing left ventricular dysfunction by the use of three distinct molecular imaging techniques

J. Reis¹, L. Cunha¹, P. Costa¹, D. Neves², T. Oliveira², A. Ferrer-Antunes², M. Faria Joao², L. Metello¹; ¹Nuclear Medicine Department, ESTSP.IPP, Porto, PORTUGAL, ²Nuclear Medicine Department, DIATON SA, Leiria, PORTUGAL.

TP069

Strategies to reduce Radiation Dose from Myocardial Perfusion Imaging:

A. Ghilardi, G. Medolago, L. Pozzi, M. Caloiero, C. Bianchi, E. Iampietro, A. Bruno; Papa Giovanni XXIII, BERGAMO, ITALY.

TP070

Impact of attenuation and scatter corrections in the quantification of SPECT brain images

S. Chaves¹, T. S. Vieira¹, J. G. Pereira¹, F. Caramelo², N. C. Ferreira²; ¹Centro Hospitalar S. João, Porto, PORTUGAL, ²Instituto Biomédico de Investigação de Luz e Imagem (IBILI – FMUC), Coimbra, PORTUGAL.

TP071

Validation of a New Reference Values's Database for Semiquantification of 123I-FP-CIT SPECT scans in one Nuclear Medicine Department

M. Elias¹, M. Queiroga¹, D. Silva¹, J. Serrano², J. Madrid², E. Carolino¹, E. Sousa¹; ¹Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisbon, PORTUGAL, ²Nuclear Medicine Department, Hospital Infanta Cristina, Badajoz, Spain, Badajoz, SPAIN.

TP072

PET- CT Determinants of Achievement Experience

C. D. R. Oliveira¹, C. Pacheco¹, A. Grilo¹, L. Vieira¹, L. Vieira², D. Faria³, D. Faria⁴, J. C. A. Farto⁵, M. C. Vázquez⁵; ¹Escola Superior de Tecnologia da Saúde de Lisboa, Lisboa, PORTUGAL, ²Faculdade de Ciências da Universidade de Lisboa, Lisboa, PORTUGAL, ³Hospital Lusíadas do Porto, Porto, PORTUGAL, ⁴Faculdade de Engenharia da Universidade do Porto, Porto, PORTUGAL, ⁵Instituto Tecnológico de Serviços Sanitários, MD Anderson Cancer Center, Madrid, SPAIN.

TP073

Comparison of GFR estimation methods in chemotherapy Monitoring

V. Rangarajan, V. Kumar, N. Purandare, S. Shah, A. Agrawal, J. Bajpai; Tata Memorial centre, Mumbai, INDIA.

TP074

Therapy planning and dose prescription in radioiodine-131 therapy for hyperthyroidism using radioiodine-123 SPECT/CT imaging

K. Hanaoka, M. Hosono, M. Otsuka, Y. Asai, M. Okumura, K. Ishii, T. Murakami; Kinki University, Osaka Sakai-city, JAPAN.

TP075

Emerging role of Bremsstrahlung SPECT/CT imaging in yttrium-90 radiosynovectomy

A. Atabaki, R. Mansberg, R. Russo, S. Gunaratne; Concord Hospital, Sydney, NSW, AUSTRALIA.

TP076

Nuclear Medicine therapies applied to small animals

D. F. F. Ribeiro, F. Lucena; Escola Superior de Tecnologia da Saúde de Lisboa, Lisbon, PORTUGAL.

TP04

Tuesday, October 13, 2015

08:00 – 09:30

Technologist Poster Session 4

TP077

Comparative retrospective study of peptide receptor radionuclide therapy (PRRT) with Y-90-DOTATOC and Y-90-DOTATATE in neuroendocrine tumours (NET)

M. Marx, H. Plagge, C. Winkler, Y. Zhao, U. Lützen, M. Zuhayra; Universitätsklinikum Schleswig-Holstein, KIEL, GERMANY.

TP078

Development of a new quantification method of dopamine transporter density with 123I-ioflupane

S. Okumiya, A. Ofuji, S. Ito; Kumamoto University, Kumamoto, JAPAN.

TP079

To Manual Handle, or to NOT Manual Handle?

C. Vroonland, S. Baank, M. Stokkel; Antonie van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS.

TP080

Evaluation of CZT-SPECT system for nuclear cardiology: comparison with conventional Anger SPECT

T. Niimi¹, M. Sugimoto¹, M. Nanasato¹, H. Maeda²; ¹Nagoya Daini Red Cross Hospital, NAGOYA, JAPAN, ²Nagoya University, NAGOYA, JAPAN.

TP081

Post therapeutic 131I Scan Total Body after a successive therapy (WBS) in Patients (Pts) affected by metastases of thyroid cancer (DTC) and 18F-FDG PET/CT (PET): usefulness of PET for staging and evolution recurrence in Pts with elevated Thyroglobulin (Tg)

L. Bertolazzi, L. Di Ciolo, V. Barbetti, C. Cananzi, M. Gaffuri, E. Piccardo, C. Motta, G. Agnese, P. Moresco; Azienda Ospedaliera Santa Corona, PIETRA LIGURE (SV), ITALY.

TP082

One pot synthesis of [18F]labelled benzyl chloride for asymmetric nucleophilic synthesis of 6-[18F]fluoro-L-DOPA

V. Orlovskaja¹, O. Fedorova¹, E. Studentsov², A. Golovina², R. Krasikova¹; ¹N.P.Bechtereva Institute of Human Brain Russian Academy of Science, St.-Petersburg, RUSSIAN FEDERATION, ²Saint-Petersburg State Institute of Technology, St.-Petersburg, RUSSIAN FEDERATION.

TP083

Comparison of 2 Methods for Reduction of Infra-Cardiac Activity in Myocardial Perfusion Imaging

M. Schalken¹, I. Rutten - Vermeltfoort¹, J. de Jong¹, M. Brink-Wieringa²; ¹Institute Verbeeten, Tilburg, NETHERLANDS, ²Elisabeth-TweeSteden Ziekenhuis, Tilburg, NETHERLANDS.

TP084

DMSA scintigraphy: Do we really need to perform geometric mean assessment?

I. G. E. El Bez, H. Boutruigua, N. Bechir, K. Trabelsi, L. Zaabar, I. Yeddes, I. Meddeb, D. Ben Sellem, B. Ltaief, I. Slim, A. Mhiri, M. Ben Slimene; Institut Salah Azaiez, Tunis, TUNISIA.

TP085

The technologist role in 177Lu dosimetry for PRRT (Peptide Receptor Radionuclide Therapy)

E. Leoni, A. Filice, A. Palmieri, G. Ghiraldini, F. Fioroni, E. Grassi, S. Cola, A. Versari; ASMN, Reggio Emilia, ITALY.

TP086

18F-Fluoride PET for quantification of axial and peripheral lesions in adjuvant-induced arthritis in Lewis rats.

R. Ouichka¹, A. Derrien¹, C. Henrionnet¹, F. Maskali², G. Karcher², P. Gillet¹, D. Loeuille³, A. Pinzano¹; ¹University Of Lorraine, Vandoeuvre-Les-Nancy, FRANCE, ²Nancyclotep, Vandoeuvre-Les-Nancy, FRANCE, ³Departement Of Rheumatology, Hospital Of Brabois, Vandoeuvre-Les-Nancy, FRANCE.

TP087

Our experiences with reinjections for non-visualisation in sentinel lymph node procedures for penile cancer

G. A. Ebbens, B. Pouw, D. Hellingman, M. L. Donswijk, M. P. M. Stokkel; Antoni van Leeuwenhoek, Amsterdam, NETHERLANDS.

TP088

Prone versus supine breast F18-FDG PET acquisition in breast cancer

R. Sanchez-Jurado¹, J. Ferrer Rebolleda¹, M. Cózar Santiago¹, R. Sanz Llorens¹, J. Aguilar Barrios¹, E. Blanco Pérez¹, C. Fuster Diana²; ¹ERESA, Valencia, SPAIN, ²University General Hospital, Valencia, SPAIN.

TP089

The effectiveness of dopamine transporter volume estimated by C-11 PE-2I PET in diagnosing Parkinsonism- Novel parameter for quantifying the total amount of dopamine transporter-

S. Nagamachi¹, R. Nishii¹, Y. Mizutani¹, Y. Umemura², R. Ohkubo², H. Takashima³, T. Hirai¹; ¹Miyazaki University, Miyazaki, JAPAN, ²Fujimoto Hayasuzu Hospital, Miyakonojou, JAPAN, ³Kagoshima University, Kagoshima, JAPAN.

TP090

Simplified and reliable quality control analysis method of 18F-Fluorocholine for a small scale hot lab

H. Hassan¹, S. Abu Bakar², K. Che A. Halim², J. Idris², A. Nordin¹; ¹Universiti Putra Malaysia, Serdang, Selangor, MALAYSIA, ²National Cancer Institute, Putrajaya, MALAYSIA.

TP091

Histopathological correlation of 123-I Metaiodobenzylguanidine (MIBG) scintigraphy findings in pediatric patients with suspected neuroblastoma

S. M. Nieves Maldonado, J. Lopez Urdaneta, P. Fierro Alanis, S. Argibay Vazquez, I. Dominguez Prado, M. C. Pombo Passin, A. Ruibal Morell; Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, SPAIN.

TP092

Nodal Visualisation in Sentinel Node Imaging

A. Vaz; St Barts Hospital, London, UNITED KINGDOM.

TP093

Preliminary Study of Multicenter Nuclear Medicine Imaging Quality Assurance by ACR Phantom in Taiwan

C. Lo, Esq., P. Kao; Chnug-Shan University Hospital, Taichung, TAIWAN.

TP094

Influence of the application of post-filter, variation of the number of iterations and attenuation correction in the tomographic image quality.

A. A. Santos¹, A. F. Fernandes², H. R. Martins¹, E. Pereira³, L. Vieira⁴; ¹Escola Superior de Tecnologia da Saúde de Lisboa - IPL, Lisboa, PORTUGAL, ²Escola Superior de Tecnologia da Saúde de Lisboa - IPL, Lisboa, PORTUGAL, ³Hospital Particular de Almada / Escola Superior De Tecnologia Da Saúde de Lisboa - Instituto Politécnico de Lisboa, Lisboa, PORTUGAL, ⁴Área Científica de Medicina Nuclear, Escola Superior de Tecnologia da Saúde de Lisboa - IPL / Instituto de Biofísica e Engenharia Biomédica, Faculdade de Ciências da Universidade de Lisboa, Lisboa, PORTUGAL.

TP095

Reference Range in Blood-Pool and Liver SUV for 18F-FDG PET/CT

Y. Parlak, D. Goksoy, G. Gumuser, E. Bilgin; Celal Bayar University, MANISA, TURKEY.

TP096

Appropriate time interval of dynamic 201TI SPECT-MPI data acquisition for quantitative myocardial blood flow analysis on cardiac dedicated ultrafast SPECT camera

G. Ogushi, S. Kudo, R. Matsuda, S. Tomiguchi, S. Shiraishi, Y. Yamashita; Kumamoto University, Kumamoto, JAPAN.

TP097

Analysis and discussion of CT attenuation correction on apical muscular of in myocardial perfusion imaging

Y. Wang; Nuclear Medicine, Huashan Hospital, Fudan University, Shanghai, CHINA.

TP098

Investigation of Methods to Reduce Staff Whole Body Radiation Exposure in a PET-CT Department

L. Alves, E. Woods, A. Jacob, C. Abreu, S. Pereira, R. Cabral, J. John; King's College London and Guy's and St Thomas' NHS Foundation Trust, London, UNITED KINGDOM.

TP099

Occupational radiation exposure of nursing staff in PET facility in association with performance status of patients

M. Hosono, N. Takahara, Y. Yakushiji, K. Sakaguchi, Y. Yamada, C. Hosokawa, K. Ishii; Kinki University Faculty of Medicine, Osaka-Sayama, JAPAN.

TP100

Obtaining medical isotope ^{99m}Tc by extracting and chromatography.

A. Rogov¹, V. Skuridin¹, E. Stasyuk¹, E. Nestwrov¹, E. Ilina¹, V. Sadkin¹, V. Chernov², R. Zelchan³, L. Larionova¹; ¹National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION, ²FSBI "RI Cardiology" SB RAMS, Tomsk, Tomsk, RUSSIAN FEDERATION, ³Cancer Research Institute of Siberian Branch of the Russian Academy of Medical Sciences, Tomsk, Tomsk, RUSSIAN FEDERATION.

TP101

New system for production of reactor medical radionuclides tested with Lu-176

D. Seifert, M. Kropáček, M. Tomeš, J. Kučera, O. Lebeda; Nuclear Physics Institute of the CAS, v. v. i., Řež, CZECH REPUBLIC.

TP102

First Danish experiences of Radium-223 treatment to patients with prostate cancer and bone metastases. Is it safe for the staff?

A. K. Cortsen, A. K. Cortsen; Rigshospitalet, Copenhagen, DENMARK.

Sponsored Symposia

Sunday, October 11, 2015

Hall G2

13:00 – 14:30

▶ **GE Healthcare:**
**Diagnostic Confidence in Molecular Imaging through
Consistent Quantification Today & Tomorrow**

Chair: Peter Bartenstein, MD, PhD, LMU, Munich, Germany

Ultra low dose attenuation correction and SUV in SPECT/CT

Christian la Fougere, MD, PhD, Universitäts-Klinikum Tübingen, Germany

Toward real standardization in PET/CT: Results with new quantitative technologies

Frederic Courbon, PhD, IUCT-Oncopole, Toulouse, France

Imaging biomarkers for dementia – future outcomes

David Brooks, PhD, Aarhus University, Denmark

Clinical experience with PET/MR at UCSF

Spencer Behr, MD, PhD, University of California - San Francisco, United States

GE Healthcare

Sponsored by:



Sunday, October 11, 2015

Hall 6

13:00 – 14:30

▶ **Bayer HealthCare Pharmaceuticals:**
The Pivotal and Evolving Role of the Nuclear Medicine Specialist in mCRPC

Chair: Val Lewington, Guy's and St Thomas' NHS Foundation Trust, and King's College London, London, UK

Welcome & Introduction

Val Lewington, Guy's and St Thomas' NHS Foundation Trust, and King's College London, London, UK

Focus on the changing role of the nuclear medicine physician in mCRPC

Val Lewington, Guy's and St Thomas' NHS Foundation Trust, and King's College London, London, UK

Recent advances in the mCRPC treatment paradigm: a nuclear medicine perspective

Sten Nilsson, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

The key role of nuclear medicine in optimizing mCRPC patient outcomes: an interactive analysis

*Joe O'Sullivan, Centre for Cancer Research and Cell Biology,
Queen's University Belfast, and Northern Ireland Cancer Centre, Belfast, UK*

Concluding remarks and close

Val Lewington, Guy's and St Thomas' NHS Foundation Trust, and King's College London, London, UK

Sponsored by:



Bayer HealthCare

Sunday, October 11, 2015

Hall E

13:00 – 14:30



BTG:

TheraSphere in Personalised Medicine - The Achievable Goal

Chair: Dr. John Buscombe, Addenbrooke's Hospital, Cambridge, UK

Sponsored by:



Monday, October 12, 2015

Hall G2

13:00 – 14:30



Genzyme:

New Trends in the Management of Thyroid Cancer

Chair: Prof. Cumali Aktolun, TiroCenter Tiroid Merkezi, Istanbul, Turkey

Challenges in Initial Risk Stratification

Dr. Elske Quak, Centre François Baclesse, Caen, France

Practical Implications of Current Trends on Thyroid Ablative Treatment

Prof. Martha Hoffmann, Wiener Privat Clinic/Radiology Center, Vienna, Austria

Practical Implications of Current Trends on Thyroid Cancer Follow up

Dr. Ioannis Iakovou, General "Papageorgiou" Hospital of Thessaloniki, Greece

Sponsored by:



Monday, October 12, 2015

Hall 6

13:00 – 14:30



Sirtex:

SIRFLOX – A New Option for Colorectal Liver Metastases

Chair: Patrick Flamen, MD, PhD, Department of Nuclear Medicine, Institut Jules Bordet, Brussels, Belgium

Welcome & Introduction

Patrick Flamen, MD, PhD, Department of Nuclear Medicine, Institut Jules Bordet, Brussels, Belgium

SIRFLOX study and results

Prof. associé Niklaus Schaefer, MD, CHUV, centre hospitalier universitaire vaudois, Service de médecine nucléaire et imagerie moléculaire, Lausanne, Suisse

SIRFLOX dosimetry

Priv.-Doz. Dr. med. Hojjat Ahmadzadehfar, Therapiestation, Klinik für Nuklearmedizin, Bonn, Germany

SIRFLOX – implications for nuclear medicine and the multidisciplinary team

Prof. Dr. med. Peter Bartenstein, LMU Klinikum der Universität München, Campus Großhadern, Klinik und Poliklinik für Nuklearmedizin, München, Germany

Panel Discussion

Close

Sponsored by:



Monday, October 12, 2015

Hall E

13:00 – 14:30



Elli Lilly and Company:

Who Should be Considered for an Amyloid Scan?

Real World Experiences Partnering in a Dementia Multi-Disciplinary Team (MDT)

Introduction – to include opening thoughts on the clinical relevance of neuro-imaging in dementia / new horizons with amyloid

Simon Hughes, Consultant in Radiology and Nuclear Medicine, Nottingham University

Difficulties to diagnose AD – why do clinicians need scans? Why is it difficult?

What are the most appropriate patient types for scans?

Richard Perry, Consultant Neurologist & Hon Senior Lecturer, Imperial College NHS Trust, Charing Cross Hospital

Development of amyloid imaging – AMYViD being first.

Practicalities of scan – how do you report out / engage your referring physician?

Simon Hughes, Consultant in Radiology and Nuclear Medicine, Nottingham University

Experiences of MDT in first UK clinical practice

Richard Perry, Consultant Neurologist & Hon Senior Lecturer, Imperial College NHS Trust, Charing Cross Hospital

Q&A

Conclusion

Sponsored by:



Exhibitors (A – Z)

Booth No.

ABT Molecular Imaging, Inc.	247/248
ABX advanced biochemical compounds	173/188
ABX-CRO advanced pharmaceutical services	226 (Internet Café)
Acom Group 	149/150
Advanced Accelerator Applications International	144/148
Advanced Cyclotron Systems Inc.	103/104
Advion Ltd.	109
AG Medical / Dilon Diagnostics	142
Agfa HealthCare	135
Ai4R SAS / ISOTOP4LIFE	174/175/186/187
ALPES – Association of Imaging Producers and Equipment Suppliers	F22
ANZSNM – Australian and New Zealand Society of Nuclear Medicine	F09
AOFNMB – Asia Oceania Federation of Nuclear Medicine and Biology	F10
ARCCNM – Asian Regional Cooperative Council for Nuclear Medicine	F10
Atlanpole Biotherapies / ISOTOP4LIFE	174/175/186/187
Bayer HealthCare	179-182
Best Cyclotron Systems, Inc.	106
Biodex Medical Systems, Inc.	244
Blue Earth Diagnostics Ltd.	102
BNMS - British Nuclear Medicine Society	F20
Bruker BioSpin	245
BTG	139
BV Cyclotron VU / THE PAVILION	224
Cambridge Isotope Laboratories, Inc.	158
CANM – Canadian Association of Nuclear Medicine	F06
Casram SA	120
Center of Molecular Research Ltd.	105
Chelatec / ISOTOP4LIFE	174/175/186/187
CHEMATECH	157
Comecer Group	122/123/136/137
Comecer Group	124
Crystal Photonics GmbH	226c
CSNM – Chinese Society of Nuclear Medicine	F08
Cyclomedica Europe Ltd.	227c

Exhibitors (A – Z)

Booth No.

DDD-Diagnostic A/S	228
DGN – German Society of Nuclear Medicine	F03
DIAsource ImmunoAssays S.A.	113
DOSIsoft SA	161
E. V. Minerve	251
EANM – European Association of Nuclear Medicine	F01
EARL – EANM Research Ltd.	F02
ec2 Software Solutions	147
Eckert & Ziegler 	211-215
Eczacibasi-Monrol Nuclear Products Co. 	228
EITA - European Isotopes Transport Association	F11/12
EL.SE. SRL	246
Eli Lilly and Company	154
Epsilon Elektronik	228
Euratom Supply Agency/European Observatory on the Supply of Medical Radioisotopes	F21
Euromedical Instruments / THE PAVILION	224
GAEDE Medizinsysteme GmbH	110/111
GE Healthcare 	193-200
Genzyme Europe BV	162/167
GeSiM mbH	100
Hermes Medical Solutions AB 	208/218
Hidex Oy	114-117
Hoy Scandinavian / THE PAVILION	224
IAEA – International Atomic Energy Agency	F07
IASON GmbH	227b
IBA SA 	205/206/220/221
IDB Holland BV / THE PAVILION	224
Institute of Isotopes Co. Ltd.	225
Inter Medical Medizintechnik GmbH	226b
INVIA Medical Imaging Solutions	159/160
inviCRO LLC	164
IRE ELiT	178
ITD Isotope Technologies Dresden GmbH	226a
ITG Isotope Technologies Garching GmbH	152

EANM Corporate Member 

Exhibitors (A – Z)

Booth No.

JSC Isotope	233/234
JSNM – Japanese Society of Nuclear Medicine	F19
Keosys / ISOTOP4LIFE	174/175/186/187
Kromek Group PLC	107
LabLogic Systems Ltd.	114-117
Lerner Pax / ISOTOP4LIFE	174/175/186/187
Lynax s.r.o.	121
M&I Materials Ltd. / THE PAVILION	224
Mallinckrodt Pharmaceuticals 	223
MAP Medical Technologies Oy 	176/185
MecMurphil Srl	101
MED Nuklear-Medizintechnik Dresden GmbH / THE PAVILION	224
Medi-Radiopharma Co., Ltd.	153
Mediso Kft. 	225
Medisystem / ISOTOP4LIFE	174/175/186/187
MiE medical imaging electronics GmbH	226d
MILabs B.V.	229/230
MIM Software Inc.	168
Mirada Medical	254/255
MOLECUBES	249
MR Solutions Ltd.	225b-225k
NICESOFT	165/166
NRG Petten / THE PAVILION	224
NUKEM Isotopes GmbH	143
ORA SPRL	243
Pars Isotope Co.	231/232
PerkinElmer	118/119
Philips Healthcare 	189-192/201-204
PI Medical Diagnostic Equipment BV / THE PAVILION	224
Piramal Imaging	235-238
PMOD Technologies Ltd.	145/146
POLATOM	227a
Progenics Pharmaceuticals, Inc.	239
QC1 GmbH	163

Exhibitors (A – Z)

Booth No.

Rad4Med.be	177/183/184
RadioMedic Ltd.	240
Rapidscan Pharma Solutions Inc. / THE PAVILION	224
Raytest Isotopenmessgeräte GmbH	112
Rotem GmbH	128/131
Rotop Pharmaka GmbH	227a
Scintomics GmbH	140
SEDECAL	169/170
Sensire Ltd.	242
Siemens Healthcare GmbH 	222
Sirtex Medical Europe GmbH 	155/156/171/172
SNM India – Society of Nuclear Medicine India	F18
SNMMI – Society of Nuclear Medicine and Molecular Imaging	F04
Southern Scientific Ltd.	114-117
Spectrum Dynamics Medical Inc.	129/130
Springer	F05
SurgicEye GmbH / THE PAVILION	224
Synthra GmbH	126/127/132/133
Taiyo Nippon Sanso Corp.	108
Tema Sinergie S.p.A. 	209/210/216/217
Theraclion SA	252
Trasis SA	125/134
TriFoil Imaging	241
Triskem International / ISOTOP4LIFE	174/175/186/187
TSNM – Turkish Society of Nuclear Medicine	F14
Uniteko Co., Ltd	250
Urenco Nederland BV / THE PAVILION	224
VANDERWILT Techniques BV / THE PAVILION	224
Von Gahlen Nederland BV	141/151
Waters Corporation	253
WFNMB – World Federation of Nuclear Medicine and Biology	F09
Wisepress Ltd	F16

Exhibitors (sorted by booth number)

Booth No.

GeSiM mbH	100
MecMurphil Srl	101
Blue Earth Diagnostics Ltd.	102
Advanced Cyclotron Systems Inc.	103/104
Center of Molecular Research Ltd.	105
Best Cyclotron Systems, Inc.	106
Kromek Group PLC	107
Taiyo Nippon Sanso Corp.	108
Advion Ltd.	109
GAEDE Medizinsysteme GmbH	110/111
Raytest Isotopenmessgeräte GmbH	112
DIAsource ImmunoAssays S.A.	113
Hidex Oy	114-117
LabLogic Systems Ltd.	114-117
Southern Scientific Ltd.	114-117
PerkinElmer	118/119
Casram SA	120
Lynax s.r.o.	121
Comecer Group	122/123/136/137
Comecer Group	124
Trasis SA	125/134
Synthra GmbH	126/127/132/133
Rotem GmbH	128/131
Spectrum Dynamics Medical Inc.	129/130
Agfa HealthCare	135
BTG	139
Scintomics GmbH	140
Von Gahlen Nederland BV	141/151
AG Medical / Dilon Diagnostics	142
NUKEM Isotopes GmbH	143
Advanced Accelerator Applications International	144/148
PMOD Technologies Ltd.	145/146
ec2 Software Solutions	147
ACOM Group 	149/150

EANM Corporate Member 

Exhibitors (sorted by booth number)

Booth No.

ITG Isotope Technologies Garching GmbH	152
Medi-Radiopharma Co., Ltd.	153
Eli Lilly and Company	154
Sirtex Medical Europe GmbH CM	155/156/171/172
CHEMATECH	157
Cambridge Isotope Laboratories, Inc.	158
INVIA Medical Imaging Solutions	159/160
DOSIsoft SA	161
Genzyme Europe BV	162/167
QC1 GmbH	163
inviCRO LLC	164
NICESOFT	165/166
MIM Software Inc.	168
SEDECAL	169/170
ABX advanced biochemical compounds	173/188
Ai4R SAS / ISOTOP4LIFE	174/175/186/187
Atlanpole Biotherapies / ISOTOP4LIFE	174/175/186/187
Chelatec / ISOTOP4LIFE	174/175/186/187
Keosys / ISOTOP4LIFE	174/175/186/187
Lerner Pax / ISOTOP4LIFE	174/175/186/187
Medisystem / ISOTOP4LIFE	174/175/186/187
Triskem International / ISOTOP4LIFE	174/175/186/187
MAP Medical Technologies Oy CM	176/185
Rad4Med.be	177/183/184
IRE ELiT	178
Bayer HealthCare	179-182
Philips Healthcare CM	189-192/201-204
GE Healthcare CM	193-200
IBA SA CM	205/206/220/221
Hermes Medical Solutions AB CM	208/218
Tema Sinergie S.p.A. CM	209/210/216/217
Eckert & Ziegler CM	211-215
Siemens Healthcare GmbH CM	222
Mallinckrodt Pharmaceuticals CM	223

EANM Corporate Member **CM**

Exhibitors (sorted by booth number)

Booth No.

IDB Holland BV / THE PAVILION	224
BV Cyclotron VU / THE PAVILION	224
Euromedical Instruments / THE PAVILION	224
Hoy Scandinavian / THE PAVILION	224
M&I Materials Ltd. / THE PAVILION	224
MED Nuklear-Medizintechnik Dresden GmbH / THE PAVILION	224
NRG Petten / THE PAVILION	224
PI Medical Diagnostic Equipment BV / THE PAVILION	224
Rapidscan Pharma Solutions Inc. / THE PAVILION	224
SurgicEye GmbH / THE PAVILION	224
Urenco Nederland BV / THE PAVILION	224
VANDERWILT Techniques BV / THE PAVILION	224
Institute of Isotopes Co. Ltd.	225
Mediso Kft. 	225
MR Solutions Ltd.	225b-225k
ABX-CRO advanced pharmaceutical services	226 (Internet Café)
ITD Isotope Technologies Dresden GmbH	226a
Inter Medical Medizintechnik GmbH	226b
Crystal Photonics GmbH	226c
MiE medical imaging electronics GmbH	226d
POLATOM	227a
Rotop Pharmaka GmbH	227a
IASON GmbH	227b
Cyclomedica Europe Ltd.	227c
DDD-Diagnostic A/S	228
Eczacibasi-Monrol Nuclear Products Co. 	228
Epsilon Elektronik	228
MILabs B.V.	229/230
Pars Isotope Co.	231/232
JSC Isotope	233/234
Piramal Imaging	235-238
Progenics Pharmaceuticals, Inc.	239
RadioMedic Ltd.	240
TriFoil Imaging	241

Exhibitors (sorted by booth number)

Booth No.

Sensire Ltd.	242
ORA SPRL	243
Biodex Medical Systems, Inc.	244
Bruker BioSpin	245
EL.SE. SRL	246
ABT Molecular Imaging, Inc.	247/248
MOLECUBES	249
Uniteko Co., Ltd	250
E. V. Minerve	251
Theraclion SA	252
Waters Corporation	253
Mirada Medical	254/255
EANM – European Association of Nuclear Medicine	F01
EARL – EANM Research Ltd.	F02
DGN – German Society of Nuclear Medicine	F03
SNMMI – Society of Nuclear Medicine and Molecular Imaging	F04
Springer	F05
CANM – Canadian Association of Nuclear Medicine	F06
IAEA – International Atomic Energy Agency	F07
CSNM – Chinese Society of Nuclear Medicine	F08
ANZSNM – Australian and New Zealand Society of Nuclear Medicine/	F09
WFNMB – World Federation of Nuclear Medicine and Biology	F09
AOFNMB – Asia Oceania Federation of Nuclear Medicine and Biology	F10
ARCCNM – Asian Regional Cooperative Council for Nuclear Medicine	F10
EITA – European Isotopes Transport Association	F11/12
TSNM – Turkish Society of Nuclear Medicine	F14
Wisepress Ltd	F16
SNM India – Society of Nuclear Medicine India	F18
JSNM – Japanese Society of Nuclear Medicine	F19
BNMS – British Nuclear Medicine Society	F20
Euratom Supply Agency/European Observatory on the Supply of Medical Radioisotopes	F21
AIPES – Association of Imaging Producers and Equipment Suppliers	F22

Company Profiles

ABT Molecular Imaging, Inc.

Booth No. 247/248

3024 Topside Business Park
Louisville, TN 37777
Phone: (865)982-0098
Email: info@abt-mi.com
Web: www.abt-mi.com

ABT Molecular Imaging offers the BG-75 "Dose on Demand" Biomarker Generator, providing in-house access to PET bio-markers. The BG-75 System, comprised of a compact accelerator, integrated micro-chemistry, and automated quality control, provides efficient, single or batch dose production for clinical use. The complete system, including dose synthesis and quality control, can be housed in a 6 x 6 meter room adjacent to the PET/CT System.

The ABT Biomarker Generator provides global, cost effective access to FDG, NaF, and other advanced PET radioisotopes on-demand.

For more information visit us at www.abt-mi.com

ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH

Booth No. 173/188

Heinrich-Gläser-Str. 10 – 14
01454 Radeberg
Germany
phone: + 49 / 35 28 / 40 41 60; fax: + 49 / 35 28 / 40 41 65
e-mail: info@abx.de
internet: <http://www.abx.de>

ABX is the leading manufacturer of PET precursors. We offer:

- FDG chemicals
- Mannose Triflate (DMF), complete kits for all FDG modules
- nucleophilic as well as electrophilic F-DOPA precursors and complete kits
- FLT, F-Choline, F-MISO, FET, NaF precursors, reagents and hardware kits
- comprehensive range of "scientific" precursors for
- oncology such as Fluoroestradiol, Choline ... and
- neurology like Raclopride, Fallypride, PK11195, beta-CIT, PIB ...
- SPECT precursors, e. g. CuMIBI,
- PEPTIDES, e. g. PSMA and Somatostatins for Gallium-68 labelling,
- O-18 WATER

We are well experienced in GMP production and also do offer custom synthesis according to Q7 chapter 19 for clinical PET studies (APIs). Our laboratories and cleanrooms are GMP certified and meet pharmaceutical standards.

ABX CRO *advanced pharmaceutical services*

**Booth No. 226
(Internet Café)**

Forschungsgesellschaft m.b.H.
Blasewitzer Strasse 78-80, 01307 Dresden, Germany
Phone: +49 351 214 440, Fax: +49 351 214 4415
E-Mail: info@abx-cro.com, Website: www.abx-cro.com

ABX-CRO is a globally operating clinical research organization with a strong focus on pre-clinical and clinical molecular imaging and molecular radiotherapy.

Based on over 15 years of experience in diagnostic and therapeutic oncology, neurology and other disease areas, ABX-CRO provides you with unique opportunities to test your drug candidates in complex pre-clinical disease models, assessed quantitatively using molecular and functional imaging (PET, SPECT, CT, MRI). We translate pre-clinical results into First in Man studies and support you with design and execution of efficient late stage clinical trials, minimizing your costs and time to marketing authorization. ABX-CRO makes translational medicine a visible reality.

To facilitate your molecular radiotherapy development or daily clinical practice, we are presenting QDOSE, our integrated radiation dosimetry package. Individualized full body dosimetry can be completed in less than 30 minutes!

ABX-CRO services include:

- Preclinical proof-of-mechanism studies from mice to non-human primates (NHP)
- Toxicology studies from mice to NHP
- Imaging or dissection radiation safety dosimetry in rodents, pigs or NHP for human extrapolation
- Human radiation safety and efficacy dosimetry in diagnostic and therapeutic imaging using PET and SPECT radionuclides
- Pharmacological imaging (micro-dosing, receptor occupancy and dose finding PET & SPECT studies with custom-labelled small molecules or biologics)
- Tracer and drug development programmes including site selection, GMP manufacturing, radiopharmaceutical and regulatory support
- Realtime e-clinical data management (Clindex®)
- Dedicated Image Core Lab services for standard and advanced image analysis and quantitative molecular and multi-modality imaging from pre-clinical to global, multi-center phase I-IV studies

ABX-CRO, paving your way into the theranostics landscape

Acom Group

Booth No. 149/150

Address: Loc. Cavallino, scn – Montecosaro – 62010 – Macerata ITALY
Contact Name: Dr Gianluca Valentini
Phone: +39 (0)733 / 22 97 39, Fax: +39 (0)733 / 56 03 52
Mail: amministrazione@acompet.it, Web site: www.acompet.it

Acom SPA is one of the most interesting company in Europe which operates in the nuclear medicine field.

Acom's aim is to improve the quality of life in oncological, cardiovascular and neurological patients.

Since 1999 ACOM has carried out in research and in collaboration with several Institutes and Universities has developed a new innovative system for Radiopharmaceuticals production using Cooper-64 and Iodine- 124. Acom is considered a leader for production of Radiopharmaceuticals and is one and only company in Europe authorized for the isotope production.

Acom's general goals are:

- to develop machines and technologies to combating cancer and thanks to this continue evolution today we have modern therapies such as Proton Therapy (PT) and Boro Neutron Capture Therapy (BNCT)
- realize disposable microchip for synthesis of radiopharmaceuticals
- to get a whole laboratory-synthesis, purifications and analysis-in microchip
- to get better protection and safety operators
- to safe volume of liquids and so costs and time for production

For any further information please visit our stand.

ADVANCED ACCELERATOR APPLICATIONS

Booth No. 144/148

20 rue Diesel F-01630 Saint Genis Pouilly, France
Phone: +33 (0)4 50 99 30 70, Fax: +33 (0)4 50 99 30 71
Web site: www.adacap.com
Email: info@adacap.com

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicine diagnostic and therapeutic products.

AAA is a European leader in the production and commercialization of molecular nuclear diagnostic radiopharmaceuticals for PET and SPECT. These radiopharmaceuticals are used for diagnosis in clinical oncology, cardiology, neurology and for inflammatory/infectious diseases. Key products include GLUSCAN®, MIBITEC/Adamibi (myocardial perfusion SPECT imaging agent) and LEUKOKIT® (leukocytes separation and labelling kit); as well as IASOCHOLINE®, IASODOPA® and IASOFLU®, which are produced and commercialized under IASON license.

AAA has a strong pipeline led by novel key oncology molecular nuclear therapy product candidate Lutathera®. Lutathera® is currently in the last stages of a pivotal Phase III trial for the treatment of midgut neuroendocrine tumors in 51 clinical centers in Europe and the US (the NETTER-1 clinical study). Lutathera® belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT) which involves targeting carcinoid tumors with radiolabeled somatostatin analogue peptides. Lutathera® has orphan drug designation in both Europe and the United States and is currently available in nine European countries (Austria, Denmark, Estonia, Finland, Greece, Portugal, Spain, Switzerland and the UK) under compassionate use or named patient programs and in France under a Cohort Temporary Authorization of Use (ATU de Cohorte).

AAA currently has 16 production sites and over 350 employees in 11 countries in Europe, Israel and North America.

Advanced Cyclotron Systems, Inc.

Booth No. 103/104

#150 - 7280 River Road, Richmond BC, V6X 1X5, Canada
Phone: 1.877.270.1493 or 1.604.276.1493
E-mail: info@advancedcyclotron.com
Web: www.advancedcyclotron.com

Advanced Cyclotron Systems, Inc. (ACSI) is a world leader in the design and manufacturing of cyclotron systems. With over 25 years of experience and more than 50 cyclotron systems installed, ACSI can provide a wide range of equipment and services worldwide. ACSI cyclotrons are used for the commercial production and distribution of PET and SPECT nuclides by internationally recognized companies and leading universities and research facilities. ACSI cyclotrons are designed, manufactured, and assembled in Richmond, Canada.

ACSI cyclotrons have the highest proton beam current output of any cyclotrons on the market. All ACSI cyclotrons are variable energy, ranging from PET cyclotrons to medium and high energy cyclotrons (up to 30 MeV) for PET and SPECT isotope production.

The versatility, high beam current and exceptional quality of ACSI cyclotrons are the reasons why many of the world's most prestigious universities and research centres, as well as some of the most successful commercial radioisotope producers have chosen ACSI cyclotrons to meet their radioisotope production needs.

For more information, please visit www.advancedcyclotron.com

Advion Ltd.

Booth No. 109

AG Medical / Dilon Diagnostics

Booth No. 142

AG Medical – Parc Les Algorithmes – Homere Bldg.
Route de l'Orme – 91190 Saint Aubin – France.
Website: www.ag-medical.com
Email: contact@ag-medical.com

Dilon Diagnostics – 12050 Jefferson Ave
Newport News, VA 23606 – USA
Website: www.dilon.com
Email: info@dilon.com

AG Medical (AGM) activities are the development, commercial deployment and after-sales-service of innovative nuclear medicine systems. AG Medical is characterized by the strong expertise of its teams and partners.

AG Medical also markets and maintains gamma cameras throughout Europe on behalf of the US company Dilon Diagnostics which develops scintigraphy systems that are notably used for breast cancer detection.

AGM has created CoTI®, a brand new device for non-stop dosimetry in I-131 uptake and treatment. This system allows the follow-up of pharmacokinetics (PK) for patients undergoing Radionuclide Therapy during which they are placed in isolation rooms.

AG Medical's dosimetry systems target the quantification and characterization of RIT agent distribution in organs being treated. They help confirm:

- The targeted organ is correctly reached by the agent (image),
- The amount of radiation (dose) absorbed by the organ and tumor: a PK curve is traced and the amount of radiation is calculated (measurement of the area under the curve).

AG Medical is at the forefront of bringing personalized medicine to Metabolic Radio Therapy.

Agfa HealthCare

Booth No. 135

Septestraat 27, 2640 Mortsel, Belgium
Phone: +32 3 444 2111, Fax: +32 3 444 7094
Website: www.agfahealthcare.com

With over a century of diagnostic imaging experience and two decades of pioneering healthcare IT, Agfa HealthCare supports its customers as they evolve from analog to digital to an IT-driven enterprise. The common goal shared by Agfa HealthCare and its customers: to improve the quality and efficiency of care.

Agfa HealthCare works to achieve this goal by delivering affordable IT solutions and imaging systems, connecting each person involved in patient care through seamless integration.

Enterprise IT solutions

As a market leader in the fast-growing sector of enterprise-wide IT, Agfa HealthCare's IT solutions work across departments and disciplines. Integrating medical, nursing, administrative and business information, and streamlining workflows and operations, they allow care providers to increase their efficiency and effectiveness, resulting in improved quality of care, speed and cost-effectiveness.

Imaging systems

Agfa HealthCare's imaging systems are designed to bring vital information to medical professionals, wherever they are, within and beyond the healthcare enterprise. They capture, process and print diagnostic images from multiple sources and across a multitude of image-intensive specialties and departments, including radiology, cardiology, women's care and intensive care units.

Nuclear Medicine

With IMPAX for Nuclear Medicine, Agfa HealthCare offers clinicians a unique solution to fully integrate the Nuclear Medicine department's workflow and optimize the inter-departmental communications. Running on one workstation the solution supports the patient's entire exam flow, from arrival at the hospital, to the final distribution of nuclear medicine results, and includes specialized functionality to process, read and report all Nuclear Medicine, SPECT, PET, and multi-modality images.

Asia Oceania Federation of Nuclear Medicine and Biology

Booth No. F10 (Entrance Hall)

Asian Regional Cooperative Council for Nuclear Medicine

Booth No. F10 (Entrance Hall)

Association of Imaging Producers and Equipment Suppliers (AIPES)

Booth No. F22 (Entrance Hall)

Avenue Louise 65
B – 1050 Brussels, Belgium
Tel: +32 2 535 89 45
E-mail: www.admin@aipes-eeig.org
Website: www.aipes-eeig.org

AIPES (*Association of Imaging Producers & Equipment Suppliers*), is the European Industrial Association for Nuclear Medicine and Molecular Healthcare) that brings the major pharmaceutical laboratories in nuclear medicine together with the major producers of medical equipment for this area of medicine, both multinationals and local medium size companies.

Associating drugs using short-life radionuclides, that, once injected into the patient, enable 3D imaging, using state-of-the-art cameras, nuclear medicine tracks important pathologies such as cancer and heart or brain dysfunction.

The promotion and defence of the actors in this highly regulated discipline requires an integrated organization like AIPES. In addition to its role as provider of a forum for addressing specific radio-pharmaceutical issues and its role as an industrial partner to the European Association of Nuclear Medicine and any other European medical society that could help in the promotion of diagnostic imaging, AIPES has as its goal, to communicate to the public the medical potential and the latest technical developments in the field of nuclear medicine.

Australian and New Zealand Society of Nuclear Medicine (ANZSNM)

Booth No. F09 (Entrance Hall)

The Australian and New Zealand Society of Nuclear Medicine (ANZSNM) was founded in 1969 and is the major professional society representing those practising Nuclear Medicine in Australia and New Zealand. The Society includes Physicians, Physicists, Chemists, Radio-Pharmacists, Technologists, Nurses and others interested in the practice of Nuclear Medicine.

ANZSNM has close ties with other professional groups in Nuclear Medicine, most particularly, the Australasian Association of Nuclear Medicine Specialists (AANMS) which represents all practising medical doctors. The Society welcomes others such as Radiologists, Cardiologists and Oncologists to participate in the Society and be involved in this area of healthcare.

The Society holds regular educational and professional development activities in each of the State Branches and a yearly annual conference which addresses recent scientific and clinical advances in Nuclear Medicine. For Australian and New Zealand nuclear medicine technologists, ANZSNM is the major provider of professional development which all technologists must carry out in order to maintain their accreditation status.

In 2016 the ANZSNM annual conference will take place in Rotorua, New Zealand from April 22-25 – with the interesting theme of "Hot Science: eruption of isotopes". In 2018 the annual conference will be part of the WFNMB 2018 Congress, to be held at the Melbourne Convention and Exhibition Centre, Victoria, Australia from 20-24 April 2018.

Baggerman Farma Consult BV

Booth No. 224

Barrierweg 3 G
5622 CL Eindhoven
Phone: +31 40 2453611
Fax: +31 40 2374460

Baggerman Farma Consult is a consultancy serving the health-care industry with a staff of 9 highly – experienced consultants. We have offered services in both Regulatory Affairs and Quality Affairs since 1987. The company can now count (radio-)pharmaceutical companies, medical device manufacturers and healthcare organizations, both in the Netherlands and many other (non-)European countries, among its clientele.

Bayer HealthCare

Booth No. 179-182

Bayer Pharma AG
Muellerstr. 178, 13342 Berlin – Germany
Phone: +49 30 468 1111
Web: www.healthcare.bayer.com

SCIENCE FOR A BETTER LIFE – medical progress for the benefit of patients.

The Bayer Group is a global enterprise with core competencies of health care, agriculture and high tech materials. Bayer HealthCare is a subgroup of Bayer AG with annual sales of 20.0 billion (2014). Bayer Healthcare has a global workforce of 60,700 employees (Dec 31, 2014) and is represented in more than 100 countries.

Bayer HealthCare is among the world's foremost innovators in the field of pharmaceutical and medical products. The mission of the Bayer subgroup is to research, develop and manufacture market innovative products that improve health of people throughout the world.

Best Cyclotron Systems, Inc.

Booth No. 106

Main Office: 8765 Ash St., Unit 7, Vancouver, BC, V6P 6T3 Canada
US Office: 7643 Fullerton Road, Springfield, Virginia, 22153 USA
Phone: 604-681-3327 (Main), 703-752-2498 (US), 1- 866-909-4647 (Toll Free)
Website: <http://www.bestcyclotron.com/index.html> or <http://www.teambest.com>
Contact Person: Richard Johnson, General Manager (richard.johnson@teambest.com)
Contact Person: Vasile Sabaiduc, Accelerator Technology Engineering Manager (vasile@teambest.com)

TeamBest® through Best Cyclotron Systems, Inc. (BCSI), offers radioisotopes and production capabilities for nuclear medicine and radiotherapy with its range of cyclotron systems. TeamBest® offers 15 MeV, 25 MeV, 35 MeV, and 70 MeV cyclotron systems, allowing for tailoring to the specific needs of the end user. Our staff assists from the planning stage, detailed design, facility construction, daily production, maintenance, and emergency repair through the TeamBest® network. We provide solutions for PET-CT and molecular imaging radiopharmaceuticals with the same excellent customized care as demonstrated in our 34-year history of radiotherapy support.

In collaboration with the Istituto Nazionale di Fisica Nucleare (INFN), Best Cyclotron Systems, Inc. has recently completed installing a 70 MeV cyclotron at the Legnaro National Laboratories (LNL) in Italy. Our team is dedicated to ensure the best quality product and have been present and assisting with the installation, calibration, and testing of the new machine.

For more information, please visit us at <http://www.bestcyclotron.com/index.html> or <http://www.teambest.com>.

Biodex Medical Systems, Inc.

Booth No. 244

20 Ramsey Road, Shirley, NY 11967 USA

Ph: 631-924-9000, Fax: 631-924-9241

Contact: Adel J Holl

E-mail: info@biodex.com

Web: www.biodex.com/nuclearmedicine

Biodex Medical Systems, Inc. continues to support the nuclear medicine and molecular imaging community with high-quality, cost-effective devices and supplies. Dose calibrators, lung ventilation systems and accessories, Clear-Lead™ Mobile Barriers and Windows, PET products, syringe shields and the Atomlab™ 960 Thyroid Uptake System are among their extensive imaging solutions.

As part of their line of Dose Calibrators, Biodex offers the Atomlab™ 500Plus, a dose calibrator/wipe test counter combination unit that is a complete, cost-effective hot lab management system.

The Atomlab™ 960 Thyroid Uptake System features unique positioning LED for accurate thyroid centering – a first in Thyroid Uptake System design. A complete, mobile, self-contained Medical Spectrometer System, the Atomlab 960 is an advanced multi-purpose spectrum analysis instrument designed for diverse nuclear medicine applications. The optional DICOM software package integrates the Atomlab 960 with your hospital management system, streamlining workflow and improving communication. Upon installation, the program is completely integrated with the uptake software for seamless operation.

For over 60 years, Biodex has worked with one constant goal: to produce and support the finest products available. See what's new...stop by booth #244!

Blue Earth Diagnostics

Booth No. 102

Blue Earth Diagnostics (BED) is focused on the development and commercialisation of PET agents with a mission to transform the clinical management of cancer through development of new molecular imaging products. Our initial focus is on our first product, fluciclovine (18F) (aka FACBC), a PET agent we are investigating in prostate cancer and glioma.

The UK based Company was formed in 2014 following the licensing of key technology from GE Healthcare. BED is funded by Syncona Partners LLP, an independent subsidiary of the Wellcome Trust.

We hope to see as many of you as possible at the meeting. If you want to get in touch to arrange a time to talk please email: contact@blueearthDx.com

British Nuclear Medicine Society (BNMS) Booth No. F20 (Entrance Hall)

The Sir Colin Campbell Building,
Triumph Road, Nottingham, NG7 2TU, UK
Phone: +44(0)115 7484 504
Email: info@bnms.org.uk
Web: www.bnms.org.uk

The British Nuclear Medicine Society (BNMS) established in 1966 is the only independent UK forum devoted to all aspects of Nuclear Medicine. The BNMS is concerned with promoting the clinical benefits of nuclear medicine and supporting the clinical practice, education, research and development of nuclear medicine within the UK. Membership is open to those who have a substantial interest and involvement in the provision of nuclear medicine services in the UK and overseas.

The official journal of the Society is **Nuclear Medicine Communications**.

Officers of the Society: Dr Alp Notghi, President, Prof Sobhan Vinjamuri, President Elect, Mrs Jilly Croasdale, Honorary Treasurer, Dr Richard Graham, Honorary Secretary.

The BNMS Annual Spring Meeting 2016, Celebrating the 50th Anniversary of the Society, will be held at The ICC, Birmingham, UK on 17th – 19th April. At the BNMS booth, delegates can find:

- Information on BNMS membership
- Information about future meetings in the UK
- BNMS Brochures and Publications
- Answers to any other questions regarding the BNMS

Bruker BioSpin

Booth No. 245

Rudolf-Plank-Str. 23
76275 Ettlingen
Germany
Phone: +49 721/5161-6500
E-Mail: imaging@bruker.com
Web: www.bruker.com/preclinical-imaging

Offering the largest range of Preclinical Imaging systems, with an unmatched 9 in-vivo modalities, Bruker is committed to supporting the scientific community with high-end instruments dedicated to disease research, translational science and Molecular Imaging.

Benefitting from more than 5 decades of passionate innovation, Bruker customers enjoy a vast portfolio of possibility; from a single source they have endless opportunities for combining multiple modalities for seamless workflow and higher productivity. Our non-invasive in-vivo imaging modalities are designed to deliver greater scientific insight based on animal-centric solutions.

BTG

Booth No. 139

BV Cyclotron VU Booth No. 224

De Boelelaan 1081

1081 HV Amsterdam

The Netherlands

Phone: +31 20 44 491 23

E-mail: web@cyclotron.nl

Contact name: Maria Vosjan, Product Development Manager

BV Cyclotron VU (BVC) is founded in 1987 and located on the campus of the VU University Amsterdam, The Netherlands. We are a market-leading provider of radiopharmaceuticals and radionuclides used in imaging techniques such as SPECT and PET for medical diagnostics and research. We currently run three modern cyclotrons and several GMP-compliant production units for the production of our radiopharmaceuticals and GMP-grade radionuclides. Driven by our passion to create products that helps to improve patients' lives, our company is strongly committed to R&D. We count on our cooperation partners for the safe and reliable distribution of our products.

Our product portfolio consists of: [^{18}F]-FDG, Zirconium-89 [^{89}Zr], Iodine-124 [^{124}I], other ^{18}F -tracers like Fluoromethylcholine, Florbetaben, and [$^{81}\text{Rb}/^{81\text{m}}\text{Kr}$]-generators.

For more information, please visit www.cyclotron.nl

Cambridge Isotope Laboratories, Inc.

Booth No. 158

Address: 3 Highwood Dr, Tewkesbury, MA, 01876 USA

Contact Name: Maureen Duffy, Vice President of Sales and Marketing

Phone: 1.978.749.8000, Fax: 1.978.749.2768

E-mail: cilsales@isotope.com

Web: www.isotope.com

Cambridge Isotope Laboratories, Inc. (CIL) is one of the world's leading suppliers of ^{18}O water and the preferred supplier to premier FDG providers. In response to the increasing needs of the PET community, CIL has undertaken multiple expansions of its ^{18}O separation facility over the past few years. The combined synthetic expertise, cGMP experience and reputation for high-quality cGMP and non-cGMP nuclear medicine compounds and precursors allows CIL and its subsidiary, ABX Advanced Biochemicals, to offer complete PET chemistry solutions for the molecular imaging community. ABX is the leading supplier of PET precursors worldwide and also offers cGMP custom synthesis and development of labeling strategies for new tracers.

Canadian Association of Nuclear Medicine (CANM)

Booth No. F06 (Entrance Hall)

P.O. Box 4383, Station E
Ottawa, Ontario, Canada K1S 2N4
Telephone: 00-1-613-882-5097
canm@canm-acmn.ca
www.canm-acmn.ca

Please stop by the Canadian Association of Nuclear Medicine (CANM) booth for the latest information about the work of the Association and our bid to host the World Federation of Nuclear Medicine and Biology (WFNMB) Congress in Vancouver, Canada in 2022. We would very much appreciate your support for our bid.

Please come and visit us at booth # F06. You will find some information about the CANM, beautiful Vancouver and you will meet some very dynamic members of the Association. We are looking forward to meet you!

Bienvenue!

CASRAM SA

Booth No. 120

Via Cantonale Nr 31
CH-6805 Mezzovico Switzerland
Phone : +41 91 611 21 10
Email : info@casram.com

CASRAM SA is a specialist of tungsten based alloys. From powder metallurgy sintering techniques down to state of the art CNC machining and 3D inspection equipment, CASRAM SA offers a unique blend of capacities and know-hows to provide you with the perfect shielding or collimating components made out of highly dense, tungsten based DENS RAM® alloys. Thanks to decades of experience in the machining of more traditional materials such as stainless steel or aluminum, Casram can provide you with ready to use PET or SPECT transportation containers, syringe shieldings or any collimation subassembly requiring tungsten based protections combined with other mechanical components. From the production of 99Tc or F18 isotopes down to SPECT imagery systems, CASRAM will be your partner for any radiation protection issue.

For more information, please visit www.casram.com or contact us.

Center of Molecular Research Ltd

Booth No. 105

CheMatech

Booth No. 157

Faculté des Sciences Mirande
9 Avenue Alain Savary
21000 Dijon – France
Phone : +33 3 80 39 61 10
Fax : +33 3 80 39 61 17
Email : info@chematech-mdt.com
Website : www.chematech-mdt.com

CheMatech is a unique company in Europe specializing in the design and synthesis of bifunctional chelating agents such as DOTA, NOTA and NODAGA derivatives. These molecules are widely used for peptides or antibodies labelling especillay with 67/68Ga, 111In, 64/67Cu. CheMatech offers a wide range of functionalized and protected chelating agents from milligrams to kilograms scale. CheMatech also realizes custom syntheses of new macrocyclic compounds.

Chinese Society of Nuclear Medicine (CSNM)

Booth No. F08 (Entrance Hall)

Contact person: Yaming Li (President of CSNM)
Department of Nuclear Medicine
The First Hospital China Medical University, Shenyang, China
Email: ymli2001@163.com

Chinese Society of Nuclear Medicine (CSNM) is a branch of Chinese Medical Association. In May 1980, the first National Conference of Nuclear Medicine was held in Shijiazhuang, Hebei province, and CSNM was found. In August 2011, the 9th National Conference was held in Xian, Shanxi province, and the 9th national committee with 63 members was organized. In October 2014, the 10th National Conference was held in Beijing. CSNM consists of a standing committee, a secretary general, 11 subcommittees, 1 young professional committee and several task groups. The standing committee and secretary general are responsible for the daily running. CSNM has 3 presidents and 4 vice-presidents. The current president is Professor Yaming Li, professor and director of the Department of Nuclear Medicine, First Hospital of China Medical University, Shenyang, Liaoning Province.

CSNM devotes its great attention to nuclear medicine extend and application in China through academic promotion, professional training, government's adviser, international exchange and related collaboration with other domestic and international associations.

COMECER GROUP

Booth No. 122/123/136/137 & 124

Via Maestri del Lavoro 90, 48014 Castel Bolognese (RA) – Italy
Phone +39-0546-656375 Fax +39-0546-656353
Email: comecer@comecer.com Website: www.comecer.com

Comecer, founded in Castel Bolognese in the mid 1970's, is a world leader in protection technologies in the field of nuclear medicine, pharmaceutical isolation technology and nuclear power plant equipment. Comecer produces shielding systems and equipment for special applications, designed for large industrial groups and research organizations. We work for hospitals, universities and pharmaceutical companies on tailored projects for the production of isolators for the treatment of toxic substances to be kept in safety. For nuclear plant management, we produce equipment for the processing, deactivation and disposal of radioactive substances deriving from nuclear plants. From 2012 Comecer is became a Part of Comecer Group after the takeover of the companies Veenstra Instruments and Vitrae Czech.

At present, the Group employs 320 people and has achieved a turnover of 55 million Euro in 2014.

With two production sites in Castel Bolognese (Italy) and Joure (The Netherlands), locations at Hradec Kralove (Czech Republic), Miami (Usa), Mumbai (India) and Beijing (China), Comecer markets its products in over 100 countries worldwide through a direct sales network and through partnerships with some of the largest producers of nuclear medicine equipment.

Crystal Photonics GmbH

Booth No. 226c

Cyclopharm Ltd.

Bldg 75 Business & Technology Park
New Illawarra Road
Lucas Heights NSW 2234 Australia
POB 350 Menai Central NSW 2234
T +61 2 9541 0411
Web: www.cyclopharm.com.au

Cyclomedica Europe Ltd.

Booth No. 227c

Unit A5 Calmount Business
Park Ballymount
Dublin 12
Ireland
T +353 1405 0506
Web: www.lungspect.com

Contacts:

Björn Altmann, GM European Operations (BAltmann@Cyclomedica.com)

Ron van Loon, GM Distributor Management & Business Development (RvanLoon@Cyclomedica.com)

Cyclomedica is a radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes.

Cyclomedica is well-known for its Technegas Generator. For more than 30 years this is the leading technology for the diagnosis of lung-embolism with a valuable diagnostic contribution to the clinical management of patients suffering from COPD and Asthma.

The Technegas technology is a structured ultra-fine dispersion of radioactive labeled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnace for a few seconds at around 2.700 °C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a SPECT camera for the superior diagnosis of pulmonary emboli.

At the EANM 2015, Cyclomedica will launch the Multi-Use Radioisotope Concentrator (ULTRALUTE).

This device permits high specific activity elution thereby extending useable life of the Tc generator. It delivers super quality high specific eluate leading to optimal labelling efficiency.

DDD-Diagnostic A/S

Booth No. 228

Scion DTU, Dr. Neergaards Vej 5E, DK-2970 Hoersholm
(Greater Copenhagen Area), Denmark
Web-site: www.ddd-diagnostic.dk
Email: info@ddd-diagnostic.dk
Phone: +45 4576 8888
Contact: Jakob Mouridsen (jmo@ddd-diagnostic.dk)

DDD Diagnostic A/S, based in Denmark, manufactures a range of gamma cameras from organ specific cameras to general purpose cameras. Until 2012, DDD Diagnostic A/S was an OEM manufacturer involved in the design and development of some of the most successful gamma camera systems used in the world. DDD has been in the market since 1987, and presently there are more than 2500 DDD-manufactured gamma cameras installed worldwide.

Today, DDD Diagnostic A/S develops and markets the gamma camera systems described below under its own brand name. DDD cameras are durable and reliable with small footprint and superb image quality.

QuantumCam, a dual-head general purpose SPECT camera that can be used for routine nuclear medicine procedures and useful in hospitals with limited space

CorCam, a dedicated cardiac camera with 90-degree fixed detector design that allows performance of prone- and supine cardiac imaging

Solo, a small Field of View system for planar imaging that can be used for low and high energy isotopes

Solo Mobile, a mobile small Field of View gamma camera that runs on battery and easily can be moved around the various hospital departments

NephroCam, a large Field of View, single-detector camera for Radioisotope Renography

DDD-Diagnostic A/S is represented worldwide by a number of independent local companies with exclusive rights for marketing, selling and servicing the products developed and manufactured under DDD Diagnostic's own brand.

Please visit the DDD-Diagnostic Booth #228

DIAsource ImmunoAssays SA

Booth No. 113

Rue du Bosquet 2
1348 Louvain-La-Neuve, Belgium
Contact person : Peter Kerckx
Mobile : +32 475 57 76 86
Email: peter.kerckx@diasource.be
Website: www.diasource-diagnostics.com

DIAsource ImmunoAssays (formerly BioSource), an international diagnostic company based in Belgium, develops, manufactures and markets clinical diagnostic products in the field of endocrinology and infectious diseases.

We are committed to Vitamin D, including IVD and RUO Products. Our panel of assays allows the performant detection and measurement of various forms of Vitamin D metabolites: 25OH Vitamin D, 1,25(OH)₂ Vitamin D.

Constantly looking for new technologies and applications, we put our expertise in the development of new antibodies and assays to measure relevant biomarkers. We are strengthening our position in the diagnostic market by validating our ELISA assays on our open automate. These innovations mark a turning point for our company, and makes of DIAsource, already renowned in the RIA market, a complete diagnostic provider.

We also provide selected instrumentation: we offer Elisa reader, washer and shaker, along with open and closed fully automated Elisa platforms helping our customers to automate their tests.

Present in more than 75 countries through his professional network of 80 distributors, DIAsource also sells directly his own products and products from other selected manufacturers to IVD laboratories in some European countries.

DOSIsoft

Booth No. 161

E. V. Minerve

Booth No. 251

ec2 Software Solutions

Booth No. 147

Eckert & Ziegler Strahlen- und Medizintechnik AG

Booth No. 211-215

Robert-Rössle-Str. 10, 13125 Berlin, Germany
Phone: +49 (0)30 941084-0, Fax: +49 (0)30 941084-112
E-Mail: info@ezag.de, Website: www.ezag.com

Eckert & Ziegler Radiopharma – www.ezag.com/radiopharma

We offer comprehensive supply of radiochemicals, radiopharmaceuticals (Yttriga and FDG), the GalliaPharm – world's first pharmaceutical grade GMP $^{68}\text{Ge}/^{68}\text{Ga}$ generator, chemical grade $^{68}\text{Ge}/^{68}\text{Ga}$ Generators, a wide range of radiosynthesis technology (Modular-Lab), radiochromatography equipment and accessories, GMP compliant production facilities, clinical trial support with own cyclotron network in central Europe, in-house and at-site trainings and workshops as well as expertise for tracer development and validation.

Eckert & Ziegler Isotope Products – www.ezag.com

Eckert & Ziegler Isotope Products offers the world's largest range of sealed radiation sources for quality control in nuclear imaging, therapeutic radiology and biomedical applications. Products include Co-57 flood sources, OEM-quality replacement Ge-68 and Gd-153 sources for PET and SPECT applications, a complete range of multi-modal markers and other reference or calibration products necessary for today's nuclear medicine departments.

Eczacıbaşı-Monrol Nuclear Products

Booth No. 228

Address: Barbaros Mh. Sutcuolu Cad. No:72/A Atasehir-Istanbul /TURKEY
Phone: 0090-216-544-0-544 , Fax: 0090-216-472-41-48
E-mail: info@monrol.com , Website: www.monrol.com

Eczacıbaşı-Monrol Nuclear Products has been leading the development of the Turkish nuclear medicine market with the production of high-quality radiopharmaceuticals and is the first company in Turkey carrying out radioisotope research and development.

Eczacıbaşı-Monrol has 11 world-class production facilities, 7 in Turkey and 4 international (Bulgaria, Poland, Romania, Egypt) employing modern and environment-friendly technologies. The company also has been operating cyclotrons in Kuwait, United Arab Emirates and Libya. Both local and international facilities are utilized by a range of PET and SPECT products complying fully with all national and international regulations related to its manufacturing and service activities, including current GMP, to ensure that its products are of the highest quality. EU-GMP licence has been certified by Danish Medicine Authority in 2010.

In addition to organic growth in Turkey and internationally, Eczacıbaşı-Monrol has expanded its product portfolio through the acquisition of *Mol-Image* in 2011 and *Capintec* in 2012. *Mol-Image* is a high-tech R&D company involved in the development and manufacturing of new equipment for nuclear medicine, as well as chemicals, radiopharmaceuticals, and radiation protection products. Acquisition of *Capintec*, the world's best-known brand in the field of radiation measurement and protection products for nuclear medicine, represents a major step towards its target of global growth.

Edizioni Minerva Medica

Booth No. F13 (Entrance Hall)

Since 1909, Edizioni Minerva Medica publishes specialist journals and books which are distributed worldwide, among which The Quarterly Journal of Nuclear Medicine and Molecular. The journal is indexed by Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus and the latest Impact Factor available is 2.033.

EL.SE. S.r.l

Booth No. 246

Head Office, Via Carlo Goldoni, 18, 20090 Trezzano Sul Naviglio (MI), Italy

Branch Office, Via Nazionale, 83, 61029 Urbino (PU), Italy

Phone: +39 02 48409290, Fax +39 02 48409294

Email: info@el-se.com, Web: www.el-se.com

EL.SE. S.r.l. is an Italian company founded in 1990 having a long-term experience in production and supply of equipments and services for Medical and Industrial fields. In the Medical field EL.SE has dedicated divisions and skilled people for Nuclear Medicine, Radiotherapy, Radiodiagnostics and Radioprotection. The internal production is mainly focused on radiation detection and radioprotection systems, including portable monitors, area monitoring systems, radioactive waste detection systems, wastewater disposal systems, radiopharmaceutical manipulation systems, and shielding accessories.

Eli Lilly and Company

Booth No. 154

Lilly Corporate Center

Indianapolis, IN 46285

Phone: +1 317 276 3233

Fax: +1 317 276 6900

Web: www.lilly.com

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. Founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com.

ERS (Epsilon Radioactive Sources)

Booth No. 228

E-Mail: info@epsilonsources.com

Phone: +90-212-219 56 57

Fax: +90-212-219 42 88

19 Mayıs Mh. Dr. Şevket Bey Sk. No:5 Şişli-İstanbul-Türkiye

Contact: Pınar Okumuş – Sales Specialist (pinar.okumus@epsilonsources.com)

Web Site: <http://www.epsilonsources.com/>

Epsilon Electronics was established in 1993 to provide sales, marketing and technical service activities in the healthcare sector. The company has initiated its product research and development activities in 2008 and started to produce high quality Ge-68 reference and calibration sources for Siemens PET and PET-CT systems. As a result of increasing demand and local growth, in 2012, Epsilon Electronic's production facility has been moved to a new location with high production capacity in order to serve both local and international markets.

In 2013, ERS (Epsilon Radioactive Sources) brand name was established and Epsilon Electronics started producing nuclear medicine reference and calibration sources under ERS brand name.

The company has enriched its product range by adding Ge-68 reference and calibration sources for General Electric PET and PET-CT systems in 2013, and Na-22 reference and calibration sources for Philips PET and PET-CT systems, Co-57 flood sources, dose calibrator reference sources, spot markers, rod sources in 2014 respectively.

ERS serves high quality radioactive source products including PET and PET-CT sources, dose calibrator sources, flood sources, spot markers and rod sources for the nuclear medicine market in Europe, Middle East, South Africa and Far East countries through its specialized distributor network.

Epsilon Electronics continues to invest in research and development activities of ERS in order to develop new and customized sources and sustain international growth.

Euromedical Instruments SARL

Booth No. 224

3 rue de l'Arrivée,

Bur 1018bis – BP 241

75749 Paris Cedex 15, France

E-mail : sales@em-instruments.com

Phone : +33 - 983 62 63 17

Fax: +33 – 972 38 81 35

EUROMEDICAL Instruments sarl is the exclusive worldwide sales and marketing company of the Europrobe 3, a state-of-the-art surgical gamma probe manufactured by EUROAD SA, Strasbourg, France, one of the main manufacturers in the world for this type of equipment.

EURORAD SA, founded in 1982 (based in France) is a high technology company specialised in R&D, Production and Service of mono and polycrystalline semiconductors for radiation detectors.

The Europrobe 3 has been specifically designed to meet the needs of surgeons and nuclear medicine physicians. It enables to accurately detect areas of increased radionuclide uptake. Europrobe 3 is unsurpassed in its ability to detect a wide range of isotopes, and is ideal for use in a wide range of applications including, radioguided surgery, sentinel node detection, direct detection of labeled cells...

With a single Readout Module and a whole range of gamma probe options, Europrobe 3 fulfils all the needs of per-operative and percutaneous detection within 7 major clinical fields: Breast, Gynaecology, Dermatology, Head&Neck, Endocrinology, Urology and Nuclear medicine.

Europrobe systems are commercialised in 67 countries worldwide, with over 2000 systems sold since the launch of its first version in 1998, and endorsed by KOLs such as Institut Gustave Roussy, in France.

For more info, please visit www.em-instruments.com and www.eurorad.com

European Association of Nuclear Medicine

Booth No. F01 (Entrance Hall)

Address: Schmalzhofgasse 26, 1060 Vienna, Austria

Phone: +43 (0)1 890 44 27, Fax: +43 (0)1 890 44 27-9

E-mail: office@eanm.org, Website: www.eanm.org

At the EANM booth, congress attendees will:

- find information on the increasing eLearning opportunities
- find terminals to settle their membership payment or update their membership information
- find information on various educational programmes
- be offered EANM brochures and publications
- find answers to any questions/suggestions regarding EANM

EANM Research Ltd (EARL)

Booth No. F02 (Entrance Hall)

Address: Schmalzhofgasse 26, 1060 Vienna, Austria

Phone: +43 (0)1 890 44 27, Fax: +43 (0)1 890 44 27-9

E-mail: earl@eanm.org, Website: <http://earl.eanm.org>

EARL is a 100% subsidiary of the EANM, founded in 2006 in order to promote research in the field of nuclear medicine and molecular imaging. Its focus is on enhancing quality of nuclear medicine practice for the benefit of public health. EARLs activities are:

- EARL FDG-PET/CT Accreditation: providing a minimum standard of PET/CT scanner performance in order to harmonise the acquisition and interpretation of PET and PET/CT scans, which is essential in multicentre trials as well as in clinical practice. As of July 2013, 85 PET/CT sites in 15 countries are participating in the accreditation programme.
- EARL Taskforce EU grants: competing for EU research grants, positioning nuclear medicine within the EU research agenda
- European Initiative for PET as an Imaging Biomarker (EPIB)
- Facilitation of multicentre research projects

To learn more about EARL and the projects we are currently conducting, please visit the EARL booth.

European Isotopes Transport Association (EITA)

Booth No. F11/12 (Entrance Hall)

Maanstraat 17-19

B-2800 Mechelen

Website: info@eita.org

e-mail: www.eita.org

Contact Persons at EANM Congress:

Mr. Serge Goossens, Mrs. Ioanna Kokkineli, Mr. Arno Meinl

EITA is a nonprofit association which was founded in 1998 by European logistic companies trained licensed and highly sophisticated in transport and handling of radioactive isotopes. The member companies are specialized in road transport as well as in airfreight handling and transport of radioactive products, mainly used for medical purpose and/or research.

The key objectives of EITA:

- To perform all services in a high quality, that is appropriate to the demands of the producers as well as to those of the users and public. To underline this purpose EITA has created its own Quality Label.
- To guarantee that all transports and handling manipulations are done in consideration of the necessary level of safety and security, that is required for these products.
- To enable the members to present themselves to the relevant public.
- To hold up permanent contact to industry and competent authorities to be able to react immediately to all changes in market conditions as well as in legal standards.

Companies, which are working and licensed in transport, handling and storage of radioactive materials are welcome to become members of EITA.

European Observatory on the Supply of Medical Radioisotopes

Booth No. F21 (Entrance Hall)

Phone: +352-4301-32998

E-mail: Esa-AAE@ec.europa.eu

Web: http://ec.europa.eu/euratom/observatory_radioisotopes.html

The European Observatory on the supply of medical radioisotopes was established by the EU institutions and industry stakeholders in 2012 to help to implement a policy adopted by the Council of the EU, with a view to ensuring the continuity of supply of Mo-99/Tc-99m in the EU. The Observatory is aimed at bringing together all relevant information to the decision makers in the EU institutions and national governments in order to assist them in defining strategies as well as policies for their implementation. It has four general strategic objectives: to support a secure Mo-99/Tc-99m supply across the EU, ensure that the issue of Mo-99/Tc-99m supply is given high political visibility, encourage the creation of a sustainable economic structure of the supply chain and establish periodic reviews of the supply capacities and demand. To reach these objectives the Observatory, composed of members from the EU institutions and various industry stakeholders most of which are grouped within the Association of Imaging Producers & Equipment Suppliers (AIPES), functions through four Working Groups: 1-global reactor scheduling and Mo-99 supply monitoring, 2-full-cost recovery mechanisms, 3-management of high-enriched uranium (HEU) / low-enriched uranium (LEU) conversion and 4-capacity and infrastructure development.

GAEDE Medizinsysteme GmbH

Booth No. 110/111

Im Moos 6, D-79112 Freiburg, Germany
phone: +49-(0)7665-93457-0, fax: +49-(0)7665-93457-20
web: www.gaede.com, e-mail: info@gaede.de

For more than 25 years GAEDE has been known as the company in Germany that develops, produces and distributes its own nuclear medical systems and software.

The production center is located in Freiburg, in the south west of Germany.

Having regional marketing and service centers as well as distributing companies abroad, GAEDE provides service for many installed systems in Germany, Austria, France and Switzerland as well as in other countries.

With the development of new completely digital detector electronics and a dual detector SPECT system with variable detector positioning the production focus has now shifted to these systems, with interest from customers all over the world.

For certain camera systems of other manufacturers GAEDE offers the refurbishment of detectors and modernization of the nuclear medical processing system.

Range of Products

GKS-2000	Dual Head SPECT Camera	54 cm x 40 cm
GKS-2000 Cardiac	Dual Head Cardiac Camera	41 cm x 23 cm
GKS-1000	SPECT Camera	54 cm x 40 cm
GKS-400	Planar Camera	40 cm x 40 cm
GKS-300	Medium Field Camera	30 cm x 30 cm
GKS-200	Small Field Camera	23 cm x 23 cm
GKS-1	Thyroid Camera	18 cm x 18 cm

Field of View:

For more details please visit our website: www.gaede.com

GE Healthcare

Booth No. 193-200

Pollards Wood, Nightingales Lane
Chalfont, St Giles, Bucks HP8 4SP
United Kingdom
Phone: + 44 1494 544000
Website: www.gehealthcare.com

GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE Healthcare works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients.

Genzyme a Sanofi Company

Booth No. 162/167

Gooimeer 10
1411 DD Naarden
The Netherlands
Phone: +31 35 699 1200

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases, endocrinology and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. Genzyme's portfolio of transformative therapies represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world's largest pharmaceutical companies, with a shared commitment to improving the lives of patients.

For more information please visit www.genzyme.com

German Society of Nuclear Medicine (DGN e.V.)

Booth No. F03 (Entrance Hall)

Nikolaistraße 29
D-37073 Göttingen
Phone: 0551 488-57401
Email: office@nuklearmedizin.de
Web: www.nuklearmedizin.de

The German Society of Nuclear Medicine (DGN e.V.) is a scientific society which has its headquarter in Göttingen. Its goal is to promote nuclear medicine in basic and applied research in the fields of diagnostics, therapy, and radiation protection. This is done at national and increasingly at the international level.

The DGN e.V. has about 1,500 members, including not only specialists in nuclear medicine and doctors of other disciplines but also engineers and scientists. The president of the DGN e.V. is Prof. Dr. Jörg Kotzerke, Department of Nuclear Medicine, University Hospital Carl Gustav Carus in Dresden.

For more information, please visit www.nuklearmedizin.de

GeSiM mbH

Booth No. 100

HERMES MEDICAL SOLUTIONS – guiding personalised medicine

Booth No. 208/218

HERMES Medical Solutions, a global leader in medical imaging since 1976 with more than 26,000 users worldwide, offers robust, flexible and cost-effective solutions for analytics, visualization and reporting of all medical imaging data.

With vendor neutral connectivity, **HERMES** bridges the gap between existing or legacy equipment and the future expansion of your department. **HERMES** unique clinical expertise, experience and software portfolio offers you the flexibility to answer the ever changing clinical demands of today's healthcare landscape. **HERMES** opens the doorway for precise, personalised medicine, builds efficiency into routine practice and equips the physician with diagnostic confidence.

With more than 40 years of collective clinical expertise, **HERMES** is the gold standard for medical imaging, treatment and research solutions.

HERMES innovations shown at EANM 2015:

1. SUV SPECT

- Absolute Quantitative Reconstruction for any SPECT/CT Camera
- Report SPECT/CT with the same Accuracy and Confidence as PET/CT

2. New Tools for Fast and Robust Disease Detection and Tracking:

- Oncology -Tumor Finder Automatic Quantification
- Pulmonology – Lung Lobar Quantification and SPECT VQ
- Gastroenterology – Liver Function Quantification for Surgical Planning
- Neurology – Sophisticated Whole-Brain and Region-Based Quantification
- Cardiology – Myocardial Function and Coronary Artery Flow
- Endocrinology – Parathyroid, Thyroid Function, Adrenal Gland Tumor, Neuro-endocrine Tumor Finder

3. New Tools for Therapy Guiding, Planning and Tracking

- Surgery
- Biopsy
- Radiation therapy
- Chemotherapy
- Radionuclide therapy
- Immunotherapy
- Proton therapy

4. IT Solutions

- Vendor Neutral Global Archiving
- Integration of any Modality and Vendor
- Enterprise-Class Database & Hardware Solutions
- Complete Regulatory Compliance
- Secure Cloud

Hidex Oy

Booth No. 114-117

Mustionkatu 2, 20750 Turku, Finland

Phone: +358 8435570

Email: info@hidex.com

Web: www.hidex.com

Contact name: Ville Haaslahti, Managing Director

Hidex is a high technology company which develops and manufactures high performance analysis equipment for life science research, radiation measurement and nuclear medicine.

We specialize in Oxygen-15 radiowater system for blood flow studies. Hidex offers a complete range from system components, installation and consumables to image analysis software and study protocols.

Our automatic gamma counter is designed for the modern nuclear medicine laboratory. Compact size, touchscreen software, onboard analytical balance and protocols designed for PET quality control, GFR and more traditional nuclear medicine protocols makes life easy in the laboratory.

Hoy Scandinavian ApS

Booth No. 224

Jacob Mollersgade 4

9560 Hadsund, Denmark

Phone: +45-70271097

E-mail: ole.hoj@hoyscientific.dk

Hoy Scandinavian ApS develops and manufactures a product line called "Hoy Exclusive", which is an in-house product line, offering quality products for radiation protection in nuclear medicine, PET departments and radiochemistry. The product portfolio has a modern, timeless, Scandinavian design and offers maximum ergonomic comfort aligned to European standards. The product portfolio offers a wide range of products, such as syringe shielding, vial shields, waste containers etc. Furthermore, the company also offers shielding for PET, CT and PET/MR (non magnetic).

Over the last years the company has expanded its activities strongly in the field of development and sales of customized assignments such as desk/wall/waste coverings, customized lead glass (dimension and thickness), hot cells, alterations and moving of radiochemistry departments.

IASON GmbH

Booth No. 227b

Feldkirchner Strasse 4

A-8054 Graz-Seiersberg, Austria

Tel: +43(0)316/284 300 0

Fax: +43(0)316/284 300 4

Email: office@iason.eu, www.iason.eu

IASON is one of the leading European radiopharmaceutical companies, having established Europe's most advanced cyclotron-based pharmaceutical production centers where fluor-18 based radiopharmaceuticals for application in positron-emission-tomography are produced.

It is the mission of IASON to comply with pharmaceutical rules and to establish products on the basis of Marketing Authorizations.

Furthermore, IASON delivers special products for laboratory medicine markets. We specialize in the supply of selected parameters on RIA and ELISA, which are the basis for diagnostics in laboratory medicine. Development and production of our own products plays a central role at IASON, helping us to provide our costumers with state-of-the-art technology combined with extraordinary service.

IASON is specialist in laboratory reagents (ELISA, RIA) and the automatization of ELISA tests devices. Secondly IASON is one of the most experienced companies having established Europe's most up to date pharmaceutical production centers based on cyclotron nuclide production and market registered in EU-products of ^{18}F -PET-Tracers.

IBA / IBA Molecular

Booth No. 205/206/220/221

IBA RadioPharma Solutions

Chemin du cyclotron 3, 1348 Louvain-la-Neuve, Belgium

Phone : +32 10 47 58 58

E-mail : info-cyclo@iba-group.com

Web : www.iba-radiopharmaSolutions.com

Based on longstanding expertise, IBA RadioPharma Solutions supports hospitals and radiopharmaceutical distribution centers with their in-house radioisotopes production by providing them global solutions, from project design to the operation of their facility. In addition to high-quality technology production equipment, IBA has developed in-depth experience in setting up GMP radiopharmaceuticals production centers.

IBA Molecular

BP 32, 91192 Gif-sur-Yvette Cedex, France

Phone: +33 1 69 85 70 70

E-mail: genevieve.duhalgouet@ibamolecular.eu

Web : www.ibamolecular.eu

IBA Molecular has a unique worldwide expertise in daily production and distribution of SPECT and PET radiopharmaceuticals which are used in hospitals to accurately image or cure cancer, neurological and cardiac diseases.

IDB Holland bv/IDB Radiopharmacy bv

Booth No. 224

Weverstraat 17

5111 PV Baarle-Nassau

The Netherlands

Phone: +31 135079558

E-mail: sales@idb-holland.com

Website: www.idb-holland.com

Contact person: Philippe van Overeem

IDB Holland bv was founded in 1982 to promote the sales and use of radiopharmaceuticals, radio nuclides and various sealed and unsealed sources for the use in Nuclear Medicine Departments, Industry and Research Laboratories.

IDB Holland bv has the expertise and know-how that comes from over 30 years of experience in sales and shipping radioactive sources and radiopharmaceuticals to customers around the world.

IDB Holland and IDB Radiopharmacy continue to add new products to their portfolio, like LuMark® Lu-177 chloride. This production has received the license and Marketing Authorization from EMA, covering the EU, Norway, Iceland and Liechtenstein.

IDB started their GMP production of Lu-177 chloride in 2011 and sees a very strong growth in the weekly requested activities by customers worldwide. IDB currently has the ability to produce +/- 200 Ci on a weekly basis.

IDB Holland is one of the world's leading manufacturers of Lutetium 177. IDB Holland's brand name LuMark stands out as the premium brand of Lu-177. Quality in production and testing, weekly availability, shipment worldwide and a high service degree in

sales and after sales are the key components in IDB Holland's market approach. LuMark Lu 177 is by all standards the leading brand in Lutetium 177.

IDB Holland bv also provides custom made products for Industry, Research Laboratories and Nuclear Medicine Departments.

Institute of Isotopes Co. Ltd.

Booth No. 225

1121 Budapest, Konkoly-Thege M. u. 29-33. HUNGARY

Phone: +36 1 395 9081, +36 1 392 2577 Fax: +36 1 395 9247, +36 1 392 2575

E-mail: commerce@izotop.hu

Website: www.izotop.hu

Contact person: Mrs. Judit SZENDE, Director of Sales and Purchase

Institute of Isotopes Co. Ltd. is the major Hungarian centre for the research, development and production of radioisotopes and other products for a broad range of application areas, especially healthcare, research and industry. Hundreds of products manufactured in our facilities are distributed worldwide. All of IZOTOP's manufacturing and other activities operate in accordance with ISO 9001 and ISO 14001 quality assurance system. We have GMP Certificate for pharmaceutical preparation. Immunoassay Business Line has certified quality management system according to ISO 13485 standard for design, production and distribution of radioactive immunoassay kits.

Business units:

Radiopharmaceutical:

- Radiochemicals (^{125}I , ^{131}I)
- Radiopharmaceuticals:
 - ✓ **Thyrotop ^{131}I sodium iodide hard capsules**
 - ✓ **^{131}I sodium iodide sterile solution, drug substances**
 - ✓ **^{131}I -MIBG injection for therapy and for diagnostic use**
- Cold kits for $^{99\text{m}}\text{Tc}$ -labelling: DMSA, DTPA, PYRON, FYTON, MDP, TECHIDA, EC ^{153}Sm -MULTIBONE

Immunoassay:

- Immunoassay kits for diagnostic (thyroid, tumour markers, protein hormones etc.) and research purposes (RIA/IRMA and ELISA)
- **New research kits: rCorticosterone ELISA, rInsulin ELISA and rInsulin IRMA**

Synthesis:

- Organic compounds labelled with ^{14}C or ^3H radioisotopes
- Custom synthesis
- Radiochemical repurification service for ^{14}C , ^3H labelled compounds
- **Service for GMP syntheses** of ^{14}C labelled Active Pharmaceutical
- Ingredients (APIs or Drug Substances) will be **available from the end of 2015**

Radiation Technique:

- ^{192}Ir and ^{60}Co sealed industrial sources
- Laboratory and industrial gamma irradiators
- Hot cells, hot-cell lines
- Containers for transportation of radioactive material

Inter Medical Medizintechnik, GmbH

Booth No. 226b

Daimlerstraße 34-36, D-32312 Lubbecke, Germany
Phone: +49-5741-2359 0, Fax: +49-5741-2359-10
contact@IntMed.de
www.IntMed.de

The **Inter Medical Medizintechnik GmbH** Company is specialized in medicine software and hardware with the focal point in Nuclear Medicine technique.

Long time experience in product innovations, development and production of

Nuclear systems make **Inter Medical** to a competent partner for all technical requirements in the Nuclear Medicine and other medical departments.

Quality on each step of our business is our main goal, also expressed through the certifications for the European ISO standard given to Inter Medical.

Visit our booth to see how we can enhance your institute with our product portfolio of 1-2-3-n Head **Gamma Cameras**.

International Atomic Energy Agency (IAEA)

Booth No. F07 (Entrance Hall)

The IAEA is a worldwide focal point for cooperation in the nuclear field. Set up in 1957 as an independent intergovernmental, science and technology-based organization, the IAEA is known as the world's Atoms for Peace organization within the United Nations family. The Agency works together with over 160 Member States and multiple partners worldwide to promote the safe, secure and peaceful use of nuclear technologies and seeks "to accelerate and enlarge the contribution of atomic energy to peace, health and prosperity throughout the world", as stated in Article II of its statute.

The goal of the IAEA programme in Human Health is to enhance capabilities of Member States to address health needs related to the prevention, diagnosis and treatment of health problems through the application of radiation medicine.

The Nuclear Medicine and Diagnostic Imaging (NMDI) Section focuses in particular on enhancing Member States' capabilities by providing various areas of support and activities related to Education, Research, Services and Quality Management in order to develop the practice of NMDI and ultimately improve patient care. In addition, the NMDI Section keeps a close watch on technological trends and new clinical applications in order to continuously evaluate the needs of Member States in the fields of nuclear medicine and radiology as well as reinforcing capabilities of Member States to use existing and new therapeutic applications of radionuclides and interventional imaging procedures.

INVIA Medical Imaging Solutions

Booth No. 159/160

3025 Boardwalk Street, Suite 200
Ann Arbor, Michigan, 48108, USA
Phone: +1.734.205.1231
Email: info@inviasolutions.com
Website: www.inviasolutions.com

Based in Ann Arbor, Michigan, INVIA is dedicated to advancing patient care by developing state-of-the-art, non-invasive cardiology imaging software solutions. Physicians use our software, Corridor4DM, to accurately quantify, review, and report cardiac perfusion, function, and anatomy. 4DM originated at The University of Michigan, an institution devoted to excellence and leadership. Today, INVIA preserves close-ties to the University and remains dedicated to quality; committed to accuracy; and devoted to 4DM customers.

With a foundation of clinically validated algorithms, Corridor4DM provides advanced cardiovascular quantification and image displays in a single, configurable application which has been commercially available for more than 13 years. 4DM is integrated with all major scanner and PACS environments. 4DM is also available as stand-alone software that can be installed on Windows laptops and PCs.

Visit us at booth #159/160 to explore Corridor4DM v2015 and its latest features, including SPECT reconstruction with motion correction and advanced CFR quantification.

For more information, visit www.inviasolutions.com

inviCRO, LLC

Booth No. 164

27 Drydock Ave 7th Floor West
Boston, MA 02210, USA

inviCRO is an imaging informatics company offering full-service tissue-to-human imaging, analysis and data management services powered by their industry-leading software platforms. In addition to their multi-modality imaging facility in Boston's Innovation District, inviCRO's services are delivered through a network of validated partners highlighted by the co-managed cyclotron facility at the Translational Imaging Center (inviCRO, MPI Research, 3DI). inviCRO's image processing suite (VivoQuant™) and data management platform (iPACS®) are used by a majority of the top 25 pharmaceutical companies. The interdisciplinary team of inviCRO scientists have managed and/or processed 500+ imaging trials across a broad spectrum of therapeutic areas.

IRE ELiT

Booth No. 178

Isotope Technologies Dresden GmbH

Booth No. 226a

Rosendorfer Ring 42
01328 Dresden, Germany
info@isotope-td.de
www.isotope-td.de

The Isotope Technologies Dresden GmbH (ITD) is a worldwide operating company. Our target groups are the manufacturers and users of radioactive material in the form of sealed sources, radiochemical and radiopharmaceuticals.

The product spectrum of ITD includes the facilities and devices needed for the handling of radioactive material:

- Hot cells, mini-cells, dispensing cells,
- radiochemical hoods,
- places for aseptic works,
- shielding equipment and other specific solutions for radiation protection for α -, β - and γ -radiation,
- laboratory equipment like containers, safes, tables and lead shielding for table works,
- manipulators,
- facilities for the production of the radiochemicals and radiopharmaceuticals,

The team of ITD with experienced designers and technicians and the project management guarantee a high quality of the all products manufactured by ITD.

The spectrum of our service includes innovative design of the products according the specific requirements of the customer and the training of the staff of the customer.

Are you interested in our services in the field of radiation protection, radiochemistry and radiopharmaceuticals? We can jointly implement a customized solution for you.

ITG Isotope Technologies Garching GmbH

Booth No. 152

Lichtenbergstrasse 1
85748 Garching/Munich, Germany
Email: info@itg-garching.de
Web: www.itg-garching.de

ITM Isotopen Technologien München AG was founded in 2004 and is a privately held group of highly specialized radiopharmaceutical companies, dedicated to the development and proprietary production of novel radiopharmaceuticals and radiomedical devices. Its subsidiary ITG Isotope Technologies Garching GmbH was founded three years later, in 2007, in close collaboration with the Technical University Munich (TUM) and the new FRM-II Neutron Source. Today, more than 50 highly trained employees bring in their profound knowledge and experience of meanwhile more than a decade, focusing on next generation radioisotope sourcing and processing for the treatment of numerous serious oncological diseases. The ITM Group develops and commercializes its unique product portfolio and innovative pipeline also by reaching global strategic alliances with leading partners in the pharmaceutical industry. The Group's main goal is to improve the wellbeing and quality of life of patients by bringing a new generation of targeted radiopharmaceuticals for theranostics to the market.

Japanese Society of Nuclear Medicine (JSNM)

Booth No. F19 (Entrance Hall)

Since the establishment of the Japanese Society of Nuclear Medicine (JSNM) in 1964, the JSNM has kept on contributing worldwide collaborating with the SNMMI, the EANM, the WFNMB and the IAEA for the development of nuclear medicine. The JSNM also vigorously works together with the AOFNMB (Asia Oceania Federation of Nuclear Medicine and Biology), the ARCCNM (Asian Regional Cooperative Council for Nuclear Medicine) and the ANMB (Asian Nuclear Medicine Board) for the regional development. The JSNM provides young doctors and medical staffs of developing countries with training course, educational programs, and research opportunities at cities of Sapporo, Osaka, Gunma, Kanazawa, etc.

The JSNM is now in the bidding campaign for the 13th congress of the WFNMB (World Federation of Nuclear Medicine) in 2022. The vote will be taken at the occasion of the EANM meeting in 2016. Your support is sincerely appreciated.

JSC Isotope

Booth No. 233/234

KEOSYS / LEMER PAX / MEDISYSTEM /TRISKEM/ Ai4R / CHELATEC / ISOTOP4LIFE

Booth No. 174/175/186/187

LEMER PAX, MEDISYSTEM, KEOSYS, TRISKEM, Ai4R and CHELATEC, six companies from the Western France radiopharmaceutical hub ISOTOP4LIFE www.isotop4life.com present their fully-integrated offer:

LEMER PAX

www.lemerpax.com

Email: contact@lemerpax.com

Since 1970, the pioneer in radiation protection, has developed a wide range of shielding products for medical, radio pharmaceutical and industrial applications. Lemer Pax products are designed and manufactured in accordance with international quality standards (Iso 9001 & Iso 13485 labels).

In 2013, Lemer Pax, world leader in radiation protection, received the INPI Innovation Trophy from Fleur Pellerin, Delegate Minister for SMEs, Innovation and Digital Economy. The National Institute of Industrial Property, which issues patents, trademarks, designs and models, wanted to reward an innovative SME whose international success has beneficial economic effects throughout the entire region.

To meet the special needs of their clients all over the world and stay ahead innovation and ergonomics, Lemer Pax takes the opportunity of this EANM exhibition located in Hamburg, to present "Your Trusted Partner": "Posijet®" for the fractionation and injection of high energy radiopharmaceuticals; the automatic fractionation shielded hot cell: "EasyPet®"; "EasyPharma® Compact Vision+" which offers innovative solutions to ensure total visibility of the work area and comfort of use in a perfectly safe environment; the latest standards in manual injection: "Hook®" and "EasySqueeze®"; the ergonomic shielded carrier case designed to protect users and ensure transportation of contaminated syringes: "EasyBox®"; the new shielded waste bin: "EasyDrop®"; and its catalogues Lemer Pax whose one specially dedicated for its distributors.

Feel free to visit Lemer Pax and "drive" Posijet® on booths number 174/175/186/187.

KEOSYS

www.keosys.com

Email: contact@keosys.com

Founded in 2001, Keosys is now a global leader in medical imaging. Our innovative solutions are used every day in clinical routine and clinical trials. Thanks to its strong experience, Keosys relies on a deep technology and the expertise of a team of imaging scientists, physicians and software engineers. Our team endeavors to combine the latest scientific discoveries and technological progresses applied to a simple and ergonomic solution with practical applications for the diagnosis and management of exams.

Keosys provides full medical imaging services for clinical routine and multicenter clinical trials:

- **Keosys' Advanced Medical Imaging Software Suite:** composed by a PACS system for storage & diffusion and a solution dedicated to multimodal diagnosis for visualization and post-processing of medical images. This software suite is vendor neutral for radiology & nuclear medicine and can be deployed to workstation, application server and cloud computing like telemedicine platform.
- **Imagys:** the innovative web solution for medical imaging management (de-identification, download, centralization, online visualization and assessment software for nuclear medicine and radiology). Imagys is becoming the reference in the field of Clinical Trials Imaging Management System with a fully integrated workflow.

Headquartered in France, Keosys also has a subsidiary in Philadelphia (USA) and an office in Singapore thus enabling the company to equip more than 1500 reference centers all around the world.

MEDISYSTEM

www.medisystem.fr

Focused on nuclear medicine department, this CEA spin off with over 30 years' experience is a French radiation protection leader. Medisystem offers a broad portfolio of performance and ergonomic driven solution that provides effective quality and security to nuclear medical and industry applications.

This major actor provides innovative and customer adapted solutions in accordance with regulatory and legal compliance to enhance protection in nuclear activity. Strengthened by its experience and expertise in customer needs, Medisystem makes continuous improvements on product quality. The last hot cell generation, Medi 9000® provides better performance, comfort and functional design thanks to new technologies integration. It also focuses on ergonomics enhancing user friendly and reducing shielded products weight such as syringe carrier or injection shield ALARA®.

As a French leader Medisystem is competing in the export distribution market thanks to a range of distributors who trust their ergonomic and innovative solutions. Make sure to visit Medisystem at the EANM exhibition booth 175.

CHELATEC

www.chelatec.fr

CHELATEC is a private company founded in 2000, providing Research and Development services in Radiolabelling and Preclinical Studies. Areas of expertise include: Radiopharmaceuticals, Customized radiolabeling, Small animal studies, Binding assay, Immunoreactivity... Our three-years perspective: Business Units dedicated to the centralized manufacturing of Radiopharmaceuticals for clinical applications.

AI4R

www.ai4r.com

Ai4r is an innovative company which offers new-generation imaging solutions designed for leading-edge research. Ai4r has imagined and designed the Beaver range: a new generation of digital autoradiography system created with the main objective of renewing the experience of preclinical trials. Resulting from 10 years of research, the Beaver range uses an innovative technology that provides better image quality, shorter acquisition time, greater freedom of manipulation and improved user comfort.

TRISKEM

www.triskem-international.com

TrisKem International is a leading provider of extraction chromatographic resins and solutions for the separation of radioactive elements.

TrisKems main product line consists of a wide selection of different extraction chromatographic resins which allow the separation of radionuclides from various samples and matrices (irradiated targets, environmental, medical and bioassay as well as waste and decommissioning samples). Our products are standard technology in radiochemistry and they are used by international accredited laboratories and monitoring agencies such as the IAEA, AREVA, IRSN, CEA, BfS...).

Our resins are increasingly finding application in the production and quality control of radionuclides (such as Cu-64/7, Sc-44/7, Zr-89, alpha emitters...) for medical use, and are employed by leading radionuclide manufacturers worldwide.

TrisKem International places a strong focus on the development of new resins and separation methods to meet your separation needs. If you'd like to receive more detailed information, or if you'd like to discuss a specific separation problem please contact us under: contact@triskem.fr.

We look forward to meeting you at the EANM exhibition booth 139-141/144.

ISOTOP4LIFE

www.isotop4life.com

The first consortium dedicated to Radioisotopes applications, aiming at mutualisation and coordination of skills and actors concerned by the use of radioisotopes for health in order to overcome hurdles to innovation in the radiopharmaceutical domain. The main goal of ISOTOP4LIFE is to facilitate the use of Radiopharmaceuticals for diagnostic and therapeutic applications.

ISOTOP4LIFE is a one-stop offer providing R&D, technology transfer and industrialization capacities, with academic, clinical, industrial partners as well as a high-energy, high-intensity cyclotron ARRONAX. It is also a commercial coordination offer with an identified gate for Pharmaceutical industry.

ISOTOP4LIFE is leading the project of "LA FABRIQUE", a building dedicated to GMP production in order to welcome companies and academics for radiopharmaceuticals production and distribution at a National and European level. LA FABRIQUE should be operational by mid-2018 but is already open to future customers and for collaborations.

Kromek Group PLC

Booth No. 107

NETPark
Thomas Wright Way
Sedgefield, County Durham, TS21 3FD, UK
Tel: +44 (0) 1740 626060
Fax: +44 (0) 1740 626061
E-Mail: sales@kromek.com

Kromek has a portfolio of products for specific detection, identification and quantification of radioactive materials, which are differentiated by their sensitivity, high resolution, and small form factor allowing unprecedented flexibility in deployment. Applications include civil radiation detection, industrial process control, environmental monitoring and personal detection use for the public.

LabLogic Systems Limited

Booth No. 114/117

Paradigm House,
3 Melbourne Avenue,
Sheffield, England, UK, S10 2QJ
Phone: +44 114 266 7267
Fax: +44 114 266 3944
Contact: Elvir Zahirovic
E-mail: solutions@lablogic.com or ezahirovic@lablogic.com
Web: www.lablogic.com

LabLogic is a manufacturer of instruments and software to the Life Science, PET/Nuclear Medicine and Radiation Safety sectors. We have over 35 years' experience and expertise in providing solutions within highly regulated environments.

Within PET and Nuclear Medicine, LabLogic have a range of market leading products which can be found in some of the world's most prestigious laboratories. Our products include a range of QC equipment including innovative r-TLC, r-HPLC instruments and a single point of control radiochromatography software package – Laura for PET. The complete QC package is also available from LabLogic, just ask about the QC solution.

Furthermore Lablogic offer PETra, a purpose built PET LIMS system designed to improve efficiency and compliance. What's unique about PETra is that it directly captures data from all the equipment used. It acts as a central repository all information within PET production including batch record management, QMS, trending, inventory, instrument maintenance etc.

At EANM'15 LabLogic will be officially launching its Tracer QC to the European market. This radical new system for PET QC utilises an instrument smaller than a desktop PC to perform the essential QC tests with just single touch operation. For further information please contact us or visit booth #114/117 at the show.

Lynax s.r.o.

Booth No. 121

M&I Materials Limited

Booth No. 224

Hibernia Way, Trafford Park, Manchester, M32 0ZD, UK
Phone: +44 (0)161 864 5454
Email: stevejeffery@mimaterials.com
Website: www.mimaterials.com and www.wolfmet.com

M&I Materials Limited produces Wolfmet tungsten shielding for reducing radiation exposure in nuclear medicine. Applications include custom-built FDG transport containers, syringe and vial shields and collimators for gamma cameras and radiotherapy applications.

In addition, we can now offer MRI-compatible tungsten for use with PET/MRI and SPECT/MRI.

Benefits of using Wolfmet Tungsten Shielding:

- Easy to clean and keep sterile
- Lighter and smaller, but with the same protection as lead
- Clean to handle: no protective paint required
- Environmentally stable, non-toxic and inert (RoHS compliant)
- Lightweight and unbreakable, tungsten has a long life.

Wolfmet has a team of specialist engineers, who are always available to assist with design/development and production of series production or one off-items. Please visit our stand for more information today.

Mallinckrodt Pharmaceuticals

Booth No. 223

Westerduinweg 3
P.O. Box 3
1755 ZG PETTEN
The Netherlands
Phone: +31 224 56 7041
E-mail: jeannine.van.den.hout@mallinckrodt.com
Website: www.mallinckrodt.com

Mallinckrodt Pharmaceuticals is focused on safely providing patients with vital imaging products, including nuclear medicine agents and other specialty pharmaceutical products and active pharmaceutical ingredients, as we manage complexity and help to improve lives. Our products, including Octreoscan™ (Kit for the Preparation of Indium In-111 Pentetreotide) and Ultra-Technekow™ Tc-99m generators, offer significant benefits to nuclear medicine departments.

MAP Medical Technologies Oy

Booth No. 176/185

Address: Elementitie 27, 41160 Tikkakoski, Finland

Phone: +358 14 3345 211

Fax: +358 14 3753 611,

E-mail: jarmo.haukka@mapmedical.fi

Website: www.mapmedical.fi

MAP Medical Technologies Oy, founded in 1991, is an independent Finnish company. The mission of our company is to develop and manufacture radiopharmaceuticals to serve nuclear medicine professionals. Our highly devoted team and modern production facilities offer a unique setting for production of best quality pharmaceuticals.

We can provide to our customers and partners several products and services in the field of nuclear medicine.

- Our products: Generic radiopharmaceuticals like Mo-99/Tc-99m generator, P-32 solution for injection, iodine capsules for therapy and diagnosis, FDG, F-choline, NaF and other products.
- Investigational products: New diagnostic radiopharmaceuticals in close collaboration with our partners in prominent research institutions for such degenerative brain disorders like Parkinson's disease, Alzheimer's disease and others, which are related to activity and amount of neurotransmitters like dopamine, serotonin and others.
- Contract manufacturing of radiopharmaceuticals: We can offer our GMP facility and know how to other medical communities to test label and produce their own radiopharmaceutical compounds. We have possibility a small scale manufacturing set up for the customer needs. With this unique set up we can save both money and time of the customer for example in production for clinical trial batch.

We see that a close collaboration with nuclear medicine professionals and full commitment to R&D will make the difference. Together we can help people to achieve better medical care with easy, reliable and cost effective manner.

MecMurphil Srl

Booth No. 101

MED Nuklear-Medizintechnik Dresden GmbH

Booth No. 224

Dornblüthstraße 14A

01277 Dresden, Germany

Contact: Frank van Berlo

Phone: +49 (0)2594 9424-26,

Fax: +49 (0)2594 9424-45

E-mail: vanberlo@nuklear-medizintechnik.de

Website: www.nuklear-medizintechnik.de

MED Nuklear-Medizintechnik Dresden GmbH designs and manufactures laboratory counter and radiation monitoring systems for nuclear medicine, PET-centers and therapy stations:

- dose calibrators (also customer-specifically and OEM)
- uptake-counters, incorporation counters, well counters, waste water counters
- patient dose monitoring systems and area dose rate monitors
- contamination monitors with plastic-scintillation detectors (portable and hand-foot-clothing monitors)
- waste and release monitors
- radiation protection accessories

MEDI-RADIOPHARMA Co., Ltd.

Booth No. 153

2030 Érd, Szamos utca 10-12. Hungary

Phone: +36-23-521-261

Fax: +36-23-521-260

E-mail: order@mediradiopharma.hu

www.mediradiopharma.com

MEDI-RADIOPHARMA is a private company established for research, development and manufacturing a wide scale of generic in vivo kits for Tc-99m labelling as MIBI, HM-PAO, MAA, HSA nanocolloid, MDP, DMSA, Br-IDA and more others. Three medicinal products (Senti-Scint, Nano-Scan and Nano-Albumon kit) are available with different particle sizes allowing to select appropriate product for various sentinel studies. The products are registered in several countries all over the world and the kits are manufactured under cGMP conditions.

The company's mission is to provide high quality products to customers on reasonable price to support daily need of nuclear medicine world-wide.

The company also offers kits for rapid quality control of in-house labelled radio-pharmaceuticals (regardless the manufacturer): MediCheck Q.C. kit and Medi-Media Fill kit is for checking the aseptic manufacturing environment and personnel.

Active Pharmaceutical Ingredients are produced in recently opened new API GMP laboratory.

Medi-Radiopharma team welcomes you to visit on the booth No.: 153. for mutual exchanging opinions about conventional and new radiopharmaceuticals.

Mediso Imaging Systems

Booth No. 225

Mediso have been working in the field of nuclear and molecular medicine since 1990 with a profile of development, manufacturing, sales and servicing of multi-modality in-vivo imaging systems. The company offers complete solutions from hardware design to evaluation and quantification software, both for clinical patient care and high-level life science research into all animal models in between rodents and primates. Besides the unique triple-modality clinical SPECT-CT-PET hybrid AnyScan® system, Mediso launched the world's first pre-clinical integrated PET-MRI and SPECT-MRI cameras as members of the nanoScan® high-end small animal imager family, consisting of SPECT, PET, CT and MRI modalities. Mediso runs successfully two complex clinical diagnostic, research and educational centres and offers clinical and evaluation software trainings for the international medical community.

MiE medical imaging electronics GmbH

Booth No. 226d

Hauptstrasse 112, 23845 Seth, Germany

Tel.: +49 (0)4194 / 99 55-0, Fax: +49 (0)4194 / 99 55-55

E-Mail: mie@miegermany.de, website: www.miegermany.de

MiE has produced nuclear medicine systems (SPECT & PET) and accessories for the complete customer needs since 1981. During this time MiE have gained extensive experience in user specific requirements and have adapted it to the market and specific user needs.

Our workstation name SCINTRON is developed to close the gap between shortened development cycles and more durable mechanics and electronics. This computer is design to acquire, process and view studies from our manufactured, remanufactured and already installed Gamma Camera and PET systems.

The in-house research, development, electronic and mechanic department ensure that we provide always the latest technologies. This allows us to meet the specific needs of our customers. MiE guarantees min. 10 years spare part support on every system.

The MiE company is certified in accordance with EN ISO 9001:2008, EN ISO 13485:2012 + AC: 2012 and all our systems are with Annex II of Directive 93/42/EWG approved. Also, we are registered at the FDA - our systems are 510(k) approved since 1995. This extensive certification is the basis for the manufacture and distribution of medical products on the world market.

MILabs B.V.

Booth No. 229/230

MILabs provides high-end and hybrid molecular imaging systems (PET, SPECT, CT) for biomedical research and SPECT for clinical imaging. Today, MILabs systems have a proven quarter-mm SPECT and three-quarter mm PET resolution, and contribute worldwide to the development of new diagnostic solutions and therapies for diseases such as diabetes, cancer, cardiac and neurodegenerative diseases. MILabs' VECTor option enables simultaneous and ultra-high resolution PET and SPECT. The recently launched G-SPECT provides unsurpassed resolution and speed for clinical imaging. MILabs systems have in common that they provide unsurpassed resolution, and are extremely reliable, versatile, and user friendly. For more information see www.milabs.com.

MIM Software Inc.

Booth No. 168

25800 Science Park Drive - Suite 180

Cleveland, OH 44122 USA

Phone: +1 216.455.0600 or +1 866.421.2536 (U.S. toll free)

Website: www.mimsoftware.com

MIM Software Inc. provides vendor neutral solutions for multi-modality image review and fusion for radiology and nuclear medicine. These solutions are offered for computer workstations, as well as mobile and cloud-based platforms. MIM® products are sold globally to imaging centers, hospitals, specialty clinics, research organizations, and pharmaceutical companies.

In addition, the MIM® software suite includes specialty solutions, such as MIMneuro® with quantitative PET/SPECT analysis for detecting neurological disorders for the following tracers: FDG, Amyvid, NeuraCeq, HMPAO and DaTscan. MIMcardiac® provides functionality for CTCA/PET/SPECT fusions and stress-rest difference images. MIM Encore™ software, provides tools for therapy response, automated serial exam review, and automatic PET tumor edge detection. MIM SurePlan™ LiverY90 provides a comprehensive solution for Y90 microsphere therapy planning. Supporting all these programs are MIMpacs™, a diagnostic-quality display and archiving solution that is easily integrated for fast data transfer and automated study routing and retrieval. Professionals can collaborate securely and reliably by sharing images from anywhere, at any time with MIMcloud™ and Mobile MIM™, a remote diagnostic imaging tool for the iPad®, iPhone®, and iPod touch®. MIM Software also provides Maestro™ and Symphony™ as solutions for Radiation Oncology. All these solutions provide unmatched efficiency and save time while enhancing patient care.

Mirada Medical

Booth No. 254/255

MOLECUBES

Booth No. 249

MR SOLUTIONS Ltd.

Booth No. 225b-225k

Ashbourne House, Old Portsmouth Road
Guildford, Surrey, UK
Tel +44 (0) 1483 532146, Fax +44 (0) 1483 594084
e-mail information@mrsolutions.com
www.mrsolutions.com

MR SOLUTIONS (MRS) showcases its' expanding range of Cryogen free preclinical MR Imaging systems, providing the market with essential choices for innovation and quality.

The MRS range now includes MRS-3017 (3T - 17cm bore), MRS-3031 (3T - 31cm bore), MRS-7017 (7T - 17 cm bore) and MRS-7024 (7T – 24 cm bore). MR SOLUTIONS preclinical MRI systems are free of liquid helium making their installation very easy. All the MRS magnets are rampable allowing the user to vary their field strength. MRS systems are based on superconducting magnet delivering consistently high homogeneity.

MR SOLUTIONS accessorizes its MRI with additional modalities including a new generation of PET and SPECT scanners for simultaneous and sequential acquisition

The revolutionary development of MRS' cryogen free superconducting technology with negligible stray field make these systems an ideal addition to any laboratory, they can be installed side-by-side with any other existing modalities, such as: PET/CT, SPECT/CT, CT and Optical systems, allowing for space savings and cost effectiveness.

MR SOLUTIONS' 30 years of MRI, application, technology hardware & software innovation, make the company a key player in the preclinical multi-modality imaging research industry.

NICESOFT

Booth No. 165/166

NRG

Booth No. 224

Westerduinweg 3
1755 LE PETTEN
THE NETHERLANDS
Phone: +31(0) 224 568080
Mobile phone: +31(0)6 10 41 30 51
E-mail: e-mail@nrg.eu

NRG is an internationally-operating nuclear service-provider. It employs almost 500 expert and innovative employees and consultants of the highest calibre. The company works globally in nuclear consultancy & engineering and radioactive waste management.

NRG operates the High Flux Reactor and is European market leader in the production and supply of medical isotopes. In the Netherlands, NRG is the authority on integrated radiation protection.

The company works for and with partners in health care, industry, utilities, science and governments. NRG's core activities are spread across the units Irradiation Solutions, Consultancy & Services, and Research & Innovation.

Visit NRG at www.nrg.eu

NUKEM Isotopes GmbH

Booth No. 143

Industriestrasse 13
63755 Alzenau, GERMANY
phone: +49 (0) 6023 91 1611
fax +49 (0) 6023 91 1614
e-mail: juergen.laucht@nukemisotopes.de
website: www.nukem-isotopes.com

NUKEM Isotopes GmbH offers and markets Oxygen-18 for use in PET as well as Oxygen-17, Xenon-129 and Nitrogen-15 products for use in MRI

- **Oxygen-18** in the form of water is used to create tailored organochemical compounds labelled with the radio isotope ¹⁸F (for example, 2-fluoro-2-deoxy glucose [¹⁸FDG]). These are used for Positron Emission Tomography (PET), the latest cancer diagnostic technique
- **Oxygen-17** in the form of gas is a paradigm shifting contrast medium for NMR imaging and provides a breakthrough of Magnetic Resonance Imaging using standard clinical MRI scanners.
- **Oxygen-17** is available in the form of water with different enrichments up to 90 at.-%.
- **Xenon-129** is in the form of gas is one of the most promising non-invasive and non-radioactive gases for MRI-Imaging of the lung. Xe-129 is available as pure gas and gas mixture à 1% (or 3%) Xe-129, 10%, N₂, 89% (or 87%) He.
- **Nitrogen-15** in form of gas could have a potential as lung imaging agent especially in high field MRI scanners due to its similar behaviour to air. It is available in form of gas, Ammonium salts and Nitrates.

Our products are manufactured under conditions in compliance with cGMP requirements of 21 Code of Federal Regulations: Parts 210 and 211.

OPTIMIZED RADIOCHEMICAL APPLICATIONS (ORA) Booth No. 243

50B, Rue de la Gendarmerie, 5600, Philippeville, Belgium
Phone: +32 71 61 38 23
E-mail : info@oradiochem.eu
Website : www.oradiochem.eu and www.neptis-vsa.com
Contact Name: Vincent Tadino, Managing Director

ORA is a leading supplier of innovative radiochemistry solutions for the radiopharmaceutical industry. By offering more freedom and a better efficiency for the competitive deployment of new PET tracers to support the nuclear medicine community, ORA provides the range of NEPTIS® synthesizers, open and flexible platforms and is a certified ISO13485 Medical Devices company.

NEPTIS® is the combination of a multi-purposes PET synthesizer and an advanced software system meeting the latest GMP requirements. This combination offers the capability of creating an unlimited number of individualized radiotracer synthesis applications. NEPTIS® helps therefore in restoring freedom for researchers with an open platform, in providing developers with a robust tool from clinical trials to commercial production, and in offering producers a guarantee for reliable and repetitive performance.

The proven expertise of ORA coupled with the NEPTIS® platform and its extensive regulatory documentation support, makes it possible to meet new challenges of maximizing current PET tracers production and speeding up the development of new drugs to market.

PARS Isotope Co.

Booth No. 231/232

PerkinElmer

Booth No. 118/119

Philips Healthcare

Booth No. 189-192/201-204

Europe:

P.O. Box 10.000

5680 DA Best, The Netherlands

Web: <http://www.philips.co.uk/healthcare-solutions/advanced-molecular-imaging>

Email: healthcare@philips.com

Delivering innovation that matters to you

As a global leader in healthcare, Philips is guided by the understanding that there is a patient at the center of everything we do.

Addressing the world's most prevalent diseases starts with the clinician's ability to visualize clearly and accurately within the human body. Philips Advanced Molecular Imaging is advancing care by providing low dose molecular and hybrid imaging, enhanced lesion detectability, and the ability to share diagnostic information virtually anytime, anywhere. We have made a lasting impact by introducing innovations such as Time-of-Flight PET, hybrid SPECT/CT and whole body PET/MR. And today, we continue to bring solutions that enhance quantitative accuracy of molecular imaging and enable new clinical applications like the new Vereos PET/CT, the first digital PET/CT scanner.

We bring people and technology together in uniquely meaningful ways. By integrating imaging and information, we offer a new generation of tools to enhance the diagnosis, treatment and management of diseases.

PI Medical Diagnostic Equipment B.V.

Booth No. 224

PI Medical Diagnostic Equipment B.V.

Riperwalden 1

NL-8406 ET TIJNJE

Phone: +31 513 411892, Fax: +31 513 411061

E-mail: info@pi-medical.nl, Website: www.pi-medical.nl

PI Medical Diagnostic Equipment B.V. offers a wide range of instruments and accessories for the nuclear medicine market in the Netherlands. The product range includes FDG dispensing systems, dose calibrators, contamination and radiation monitors, PET and SPECT phantoms and other QA devices, radiation shielding materials, laser systems for PET/CT, patient positioning devices, etc.

PI Medical is specialized in gamma probes and hand-held gamma cameras for the sentinel node procedure, the company has been deeply involved in the development of these products.

PI Medical works closely together with a group of well established international producers of high-quality equipment in the NM field.

PIRAMAL IMAGING

Booth No. 235-238

Piramal Imaging, a division of Piramal Enterprises, Ltd., was formed in 2012 with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG. By developing novel PET tracers for molecular imaging, Piramal Imaging is focusing on a key field of modern medicine. Piramal Imaging strives to be a leader in the molecular imaging field by developing innovative products that improve early detection and characterization of chronic and life threatening diseases, leading to better therapeutic outcomes and improved quality of life.

PMOD Technologies Ltd.

Booth No. 145/146

Sumatrastrasse 25, CH-8006 Zürich, Switzerland

Phone: +41 44 350 46 00

E-mail: info@pmod.com

Website: www.pmod.com

As a spin-off of the Zurich PET research center, we provide a powerful suite of software tools for the quantitative processing of human and preclinical image data. Since 1996, the PMOD tools have evolved as the standard platform for kinetic modeling, both in the brain and the heart. A complete set of models is available for interactive time-activity curve modeling and parametric mapping, and custom solutions can be readily integrated. Additionally, comprehensive solutions are offered for all necessary pre-processing steps such as multi-modal image matching, brain image normalization, and volume-of-interest definition. Our further specialty is the pattern analysis of brain PET images. A general brain tool is available as well as a dedicated tool for the discrimination of the Alzheimer's dementia from FDG images. Moreover, a tool for automated PET image segmentation is available, and most recently, a tool for geometric models and simulation interfaces has been launched. Our software is being continually evolved in collaboration with major international research sites. Today, more than 400 sites with well over 1000 active users are relying on the platform-independent PMOD tools worldwide.

POLATOM

Booth No. 227a

POLATOM, Radioisotope Centre of National Centre for Nuclear Research

Address: 05-400 Otwock, Andrzej Soltan str. 7, Poland

Phone: +48 22 273 18 20, +48 22 273 18 40

Fax: +48 22 779 73 81

E-mail: export@polatom.pl

Website: www.polatom.pl

Contact: Krzysztof Banko – Commercial Director

Radioisotope Centre POLATOM is manufacturer and distributor of the radioisotopic products applied in medicine, research and development, industry and environment protection.

In the nuclear medicine field, POLATOM offers the radiopharmaceuticals for diagnosis and therapy: ^{131}I -Sodium iodide capsules, ^{131}I -solution for injection, ^{131}I -hippurate, ^{131}I -MIBG,

^{123}I -MIBG, ^{89}Sr -Strontium chloride, ^{32}P -Ortho-phosphate, kits for technetium labelling (Tektrotyd, PoltechMIBI, PoltechColloid, PoltechDMSA, PoltechDTPA, PoltechMBRIDA, PoltechMDP, PoltechRBC, Techimmuna), ^{99}Mo / $^{99\text{m}}\text{Tc}$ generators, ItraPol ^{90}Y and LutaPol ^{177}Lu for peptide labelling and accessories for nuclear medicine.

The medical production is certified for compliance with Good Manufacturing Practice (GMP).

Quality Assurance System established at the Radioisotope Centre POLATOM in the area of manufacturing, sales, dispatching and transport of radioactive materials is certified according to PN-EN ISO 9001:2009.

POLATOM is a world famous supplier of high quality radiopharmaceuticals and diagnostic kits for nuclear medicine and important manufacturer of radiochemical products for customers all over the world.

Progenics Pharmaceuticals, Inc.

Booth No. 239

QC1 GmbH

Booth No. 163

Diepenbrockstr. 18
48145 Münster, Germany
Phone: +49 251 132 600
Fax: +49 251 6749 8316
E-mail: mail@qc1.com
www.qc1.com

QC1 provides automated and miniaturized quality control systems for PET/MI tracers. For example an automated rapid QC system for 18F-FDG that follows major pharmacopoeias like USP and Pharm Eur.

With a small footprint of about 50 cm by 50 cm the system includes a GC, radio-HPLC, HPLC, radio-TLC, pH test, osmometer, Kryptofix® test, gamma spectrometer and half-life time determination. The modular analytical system can be adapted to almost any QC task and tracer, standard tracers as well as proprietary tracers. It can be easily extended with future modules for new upcoming tests.

Rad4Med.be

Booth No. 177/183/184

The Belgian Network for Radiation Applications in Healthcare

Web: www.rad4med.be, E-mail: contact@rad4med.be

Contact person at EANM and coordinator of the network:

Frank Deconinck (Frank.Deconinck@vub.ac.be)

Rad4Med.be is The Belgian Network for Radiation Applications in Healthcare; a structure aimed at promoting this sector and the Belgian expertise worldwide. By creating awareness about the use of radioactivity in healthcare and by improving its visibility, Rad4Med.be will provide potential international partners with a catalogue of competencies available in Belgium, and will show that all important issues related to the radiation applications can be addressed within the country. Indeed, the entire supply chain and therefore the complete value chain, from the production of the radionuclides, followed by the synthesis of radiopharmaceuticals up to their diagnostic and therapeutic applications, both pre-clinical and clinical, as well as the activities related to proton therapy, all are represented at the highest quality standards in Belgium.

Rad4Med.be gathers 60 members (companies, university laboratories, hospitals, research centers, training centers and associations). For more information and to download the Rad4Med.be full members' directory, please visit our website (www.rad4med.be).

Don't hesitate also to visit some of our members and highly innovative Belgian SMEs present this year on the Belgian booth (ANMI, Camel-IDS, Elysia, Medraysintell, M2Target and SCK•CEN) or on their own booth (IBA, IRE-ELiT, ORA-NEPTIS and Trasis).

RadioMedic Ltd.

Booth No. 240

Rapiscan Pharma Solutions EU Ltd

Booth No. 224

Regent's Place, 338 Euston Road, London, NW1 3BT, United Kingdom

Ph +44 (0) 2075448464, Fax +44 (0) 2075448401

Contact: Brent Blackburn

E-mail: info@rapiscanpharma.com,

Website: www.rapiscan-mpi.com, www.rapiscanpharma.com

Rapiscan Pharma Solutions (RPS) EU Ltd is committed to improving patient care by advancing novel technologies for the timely and efficient diagnosis of cardiovascular disease.

The company works with partners world-wide to market Rapiscan® (regadenoson). Rapiscan is the only infusion pump free, single unit dose pharmacological stress agent approved for use as a selective coronary vasodilator for radionuclide myocardial perfusion imaging (MPI) in adult patients unable to undergo adequate exercise stress. Rapiscan is a selective, low-affinity, and therefore short-acting, A_{2A} adenosine receptor agonist that can be administered as a 10-second intravenous injection without the need for weight-based dosing. Rapiscan causes a maximum increase in coronary artery blood flow in 30 seconds and for a duration long enough for myocardial extraction of the radiopharmaceutical.

To learn more about Rapiscan see www.rapiscan-mpi.com.

raytest Isotopenmessgeraete GmbH

Booth No. 112

Headquarter:

Benzstrasse 4

75339 Straubenhardt, Germany

Tel.: (+49) 07082 9255-0, Fax: (+49) 07082 9255-4444

E-mail: info@raytest.de

For more than 25 years raytest has developed and manufactured instruments for detection technology in the fields of radioactive isotopes and molecular imaging. Detection of radioactively labelled compounds is our core competence, having our roots in applications such as radioactive HPLC, TLC and GC. This allows us to plan and offer complete GMP and European Pharmacopeia compliant, turnkey solutions for the quality control of a huge variety of PET and SPECT tracers. Besides that, raytest has recently developed a range of synthesis instruments (SynChrom) for the automated synthesis of PET compounds via electrophilic and nucleophilic substitution. Additionally a cassette based synthesizer for the GMP compliant labelling of peptides with metal isotopes is available. The company has standardised instruments for routine compounds and customised systems for the development of new ligands for PET research.

The range of nuclear instruments offered by raytest extends from GLP compliant systems and software for pharmaceutical metabolic studies to *in-vivo* systems for small animal PET, SPECT and CT imaging. The raytest range of molecular imaging systems is encompassed by a series of instruments for applications ranging from gel documentation, chemiluminescence and multi-wavelength fluorescence to *in-vivo* small animal imaging.

Raytest is headquartered in Germany with a network of worldwide subsidiary companies and distributors. For more information about the company and its products, please visit our website at www.raytest.com.

Rotem GmbH

Booth No. 128/131

Address: Rathenaustraße 4, D-04179 Leipzig, Germany
Telephone: +49 341 2444925, Fax: +49 341 2444922
E-mail: rotemeur@hyox18.de
Contact: Julia Möbius
URL: www.rottem-medical.com

Rotem, a longtime world leader in consumables for PET imaging, supplies cyclotrons around the world with complete packages for radiotracer production. Our product line is centered on Oxygen-18 enriched water, plastic cassettes, precursors and full reagent kits for various synthesis modules. All products are cGMP certified by EU & PIC/S and are manufactured at our US FDA-inspected facility. Production is supported by Rotem's ISO 17025 certified analytical lab with a wide array of equipment and QC method development capabilities. Rotem's Mannose Triflate holds a certificate of suitability from the EDQM. Users enjoy full technical and regulatory support from our highly qualified staff.

Rotem is particularly active in the design and production of consumables for radiotracers under development. These projects benefit from our interdisciplinary expertise, the result of a longstanding and close cooperation with radiopharmacies worldwide. Rotem GmbH in Leipzig serves European customers, with local representatives in France, Belgium, the U.K. and Eire.

ROTOP Pharmaka GmbH

Booth No. 227a

Address: Bautzner Landstrasse 400, 01328 Dresden, Germany
Contact Name: Mr. Jens Junker (CEO)
Phone: +49 (0) 351 26310-0, Fax: +49 (0) 351 26310-313
E-mail: service@rotop-pharmaka.de, Website: www.rotop-pharmaka.de

ROTOP develops, produces and distributes pharmaceutical products for nuclear medicine.

Our core competences include kits for the preparation of Tc-99m radiodiagnostics. Agents as well as sterile lyophilisates and solutions are strictly produced according to regulations laid down in the Good Manufacturing Practice (GMP). A comprehensive quality control system guides and monitors internal production, contract manufacturing and distribution.

Our portfolio includes:

- A comprehensive range of ^{99m}Tc kits
- GMP-compliant production of agents for ^{99m}Tc kits
- Quality control sets for ^{99m}Tc radiopharmaceuticals
- Distribution of pharmaceuticals that are produced by subcontractors for ROTOP
- Distribution of merchandise
- Production of clinical investigational products

The ROTOP trademark stands for quality and dependability. We place great emphasis on staying in close contact with our clients and on providing optimal service for the best possible individual solutions.

We will be happy to welcome you at our booth #227a.

SCINTOMICS

Booth No. 140

Scintomics is a worldwide active private company providing synthesizers for research and GMP production of innovative and routine radiopharmaceuticals, quality control equipment and corresponding services.

SCINTOMICS GRP synthesizers combine functionality and performance with simplicity and GMP/cGMP-design into one modular and upgradable system. By exploiting ready-to-use GMP kits for cost-efficient fixed-tubing modules or disposable cassette modules, the GRP-series has been especially developed to meet the requirements of routine GMP production in a clinical environment. This makes the GRP synthesizer a unique and valuable tool to establish and maintain an optimum work flow and patient care in the daily routine. In addition, SCINTOMICS offers innovative peptide precursors for radiometallation, such as the first highly specific DOTA-conjugated CXCR4 ligand ^{68}Ga -Pentixafor, the PSMA inhibitors PSMA-HBED-CC and PSMA I&T for imaging and therapy, the first TRAPbased RGD imaging probe ^{68}Ga -Avebetrin, the sst-ligand HA-DOTATATE and other sst-ligands.

SEDECAL

Booth No. 169/170

Sensire Ltd.

Booth No. 242

Raivaajantie 1
80100 Joensuu
Finland
Phone: + 358 207 999 790
Email: info@sensire.fi
Web: www.sensire.fi

Full-service Quality Monitoring Solutions for Nuclear Medicine, Healthcare and Pharmaceutical Industries and for Property Monitoring

Quality Safeguarded by Sensire

Sensire Ltd, founded in 2001, is known for providing turnkey monitoring services to secure their customers' critical quality processes and day-to-day business. Today, Sensire's innovative monitoring solutions are widely used to safeguard quality in food, healthcare and pharmaceutical industries, as well as for monitoring industrial processes.

Our mission is to safeguard quality throughout our customers' value chains by delivering automated full-service monitoring solutions that are reliable, adaptable, and easy to use. We are driven to provide the best service experience and bring our customers the latest technological tools to help them ensure the highest level of quality, efficacy, and safety - whether it's about protecting patient wellbeing, minimizing food wastage, or improving environmental sustainability.

Siemens Healthcare GmbH

Booth No. 222

Siemens is a pioneer in the development of innovative molecular imaging technologies and biomarker solutions.

Our all-new Symbia™ family covers the full SPECT product portfolio from entry-level SPECT systems to advanced SPECT/CT products, all optimized for precise lesion detection and high image quality.

Leveraging our xSPECT¹ technology, Symbia Intevo™¹ provides accurate and reproducible quantification and multimodal reconstruction of bone studies.

Our Biograph mCT™ family, including Biograph mCT Flow™¹, is optimized for accurate PET imaging of all patients². Depending on the clinical need, the CT functionality can be adapted to today's high-end CT applications, including single-source, dual-energy imaging.

With Biograph mMR, Siemens has truly pioneered PET/MR. The latest edition combines advanced MR technology with stable PET architecture for precise PET/MR imaging.

syngo®.via³ and Symbia.net, our scalable clinical software solutions, offer comprehensive capabilities for processing and reading molecular imaging studies.

The Eclipse™ cyclotron, our radiochemistry modules, and Siemens' PETNET Solutions biomarker production and distribution network complete our comprehensive portfolio.

¹ Biograph mCT Flow, Symbia Intevo and xSPECT are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

² Patients up to 227 kg (500 lbs).

³ syngo.via can be used as a standalone device or together with a variety of syngo.via-based software options, which are medical devices in their own right. syngo.via and the syngo.via-based software options are not commercially available in all countries. Due to regulatory reasons its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

Sirtex Medical Europe GmbH

Booth No. 155/156/171/172

Joseph-Schumpeter-Allee 33
53227 Bonn, Germany
E-mail: info@sirtex-europe.com
Website: www.sirtex.com
Phone: + 49 (0) 228 18407 30
Fax: +49 (0) 228 18407 35

Sirtex is a global life-sciences company that is actively engaged in the field of liver-directed therapies for cancer patients. Our innovative technology, SIR-Spheres® microspheres (*Yttrium-90 resin beads*), is a medical device used in interventional oncology to deliver Selective Internal Radiation Therapy (SIRT), also known as radioembolisation, to the liver. This treatment for inoperable liver cancer delivers high doses of radiation directly to the site of tumours whilst conserving normal liver parenchyma.

SIR-Spheres® microspheres were approved in 2002 for use in the treatment of unresectable liver tumours within the European Union under a CE Mark and for the treatment of colorectal cancer liver metastases in combination with FUDR intra-arterial chemotherapy by the US Food & Drug Administration. SIR-Spheres® microspheres are presently used to treat a variety of unresectable liver metastases as well as in hepatocellular carcinoma at 250+ institutions in Europe and the Middle East, 380+ centres in North America and 100+ in Asia-Pacific region. To date, more than 40,000 treatments have been delivered world-wide.

* SIR-Spheres is a Registered Trademark of Sirtex SIR-Spheres Pty Ltd

Society of Nuclear Medicine and Molecular Imaging (SNMMI)

Booth No. F04 (Entrance Hall)

Address: 1850 Samuel Morse Drive, Reston, Virginia 20190, United States
Phone: 703-708-9000, Fax: 703-708-9020, E-mail: nwenzel-lamb@snmmi.org
Contact at SNMMI: Nikki Wenzel-Lamb, MBA
Website: www.snmmi.org

The Society of Nuclear Medicine and Molecular Imaging (SNMMI), headquartered in Reston, Va., is a nonprofit scientific and professional organization, founded in 1954, that promotes the science, technology and practical application of nuclear medicine and molecular imaging. SNMMI strives to be a leader in unifying, advancing and optimizing molecular imaging, with an ultimate goal of improving human health. With 18,000 members worldwide, SNMMI represents nuclear and molecular imaging professionals, all of whom are committed to the advancement of the field.

In addition to publishing journals, newsletters and books, the Society also sponsors international meetings and workshops designed to increase the competencies of nuclear medicine and molecular imaging practitioners and to promote new advances in the science of nuclear medicine, molecular imaging and therapy. The Society maintains an active advocacy program to promote and encourage research and the advancement of nuclear medicine science and produces a number of programs to help physicians and technologists remain current with the latest advances. The Society also sponsors education programs for consumers to help them understand nuclear medicine, molecular imaging and therapy and the constructive role it can play in both diagnostic and therapeutic therapies.

Society of Nuclear Medicine India (SNMI)

Booth No. F18
(Entrance Hall)

Southern Scientific Ltd.

Booth No. 114-117

Scientific House
The Henfield Business Park
Shoreham Road, HENFIELD
West Sussex, BN5 9SL
United Kingdom
Phone: +44 1273 497600, Fax: +44 1273 497626

Contact: Scott Baker
E-mail: info@southernscientific.co.uk, Web: www.southernscientific.co.uk

Southern Scientific manufacture a range of contamination monitors and probes for medical applications, including the Radhound, Handhound and Care Wise C-Trak Galaxy Gamma Probe.

The Radhound monitor is available with a wide range of probes suitable for detecting Alpha, Gamma and Beta isotopes.

The Radhound X has an integrated GM monitor with the facility to be set up for use with more than one probe to a maximum of six.

The Handhound is a voice-activated hand monitor. All measurements are logged against a user and are easily downloaded to a USB.

The Fidelis Secondary Standard Dose Calibrator provides unsurpassed accuracy and traceability to the national physical laboratory primary standard. This instrument can be used for calibrating other dose calibrators in satellite hospitals, thus ensuring an income. The Fidelis is used as the primary standard in some countries.

The company now manufactures the Care Wise C-Trak Galaxy Gamma Probe System. This system provides accurate and precise detection of gamma radiation and is used during sentinel node biopsies in breast, melanoma and other types of cancer.

Southern Scientific is also a distributor for Amici lung ventilation products, the Capintec range of products, Digirad single head and cardiac cameras, and the MiE range of general purpose gamma cameras.

We are looking for distributors in certain countries. If you interested, please visit us on our stand.

Spectrum Dynamics Medical

Booth No. 129/130

2478 Embarcadero Way Palo Alto, CA 94303, USA or
Rue de Lausanne 29 1110 Morges Switzerland
Phone: +1 650 800 7030 or +41 21 804 80 00
Fax: +1 925 237 8275 or +41 21 804 80 02
Email: info@spectrum-dynamics.com
Website: www.spectrum-dynamics.com

Spectrum Dynamics Medical, a Biosensors company, revolutionized the practice of nuclear cardiology with the 1st clinical & commercially available CZT imaging scanner.

The D-SPECT® and D-SPECT-L™ nuclear cardiology imaging systems dramatically enhances image quality, improves workflow, allows the ability to reduce radiation exposure by implementing unique ultra low dose protocols and provides the platform for upcoming advanced imaging protocols.

Springer

Booth No. F05 (Entrance Hall)

SurgicEye GmbH Booth No. 224
Friedenstr. 18A
81671 Muenchen, Germany
Phone: +49 89 54 99 89 001, Email: info@surgiceye.com
Website: www.surgiceye.com

SurgicEye GmbH is a leading solution provider for nuclear medicine solutions beyond images. SurgicEye is engineering innovative solutions to expand the use of nuclear medicine images from pure diagnosis to guided interventions and radio-guided surgery. With the declipse®SPECT Suite and the hybrid SPECT ultrasound imaging, SurgicEye enables increased quality during needle guidance and during surgery. Application domains are in tumor imaging for non-surgical sentinel lymph node mapping and biopsy, thyroid cancer, parathyroid detection, and a larger range of research applications in radio-guided surgery.

Synthra GmbH

Booth No. 126/127/132/133

Albert-Einstein-Ring 21, Hamburg, D-22761 Germany
CEO: Dr. Bruno Nebeling
Phone: +49 (0)40 88167437-0
Fax: +49 (0)40 8816743728
Mail: info@synthra.com; Web: www.synthra.com

Synthra is not alone on the radiosynthesizer market for F-18, Ga-68 and C-11, but we are since many years sole in commanding C-11 modules for clinical and research productions. In this complex field of Carbon 11 we have for sure the longest experience of all what is definitely visible in the construction of each of our products. There is no tracer that can't be produced by them.

Within the last 2 years Synthra has increased sales of modules tremendously for its proven technology which offers the highest degree of user flexibility in order to develop and design own routine and research tracers.

Synthra Users all over the world take good advantage of the fact that the Synthra modules hardly need any maintenance to work smoothly.

In 2015 Synthra has built-up a User's Group in which all users shall learn from the experience of the others. By the opportunity of EANM in Hamburg we will have our first User Group Meeting to install a Synthra Knowledge Network.

In our Synthra Users Group broad expertise, technology and a wide product range will be bundled to a strong Synthra Network sharing knowledge by multiplying.

TAIYO NIPPON SANSO CORPORATION

Booth No. 108

TAIYO NIPPON SANSO, established in 1910, is a leading global industrial gas manufacturer. We developed the most energy efficient Oxygen-¹⁸O separation process utilizing our cryogenic air separation and ultra-clean technology. Since 2004, we have been supplying more than 100kg of Water-¹⁸O annually to the world PET market. To meet the growing demand we completed our second plant with capacity of 200kg/year in November, 2013 and the third plant with capacity of 300kg in March 2015 by using state-of-the art separation technology.

The largest capacity of 600kg/year with these three independent plants will enable us to secure the stable supply of the highest and consistent quality of Water-¹⁸O.

Thereby, we continue to contribute to the advancement of the PET industry, securing the stable supply of the highest quality Water-¹⁸O.

Tema Sinergie, S.p.A

Booth No. 209/210/216/217

Via Malpighi, 120 – 48018 Faenza RA ITALY
Ph: +39 0546 622 663, Fax +39 0546 621 640
E-mail tema@temasinergie.com Website www.temasinergie.com

Tema Sinergie is a dynamic and innovative company that designs, produces and installs solutions and systems suitable for PET Cyclotron, Nuclear Medicine, Radiotherapy, Radiodiagnostics, Industrial and Metrology applications; and works with Hospitals, Research Laboratories & Institutes, Universities and Industrial Companies that work in fields requiring the control of ionizing radiation. For over twenty-five years, **Tema Sinergie** has improved the design and production of complete systems for the handling of Radiopharmaceuticals, to meet the highest standards for GMP and radioprotection safety levels, while improving the work quality of all who are involved in Radiochemistry & Radiopharmaceuticals R & D and Nuclear Medicine.

Tema Sinergie will be showing several kinds of equipments among which you will find some of its flagship products such as Karl100, the smallest and safest dose administration system; AGLTS, the most advanced GMP compliant glove integrity testing system for isolators and RABs; and ENVIRO, a complete real time monitoring system for the detection and measurement of environmental radiation, air contamination, temperature, humidity and pressure.

THERACLION

Booth No. 252

102, rue Etienne Dolet
92240 MALAKOFF France
Phone: +33 1 55 48 90 70
Email : contact@theraclion.com
Website : www.theraclion.com

Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). We offer an innovative echotherapy solution that combines HIFU therapy with ultrasound as a system for locating target areas for the non-invasive treatment of benign tumours. Theraclion is currently the only company in the industry offering a completely non-invasive treatment for breast fibroadenomas and benign thyroid nodules. This solution is a genuine alternative to surgery and to minimally-invasive techniques.

TRASIS S.A.

Booth No. 125/134

Rue Gilles Magnée 90 - 4430 Ans - Belgium
Phone: +32 4 365 86 57
Email: info@trasis.com
Web: www.trasis.com
Contact person: Gauthier Philippart, CEO

Trasis is specialized in the development and the manufacturing of innovative and high quality radiopharmaceutical equipment. By carefully listening to professional users and markets trends, Trasis provides practical and reliably designed systems for automated synthesis, dispensing and packaging of radio-pharmaceuticals.

AllinOne is a multiple purpose radiochemistry unit featuring synthesizer, HPLC & reformulation in a single compact box, able to efficiently produce the most complex compounds such as nucleophilic F-DOPA, F-Thyrosine, FMT as well as FDG in multiple runs. AllinOne's versatility also helps researchers address the growing need for new tracers.

MiniAIO is designed for simpler processes and to cost efficiently produce compounds such as 18F-FDG, 68Ga/177Lu-peptide conjugates or 18F-NaF and requires less space in the hot cell.

Unidose, a high speed dose dispenser dedicated to hospitals, simplifies the procedures and reduces drastically the exposure to the technologists.

Quickfill, a fast and robust tool for distribution of patient doses from radio-pharmacies.

TriFoil Imaging

Booth No. 241

Turkish Society of Nuclear Medicine (TSNM)

Booth No. F14
(Entrance Hall)

Uniteko

Booth No. 250

77, Seondong-gil, Gwangju-si, Gyeonggi-do, S.Korea

Phone: +82 31 719 0533

Fax: +82 31 624 0539

E-mail: sales@uniteko.co.kr

Web: www.uniteko.co.kr

Contact person at EANM: Kwak. ChanHyo

Uniteko was originally started in 2004 and has constantly developed since then. Incorporated in 2010, Uniteko has accelerated its rate of growth as a leader of radiation measurement system developer.

We have many customers including general hospitals, a variety of R&D institutes, nuclear power plants, military-related institutes, and fire-defense related institutes. Our product areas include import and developing of radiation measurement equipments and systems and radiation shielding equipments. In addition, we are a supplier of many types of isotopes for biological and chemical research purpose, a consultant for radiation safety and a service provider for radiation-related businesses. We are growing with our reliable supplying and customer satisfactory service, and are trying to be a leading company with sustainable investment for new facility and system development.

URENCO Stable Isotopes

Booth No. 224

URENCO Nederland B.V.

Drienemansweg 1

P.O. Box 158

7600 AD Almelo

The Netherlands

Phone: +31 (0)546-545151

Email: isotopes@ureenco.com

URENCO is an independent, global energy and technology group. It operates from plants in Germany, the Netherlands and the United Kingdom, using its own centrifuge technology. Its focus is on providing safe, cost effective and reliable uranium enrichment services for civil power generation within a framework of environmental, social and corporate responsibility. Its goal is to further increase worldwide market share and to become the leading supplier in the extended global enrichment market.

URENCO Stable Isotopes

The advanced centrifuge technology used and owned by URENCO is the result of over thirty years of continuous development. Due to its versatility, application of the gas centrifuge is not limited to the separation of Uranium isotopes: it is also employed for the separation of other isotopes. The production of these stable isotopes started as a diversification project at the URENCO enrichment plant in Almelo, the Netherlands in the early 1990s.

URENCO Stable Isotopes has the facilities, personnel and resources to supply a wide range of isotopes to numerous clients in industrial, medical and research markets from its cascades. Current isotopes which we enrich are Zinc, Cadmium, Iridium, Selenium, Germanium, Titanium and Tungsten. URENCO can deliver isotopes in many different chemical forms such as oxide, chloride, fluoride or elemental. Besides the established markets, new applications are created, thus continually expanding our product portfolio.

VANDERWILT techniques bv

Booth No. 224

Parallelweg-zuid 33-02

5281 LB Boxtel

The Netherlands

Phone: +31 (0)411 686019

Fax: +31 (0)411 624091

Website: www.FOR-MED.nl

E-mail: G.Vanderwilt@wxs.nl

Contact person: ing. Gijs Vanderwilt

VANDERWILT techniques is a design, engineering and manufacturing company for medical devices in nuclear imaging and custom made accessories:

- Treatment tables and accessories
- Specially designed (floating) hovercraft tables
- Custom-moulded polymer FOR-MED patient positioning supports
- Dedicated pinhole collimators
- Custom-made tungsten syringe shields
- Lead and tungsten vial containers
- NEMA-hallmarked quality phantoms
- High Resolution Micro phantoms for small animal systems
- Test collimators
- Thyroid phantom
- Simulation phantoms to ensure camera quality and emulate patient data for human and small animal use.
- Dynamic Heart phantom (AGATE)
- Place resolution phantoms and NEMA calibration panels
- Special custom build projects

VANDERWILT techniques design and manufacture customized products for daily laboratory and clinical nuclear medicine practice as well as research purposes, using state-of-the-art and innovative production methods.

Typically, our customers are universities, hospitals and nuclear medicine departments, as well as radiopharmaceutical and imaging equipment companies.

Von Gahlen Nederland BV

Booth No. 141/151

Waters Corporation

Booth No. 253

34 Maple Street
Milford, MA 01757

Phone: + 1 508 478 2000

email: info@waters.com

website: www.waters.com

Contact person at EANM: Sherri Naughton

For over 50 years, the Waters Corporation has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.

Waters creates business advantages for laboratory-dependent organizations by delivering ultra performance liquid chromatography, high performance liquid chromatography, chromatography columns and chemistry products, mass spectrometry systems, laboratory informatics solutions, and comprehensive service programs to enable significant advancement in healthcare delivery, environmental management, food safety, and water quality.

To bring a new product to market – and to maintain quality after that product's release – companies both large and small must balance many factors for success. Waters partners with organizations around the world to provide exactly the technologies and services that fully support your scientific and operational needs.

Whether that means optimizing your current laboratory output, or implementing a scalable and forward-looking solution that empowers you to achieve the innovation, productivity, and profitability goals that define your success, Waters works with you every step of the way.

At EANM - booth 253 - we discuss our sample preparation solutions for purifying Positron Emission Tomography (PET) imaging agents. We offer standard products as well as custom manufacturing to produce devices for your specific requirements.

Wisepress Medical Bookshop

Booth No. F16 (Entrance Hall)

25 High Path


Merton Abbey

London SW19 2JL, UK

Phone: +44 20 8715 1812, Fax: +44 20 8715 1722

marketing@wisepress.com, www.wisepress.com

Wisepress.com, Europe's leading conference bookseller, has a range of books and journals relevant to the themes of the meeting. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers. Follow us on Twitter for the latest news @WisepressBooks.



BOOTH # EXHIBITOR

100	GeSiM mbH
101	MecMurphil Srl
102	Blue Earth Diagnostics Ltd.
103/104	Advanced Cyclotron Systems Inc.
105	Center of Molecular Research Ltd.
106	Best Cyclotron Systems
107	Kromek Group PLC
108	Taiyo Nippon Sanso Corp.
109	Advion
110/111	GAEDE Medizinsysteme GmbH
112	Raytest Isotopenmessgeräte GmbH
113	DIAsource ImmunoAssays SA
114-117	LabLogic Systems Ltd. / Southern Scientific Ltd. / Hidex Oy
118/119	PerkinElmer
120	Casram SA
121	Lynax s.r.o.
122/123/136/137	Comecer Group
124	Comecer Group
125/134	Trasis SA
126/127/132/133	Synthra GmbH
128/131	Rotem GmbH
129/130	Spectrum Dynamics Medical, Inc.
135	Agfa HealthCare
139	BTG
140	Scintomics GmbH
141/151	Von Gahlen Nederland BV
142	AG Medical / Dilon Diagnostics
143	NUKEM Isotopes GmbH
144/148	Advanced Accelerator Applications International
145/146	PMOD Technologies Ltd.
147	ec ² Software Solutions
149/150	ACOM Group
152	ITG Isotope Technologies Garching GmbH
153	Medi-Radiopharma Co., Ltd.

BOOTH # EXHIBITOR

154	Eli Lilly and Company
155/156/171/172	Sirtex Medical Europe GmbH
157	Chematech
158	Cambridge Isotope Laboratories Inc.
159/160	INVIA Medical Imaging Solutions
161	DOSISOFT S.A.
162/167	Genzyme Europe BV
163	QC1 GmbH
164	inviCRO
165/166	NICESOFT
168	MIM Software Inc.
169/170	SEDECAL
173/188	ABX advanced biochemical compounds
174/175/186/187	ISOTOP4LIFE:
	- Keosys
	- Chelatec
	- Lemer Pax
	- Medisystem
	- Ai4R
	- Triskem
176/185	MAP Medical Technologies Oy
177/183/184	RAD4MED.BE:
	- ANMI
	- CamelHDS
	- Elysia
	- IRE ELiT
	- M2Target
	- MEDraysintell
	- SCK-CEN
178	IRE ELiT
179-182	Bayer HealthCare
189-192/201-204	Philips Healthcare
193-200	GE Healthcare
205/206/220/221	IBA / Cyclomedica Europe Ltd.

From:

- Lecture Halls - Registration Area - Main Entrance



BOOTH # EXHIBITOR

208/218	HERMES Medical Solutions AB
209/210/216/217	Tema Sinergie S.p.A.
211-215	Eckert & Ziegler
222	Siemens Healthcare
223	Mallinckrodt Pharmaceuticals
224	THE PAVILION:
	- IDB Holland BV/IDB Radiopharmacy BV
	- Urenco Nederland BV
	- VANDERWILT Techniques BV
	- BV Cyclotron VU
	- M&I Materials
	- Rapidscan Pharma Solutions, Inc
	- NRG Petten
	- PI Medical Diagnostic Equipment BV
	- SurgicEye GmbH
	- MED Nuklear-Medizintechnik Dresden GmbH
	- Euromedical Instruments
	- Hoy Scandinavian
225	Mediso / Institute of Isotopes Co. Ltd.
225b-225k	MR Solutions Ltd.
226	ABX-CRO advanced pharmaceutical services
226a	ITD Isotope Technologies Dresden GmbH
226b	Inter Medical Medizintechnik GmbH
226c	Crystal Photonics GmbH
226d	MiE medical imaging electronics GmbH
227a	Polatom / Rotop Pharmaka GmbH
227b	IASON GmbH
227c	Cyclomedica Europe Ltd.
228	Eczacibasi-Monrol Nuclear Products Co. / Epsilon Elektronik / Capintec / DDD-Diagnostic AS
229/230	MILabs
231/232	Pars Isotope Co.
233/234	JSC Isotope
235-238	Piramal Imaging
239	Progenics Pharmaceuticals, Inc.

BOOTH # EXHIBITOR

240	RadioMedic Ltd.
241	TriFoil Imaging
242	Sensire Ltd.
243	ORA-NEPTIS
244	Biodex Medical Systems, Inc.
245	Bruker BioSpin
246	EL.SE. SRL
247/248	ABT Molecular Imaging
249	MOLECUBES
250	Uniteko
251	E.V. Minerve
252	Theraclion
253	Waters Corporation
254/255	Mirada Medical



EANM Corporate Member

Corporate Members

EANM wishes to thank the following companies for their support as Corporate Members:

ACOM SPA



Eckert & Ziegler Isotope Products GmbH



Eczacıbaşı Monrol Nuclear Products Co.



GE Healthcare



IBA Molecular



Mallinckrodt Pharmaceuticals



MAP Medical Technologies Oy



Mediso Medical Imaging Systems



Philips Medical Systems Nederland B.V.



Siemens Healthcare GmbH



Sirtex Medical Europe GmbH



Tema Sinergie S.p.A.



Imprint

Publisher

European Association of Nuclear Medicine (EANM)
Schmalzhofgasse 26, 1060 Vienna, Austria
Phone: +43-(0)1-890 44 27 | Fax: +43-(0)1-890 44 27-9
Email: office@eanm.org | URL: www.eanm.org



Editors

Wim J.G. Oyen, MD, PhD, EANM Congress Chair 2014-2016
Andreas Felser, EANM Executive Director
Annetta Florentis, EANM Project Manager, Congress

Content

No responsibility is taken for the correctness of this information.
Information as per date of printing August 2015.

Layout & Design

kreativ · Mag. Evelyne Sacher-Toporek
Linzer Strasse 358a/1/7, 1140 Vienna, Austria
Phone: +43-(0)1-416 52 27 | Fax: +43-(0)1-416 85 26
Email: office@kreativ-sacher.at | URL: www.kreativ-sacher.at



Printing

„agensketterl“ Druckerei GmbH
Kreuzbrunn 19, 3001 Mauerbach, Austria
Phone: +43-(0)1-576 10 | Fax: +43-(0)1-576 10-666
Email: info@diedrucker.biz | URL: www.agensketterl.at





HIGH QUALITY IS NO COINCIDENCE. IT IS OUR COMMITMENT!



EARL FDG-PET/CT Accreditation Programme

The EARL FDG-PET/CT accreditation ensures similar performance of PET/CT Systems within a multicentre setting by harmonising acquisition and interpretation of PET/CT Scans.

EARL created a NEMA phantom video for you. This video presents the phantom measurement required to attain and maintain PET/CT EARL Accreditation.

The accreditation process is a test of overall quantitative accuracy.

Accreditation is absolutely necessary to make Nuclear Medicine a more reliable partner for our clinical colleagues by guaranteeing high standards.

If you have any further questions, please do not hesitate to contact EARL: earl@eanm.org



Scan me!

RESEARCH
4LIFE[©]

an EANM initiative



OUR MISSION

Managing Complexity.
Improving Lives.

OUR VALUES

Quality. Integrity. Service.

OUR HALLMARKS

Engaged. Competitive.
Collaborative.
High Performing.
Trustworthy.

Visit our booth #223 and discuss with us how we secure:

- Short, medium and long term availability of Mo-99/Tc-99m generators
- Efficient transition to LEU based Mo-99 production
- Continued access to critical diagnostic procedures for patients



Mallinckrodt
Pharmaceuticals

A Siemens Symbia Intevo PET/CT scanner is shown in a clinical setting. The machine is white with a large circular gantry. A patient bed is partially visible. A small monitor on the right displays a 3D reconstruction of a human spine, showing the vertebrae in blue and red. The Siemens logo is visible on the top of the gantry.

SIEMENS

Visit
Siemens at
EANM 2015
booth 222

Symbia Intevo

xSPECT, the difference between seeing and knowing.

siemens.com/see-the-unseen

Conventional SPECT/CT is limited in its ability to deliver definitive and timely answers to clinical questions. Siemens addresses these challenges with Symbia Intevo™* and xSPECT* technology by completely integrating SPECT and CT data during image reconstruction.

The higher resolution and clinical detail of xSPECT Bone* supports physicians' ability to distinguish between degenerative disease and cancer, reducing the need for follow-up exams. xSPECT Quant* generates quantitative

measurements** of disease uptake that are both accurate and reproducible, facilitating therapy planning and early modification of patient treatment to reduce costs associated with ineffective therapies.

* Symbia Intevo, xSPECT, xSPECT Bone and xSPECT Quant are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

** For ^{99m}Tc and LEHR only.